<SEC-DOCUMENT>0000950123-21-004461.txt : 20210623
<SEC-HEADER>0000950123-21-004461.hdr.sgml : 20210623
<ACCEPTANCE-DATETIME>20210409213034
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-004461
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20210412
<PUBLIC-REL-DATE>20210623
DATE AS OF CHANGE:		20210412

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sight Sciences, Inc.
		CENTRAL INDEX KEY:			0001531177
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				800625749
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04646
		FILM NUMBER:		21819185

	BUSINESS ADDRESS:	
		STREET 1:		3000 SAND HILL ROAD
		STREET 2:		BUILDING 3, SUITE 105
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		(415) 889-0550

	MAIL ADDRESS:	
		STREET 1:		3000 SAND HILL ROAD
		STREET 2:		BUILDING 3, SUITE 105
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Draft Registration Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on April&nbsp;9, 2021
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>3841</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">80-0625749</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4040 Campbell Ave, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park CA 94025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">877-266-1144</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Paul Badawi
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4040 Campbell Ave, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park CA 94025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">877-266-1144</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of
agent for service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Peter N. Handrinos</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wesley C. Holmes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>200 Clarendon Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">948-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alan F. Denenberg</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephen Salmon</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1600 El Camino Real</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, CA 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT
STYLE="white-space:nowrap">752-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this Registration
Statement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement&nbsp;for&nbsp;the&nbsp;same&nbsp;offering.&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#9744;<B></B><B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#9746;<B></B><B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&#9746;<B></B><B></B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act. </B>&#9744;<B></B><B> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities To Be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering Price (1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee (2)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. Includes the aggregate offering price of additional shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>Subject to Completion, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PRELIMINARY PROSPECTUS
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g01a31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is Sight
Sciences, Inc.&#146;s initial public offering. We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. Prior to this offering, there has been no public market for
our common stock. We estimate that the initial public offering price of our common stock will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We intend to apply to list our common stock on The Nasdaq Global Market under the symbol
&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging
growth company&#148; and &#147;smaller reporting company&#148; under the federal securities laws and, as such, are subject to reduced public company disclosure standards. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth
Company and a Smaller Reporting Company.&#148; </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves risks. See &#145;&#145;<A HREF="#rom90195_2">Risk
 Factors</A>&#146;&#146; beginning on page 15 of this prospectus. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions paid by us(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriters&#148; beginning on page&nbsp;207 for additional information regarding
underwriting compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock for a period of 30 days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect
to deliver the shares against payment to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 through the book-entry facilities of the Depository Trust Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Morgan&nbsp;Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>BofA&nbsp;Securities</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Piper&nbsp;Sandler</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021.
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g68f91.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Power of Sight </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">SIGHT SCIENCES </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g49i05.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">SIGHT SCIENCES OMNI&reg; Surgical System TearCare&reg; System </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_4">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_9">SELECTED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_13">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_19">UNDERWRITERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom90195_23">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in
this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing
prospectus related thereto is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to trademarks, trade names and service marks appearing in this prospectus that are important to our business.
Solely for convenience, the trademarks, trade names and service marks may appear in this prospectus without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and TM symbols, but any such references are not intended to indicate, in any
way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in
this prospectus are the property of their respective owners. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with,
or endorsement or sponsorship of us by, these other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have done anything that would permit this
offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, (the 25th day after the date of
this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed
information included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully read this entire prospectus, including the information under the sections titled &#147;Risk Factors,&#148;
&#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes thereto included elsewhere in
this prospectus, before making an investment decision. Unless the context requires otherwise, references in this prospectus to &#147;Sight Sciences,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Sight
Sciences, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
mission is to transform ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world&#146;s most prevalent eye diseases. We are passionate about improving
patients&#146; lives. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing products that are intended to restore natural physiological functionality to diseased eyes;
developing and marketing products that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient friendly solutions to ophthalmologists and optometrists (together,
eyecare professionals or ECPs); and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in
new treatment paradigms and to create an interventional mindset in eyecare whereby our products may be used in procedures which supplant conventional outdated approaches. We believe current eyecare treatment models rely heavily on prescription
medications, symptom relief, or either flawed or highly invasive, later-stage procedural interventions and fail to adequately address the true underlying cause of disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our currently marketed products, the OMNI Surgical System, or OMNI, and the TearCare System, or TearCare, target two of the world&#146;s most
prevalent and underserved eye diseases, glaucoma and dry eye disease, or DED, respectively. Glaucoma, a group of chronic, often asymptomatic, diseases that damage the optic nerve, is the world&#146;s leading cause of irreversible blindness. Primary
open-angle glaucoma, or POAG, is the most prevalent form of glaucoma. Dry eye complaints are the most common reason for a patient visit to an eye doctor and DED symptoms have a significant impact on the quality of life and productivity of patients.
If left untreated, DED can be extremely painful, leading to permanent cornea damage and vision impairment. We estimate the annual addressable U.S. market opportunities for OMNI and TearCare are approximately $6&nbsp;billion and approximately
$10&nbsp;billion, respectively, while 2020 U.S. manufacturer revenues in the surgical glaucoma and DED markets were approximately $350&nbsp;million and $2.4&nbsp;billion, respectively, demonstrating that currently available solutions have not
addressed a large part of the market need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OMNI is a handheld, single use, therapeutic device that allows ophthalmic surgeons to reduce
intraocular pressure, or IOP, in adult glaucoma patients with a safe, <I>ab interno</I>, minimally invasive glaucoma surgery, or MIGS. We believe OMNI delivers the highest level of effectiveness of any available MIGS product, as it is the only
device which provides access to 360 degrees and all three key points of resistance of an eye&#146;s diseased conventional outflow pathway through a single clear corneal microincision. We believe our recently expanded indication for use of OMNI is
among the most comprehensive in MIGS. The FDA has authorized the use of OMNI for reducing IOP in all adult POAG patients both by itself on a standalone basis, which we refer to as Standalone procedures, or in combination with cataract procedures,
which we refer to as Combination Cataract procedures. We believe OMNI is the first custom-designed <I>ab interno</I> <I></I>MIGS device that was cleared by the FDA to be used in <I>ab interno</I> MIGS
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedures for lowering IOP in both Combination Cataract and Standalone cases for all adults with POAG based upon the review of <I>a</I><I>b</I><I>
</I><I>i</I><I>n</I><I>ter</I><I>n</I><I>o</I><I> </I>Combination Cataract and Standalone clinical data. Several competing MIGS devices, including the current market leaders, have only been authorized by the FDA for use in Combination Cataract
procedures for adult patients with Mild-to-Moderate severity. We sell OMNI to facilities where ophthalmic surgeons perform outpatient procedures, mainly ambulatory surgery centers, or ASCs, and hospital outpatient departments, or HOPDs. Our Surgical
Glaucoma segment, which includes OMNI, represented 94% of our total revenues for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021,
OMNI was cleared by the FDA for an expanded indication for use based upon the review of clinical data from ROMEO, our recently completed U.S. multi-center clinical study of OMNI in Combination Cataract and Standalone procedures. In ROMEO, we
observed that Standalone OMNI patients with preoperative IOP greater than 18 mmHg experienced a mean IOP reduction of 28% (from 21.8 mmHg to 15.6 mmHg) and a mean reduction in hypotensive medication usage of 35% (from 1.71 medications to 1.17
medications) 12 months after treatment. In Combination Cataract patients with preoperative IOP greater than 18 mmHg, we observed a mean IOP reduction of 31% (from 21.9 mmHg to 15.1 mmHg) and a mean reduction in hypotensive medication usage of 45%
(from 2.04 medications to 1.13 medications) 12 months after treatment. The Standalone procedure market, which we estimate represents greater than 85% of the addressable U.S. POAG market, is significantly underpenetrated relative to the Combination
Cataract market. The development and penetration of the Standalone market is a key element of our growth strategy and we believe that OMNI has the degree of effectiveness and consistency of clinical outcomes to establish a more proactive,
interventional treatment paradigm. We believe our recently expanded indication for use of OMNI will help us effectively develop the Standalone market and capitalize on the potential of the Combination Cataract market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TearCare is a technologically sophisticated system which utilizes a wearable, <FONT STYLE="white-space:nowrap">open-eye</FONT> design to apply
localized heat to eyelids in an anatomically customized way. We believe TearCare has a compelling physiological profile to address obstructions from meibomian gland dysfunction, or MGD, which is the primary cause of evaporative DED, a disease
characterized by low quality tears that evaporate prematurely. In OLYMPIA, our large randomized control trial, or RCT, TearCare was associated with statistically significant clinical improvements in all assessed signs and symptoms of DED at all time
periods measured (both two weeks and four weeks post-treatment) and had a statistically significantly higher proportion of subjects improving by at least one OSDI (patient reported outcomes survey) category than did the group receiving a single
treatment using a version of the first device <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including MGD. We sell
TearCare to optometry and ophthalmology practices through a targeted commercial approach. Our initial strategic focus for TearCare is on improving patient access, as we believe that MGD is one of the most prevalent diseases in all of medicine that
lacks any meaningful reimbursement coverage by Medicare and private payors. Our long-term plan is to maximize patient access to TearCare and further develop the MGD procedures market. This plan leverages a rigorous clinical trial program designed to
demonstrate the safety, effectiveness and durability of TearCare treatments and a comprehensive effort to educate patients, providers and third-party payors regarding the benefits of TearCare treatments. Our Dry Eye segment, which includes TearCare,
represented 6% of our total revenues for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are deeply committed to continuing to conduct clinical
studies to evaluate the safety and effectiveness of our products, and we believe the results of our clinical studies will be critical to our continued growth. We are currently conducting robust clinical trial programs in both glaucoma and DED, with
11 ongoing or planned studies, including several <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> RCTs against market leading products. We also support investigator- initiated trial, or IIT, programs, of
which eight are completed and two are currently in progress. We are focused on continuous innovation and seek regular input from our network of expert employees (including several ophthalmologists on staff), advisors and customers to rapidly iterate
our <FONT STYLE="white-space:nowrap">pre-</FONT> and post-commercial product designs with the aim of better satisfying the needs of our customers and their patients, and increasing adoption and utilization of our solutions. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced significant growth and market adoption since commercially launching OMNI
in February 2018 and initiating controlled commercial sales of TearCare in April 2019. We generated revenue of $7.5&nbsp;million, $23.3&nbsp;million, and $27.6&nbsp;million for the years ended December&nbsp;31, 2018, 2019, and 2020, respectively.
Gross margin was 68.9%, 72.0%, and 66.7% for the years ended December&nbsp;31, 2018, 2019, and 2020, respectively. We also incurred net losses of $14.3&nbsp;million, $25.9&nbsp;million, and $34.5&nbsp;million for the years ended December&nbsp;31,
2018, 2019, and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advancements in treatment effectiveness across a number of prominent eye diseases has been limited in recent years due to a lack of significant
innovation. We believe that we are favorably positioned with each of our products to transform treatment paradigms and, over time, to broadly improve the quality of patient care throughout ophthalmology and optometry. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary Open-Angle Glaucoma </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma, a group of chronic, often asymptomatic, diseases that damage the optic nerve, is the world&#146;s leading cause of irreversible
blindness. Glaucoma does not have a cure and is a progressive disease; if left untreated or insufficiently treated, glaucoma can lead to irreversible disability and blindness. In patients with POAG, aqueous humor builds up in the anterior chamber of
the eye and the resultant tension can interfere with the blood supply to the optic nerve in the back of the eye, resulting in optic nerve cell death and irreversible vision loss. Decades of research have demonstrated that the fluid buildup primarily
results from malfunctions in the eye&#146;s drainage system, which is known as the conventional aqueous outflow pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020,
102&nbsp;million people worldwide were estimated to suffer from glaucoma. POAG is the most prevalent form of glaucoma and in 2020 affected over 60&nbsp;million people worldwide and 4.1&nbsp;million people in the United States, of whom
3.4&nbsp;million were diagnosed. We estimate the current annual addressable U.S. market opportunity for OMNI is approximately $6&nbsp;billion, while 2020 U.S. manufacturer revenues in the surgical glaucoma market were approximately
$350&nbsp;million, demonstrating that currently available surgical solutions have not addressed a large part of the market need. In the U.S., currently marketed trabecular bypass stents are effectively precluded from participating in over 85% of
this addressable market because they are only authorized for use in Combination Cataract procedures in patients with Mild-to-Moderate severity and we estimate that less than 15% of the diagnosed POAG population in the U.S. will require cataract
surgery in a given year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dry Eye Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DED refers to a group of disorders caused by either poor quality tears, known as evaporative DED, or inadequate tear production, known as
aqueous deficient DED. There are an estimated 739&nbsp;million people globally and 38&nbsp;million people in the U.S. who suffer from DED. DED is the most common reason for a patient visit to an eye doctor, yet of the 38 million people with DED in
the U.S., only 17&nbsp;million have been diagnosed with DED. If left untreated, DED can be extremely painful and lead to permanent cornea damage and vision impairment. Studies have shown that evaporative DED resulting from MGD is associated with
approximately 86% of all DED cases. Meibum is an oily secretion that forms the protective outer layer of healthy tears and prevents premature tear evaporation. For patients with MGD, meibum hardens within the meibomian glands, which are located in
the eyelids, causing obstructions that prevent it from flowing freely onto the tear film. We estimate that the addressable U.S. market for MGD treatment is approximately $10&nbsp;billion per year, as compared to MGD procedures representing less than
$100&nbsp;million of U.S. manufacturer revenues in 2020, demonstrating that currently available MGD procedures have not addressed a large part of the market need. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Alternatives and Limitations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A variety of pharmaceutical and procedure-based treatment alternatives exist for POAG and DED but there is no cure for either disease. Because
many of the current alternatives focus on treating symptoms rather than the underlying causes of the disease, they offer suboptimal effectiveness and durability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary Open-Angle Glaucoma </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
current treatment paradigm for POAG includes less invasive options, such as prescription eyedrops and laser treatments for Mild and Moderate cases, and more invasive conventional surgical procedures for more severe cases. Each of these treatment
modalities addresses just a single aspect of the disease at a specific point in the progression of the disease state. As a complex and progressive disease, there is no &#147;one size fits all&#148; treatment for POAG. Physicians have historically
used a combination of treatments because no single treatment could adequately slow disease progression to a manageable level over the long term. Further, due to the progressive nature of the disease, any intervention can become ineffective as the
disease state matures. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Prescription eyedrops</B> seek to increase aqueous outflow or reduce aqueous production. Prescription eyedrops
are the most common first line therapy used to treat ocular hypertension, or OHT, and Mild glaucoma and often continue to be utilized as part of the treatment for Moderate and Advanced/Severe patients. The effectiveness of prescription eyedrops can
be limited by patient behavior and compliance, providing inconsistent protection from glaucoma progression for many who face adherence challenges. If a single prescription medication fails to control IOP, additional medications may be prescribed.
Although this step may contribute incremental effectiveness, adding medications can further complicate the treatment regimen, potentially hindering patient compliance, and exacerbate side effects. Studies have demonstrated that chronic use of
glaucoma medication contributes to ocular surface disease, an inflammation of the ocular surface that is not only irritating and painful, further contributing to poor adherence, but can also contribute to greater risk of surgical failure should
traditional glaucoma surgery, such as trabeculectomy, be required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Sustained pharmaceutical delivery</B> through an intraocular implant is a newer method of drug administration.
While intracameral sustained delivery mitigates issues relating to patient medication adherence, it could introduce new challenges associated with the risks of leaving an intracameral implant in the eye over several months or years, or the
procedural complexity and risks associated with implanting objects in the eye and potentially removing them. Only one intraocular drug delivery implant to treat glaucoma has been authorized for use by the FDA, and it is currently limited to a single
six month treatment per eye without retreatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selective laser trabeculoplasty, or SLT,</B> offers a <FONT STYLE="white-space:nowrap">non-invasive,</FONT>
energy-based solution and short recovery times, with effectiveness similar to certain eyedrops, but with a waning treatment effect at less than one year for up to half of patients. The effectiveness of continued laser therapy after a second
treatment is not known at this time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>MIGS stents</B>, particularly trabecular bypass stents, have steadily grown in usage among surgeons performing
Combination Cataract procedures because the devices are efficient to implant, involve minimal complications and provide incremental effectiveness over cataract surgery itself. However, the FDA has only authorized trabecular bypass stents for use in
Combination Cataract procedures for Mild-to-Moderate cases, limiting their authorized use to less than 15% of all U.S. POAG patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Conventional invasive surgeries</B> include trabeculectomy (also called filtering surgery) and tube shunt
implantation, which are bleb-forming procedures, and have each been in use for several decades. Blebs are blister-like reservoirs surgically created on the outside of the eye intended to serve as permanent, artificial drainage channels. Conventional
surgery techniques are multi-step invasive procedures and are most typically utilized for maximal reductions in IOP to prevent visual field loss in Advanced/</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Severe disease when medications, lasers or MIGS treatment of the conventional outflow pathway have failed. Despite their success at reducing IOP, serious complications or even surgical failure
are not uncommon. These conventional surgeries are considered a last line of defense for Advanced/Severe stage patients because they create a physiologically artificial pathway that can be difficult to control, carry a life-long risk of
complications (e.g., hypotony, blebitis, bleb failure), and typically require longer recovery periods. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dry Eye Disease
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although MGD is the primary root cause of DED, we believe it is relatively new to eyecare research and product development. In
contrast, we believe aqueous deficiency, which is a less prominent root cause of DED, has historically dominated the medical community&#146;s mindset regarding DED and has been synonymous with the disease. This has contributed to the current DED
treatment market being characterized by an abundance of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> or OTC, artificial tears and lubricating eyedrops, and prescription DED eyedrops. Given the
relatively recent focus on and understanding of MGD, MGD procedures for DED have had limited commercial traction and represent a significant but underdeveloped market opportunity. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>OTC artificial tears and lubricating eyedrops</B> are palliative and <B>prescription eyedrops</B> aim to
alleviate inflammation and/or increase aqueous layer tear production. Although several DED prescription eyedrops have achieved commercial and clinical success, we believe they are limited in their ability to treat the substantial majority of DED
sufferers. None of the prescription DED eyedrops are indicated to treat MGD, the primary underlying cause of evaporative DED, which is associated with 86% of DED cases. Furthermore, patient <FONT STYLE="white-space:nowrap">non-compliance,</FONT> the
high rate of side effects, and high <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs further limit the ability of prescription eyedrops to treat DED effectively and with maximal patient access.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>MGD procedures</B> represented less than $100&nbsp;million of U.S. manufacturer revenues in 2020. In general,
available devices for the treatment of MGD can be difficult for providers to administer, which places significant oversight demands on the physician, may be uncomfortable for patients and/or have limited effectiveness. These devices may also require
high upfront capital equipment purchases for providers, which lowers the overall economic value proposition to eyecare stakeholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solutions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The OMNI Surgical System
and the TearCare System are interventional ophthalmology devices. The past, current and ongoing development of OMNI and TearCare follows our internal product development approach, which is governed by four fundamental requirements that we believe
are critical to delivering the most effective, safe and consistent clinical outcomes for patients with eye disease: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comprehensive Understanding of Disease Physiology.</B> We review and analyze all available clinical data,
science and literature that is relevant to a disease to achieve a sound understanding of its underlying cause(s), which guides the development of any of our products. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Treatment of Underlying Causes.</B> Healthy eyes are self-regulating marvels of evolution, biomechanics,
chemistry and physiology. We believe that restoring the natural functionality of diseased eyes by comprehensively treating underlying cause(s) of disease provides the optimal combination of effectiveness and safety. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Intuitive Design.</B> Our products are designed to transform complex, impractical or invasive treatment
approaches into intuitive, minimally invasive, user-friendly procedures. Our product development goals are focused on delivering a preferred &#147;go to&#148; treatment of choice to ophthalmologists and optometrists. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patient Access.</B> We seek to maximize the availability and accessibility of our products for as many
patients as possible. We believe that our devices have the potential to offer differentiated clinical, experiential and economic value to all eyecare stakeholders. For conditions where patients lack optimal treatment access due to insurance coverage
limitations or difficult patient pay economics, we plan to demonstrate the value proposition of our solutions through rigorous clinical trial data and real-world results to improve access. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OMNI Surgical System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commercially
launched in February 2018, OMNI is a handheld, single-use, therapeutic device used by ophthalmic surgeons to reduce IOP in adult glaucoma patients. Each OMNI Surgical System consists of 29 separate precision-engineered parts that have been optimized
for intuitive use, performance and effectiveness. OMNI facilitates the sequential completion of two well-established, historically invasive glaucoma procedures, canaloplasty and trabeculotomy, with an efficient, minimally invasive approach using
just a single, bloodless and sutureless clear corneal microincision. Conventional canaloplasty and trabeculotomy procedures have been used to effectively treat glaucoma for decades but involve invasive approaches that are difficult to perform,
traumatize the eye, have higher risk of intraoperative and post-operative complications and require longer patient recovery times. OMNI transforms these two distinct, historically invasive <I>ab externo</I> glaucoma procedures into a single,
sequential, <I>ab interno</I> MIGS procedure. MIGS procedures leverage a one to two millimeters clear corneal incision for intraocular access similar to cataract surgery and have a strong demonstrated safety profile, characterized by minimal trauma
to the eye and quick patient recovery times. OMNI is the only MIGS device currently on the market that provides access to 360 degrees of the diseased conventional outflow pathway and can address all three key points of resistance in the conventional
outflow pathway (trabecular meshwork, Schlemm&#146;s canal, and the distal collector channels) through a single clear corneal incision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received 510(k) clearance from the FDA and a CE Mark to market OMNI in the U.S. and the EU, respectively. OMNI is indicated for
canaloplasty followed by trabeculotomy to reduce IOP in adult patients with POAG in the U.S. and with open-angle glaucoma, or OAG, in the EU. We believe that OMNI is the only device that is authorized by the FDA as an <I>ab interno</I> procedure to:
reduce IOP in adult patients with POAG across the spectrum of disease severity; be used in Mild-to-Moderate Combination Cataract or Standalone procedures; access 360 degrees of the diseased conventional outflow pathway through a single clear corneal
incision; and facilitate two consecutive procedures, canaloplasty and trabeculotomy, to comprehensively treat all three points of resistance in the conventional outflow pathway in a single operating room visit. The procedure enabled by OMNI,
canaloplasty followed by trabeculotomy, is covered and reimbursed by all Medicare Administrative Contractors, or MACs, and numerous private insurers, covering an estimated 67% of U.S. POAG sufferers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Published data from ROMEO and several single surgeon datasets show a remarkable consistency in IOP reduction following treatment with OMNI.
Almost all patients across these groups (98 of 103, 95%) had an IOP decrease following treatment with OMNI, and three out of four (77 of 103, 75%) had at least a 20% decrease. Patients in these studies also experienced reductions in the use of
glaucoma medication following their OMNI procedures, a benefit not observed in the &#147;medication washout&#148; trabecular bypass stent trials designed to isolate and thereby maximize IOP reduction in a non-real world manner. We believe the
consistent therapeutic outcomes OMNI delivers are important for patients and surgeons alike. For patients, we believe the anxiety that may accompany the need for ocular surgery can be tempered with the knowledge that there is a high likelihood of
success. For surgeons, consistent outcomes simplify the treatment choice and the decision to perform a procedure. We believe this is especially important for Standalone MIGS procedures which must deliver a very high consistency of efficacy and a
very high degree of effectiveness to not only justify the procedure, but also provide surgeons with enough confidence to recommend Standalone surgery to their patients and take them to the operating room for a singular reason. We believe delivering
consistently effective results will be crucial to unlocking the Standalone market, as well as capitalizing on the full potential of the Combination Cataract market, which we believe is currently capturing less than one-third of its potential
procedure volume in the U.S. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TearCare System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TearCare is our newest marketed product, comprised of a <FONT STYLE="white-space:nowrap">re-usable</FONT> hardware controller, the SmartHub,
and a breakthrough wearable, software-controlled eyelid technology, the SmartLids. TearCare serves as an elegant, compact, portable, intuitive solution that enables the application of localized heat to the eyelids in an anatomically customized way.
We believe TearCare presents a compelling physiological profile to potentially address DED due to MGD. Applied adhesively and <FONT STYLE="white-space:nowrap">non-invasively</FONT> to the outside of the eyelids, single-use SmartLids deliver a
precise therapeutic level of heat into the meibomian glands. Engineering SmartLids to remain comfortably adhered to virtually all shapes and sizes of eyelids while allowing freedom to blink and delivering precise therapeutic heat is one of our most
significant design accomplishments. This heating process is intended to melt obstructions in the glands and restore the production and release of healthy, clear liquid meibum, which forms the outer protective layer of tears and helps prevent
premature tear evaporation. Additionally, the proprietary, highly conformant, <FONT STYLE="white-space:nowrap">open-eye</FONT> design of TearCare allows patients to blink naturally throughout the thermal portion of the procedure, which facilitates
movement of melted meibum and also provides a comfortable treatment experience. TearCare can be utilized by an ECP in a straightforward <FONT STYLE="white-space:nowrap">in-office</FONT> procedure and accommodated during the course of a routine
patient visit. In our OLYMPIA RCT, we observed that a single use of TearCare was associated with clinically significant improvements in all of the signs and symptoms of DED assessed within two weeks of treatment in subjects with MGD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began selling TearCare in a controlled product launch in April 2019. The initial phase of launch was successful in garnering valuable
feedback from our customers and the broader DED community as well as demonstrating the existing market demand for an effective MGD solution. Our goals with the development of TearCare are to fully transform the current, outdated treatment paradigm,
which relies primarily on OTC and prescription eyedrops, and establish our clinically proven eyelid procedure as the standard of care for the millions of patients suffering from evaporative DED caused by MGD. We are executing our long-term plan to
maximize patient access to TearCare and further develop the MGD procedures market by leveraging a rigorous clinical trial program designed to demonstrate the safety, effectiveness and durability of TearCare treatments, and a comprehensive effort to
educate patients, providers and third-party payors regarding the benefits of TearCare treatments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Success Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following factors will drive the future success and growth of our company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Large market opportunities in eyecare with flawed treatment paradigms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continual development of innovative technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consistent delivery of exceptional customer experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prioritization of clinical excellence and market education; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Focus on strong economics and value creation for all eyecare stakeholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Scale culture built on community, passion, courage and perseverance. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Growth Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to
transform ophthalmology and optometry with proprietary solutions that target the underlying causes of the world&#146;s most prevalent eye diseases. We believe the following elements of our growth strategy will advance our mission and contribute to
our future growth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish OMNI as the standard of care for interventional glaucoma treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop the MGD treatment market through a clinically-driven, patient
<FONT STYLE="white-space:nowrap">access-led</FONT> strategy for TearCare; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drive adoption and utilization of our products by leveraging additional clinical studies and market education;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deepen and broaden our commercial organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand into international markets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuously innovate premium product offerings throughout eyecare. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is
subject to a number of risks and uncertainties of which you should be aware before making an investment decision. You should consider all of the information set forth in this prospectus and, in particular, the specific factors set forth under
&#147;Risk Factors&#148; in deciding whether to invest in our common stock. These risks include, without limitation, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since inception and expect to incur significant additional losses for the
foreseeable future which may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business is highly dependent on the success of two current commercial products, and in particular OMNI. The
development of TearCare for expanded indications depends upon positive clinical data, and the safety and efficacy of our products are not yet supported by long-term clinical data, which could delay or prevent clearance by regulatory authorities or
limit sales if cleared, certified or approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we may need additional funding in order to finance our planned operations.
The inability to raise funds on acceptable terms, if at all, when needed, may force use to delay, reduce or eliminate our product development programs and commercialization efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The COVID-19 pandemic has impacted, and likely will continue to impact, our operations and financial results and
may materially and adversely affect our business and financial results in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are subject to extensive and costly government regulation on federal, state and foreign levels and we may not
receive, or may be delayed in receiving, the necessary regulatory clearances, certifications or approvals for our future products or modifications to our current products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may incur significant liability if it is determined that we are not complying with federal, state or foreign
regulatory requirements, such as if it is determined that we are promoting off-label uses of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in public health insurance coverage and reimbursement rates may affect the adoption of our products and
our future revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Developments by competitors may render our products or technologies obsolete or noncompetitive and the
development of new products, technologies, procedures, medications or other therapies could replace or reduce the importance of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties for the manufacture and supply of OMNI and TearCare; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend on a limited number of single source suppliers for some of the components, accessories and materials
used in OMNI and TearCare and any shortfall in the supply chain may cause our business to materially suffer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain, protect, maintain, enforce and adequately protect our intellectual property rights
with respect to our technology and current and future products, or if the scope of the patent </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and
commercialize our technology and current and future products may be adversely affected; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers or
other significant personnel or experience increases in our compensation costs, our business may materially suffer. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of
Being an Emerging Growth Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our
Business Startups Act of 2012, as amended, or the JOBS Act. As such, we may take advantage of certain exemptions from various reporting requirements that are otherwise applicable to public companies. These exemptions include, but are not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The option to present only two years of audited financial statements and only two years of related
management&#146;s discussion and analysis of financial condition and results of operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Not being required to submit certain executive compensation matters to stockholder advisory votes, such as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay,&#148;</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-frequency,&#148;</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;say-on-golden</FONT></FONT> parachutes;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Not being required to disclose certain executive compensation-related items such as the correlation between
executive compensation and performance and comparisons of the chief executive officer&#146;s compensation to median employee compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage
of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if prior to the end of such five-year period, (i)&nbsp;our annual gross revenue exceeds $1.07&nbsp;billion,
(ii)&nbsp;we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in the previous three-year period or (iii)&nbsp;we become a &#147;large accelerated filer&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act), we will cease to be an emerging growth company prior to the end of such five-year period. We will be deemed to be a &#147;large
accelerated filer&#148; at such time that we (a)&nbsp;have an aggregate worldwide market value of common equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700.0&nbsp;million or more as of the last business day of
our most recently completed second fiscal quarter, (b)&nbsp;have been required to file annual and quarterly reports under the Exchange Act, for a period of at least 12 months and (c)&nbsp;have filed at least one annual report pursuant to the
Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which
this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting
companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an
extended transition period for complying with new or revised accounting standards. We have elected not to &#147;opt out&#148; of the exemption for the delayed adoption of certain accounting standards, and, therefore, we will adopt new or revised
accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined under the Securities Act and Exchange Act. We may continue to be a smaller
reporting company so long as either (i)&nbsp;the market value of shares of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million
during the most recently completed fiscal year and the market value of shares of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company at the time we
cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two
most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies,
if we are a smaller reporting company under the requirements of (ii)&nbsp;above, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of Delaware in February 2010 under the name Sight Sciences, Inc. Our principal executive offices are located at 4040 Campbell Ave, Suite 100, Menlo Park CA 94025 and our telephone number is (877) <FONT
STYLE="white-space:nowrap">266-1144.</FONT> Our website address is <I>www.sightsciences.com</I>. The information contained in, or accessible through, our website is not incorporated by reference into this prospectus, and you should not consider
information on our website to be part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock at
the public offering price, less estimated underwriting discounts and commissions. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase
additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase additional shares of common stock), at an assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts
and commissions and the estimated offering expenses payable by us. We anticipate that we will use the net proceeds of this offering to fund ongoing and future clinical trials for OMNI and TearCare, to support the marketing and sales efforts for our
products, for research and development and for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; beginning on page&nbsp;86 for additional information. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; beginning on page 15 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of
shares of our common stock to be outstanding after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the exercise of stock options outstanding under our 2011 Stock Incentive Plan, or our Existing Plan, as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, at a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares
of our common stock reserved for future issuance under our 2021 Incentive Award Plan, referred to as our 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our
common stock reserved for future issuance under our 2021 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock that will become available for future issuance under our 2021 Employee Stock Purchase Plan, or the 2021 ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of
our common stock reserved for future issuance under our 2021 ESPP; and </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon the
exercise of warrants outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which warrants shall not expire upon the closing of this offering if not exercised. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT> stock split of our common stock, which will become effective prior to the effectiveness of the registration
statement of which this prospectus forms a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The automatic conversion of all outstanding shares of our Series A, Series B, Series C, Series D, Series E and
Series F redeemable convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The automatic conversion of outstanding warrants to purchase shares of our redeemable convertible preferred stock
into warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No exercise of outstanding options or warrants after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No exercise by the underwriters of their option to purchase additional shares of our common stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The filing and effectiveness of our restated certificate of incorporation and the adoption of our amended and
restated bylaws, each of which will occur upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Financial and Other Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth our summary consolidated financial data as of, and for the periods ended on, the dates indicated. We have
derived the consolidated statements of operations and comprehensive loss data for the years ended December&nbsp;31, 2018, 2019 and 2020 from our audited consolidated financial statements included elsewhere in this prospectus. We have derived the
consolidated balance sheet data as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 from our unaudited consolidated financial statements included elsewhere in this prospectus. We have prepared
the unaudited consolidated financial information set forth below on the same basis as our audited consolidated financial statements and have included all adjustments, consisting only of normal recurring adjustments, that we consider necessary for a
fair presentation of our financial position and results of operations as of the applicable dates and for the applicable periods. Our historical results are not necessarily indicative of the results that should be expected for any future period. You
should read the following summary financial and other data set forth below together with the more detailed information contained in &#147;Selected Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>in thousands, except share data</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations and Comprehensive Loss Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 23,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 27,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and
administrative<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share outstanding attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding used in computing net loss per share attributable to
common stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,611,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,693,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,678,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share outstanding, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding used in computing net loss per share
attributable to common stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes stock-based compensation as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the statements of operations and Note 13 to our consolidated financial statements included elsewhere in
this prospectus for an explanation of the method used to compute the historical net loss per share and pro forma net loss per share and the number of shares used in the computation of the per share amounts for the years ended December&nbsp;31, 2018,
2019 and 2020. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Consolidated Balance Sheet Data</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B><br><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<B><SUP STYLE="font-size:85%; vertical-align:top">(</SUP></B><SUP
STYLE="font-size:85%; vertical-align:top">1</SUP><B><SUP STYLE="font-size:85%; vertical-align:top">)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working capital is defined as total current assets less total current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma consolidated balance sheet data gives effect to (i)&nbsp;the automatic conversion of all of our
outstanding shares of redeemable convertible preferred stock into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which will occur upon the closing of this offering,
(ii)&nbsp;the automatic conversion of outstanding warrants to purchase shares of our redeemable convertible preferred stock into warrants to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock, and the related reclassification of redeemable convertible preferred stock warrant liability to additional paid in capital and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of
incorporation upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as consolidated adjusted balance sheet data gives further effect to the issuance and sale by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the
price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted consolidated balance sheet data is illustrative only and will change based on the actual initial public offering
price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, working capital, total assets, additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital and total stockholders&#146; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares of
common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
(decrease) of 1.0&nbsp;million shares in the number of shares of common stock offered by us would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, working capital, total assets, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, and total stockholders&#146; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
together with all of the other information in this prospectus, including the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the accompanying
notes thereto included elsewhere in this prospectus, before investing in our common stock. Many of the risks and uncertainties are, and will be, exacerbated by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and any worsening of the
global business and economic environment as a result. The risks and uncertainties described below are not the only ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors
that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects, as well as our
ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an
early-stage company with a history of significant losses, we expect to incur losses in the future and we may not be able to achieve or sustain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred annual net losses since our formation in 2010. For the years ended December&nbsp;31, 2018, 2019 and 2020, we had net losses of
$14.3&nbsp;million, $28.9&nbsp;million and $34.4&nbsp;million, respectively. As of December&nbsp;31, 2020, we had an accumulated deficit of $89.8&nbsp;million. To date, we have financed our operations primarily through equity and debt financings and
from sales of our products, the OMNI Surgical System, or OMNI, a device that enables canaloplasty followed by trabeculotomy for the reduction of intraocular pressure in adult patients with primary open-angle glaucoma, or POAG, and our TearCare
System, or TearCare, to apply localized heat where the medical community recommends the application of warm compress to the eyelids, as well as predicates to OMNI. The losses and accumulated deficit have primarily been due to the substantial
investments we have made to develop our products, costs related to our sales and marketing efforts, general research and development expenses, including costs related to clinical trials and regulatory initiatives to obtain marketing clearance, and
infrastructure improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a public company, we will incur significant legal, accounting and other expenses that we did
not incur as a private company. Accordingly, we expect to continue to incur losses for the foreseeable future and we cannot assure you that we will ever achieve profitability or that, if we do become profitable, we will sustain profitability. Our
failure to achieve and sustain profitability in the future would make it more difficult to finance our business and accomplish our strategic objectives, which would have a material adverse effect on our business, financial condition and results of
operations. In addition, failure of our products to significantly penetrate our target markets would negatively affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our revenue has been primarily generated from the sales of our products and is expected to continue to be so generated for the near future, and we are
therefore highly dependent on the success of those products, and particularly on OMNI. We have limited commercial sales experience regarding our products, which makes it difficult to evaluate our current business, predict our future prospects and
forecast our financial performance and growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began selling VISCO360 and TRAB360, commercial predicate devices to OMNI, in
2015 and TearCare in 2019 and therefore do not have a long history operating as a commercial company. Currently, we are highly dependent on the success of OMNI and TearCare. To date, our revenue has primarily been derived, and we expect it to
continue to be substantially derived in the near future, from sales of our Surgical Glaucoma and Dry Eye products. We are particularly dependent on the success of OMNI, which accounted for 94% of our total revenues for the year ended
December&nbsp;31, 2020. Because we devote substantially all of our resources to these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products and rely on them as our sole source of revenue, any factors that negatively impact our products, and particularly OMNI, or result in a decrease in sales, could have a material adverse
effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the next several years, we expect to continue to devote a
substantial amount of resources to expand our commercialization efforts, drive increased adoption of our products and continue to develop new and improved products. Our limited commercialization experience and limited number of <FONT
STYLE="white-space:nowrap">FDA-cleared</FONT> products make it difficult to evaluate our current business and predict our future prospects. These factors also make it difficult for us to forecast our future financial performance and growth, and such
forecasts are subject to a number of uncertainties, including our ability to successfully complete preclinical studies and clinical trials and obtain FDA <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance for our current products and for
future planned products or changes to existing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ophthalmologist and optometrist (together, eyecare professionals or ECPs)
awareness of, and experience with, our products is currently limited. As a result, our products have limited product and brand recognition within the ophthalmic industry. The novelty of our products, together with our limited commercialization
experience, makes it difficult to evaluate our current business and predict our future prospects. A number of factors, including some outside of our control, may contribute to fluctuations in our financial results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ECP and patient demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to obtain and maintain reimbursement coverage for procedures in which our products are used;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in reimbursement rates by government or commercial payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The results of our clinical trials or investigations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive or negative media coverage, or public, patient and/or physician perception, of our products or competing
products and treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any safety or effectiveness concerns that arise regarding our products for either their currently authorized uses
or the uses for which we are developing our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The effectiveness of our marketing and sales efforts, including our ability to have a sufficient number of
qualified sales representatives to sell our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unanticipated delays in product development or product launches; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to raise additional capital on acceptable terms, or at all, if needed to support the
commercialization of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to achieve and maintain compliance with all regulatory requirements applicable to our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to obtain, maintain, protect and enforce our intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability of patients to access elective procedures at facilities that utilize our products because of the
novel strain of coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and related government restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our third-party manufacturers&#146; ability to supply our products in a timely manner, in accordance with our
specifications, and in compliance with applicable regulatory requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Introduction of new products or alternative treatments that compete with our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is therefore difficult to predict our future financial performance and growth, and such forecasts are inherently limited and subject to a
number of uncertainties. If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks
successfully, our operating and financial results could differ materially from our expectations and our business could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is dependent upon the broad adoption of our products by ECPs and patients. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth and profitability largely depend on our ability to increase ECP and patient awareness of our products and on the willingness
of ECPs and patients to adopt our products. ECPs may not adopt our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our products are clinically differentiated
from, or otherwise preferable to, available alternatives. Even if we are able to raise awareness among ECPs, they may be slow to change their medical treatment practices and may be hesitant to select our products for a variety of reasons, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lack of experience with our products and concerns that we are relatively new to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Perceived liability risk generally associated with the use of new products and treatment options;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lack, or perceived lack, of sufficient clinical evidence, including long-term data, supporting clinical benefits
or the cost-effectiveness of our products over existing treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The failure of key opinion leaders to provide recommendations regarding our products, or to assure physicians,
patients and healthcare payors of the benefits of our products as an attractive alternative to other treatment options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Perceptions that our products are unproven; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Long-standing relationships with companies, distributors and salespeople that sell competing products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our inability to strengthen and maintain relationships with ECPs and other industry professionals and
organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lack of availability of adequate third-party payor coverage or reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Competitive response and negative selling efforts from providers of alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Challenges of integrating TearCare into established ophthalmologic and optometric practices; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Perceptions regarding the time commitment and skill development that may be required to gain familiarity and
proficiency with our products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To effectively market and sell our products, we will need to continue to educate the
medical community about the safety, efficacy, necessity and efficiency of our products and about the patient populations that would potentially benefit from the use of our products. We focus our sales, marketing and education efforts primarily on
our target ECP providers, ambulatory surgery centers, hospital outpatient departments and potential patient populations. However, we cannot assure you that we will achieve broad education or market acceptance. For example, if first-line ECPs or
primary care physicians that serve as the early point of contact for patients are not made aware of our OMNI products, they may not refer patients to ECPs who utilize our products, and those patients may be treated with alternative procedures or
treatments. In addition, some physicians may choose to utilize our products on only a subset of their total patient population or may not adopt our products at all. If we are not able to effectively demonstrate that our products are beneficial for a
broad range of patients, adoption of our products will be limited and may not occur as rapidly as we anticipate or at all, which would have a material adverse effect on our business, financial condition and results of operations. Further, if we are
unable to obtain or maintain favorable third-party reimbursement coverage of procedures in which our OMNI product is used, or if we are unable to obtain favorable reimbursement for procedures in which TearCare is used, adoption of our products by
ECPs and patients will suffer. We cannot assure you that our products will achieve broad market acceptance among payors, physicians and patients. Any failure of our products to satisfy demand or to achieve meaningful market acceptance and
penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adoption of OMNI and TearCare depends upon appropriate physician training, practice and patient selection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our products depends in part on the skill of the ECPs utilizing and administering products to treat patients and on their
adherence to our stated patient selection criteria and the proper techniques that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide in training sessions. We train ECPs on the correct use of OMNI. However, ECPs rely on their previous medical training and experience when performing ophthalmic surgical procedures and may
deviate from the techniques we provide in training sessions. Furthermore, we cannot guarantee that all such ECPs who use OMNI will have the necessary skills or experience to safely and effectively perform these procedures. Similarly, though we train
ECPs to ensure correct use of TearCare, including placement of TearCare SmartLids on patients&#146; eyelids, we cannot guarantee that all such ECPs will have the necessary skills or experience to safely and effectively use these devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not control which physicians utilize these medical devices in their treatments or how much training they receive, and physicians who
have not completed our training sessions may nonetheless attempt to use OMNI as part of an ophthalmic surgical procedure or use TearCare to apply localized heat. In addition, a perception by physicians that OMNI or TearCare are difficult to use may
negatively impact adoption by ECPs. If ECPs utilize these devices in a manner that is inconsistent with our labeled indications or with components that are not part of our products, such as viscoelastic fluid that is incompatible with OMNI or
without adhering to or completing our training sessions, the patient outcomes may be negative. This could negatively impact the perception of patient benefits and safety associated with OMNI and TearCare and limit adoption of our devices, which
would have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development of TearCare for expanded
indications depends upon positive clinical data, and the safety and efficacy of the product for the intended uses for which we are seeking clearance, certification or approval are not yet supported by long-term clinical data, which could delay or
prevent clearance by the FDA (or other foreign authorities) or limit sales if cleared, certified or approved and our products might therefore prove to be less safe or effective than initially thought. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing TearCare for expanded indications for which we are seeking clearance by the FDA, including for the application of localized
heat therapy in adult patients with evaporative DED due to MGD, when used in conjunction with pressure to the eyelids to express the meibomian glands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting and intend to continue conducting additional clinical trials or investigations to develop our devices for expanded
indications. Historical clinical results, including interim results, are not necessarily predictive of future clinical results, and we cannot assure you that the results reported in these studies will be consistent with, or better than, currently
available clinical data. Moreover, the outcomes and updates resulting from these studies, including interim results, may be compared to the results of other products and treatments for POAG or MGD, and if the comparisons are not favorable, it may
limit the ability to obtain clearance, certification or approval of the devices for the expanded indications for which we are seeking clearance, certification or approval, as well as adoption of our products for their current authorized uses. In
addition, our competitors and other third parties may also conduct clinical trials or investigations of our products without our participation. Unfavorable or inconsistent clinical data from existing or future clinical trials or investigations
conducted by us, our competitors or other third parties, the interpretation of our clinical data or findings of new or more frequent adverse events, could subject us to mandatory or voluntary product recalls, suspension or withdrawal of FDA or other
clearance, certification or approval, significant legal liability or harm to our business reputation and could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products will be adopted and compete, in part, based on long-term data regarding patient outcomes and the risk of our products relative to
other treatment options. The long-term clinical outcomes of the use of OMNI for its cleared uses are not known and, due to the novelty of our products, there is no <FONT STYLE="white-space:nowrap">long-term</FONT> data regarding patient outcomes
beyond our clinical trials or investigations. The results of short-term clinical experience of our products do not necessarily predict long-term clinical outcomes. We believe that ECPs will compare the rates of long-term clinical outcomes for
procedures using our products for their authorized uses against alternative procedures and treatment options. If the long-term data does not meet ECPs&#146; expectations, or if the long-term data indicates that our products are not as safe or
effective as other treatment options or as current short-term data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would suggest, physicians may recommend alternative treatments for their patients and our products may not become widely adopted, which will negatively affect our business, financial condition
and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The safety and efficacy of some of our products is not yet supported by long-term clinical data, which could limit
sales, and our products might therefore prove to be less safe or effective than initially thought. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The products that we market in
the United States are regulated as medical devices by the FDA. OMNI has received premarket clearance under Section&nbsp;510(k) of the Federal Food, Drug, and Cosmetic Act, or the FDCA. In the 510(k) clearance process, before a device may be marketed
the FDA must determine that a proposed device is &#147;substantially equivalent&#148; to a legally-marketed &#147;predicate&#148; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally
marketed prior to May&nbsp;28, 1976 (preamendments device), a device that was originally on the U.S. market pursuant to an approved PMA application and later down-classified, or a 510(k)-exempt device. This process is typically shorter and generally
requires the submission of less supporting documentation than the FDA&#146;s PMA process and does not always require long-term clinical studies. TearCare is currently marketed as a 510(k)-exempt device, and did not undergo premarket clearance prior
to marketing. We are developing TearCare for use in, and seeking FDA clearance for, the application of localized heat therapy in adult patients with evaporative DED due to MGD, when used in conjunction with pressure to the eyelids to express the
meibomian glands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA, manufacturers of medical devices are required by the Medical Devices Directive
to collect post-marketing clinical data in relation to their CE marked medical devices. Post-market surveillance includes the conduct of post-market clinical <FONT STYLE="white-space:nowrap">follow-up</FONT> studies permitting manufacturers to
gather information concerning quality, safety or performance of medical devices after they have been placed on the market in the EU. All information collected as part of the post-market surveillance process must be reviewed, investigated and
analyzed on a regular basis in order to determine whether trending conclusions can be made concerning the safety or performance of the medical device and decisions must be taken in relation to the continued marketing of medical devices currently on
the market. We expect to incur ongoing costs to comply with these post-market clinical obligations in EEA markets for so long as we continue to market and sell products in those markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting and intend to continue conducting additional clinical trials, including clinical trials to develop TearCare for an expanded
indication. In addition, our competitors and other third parties may also conduct clinical trials of our products without our participation. If future patient studies or clinical testing do not support our belief that our products are advantageous
for their intended uses, market acceptance of our products could to increase or could decrease and our business could be harmed. Moreover, if future results and experience by us, our competitors or other third parties, indicated that our products
cause unexpected or serious complications or other unforeseen negative effects, we could be subject to mandatory or voluntary product recalls, suspension or withdrawal of FDA or other governmental clearance or approval or CE Certificates of
Conformity, significant legal liability or harm to our business reputation, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that ECPs will compare the rates of long-term clinical outcomes for procedures using our products for their authorized uses against
alternative procedures and treatment options. If we choose to, or are required to, conduct additional studies, such studies or experience could reduce the rate of coverage and reimbursement by both public and private third-party payors for
procedures that are performed with our products, slow market adoption of our products by ECPs, significantly reduce our ability to achieve expected revenues and prevent us from being profitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in training on, and marketing and selling, our products and we may provide
inadequate training, fail to increase our sales and marketing capabilities or fail to develop broad brand awareness in a cost-effective manner. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience marketing and selling our products. In the United States, we currently rely on our direct sales force and, in
certain targeted geographic regions or customer verticals, independent sales representatives and distributors, and any failure to maintain and grow our sales force could harm our business. In Europe, we currently rely on a combination of direct
sales personnel and independent distributors to sell our products, and we intend to grow our international sales through a combination of direct and distributor sales. If we are unable to identify and retain productive direct sales representatives
and distributors in the international territories and jurisdictions that we have targeted for commercial expansion, we may not be able to achieve projected revenue goals and our business could suffer. Our sales representatives are trained and
possess product specific sales expertise, which we believe is critical in driving the awareness and adoption of our products. The members of our U.S. sales force are <FONT STYLE="white-space:nowrap">at-will</FONT> employees. The loss of these
personnel to competitors, or otherwise, could materially harm our business. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent expertise and qualifications, or if we are unable to successfully
instill such expertise in replacement personnel, our business, financial condition and results of operations could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to generate future growth, we plan to continue to significantly expand and leverage our commercial infrastructure to increase our
customer base and increase adoption by existing customers to drive our growth. Identifying and recruiting qualified sales and marketing professionals and training them on our products, on applicable federal and state laws and regulations and on our
internal policies and procedures requires significant time, expense and attention. It can take several months or more before a sales representative or distributor representative is fully trained and productive. Our direct sales force may subject us
to higher fixed costs than those of companies with competing products or treatments that rely more heavily on independent third parties, placing us at a competitive disadvantage. Our business may be harmed if our efforts to expand and train our
sales force and distribution chain do not generate a corresponding increase in product sales and revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products. Any failure to
hire, develop and retain effective sales personnel, to identify and train distributors and independent sales representatives in targeted international territories, to achieve desired productivity levels in a reasonable period of time or timely
reduce fixed costs, could have material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to
increase our customer base and achieve broader market acceptance of our products will depend, to a significant extent, on our ability to expand our sales and marketing and educational efforts. We plan to dedicate significant resources to our sales
and marketing initiatives, and educational programs through leading medical publications and at large industry and scientific meetings, both directly and through key opinion leaders. Our business may be harmed if these efforts and expenditures do
not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our brand in a cost-effective manner is critical to achieving broad acceptance of our products and reaching new ECPs and
patients. Brand promotion activities may not impact ECP or patient awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote,
maintain and protect our brand, we may fail to attract or retain the market acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is an important factor for the broad
adoption of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products are designed to be used in a limited number of procedures, and there is a limited total addressable market
for our products. The sizes of the potential and actual markets for our current products have not been established with precision and may be smaller than we estimate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently market our OMNI device for use in the U.S. and select European geographies for canaloplasty followed by trabeculotomy to reduce
intraocular pressure in adult patients with POAG. POAG, is the most </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prevalent form of glaucoma and affects 4.1&nbsp;million people in the United States and over 60&nbsp;million people worldwide. We currently market TearCare as a 510(k) powered heating pad for the
delivery of localized heat where the current medical community recommends application of a warm compress, and are seeking FDA clearance of TearCare for the application of localized heat therapy in adult patients with evaporative DED due to MGD, when
used in conjunction with pressure to the eyelids to express the meibomian glands. There are an estimated 739 million people globally and 38 million people in the U.S. who suffer from DED. DED is the most common reason for a patient visit to an eye
doctor, yet of the 38 million people with DED in the U.S., only 17 million have been diagnosed with DED. Studies have shown that evaporative DED resulting from MGD is associated with approximately 86% of all DED cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total addressable markets for our products are subject to change and, even assuming TearCare were cleared for the application of localized
heat therapy in adult patients with evaporative DED due to MGD, when used in conjunction with pressure to the eyelids to express the meibomian glands, may be further limited by FDA restrictions or more narrowly defined indications, any of which
could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our estimates of the total
addressable markets for our products are based on a number of internal and third-party estimates, including, without limitation, the number of patients with POAG and, if TearCare is cleared for such use, MGD, and the assumed prices at which we can
sell our products in markets that have not yet been fully established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our
assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current products may prove to be incorrect. If the
actual number of patients who would benefit from our products or the price at which we can sell our products is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations and financial results have been, and will continue to be, adversely impacted by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in the United States and the rest of the world.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT>
was identified in Wuhan, China. Since then, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> and the resulting disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> has spread worldwide. In response to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, numerous state and local jurisdictions have imposed, and others in the future may impose,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders, quarantines, executive orders and similar government orders and restrictions for their residents. Such orders or restrictions have
resulted in work stoppages, slowdowns and delays, travel restrictions and cancellation of events. Disruptions or potential disruptions to our business from <FONT STYLE="white-space:nowrap">COVID-19</FONT> or a future pandemic could include the
inability of our component suppliers and manufacturers to produce our products, components, accessories on a timely basis, or at all; disruptions in our logistics and distribution providers to deliver our products to customers on a timely basis, or
at all; inventory shortages or obsolescence; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business; delays in growing or reductions in our sales organization, including through delays in
hiring, <FONT STYLE="white-space:nowrap">lay-offs,</FONT> furloughs or other losses of sales representatives; limitations on the ability of our sales representatives and distributors to reach potential customers and reduced opportunities for market
education; business adjustments or disruptions of certain third parties, including suppliers and customers; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#146; capacity to
manufacture our products. For example, as a result of restrictions related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic our sales representatives have been curtailed in their ability to conduct
<FONT STYLE="white-space:nowrap">in-person</FONT> meetings and demonstrations, and our market education and training efforts have been limited. We may also experience delays in initiating or completing any clinical trials or investigations that we
intend to conduct or are conducting, and we do not know whether our clinical trials or investigations will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We experienced a significant decrease in our revenues for both of our products in the second
quarter of 2020 as compared to the first quarter of 2020. As elective eye care procedures in many facilities that utilize OMNI and TearCare were temporarily suspended by governmental authorities, many patients avoided visiting ECPs, and, even in
areas that allowed elective procedures, ECPs and healthcare facilities in general severely cut back on the scheduling and performance of such procedures. We felt the decrease in demand due to <FONT STYLE="white-space:nowrap">COVID-19</FONT> most
significantly in the latter part of the quarter ended March&nbsp;31, 2020 and the first half of the quarter ended June&nbsp;30, 2020. Beginning in June 2020, we began to see an increase in the number of procedures using our products. In the first
quarter of 2021, our customers experienced a significant number of procedure cancellations which we believe was largely driven by patients postponing procedures until their <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccinations were completed
as opposed to any restrictions imposed on elective procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
any new variants of the virus, the nature, extent and effectiveness of containment and treatment measures, the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the potential economic impact brought by and the duration of any pandemic, epidemic or outbreak of an infectious disease, including
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> may be difficult to assess or predict, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in, and may continue to result in, significant disruption of global financial
markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> could materially affect our business. Such economic recession could have a material adverse effect on our long-term business as hospitals and surgical centers curtail and reduce capital and overall
spending. In addition, the current economic downturn is resulting in significant job losses and reductions in disposable income and if patients are unable to obtain or maintain health insurance policies, this may significantly impact their ability
to pay for the procedures utilizing our products, further negatively impacting our business, financial condition and results of operations. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business
and financial results, it may also have the effect of heightening many of the other risks described in this &#147;Risk Factors&#148; section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may not be able to maintain adequate levels of third-party coverage and reimbursement for procedures in which OMNI is used, and third parties may rescind or modify their coverage or delay payments related to OMNI. We may not be able to secure any,
or adequate levels of, third-party coverage and reimbursement for procedures in which TearCare is used, and even if third parties provide coverage they may rescind or modify their coverage or delay payments related to TearCare. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive revenue from sales of OMNI to physicians, ambulatory surgery centers and hospital outpatient departments, which typically bill all or
a portion of the costs and fees associated with our products to various third-party payors, including Medicare, Medicaid, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations, and then
bill patients for any applicable deductibles or <FONT STYLE="white-space:nowrap">co-payments.</FONT> As a result, access to adequate coverage and reimbursement for procedures in which OMNI is used by third-party payors is essential to its acceptance
and adoption by patients and ECPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also derive revenue from sales of TearCare to ECPs and eye care clinics, which also bill all or a
portion of the costs and fees associated with treatments and products to patients or, on a limited basis, to third-party payors. We believe that access to adequate coverage and reimbursement for procedures in which TearCare is used by third-party
payors is important to the broad acceptance and adoption of TearCare. Currently, however, no payors have formal policies establishing coverage for the procedures in which TearCare is used. We are pursuing a comprehensive long-term market development
and patient access plan for TearCare and focusing our efforts on partnering with key strategic accounts to pursue prior authorization approvals and reimbursement claims for procedures in which TearCare is used, but there is no guarantee that we will
be successful. If patients are not willing to pay for procedures in which TearCare is used, or if third-party payors continue to refuse to provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage and reimbursement or provide insufficient levels of coverage and reimbursement, it could have a negative impact on ECPs&#146; adoption of TearCare and sales of TearCare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement by governmental and third-party payors may depend upon a number of factors, including the determination that the
product or service and its use or administration for a particular patient is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A covered benefit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Supported by clinical data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Supported by guidelines established by the relevant professional societies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of
controlling healthcare costs. In addition, no uniform policy of coverage and reimbursement for procedures using our products exists among third-party payors. Therefore, coverage and reimbursement for procedures using our products can differ
significantly from payor to payor. Obtaining and maintaining coverage and reimbursement can be a time-consuming process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products. We may
not be able to provide data sufficient to satisfy governmental and third-party payors that procedures using our products should be covered and reimbursed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the American Medical Association, or AMA, generally assigns specific billing codes for procedures under a coding system
known as Current Procedure Terminology, or CPT, which surgeons use to bill third-party payors and receive reimbursement. Once a permanent (Category I) CPT code is established for a service, the Centers for Medicare&nbsp;&amp; Medicaid Services, or
CMS, establishes payment levels under Medicare, while other payors may establish rates and coverage rules independently. Canaloplasty followed by trabeculotomy procedures using OMNI are typically billed using the Category I CPT code 66174, which
describes canaloplasty. Coding for ophthalmic surgical procedures is complex, and changes to the codes used to report services performed with our products may result in significant changes in reimbursement, which could negatively impact our revenue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AMA maintains a subset of temporary (Category III) CPT codes used for new and emerging technologies. For example, TearCare was
assigned a Category III CPT code effective beginning January&nbsp;1, 2020. Coverage for Category III CPT codes is often limited. Medicare does not generally establish national payment rates for Category III CPT codes on the Medicare Physician Fee
Schedule, or MPFS. As a result, individual Medicare contractors and private payors may establish their own payment rates for services described by Category III CPT codes, which payment rates may be materially below the final reimbursement rates that
we are currently targeting, or may determine not to reimburse services described by Category III CPT codes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payors also continually
review new and existing technologies for possible coverage and can deny or reverse coverage for new or existing products and procedures. There can be no assurance that third-party payor policies provide coverage, or will continue to provide
coverage, for procedures in which OMNI is used. If coverage policies change such that Medicare no longer covers procedures in which our products are used, there would be a material adverse effect on our business, financial condition and results of
operations. For example, Medicare Administrative Contractors could issue local coverage determinations that could restrict the patients eligible for treatment with our products or that are otherwise unfavorable to our business. If we are not
successful in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reversing any proposed <FONT STYLE="white-space:nowrap">non-coverage</FONT> policies, or if third-party payors that currently cover or reimburse procedures in which our products are used reverse
or limit their coverage in the future, or if other third-party payors issue similar policies, this could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we believe that future coverage and reimbursement may be subject to increased restrictions, such as additional prior authorization
requirements, both in the United States and in international markets. Third-party coverage and reimbursement for procedures using our products or any of our products in development for which we may receive regulatory clearance, certification or
approval may not be available or adequate in either the United States or international markets. Further, other devices or treatments that compete with our products may be more widely covered or subject to different
<FONT STYLE="white-space:nowrap">co-pay</FONT> policies and requirements, which could impact demand for our products. If hospital, surgical center, ECP and/or patient demand for our products is adversely affected by third-party reimbursement
policies and decisions, it could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market for our
products is highly competitive. Our competitors may have longer operating histories, more established products and greater resources than we do, and may be able to develop or market treatments that are safer, more effective or gain greater
acceptance in the marketplace than our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device industry is highly competitive, subject to rapid change and
significantly affected by the introduction of new products and technologies and the other activities of industry participants. We compete, or plan to compete, with medical device and pharmaceutical companies that develop and commercialize products
for eye conditions, including Glaukos, Ivantis, AbbVie/Allergan, Novartis, Alcon, and Johnson&nbsp;&amp; Johnson. These companies, or other entrants into the market, may have or develop competing technologies, other products that are in or that
enter clinical trials, new devices or additional indications for existing devices that could demonstrate better safety, effectiveness, clinical results, lower costs or greater ECP and market acceptance than our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete, or may compete in the future, against other companies which have longer, more established operating histories and significantly
greater financial, technical, marketing, sales, distribution and other resources, which may prevent us from achieving significant market penetration or improved operating results. These companies may enjoy several competitive advantages, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established treatment patterns pursuant to which prescription medications, traditional glaucoma surgery or more
conventional MIGS devices are generally first-line therapies for the treatment of POAG and eye drops or warm-compresses are first-line therapies for the treatment of MGD; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established relationships with ECPs who are familiar with their products and procedures for the treatment of POAG
or MGD; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established relationships with key stakeholders, including hospital outpatient departments, ambulatory surgery
centers, optometrists and ophthalmologists, general practitioners and administrators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Greater financial and human capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Significantly greater name recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional lines of products, and the ability to offer rebates or bundle products to offer greater discounts or
incentives to gain a competitive advantage; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established sales, marketing and worldwide distribution networks. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the major hurdles to adoption of our products will be overcoming established treatment patterns, which will require educating ECPs and
supportive clinical data. However, because of the size of the market opportunity for devices used in procedures to address POAG and MGD, we believe current and potential future competitors will dedicate significant resources to aggressively promote
their products or develop new products or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatments, such as Glaukos&#146; iStent infinite. Further, new treatment options may be developed that could compete more effectively with our products due to the prevalence of POAG and MGD, and
the research and technological progress that exist within the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to manufacture and supply OMNI and TearCare, and we
may encounter delays or incur additional costs when we add new manufacturers and suppliers for our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business strategy
depends on our ability to manufacture our current and future products in sufficient quantities and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements and
managing manufacturing costs. We do not have any internal manufacturing capabilities or infrastructure. OMNI is currently being produced and assembled by Second Source Medical LLC and Peter&#146;s Technology (Suzhou) CO LTD., or Peter&#146;s, a
subsidiary of Peter&#146;s Co., Ltd., a Taiwan-based manufacturer. We intend to fully transition OMNI production to Peter&#146;s and an additional high-volume contract manufacturer with domestic U.S. production facilities by the end of the third
quarter of 2021. The Peter&#146;s Supply Agreement governs the assembly and supply of OMNI, pursuant to which Peter&#146;s purchases components from our approved suppliers for assembly and we make purchases on a purchase order basis. We may
encounter delays or incur additional costs in connection with the transition to a new contract manufacturer with domestic U.S. production facilities for OMNI production. For the production of TearCare, we currently have supply arrangements with
separate U.S. medical device manufacturers for the production of each of TearCare&#146;s SmartLids and TearCare&#146;s SmartHubs. These companies manufacture, assemble, inspect, test, package and ship OMNI and TearCare and related accessories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our existing manufacturers have generally met our demand requirements on a timely basis in the past, their ability and willingness to
continue to do so going forward may be limited for several reasons, including if any of our manufacturers&#146; facilities suffer damage or a force majeure event, our relative importance as a customer to each manufacturer or their inability to
provide assembly services to manufacture our products, which may be affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. An interruption in our commercial operations could occur if we encounter delays or difficulties in
securing these manufactured products if we cannot obtain an acceptable substitute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of identifying alternative manufacturing
facilities for any other reason could be time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance specifications of our products. If we are required to change any of our contract
manufacturers, we will be required to verify that the new manufacturer maintains facilities, procedures and operations that comply with our quality and applicable regulatory requirements, which could further impede our ability to manufacture our
products in a timely manner. We cannot assure you that we will be able to identify and engage alternative contract manufacturers on similar terms or without delay. Furthermore, our contract manufacturers could require us to move to a different
production facility. The occurrence of any of these events could harm our ability to meet the demand for our products in a timely and cost-effective manner, which could have a material adverse effect on our business, financial condition and results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to numerous other risks relating to our reliance on third parties, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inability to renew or extend contracts and arrangements with such third parties or renew any such contracts or
arrangements on terms that are favorable to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interruption of supply resulting from modifications to, or discontinuation of, a third-party&#146;s operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays in shipments resulting from uncorrected defects, reliability issues or a third-party&#146;s failure to
manufacture and supply components, accessories and materials that consistently meet our agreed specifications and quality requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inability to obtain adequate supply or services in a timely manner or on commercially reasonable terms;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternative suppliers for our
products and product components in a timely manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inability to design or modify production processes to enable us to produce future products efficiently or
implement changes in current products in response to design or regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inability to comply with applicable provisions of the FDA&#146;s Quality System Regulation, or QSR, or other
applicable laws or regulations enforced by the FDA, state and foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inability to ensure the quality of products and components manufactured by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Failure to timely increase production capacity or volumes to meet demand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Production delays related to the evaluation and testing of products and components from alternative third parties
and corresponding regulatory qualifications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An outbreak of disease or similar public health threat, such as the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, particularly as it may impact our supply chain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Long lead time for the production of certain components of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Price fluctuations due to a lack of long-term supply arrangements with certain of our suppliers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk of delays or interruption stemming from trade wars; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General delays in delivery by our suppliers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes. As demand for our
products increases, we will have to invest additional resources to manage the manufacturing process. If we fail to secure increased production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not
increase in line with our expectations and our operating margins could fluctuate or decline. In addition, although some future products may share product features, components, <FONT STYLE="white-space:nowrap">sub-assemblies</FONT> and materials with
our existing products, the manufacture of these products may require modification of the current production processes or unique production processes, the identification of new suppliers for specific components, sub-assemblies and materials or the
development of new manufacturing technologies. It may not be possible for our current third-party manufacturers to produce these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current
operating margins, all of which could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on a
limited number of single source suppliers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a limited number of third-party manufacturers, many of which are single
source suppliers, for a portion of the components, accessories and materials that we utilize in our products. These items are critical and, for certain items, there are relatively few or no readily available alternative sources of supply. These
single source suppliers may be unwilling or unable to supply these items reliably and at the levels we anticipate or that are required by the market. Additionally, although we require our suppliers and providers to supply us with components and
services that meet our specifications and other applicable legal and regulatory requirements in our agreements and contracts, and appropriate inspections, testing or other acceptance activities are performed to ensure the components meet our
requirements, there is a risk that these third parties will not always act consistent with our best interests, and may not always supply components or provide services that meet our requirements or in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our suppliers have generally met our demand requirements on a timely basis in the past, we cannot guarantee that suppliers will in the
future be able to meet our demand, either because of acts of nature, global pandemics, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the nature of our agreements with those suppliers or our relative importance to them as a
customer, and our suppliers may decide in the future to discontinue or reduce the level of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business they conduct with us. We may also fail to obtain additional suppliers for any of the components used in our products. If we are unable to meet our demand requirements on a timely basis,
we may not have a sufficient number of our products available for delivery to support ECPs that utilize our products as part of their treatment. Any shortfall in the supply of products may result in lower adoption and usage rates of our products and
have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The failure of third parties to meet their
contractual, regulatory, and other obligations could adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on suppliers, vendors, outsourcing
partners, consultants, alliance partners and other third parties to help research, develop, manufacture, commercialize and distribute our products and manage certain parts of our business. Using these third parties poses a number of risks, such as:
(i)&nbsp;they may not perform to our standards or legal requirements; (ii)&nbsp;they may not produce reliable results; (iii)&nbsp;they may not perform in a timely manner; (iv)&nbsp;they may not maintain confidentiality of our proprietary
information; (v)&nbsp;disputes may arise with respect to ownership of rights to technology developed with our partners; and (vi)&nbsp;disagreements could cause delays in, or termination of, the research, development or commercialization of our
products or result in litigation or arbitration. Moreover, some third parties are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy and data
security risk given current legal and regulatory environments. Failure of third parties to meet their contractual, regulatory, and other obligations may materially adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The failure of OMNI or TearCare to meet patient expectations or the occurrence of adverse events from use of OMNI or TearCare could limit their adoption
and impair our financial performance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends in part upon patients having an experience with our products that
meets their expectations in order to increase ECPs&#146; demand for our products as a result of positive feedback, social media and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">word-of-mouth.</FONT></FONT> Patients may be
dissatisfied if their expectations of the procedures performed by ECPs using our products, among other things, are not met. Despite what we believe to be the strong safety profile of our products for their intended uses, patients may experience
adverse events following canaloplasty or trabeculotomy with OMNI, including, but not limited to, hyphema, mild anterior chamber inflammation and spikes in intraocular pressure. Similarly, patients may experience adverse events following application
of localized heat with TearCare, including discomfort, pain or erythema of the eyelids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If experiences with OMNI or TearCare do not meet
the expectations of patients, or if patients experience adverse events, it could discourage the patient and treating physician from referring our products to others. Dissatisfied patients may express negative opinions through social media or other
public forums. Any failure to meet patient expectations and any resulting negative publicity could harm our reputation and future sales and therefore adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but keep limited
components, <FONT STYLE="white-space:nowrap">sub-assemblies,</FONT> materials and finished products on hand. To ensure adequate inventory supply and manage our operations with our third-party suppliers, we forecast anticipated materials requirements
and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions. Our ability to accurately forecast demand for our products could be negatively affected by many factors, including
our limited historical commercial experience, rapid growth, failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast
customer acceptance and adoption of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory levels in excess of customer demand may result in a portion of our inventory
becoming obsolete or expiring, as well as inventory write-downs or write-offs, which would negatively impact our gross margins and impair the strength of our brand. Conversely, if we underestimate customer demand for our products or our own
requirements for components, <FONT STYLE="white-space:nowrap">sub-assemblies</FONT> and materials, our third-party suppliers may not be able to deliver components, <FONT STYLE="white-space:nowrap">sub-assemblies</FONT> and materials to meet our
requirements, which could result in inadequate inventory levels or interruptions, delays or cancellations of deliveries to our customers, any of which would damage our reputation, customer relationships and business. In addition, several components,
<FONT STYLE="white-space:nowrap">sub-assemblies</FONT> and materials incorporated into our products require lengthy order lead times, and additional supplies or materials or additional manufacturing capacity may not be available when required on
terms that are acceptable to us, or at all, and our third-party suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand
for our products and our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our quarterly and annual results may fluctuate significantly and
may not fully reflect the underlying performance of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual results of operations, including our
revenue, may vary significantly in the future, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons of our operating results may not be meaningful. Accordingly, the results of any one
quarter or period should not be relied upon as an indication of future performance or of the results for the year in which such quarter or period occurs. Our quarterly and annual financial results may fluctuate as a result of a variety of factors,
many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. Fluctuations in quarterly and annual results may decrease the value of our common stock or result in volatility of our common
stock after this offering. Because our quarterly results may fluctuate, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons may not be the best indication of the underlying results of our
business and should only be relied upon as one factor in determining how our business is performing. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The level of demand for our products which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results of clinical trials or investigations involving the use of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulatory decisions or announcements, including product recalls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data and results relating to our products that are presented in journal publications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expenditures that we may incur to acquire, develop or commercialize additional products and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sales and marketing efforts and expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pricing pressures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rate at which we grow our sales force and the speed at which newly hired salespeople become effective;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in the productivity of our sales force; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to expand the geographic reach of our sales force; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The degree of competition in our industry and any change in the competitive landscape of our industry, including
consolidation among our competitors or future partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in coverage and reimbursement policies with respect to our procedures in which our products are used, and
potential future products that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive or negative coverage in the media or clinical publications of our products or products of our
competitors or our industry; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing of customer orders or medical procedures using our products and the number of available selling days
in any quarterly period, which can be impacted by holidays, the mix of products sold and the geographic mix of where products are sold; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing and cost of, and level of investment in, research, development, licenses, regulatory approval,
commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our products, which may change from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The cost of manufacturing our products, which may vary depending on the quantity of production and the terms of
our agreements with third-party suppliers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Future accounting pronouncements or changes in our accounting policies. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our long-term growth depends on our ability to enhance our products, expand our indications and develop and commercialize additional products in a
timely manner. If we fail to identify, acquire and develop other products, we may be unable to grow our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The markets for
our products are highly competitive, dynamic, and marked by rapid and substantial technological development and product innovation. New entrants or existing competitors could attempt to develop products that compete directly with ours. Demand for
our products and future related products could be diminished by equivalent or superior products and technologies offered by competitors. If we are unable to innovate successfully, our products could become obsolete and our revenue would decline as
our customers purchase our competitors&#146; products. Developing and improving products is expensive and time-consuming and could divert management&#146;s attention away from our existing products. The success of any new product offering or product
enhancements to our solution will depend on several factors, including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maintaining strong relationships with ECPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Assemble sufficient resources to acquire or discover additional products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Properly identify and anticipate physician and patient needs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop and introduce new products and product enhancements in a timely manner; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Avoid infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical
trials or investigations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain the necessary regulatory clearances, certifications or approvals for expanded indications, new products or
product modifications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Comply with the requirements of FDA and similar foreign regulatory authorities regarding the marketing of new
devices or modified products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Produce new products in commercial quantities at an acceptable cost; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide adequate training to potential users of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Receive adequate coding, coverage and reimbursement for procedures performed with our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop an effective and dedicated sales and marketing team. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to develop or improve products, applications or features due to constraints, such as insufficient cash resources, high
employee turnover, inability to hire personnel with sufficient technical skills or a lack of other research and development resources, we may not be able to maintain our competitive position compared to other companies. Furthermore, many of our
competitors devote a considerably greater amount of funds to their research and development programs than we do, and those that do not may be acquired by larger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies that could allocate greater resources to research and development programs. Our failure or inability to devote adequate research and development resources or compete effectively with
the research and development programs of our competitors could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may choose to focus our efforts and
resources on potential products or indications that ultimately prove to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products
or profitable market opportunities, be required to forego or delay pursuit of opportunities with other potential products or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such potential
products through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights, which could adversely impact our business, financial condition
and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in public health insurance coverage and government reimbursement rates for our products could affect the
adoption of our products and our future revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal government is considering ways to change, and has changed, the manner
in which healthcare services are paid for in the U.S. Individual states may also enact legislation that impacts Medicaid payments to hospitals, surgical centers and physicians. In addition, CMS establishes Medicare payment levels for hospitals,
surgical centers and physicians on an annual basis, which can increase or decrease payment to such entities, including for procedures involving our products. Internationally, medical reimbursement systems vary significantly from country to country,
with some countries limiting medical centers&#146; spending through fixed budgets, regardless of levels of patient treatment, and other countries requiring application for, and approval of, government or third-party reimbursement. Even if we succeed
in bringing our products to market in additional foreign countries, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially
acceptable quantities at acceptable prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost-containment efforts of our customers, purchasing groups and governmental organizations could have
a material adverse effect on our sales and results of operations. Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell our products at prices
necessary to support our current business strategies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to reduce costs, many clinics and hospitals in the United
States, including some of our customers, are members of Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, or IDNs. GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer
these negotiated prices to affiliated hospitals and other members. GPOs and IDNs typically award contracts on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">category-by-category</FONT></FONT> basis through a competitive bidding
process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain
new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our products, thereby reducing our revenue and margins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract
positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category,
members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60&nbsp;to 90 days&#146; notice. Accordingly, the members of such groups
may choose to purchase alternative products due to the price or quality offered by other companies, which could result in a decline in our sales volumes and revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare costs have risen significantly over the past decade, which has resulted in or led
to numerous cost reform initiatives by legislators, regulators and third-party payors. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate purchasing power, which may create more requests for pricing concessions
in the future. Additionally, GPOs, IDNs and large single accounts may continue to use their market power to consolidate purchasing decisions for hospitals. We expect that market demand, government regulation, third-party coverage and reimbursement
policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among our customers, which may exert further downward pressure on the prices of our products. Such
downward pressure on the prices of our products may affect our results of operations and our ability to support our current business strategies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may not be able to achieve or maintain satisfactory pricing and margins for our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical device companies have a history
of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our products or maintain prices at the levels we have historically achieved. Any decline in the amount that payors reimburse our customers for
procedures that use OMNI or in the amount that customers are willing to pay or that payors reimburse for procedures that use TearCare in the future, could make it difficult for customers to continue using, or to adopt, our products and could create
additional pricing pressure for us. If we are forced to lower the price we charge for our products or add more components to our products, our gross margins will decrease, which will adversely affect our ability to invest in and grow our business.
If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode. We are, and will continue to be, subject to significant pricing pressure, which
could harm negatively affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to manage the anticipated growth of our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to grow, we need to expand our commercial team, and general and administrative infrastructure. In addition to
the need to scale our organization, future growth will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. Rapid expansion in personnel could mean that less
experienced people market and sell our products, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations. In addition, rapid and significant growth may strain our administrative and operational
infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. For example, we currently rely on a combination of direct
sales personnel and independent distributors to sell our products in Europe, and we intend to grow our international sales through a combination of direct and distributor sales. If we are unable to manage our growth effectively, it may be difficult
for us to execute our business strategy and our business could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As demand for our current products or any of our future
products increases, we will need to continue to expand customer service, billing and systems processes and enhance our internal quality assurance program. We cannot assure you that any increases in scale, related improvements and quality assurance
will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher
costs of processing data or inability to meet increased demand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance issues, service interruptions or price increases by our shipping
carriers and distributors could negatively affect our business, financial condition and results of operations and harm our reputation and the relationship between us and the ECPs we work with. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expedited, reliable shipping is essential to our operations. We rely heavily on providers of transport services for reliable and secure <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-to-point</FONT></FONT> transport of our products to our customers and for tracking of these shipments. Should a carrier encounter delivery performance issues such as loss, damage or
destruction of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
systems, it would be costly to replace such systems in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our solution and increased cost and expense
to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters or other service interruptions affecting delivery
services we use would adversely affect our ability to process orders for our products on a timely basis. These factors could negatively affect our business, financial condition and results of operations and harm our reputation and the relationship
between us and the ECPs we work with. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products may become obsolete in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device industry is characterized by rapid and significant change. There can be no assurance that other companies will not succeed
in developing or marketing devices or products that are more effective than our products or that would render our products obsolete or noncompetitive. Additionally, new surgical procedures, medications and other therapies could be developed that
replace or reduce the importance of our products. Accordingly, our success will depend in part on our ability to respond quickly to medical and other changes through the development and introduction of new products. Product development involves a
high degree of risk, and there can be no assurance that our new product development efforts will result in any commercially successful products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
bear the risk of potential warranty claims on our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide limited warranties regarding our products, including
warranties pertaining to freedom from defects and conformance to specifications. We are generally obligated under our sales contracts to repair, replace or credit or refund the purchase price of defective products. As a result, we bear the risk of
potential warranty claims on our products. In the event that we attempt to recover some or all of the expenses associated with a warranty claim against us from our suppliers or vendors, we may not be successful in claiming recovery under any
warranty or indemnity provided to us by such suppliers or vendors and any recovery from such vendor or supplier may not be adequate. In addition, warranty claims brought by our customers related to third-party components may arise after our ability
to bring corresponding warranty claims against such suppliers expires, which could result in costs to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may enter into collaborations, <FONT
STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or product improvements or the generation of
significant future revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements,
joint ventures, strategic alliances, partnerships or other arrangements to develop new products or product improvements and to pursue new markets. Proposing, negotiating and implementing collaborations,
<FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales,
technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or
at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations
may not result in the development of products that achieve commercial success or viable product improvements or result in significant revenues and could be terminated prior to developing any products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could
create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts
may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any future
collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any future
collaborators devote to our or their future products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes between us and any collaborators we may have in the future may result in
litigation or arbitration which would increase our expenses and divert the attention of our management. These arrangements may consume management time and resources to establish and maintain. Further, these transactions and arrangements will be
contractual in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such
rights at a premium. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our products, could delay the development and commercialization of our products and reduce their
competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into <FONT STYLE="white-space:nowrap">in-bound</FONT> intellectual property license agreements, we may not be able to fully
protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our
licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we
would. Further, entering into such license agreements could impose various diligence, commercialization, royalty or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to
terminate our license and/or seek damages arising out of the alleged breach, which could adversely affect our competitive business position and harm our business prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter. Although we carry product liability
insurance in the United States, we can give no assurance that such coverage will be available or adequate to satisfy any claims. Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on
acceptable terms, if at all. If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant
liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations.
Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management&#146;s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market,
product recalls or market withdrawals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that operating as a public company will make it more difficult and more expensive
for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us
to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant
uninsured liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on our senior management team and the loss of one or more key employees or an inability to
attract and retain highly skilled employees will negatively affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends largely on the continued services of key members of our executive management team and others in key management positions.
For example, the services of Paul Badawi, our Chief Executive Officer, Jesse Selnick, our Chief Financial Officer, Shawn O&#146;Neil, our Chief Commercial Officer, and Sam Park, our Chief Operating Officer, are essential to driving adoption of our
products, executing on our corporate strategy and ensuring the continued operations and integrity of financial reporting within our company. In addition, the services of our sales professionals are critical to driving the growth in sales of our
products. Any of our employees may terminate their employment with us at any time. We currently maintain a key person life insurance policy on Mr.&nbsp;Badawi. If we lose one or more key employees, we may experience difficulties in competing
effectively, developing our technologies and implementing our business strategy, which in turn would negatively affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, our research and development programs, clinical and quality operations and sales efforts depend on our ability to attract and retain highly skilled engineers and sales professionals, as well as experienced regulatory, quality and clinical
professionals. We may not be able to attract or retain qualified professionals in the future due to the competition for qualified personnel. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and
retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than we do. If we hire employees from competitors or other companies, their former employers may
attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their
employment. If the perceived benefits of our stock awards decline, either because of unfavorable fluctuations or declines in our stock price or for other reasons, it may harm our ability to recruit and retain highly skilled employees. Many of our
employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to
the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock, particularly after the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described herein. Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees. If we fail to attract new personnel
or fail to retain and motivate our current personnel, it will negatively affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
use, misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our products may result in injuries that lead to product liability suits, which could be expensive, divert management&#146;s attention and harm our reputation and business. We
may not be able to maintain adequate product liability insurance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products are cleared or authorized by the FDA to be marketed
for certain specific intended uses. If physicians elect to use our products in manners outside of the intended uses that have been cleared or authorized by the FDA, then such <FONT STYLE="white-space:nowrap">off-label</FONT> use of our products may
result in outcomes and adverse events that are sight threatening, necessitate medical or surgical intervention to preclude permanent impairment of vision, or result in a permanent impairment of vision, potentially leading to product liability
claims. However, we cannot prevent a physician from using our products for <FONT STYLE="white-space:nowrap">off-label</FONT> applications or using components or products that are not our products when performing procedures with our products. There
may be increased risk of injury to patients if physicians attempt to use our devices <FONT STYLE="white-space:nowrap">off-label.</FONT> In addition, we cannot guarantee that physicians are trained by us or their peers prior to utilizing our
products. Complications resulting from the use of our products <FONT STYLE="white-space:nowrap">off-label</FONT> or use by physicians who have not been trained appropriately, or at all, may not effectively treat the applicable conditions and may
expose us to product liability claims or litigation by our customers or their patients and may harm our reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if our products are defectively designed, manufactured or labeled, contain
defective components or are misused, we may become subject to costly litigation initiated by hospitals, surgical centers, ECPs or patients. Product liability claims are especially prevalent in the medical device industry and could harm our
reputation, divert management&#146;s attention from our core business, attract negative publicity, be expensive to defend and may result in sizable damage awards against us. Although we maintain product liability insurance, we may not have
sufficient insurance coverage for future product liability claims. We are not able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought
against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation, significantly increase our expenses, and reduce product sales. Product liability claims
could cause us to incur significant legal fees and deductibles and claims in excess of our insurance coverage would be paid out of cash reserves, harming our financial condition and operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need additional funding beyond the net proceeds of this offering to finance our planned operations, and may not be able to raise capital on
acceptable terms, if at all, which could force us to delay, reduce or eliminate our product development programs and commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. Since our
inception, our operations have been financed primarily by net proceeds from the sale of our convertible preferred stock in private placements, indebtedness and, to a lesser extent, product revenue from sales of our products. As of December&nbsp;31,
2020, we had $61.5&nbsp;million in cash and cash equivalents, and an accumulated deficit of $89.8&nbsp;million. Based on our current planned operations, we expect that our cash and cash equivalents and additional borrowings available under our
credit facility will enable us to fund our operations for at least the next twelve months. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to invest in clinical trials or investigations that are designed to provide clinical evidence of the safety and efficacy
of our products, the growth of our sales and marketing organization, and research and development of product improvements and future products. Moreover, we expect to incur additional expenses associated with operating as a public company, including
legal, accounting, insurance, exchange listing and SEC compliance, investor relations and other expenses. Because of these and other factors, we expect to continue to incur net losses and negative cash flows from operations for the foreseeable
future. Our future funding requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The degree and rate of market acceptance of our products and procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Whether we acquire third-party companies, products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repayment of debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scope and timing of investment in our sales force and expansion of our commercial organization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The impact on our business from the ongoing and <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or any
other pandemic, epidemic or outbreak of an infectious disease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scope, rate of progress and cost of our current or future clinical trials or investigations and registries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The cost of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The cost and timing of additional regulatory clearances, certifications or approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The costs associated with any product recall that may occur; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The costs of attaining, defending, protecting and enforcing our intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The terms and timing of any other collaborative, licensing and other arrangements that we may establish;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The emergence of competing technologies or other adverse market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rate at which we expand internationally. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek to raise additional capital through equity offerings or debt financings and such additional financing may not be available to us
on acceptable terms, or at all. In addition, any additional equity or debt financing that we raise may contain terms that are not favorable to us or our stockholders. For example, if we raise funds by issuing equity or equity-linked securities, the
issuance of such securities could result in dilution to our stockholders. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of our common stock. In addition, the issuance of additional
equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline, and the price per share at which we sell additional shares of our common stock, or securities convertible into or exercisable or
exchangeable for shares of our common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the terms of debt securities issued or borrowings could impose significant restrictions on our operations including restrictive
covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to pay dividends, limitations on our ability to acquire or license intellectual property rights, and other operating
restrictions that could adversely affect our ability to conduct our business. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms, such as relinquishment or
licensing of certain technologies or products that we otherwise would seek to develop or commercialize ourselves, or reserve for future potential arrangements when we might otherwise be able to achieve more favorable terms. In addition, we may be
forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain adequate financing on terms satisfactory to us when we require it, we may terminate or delay the development of one
or more of our products, delay clinical trials or investigations necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products. If this were to occur, our
ability to grow and support our business and to respond to market challenges could be significantly limited, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, we entered into a new loan and security agreement with MidCap Financial Services, which provides for a term loan facility and
revolving line of credit, or the 2020 MidCap Credit Facility. The 2020 MidCap Credit Facility consists of a term loan of up to $35.0&nbsp;million, or the 2020 Term Loan, which has a stated floating interest rate equal to reserve-adjusted LIBOR plus
7.00%, and a revolving line of credit of $5&nbsp;million, or the 2020 Revolver, with a stated floating interest rate equal to reserve-adjusted LIBOR plus 4.50%, a 0.5% unused line fee and a 0.5% collateral management fee. As of December&nbsp;31,
2020, we had an aggregate of approximately $35.0&nbsp;million in principal borrowings outstanding under the 2020 MidCap Credit Facility, excluding debt discounts. We must make interest payments under the 2020 MidCap Credit Facility, which has
diverted and will continue to divert resources from other activities. We incurred an aggregate interest expense of $1.9&nbsp;million and $2.4&nbsp;million in the years ended December&nbsp;31, 2019 and December&nbsp;31, 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the 2020 MidCap Credit Facility are collateralized by a security interest in substantially all of our assets, and we are
subject to customary financial and operating covenants limiting our ability to, among other things, relocate or dispose of assets, undergo a change in control, merge or consolidate, enter into certain transactions with affiliates, make acquisitions,
incur debt, pay dividends, grant liens, store certain amounts of inventory or equipment with third parties and make investments, in each case subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain exceptions. We are also subject to minimum trailing revenue targets that are evaluated on a monthly basis. The covenants related to the 2020 MidCap Credit Facility, as well as any future
financing agreements into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have not previously breached and are not currently in breach of these or any other covenants contained in the 2020 MidCap Credit
Facility, there can be no guarantee that we will not breach these covenants in the future. Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a
default under the 2020 MidCap Credit Facility. If not waived, future defaults could cause all of the outstanding indebtedness under the 2020 MidCap Credit Facility to become immediately due and payable and terminate commitments to extend further
credit and foreclose on the collateral granted to it to collateralize such indebtedness. If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in
the event of a default, our assets could be foreclosed upon and we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business as a going
concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from
our operating activities. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. We cannot
assure you that our business will be able to generate sufficient cash flow from operations or that future borrowings or other financings will be available to us in an amount sufficient to enable us to service our indebtedness and fund our other
liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, capital expenditures or other general corporate purposes, we will be
less able to plan for, or react to, changes in our business, industry and in the economy generally. This may place us at a competitive disadvantage compared to our competitors that have less indebtedness or greater financial resources to service
their debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uncertainty relating to the LIBOR calculation process and potential phasing out of LIBOR after 2021 may adversely affect the market
value of our current or future debt obligations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The London Inter-bank Offered Rate, or LIBOR, and certain other interest
&#147;benchmarks&#148; may be subject to regulatory guidance and/or reform that could cause interest rates under our current or future debt agreements to perform differently than in the past or cause other unanticipated consequences. The United
Kingdom&#146;s Financial Conduct Authority, which regulates LIBOR, has announced that it intends to stop encouraging or requiring banks to submit LIBOR rates after 2021, and it is unclear if LIBOR will cease to exist or if new methods of calculating
LIBOR will evolve. If LIBOR ceases to exist or if the methods of calculating LIBOR change from their current form, there may be adverse impacts on the financial markets generally and interest rates on borrowings under our 2020 Term Loan and 2020
Revolver may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire other companies or technologies, which could fail to result in a commercial product or net
sales, divert our management&#146;s attention, result in additional dilution to our stockholders and otherwise disrupt our business and adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently have no agreements or commitments to complete any such transactions and are not involved in negotiations to do so, we may
in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities. However, we cannot assure you
that we would be able to successfully complete any acquisition we choose to pursue, or that we would be able to successfully integrate any acquired </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">business, product or technology in a cost-effective and <FONT STYLE="white-space:nowrap">non-disruptive</FONT> manner. The pursuit of potential
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are
consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies.
Furthermore, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize, or such strategic alliance, joint venture or acquisition may be prohibited. In November 2020, we amended our credit facilities and
entered into the 2020 Term Loan and 2020 Revolver. The 2020 Term Loan and the 2020 Revolver restrict our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to successfully integrate any acquired personnel, operations and technologies, or effectively manage the combined business
following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business fails to meet
our expectations, our business, financial condition and results of operations may be negatively affected. Additional risks we may face in connection with acquisitions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Diversion of management time and focus from operating our business to addressing acquisition integration
challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coordination of research and development and sales and marketing functions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Integration of product and service offerings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Retention of key employees from the acquired company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in relationships with strategic partners as a result of product acquisitions or strategic positioning
resulting from the acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cultural challenges associated with integrating employees from the acquired company into our organization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Integration of the acquired company&#146;s accounting, management information, human resources and other
administrative systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The need to implement or improve controls, procedures, and policies at a business that prior to the acquisition
may have lacked sufficiently effective controls, procedures and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial reporting, revenue recognition or other financial or control deficiencies of the acquired company that
we don&#146;t adequately address and that cause our reported results to be incorrect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Liability for activities of the acquired company before the acquisition, including intellectual property
infringement claims, misappropriation or other violation, violations of laws, commercial disputes, tax liabilities and other known and unknown liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unanticipated write-offs or charges; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Litigation or other claims in connection with the acquired company, including claims from terminated employees,
customers, former stockholders or other third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to address these risks or other problems encountered
in connection with acquisitions and investments could cause us to fail to realize the anticipated benefits of these acquisitions or investments, cause us to incur unanticipated liabilities, and harm our business generally. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxing authorities may successfully assert that we should have collected or in the future should
collect sales and use, gross receipts, value added or similar taxes and may successfully impose additional obligations on us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One
or more jurisdictions may seek to impose additional tax collection obligations on us, including for past sales. A successful assertion by a state, country, or other jurisdiction that we should have been or should be collecting additional sales, use,
or other taxes on our services could, among other things, result in substantial tax liabilities for past sales, create significant administrative burdens for us, discourage users from purchasing our products, or otherwise harm our business, results
of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards, disallowed interest expense carryforwards and
research and development carryforwards may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had U.S. federal and state net operating
loss carryforwards, or NOLs, of $85.3&nbsp;million and $83.5&nbsp;million, respectively, and U.S. federal and state research and development credit carryforwards of $0.8&nbsp;million and $0.9&nbsp;million, respectively. In general, under Sections
382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change by value in its equity ownership over a rolling
three-year period, is subject to limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating losses, or NOLs, and its research and development credit carryforwards to offset future taxable income. Our
existing NOLs and research and development credit carryforwards could be subject to limitation under Sections&nbsp;382 and 383 of the Code if we have undergone, or undergo in the future, any ownership changes for purposes of these provisions. If our
NOLs and research and development credit carryforwards are subject to these limitations, we may not be able to utilize a material portion of the NOLs and research and development credit carryforwards, even if we attain profitability. In addition,
our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules similar to
those applicable to NOLs and other attributes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the tax benefit of NOLs, temporary differences and credit carryforwards are
required to be recorded as an asset to the extent that we assess that realization is more likely than not. We believe that recognition of the deferred tax asset arising from these future tax benefits is not likely to be realized and, accordingly,
have provided a valuation allowance of $14.4&nbsp;million and $24.5&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The impact of the Tax Cuts and Jobs Act and the CARES Act on our financial results is not entirely clear and could differ materially from the financial
statements provided herein. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the United States enacted the Tax Cuts and Jobs Act, or the TCJA, that
significantly reformed the Code. The TCJA, among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction
for interest expense; limitation (as modified by the CARES Act as discussed below) of the deduction for NOLs and elimination of NOL carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any such
tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020,
the President signed the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), aimed at helping American workers and businesses impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The CARES Act, among other
things, temporarily removes the <FONT STYLE="white-space:nowrap">current-law</FONT> taxable income limitation established under the Tax Cuts and Jobs Act of 2017, and permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable
years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years. The NOL provisions of the CARES Act is not expected to result in a cash benefit to
the Company nor did it impact our NOL balance upon enactment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements contained herein reflect the effects of the TCJA and the CARES Act
based on current guidance. However, there remain uncertainties and ambiguities in the application of certain provisions of the TCJA and the CARES Act, and, as a result, we made certain judgments and assumptions in the interpretation thereof. The
U.S. Treasury Department and the Internal Revenue Service may issue further guidance on how the provisions of the TCJA and the CARES Act will be applied or otherwise administered that differs from our current interpretation. In addition, the TCJA
and the CARES Act could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation on us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The planned international expansion of our business will expose us to market, regulatory, political, operational, financial and economic risks
associated with doing business outside of the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to increase our international presence, including securing
additional regulatory approvals in targeted countries outside the United States. This strategy may include establishing and maintaining physician outreach and education capabilities outside of the United States and expanding our relationships with
international payors. Doing business internationally involves a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Difficulties in staffing and managing our international operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import
restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reduced or varied protection for intellectual property rights in some countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtaining regulatory clearance, certification or approval where required for our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Requirements to maintain data and the processing of that data on servers located within such countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complexities associated with managing multiple payor reimbursement regimes, government payors or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Limits on our ability to penetrate international markets if we are required to manufacture our products locally;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial risks, such as longer payment cycles, difficulty collecting accounts receivable, foreign tax laws and
complexities of foreign value-added tax systems, the effect of local and regional financial pressures on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions on the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">site-of-service</FONT></FONT> for use of our products and the economics related thereto for physicians, providers and payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in foreign currency exchange rates and costs associated with hedging against such changes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Natural disasters, political and economic instability, including wars, terrorism, political unrest, outbreak of
disease, boycotts, curtailment of trade and other market restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulatory and compliance risks that relate to maintaining accurate information and control over activities
subject to regulation under the United States Foreign Corrupt Practices Act of 1977, or FCPA, U.K. Bribery Act of 2010 and comparable laws and regulations in other countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could significantly harm our future international expansion and operations and, consequently, have a material adverse
effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws and
any investigation, and the outcome of any investigation, by government agencies of possible violations by us of the FCPA could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA and similar worldwide anti-bribery laws prohibit companies and their intermediaries from corruptly providing any benefits to
government officials for the purpose of obtaining or retaining business. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to
impose against corporations and individuals for violations of economic sanctions laws, export control laws, the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes and regulations, including those established by the Office of
Foreign Assets Control, or OFAC. In addition, the U.K. Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that fails to prevent
bribery by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented adequate procedures to prevent bribery. Under these laws and regulations, as well as
other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business
practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other
sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commenced commercial sales of OMNI in certain European countries through a combination of direct sales personnel and
independent distributors, and we are also in the process of conducting an <FONT STYLE="white-space:nowrap">EU-based</FONT> clinical investigation. Further, a portion of our business with respect to our manufacturing is conducted outside of the
United States. We expect our international activities to increase in the future. Though we maintain policies, internal controls and other measures reasonably designed to promote compliance with applicable anticorruption and anti-bribery laws and
regulations, and certain safeguards designed to ensure compliance with U.S. trade control laws, our employees or agents may nevertheless engage in improper conduct for which we might be held responsible. Any violations of these anti-corruption or
trade controls laws, or even allegations of such violations, can lead to an investigation and/or enforcement action, which could disrupt our operations, involve significant management distraction, and lead to significant costs and expenses,
including legal fees. If we, or our employees or agents acting on our behalf, are found to have engaged in practices that violate these laws and regulations, we could suffer severe fines and penalties, profit disgorgement, injunctions on future
conduct, securities litigation, bans on transacting government business, delisting from securities exchanges and other consequences that may have a material adverse effect on our business, financial condition and results of operations. In addition,
our reputation, our net sales or our stock price could be adversely affected if we become the subject of any negative publicity related to actual or potential violations of anti-corruption, anti-bribery or trade control laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in government trade policies, including the imposition of tariffs and export restrictions, could have a negative impact on our manufacturing
process, which may materially and adversely affect our sales and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain public officials, including
members of the current U.S. Congress, have made public statements indicating the possibility of significant changes in U.S. trade policy and have taken certain actions that may impact U.S. trade policy, including imposing new or increased tariffs on
certain goods imported into the United States during the Trump administration. For example, the United States and China have imposed a number of tariffs and other restrictions on items imported or exported between the United States and China, and
have proposed to impose a number of additional tariffs. We cannot predict what actions may ultimately be taken with respect to tariffs or trade relations between the United States and China or other countries, what products may be subject to such
actions, or what actions may be taken by the other countries in retaliation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since certain of our critical product and product component
manufacturers are located outside the United States, such changes, if adopted, could have a negative impact on our business and make our products more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expensive and less competitive in domestic markets. Furthermore, changes in U.S. trade policy could trigger retaliatory actions by affected countries, which could impose restrictions on our
ability to do business in or with affected countries or prohibit, reduce or discourage purchases of our products by foreign customers. Changes in, and responses to, U.S. trade policy could reduce the competitiveness of our products and cause our
sales to decline, which could materially and adversely impact our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The United
Kingdom&#146;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from
the European Union and ratified a trade and cooperation agreement governing its future relationship with the European Union. The agreement, which is being applied provisionally from January&nbsp;1, 2021 until it is ratified by the European
Parliament and the Council of the European Union, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely
sets forth a framework in many respects and will require complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue to work on the rules for implementation, significant political and economic
uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the end of the &#147;Brexit&#148; Transition Period, from January&nbsp;1, 2021 onwards, the Medicines and Healthcare Products
Regulatory Agency, or the MHRA, will be responsible for the UK medical device market. The new regulations will require medical devices to be registered with the MHRA (but manufacturers will be given a grace period of four to 12 months to comply with
the new registration process). Manufacturers based outside the UK will need to appoint a UK Responsible Person to register devices with the MHRA in line with the grace periods. By July&nbsp;1, 2023, in the UK (England, Scotland, and Wales), all
medical devices will require a UKCA (UK Conformity Assessed) mark but CE marks issued by EU Notified Bodies will remain valid until this period. However, UKCA marking alone will not be recognized in the EU. The rules for placing medical devices on
the Northern Ireland market will differ from those in the UK. These modifications may have an effect on the way we conduct our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect
on global economic conditions and financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Asset valuations, currency exchange rates and
credit ratings have been and may continue to be subject to increased market volatility. Lack of clarity about future United Kingdom laws and regulations as the United Kingdom determines which European Union laws to replace or replicate could depress
economic activity and investment in healthcare technology products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withdrawal has also given rise to calls for the governments of
other EU member states to consider withdrawal. These developments, or the perception that any of them could occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial
markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors could depress economic activity and restrict our access to capital, which
could have a material adverse effect on our business, financial condition and results of operations and reduce the price of our common stock. Any of these factors could have a material adverse effect on our business, financial condition and results
of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Security breaches, loss of data and other disruptions could compromise sensitive information related
to our business or our customer&#146;s patients, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we may become exposed to, or collect and store, sensitive data, including procedure-based information
and legally-protected health information, credit card, and other financial information, insurance information, and other potentially personally identifiable information. We also store sensitive intellectual property and other proprietary business
information. We are taking measures to implement policies and procedures designed to ensure compliance with applicable data security and privacy-related laws and regulations and protect sensitive information from unauthorized access or disclosure.
However, our information technology, or IT, and infrastructure, and that of our third-party billing and collections provider and other technology partners and providers, may be vulnerable to cyber-attacks by hackers or viruses or breaches due to
employee error, malfeasance or other disruptions. We rely extensively on IT systems, networks and services, including internet sites, data hosting and processing facilities and tools, physical security systems and other hardware, software and
technical applications and platforms, some of which are managed, hosted, provided and/or used by third parties or their vendors, to assist in conducting our business. A significant breakdown, invasion, corruption, destruction or interruption of
critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. The ever-increasing use and evolution of technology, including
cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers&#146; systems, portable media or storage devices. For example,
companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We could also experience a business interruption, theft of
confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Although
the aggregate impact on our operations and financial condition has not been material to date, we have been the target of events of this nature and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and
becoming more prevalent in the industry. We are investing in protections and monitoring practices of our data and IT to reduce these risks and continue to monitor our systems on an ongoing basis for any current or potential threats. There can be no
assurance, however, that our efforts will prevent breakdowns or breaches to our or our third-party providers&#146; databases or systems, and such breakdowns or breaches could adversely affect our business, financial condition and reputation. We also
intend to mitigate the risks related to these risks by purchasing cybersecurity insurance. However, such insurance, if purchased, will not necessarily cover all costs and impacts related to these risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
success will depend on our, and any of our future licensors&#146;, ability to obtain, maintain and protect our intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on our, and any of our future licensors&#146;, success in obtaining and maintaining issued patents,
trademarks and other intellectual property rights in the United States and elsewhere and protecting our proprietary technology. If we, or any of our future licensors, do not adequately protect our intellectual property and proprietary technology,
competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a combination of contractual provisions, confidentiality procedures and patent, copyright, trademark, trade secret and other
intellectual property laws to protect the proprietary aspects of our products, brands, technologies and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and
proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and <FONT STYLE="white-space:nowrap">know-how</FONT> and obtaining and maintaining other intellectual property rights.
We may not be able to obtain or maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, despite our efforts to enter into confidentiality agreements with our
employees, consultants, suppliers, clients and other vendors who have access to information that we regard as proprietary, our trade secrets, data, <FONT STYLE="white-space:nowrap">know-how</FONT> and other proprietary information and technology
could be subject to unauthorized access, use, misappropriation, or disclosure to unauthorized parties, and could otherwise become known or be independently discovered by third parties. Our intellectual property, including trademarks, could be
challenged, invalidated, infringed, misappropriated, violated and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced
to <FONT STYLE="white-space:nowrap">re-brand</FONT> our products, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands and suffering other competitive harm. Third parties may also adopt
trademarks similar to ours, which could harm our brand identity and lead to market confusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain and maintain intellectual
property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property
laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents,
trademarks, data, technology and other intellectual property and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business relies, in part, on our ability to obtain, maintain, expand, enforce, and defend the scope of our intellectual property portfolio
or other proprietary rights, including making any payments required in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights. The process of applying for and obtaining a patent is
expensive, time consuming and complex, and we may not be able to prepare, file, prosecute, maintain, enforce or license all necessary or desirable patent applications and patents at a reasonable cost, in a timely manner, or in all jurisdictions
where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all. It is also possible that we may fail to identify patentable aspects of inventions made in the course of development and
commercialization activities before it is too late to obtain patent protection on them. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects
of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such
output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the
United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending
patent applications, or that we were the first to file for patent protection of such inventions. Moreover, depending on the terms of any future <FONT STYLE="white-space:nowrap">in-licenses</FONT> to which we may become a party, we may not have the
right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology <FONT STYLE="white-space:nowrap">in-licensed</FONT> from third parties. Therefore, these patents and patent applications
may not be prosecuted, maintained, and/or enforced in a manner consistent with the best interests of our business. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard
as proprietary. Additionally, if there are material defects in the form, preparation or prosecution of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability
to prevent competition from third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of medical device
companies may involve complex legal and factual questions and have been the subject of much litigation in recent years, and therefore, the scope, validity and enforceability of any patent claims that we have or may obtain cannot be predicted with
certainty. We cannot offer any assurances about which of our patent applications will issue, the breadth of any resulting patent or whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or
challenged by third parties. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents will be sufficient to stop a competitor from developing and commercializing a product in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner that would be competitive with one
or more of our products, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for
our commercial success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20
years. Further, if we encounter delays in any future regulatory approvals, the period of time during which we could market a product under patent protection could be reduced, and, given the amount of time required for the development, testing and
regulatory review of planned or future products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Though an issued patent is presumed valid and enforceable, its
issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Patents, if issued, may be challenged, deemed
unenforceable, invalidated, narrowed or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or reduction in the scope of one or more of the
claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be
costly. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third party receiving a patent right sought by us, which in turn could
affect our ability to commercialize our products. Competitors could purchase our products and attempt to replicate or reverse engineer some or all of the competitive advantages we derive from our development efforts, willfully infringe,
misappropriate or otherwise violate our intellectual property rights, design around our patents, or develop and obtain patent protection for more effective technologies, designs or methods. We may be unable to prevent the unauthorized disclosure or
use of our technical knowledge or trade secrets by consultants, suppliers, vendors, former employees and current employees. Further, the laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the
United States, and we may encounter significant problems in protecting our proprietary rights in these countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of
the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our products are invalidated, found unenforceable or interpreted narrowly, or if a court found that valid, enforceable patents held by
third parties covered one or more of our products, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our patents and patent applications may in the future be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we
are unable to obtain an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties,
including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents
against third parties, and such cooperation may not be provided to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is
uncertain, and we cannot ensure that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any of our patents, or any of our pending patent applications, if issued, will include claims having a scope
sufficient to protect our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any of our pending patent applications will issue as patents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will be able to successfully commercialize our products on a substantial scale, if approved, before our
relevant patents we may have expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We were the first to make the inventions covered by each of our patents and pending patent applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We were the first to file patent applications for these inventions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others will not develop similar or alternative technologies that do not infringe our patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any of our challenged patents will be found to ultimately be valid and enforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will
provide us with any competitive advantages or will not be challenged by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will develop additional proprietary technologies or products that are separately patentable; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercial activities or products will not infringe upon the patents of others. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.
Issued patents may be challenged, narrowed, invalidated or circumvented. Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents owned by or that are in the future licensed to us.
Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own products and practicing our own technology. Alternatively,
third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement.
In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid, unenforceable or not infringed; competitors may then be able to market products and use manufacturing and analytical processes that are
substantially similar to ours. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act.
The federal government retains a &#147;nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#148; for its own benefit. The Bayh-Dole Act also provides federal agencies with <FONT
STYLE="white-space:nowrap">&#147;march-in</FONT> rights.&#148; <FONT STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the patent owner or successors in title to the patent to grant a
&#147;nonexclusive, partially exclusive, or exclusive license&#148; to a &#147;responsible applicant or applicants.&#148; If the patent owner refuses to do so, the government may grant the license to itself. We cannot be sure that if we acquired
intellectual property in the future it will be free from government rights or regulations pursuant to the Bayh-Dole Act. If, in the future, we own, <FONT STYLE="white-space:nowrap">co-own</FONT> or license in technology which is critical to our
business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. Any of the foregoing could have a material
adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance
with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance
with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on issued patents often
must be paid to the USPTO and foreign patent agencies over the lifetime of the patent and/or applications and any patent rights we may obtain in the future. While an unintentional lapse of a patent or patent application can in many cases be cured by
payment of a late fee or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to
respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering
our products, we may not be able to stop a competitor from marketing products that are the same as or similar to our products, which would have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our current
and/or future products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property rights, including patent rights that are important or
necessary to the development and commercialization of our current and/or future products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our current and/or future products, in which case we
would be required to acquire or obtain a license to such intellectual property from these third parties, and we may be unable to do so on commercially reasonable terms or at all. The licensing or acquisition of third-party intellectual property
rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a
competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We
also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party
intellectual property rights, we may not be able to develop, manufacture or market a product or future product, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products, and
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our patents or our future patents. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to obtain patents and the breadth of any patents obtained is uncertain in part because, to date, some legal principles remain
unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States and other countries. Furthermore, changes in either patent laws or interpretations of patent laws in the
United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution,
enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are
interpreted. The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In
addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States
Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain or license in the
future. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are
interpreted. Changes in patent laws and regulations in other countries or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdictions, changes in the governmental bodies that enforce them, or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new
patents or to enforce patents that we own or may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may
encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other
countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement in a patent issued in one country is not similar to the
interpretation given to the corresponding patent issued in other countries, our ability to protect our intellectual property in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States
and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted
into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. Any of the foregoing could have a material adverse effect
on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become a party to intellectual property litigation or administrative
proceedings that could be costly, time-consuming, unsuccessful, and could interfere with our ability to sell and market our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, upon our ability and the ability of future collaborators, if any, to develop, manufacture, market and
sell our products and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The medical device industry has been characterized by extensive
litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual
property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business. It is possible that U.S. and foreign patents and pending patent applications controlled by third parties may be alleged to
cover our products, or that we may be accused of misappropriating third parties&#146; trade secrets or infringing third parties&#146; trademarks. We may in the future become party to, or be threatened with, adversarial proceedings or litigation
regarding intellectual property rights with respect to our products and technology, including interference proceedings, post grant review and <I>inter partes</I> review before the USPTO or equivalent foreign regulatory authority. Third parties may
assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Because patent applications can take many years to issue and because publication schedules for pending
applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents, which our current or future products infringe. Also, because the claims of published patent applications can
change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise
assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on the
commercial success of our current and any future products. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to
present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in
foreign courts in order to successfully challenge a third-party claim of patent infringement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to infringe, misappropriate
or otherwise violate a third party&#146;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a
license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty
payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and
attorneys&#146; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our products or force us to cease some or all of our
business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our products include components that we purchase from vendors, and may include design components
that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or
obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use our technologies or product names. As the number of
competitors in our market grows and the number of patents issued in this area increases, the possibility of patent infringement claims against us may increase. Moreover, individuals and groups that are
<FONT STYLE="white-space:nowrap">non-practicing</FONT> entities, commonly referred to as &#147;patent trolls,&#148; purchase patents and other intellectual property assets for the purpose of making claims of infringement in order to extract
settlements. From time to time, we may receive threatening letters, notices or &#147;invitations to license,&#148; or may be the subject of claims that our products and business operations infringe, misappropriate or otherwise violate the
intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management&#146;s attention and resources, damage our reputation and brand and cause us to incur significant expenses
or make substantial payments. In addition, vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third-party&#146;s patent or trademark or of misappropriating a
third-party&#146;s trade secret. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that we were the first to file any patent application related to our products, in
part because patent applications are confidential for a period of time after filing. Competitors may also contest our patents, if issued, by demonstrating that the claimed invention was not original, was not novel or was obvious. In litigation, a
competitor could claim that our patents are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents,
patent applications or other intellectual property, as a result of the work they performed on our behalf. Although we generally require all of our employees and consultants and any other partners or collaborators who have access to our proprietary <FONT
STYLE="white-space:nowrap">know-how,</FONT> information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our
intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any lawsuits relating to intellectual property rights could subject us to significant liability for damages and invalidate our intellectual
property or proprietary rights. Any potential intellectual property litigation also could force us to do one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stop making, selling or using products or technologies that allegedly infringe, misappropriate or otherwise
violate the asserted intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lose the opportunity to license our intellectual property to others or to collect royalty payments based upon
successful protection and assertion of our intellectual property rights against others; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incur significant legal expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pay substantial damages or royalties to the party whose intellectual property rights we may be found to be
infringing, misappropriating or otherwise violating; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pay the attorney&#146;s fees and costs of litigation to the party whose intellectual property rights we may be
found to be infringing, misappropriating or otherwise violating; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Redesign those products or technologies that contain the allegedly infringing intellectual property, which could
be costly, disruptive and infeasible; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attempt to obtain a license to the relevant intellectual property from third parties, which may not be available
on reasonable terms or at all, or from third parties who may attempt to license rights that they do not have. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. Although patent, trademark, trade secret, and
other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any litigation or claim against us, even those without merit and even those where we prevail, may cause us to incur substantial costs, and
could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. Such litigation or proceedings could substantially increase our operating losses and reduce the resources
available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to
sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources and more mature and developed intellectual property portfolios. We could encounter delays in product introductions
while we attempt to develop alternative methods or products. If we fail to obtain any required licenses or make any necessary changes to our products or technologies, we may have to withdraw existing products from the market or may be unable to
commercialize one or more of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If third parties assert infringement, misappropriation or other claims against our customers,
these claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, regardless of the merits of these claims. If any of these claims succeed or settle, we may be forced to pay damages or settlement payments
on behalf of our customers or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine priority
with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or force us to take a license under the patent rights of the prevailing party, if available. Furthermore, our business
could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may also become involved in other proceedings, such as reexamination, <I>inter partes</I> review, derivation or opposition proceedings before
the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Our defense of any litigation or interference proceedings may fail and, even if successful, may result in substantial
costs and distract our management and other employees. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing our products or using product names, which would
have a significant adverse impact on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, competitors or other
third parties may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property, and we may file lawsuits or initiate other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. In certain circumstances it may not be practicable
or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing
our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be
difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#146;s or
potential competitor&#146;s product or service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiate legal proceedings against a third party to enforce a patent covering one
of our products, the defendant could counterclaim that the patent covering our product is invalid and/or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability are common, and there are
numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe,
misappropriate or otherwise violate their intellectual property. In a patent or other intellectual property infringement proceeding, a court may decide that a patent or other intellectual property of ours is invalid or unenforceable, in whole or in
part, construe the patent&#146;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in
question. Furthermore, even if our patents or other intellectual property are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such
monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#146;s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents
or other intellectual property at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations. Moreover, even if we are successful in any
litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of
litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post grant review, <I>inter partes</I> review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings
could result in revocation of or amendment to our patents in such a way that they no longer cover our products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for
example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or
unenforceability, we may lose some, and perhaps all, of the patent protection on our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the
foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, <FONT
STYLE="white-space:nowrap">know-how,</FONT> and/or other proprietary information that is not patentable or that we elect not to patent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, trade secrets can be difficult to protect and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary
information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such
agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our
proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. We may not be able to prevent the
unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection for our trade
secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or
disclosure of such trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> or other proprietary information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for
any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of
our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. In addition, the laws of many foreign countries will not protect our
intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to
international markets or require costly efforts to protect our technology. To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third party
could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology. Our competitors may independently develop knowledge, methods and <FONT STYLE="white-space:nowrap">know-how</FONT> equivalent to
our trade secrets. Our competitors could also purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect
and enforce our intellectual property rights could substantially harm the value of our products, brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the
differentiation of our products and harm our business, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary
information. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costly and time consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related
confidentiality and nondisclosure provisions. Further, it is possible that others will independently develop the same or similar technology or products or otherwise obtain access to our unpatented technology, and in such cases we could not assert
any trade secret rights against such parties. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology or products similar to ours or competing technologies or
products, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address
<FONT STYLE="white-space:nowrap">non-competition</FONT> are difficult to enforce in many jurisdictions and might not be enforceable in certain cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of
our premises and physical and electronic security of our information technology systems. While we have confidence in these security measures and systems, agreements or security measures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is
difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. Also, if the steps taken to maintain our trade secrets we may have are deemed inadequate, we may have
insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently develop our trade secrets and proprietary information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights
throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company may attempt to commercialize competing products utilizing our proprietary technology, design,
trademarks or tradenames in foreign countries where we do not have any patents or patent applications, trademarks, and/or other forms of intellectual property and where legal recourse may be limited. This may have a significant commercial impact on
our foreign business operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents or trademarks on our current and future products in all
countries throughout the world would be prohibitively expensive. The requirements for patentability and trademark protection may differ in certain countries, particularly developing countries. The laws of some foreign countries do not protect
intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from utilizing our inventions and trademarks in all countries outside the United States. Competitors may use our
technologies or trademarks in jurisdictions where we have not obtained patent or trademark protection to develop or market their own products and further, may export otherwise infringing products to territories where we have patent and trademark
protection, but enforcement on infringing activities is inadequate. These products or trademarks may compete with our products or trademarks, and our patents, trademarks or other intellectual property rights may not be effective or sufficient to
prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may decide to abandon national and regional patent applications before they are granted. The
examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with
claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not
allow for patent protection with respect to method of treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we seek to protect our intellectual property rights in our
expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in
such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our products in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded
from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the
United States and many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor
the enforcement of patents, trademarks and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents and trademarks or marketing of competing products in violation of our proprietary rights
generally. Proceedings to enforce our patent and trademarks rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trademarks in those jurisdictions, as well as elsewhere at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Certain countries in Europe and certain developing countries, including
India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license
to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities and our competitive position may be impaired. In addition, some countries limit the enforceability of
patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by
unforeseen changes in foreign intellectual property laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees have misappropriated the
intellectual property of a third party, including trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that our
employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged
trade secrets or other proprietary information of these former employers or competitors or other third parties. In addition, we may be subject to claims that we are infringing, misappropriating or otherwise violating other intellectual property
rights, such as trademarks or copyrights. To the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or
resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result
in substantial cost and be a distraction to our management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or
ownership of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to claims that former employees, collaborators,
or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property, including as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> We may be subject to ownership
or inventorship disputes in the future arising, for example, from conflicting obligations of consultants, contractors or others who are involved in developing our products. Although it is our policy to require our employees and contractors who may
be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops
intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The
assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
valuable intellectual property, and other owners may be able to license their rights to other third parties, including our competitors. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own,
based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may
be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in
addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other
proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of
operations, and may prevent us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and
could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent
our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors, and have
registered or applied to register these trademarks. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We cannot assure you that our trademark
applications will be approved for registration. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in
proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel trademark registrations. Opposition or cancellation proceedings
may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. Our competitors may also infringe or otherwise violate our trademarks and we may not have adequate resources to enforce our trademarks,
which may have a material adverse effect on our business. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the United States, where trademark rights are acquired based on use and
not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court. In the event that our trademarks are successfully challenged, we could be forced to
rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding
our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term,
if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have become aware of a third party&#146;s use of and pending U.S. application for the TEARCLEAR trademark in connection with ophthalmic
pharmaceuticals, which we believe may be an infringement of our TEARCARE trademark. We are currently considering taking action against this third-party, which may include filing a complaint for trademark infringement in federal court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We, or current or future collaborators, might not have been the first to make the inventions covered by the
issued patent or pending patent application that we license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We, or current or future collaborators, might not have been the first to file patent applications covering
certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing, misappropriating or otherwise violating our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is possible that our pending patent applications or those that we may own in the future will not lead to
issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products and operations are subject to extensive government regulation and oversight in the United States and elsewhere. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products are regulated as medical devices by the FDA. We and our products are subject to extensive regulation in the United States and
elsewhere, including by state agencies, the FDA and the FDA&#146;s foreign counterparts. The FDA and foreign regulatory agencies regulate, among other things, with respect to medical devices: design, development, manufacturing and release;
laboratory, preclinical and clinical testing; labeling, packaging, content and language of instructions for use and storage; product safety and efficacy; establishment registration and device listing; marketing, sales and distribution; <FONT
STYLE="white-space:nowrap">pre-market</FONT> clearance and approval; service operations; record keeping procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or
serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; post-market studies; and product import and export. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations to which we are subject are complex, burdensome to understand and apply and have tended to become more stringent over time.
Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA enforces these regulatory requirements through, among other means, periodic
(unannounced) inspections and periodic reviews of public marketing and promotion materials. We do not know whether we will be found compliant in connection with any future FDA or foreign inspections or reviews. Failure to comply with applicable
regulations could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jeopardize our ability to sell our products and result in enforcement actions such as: warning letters; untitled letters; fines; injunctions; civil penalties; termination of distribution; recalls
or seizures of products; delays in the introduction of products into the market; total or partial suspension of production; refusal to grant future clearances or approvals; withdrawals or suspensions of current approvals, resulting in prohibitions
on sales of our products; and in the most serious cases, criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not receive, or may be delayed in receiving, the necessary
clearances, certifications or approvals for our future products or modifications to our current products, and failure to timely obtain necessary clearances, certifications or approvals for our future products or modifications to our current products
would adversely affect our ability to grow our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., before we can market a new medical device, or a new use of,
new claim for or significant modification to an existing product, we must first receive either clearance under Section&nbsp;510(k) of the FDCA or approval of a <FONT STYLE="white-space:nowrap">pre-market</FONT> approval application, or PMA, from the
FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#147;substantially equivalent&#148; to a legally-marketed &#147;predicate&#148; device, which
includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device), a device that was originally on the U.S.
market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#147;substantially equivalent,&#148; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence.
In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial,
manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Modifications to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to
products cleared through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#146;s 510(k) clearance process usually takes from three to 12 months, but
can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is submitted to the FDA. Despite the time,
effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they
may include significant limitations on the indicated uses for the device, which may limit the market for the device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., we have
obtained clearance from the FDA of OMNI through the 510(k) clearance process. We also market TearCare as a 510(k)-exempt device and have submitted a 510(k) premarket notification seeking an expanded label for the device. Any further modification to
these products or their intended uses may require us to submit a new 510(k) premarket notification and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the change. Specifically, any modification to a 510(k)-cleared
device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every
manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#146;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We have made modifications
to 510(k)-cleared products in the past and have determined based on our review of the applicable FDA regulations and guidance that in certain instances new 510(k) clearances or PMA approvals were not required. We may make modifications or add
additional features in the future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our
products for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be
subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product introductions or modifications
could be delayed or canceled, which could adversely affect our ability to grow our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny clearance
or approval of a device for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our inability to demonstrate to the satisfaction of the FDA that our products are safe or effective for their
intended uses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The disagreement of the FDA with the design or conduct of our clinical trials or the interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Serious and unexpected adverse device effects experienced by participants in our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The data from our preclinical studies and clinical trials may be insufficient to support clearance or approval,
where required; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacturing process or facilities we use may not meet applicable requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential for approval policies or regulations of the FDA to change significantly in a manner rendering our
clinical data or regulatory filings insufficient for clearance or approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to sell our products in member
states of the EU, our products must comply with the essential requirements of the EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with these requirements is a prerequisite to be able to affix the CE mark to our products,
without which they cannot be sold or marketed in the EU. To demonstrate compliance with the essential requirements we must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification.
Except for <FONT STYLE="white-space:nowrap">low-risk</FONT> medical devices (Class I <FONT STYLE="white-space:nowrap">non-sterile,</FONT> <FONT STYLE="white-space:nowrap">non-measuring</FONT> devices), where the manufacturer can issue an EC
Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the EU Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited or
designated by a member state of the EU to conduct conformity assessments, or a Notified Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file and the quality system
for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its
manufacturer and their conformity with the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among
other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal
conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are
supported by suitable evidence. If we fail to remain in compliance with applicable European laws and directives and corresponding EU member state laws, we would be unable to continue to affix the CE mark to our products, which would prevent us from
selling them within the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of
the 27 EU member states plus Norway, Liechtenstein and Iceland. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> with the above requirements would also prevent us from selling our products in these three countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the end of the &#147;Brexit&#148; Transition Period, from January&nbsp;1, 2021
onwards, the MHRA will be responsible for the UK medical device market. The new regulations will require medical devices to be registered with the MHRA (but manufacturers will be given a grace period of four to 12 months to comply with the new
registration process). Manufacturers based outside the UK will need to appoint a UK Responsible Person to register devices with the MHRA in line with the grace periods. By July&nbsp;1, 2023, in the UK (England, Scotland, and Wales), all medical
devices will require a UKCA (UK Conformity Assessed) mark but CE marks issued by EU Notified Bodies will remain valid until this time. However, UKCA marking alone will not be recognized in the EU. The rules for placing medical devices on the
Northern Ireland market will differ from those in the UK. Compliance with this legislation is a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in the UK. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur significant liability if it is determined that we are promoting <FONT STYLE="white-space:nowrap">off-label</FONT> uses of our products in
violation of federal and state regulations in the United States or elsewhere. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities strictly
regulate the promotional claims that may be made about medical devices. In particular, the FDA requires that medical devices be labeled, advertised and promoted only in accordance with their approved or cleared indications for use (or, in the case
of products which are exempt from premarket review, in accordance with the regulations pertaining to such premarket clearance-exempt product classification). Similar limitations are imposed through certain national and international requirements
outside of the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently market TearCare as a powered heating pad exempt from premarket clearance. We are currently seeking FDA
clearance of TearCare for the application of localized heat therapy in adult patients with evaporative DED due to MGD, when used in conjunction with pressure to the eyelids to express the meibomian glands. However, the FDA may determine that the
clinical data we have provided or will provide is insufficient to support this indication and therefore not grant or delay clearance. For example, in January 2021, the FDA requested that we provide additional information in connection with such
submission, and we are currently in the process of collecting and analyzing the requested additional data. Further, the FDA may disagree with our belief that our existing indication is broad enough to include the delivery of localized heat where the
current medical community recommends application of a warm compress, such as MGD, DED, and blepharitis, in which case the FDA could assert that we are marketing the product in a manner that causes the product not to be exempt from premarket
clearance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA does not generally regulate the behavior of physicians in their choice of treatments. While physicians may choose to
use medical devices for uses that are not described in the product&#146;s labeling and for uses that differ from those authorized by the FDA, our promotional materials, promotional activities and training methods must comply with applicable FDA
regulations and other applicable federal, state and foreign laws and regulations, including the prohibition on the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA or equivalent foreign authorities determine that our labeling, promotional materials or other communications (including
communications by our employees or other agents) constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, they could request or require that we modify our promotional materials or subject us to regulatory or enforcement
actions, including the issuance of a warning letter or untitled letter, suspension or withdrawal of a product from the market, or requiring a recall or institution of fines, which could result in the disgorgement of money, operating restrictions,
injunctions, civil fines and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an <FONT
STYLE="white-space:nowrap">off-label</FONT> use, which could result in significant fines or penalties, such as laws prohibiting false or fraudulent claims for payment of government funds, such as the U.S. federal False Claims Act. In that event, our
reputation could be damaged and adoption of our products could be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the regulatory restrictions on <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion, the FDA and other regulatory authorities allow medical device companies to engage in truthful, <FONT STYLE="white-space:nowrap">non-misleading</FONT> and
<FONT STYLE="white-space:nowrap">non-promotional</FONT> scientific exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concerning their products. If the FDA or other regulatory or enforcement authorities determine that our communications regarding our marketed products are not in compliance with the relevant
regulatory requirements and that we have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may be subject to significant liability, including civil, criminal and administrative penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might
require us to recall or withdraw a product from the market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though we have obtained FDA clearance for OMNI and currently
market TearCare in the U.S. pursuant to a 510(k) exemption, we are subject to ongoing and pervasive regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import,
export, registration, and listing of devices. For example, we must submit periodic reports to the FDA as a condition of 510(k) clearance. These reports include information about failures and certain adverse events associated with the device after
its clearance. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate
further investigation. In addition, we must maintain an active registration of our facilities and listing of our products in order to legally market them in the United States. If the FDA were to disagree with our product listing or otherwise take
issue with our registration and listing compliance, it could result in delisting of our products or other enforcement action resulting in potential inability to market our products. For example, in October 2020, the FDA communicated to us that
TearCare may not be eligible for an exemption from 510(k) clearance. In response to that communication, among other things, we are currently seeking 510(k) clearance for TearCare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions
on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory clearance to market a device, we have ongoing responsibilities under FDA
regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA,
state or foreign regulatory authorities, which may include any of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Untitled letters, warning letters or adverse publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fines, injunctions, consent decrees and civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recalls, termination of distribution, administrative detention, or seizure of our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Customer notifications or repair, replacement or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays in or refusal to grant our requests for future clearances or approvals or foreign clearance, certification
or approval of new products, new intended uses, or modifications to existing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Withdrawals or suspensions of 510(k) clearances, or requirements for new 510(k) clearances, resulting in
prohibitions on sales of our products pending such further clearance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our
reputation, business, financial condition and results of operations. In addition, the FDA may change its clearance policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay clearance or
approval of our future products under development or impact </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our ability to modify our currently cleared or 510(k)-exempt products on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our
ability to obtain new clearances or approvals, increase the costs of compliance or restrict our ability to maintain our clearances of our current products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products must be manufactured in accordance with federal, state and foreign regulations, and we could be forced to recall our devices or terminate
production if we fail to comply with these regulations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The methods used in, and the facilities used for, the manufacture of our
products must comply with the FDA&#146;s QSR and the European Union Medical Devices Directive (Council Directive 93/42/EEC), both of which are complex regulatory schemes that cover the procedures and documentation of the design, testing, production,
process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. Furthermore, we are required to maintain, and to verify that our suppliers maintain, facilities,
procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the
facilities of subcontractors. Our products are also subject to similar state regulations, various laws and regulations of foreign countries governing manufacturing and a requirement for adherence to industry standards of the International Standards
Organization, or ISO, in connection with our medical device operations outside of the United States. Failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our products or manufacturing processes
could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of clearances or approvals; seizures or recalls of our products; total or partial suspension of production or
distribution; administrative or judicially imposed sanctions; the FDA&#146;s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal
prosecution of us, our suppliers, or our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received ISO 13485:2016 certification for our quality management system. ISO
certification generally includes recertification audits every third year, scheduled annual surveillance audits and periodic unannounced audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can provide no assurance that we will be found to remain in compliance with the QSR or ISO standards upon a regulator&#146;s review. If the
FDA or other regulator, inspects any of our manufacturers&#146; facilities and discovers compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings.
Any of the actions noted above could significantly and negatively affect supply of our products. Taking corrective action may be expensive, <FONT STYLE="white-space:nowrap">time-consuming</FONT> and a distraction for management. If any of these
events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA (or
similar foreign authorities), and if we fail to do so, we would be subject to sanctions that could negatively affect our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products,
or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the FDA&#146;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA
(and other foreign regulatory authorities) when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the
malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is based on the date we become aware of the adverse event as well as on the nature of the event. We may fail to report
adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with
our reporting obligations, the FDA or its foreign counterparts could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of device clearance or
approval, seizure of our products or delay in clearance or approval of future products, which could have a negative impact on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA
and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to
health. The FDA&#146;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency
is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or
failures to comply with applicable regulations. Product defects or other errors may occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiate a correction or
removal for our products to reduce a risk to health posed by them or to remedy a violation of law that may present a risk to health, we would be required to submit a report to the FDA and may be required to submit similar notifications to other
regulatory authorities. This report could lead to increased scrutiny by the FDA, other foreign regulatory agencies and our customers regarding the quality and safety of our products. Furthermore, the submission of these reports, to the extent made
publicly available in accordance with FDA regulations, could be used by competitors against us or otherwise publicized and cause physicians to delay or cancel product orders, which will harm our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we assess a potential quality issue or complaint as not requiring either a field action or regulatory notification, regulators may review
documentation of that decision during a subsequent audit. If regulators disagree with our decision, or take issue with either our investigation process or the resulting documentation, regulatory agencies may impose sanctions and we may be subject to
regulatory enforcement actions, including warning letters, all of which will negatively affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the corrective action we take to redress a product&#146;s deficiencies or defects, the FDA or FDA&#146;s foreign counterparts may
require, or we may decide, that we will need to obtain new clearances, certifications or approvals for the device before we may market or distribute the corrected device. Seeking such clearances, certifications or approvals may delay our ability to
replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions,
administrative penalties or civil or criminal fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies are required to maintain certain records of recalls and corrections, even
if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to
report those actions as recalls, and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any
corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and will negatively affect our reputation,
business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain and maintain applicable regulatory registrations, clearances,
certifications or approvals for our products, we will be unable to market and sell our products outside of the U.S. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to
expand our sales operations outside of the U.S. Sales of our products outside of the U.S. are subject to foreign regulatory requirements that vary widely from country to country. In addition, the FDA
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulates exports of medical devices from the U.S. While the regulations of some countries may not impose barriers to marketing and selling our products or only require notification, others
require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory requirements, including obtaining registrations, clearances, certifications or approvals, can be expensive and time-consuming, and we
may not receive regulatory clearances, certifications or approvals in each country in which we plan to market our products or we may be unable to do so on a timely basis. The time required to obtain registrations, clearances, certifications or
approvals, if required by other countries, may be longer than that required for FDA clearance or approval, and requirements for such registrations, clearances, certifications or approvals may significantly differ from FDA requirements. If we modify
our products, we may need to apply for regulatory clearances or approvals before we are permitted to sell the modified product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be able to sell the
applicable product in that country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory clearance or approval by the FDA does not ensure registration, clearance, certification or
approval by regulatory authorities in other countries, and registration, clearance, certification or approval by one or more foreign regulatory authorities does not ensure registration, clearance, certification or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance, certification or approval in one country may have a negative effect on the regulatory process in others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The clinical trial or investigation process is lengthy and expensive with uncertain outcomes. Results of earlier studies may not be predictive of future
clinical trial or investigation results, or the safety or efficacy profile for such products for such uses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is
difficult to design and implement, can take many years, can be expensive and carries uncertain outcomes. The results of preclinical studies and clinical trials and investigations of our products conducted to date and ongoing or future studies,
trials and investigations of our current, planned or future products may not be predictive of the results of later clinical trials or investigations, and interim results of a clinical trial or investigation do not necessarily predict final results.
Our interpretation of data and results from our clinical trials or investigations does not ensure that we will achieve similar results in future clinical trials or investigations. In addition, preclinical and clinical data are often susceptible to
various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials or investigations have nonetheless failed to produce strong results in later
clinical trials or investigations. Products in later stages of clinical trials or investigations may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials or investigations. We
incur substantial expense for, and devote significant time to, clinical trials or investigations but cannot be certain that such trials will yield positive results relating to our products. Failure can occur at any stage of clinical testing. Our
clinical trials or investigations may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing in addition to those we
have planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initiation and completion of any of clinical trials may be prevented, delayed, or halted for numerous reasons. We may
experience delays in our ongoing clinical trials for a number of reasons, which could adversely affect the costs, timing or successful completion of our clinical trials, including related to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be required to submit an Investigational Device Exemption, or IDE, application to FDA, which must become
effective prior to commencing certain human clinical trials of medical devices, and FDA may reject our IDE application and notify us that we may not begin clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulators and other comparable foreign regulatory authorities may disagree as to the design or conduct of our
clinical trials or investigations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulators and/or institutional review boards, or IRBs, or other reviewing bodies may not authorize us or our
investigators to commence a clinical trial or investigation, or to conduct or continue a clinical trial or investigation at a prospective or specific trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical trials or investigations may produce negative or inconclusive results, and we may decide, or regulators
may require us, to conduct additional clinical trials or investigations or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The number of subjects or patients required for clinical trials may be larger than we anticipate, enrollment in
these clinical trials or investigations may be insufficient or slower than we anticipate, and the number of clinical trials or investigations being conducted at any given time may be high and result in fewer available patients for any given clinical
trial, or patients may drop out of these clinical trials or investigations at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our third-party contractors, including those manufacturing products or conducting clinical trials or
investigations on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We might have to suspend or terminate clinical trials or investigations for various reasons, including
difficulties in patient enrollment or a finding that the subjects are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may have to amend clinical trial or investigation protocols or conduct additional studies to reflect changes
in regulatory requirements or guidance, which we may be required to submit to an IRB or other reviewing bodies and/or regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulators, IRBs or other reviewing bodies, or other parties may require or recommend that we or our
investigators suspend or terminate clinical research for various reasons, including safety signals or noncompliance with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The cost of clinical trials or investigations may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical sites may not adhere to our clinical protocol or may drop out of a clinical trial or investigation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to recruit a sufficient number of clinical trial or investigation sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulators, IRBs, or other reviewing bodies may fail to approve or subsequently find fault with our manufacturing
processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical trials or investigations may be insufficient,
inadequate or not available at an acceptable cost, or we may experience interruptions in supply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval policies or regulations of FDA or applicable foreign regulatory agencies may change in a manner
rendering our clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our current or future products may have undesirable side effects or other unexpected characteristics.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the
likelihood that we encounter such difficulties or delays in our planned and ongoing clinical trials or investigations. If <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to spread, we may experience disruptions that could have a material
adverse impact on our clinical trial plans and timelines, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays in receiving authorizations from local regulatory authorities to initiate planned clinical trials or
investigations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays or difficulties in enrolling patients in our clinical trials or investigations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including
interruptions in global shipping that may affect the transport of clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic which may require us to change the ways in which our clinical trials or investigations are conducted, which may result in unexpected costs, or to discontinue the clinical trials or investigations altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Diversion of healthcare resources away from the conduct of clinical trials or investigations, including the
diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials or investigations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interruption of key clinical trial or investigation activities, such as clinical trial site monitoring, due to
limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk that participants enrolled in our clinical trials or investigations will contract <FONT
STYLE="white-space:nowrap">COVID-19</FONT> while the clinical trial or investigation is ongoing, which could impact the results of the clinical trial or investigation, including by increasing the number of observed adverse events;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delays in necessary interactions with local regulators, ethics committees and other third parties and contractors
due to limitations in employee resources or forced furlough of government employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Limitations in employee resources that would otherwise be focused on the conduct of our clinical trials or
investigations, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refusal of the FDA to accept data from clinical trials or investigations in affected geographies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors may significantly harm our business, financial condition and prospects. In addition, many of the
factors that cause, or lead to, a delay in the commencement or completion of clinical trials or investigations may also ultimately lead to the denial of regulatory approval of our product candidates, which may also significantly harm our business,
financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment in clinical trials or investigations and completion of patient <FONT
STYLE="white-space:nowrap">follow-up</FONT> depend on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial or
investigation, patient compliance, competing clinical trials or investigations and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product being studied in relation to other available therapies, including any
new treatments that may be approved for the indications we are investigating. For example, patients may be discouraged from enrolling in our clinical trials or investigations if the trial protocol requires them to undergo extensive <FONT
STYLE="white-space:nowrap">post-treatment</FONT> procedures, monitoring or <FONT STYLE="white-space:nowrap">follow-up</FONT> to assess the safety and efficacy of a product, or they may be persuaded to participate in contemporaneous clinical trials
of a competitor&#146;s product. In addition, patients participating in our clinical trials or investigations may drop out before completion of the trial or experience adverse medical events unrelated to our products. Delays in patient enrollment or
failure of patients to continue to participate in a clinical trial or investigation may delay commencement or completion of the clinical trial or investigation, cause an increase in the costs of the clinical trial or investigation and delays, or
result in the failure of the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials and investigations must be conducted in accordance with the regulations of
the FDA and other applicable regulatory authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs or other regulatory bodies at the medical institutions where the clinical
trials or investigations are conducted. In addition, clinical trials and investigations must be conducted with supplies of our devices produced under QSR requirements and other regulations. Further, clinical trials of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical devices for investigational uses must be conducted in accordance with the FDA&#146;s IDE regulations, which govern investigational device labeling, prohibit promotion of the device for
investigational uses, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Further, for certain devices which present a &#147;significant risk&#148; to human health, as defined
by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing clinical trials. We have in the past, and may in the future, conduct clinical trials and investigations that do
not comply with all applicable regulations of the FDA and other applicable regulatory authorities&#146; legal requirements, regulations or guidelines. Even if we conclude that the conduct of any of our clinical trials or investigations comply with
the applicable requirements, regulations or guidelines, there can be no guarantee that the FDA or other applicable regulatory authorities will agree with such conclusion. If the FDA determines that we have failed to comply with applicable regulatory
requirements for the conduct of our clinical trials and investigations, the FDA may refuse to accept any data generated from such clinical trials and investigations in any future premarket applications, and may take a variety of other compliance or
enforcement actions, which may result in, among other things, warning letters, untitled letters, fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements, refunds, recalls or seizures of products,
operating restrictions, total or partial suspension of production, the FDA&#146;s refusal to issue certificates to foreign governments needed to export products for sale in other countries, the FDA&#146;s refusal to grant future premarket clearances
or approvals, suspensions of current product clearances or approvals and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may rely on CROs, and
clinical trial sites to ensure the proper and timely conduct of our clinical trials or investigations and we may have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our
clinical trials or investigations in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials and investigations, fail to conduct the study to GCP
standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials and investigations that are conducted in
countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> CROs, as well as
expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our future products are cleared or approved in the U.S., commercialization of our products in foreign countries would require
clearance, certification or approval by regulatory authorities in those countries. Clearance, certification or approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater
than, those in the U.S., including additional preclinical studies or clinical trials or investigations. Any of these occurrences could have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government agencies could hinder their ability to
hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed, cleared or approved or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at
the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new devices to be reviewed and/or approved or cleared by
necessary government agencies, which would adversely affect our business. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA,
have had to furlough critical FDA employees and stop critical activities. Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its intention to postpone inspections of
foreign manufacturing facilities and products, and subsequently, on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&nbsp;10, 2020 the FDA announced its
intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the
categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Other regulatory authorities may adopt similar restrictions or other policy
measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting business as
usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, Notified Bodies must be officially designated to certify products and services in accordance with the EU Medical
Devices Regulation. Notified Bodies which have applied for designation under the EU Medical Devices Regulation are currently undergoing such designation assessments. Only a few Notified Bodies have been designated so far and the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has significantly slowed down their designation process. Without EU Medical Devices Regulation designation, Notified Bodies may not yet start certifying devices in accordance with the new
Regulation. This situation could impact the way we are conducting our business and lead to delays in recertification and compliance with the EU Medical Devices Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under normal circumstances, medical devices manufacturers must undergo <FONT STYLE="white-space:nowrap">on-site</FONT> audits by Notified
Bodies in order to maintain their <FONT STYLE="white-space:nowrap">CE-mark</FONT> certifications per the requirements of the EU Medical Devices Directive. As many <FONT STYLE="white-space:nowrap">CE-mark</FONT> certifications will become void as
part of the transition to the EU Medical Devices Regulation, Notified Bodies also have to start certifying medical devices in accordance with the EU Medical Devices Regulation. As another consequence of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, <FONT STYLE="white-space:nowrap">on-site</FONT> Notified Bodies&#146; audits have not been feasible due to quarantine and travel restrictions and most of them have been postponed. Even
though some specific measures have been implemented to determine whether remote audits can be conducted or be supplemented with an <FONT STYLE="white-space:nowrap">on-site</FONT> audit once travel restrictions are lifted, this situation could
significantly impact the ability of Notified Bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to certain federal, state and foreign fraud and abuse laws, health information privacy and security laws and transparency laws that could
subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false
claims and physician transparency laws. Our business practices and relationships with providers are subject to scrutiny under these laws. We may also be subject to privacy and security regulation related to patient, customer, employee and other
third-party information by both the federal government and the states and foreign jurisdictions in which we conduct our business. The healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual or furnishing or arranging for a good or service, for which payment may be made, in whole
or in part, under federal healthcare programs, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. The U.S. government has
interpreted this law </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
broadly to apply to the marketing and sales activities of manufacturers. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Violations of the federal Anti-Kickback Statute may result in significant civil monetary penalties, plus up to three times the
remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including significant criminal fines and imprisonment of up to 10 years. Similarly,
violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil and criminal false claims laws and civil monetary penalties laws, including the federal civil
False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal healthcare programs that are false or fraudulent. These
laws can apply to manufacturers who provide information on coverage, coding, and reimbursement of their products to persons who bill third-party payors. Private individuals can bring False Claims Act &#147;qui tam&#148; actions, on behalf of the
government and such individuals, commonly known as &#147;whistleblowers,&#148; may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the federal civil False Claims Act, the
government may impose significant civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring
remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#146;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not
need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Physician Payments Sunshine Act which requires certain applicable manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, or CHIP, to report annually to the DHHS Centers for Medicare and Medicaid Services, or CMS, information related
to payments and other transfers of value to physicians, which is defined broadly to include other healthcare providers and teaching hospitals, and applicable manufacturers and group purchasing organizations, to report annually ownership and
investment interests held by physicians and their immediate family members. Additionally, on October&nbsp;25, 2018, President Trump signed into law the &#147;Substance <FONT STYLE="white-space:nowrap">Use-Disorder</FONT> Prevention that Promoted
Opioid Recovery and Treatment for Patients and Communities Act&#148; which in part (under a provision entitled &#147;Fighting the Opioid Epidemic with Sunshine&#148;) extends the reporting and transparency requirements for physicians in the
Physician Payments Sunshine Act to physician assistants, nurse practitioners, and other <FONT STYLE="white-space:nowrap">mid-level</FONT> practitioners (with reporting requirements going into effect in 2022 for payments made in 2021). Applicable
manufacturers are required to submit annual reports to CMS. Failure to submit required information may result in significant civil monetary penalties (and additional penalties for &#147;knowing failures&#148;), for all payments, transfers of value
or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH
Act, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their business associates that perform services for them that involve
individually identifiable health </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization, including mandatory contractual terms as well as
directly applicable privacy and security standards and requirements. Failure to comply with the HIPAA privacy and security standards can result in significant civil monetary penalties, and, in certain circumstances, criminal penalties with fines
and/or imprisonment. State attorneys general can also bring a civil action to enjoin a HIPAA violation or to obtain statutory damages on behalf of residents of his or her state; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal and state laws and regulations regarding billing and claims payment applicable to our products and
regulatory agencies enforcing those laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false
claims laws, which may apply to items or services reimbursed by any <FONT STYLE="white-space:nowrap">third-party</FONT> payor, including commercial insurers or patients; state laws that require device companies to comply with the industry&#146;s
voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device
manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; consumer protection and unfair competition laws, which broadly regulate marketplace
activities and activities that potentially harm customers, foreign and state laws, including the EU General Data Protection Regulation, or GDPR, governing the privacy and security of personal (including health) information in certain circumstances,
many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws and regulations, among other things, constrain our business, marketing and other promotional and research activities by limiting
the kinds of financial arrangements, including sales programs, we may have with hospitals, ambulatory surgery centers, physicians or other potential purchasers of our products. We have entered into consulting agreements with physicians, including
some who have ownership interests in us, which could be viewed as influencing the purchase of or use of our products in procedures they perform. Compensation under some of these arrangements includes the provision of stock or stock options. Due to
the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged
under one or more of these laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any action brought against us for violations of these laws or regulations, even if successfully
defended, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. We may be subject to private qui tam actions brought by individual whistleblowers on behalf of the federal or
state governments, with potential liability under the federal False Claims Act including mandatory treble damages and significant <FONT STYLE="white-space:nowrap">per-claim</FONT> penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To enforce compliance with the healthcare regulatory laws, certain enforcement bodies have recently increased their scrutiny of interactions
between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be
<FONT STYLE="white-space:nowrap">time-and</FONT> resource-consuming and can divert management&#146;s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional
compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business, financial condition and results of
operations. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity, and be costly to respond to. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities, including those relating to providing billing, coding, coverage and
reimbursement information about procedures using our products to our customers and the sale and marketing of our products, may be subject to scrutiny under these laws. The growth of our business and sales organization and our expansion outside of
the United States may increase the potential of violating these laws or our internal policies and procedures. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause
us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current
or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to significant penalties, including significant criminal, civil, and administrative penalties, damages, fines, exclusion from participation in
government programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputation harm and disgorgement and we could be required to curtail, restructure or cease our operations. Any of the foregoing consequences will negatively
affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to governmental regulations and other legal obligations,
particularly related to privacy, data protection and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to
comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the conduct of our business, we may at times process personal data, including health-related personal data. The U.S. federal government and
various states have adopted or proposed laws, regulations, guidelines and rules for the collection, distribution, use and storage of personal information of individuals. We may also be subject to U.S. federal rules, regulations and guidance
concerning data security for medical devices, including guidance from the FDA. According to the Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers&#146; personal information secure constitutes unfair acts or
practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and
volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits
stronger safeguards. State privacy and security laws vary from state to state and, in some cases, can impose more restrictive requirements than U.S. federal law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, such as the European Union General Data Protection
Regulation (2016/679), or GDPR, govern the privacy and security of personal (including health) data in certain circumstances, some of which are more stringent than U.S. federal law and many of which differ from each other in significant ways and may
not have the same effect, thus complicating compliance efforts. The GDPR is directly applicable in each member state and is extended to the EEA. Failure to comply with these laws, where applicable, can result in the imposition of significant civil
and/or criminal penalties and private litigation. Where state laws are more protective, we must comply with the stricter provisions. In addition to fines and penalties that may be imposed for failure to comply with state law, some states also
provide for private rights of action to individuals for misuse of personal information. For example, California enacted the California Consumer Privacy Act, or CCPA, on June&nbsp;28, 2018, which went into effect on January&nbsp;1, 2020. The CCPA
creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for
data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the GDPR went into effect on May&nbsp;25, 2018 and introduces strict requirements for processing the personal data of European
Union data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to
&#128;20&nbsp;million or 4% of the annual global revenues of the preceding financial year of the noncompliant company, whichever is greater. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR
to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For
example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European
Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, from January&nbsp;1, 2021, companies have to comply with the GDPR and also the United Kingdom General Data Protection
Regulation, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#128;20&nbsp;million (&pound;17.5 million)
or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is also unclear how United Kingdom data protection laws and regulations will
develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. These changes will lead to additional costs and increase our overall risk exposure. Currently there is a four to six
month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June&nbsp;30, 2021 at the latest, whilst the parties discuss an adequacy decision. The European Commission published a draft adequacy decision on
February&nbsp;19, 2021. If adopted, the decision will enable data transfers from EU member states to the United Kingdom for a four-year period, subject to subsequent extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any actual or perceived failure by us or the third parties with whom we work to comply with privacy or security laws, policies, legal
obligations or industry standards, or any security incident that results in the unauthorized release or transfer of personally identifiable information, may result in governmental enforcement actions and investigations including by European Data
Protection Authorities and U.S. federal and state regulatory authorities, fines and penalties, litigation and/or adverse publicity, including by consumer advocacy groups, and could cause our customers, their patients and other healthcare
professionals to lose trust in us, which could harm our reputation and have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any third-party service providers with access to our or our customers&#146;, suppliers&#146;, trial patients&#146;
and employees&#146; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or
attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and
financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information.
Increasing use of social media could also give rise to liability, breaches of data security or reputational damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we work to
comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another,
and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with
such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, consultants, and other commercial partners may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our
employees, consultants, distributors and other commercial partners and business associates may engage in fraudulent or other illegal activity. Misconduct by these parties could include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intentional, reckless or negligent conduct or other unauthorized activities that violate the regulations of the FDA and other regulators (both domestic and foreign), including those laws
requiring the reporting of true, complete and accurate information to such regulators, manufacturing standards, healthcare fraud and abuse laws and regulations in the U.S. and internationally or laws that require the true, complete and accurate
reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry, including the sale of medical devices, are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. It is not always possible to identify and deter misconduct by our employees, consultants and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending
ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from
participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, any of which could adversely affect our business, financial
condition and results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and reputational harm, and divert the attention of management in
defending ourselves against any of these claims or investigations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance with environmental laws and regulations could be expensive, and the
failure to comply with these laws and regulations could subject us to significant liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development
operations involve the use of hazardous substances, such as isopropyl alcohol and various adhesives. We are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, handling,
generation, manufacture, treatment, discharge and disposal of, hazardous substances. Our products may also contain hazardous substances, and they are subject laws and regulations relating to labelling requirements and to their sale, collection,
recycling, treatment, storage and disposal. Compliance with these laws and regulations may be expensive and noncompliance could result in substantial fines and penalties. Environmental laws and regulations also impose liability for the remediation
of releases of hazardous substances into the environment and for personal injuries resulting from exposure to hazardous substances, and they can give rise to substantial remediation costs and to third-party claims, including for property damage and
personal injury. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence, and they tend to become more stringent over time, imposing greater compliance costs and increased risks and
penalties associated with violations. We cannot assure you that violations of these laws and regulations, or releases of or exposure to hazardous substances, will not occur in the future or have not occurred in the past, including as a result of
human error, accidents, equipment failure or other causes. The costs of complying with environmental laws and regulations, and liabilities that may be imposed for violating them, or for remediation obligations or responding to third-party claims,
could negatively affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare policy changes, including recently enacted
legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare
system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the
procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our
products. The Affordable Care Act, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ACA, made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the ACA: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Imposed a new federal excise tax on the sale of certain medical devices, which was suspended, effective
January&nbsp;1, 2016, and permanently repealed in December 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative
clinical effectiveness research in an effort to coordinate and develop such research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals,
physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expanded the eligibility criteria for Medicaid programs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be
additional challenges and amendments to the ACA in the future. By way of example, the Tax Cuts and Jobs Act of 2017, or TCJA, was enacted, which, among other things, removes penalties for not complying with the individual mandate to carry health
insurance. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas (Texas District Court Judge) ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was
repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and
remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March&nbsp;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review
this case, and the Court held oral argument on November&nbsp;10, 2020. The case is expected to be decided in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> It is unclear how this decision or other efforts to challenge, repeal or replace the ACA
will impact the law and our business. Any expansion in the government&#146;s role in the U.S. healthcare industry may result in decreased profits to us, lower reimbursement by payors for procedures using OMNI, and/or reduced medical procedure
volumes, any of which may have a material adverse effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April&nbsp;1, 2013
and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through March&nbsp;31, 2021, unless additional Congressional action is taken.
Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, enacted on April&nbsp;16, 2015, repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with
fixed annual updates and a new system of incentive payments that are based on various performance measures and physicians&#146; participation in alternative payment models such as accountable care organizations. It is unclear what effect new quality
and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
additional state and federal healthcare policies and reform measures to be adopted in the future, any of which could limit reimbursement for healthcare products and services or otherwise result in reduced demand for our products or additional
pricing pressure and have a material adverse effect on our industry generally and on our customers. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any
future legislation or regulation in the U.S. may negatively affect our business, financial condition and results of operations. The continuing efforts of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to generate revenue and achieve or maintain profitability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes of, or uncertainty with respect to, future coverage or reimbursement rates could affect demand for our products, which in turn
could impact our ability to successfully commercialize these devices and could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to continue sales of our products in the European Union may be materially impaired if we do not take necessary steps to comply with the
certification requirements of the new EU Medical Device Regulation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;25, 2017, the EU Medical Devices Regulation
(Regulation 2017/745) entered into force, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without
the need for adoption of EU member state laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The Medical Devices Regulation, among other
things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medical Devices Regulation was originally intended to become effective three years after publication, but in April 2020 the transition
period was extended by the European Parliament and the Council of the EU by an additional year, until May&nbsp;26, 2021. Devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May&nbsp;26, 2021 may generally
continue to be made available on the market or put into service until May&nbsp;26, 2025. Once effective, the new regulations will among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthen the rules on placing devices on the market and reinforce surveillance once they are available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish explicit provisions on manufacturers&#146; responsibilities for the
<FONT STYLE="white-space:nowrap">follow-up</FONT> of the quality, performance and safety of devices placed on the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Improve the traceability of medical devices throughout the supply chain to the
<FONT STYLE="white-space:nowrap">end-user</FONT> or patient through a unique identification number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Set up a central database to provide patients, healthcare professionals and the public with comprehensive
information on products available in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthen the rules for the assessment of certain high-risk devices, which may have to undergo an additional
check by experts before they are placed on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These modifications may have an effect on the way we design and
manufacture products and conduct our business in the EU and EEA (also including Norway, Liechtenstein and Iceland). For example, as a result of the transition towards the new regime, notified body review times have lengthened, and product
introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">EU-UK</FONT> Trade and Cooperation Agreement, or TCA, came into effect on January&nbsp;1, 2021. The TCA does not specifically refer to medical devices. However, as a result of Brexit, the EU Medical Devices Regulation will
not be implemented in the UK, and previous legislation that mirrored the EU Medical Devices Regulation in the UK law has been revoked. The regulatory regime for medical devices in the UK will continue to be based on the requirements derived from
current EU legislation, and the UK may choose to retain regulatory flexibility or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
align with the EU MDR going forward. CE markings will continue to be recognized in the UK, and certificates issued by <FONT STYLE="white-space:nowrap">EU-recognized</FONT> Notified Bodies will be
valid in the UK, until June&nbsp;30, 2023. For medical devices placed on the UK market after this period, the UK Conformity Assessment (UKCA) marking will be mandatory. In contrast, UKCA marking and certificates issued by UK Notified Bodies will not
be recognized on the EU market. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including market surveillance, enforcement activities and measures, standardization related activities,
exchanges of officials, and coordinated product recalls (or other similar actions). For medical devices that are locally manufactured but use components from other countries, the &#147;rules of origin&#148; criteria will need to be reviewed.
Depending on which countries products will be ultimately sold in, manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for placing medical devices on the Northern Ireland
market will differ from those in the UK. These modifications may have an effect on the way we design and manufacture products and we conduct our business in these countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our common stock
has never been publicly traded, and we expect that the price of our common stock will fluctuate substantially. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before this initial
public offering, there has been no public market for our common stock. The initial public offering price for our common stock will be determined through negotiations between the underwriters and us and may vary substantially from the market price of
our common stock following this offering. An active public trading market may not develop after completion of this offering or, if developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time
you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other products, technologies or businesses using our shares as
consideration. Furthermore, although our common stock has been approved for listing on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , there can be no guarantee that we will continue to satisfy
the continued listing standards of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . If we fail to satisfy such exchange&#146;s continued listing standards, we could be <FONT
STYLE="white-space:nowrap">de-listed,</FONT> which would have a negative effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this
offering, the market price of our common stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control or are related in complex ways, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in analysts&#146; estimates, investors&#146; perceptions, recommendations by securities analysts or our
failure to achieve analysts&#146; estimates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly variations in our or our competitors&#146; results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Periodic fluctuations in our revenue, which could be due in part to the way in which we recognize revenue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The financial projections we may provide to the public, any changes in these projections or our failure to meet
these projections; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Future sales of our common stock or other securities, by us or our stockholders, as well as the anticipation of <FONT
STYLE="white-space:nowrap">lock-up</FONT> releases or <FONT STYLE="white-space:nowrap">lock-up</FONT> waivers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General market conditions and other factors unrelated to our operating performance or the operating performance
of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in reimbursement by current or potential payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in operating performance and stock market valuations of other technology companies generally, or those in
the medical device industry in particular; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Actual or anticipated changes in regulatory oversight of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The loss of key personnel, including changes in our board of directors and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product recalls or other problems associated with our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legislation or regulation of our market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lawsuits threatened or filed against us, including litigation by current or former employees alleging wrongful
termination, sexual harassment, whistleblower or other claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The announcement of new products or product enhancements by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announced or completed acquisitions of businesses or technologies by us or our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announcements related to patents issued to us or our competitors and related litigation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Developments in our industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the trading prices for common stock of other medical device companies have been highly volatile as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak continues to rapidly evolve. The extent to which the outbreak may impact our business will depend on future developments, which are
highly uncertain and cannot be predicted with confidence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the stock markets generally have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual
operating performance. These fluctuations may be even more pronounced in the trading market for our common stock shortly following this offering. If the market price of shares of our common stock after this offering does not ever exceed the initial
public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
in the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention
of management from our business and harm our business, results of operations, financial condition and reputation. These factors may materially and adversely affect the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock
price or trading volume to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price and trading volume may be heavily influenced by the way analysts and investors
interpret our financial information and other disclosures. If securities or industry analysts do not publish research or reports about our business, delay publishing reports about our business, or publish negative reports about our business,
regardless of accuracy, our common stock price and trading volume could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a trading market for our common stock develops, the
trading market will be influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a newly public company, we may be slow to attract research
coverage and the analysts who publish information about our common stock will have had relatively little experience with us or our industry, which could affect their ability to accurately forecast our results and could make it more likely that we
fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could
decline. We may also fail to meet the expectations of these analysts, leading to a reduction in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the market price of our common stock. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn
could cause our stock price or trading volume to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our common stock is actively covered by analysts, we do not have any
control over the analysts or the measures that analysts or investors may rely upon to forecast our future results. Over-reliance by analysts or investors on any particular metric to forecast our future results may lead to forecasts that differ
significantly from our own. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and a smaller reporting company and we cannot be certain if the reduced disclosure
requirements applicable to us will make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company,&#148; as defined in the JOBS Act, and we expect to take advantage of certain exemptions and relief from various reporting requirements that are applicable to other public companies that are not emerging growth companies. In particular,
while we are an emerging growth company, we will not be required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; we will be exempt from any rules that could be
adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#146;s report on financial statements; we will be subject to reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while we are an emerging growth company we can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period
and, as a result, our operating results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new or revised accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2026, (2) the last day of the fiscal year in which
we have total annual gross revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the fiscal year in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700.0&nbsp;million as of the prior June 30th, or (4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during
the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a
smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for
so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter,
or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors may find our common stock less
attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. We have elected to take advantage of these exemptions and relief. If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our stock price may decline or become more volatile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you
will incur immediate and substantial dilution in the book value of your shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors purchasing common stock in this offering
will pay a price per share that substantially exceeds the pro forma as adjusted net tangible book value per share. As a result, investors purchasing common stock in this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering will incur immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share if the underwriters exercise their option to purchase additional shares in full), based on an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page of this prospectus) and our pro forma as adjusted net tangible book value per
share as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. For more information on the dilution you may suffer as a result of investing in this offering, see the section of this prospectus
entitled &#147;Dilution.&#148; If outstanding options or warrants are exercised in the future, you will experience additional dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this offering as compared to the
price offered to the public in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are restricted from immediate resale but may be
sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the
market that the holders of a large number of shares intend to sell their shares, could result in a decrease in the market price of our common stock. Upon the closing of this offering, we will
have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding based on the number of shares outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021. This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction,
unless purchased by our affiliates. Of the remaining shares,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares are currently restricted as a result of vesting restrictions, securities laws or <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (which may be waived, with or without notice, by Morgan Stanley&nbsp;&amp; Co. LLC and BofA Securities, Inc.) but will be able to be sold after the
offering as described in the section of this prospectus entitled &#147;Shares Eligible for Future Sale.&#148; Moreover, after this offering, holders of an aggregate of up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including shares of our common stock issuable upon the conversion of the shares of our convertible preferred stock that
will be outstanding immediately prior to the consummation of this offering, will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that
we may file for ourselves or other stockholders as described in the section of this prospectus entitled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares,
they can be freely sold in the public market, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section of this prospectus entitled &#147;Underwriting.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our common stock as restrictions end or pursuant to registration rights may make it more difficult for us to sell equity
securities in the future at a time and at a price that we deem appropriate. These sales also could cause the price of our common stock to fall and make it more difficult for you to sell shares of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our directors, executive officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of
our other stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, our executive officers, directors and principal stockholders each holding more than
5% of our common stock will collectively control approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares of common stock). As a result, these
stockholders, if they act together, will be able to control the management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This
concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not
approve. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of
the purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their
currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we
may invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not
yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant additional costs as a result of being a public company, and our management will be required to devote substantial time to
compliance with our public company responsibilities and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we
expect to incur costs associated with corporate governance requirements that will become applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer
Protection Act of 2010, and the Exchange Act, as well as the rules of Nasdaq. These rules and regulations are expected to significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. We
expect such expenses to further increase after we are no longer an emerging growth company. We also expect these rules and regulations to make it more expensive for us to maintain directors&#146; and officers&#146; liability insurance. As a result,
it may be more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers. Furthermore, these rules and regulations will increase our legal and financial compliance costs and will make some
activities more time-consuming and costly. We cannot predict or estimate the amount of additional costs we will incur as a public company or the timing of such costs. Accordingly, increases in costs incurred as a result of becoming a publicly traded
company may adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to more stringent state
law requirements. For example, on September&nbsp;30, 2018, California signed into law Senator Bill 826, which generally requires public companies with principal executive offices in California to have a minimum number of females on the
company&#146;s board of directors. By December&nbsp;31,&nbsp;2019, each public company with principal executive offices in California was required to have at least one female on its board of directors. By December&nbsp;31, 2021, each public company
is required to have at least two females on its board of directors if the company has at least five directors, and at least three females on its board of directors if the company has at least six directors. The new law does not provide a transition
period for newly listed companies. We are currently compliant with the requirements, but there are no assurances that we will be compliant in the future. If we fail to comply with this new law, we could be fined by the California Secretary of State,
with a $100,000 fine for the first violation and a $300,000 for each subsequent violation, and our reputation may be adversely affected. Further, in September 2020, California enacted AB 979 requiring public companies headquartered in California to
maintain minimum representation on their boards of directors from members of underrepresented communities as follow: by the end of 2021, at least one director from an underrepresented community, by end of 2022, public company boards with more than
four but fewer than nine members will be required to have at least two directors from underrepresented communities, and public company boards with nine or more members will be required to have at least three directors from underrepresented
communities. Failure to achieve designated minimum levels in a timely manner exposes such companies to financial penalties and reputational harm. If we are unable to recruit, attract and/or retain qualified members of the board and meet the
requirements of the California laws it may expose us to penalties and/or reputational harm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain effective internal control over financial reporting and effective disclosure
controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently required to comply with the rules of the SEC implementing Section&nbsp;404 and, therefore, we are not required to make a
formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon becoming a public company, we will be required to comply with the SEC&#146;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley
Act, which require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. Although we will be required to disclose
changes made in our internal controls and procedures on a quarterly basis, we are not required to make our first annual assessment of our internal control over financial reporting pursuant to Section&nbsp;404 until the year following our first
annual report required to be filed with the SEC. As an emerging growth company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to
Section&nbsp;404 until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a
report that is adverse in the event material weaknesses have been identified in our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To comply
with the requirements of being a public company, we will need to undertake actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Testing and maintaining internal control can
divert our management&#146;s attention from other matters that are important to the operation of our business. In addition, when evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to
remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section&nbsp;404. If we identify any material weaknesses in our internal controls over financial reporting or we are unable to comply with the
requirements of Section&nbsp;404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our
internal control over financial reporting once we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports. As a result, the market price of our common stock could be
materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material weaknesses in our internal control over financial reporting may cause us to fail to timely and accurately
report our financial results or result in a material misstatement of our financial statements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our
financial statements for the year ended December&nbsp;31, 2020, we identified a material weakness in our internal controls due to a lack of sufficient full-time accounting personnel with requisite experience and deep technical accounting knowledge
to (i)&nbsp;identify and resolve complex accounting issues under generally accepted accounting principles in the United States, or GAAP, and (ii)&nbsp;enable appropriate segregation of duties and reviews over the financial reviews over the financial
close and reporting process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are evaluating and implementing additional internal controls and procedures to remediate this material
weakness, however, we cannot assure you that these or other measures will fully remediate the material weakness in a timely manner or prevent future material weaknesses from occurring. As part of our remediation plan to address the material weakness
identified above, we are actively working to hire additional accounting employees with specific technical accounting and financial reporting experience necessary for a public company. We will continue to assess the adequacy of our accounting
personnel and resources, and will add additional personnel, as well as adjust our resources, as necessary, commensurate with any increase in the size and complexity of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed
upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results or report them within the timeframes required by law </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or stock exchange regulations. Failure to comply with Section&nbsp;404 could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional
material weaknesses exist or are discovered in the future, and we are unable to remediate any such material weaknesses, our reputation, financial condition, and operating results could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our restated certificate of incorporation and restated bylaws and under Delaware law could make an acquisition of our company, which may
be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our restated certificate of incorporation and our restated bylaws, which will become effective upon the closing of this offering
may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could
also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members
of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other
things, these provisions include those establishing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A classified board of directors with three-year staggered terms, which may delay the ability of stockholders to
change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of
the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the
terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability of our board of directors to alter our bylaws without obtaining stockholder approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The required approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the shares
entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual
or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The requirement that a special meeting of stockholders may be called only by the chairman of the board of
directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise
attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the
provisions of Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date
of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our restated certificate of incorporation will designate specific courts as the exclusive forum for
certain litigation that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation, which will become effective upon the closing of this offering, specifies that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum
provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder or any other claim for which the federal courts have exclusive jurisdiction; and
provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware.
Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the
sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have
notice of and to have consented to the provisions of our restated certificate of incorporation described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these
provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable,
efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors,
officers, employees and agents as it may limit any stockholder&#146;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of
similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice
of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be
inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements about us and our industry. All statements other than statements of historical facts
contained in this prospectus are forward-looking statements, including, but not limited to, statements regarding: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our plans to develop and commercialize our current or future technology or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing or outcome of our ongoing or planned clinical trials for OMNI, TearCare and any future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Business disruptions affecting our clinical trials, operations and financial results, including a public health
emergency, such as the ongoing COVID-19 pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing and our ability to obtain and maintain regulatory approvals for OMNI, TearCare and any future
products, and to comply with federal, state and foreign regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The timing and our ability to obtain and maintain adequate levels of third-party coverage and reimbursement for
OMNI, TearCare and any future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The clinical utility of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our expectation about the willingness of ECPs to use OMNI, TearCare and any future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our expectation about the size of the addressable market for OMNI, TearCare and any future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our intellectual property position, including the scope of protection we are able to obtain, maintain, protect
and enforce for intellectual property rights covering our products and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our expected use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a
smaller reporting company under the Securities Act and Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our estimates and statements regarding our future revenue, future results of operations and financial position;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our research and development costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our plans and objectives for future operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The plans and objectives of management. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;predict,&#148; &#147;potential,&#148; &#147;would&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in
this prospectus are only predictions and are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this prospectus and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this prospectus entitled &#147;Risk
Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may
not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is
not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtained the market and industry data in this prospectus from our own internal estimates and research as well as from industry and general
publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or
completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified market and industry data from third-party sources. Management&#146;s estimates are derived from publicly
available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. While we believe our internal company research as to such matters is reliable and the market
definitions are appropriate, neither such research nor these definitions have been verified by any independent source. These data involve a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk
due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to differ materially from the assumptions and estimates made by the independent parties or us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. If the underwriters&#146; option to purchase additional shares from us is exercised in full, we estimate that our net proceeds will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this
offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) the net proceeds
to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, for the following
purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund ongoing and future clinical trials for OMNI and TearCare; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to support the marketing and sales efforts for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for research and development; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which
could change in the future as our plans and business conditions evolve. We may also use a portion of the net proceeds for acquisitions or strategic investments in complementary businesses, services, products, or technologies, although currently we
have no specific agreements, commitments or understandings in this regard. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the
amounts that we will actually spend on the uses set forth above. Predicting the cost necessary to complete clinical trials can be difficult and we anticipate that we may need additional funds in the future. The amounts and timing of our actual
expenditures and the extent of clinical development may vary significantly depending on numerous factors, including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. As a result, our management will
retain broad discretion over the allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current planned operations and planned
use of the net proceeds from this offering, we expect that our cash and cash equivalents and additional borrowings available under our credit facility will enable us to fund our operations for at least the next twelve months. We have based this
estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital
lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term and intermediate-term, interest-bearing, investment-grade, securities and government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if
any, to fund the operation, development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the
discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may
deem relevant. In addition, we have entered into, and in the future may enter into additional, agreements that contain restrictions on payments of cash dividends, including the 2020 Term Loan and 2020 Revolver discussed elsewhere in this prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On a pro forma basis to give effect to (i)&nbsp;the automatic conversion of all outstanding shares of our
redeemable convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the closing of this offering, (ii)&nbsp;the automatic conversion
of outstanding warrants to purchase shares of our redeemable convertible preferred stock into warrants to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, and the
related reclassification of redeemable convertible preferred stock warrant liability to additional paid in capital and (iii)&nbsp;the filing and effectiveness of our restated certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted
information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the
following table together with our financial statements and the related notes appearing at the end of this prospectus and the &#147;Selected Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and &#147;Description of Capital Stock&#148; sections of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands, except share data)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock warrant liability</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock<BR>Convertible Preferred Stock, $0.001 par value;
14,241,390 shares authorized, 12,767,202 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.001 per share; 21,831,000
shares&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, pro forma and pro forma as adjusted;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued
and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of
each of cash and cash equivalents, total stockholders&#146; (deficit) equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number
of shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
offered by us remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000
shares in the number of shares offered by us at the assumed initial public offering price per share would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; (deficit) equity and total
capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information presented in the table above does not include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the exercise of stock options outstanding under our Existing Plan as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the exercise of stock options granted after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 under the Existing Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock reserved for future issuance under our 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the 2021
Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock that will become available for future issuance under our 2021 ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future
issuance under the 2021 ESPP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the
exercise of warrants outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants shall not expire upon the closing of this offering if not exercised. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 we had a historical net tangible
book value (deficit) of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. Our historical net tangible book value (deficit) is the amount
of our total tangible assets less our total liabilities and the carrying value of our preferred stock, which is not included within stockholders&#146; equity. Historical net tangible book value (deficit) per share represents historical net tangible
book value (deficit) divided by the number of shares of our common stock outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021 was $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock.
Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all shares of our preferred stock outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
upon the closing of this offering. Pro forma net tangible book value per share represents our pro forma net tangible book value divided by the total number of shares outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 after giving effect to the pro forma adjustment described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to receipt of the net proceeds from our issuance and the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 would have been
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
This represents an immediate increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution in
pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering. Dilution per share to new
investors purchasing common stock in this offering is determined by subtracting the pro forma as adjusted net tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. The
following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value (deficit) per share as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information described above is illustrative only and will change based on the actual initial
public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net
tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution to new investors purchasing common stock in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us remains the same and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) the total consideration paid by new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase, would increase the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a
decrease, would decrease the percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming no change in the assumed initial
public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this
offering. If the underwriters&#146; option to purchase additional shares is exercised in full, our pro forma as adjusted net tangible book value per share after this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing an immediate increase in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, on the pro forma as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to common
stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors purchasing common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new
investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and, in the case of an increase, would increase the percentage of total consideration paid by new investors
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming that the number of shares offered by us remains the same. Similarly, each increase (decrease) of 1,000,000 shares in the
number of shares offered by us at the assumed public offering price would increase (decrease) the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
and, in the case of an increase, would increase the percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a
decrease, would decrease the percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming no change in the assumed initial
public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this
offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors
purchasing common stock in this offering would be increased to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information presented in the tables and discussions above is based on the number of shares of our common stock outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock issuable upon the exercise of stock options outstanding under our Existing Plan as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock issuable upon the exercise of stock options granted after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 under our Existing Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares
of our common stock reserved for future issuance under our 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the
2021 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock that will become available for future issuance under our 2021 ESPP, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future
issuance under the 2021 ESPP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the
exercise of warrants outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants shall not expire upon the closing of this offering if not exercised. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding stock options or warrants are exercised, new stock options or warrants are issued, or we issue additional
shares of common stock in the future, there will be further dilution to new investors purchasing common stock in this offering. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we
believe we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derived the selected consolidated statements of operations and comprehensive loss data for the fiscal years ended December&nbsp;31, 2018,
2019 and 2020 and the consolidated balance sheet data as of December&nbsp;31, 2018, 2019 and 2020 from our audited consolidated financial statements included elsewhere in this prospectus. The selected consolidated financial data included in this
section is not intended to replace the consolidated financial statements and related notes included elsewhere in this prospectus. You should read the selected financial data set forth below in conjunction with our consolidated financial statements,
the notes to our financial statements and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contained elsewhere in this prospectus. Our historical results are not necessarily indicative of our
future performance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>in thousands, except share data</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations and Comprehensive Loss Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 23,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 27,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and
administrative<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share outstanding attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding used in computing net loss per share attributable to
common stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,611,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,693,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,678,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share outstanding, basic and diluted (unaudited)&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding used in computing net loss per share
attributable to common stockholders, basic and diluted (unaudited)<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes stock-based compensation as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the statements of operations and Note 13 to our consolidated financial statements included elsewhere in
this prospectus for an explanation of the method used to compute the historical net loss per share and pro forma net loss per share and the number of shares used in the computation of the per share amounts for the years ended December&nbsp;31, 2018,
2019 and 2020. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Consolidated Balance Sheet Data</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 21,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP
STYLE="font-size:85%; vertical-align:top">1</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working capital is defined as total current assets less total current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the section of
this prospectus titled &#147;Selected Financial Data&#148; and our financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this
prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk
Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by these forward-looking statements. You should carefully read the &#147;Risk Factors&#148; to gain an understanding of the
important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section of this prospectus titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to transform
ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world&#146;s most prevalent eye diseases. We are passionate about improving patients&#146; lives. Our business
philosophy is grounded in the following principles: comprehensively understanding disease physiology, developing products that are intended to restore natural physiological functionality to diseased eyes; developing and marketing products that
achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects, providing intuitive, patient friendly solutions to ophthalmologists and optometrists; and delivering compelling economic value to all
stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare
whereby our products may be used in procedures which supplant conventional outdated approaches. We believe current eyecare treatment models rely heavily on prescription medications, symptom relief, or either flawed or highly invasive, later-stage
procedural interventions, and fail to adequately address the true underlying cause of disease. We have focused our initial product development on the treatment of two of the world&#146;s most prevalent and underserved eye diseases, glaucoma and dry
eye disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commercial products in each of our two reportable segments, Surgical Glaucoma and Dry Eye. Our Surgical Glaucoma
segment consists of sales of the OMNI Surgical System, or OMNI, and also included sales of VISCO360 and TRAB360, OMNI&#146;s predicate devices, until they were discontinued in the first quarter of 2019. Our Dry Eye segment includes sales of the
TearCare System, or TearCare, and related components and accessories. For the year ended December&nbsp;31, 2020, 94% and 6% of our revenues were derived from our Surgical Glaucoma and Dry Eye segments, respectively. We primarily sell both systems
through a highly-involved direct sales model that offers intensive education, training and customer service. We believe this philosophy and model not only enables us to differentiate our products and our overall company from competitors, but also to
expand our addressable market by educating ECPs, patients and other stakeholders on our products and evolving treatment paradigms. Outside of the U.S., we have historically sold OMNI primarily through a network of distributors, although we
anticipate we will begin employing a small direct sales force in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commercially launched OMNI and TearCare in February 2018 and
April 2019, respectively. In May 2020, we introduced a new version of the OMNI Surgical System called OMNI Next Gen that incorporated extensive feedback from our physician users and that we believe improved upon the first-generation device. We sell
OMNI to facilities where ophthalmic surgeons perform outpatient procedures, mainly ASCs and HOPDs, which are typically reimbursed by Medicare or private payors for procedures using our products. We sell TearCare to optometrist and ophthalmologist
practices. Currently, there is no meaningful reimbursement coverage by Medicare or private payors for MGD procedures, including TearCare, and patients typically pay out-of-pocket for TearCare. We are continuing our controlled commercial launch and
are focused upon comprehensive, clinical data-driven long-term market development plan that aims to improve awareness and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patient access to TearCare. As of December&nbsp;31, 2020, we employed 82 people to execute our commercial strategy in direct sales, marketing, training and professional services. The overall
success of our approach to eyecare to date is evidenced by the over 60,000 estimated uses of OMNI and its direct predicates in over 1,000 hospitals and ASCs in the U.S. and Europe, and approximately 10,000 estimated uses of TearCare in nearly 400
eyecare facilities in the U.S. through March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no manufacturing facilities of our own and instead contract with
third parties for our production requirements. We believe our suppliers will be able to meet our current and anticipated manufacturing needs across all of our products. We do not currently plan to manufacture our products or any related components
ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our gross margin in our Surgical Glaucoma segment for the year ended December&nbsp;31, 2020 was 72.8%. Beginning with the
production of finished goods inventory in February 2021, we are in the process of shifting our primary production of OMNI from a U.S.-based third-party contract manufacturer that has been able to partner closely with us on customization initiatives
related to the development of OMNI and its predicate devices, to a network of lower cost, higher volume contract manufacturers in the U.S. and Asia. We believe that these cost optimization initiatives, which we expect to complete in 2021, will
enable us to improve gross margins in our Surgical Glaucoma segment. The TearCare System includes the SmartHub component, which is typically only sold in initial purchase orders, and single-use SmartLids which are sold as part of initial purchase
orders and through repeat orders as the ECP performs procedures over time. In an effort to build a meaningful TearCare installed base and encourage product trial and adoption by ECPs, our pricing strategy for SmartHubs has not focused on gross
profit maximization. As the installed base of TearCare customers grows, we believe SmartLids, which generate higher gross margins than SmartHubs, will increase as a proportion of total Dry Eye segment revenues and gross profit. Given the earlier
stage of TearCare&#146;s commercial development and our pricing strategy with respect to SmartHubs, we expect our Dry Eye segment&#146;s gross margins to be lower than our Surgical Glaucoma segment&#146;s gross margins for the near and medium-term.
Our gross margin for our Dry Eye segment for the year ended December&nbsp;31, 2020 was (30.5%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe in the importance of continued
strategic investment in initiatives that: further demonstrate our products&#146; clinical effectiveness and safety to potential customers, patients, payors and regulators; enhance our commercial capabilities, including resources dedicated to sales,
marketing and education; ensure the broadest possible patient access to the treatment alternatives that our products are cleared to offer, enhance and improve upon our existing product technologies; and allow us to innovate new products, devices or
drugs, in glaucoma and dry eye or in new eye disease areas. As a result, we intend to continue to invest in clinical studies, sales and marketing, education initiatives, market access, and product development. Because of these and other factors, we
expect to continue to incur net losses for at least the next several fiscal years. Moreover, we expect to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations
of the SEC and those of the Nasdaq Stock Market, additional insurance expenses, investor relations activities and other administrative and professional services. As a result of these and other factors, we may require and seek additional debt and
equity financing to fund our operations and planned growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, our primary sources of capital have been private placements of
redeemable convertible preferred stock, debt financing arrangements and revenue from sales of our products. Since inception, we have raised a total of $150.2&nbsp;million in net proceeds from private placements of redeemable convertible preferred
stock and the incurrence of debt. As of December&nbsp;31, 2020, we have an outstanding term loan balance of $35.0&nbsp;million (excluding debt discount and amortized debt issuance costs). As of December&nbsp;31, 2020, we had cash and cash
equivalents of $61.5&nbsp;million and an accumulated deficit of $90.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2018, 2019
and 2020, we generated revenue of $7.5&nbsp;million, $23.3&nbsp;million, and $27.6&nbsp;million, respectively. Gross margin was 68.9%, 72.0%, and 66.7% for the years ended December&nbsp;31, 2018, 2019, and 2020, respectively. Our net loss was
$14.3&nbsp;million, $25.9&nbsp;million, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$34.7&nbsp;million for the years ended December&nbsp;31, 2018, 2019, and 2020, respectively. For the years ended December&nbsp;31, 2018, 2019 and 2020, substantially all of our revenue was
generated from customers in the U.S. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> emerged in Wuhan, China. The World Health
Organization declared <FONT STYLE="white-space:nowrap">COVID-19</FONT> to be a pandemic, spreading across the globe and impacting worldwide economic activity. In 2020, certain U.S. federal, state and local governmental authorities issued <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> orders, proclamations and/or directives, including restrictions on elective procedures and therapies, aimed at minimizing the spread of <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> As such, the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacted and is expected to continue to impact demand for our products, which are used in procedures and therapies that are
considered elective. Although some of these governmental restrictions have since been lifted or scaled back, recent and future surges of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may result in restrictions being
<FONT STYLE="white-space:nowrap">re-implemented</FONT> in response to efforts to reduce the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We experienced a significant decrease in our revenues for both of our products in the second
quarter of 2020 as compared to the first quarter of 2020. As elective eye care procedures in many facilities that utilize our products were temporarily suspended by governmental authorities, many patients avoided visiting ECPs, and, even in areas
that allowed elective procedures, ECPs and healthcare facilities in general substantially reduced or. in some cases halted, the scheduling and performance of such procedures. The decrease in demand for our products due to <FONT
STYLE="white-space:nowrap">COVID-19</FONT> most significantly impacted our revenues in the latter part of the quarter ended March&nbsp;31, 2020 and the first half of the quarter ended June&nbsp;30, 2020. Beginning in June 2020, we began to see an
increase in the number of procedures using our products. In the first quarter of 2021, our customers experienced a significant number of procedure cancellations which we believe were largely driven by patients postponing in-office treatments until
their <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccinations were completed (as opposed to any restrictions imposed on elective procedures), impacting our revenues. As vaccine availability and the vaccinated population increases across the
U.S., we expect the recovery of our end markets to resume in the second quarter of 2021 and throughout the remainder of the year, provided that the lifting of restrictions on elective procedures and therapies continues and such restrictions are not
reimposed. As a result, we believe that over the course of 2021, there may be a modest benefit to our revenues as glaucoma and DED patients schedule previously deferred elective procedures, provided that the lifting of restrictions on elective
procedures and therapies continues and such restrictions are not reimposed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are continuing to closely monitor the global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In order to operate in a safe manner, we are following the health and safety guidelines of the U.S. Centers for Disease Control and Prevention, Occupational Safety and Health Administration, and
local and state public health departments where we operate. The majority of our employees at our headquarters have been asked to work from home, with only limited access given to employees to work in the office when necessary. For roles that require
employees to be <FONT STYLE="white-space:nowrap">on-site,</FONT> such as our R&amp;D and manufacturing technical staff, we are providing protective equipment, practicing social distancing, and enforcing mask wearing and we have increased
sanitization standards. In addition, we have created a business continuity plan and incident management team to respond quickly and effectively to <FONT STYLE="white-space:nowrap">COVID-19</FONT> related issues in order to offer customers
uninterrupted products, services and support while safeguarding the best interests of employees, suppliers and stakeholders. The ultimate impact of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our operations is unknown and
will depend on future developments which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the status of health and safety actions
taken to contain its spread and any additional preventative and protective actions that governments, or we, may direct, any resurgence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> that may occur and how quickly and to what extent economic and
operating conditions normalize within the markets in which we operate. The global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could disrupt the operations of our third-party manufacturers and other suppliers. Although we have not
experienced disruptions in our supply chain to date, we cannot predict how long the pandemic and measures intended to contain the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> will continue and what effect
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and the associated containment measures will have on our suppliers and vendors, in particular for any of our suppliers and vendors that may not qualify as essential businesses and suffer more
significant disruptions to their business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operations. We are working closely with our manufacturing partners and suppliers to help ensure we are able to source key components and maintain appropriate inventory levels to meet customer
demand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Factors Affecting our Business and Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there are several important factors that have impacted and that will continue to impact our business and results of operations.
These factors include, but are limited to: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our product development approach is a key differentiator of our team and our company. We are focus on continuous innovation and
design and utilize input from our network of expert employees (including several ophthalmologists on staff), advisors and customers to rapidly iterate our pre-and post-commercial product designs with the aim of better satisfying the needs of our
customers and their patients, and increasing adoption and utilization of our solutions. Once our products are launched, our customer feedback loop helps us further develop our products. This is particularly evident in the evolution of our OMNI
Surgical System, which originated from the combined functionality of two internally developed, commercial predicate devices, each of which had their own multiple commercial iterations. We further refined ergonomics and functionality in OMNI Next
Gen, which we launched in May 2020. Our future growth is dependent on our ability to continue innovating and applying our expertise of disease physiology to improve existing products and develop new products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Education and Training on the Benefit of our Products
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> Existing Treatment Alternatives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key drivers of our success is educating ophthalmologists, optometrists, patients, and third-party payors about the clinical and
safety benefits of our products and of the benefits of more proactive, interventional approach to treating glaucoma and DED. We believe the required market education and development is best accomplished through a differentiated, highly involved
commercial approach. As such, we devote significant resources to onboarding our sales professionals and to continuously augmenting their knowledge and capabilities. Our sales professionals provide ECPs with the necessary education, training and
support to adopt and continue to use our products. We believe that increasing acceptance and usage of our products will require continued investment in our sales force and education efforts to ensure ECPs, patients and third-party payors learn more
about our products and appreciate our benefits to their target patient populations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maximizing Product Usage by Customers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Demand for our products will be highly dependent on our ability to develop their potential addressable markets and maximize the breadth of
patients our products can serve. OMNI is indicated for canaloplasty followed by trabeculotomy to reduce IOP in adult patients with POAG in the U.S. and with OAG, in the EU. We believe that OMNI is the only device that is authorized by the FDA as an
<I>ab interno </I>procedure to: reduce IOP in adult patients with POAG across the spectrum of disease severity; be used in Mild-to-Moderate Combination Cataract or Standalone procedures; access 360 degrees of the diseased conventional outflow
pathway through a single clear corneal incision; and facilitate two consecutive procedures, canaloplasty and trabeculotomy, to comprehensively treat all three points of resistance in the conventional outflow pathway in a single operating room visit.
Our ability to establish OMNI as the standard of care for all POAG patients by continuing to grow its adoption and utilization in Combination Cataract procedures and by pioneering the development of the market for interventional Standalone
procedures will have a substantial impact on our future growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TearCare serves as an elegant, compact, portable, intuitive solution that
enables the application of localized heat to the eyelids in an anatomically customized way, and we believe it presents a compelling physiological profile to potentially address MGD. The current DED treatment market primarily consists of an abundance
of OTC and prescription eyedrops that seek to lubricate the ocular surface, alleviate inflammation and/or increase tear production. However, OTC and prescription eyedrops are incapable of clearing obstructions in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meibomian glands and do not address MGD&#146;s eyelid-borne physiology and poor tear quality. MGD is associated with 86% of DED cases and is a leading root cause of evaporative DED, which is
characterized by low quality tears that evaporate prematurely. Clinical studies have demonstrated that treating MGD by liquefying and removing clogged meibum is the most effective method to eliminate obstructions and restore the lipid layer of tear
film, thereby preventing premature evaporation of tears. TearCare was designed to be administered during the course of a routine office visit to an ECP, which makes it convenient for patients, and allows providers to maintain procedural throughput
in their practices. Our ability to improve patient access and market education on TearCare and the benefits of proactive MGD treatment will be key drivers of TearCare&#146;s future growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operational excellence and cost efficiency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We aim to achieve operating and financial milestones with optimal capital efficiency, and focus on our market value relative to invested
capital as a key measurement of our performance. Since our inception, we have received net proceeds of $150.2&nbsp;million from equity and debt financings. With a portion of these net proceeds (our December 31, 2020 cash and equivalents was $61.5
million), we believe we have developed and commercially launched two clinically differentiated products, funded multiple completed and ongoing clinical trials, and built our management team and company infrastructure to support the continued growth
of our business. We believe that this level of operational and commercial progress relative to our total capital investment to date compares favorably to medical technology peers. We seek to design products that can achieve attractive long-term
gross margins. For example, we have targeted the achievement of significantly higher gross margins as one of our long-term objectives for our Surgical Glaucoma segment. The achievement of this objective will be supported by our shift to high-volume
contract manufacturers in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently derive all of
our revenue from the sale of OMNI to ASCs and HOPDs and TearCare to ophthalmology and optometry practices. During each of the years ended December&nbsp;31, 2018, 2019 and 2020, the revenues from our Surgical Glaucoma segment, including OMNI and its
predicate devices, accounted for over 90% of our total revenues. Substantially all of our revenues for 2018, 2019 and 2020 were generated from sales within the U.S. Our OMNI customers place orders based on their expected procedure volume and reorder
as needed, typically on a biweekly, monthly or bimonthly basis. Our TearCare customers typically purchase a TearCare System which consists of one or more SmartHubs, multiple <FONT STYLE="white-space:nowrap">single-use</FONT> SmartLids and other
accessories. After utilizing their initial inventory, customers will reorder SmartLids as needed. No single customer accounted for 10% or more of our revenue for any of the years ended December&nbsp;31, 2018, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The growth in our revenue from 2018 to 2020 was driven by the demand for elective surgery and treatment utilizing our products. Such demand is
often lower during summer months because of ECP vacations and in winter months in certain parts of the world because of fewer business or surgery days due to holidays and adverse weather conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Goods Sold and Gross Margin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products are produced by third-party manufacturers. Our cost of goods sold consists primarily of amounts paid for our products to
third-party manufacturers, and our manufacturing overhead costs, which consist primarily of personnel expenses, including salaries, benefits and stock-based compensation, and reserves for excess, obsolete and
<FONT STYLE="white-space:nowrap">non-sellable</FONT> inventory. Cost of goods sold also includes depreciation expenses for production equipment which we provide to our third-party manufacturers and certain direct costs, such as shipping and handling
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a
variety of factors, including differences in segment gross margins, changes in average selling </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prices, product sales mix, production and ordering volumes, manufacturing costs, product yields, and headcount. In the near term, we expect our gross margins to increase as we transition
production of OMNI to lower-cost manufacturers and as we expect Surgical Glaucoma revenues will grow as a percentage of our overall revenue mix. In general, we expect our gross margins to increase over the long-term to the extent our production and
ordering volumes increase and to the extent we spread the fixed portion of our overhead costs over a larger number of units produced. We intend to use our design, engineering and manufacturing <FONT STYLE="white-space:nowrap">know-how</FONT> and
capabilities to further advance and improve the efficiency of our suppliers&#146; manufacturing processes, which we believe will reduce costs and increase our gross margins. Our gross margins could fluctuate from quarter to quarter as we transition
to new suppliers, introduce new products and adopt new manufacturing processes and technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development, or R&amp;D, expenses consist primarily of engineering, product development, clinical studies to develop and support
our products, including clinical trial design, clinical trial site initiation and study costs, internal and external costs associated with our regulatory compliance and quality assurance functions, medical affairs, cost of products used for clinical
trials and other costs associated with products and technologies &#150; either new or enhancements of existing platforms &#150; that are in development. These expenses also include personnel expenses, including salaries, benefits and stock-based
compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation expenses for equipment and an allocation of IT and facility overhead expenses. Our R&amp;D expenses as a percentage of revenue may vary over time
depending on the level and timing of new product development efforts, as well as clinical development, clinical trial and other related activities. We expect our R&amp;D expenses to increase for the next several years as we continue to invest in our
active clinical trial program, develop new products and improve our existing products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative, or SG&amp;A, expenses consist primarily of personnel expenses, including salaries, benefits and
stock-based compensation related to selling, marketing and corporate functions, allocation of IT and facility overhead expenses, bad debt expense, finance, legal and human resource costs. Other SG&amp;A expenses include training, travel expenses,
promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees (including external legal, audit, consulting and tax fees), insurance costs, and general corporate expenses. We
expect SG&amp;A expenses to continue to increase in absolute dollars as we expand our infrastructure to both drive and support the anticipated growth in revenue and due to additional legal, accounting, insurance and other expenses associated with
being a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists primarily of interest incurred on our outstanding indebtedness and <FONT STYLE="white-space:nowrap">non-cash</FONT>
interest related to the amortization of debt discount and issuance costs associated with our outstanding loan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned on our balances of cash and cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
income (expense), net primarily consists of gains and losses resulting from the remeasurement of the fair value of our redeemable convertible preferred stock warrant liability at each balance sheet date. We will continue to record adjustments to the
estimated fair value of the redeemable convertible preferred stock warrants until they are exercised. At time of the redeemable convertible preferred stock warrants are exercised, the final fair value of the warrant liability will be reclassified to
stockholders&#146; deficit and we will no longer record any related periodic fair value adjustments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2020 (dollars in thousands) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 22,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 26,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Percentage of total revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>95.5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>94.1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Percentage of total revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>4.5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>5.9</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">662.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue</I>. Revenue in 2020 was $27.6&nbsp;million, an increase of $4.3&nbsp;million, or 18.4%, from our
revenue in 2019. Surgical Glaucoma and Dry Eye sales contributed $3.7&nbsp;million and $0.6&nbsp;million, respectively, to such increase from 2019 to 2020. The overall increase in revenue was primarily attributable to an increase in the number of
OMNI units sold, which resulted in $3.9&nbsp;million increase in Surgical Glaucoma revenues, as well as the benefit of a full year of commercial sales of our Dry Eye Segment&#146;s TearCare System, which was launched in April 2019. These increases
were partially offset by $0.2&nbsp;million of revenue decrease from 2019 to 2020 due to the discontinuation of TRAB360 and VISCO360 sales in March 2019. Throughout 2019 and 2020, we expanded our overall commercial team from 31 professionals as of
January&nbsp;1, 2019 to 82 professionals as of December&nbsp;31, 2020. As result, we increased the number of surgeons and facilities that have been trained on, and the number of facilities that order, OMNI and TearCare. Revenue for the full year
2020 was negatively impacted by a steep decline in the number of products sold, in particular, during the second quarter of 2020 due primarily to the effects of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As a result, our
revenues for the second quarter of 2020 decreased by $2.5&nbsp;million as compared to the second quarter of 2019. Surgical Glaucoma represented 95.5% and 94.1% of our revenues generated in 2019 and 2020, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Goods Sold and Gross Profit</I>. The $2.7&nbsp;million increase in cost of goods
sold from 2019 to 2020 was attributable to a $1.4&nbsp;million write-down in 2020 of legacy OMNI inventory which is being replaced with OMNI Next Gen units, and a $1.3&nbsp;million increase in the cost of materials and manufacturing overhead driven
by increased production to support our sales growth and as a result of increased headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our total gross profit increased
$1.6&nbsp;million from $16.8&nbsp;million to $18.4&nbsp;million from 2019 to 2020. Our total gross margin declined from 72.0% to 66.7% between 2019 and 2020 primarily due to the legacy OMNI inventory write-down and increased sales in our lower
margin Dry Eye segment as a percentage of total sales. Gross margin in our Surgical Glaucoma segment decreased from 77.0% in 2019 to 72.8% in 2020, and in our Dry Eye segment gross margin increased from (35.2)% in 2019 to (30.5)% in 2020. Excluding
our OMNI inventory write-down, Surgical Glaucoma gross margins in 2020 would have increased to 78.2% due to a higher volume of units sold covering fixed costs. Our Dry Eye segment had a lower gross margin than our Surgical Glaucoma segment because
TearCare is earlier in its commercial cycle than OMNI and SmartHub equipment is priced to encourage new user adoption rather than to maximize gross profit for its <FONT STYLE="white-space:nowrap">one-time,</FONT> upfront purchase by ECPs. Our Dry
Eye segment had a negative gross margin in each of 2019 and 2020, due primarily to $0.1&nbsp;million and $0.4&nbsp;million of inventory reserve charges in 2019 and 2020, respectively, and sales unit volumes which were not sufficient to cover
$0.6&nbsp;million and $0.9&nbsp;million of unabsorbed manufacturing overhead in 2019 and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development
Expenses</I>. The $0.8&nbsp;million increase in R&amp;D expenses from 2019 to 2020 was primarily attributable to costs related to OMNI Next Gen, including an increase of $0.5&nbsp;million in contract manufacturing for Dry Eye product development,
$0.4&nbsp;million in patent related legal expenses, $0.3&nbsp;million in facility and information technology related expenses to support business growth and an increase of $0.3&nbsp;million in personnel expenses primarily as a result of increased
headcount, partially offset by a decrease of $0.1&nbsp;million in travel expenses due in part to the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and a decrease of $0.5&nbsp;million in costs associated with our clinical studies
as a result of completion of two clinical trials during the year. We expect our clinical trial costs to increase as we initiate and execute additional clinical trials over the coming years, develop new products and improve our existing products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selling, General, and Administrative Expenses</I>. The $9.0&nbsp;million increase in SG&amp;A expenses from 2019 to 2020 was primarily
due to our continued commercial investment and scaling of operations and corporate headcount to support our growth, which resulted in an increase of $7.6&nbsp;million in personnel expenses through headcount increases during the year, and a
$1.4&nbsp;million net increase in <FONT STYLE="white-space:nowrap">non-personnel</FONT> SG&amp;A expenses. Our largest areas of growth in <FONT STYLE="white-space:nowrap">non-personnel</FONT> SG&amp;A expenses between 2019 and 2020 were promotional
and advertisement expenses related to OMNI Next Gen launch, facility and information technology related expenses to support business growth, and legal fees related to general and regulatory matters. These increases were partially offset by a
decrease in conference, tradeshows, training and travel expenses as a result of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense</I>. The $0.4&nbsp;million increase in interest expense from 2019 to 2020 was attributable to the debt financing in
November 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income and Other Income (Expense), Net.</I> The $0.1&nbsp;million decrease in interest income from 2019 to
2020 was primarily due to lower interest on our cash and equivalents in 2020. The increase in other income (expense), net, from 2019 to 2020 was attributable primarily to the remeasurement of our convertible preferred stock warrants and recognition
of the change in fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2018 and 2019 (dollars in thousands) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Percentage of total revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>100</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>95.5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Percentage of total revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>4.5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,300.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(233.3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue</I>. Revenue in 2019 was $23.3&nbsp;million, an increase of $15.8&nbsp;million, or 210.1%, from our
revenue in 2018. Sales from our Surgical Glaucoma and Dry Eye segments contributed $14.8&nbsp;million and $1.0&nbsp;million, respectively, to our year-over-year revenue growth in 2019. The growth from 2018 to 2019 reflects the impact of the
commercial launch of OMNI in February 2018 and TearCare in April 2019 which was partially offset by a decrease of $2.5&nbsp;million in revenues as a result of discontinuing the sale of TRAB360 and VISCO360 in March 2019. Over the course of the
periods indicated, we trained a significant number of ECPs on our products, increased our sales efforts, including expanding our commercial team from 14 professionals as of January&nbsp;1, 2018 to 70 professionals as of December&nbsp;31, 2019, and
cultivated adoption and recurring use of our products by key accounts, resulting in the increase in the number of units ordered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cost
of Goods Sold and Gross Profit</I>. Our cost of goods sold increased $4.2&nbsp;million from 2018 to 2019 due to a $3.9&nbsp;million increase in the cost of materials and manufacturing overhead driven by the increase in the number of units sold and
the introduction of TearCare, including the associated <FONT STYLE="white-space:nowrap">ramp-up</FONT> of production capacity in the middle of 2019, by an increase in personnel expenses primarily as a result of increased manufacturing-related
headcount, and an increase in reserves for excess, obsolete and <FONT STYLE="white-space:nowrap">non-sellable</FONT> inventory and shipping and handling expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our total gross profit increased by $11.6&nbsp;million from 2018 to 2019, including
$12.0&nbsp;million of Surgical Glaucoma gross profit growth and ($0.4) million of gross profit declines in Dry Eye. Overall, our gross margin increased by 3.1% from 2018 to 2019 primarily due to the impact of the economies of scale in Surgical
Glaucoma as the volumes of OMNI products sold continued to increase. The overall increase in our gross margin was partially offset by the introduction in <FONT STYLE="white-space:nowrap">mid-2019</FONT> of TearCare in our Dry Eye segment, which had
a negative gross margin in 2019. The gross margin in our Surgical Glaucoma segment sales increased from 68.9% in 2018 to 77.0% in 2019, while the gross margin in our Dry Eye segment sales was (35.2)% in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses</I>. The $2.7&nbsp;million increase in R&amp;D expenses from 2018 to 2019 was primarily attributable to
an increase of $1.6&nbsp;million in costs associated with our clinical studies, an increase of $1.3&nbsp;million in personnel expenses primarily as a result of increased headcount, and an increase of $0.4&nbsp;million related to development of the
OMNI Next Gen prototype. The increase was offset in part by a $1.0&nbsp;million decrease in contract manufacturing set up related expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expenses</I>. The $18.7&nbsp;million increase in SG&amp;A expenses from 2018 to 2019 was primarily due
to our continued investment in commercial capabilities and in the infrastructure to support our growth, which resulted in an increase of $10.4&nbsp;million in total personnel expenses, an increase of $2.0&nbsp;million in travel and entertainment
expenses, an increase of $2.4&nbsp;million in <FONT STYLE="white-space:nowrap">non-labor</FONT> commercial spend, including promotional activities, conferences and tradeshows and marketing initiatives, an increase of $0.8&nbsp;million in facility
and information technology related expenses, an increase of $1.0&nbsp;million in sales training and demos, an increase of $0.9&nbsp;million in consulting services to support business growth and an increase of $0.4&nbsp;million in legal fees related
to general and regulatory matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense</I>. The $2.0&nbsp;million increase in interest expense from 2018 to 2019 was
primarily attributable to the additional interest expense associated with the $14.0&nbsp;million of borrowings under the 2019 Term Loan. We did not have any debt prior to entering into the 2019 Term Loan and 2019 Revolver in January 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income and Other Income (Expense), Net. </I>The $0.2&nbsp;million increase in interest income from 2018 to 2019 was primarily due
to higher average cash balances in 2019, resulting from the proceeds from our 2019 Term Loan and our Series D redeemable convertible preferred stock financing. The $35&nbsp;thousand increase in other expense, net, from 2018 to 2019 was attributable
primarily to the remeasurement of our convertible preferred stock warrants and recognition of the change in fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities.</I><B><I> </I></B>Net cash used in operating activities for the year
ended December&nbsp;31, 2020 was $32.2&nbsp;million, consisting primarily of a net loss of $34.7&nbsp;million, which included a $2.2&nbsp;million benefit from the proceeds from our Paycheck Protection Program, or PPP, loan under the Coronavirus Aid,
Relief, and Economic Security Act, or CARES Act, and an increase in net operating assets of $0.7&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $4.0&nbsp;million. The $0.7&nbsp;million increase in our
operating assets was primarily due to a $1.5&nbsp;million increase in accounts receivable, a $1.7&nbsp;million increase in our inventory, and $0.7&nbsp;million increase in our prepaid expenses, each to support the continued growth of our operations,
partially offset by $1.9&nbsp;million increase in accrued compensation and $2.0&nbsp;million in accrued and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other liabilities. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of a $1.4&nbsp;million provision for excess and obsolete inventories, primarily related to the
write-down of legacy first generation OMNI inventory due to the launch of our OMNI Next Gen in 2020, $0.5&nbsp;million related to stock-based compensation, $0.6&nbsp;million of right of use asset amortization related to office lease,
$0.6&nbsp;million of accretion of debt discount and amortization of debt issuance costs and $0.6&nbsp;million in depreciation and amortization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2019 was $25.0&nbsp;million, consisting primarily of a net loss of
$25.9&nbsp;million and an increase in net operating assets of $0.3&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.2&nbsp;million. The increase in net operating assets was primarily due to increases
in accounts receivable of $2.3&nbsp;million, inventories of $1.8&nbsp;million and other noncurrent assets to support the growth of our operations, partially offset by similar growth in our accounts payable, accrued compensation and accrued and other
liabilities as we scaled our operations. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of depreciation and amortization of $0.3&nbsp;million, the accretion of debt discount and amortization of debt issuance costs
of $0.5&nbsp;million, stock-based compensation of $0.1&nbsp;million and <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense of $0.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2018 was $14.5&nbsp;million, consisting primarily of a net loss of
$14.3&nbsp;million and an increase in net operating assets of $0.4&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.2&nbsp;million. The increase in net operating assets was primarily due to increases
in accounts receivable of $1.4&nbsp;million, prepaid expenses of $0.6&nbsp;million and inventories of $0.2&nbsp;million to support the growth of our operations, partially offset by similar increases in our accounts payable of $1.0&nbsp;million,
accrued compensation of $0.5&nbsp;million and accrued and other liabilities of $0.3&nbsp;million as we scaled our operations. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of depreciation and amortization and
stock-compensation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities.</I><B><I> </I></B>Net cash used in investing activities in the
years ended December&nbsp;31, 2020, 2019 and 2018 was $0.9&nbsp;million, $0.7&nbsp;million and $0.6&nbsp;million, consisting of purchases of property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Provided by Financing Activities.</I><B><I> </I></B>Net cash provided by financing activities in the year ended December&nbsp;31,
2020 of $73.4&nbsp;million primarily relates to proceeds from issuance of debt of $20.3&nbsp;million, proceeds of $53.4&nbsp;million from the issuance of our Series E redeemable convertible preferred stock and Series F redeemable convertible
preferred stock, partially offset by the related offering costs of $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in the
year ended December&nbsp;31, 2019 was related to proceeds from issuance of debt of $14.0&nbsp;million and proceeds from issuance of Series D redeemable convertible preferred stock of $30.7&nbsp;million, offset by $2.1&nbsp;million in the related
offering costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in the year ended December&nbsp;31, 2018 of $12.2&nbsp;million primarily
relates to proceeds from the issuance of Series C redeemable convertible preferred stock during 2018, offset by issuance costs of $0.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, our primary sources of capital have been private placements of redeemable convertible preferred stock, debt
financing agreements and revenue from the sale of our products. Since our inception, we have raised an aggregate of approximately $117.3&nbsp;million in net proceeds from the sale of our redeemable convertible preferred stock and borrowed
$32.9&nbsp;million of net proceeds under our term loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had cash and cash equivalents of
$61.5&nbsp;million, an accumulated deficit of $90.0&nbsp;million, $35.0&nbsp;million outstanding under our term loan agreement (before debt discount) and $2.2&nbsp;million outstanding under our PPP loan. Based on our current planned operations, we
expect our cash and cash equivalents and additional borrowings available under the 2020 Term Loan and the 2020 Revolver will enable us to fund our operations for at least the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MidCap Loan Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, we entered into a loan and security agreement, or the 2019 MidCap Credit Facility, with MidCap Financial Services, or the
Lender, which provided for a term loan facility, or the 2019 Term Loan, and a revolving line of credit, or the 2019 Revolver. The original agreement included a maximum of $25.0&nbsp;million credit facility consisting of a senior secured 2019 Term
Loan of up to $20.0&nbsp;million and a $5.0&nbsp;million 2019 Revolver. In November 2020, we entered into a loan and security agreement, or the 2020 MidCap Credit Facility, with the Lender, which replaced the 2019 MidCap Credit Facility, and
provided for a term loan facility, or the 2020 Term Loan, and a revolving line of credit, or the 2020 Revolver. The 2020 MidCap Credit Facility includes a maximum of $40.0 million credit facility consisting of a senior secured term loan of up to
$35.0 million and a $5.0 million revolver. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>2019 Term Loan </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Term Loan had a four-year term and a stated floating interest rate which equated to reserve-adjusted LIBOR, <I>plus</I> 6.75%. Under
certain circumstances, the floating interest rate could have been based on the prime rate instead of LIBOR. The Term Loan was split into three tranches as follows: (i)&nbsp;the Tranche One Loans provided for $12.0 million in term loans,
(ii)&nbsp;the Tranche Two Loans provided for up to $2.0&nbsp;million in term loans, and (iii)&nbsp;the Tranche Three Loans provided for up to $6.0&nbsp;million in term loan. We borrowed $14.0&nbsp;million under the Tranche One Loans and Tranche Two
Loans. Although the conditions necessary to draw the Tranche Three Loans had been met as of December&nbsp;31, 2019, we did not draw the Tranche Three Term Loans. The 2019 Term Loan required 18 interest only payments, which began on January&nbsp;31,
2019, followed by 30 equal monthly installments of principal, plus interest. The interest-only period was extended by an additional six months upon achievement of a milestone defined in the agreement with respect to the Tranche Three Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incurred $1.5&nbsp;million of issuance costs in conjunction with the 2019 Term Loan which were netted against the borrowed funds in the
balance sheet and were being accreted using the effective interest method as interest expense over the contractual period of four years. The 2019 Term Loan had an effective interest rate of 14.52% per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the funding of Tranche One Loans and Tranche Two Loans under the 2019 Term Loan, we issued a <FONT
STYLE="white-space:nowrap">10-year</FONT> warrant to the Lender to purchase 29,514 shares of our Series C redeemable convertible preferred stock, or the 2019 MidCap Warrants, at an exercise price of $9.4868 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the 2019 MidCap Warrants was $0.2&nbsp;million. The 2019 MidCap Warrants were recorded at the fair value as a debt
discount and as a warrant liability. The debt discount was being accreted using the effective interest method as interest expense over the contractual period of four years for the 2019 Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Term Loan granted us the right to voluntarily prepay the borrowings in full, with a prepayment premium beginning at 3.0% in the first
year from tranche funding and declining to 2.0% in the second year from tranche funding, to 1.0% in the third year from tranche funding thereafter. In addition, a final payment fee of 5% of the original Tranche One Loans and Tranche Two Loans
amounts borrowed was payable at the end of the term or when the borrowings are repaid in full. The borrowings were collateralized by a security interest in substantially all of our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Term Loan terms included making us subject to financial covenants related to minimum trailing net revenue targets that began on
January&nbsp;1, 2019 and were tested on a monthly basis. As of December&nbsp;31, 2019, we were in compliance with the applicable financial covenants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>2019 Revolver </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Revolver had a
four-year term and had a stated floating interest rate which equated to reserve-adjusted LIBOR, <I>plus</I> 4.25%. Under certain circumstances, the floating interest rate could have been based on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prime rate instead of LIBOR. An unused line fee of 0.5% was payable monthly based on the average unused balance and a collateral management fee of 0.5% was payable monthly based on the
outstanding balance of the 2019 Revolver. We could have requested to increase the 2019 Revolver commitment amount to $10.0&nbsp;million under the terms of the agreement. As of December&nbsp;31, 2019, $4.0&nbsp;million was available to be drawn under
the 2019 Revolver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Revolver provided for a prepayment premium equal to an amount determined by multiplying the commitment amount
by 3.0% in the first year, 2.0% in year 2, and 1.0% thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Revolver had not been drawn upon as of December&nbsp;31, 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Amendment to MidCap Loan Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, we amended the 2019 Term Loan and 2019 Revolver agreements which resulted in an increase to our term loan borrowing
availability, an extension of maturities and <FONT STYLE="white-space:nowrap">non-amortization</FONT> periods, and changes to a number of other terms and conditions as summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>2020 Term Loan </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended term loan
extended the maturity date to November&nbsp;1, 2025 and increased the stated floating interest rate to reserve-adjusted LIBOR, <I>plus </I>7.00%. Outstanding principal amounts of Tranche One Loans and Tranche Two Loans borrowed under the 2019 Term
Loan were designated as Tranche One Loans and Tranche Two Loans under the 2020 Term Loan, and the Tranche Three Loans commitment amount was increased to $21.0&nbsp;million. We drew the entire commitment amount of the Tranche Three Loans in November
2020. The 2020 Term Loan begins to amortize on December&nbsp;1, 2022, and, if certain conditions are met, the initiation of the amortization period can be extended to December&nbsp;1, 2023 or December&nbsp;1, 2024. In addition, the final payment fee
was increased to 6.0&nbsp;%. We are subject to financial covenants related to minimum trailing revenue targets that began on November 30, 2020, and are tested on a monthly basis. As of December&nbsp;31, 2020, the Company was in compliance with the
applicable financial covenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incurred $0.7&nbsp;million of issuance costs in conjunction with the 2020 Term Loan which were netted
against the borrowed funds in the balance sheet and are being accreted using the effective interest method as interest expense over the contractual period of five years. The 2020 Term Loan had an effective interest rate of 13.59% per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the funding of the 2020 Term Loan, we issued a <FONT STYLE="white-space:nowrap">10-year</FONT> warrant to the Lender to
purchase 300,000 shares of our Series F redeemable convertible preferred stock at an exercise price of $21.8779 per share, or the 2020 MidCap Warrant, with the estimated fair value of $1.8&nbsp;million. The 2020 MidCap Warrants were recorded at the
fair value as a debt discount and as a warrant liability. The debt discount is being accreted using the effective interest method as interest expense over the contractual period of four years for the 2020 Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other key terms of the 2020 Term Loan remained substantially unchanged compared to those of 2019 Term Loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>2020 Revolver </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Revolver extended
maturity date to November&nbsp;1, 2025 and increased the stated floating interest rate to reserve-adjusted LIBOR plus 4.50%. As of December&nbsp;30, 2020, $4.8&nbsp;million was available to be drawn under the 2020 Revolver which remains undrawn
upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the 2020 Term Loan and the 2020 Revolver are guaranteed by us and our future subsidiaries, subject to
exceptions for certain foreign subsidiaries. Our obligations under the agreements are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
secured by substantially all of our assets, including our material intellectual property. Additionally, we are subject to customary affirmative and negative covenants, including covenants that
limit or restrict the ability of us to, among other things, incur indebtedness, grant liens, merge or consolidate, make investments, dispose of assets, make acquisitions, pay dividends or make distributions, repurchase stock and enter into certain
transactions with affiliates, in each case subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other key terms of the 2020 Revolver remained substantially
unchanged compared to those of 2019 Revolver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Term Loan and the 2020 Revolver each contain events of default that include, among
others, <FONT STYLE="white-space:nowrap">non-payment</FONT> of principal, interest or fees, breach of covenants, inaccuracy of representations and warranties, cross-defaults and bankruptcy and insolvency events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paycheck Protection Program Loan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May
2020, we received a loan of $2.2&nbsp;million pursuant to the Paycheck Protection Program, or PPP, under the CARES Act. The Small Business Administration required that PPP loans only be used for eligible payroll costs, business mortgage interest
payments, rent or utilities. Per SBA guidelines, we would be eligible to apply for loan forgiveness if we used the loan proceeds for acceptable expenses during the 8-week period after disbursement. We believe we have satisfied all of the terms and
conditions of the PPP loan and applied for loan forgiveness in September 2020. The Company has elected to recognize this government grant income as a reduction of the related expenses and expects a decision from the SBA on loan forgiveness in the
second quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the PPP loan, we executed a promissory note in favor of Bank of America. If the SBA confirms
full and complete forgiveness of the unpaid balance of the PPP loan and reimburses Bank of America for the total outstanding balance, principal and interest, our obligations under the PPP loan will be deemed fully satisfied and paid in full. If the
PPP loan is not forgiven, we will be required to repay the PPP loan by May 2022 at a fixed interest rate not greater than 1%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lease Agreements
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Menlo Park, California, where we lease approximately 10,823 square feet of office, research
and development, engineering and laboratory space which is currently pursuant to a sublease agreement which was effective as of September&nbsp;17, 2019 and expires on July&nbsp;31, 2021. Effective August&nbsp;1, 2021, we will remain in the same
space under a new lease agreement with the direct landlord to that space which will extend through August&nbsp;31, 2024. We also lease approximately 2,040 square feet of office space, which is primarily used by our commercial leadership team, in
Southlake, Texas, pursuant to a lease that commenced on April&nbsp;30, 2019 and expires on May&nbsp;15, 2024.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The
preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various
other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may
differ from these estimates under different assumptions or conditions and any such differences may be material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant
accounting policies are more fully described in Note 2 to our financial statements included elsewhere in this prospectus, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to
our financial condition and results of operations and require our most difficult, subjective and complex judgments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under
each of its arrangements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify the contract with a customer, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify the performance obligations in the contract, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Determine the transaction price, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Allocate the transaction price to performance obligations in the contract, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recognize revenue as the performance obligations are satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue is generated from the sale of our products from our Surgical Glaucoma product portfolio and our Dry Eye product portfolio to
hospitals, medical centers and ECPs in the United States through sales representatives and distributors. Our contracts are in the form of a combination of signed agreements and/or purchase orders. We account for a contract with a customer when there
is approval and commitment from both parties, the rights and obligations of the parties are identified, payment terms are identified, the contract has commercial substance, and it is probable that we will collect substantially all of the
consideration to which it will be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our Surgical Glaucoma and Dry Eye products specified in a contract represents a
distinct good and is accounted for as separate performance obligation. Revenue is recognized when control of promised goods is transferred to a customer in amount that reflects the consideration that we expect to receive in exchange for those goods.
Control of our products is transferred to our customers at a point in time, either upon shipment or delivery of the product to the customer under our standard terms and conditions. The customer is able to direct the use of, and obtain substantially
all of the benefits from, the product at the time the product shipped or is delivered. We consider control to have transferred upon shipment or delivery because we have a present right to payment at that time, the customer has legal title to the
asset, we have transferred physical possession of the asset, the customer has accepted the asset, and the customer has significant risks and rewards of ownership of the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments for our contracts are typically due within 30 days of transfer of control of our products to its customers. We exclude taxes assessed
by governmental authorities on revenue-producing transactions from the measurement of the transaction price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of
business, we do not accept product returns, unless the item is defective as manufactured. We establish provisions for estimated returns and warranties. In addition, we do not typically provide customers with the right to a refund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contracts all have an original duration of one year or less. As a practical expedient, we do not consider the time value of money for such
contracts. Further, because of the short duration of these contracts, we do not disclose the transaction price for the remaining performance obligations as of the end of each reporting period or when we expect to recognize this revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense shipping and handling costs as incurred and include them in the cost of goods sold. In those cases where we bill shipping and
handling costs to customers, we will classify the amounts billed as a component of revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a practical expedient, we recognize the
incremental costs of obtaining contracts, such as sales commissions, as an expense when incurred since the amortization period of the asset we otherwise would have recognized is one year or less. Sales commissions are recorded within selling,
general, and administrative expenses in the statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory represents finished goods purchased from a third-party manufacturer and is valued at the lower of cost or net realizable value. Cost
is determined using actual costs on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> basis for all inventory. Net realizable value is determined as the estimated selling prices in the ordinary
course of business, less reasonably predictable costs of completion, disposal, and transportation. We regularly review inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life to record a
provision for excess and obsolete inventory when appropriate. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of
expected requirements. The estimate of excess quantities is judgmental and primarily dependent on our estimates of future demand for the particular product </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation and Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure and record the expense related to stock-based payment awards based on the fair value of those awards as determined on the date of
grant. We recognize stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period and use the straight-line method to recognize stock-based compensation, and account for forfeitures
as they occur. Prior to our initial public offering, we selected the Black-Scholes-Merton, or Black-Scholes, option-pricing model as the method for determining the estimated fair value for stock options. The Black-Scholes option-pricing model
requires the use of highly subjective and complex assumptions, which determine the fair value of share-based awards, including the option&#146;s expected term, expected volatility of the underlying stock, risk-free interest rate and expected
dividend yield. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected Term: The expected term was calculated using the simplified method. The simplified method is based on
the vesting period and the contractual term for each grant or for each vesting tranche for awards with graded vesting. The midpoint of the vesting date and the maximum contractual expiration date is used as the expected term under this method. For
awards with multiple vesting tranches, the time from grant until the midpoints for each of the tranches may be averaged to provide an overall expected term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected Volatility: We used an average historical stock price volatility of a peer group of publicly traded
companies to be representative of its expected future stock price volatility, as we did not have any trading history for our common stock. For purposes of identifying these peer companies, we considered the industry, stage of development, size, and
financial leverage of potential comparable companies. For each grant, we measured historical volatility over a period equivalent to the expected term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk-Free Interest Rate: The risk-free interest rate is based on the implied yield currently available on US
Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues with remaining terms equivalent to the expected term of a stock award. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected Dividend Yield: We have not paid, and do not anticipate paying, any dividends in the near future.
Accordingly, we estimated the dividend yield to be 0%. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our initial public offering, the fair value of our
common stock was determined by the board of directors with assistance from management and, in part, on input from an independent third-party valuation firm. The board of directors determines the fair value of common stock by considering a number of
objective and subjective factors, including valuations of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance, the lack of liquidity our common stock and the general and industry-specific
economic outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute
of Certified Public Accountants Practice Aid,&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the Practice Aid. The methodology to determine the fair value of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock included estimating the fair value of the enterprise using the &#147;backsolve&#148; method, which estimates the fair value of our company by reference to the value and preferences
of our last round of financing, as well as our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used to determine the estimated fair value of our common
stock are based on numerous objective and subjective factors, combined with management&#146;s judgment, including external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our stage of development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The prices at which we sold shares of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our financial condition and operating results, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The progress of our research and development efforts, our stage of development, and business strategy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Equity market conditions affecting comparable public companies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General U.S. market conditions and the lack of marketability of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine
the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Income approach.</I><I></I>&nbsp;The income approach attempts to value an asset or security by estimating the
present value of the future economic benefits it is expected to produce. These benefits can include earnings, cost savings, tax deductions, and disposition proceeds from the asset. An indication of value may be developed in this approach by
discounting expected cash flows to their present value at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation over the asset&#146;s holding period, and the risks associated with realizing the
cash flows in the amounts and at the times projected. The discount rate selected is typically based on rates of return available from alternative investments of similar type and quality as of the valuation date. The most commonly employed income
approach to valuation is the discounted cash flow analysis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Market Approach.</I><I></I>&nbsp;The market approach attempts to value an asset or security by examining
observable market values for similar assets or securities. Sales and offering prices for comparable assets are adjusted to reflect differences between the asset being valued and the comparable assets, such as, location, time and terms of sale,
utility, and physical characteristics. When applied to the valuation of equity, the analysis may include consideration of the financial condition and operating performance of the company being valued relative to those of publicly traded companies or
to those of companies acquired in a single transaction, which operate in the same or similar lines of business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cost Approach.</I><I></I>&nbsp;The cost approach to valuation is based upon the concept of replacement cost as
an indicator of value and the notion that an investor would pay no more for an asset than what it would cost to replace the asset with one of equal utility. The cost approach estimates value based upon the estimated cost of replacing or reproducing
the asset, less adjustments for physical deterioration and functional obsolescence, if relevant. When applied to an enterprise, a type of cost approach referred to as the Net Asset Method is sometimes employed. This method measures the value of
equity as the sum of the values of its assets reduced by the sum of the values of its liabilities. The resulting equity is reflective of a 100% ownership interest in the business. This approach is frequently used in valuing holding companies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our early stage of development and other relevant factors, our board of directors considered all three
approaches and have chosen to apply both income and market approaches in our analyses. Our board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors determined these approaches were the most appropriate methods for allocating our enterprise value to determine the estimated fair value of our common stock for valuations performed for
periods as of December&nbsp;31, 2020 or earlier. In determining the estimated fair value of our common stock, our board of directors also considered the fact that our stockholders could not freely trade our common stock in the public markets.
Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. The estimated fair value of our common stock at each grant date reflected <FONT
STYLE="white-space:nowrap">a&nbsp;non-marketability&nbsp;discount</FONT> partially based on the anticipated likelihood and timing of a future liquidity event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, the fair value of each share of underlying common stock will be determined based on the closing quoted
market price of our common stock on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our redeemable convertible preferred stock warrants require liability classification and accounting as the underlying redeemable convertible
preferred stock is considered contingently redeemable and may obligate us to transfer assets to the holders at a future date upon occurrence of a deemed liquidation event. The warrants are recorded at fair value upon issuance and are subject to
remeasurement to fair value at each balance sheet date, with any changes in fair value recognized as other expense in the statements of operations. The warrants liability is recorded as other noncurrent liabilities in the balance sheets. We will
continue to adjust the warrant liability for changes in fair value until the earlier of the exercise or expiration of the redeemable convertible preferred stock warrants, occurrence of a deemed liquidation event, or conversion of redeemable
convertible preferred stock into common stock. At that time, the liability associated with the redeemable convertible preferred stock warrants that are converted into warrants to purchase common stock will be reclassified to additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, while the liability associated with any expired warrants will be recognized as a gain within the statements of operations and comprehensive loss. As a result, the redeemable convertible preferred
stock warrant liability will be settled and will no longer be subject to remeasurement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
risk associated with fluctuating interest rates is primarily limited to our cash equivalents, which are carried at quoted market prices. Due to the short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point
change in interest rates would not have a material effect on the fair value of our cash equivalents. We do not currently use or plan to use financial derivatives in our investment portfolio. As December&nbsp;31, 2020, we had
$&nbsp;&nbsp;&nbsp;&nbsp;million in variable rate debt outstanding. Our 2020 Term Loan bears interest per annum at 7.00% plus LIBOR for such interest period, and our 2020 Revolver bears interest per annum at 4.50% plus LIBOR for such interest
period. A hypothetical change in interest rates of 10% would have resulted in a change of $&nbsp;&nbsp;&nbsp;&nbsp;million in interest expense in 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business is primarily conducted in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position or cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Jumpstart Our Business Startups Act of 2012 (JOBS Act) permits an &#147;emerging growth company&#148; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We
have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised
accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 to our financial statements included elsewhere in this prospectus for new accounting pronouncements not yet adopted as of the date
of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to transform
ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world&#146;s most prevalent eye diseases. We are passionate about improving patients&#146; lives. Our business
philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing products that are intended to restore natural physiological functionality to diseased eyes; developing and marketing products that
achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient friendly solutions to ophthalmologists and optometrists (together, eyecare professionals or ECPs), and
delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create
an interventional mindset in eyecare whereby our products may be used in procedures which supplant conventional outdated approaches. We believe current eyecare treatment models rely heavily on prescription medications, symptom relief, or either
flawed or highly invasive, later-stage procedural interventions, and often fail to adequately address the true underlying cause of disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused our initial product development efforts on the treatment of two of the world&#146;s most prevalent and underserved eye
diseases, glaucoma and dry eye disease, or DED. We estimate the annual addressable U.S. market opportunities for the products in our Surgical Glaucoma and Dry Eye segments are approximately $6&nbsp;billion and approximately $10&nbsp;billion,
respectively, while 2020 U.S. manufacturer revenues in the surgical glaucoma and DED markets were approximately $350&nbsp;million and $2.4&nbsp;billion, respectively, demonstrating that currently available solutions have not addressed a large part
of the market need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma, a group of chronic, often asymptomatic, diseases that damage the optic nerve, is the world&#146;s leading
cause of irreversible blindness. Glaucoma does not have a cure and is a progressive disease; if left untreated or insufficiently treated, glaucoma can lead to irreversible disability and blindness. An estimated 102&nbsp;million people worldwide
suffer from glaucoma. Primary open-angle glaucoma, or POAG, is the most prevalent form of glaucoma and affects over 60&nbsp;million people worldwide, including 4.1&nbsp;million people in the United States, of whom 3.4&nbsp;million have been
diagnosed. One of the greatest risk factors for POAG, and the only risk factor that can be controlled, is elevated intraocular pressure, or IOP. IOP is caused by malfunctioning drainage pathways in the eye that provide abnormal resistance to the
outflow of aqueous humor, a clear, watery fluid which bathes and nourishes the lens and maintains pressure within the eye. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 1. OMNI Enables New Glaucoma Treatment Paradigm </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g97e03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OMNI Surgical System, or OMNI, is a handheld, single use, therapeutic device that allows ophthalmic
surgeons to reduce IOP in adult glaucoma patients. OMNI allows the ophthalmic surgeon to sequentially complete two well-established but historically invasive <I>ab externo</I> glaucoma procedures, canaloplasty and trabeculotomy, in an efficient,
minimally invasive manner using a single, bloodless and sutureless clear corneal microincision. Conventional canaloplasty and trabeculotomy procedures have been used to effectively treat glaucoma for decades but involve invasive approaches that are
difficult to perform, traumatize the eye, have higher risk of intraoperative and post-operative complications and require longer patient recovery times. OMNI allows ophthalmic surgeons to transform these two distinct, historically invasive <I>ab
externo</I> glaucoma procedures into a sequential, <I>ab interno</I> minimally invasive glaucoma surgery, or MIGS, procedure. MIGS procedures are performed through a one to two millimeters clear corneal incision similar to those used in cataract
surgery for intraocular access and have a strong demonstrated safety profile, characterized by minimal trauma to the eye and quick patient recovery times. The FDA has authorized the use of OMNI for reducing IOP in all adult POAG patients both by
itself on a standalone basis, which we refer to as Standalone procedures, or in combination with cataract procedures, which we refer to as Combination Cataract procedures. Several competing MIGS devices, including the current market leaders, have
only been authorized by the FDA for use in Combination Cataract procedures for adult patients with Mild-to-Moderate severity. We estimate that over 85% of the U.S. addressable market opportunity for POAG cannot be served with Combination Cataract
procedures because less than 15% of POAG patients receive cataract surgery in any given year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that OMNI delivers the highest
level of effectiveness of any available MIGS product, as it is the only device that provides access to 360 degrees of the diseased conventional outflow pathway and can address all three key points of resistance in the conventional outflow pathway
(trabecular meshwork, Schlemm&#146;s canal, and the distal collector channels), through a single clear corneal incision. OMNI&#146;s indication for use, which we believe is among the most comprehensive in MIGS, was cleared by the FDA in March 2021
based upon the review of clinical data from ROMEO, our recently completed U.S. multi-center clinical study of OMNI in Combination Cataract and Standalone procedures. In ROMEO, we observed that Standalone OMNI patients with preoperative IOP greater
than 18 mmHg experienced a mean IOP reduction of 28% (from 21.8 mmHg to 15.6 mmHg) and a mean reduction in hypotensive medication usage of 35% (from 1.71 medications to 1.17 medications) 12 months after treatment. In Combination Cataract patients
with preoperative IOP greater than 18 mmHg, we observed a mean IOP reduction of 31% (from 21.9 mmHg to 15.1 mmHg) and a mean reduction in hypotensive medication usage of 45% (from 2.04 medications to 1.13 medications) 12 months after treatment. We
believe it is noteworthy that our Standalone IOP and medication reduction results are highly comparable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our Combination Cataract results, as it supports our belief that OMNI is the key driver of IOP and medication reduction in both Standalone and Combination Cataract procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 2. Conventional Outflow Pathway &#150; Three Primary Points of Resistance </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g31y24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OMNI has received 510(k) clearance from the FDA and a CE Mark to be marketed in the U.S. and the EU,
respectively, for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm&#146;s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce IOP in adult patients with POAG in the U.S. or with open angle
glaucoma, or OAG, in the EU. We believe OMNI is the first custom-designed, <I>ab interno </I>MIGS device that was cleared by the FDA to lower IOP in both Combination Cataract and Standalone cases for all adults with POAG based upon the review of
<I>ab interno</I> Combination Cataract and Standalone clinical data. By comparison, trabecular bypass stents are indicated for use only in Combination Cataract procedures for patients with Mild-to-Moderate severity in the U.S. Other MIGS devices are
only authorized for cases with failed prior glaucoma surgery or that are unresponsive to maximum tolerated medical therapy, which are known as Refractory cases, or do not have indications for use that were based on the FDA&#146;s review of
accompanying <I>ab interno</I> clinical data. Trabecular bypass stents were the first MIGS implant devices to be authorized by the FDA. We believe the combination of their restricted indication for use and their market leadership position has
unnaturally skewed the U.S. MIGS market towards Combination Cataract procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to establish OMNI as the standard of care
for all POAG patients by continuing to grow its adoption and utilization in the existing Combination Cataract market segment, which we believe remains underpenetrated and estimate is capturing less than one-third of its current potential procedural
volume, and by pioneering the development of the Standalone market segment (over 85% of the potential U.S. POAG market). Published data from ROMEO and several single surgeon datasets show a remarkable consistency in IOP reduction following treatment
with OMNI. Almost all patients across these groups (98 of 103, 95%) had an IOP decrease following treatment with OMNI, and three out of four (77 of 103, 75%) had at least a 20% decrease. Patients in these studies also experienced reductions in the
use of glaucoma medication following their OMNI procedures, a benefit not observed in the &#147;medication washout&#148; trabecular bypass stent trials designed to isolate and thereby maximize IOP reduction in a non-real world manner. We believe the
consistent therapeutic outcomes OMNI delivers are important for patients and surgeons alike. For patients, we believe the anxiety that may accompany the need for ocular surgery can be tempered with the knowledge that there is a high likelihood of
success. For surgeons, consistent outcomes simplify the treatment choice and the decision to perform a procedure. We believe this is especially important for Standalone MIGS procedures which must deliver a very high consistency of efficacy and a
very high degree of effectiveness to not only justify the procedure, but also provide surgeons with enough confidence to recommend Standalone surgery to their patients and take them to the operating room for a singular reason. We believe delivering
consistently effective results will be crucial to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unlocking the Standalone market, as well as capitalizing on the full potential of the Combination Cataract market. An internal field study of our user base has indicated that Standalone
procedures in 2020 constituted greater than 20% of our customers&#146; total OMNI procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After receiving our initial FDA 510(k)
clearance for OMNI in late 2017, we began the commercial sale of the device in February 2018. We primarily sell OMNI in the U.S. through our dedicated Surgical Glaucoma sales team, which includes a subset of representatives solely focused on
educating existing and potential customers and primary care ECPs on the broad utility and use cases for OMNI and on Standalone treatment alternatives generally. Our commercial strategy for OMNI centers on building confidence and conviction amongst
the glaucoma community through continued execution of our clinical trials and publishing their results in peer-reviewed journals. In addition, our highly involved sales and training model serves to promote a world-class surgical experience and
identify additional OMNI use cases within its cleared indication, including in additional Standalone procedures and across all addressable POAG severities. The procedure enabled by OMNI, canaloplasty followed by trabeculotomy, is covered and
reimbursed by all Medicare Administrative Contractors, or MACs, and numerous private insurers, covering an estimated 67% of U.S. POAG sufferers. Designed for use in well-established clinical procedures, and with advantages that have been observed to
promote safe, effective and highly consistent clinical outcomes, we believe that OMNI has the potential to establish a more proactive, interventional paradigm for IOP reduction in POAG. Our Surgical Glaucoma segment, which includes OMNI, represented
94% of our total revenues for the year ended December 31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TearCare System, or TearCare, is a technologically sophisticated
system which utilizes a wearable, <FONT STYLE="white-space:nowrap">open-eye</FONT> design to apply localized heat to the eyelids in an anatomically customized way. We believe TearCare has a compelling physiological profile to address obstruction
from meibomian gland dysfunction, or MGD, which is the primary cause of evaporative DED, a disease characterized by low quality tears that evaporate prematurely. Dry eye complaints are the most common reason for a patient visit to an eye doctor.
There are an estimated 739 million people globally and 38 million people in the U.S. who suffer from DED. DED is the most common reason for a patient visit to an eye doctor, yet of the 38 million people with DED in the U.S., only 17 million have
been diagnosed with DED. Dry eye symptoms have a significant impact on the quality of life and productivity of patients suffering from DED. If left untreated, DED can be extremely painful, leading to permanent cornea damage and vision impairment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies have shown that evaporative DED resulting from MGD is associated with approximately 86% of all DED cases. In healthy eyes, there
are <FONT STYLE="white-space:nowrap">25-30</FONT> meibomian glands located within each of the upper and lower eyelids. These glands produce and secrete an oily substance called meibum which forms the outer layer of healthy tears, which is also known
as the lipid layer. Meibum normally has an olive <FONT STYLE="white-space:nowrap">oil-like</FONT> consistency and contributes a vital element of the tear film that prevents premature tear evaporation. In patients with MGD, meibum hardens within the
glands causing obstructions that can partially or completely block the oily secretions from reaching the tear film. The resulting compromised outer surface of the tear leads to accelerated tear evaporation and DED. Third-party clinical studies have
also demonstrated that treating MGD by liquefying and removing clogged meibum is the most effective method of eliminating obstructions and restoring a healthy tear film lipid layer, thereby preventing premature evaporation of tears. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 3. Progression of DED and Ocular Surface Disease </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g56a28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TearCare is designed to enable ECPs to heat and liquefy meibomian gland blockages, followed promptly by
manual, comprehensive clearing of these blockages with a separate clearance tool. We developed TearCare to serve as an elegant, compact, portable, and intuitive solution comprised of a <FONT STYLE="white-space:nowrap">re-usable</FONT> hardware
controller, the SmartHub, and a breakthrough, wearable, software-controlled eyelid technology, the SmartLids. Applied adhesively and <FONT STYLE="white-space:nowrap">non-invasively</FONT> to the outside of the eyelids, single-use SmartLids deliver a
precise therapeutic level of heat into the meibomian glands. Engineering SmartLids to remain comfortably adhered to virtually all shapes and sizes of eyelids while allowing freedom to blink and delivering precise therapeutic heat is one of our most
significant design accomplishments. This heating process is intended to melt obstructions in the glands and restore the production and release of healthy, clear meibum onto the tear surface. The proprietary, highly conformant, <FONT
STYLE="white-space:nowrap">open-eye</FONT> design of TearCare allows patients to blink naturally throughout the thermal portion of the procedure, which facilitates movement of melted meibum and also provides a comfortable patient experience.
TearCare can be utilized by an ECP in a straightforward <FONT STYLE="white-space:nowrap">in-office</FONT> procedure and can be accommodated during the course of a routine patient visit. Additionally, TearCare does not require a large capital
equipment investment by ECPs, and we believe that it offers an attractive economic value proposition to providers, patients and third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In OLYMPIA, our large multi-center, randomized control trial, or RCT, TearCare was associated with statistically significant clinical
improvements in all assessed signs and symptoms of DED at all time periods measured (both two weeks and four weeks post-treatment) and had a statistically significantly higher proportion of subjects improving by at least one OSDI (patient-reported
outcomes survey) category than did the comparator group receiving a single treatment using a version of the first device FDA-cleared for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the
eyelids, including MGD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began selling TearCare in a controlled product launch in <FONT STYLE="white-space:nowrap">mid-2019</FONT> to
DED-focused ECP practices through a dedicated commercial team. The initial launch phase was successful in garnering valuable feedback from our customers and the broader DED community as well as demonstrating the existing market demand for the
product. We believe the MGD market requires additional ECP and patient education, including clinical data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to differentiate procedural and product alternatives, and enhanced patient access through the potential advancement of reimbursement coverage. Our goals with the development of TearCare are to
fully transform the current outdated treatment paradigm based primarily on over-the-counter, or OTC, and prescription eyedrops which do not address obstruction of the meibomian glands, the primary root cause of MGD, and establish use of TearCare as
the standard of care for the millions of patients suffering from evaporative DED caused by MGD. TearCare is currently indicated for the application of localized heat where the medical community recommends the application of warm compress to the
eyelids, and we are currently seeking 510(k) clearance from the FDA for an expanded indication for use in adult patients with evaporative DED due to MGD. Revenues from our Dry Eye segment, which includes TearCare and related accessories, represented
6% of our total revenues for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical data supports our belief that our products may offer
compelling advantages relative to current treatment alternatives, as evidenced by ROMEO, our multi-center study involving 129 subjects for OMNI, and our OLYMPIA RCT involving 135 subjects for TearCare. We have subjected the findings from our studies
for OMNI and TearCare to the peer-review process, resulting in six publications in leading ophthalmology and optometry journals to date. We are deeply committed to continuing to conduct clinical studies to evaluate the safety and effectiveness of
our products, and we believe the results of these studies will be critical to our continued growth. We are currently conducting robust clinical trial programs in both glaucoma and DED, with 11 ongoing or planned studies, including several
head-to-head RCTs against market leading products. We also support investigator-initiated trial, or IIT, programs, of which eight are completed and two are currently in progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on continuous innovation and seek regular input from our network of expert employees (including several ophthalmologists on staff),
advisors and customers to rapidly iterate our <FONT STYLE="white-space:nowrap">pre-</FONT> and post-commercial product designs with the aim of better satisfying the needs of our customers and their patients, and increasing adoption and utilization
of our solutions. This is particularly evident in the evolution of OMNI, which originated from the combined functionality of two internally developed, commercial predicate devices, each of which went through multiple commercial iterations. We
further refined the ergonomics and functionality in OMNI Next Gen, which we launched in May 2020. Our desire and capability to continuously and rapidly innovate our products is a core competency of our company. Our treatment philosophy and approach
to product innovation have resulted in a patent portfolio of 25 issued U.S. patents, 29 issued patents outside of the U.S., 17 pending U.S. patent applications and 13 pending foreign patent applications as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall success of our innovative approach to eyecare to date has been confirmed by the nearly 60,000 estimated uses of OMNI and its
direct predicates in over 1,000 hospitals and ambulatory service centers, or ASCs, in the U.S. and EU, and approximately 10,000 estimated uses of TearCare in nearly 400 eyecare facilities in the U.S. through March&nbsp;31, 2021. We have experienced
significant growth and market adoption since launching OMNI and are executing a long-term plan for further development of the market for TearCare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there is a
significant opportunity to broadly improve existing treatment paradigms throughout ophthalmology and optometry to benefit more patients worldwide. Advancements in treatment effectiveness across a number of prominent eye diseases have been limited in
recent years due to a lack of significant innovation. We believe that there are few companies in eyecare that excel in both product development and commercial activities. As a result, conventional treatment algorithms that rely heavily on
prescription medications and symptom relief, but fail to comprehensively address the true underlying cause of the disease, have persisted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our objective is to develop products that enable us to open new treatment paradigms and create an interventional mindset in eyecare. We
believe that our track record with OMNI and TearCare has demonstrated our ability to leverage our internal capabilities in product development, clinical trial execution, and commercialization </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to bring viable products to market efficiently and to rapidly refine and innovate them based on real-world input from our customers and advisors. We believe that our products have the potential
to transform the treatment paradigms of their respective target diseases. Through continued product and technological innovation, the generation and compilation of differentiated clinical data, and our highly involved and training-intensive user
experience programs, we strive to transform and lead two of the most prevalent and most underpenetrated segments of eyecare &#150; POAG and DED. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary Open-Angle Glaucoma </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma, a group of chronic, often asymptomatic, diseases that damage the optic nerve, is the world&#146;s leading cause of irreversible
blindness. Glaucoma does not have a cure and is a progressive disease; if left untreated or insufficiently treated, glaucoma can lead to irreversible disability, vision loss and blindness. In 2020, 102&nbsp;million people worldwide were estimated to
suffer from glaucoma. POAG is the most prevalent form of glaucoma and in 2020 affected over 60&nbsp;million people worldwide and 4.1&nbsp;million people in the U.S., of whom 3.4&nbsp;million were diagnosed. Elevated IOP caused by malfunctioning
drainage pathways in the eye with abnormal resistance to the outflow of aqueous humor, is one of the greatest risk factors for POAG and the only one that can be controlled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In patients with POAG, increased resistance to aqueous humor outflow causes pressure to build up in the eye and the resultant tension applies
stress to and cuts off the blood supply to the optic nerve in the back of the eye, resulting in optic nerve cell death and irreversible vision loss. Decades of research have demonstrated that the fluid buildup primarily results from malfunctions in
the eye&#146;s conventional outflow pathway for aqueous humor. If left untreated, glaucoma can damage the optic nerve, resulting in permanent partial or complete loss of vision. The stages of glaucoma are classified based on risk of visual loss on a
scale that ranges from ocular hypertension, or OHT, to Mild, to Moderate, then Advanced/Severe, and finally, <FONT STYLE="white-space:nowrap">End-Stage.</FONT> In the U.S., it is estimated that Mild and Moderate cases each account for approximately
40% of all POAG cases with the remaining 20% representing Advanced/Severe cases. There is no universally accepted standard for diagnosis of glaucoma severity. OHT, which is characterized by elevated IOP without indications of optic nerve damage or
changes in visual field, is a condition that will often progress to glaucoma. While physicians may vary in their diagnostic approach to an individual patient&#146;s stage of glaucoma, Mild and Moderate diagnoses are generally attributed to the
abnormal appearance of the optic nerve head (i.e.,&nbsp;cupping) with early visual field loss for Moderate cases only, followed by visual abnormalities in both left and right hemispheres of the visual fields for Advanced/Severe cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current treatment paradigm for POAG includes less invasive options such as prescription eyedrops and laser treatments for milder cases and
more invasive conventional surgical procedures for more severe cases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription eyedrops and laser treatments seek to increase aqueous
outflow or reduce aqueous production while conventional surgical procedures seek to improve drainage by creating new, artificial, or unnatural outlets for aqueous fluid that bypass the conventional outflow pathway. These conventional surgical
procedures involve incisions to the conjunctiva and sclera that can cause significant trauma and scarring to the eye. Safety concerns for conventional surgical procedures are such that they are typically reserved for Severe cases where the risk of
vision loss is imminent and outweighs the risk of the invasive procedure itself. Each of these treatment modalities addresses just a single aspect of the disease at a specific point in the progression of the disease state. As a complex progressive
disease, there has historically been no &#147;one size fits all&#148; treatment for glaucoma. Physicians have historically used a combination of treatments because no single treatment could adequately slow disease progression to a manageable level
over the long term. Further, due to the progressive nature of the disease, data suggest that legacy interventions can become ineffective as the disease state matures. In 2019, worldwide glaucoma prescription medications were estimated to represent
over 80% of the nearly $6&nbsp;billion global glaucoma treatment market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">POAG is the most common type of OAG and is characterized by an
open, normal appearing anterior chamber and angle, elevated IOP, typical optic nerve head damage and associated visual field loss, but no other detectable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underlying ocular or systemic disease. In healthy eyes, the majority of aqueous fluid drains via the conventional outflow pathway &#151; passing through the trabecular meshwork into
Schlemm&#146;s canal and out of the eye through the distal collector channels that connect to the episcleral venous system, with the remainder draining from the alternative uveoscleral or unconventional pathway. We believe treating the conventional
outflow pathway with minimally invasive access offers the safest and most effective treatment option for POAG. The <I>ab interno</I> approach involves minimal trauma to the eye, enabling fast healing times with minimal complications, and does not
compromise the structural integrity of the eye, thereby allowing episcleral venous pressure, which acts as the body&#146;s natural IOP backstop, to ensure that IOP will not be inadvertently reduced to dangerously low levels (5 mmHg or less), a
condition known as hypotony. Other approaches, such as invasive filtering procedures (e.g., trabeculectomy) or suprachoroidal bypass procedures, create artificial drainage channels and are susceptible to serious complications, including hypotony,
which can develop when drainage from artificial pathways cannot be adequately controlled. Hypotony can lead to corneal decompensation, accelerated cataract formation, and vision loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, MIGS procedures have gained in popularity due to favorable safety profiles, demonstrable effectiveness, and minimal disruption and
trauma to ocular tissues. Trabecular bypass stents were the first MIGS implants to come to market in 2012. During a trabecular bypass stent procedure, one or more stents are implanted into the trabecular meshwork through the same type of
microincision used to perform cataract surgery. As an implant into the trabecular meshwork, trabecular bypass stents address only one (the diseased trabecular meshwork) of three points of potential resistance in the conventional outflow pathway, and
have only modest incremental <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> effectiveness <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> cataract surgery alone. To date, the FDA has only
authorized trabecular bypass stents for use in Combination Cataract surgery for patients with Mild-to-Moderate severity. To attain expanded indications beyond the Mild-to-Moderate Combination Cataract segment in the U.S., we believe trabecular
bypass stents will need to demonstrate safety and effectiveness when used alone and without the assistance of the well documented <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> impact of cataract surgery itself. It is estimated that there were
approximately 205,000 MIGS stent procedures in the U.S. in 2020. In 2019, without COVID-19 related impacts, there were an estimated 220,000 MIGS stent procedures in the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternative bypass stents, another category of implantable MIGS device, have been designed to artificially shunt aqueous humor from the
anterior chamber away from the conventional outflow pathway and into the subconjunctival or suprachoroidal spaces in the eye. Alternative bypass stents create a new drainage channel, circumventing the diseased conventional outflow pathway. Currently
available alternative bypass stents have only been approved for Refractory cases, such as failed prior surgeries and those unresponsive to maximum tolerated medical therapy, which limits their potential market due to the relatively lower incidence
of Refractory cases. Alternative bypass stents that are implanted in a manner that shunts fluid unnaturally have greater safety concerns than MIGS devices that leverage the conventional outflow pathway. In 2018, Alcon&#146;s Cypass stent was
withdrawn from the market due to concerns over rates of corneal endothelial cell loss. The FDA classified the event as a Class&nbsp;I recall, which indicates there is a reasonable probability that use of the product will cause serious adverse health
consequences or death. The Cypass product has not returned to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In surgical glaucoma, each diseased eye requires an independent
procedure and, as a result, requires its own surgical device for the treatment. Applying a ratio of 1.8 assumed eyes with POAG per affected person (or 80% with bilateral POAG) to the estimated 3.4&nbsp;million people diagnosed with POAG in the U.S.
results in a total addressable treatment population of 6.1&nbsp;million diagnosed eyes with POAG. Based on estimated blended average selling prices for MIGS devices, the implied total addressable market opportunity in the U.S. for devices that could
effectively treat all diagnosed POAG sufferers is approximately $6&nbsp;billion. We estimate that currently available trabecular bypass stents are effectively precluded from participating in over 85% of this addressable market given the limitations
of their indications for use and the fact that less than 15% of the diagnosed U.S. POAG population has cataract surgery each year based on the estimated 774,000 eyes that had OHT or any type of glaucoma among all of the cataract surgeries performed
in 2019. Currently available alternative bypass stents are limited to Refractory cases, which we believe represents a smaller portion of the total U.S. POAG market. The current market for glaucoma surgery devices that can deliver both the
effectiveness to substantially reduce IOP and/or <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> medication utilization, and a best-in-class safety profile, has potential for substantial growth and expansion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, MIGS devices, which we define as implantable microstents and non-implantable
Schlemm&#146;s canal surgery devices that facilitate aqueous drainage and access the eye using an <I>ab interno </I>approach via sutureless corneal microincisions, make up the largest and fastest growing segment of the surgical glaucoma market. MIGS
devices accounted for an estimated $342&nbsp;million of the total estimated $575&nbsp;million global glaucoma surgical device market in 2020. In 2019, without COVID-related procedural impacts, MIGS devices accounted for $422&nbsp;million out of the
$706&nbsp;million global glaucoma surgical devices market. Due to the estimated greater than 60% market share held by trabecular bypass stents, however, the U.S. MIGS device market has been unnaturally skewed toward the Combination Cataract
Mild-to-Moderate severity segment for which trabecular bypass stents have been authorized. We expect the overall MIGS device market to grow well beyond its current size as surgeons employ more comprehensive and consistently effective <FONT
STYLE="white-space:nowrap">non-implantable</FONT> procedures to treat a broader range of patients. The Combination Cataract market is also expected to exhibit market growth, as we estimate that current Combination Cataract procedure volumes
represent less than one-third of their potential in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prevalence of POAG is projected to increase in the U.S. due to aging
populations (glaucoma primarily affects people over 60), demographic shifts (POAG has a higher incidence among black and Hispanic populations), and the growth of other medical conditions associated with glaucoma such as diabetes, heart disease and
high blood pressure. In addition, glaucoma has been historically underdiagnosed but recent medical advancements in screening protocols and diagnostic testing combined with growing awareness have contributed to more accurate diagnosis rates. As
surgical glaucoma procedures evolve to become more efficient, less invasive and safer while offering increased effectiveness, the potential for these treatments to become the standard of care for POAG patients earlier in the continuum of disease
progression continues to increase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dry Eye Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DED refers to a group of disorders caused by either low quality tears, known as evaporative DED, or inadequate tear production, known as
aqueous deficient DED. Studies have shown that dry eye symptoms have a significant impact on patient quality of life and productivity and are the most common reason for a patient visit to an eye doctor. If left untreated, DED can be extremely
painful, and lead to permanent cornea damage and vision impairment. Studies have also shown that evaporative DED resulting from meibomian gland dysfunction, or MGD, is associated with approximately 86% of all DED cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MGD is a chronic, multifactorial abnormality of the meibomian glands that alters gland morphology and physiology. In healthy eyes, there are <FONT
STYLE="white-space:nowrap">25-30</FONT> meibomian glands located within each of the upper and lower eyelids. These glands produce and secrete an oily substance called meibum which forms the outer layer of healthy tears and helps prevent premature
tear evaporation. Healthy meibum has the consistency of olive oil and is released with each blink. Alterations in meibum chemistry and gland hyperkeratinization can lead to hyposecretion and ultimately the accumulation and hardening of meibum within
the meibomian glands. The resulting gland obstruction, if not treated effectively and efficiently, can cause <FONT STYLE="white-space:nowrap">up-regulation</FONT> of neighboring glands, gland inflammation, and atrophy of the glands, causing MGD. MGD
greatly affects the ocular surface leading to tear film instability, rapid tear evaporation and drying, tear hyperosmolarity and subsequent inflammatory damage of the ocular surface. Clinically, these changes result in symptoms such as visual
degradation, blurred vision, ocular fatigue, ocular discomfort and foreign body sensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are an estimated 739&nbsp;million people
globally and 38&nbsp;million people in the U.S. who suffer from signs and symptoms of DED. Of the 38&nbsp;million people with DED in the U.S., only 17&nbsp;million have been diagnosed with DED, of which an estimated 14&nbsp;million diagnosed
sufferers have evaporative DED associated with MGD. MGD prevalence is expected to continue to grow as the population ages and behavioral risk factors like contact lens usage, LASIK surgery, prescription medication usage, and screen viewing time
become more common. We estimate that based on current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenditure levels for DED prescription eyedrops and the estimated size of the MGD patient
population, the addressable U.S. market for MGD treatment is approximately $10&nbsp;billion per year, as compared to MGD procedures representing less than $100&nbsp;million of U.S. manufacturer revenues in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2020 (in total, U.S. DED treatments represented $2.4 billion of 2020 manufacturer revenues). We believe that evaporative DED caused by MGD is one of the most prevalent diseases in all of medicine
that lacks any meaningful reimbursement coverage by Medicare and private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although MGD is the primary root cause of DED, we
believe it is relatively &#147;new&#148; to eyecare research and product development. As a result, despite the enormous population of DED sufferers, the vast majority of eyecare centers have underdeveloped DED treatment practices. We believe this is
the direct result of the limited effectiveness of prevailing medications and treatments, and the practically nonexistent reimbursement coverage regimes currently in place among third party payors for MGD procedures and associated meaningful
limitations on patient access. We believe that any devices that have been clinically proven to be safe and effective and authorized by the FDA for use in MGD procedures will have the opportunity to drive ECP and patient adoption and improve patient
access. There are approximately 40,000 optometrists and approximately 20,000 general ophthalmologists who regularly see patients with DED at over 40,000 eyecare facilities in the U.S. Only an estimated 5,000 of these facilities, however, have what
we consider to be high volume DED practices today. We define &#147;high volume&#148; as facilities that write more than 36 DED prescriptions per month or actively perform <FONT STYLE="white-space:nowrap">in-office</FONT> DED procedures, such as
punctal plug insertion, amniotic membrane grafts or thermal-based MGD procedures. Similar to glaucoma, we believe that improvements in third-party diagnostic capabilities, combined with increasing professional and patient awareness will drive
increased diagnosis and treatment of DED. We believe that significant growth of the MGD procedure market will result from increasing patient access through the potential establishment of broad-based third-party payor coverage, and from greater
adoption by ECPs as they accumulate experience in integrating and administering new and improved procedure-based DED solutions in their practices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Alternatives and Limitations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
variety of pharmaceutical and procedure-based treatment alternatives exist for POAG and DED but there is no cure for either disease. Because many of the current alternatives focus on treating symptoms rather than the underlying causes of the
disease, they offer suboptimal effectiveness and durability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary Open-Angle Glaucoma </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians classify POAG based on risk of visual loss on a scale that ranges from Mild, to Moderate, then Advanced/Severe. General
ophthalmologists and optometrists who provide primary eyecare services are typically the first to diagnose and treat POAG. These frontline ECPs typically diagnose OHT or Mild-to-Moderate cases and will refer patients to glaucoma specialists when
more advanced treatment is necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ongoing treatment is complicated by the progressive and chronic nature of POAG. We believe
prescription medications and surgical interventions currently offered to treat POAG patients yield suboptimal outcomes due to non-compliance, limited durability of effect, or invasiveness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 1: Treatments for Management of High Intraocular Pressure by Stage of Progression </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Stage</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Notes</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><I>Ocular&nbsp;Hypertension</I></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Topical&nbsp;eyedrops&nbsp;or&nbsp;monitor&nbsp;IOP</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Some practitioners prefer to treat with topical eyedrops to reduce the risk of developing glaucoma.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><I>Mild POAG</I></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topical eyedrops</P> <P STYLE="font-size:33pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selective Laser Trabeculoplasty (SLT)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Microinvasive glaucoma surgery (MIGS)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prostaglandin analogs are generally first line due
to effectiveness, safety and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-day</FONT></FONT> dosing; other classes of medications may be added if needed.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May be a first line alternative to eyedrops where there is risk for poor tolerance or
compliance.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Combination Cataract procedures can be employed if cataract surgery is
indicated due to minimal added risk with MIGS; trabecular bypass stents are limited to Combination Cataract procedures. Interventional Standalone MIGS procedures such as those using OMNI, are also available.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><I>Moderate POAG</I></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sequenced as for Mild, but because there is more advanced disease, threshold for escalating to next
steps is reduced.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bleb-forming procedures (e.g., trabeculectomy,
tube-shunts)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approved Standalone MIGS procedures, such as those
using OMNI, may be performed in advance of traditional invasive surgeries or if such surgeries have failed.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bleb-forming (filtration) surgeries provide maximum <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> effectiveness but are reserved for cases where drugs
and less invasive procedures have failed to halt or sufficiently slow disease progression. Very infrequent usage at this stage.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">High rate of <FONT STYLE="white-space:nowrap">post-op</FONT> bleb management/revision; potential risks for sight-threatening adverse events.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><I>Advanced/Severe POAG</I></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Bleb-forming procedures</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Risk of vision loss high, benefit of maximum <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> balances surgical risks. Approved
Standalone MIGS procedures may be performed after failed conventional surgeries</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription eyedrops are the most common first line therapy used to treat OHT and Mild glaucoma and often
continue to be utilized for the treatment of Moderate and Advanced/Severe patients. There are a broad range of prescription medications available to treat glaucoma including prostaglandin analogs, beta blockers, carbonic anhydrase inhibitors and
alpha agonists. These medications typically work to either increase the drainage of aqueous fluid through the uveoscleral and conventional pathways (prostaglandin analogs), reduce the production of aqueous fluid (beta blockers, carbonic anhydrase
inhibitors) or both (alpha agonists). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effectiveness of prescription eyedrops for POAG patients is dependent on patient behavior and
compliance, providing inconsistent protection from POAG progression for those who have adherence challenges. POAG disproportionately affects an older demographic who may experience several barriers to adhering to medication regimens, including
physical limitations that inhibit the self-instillation of eyedrops, forgetfulness, and difficulties following the medication schedule. For example, a systematic review of 29 studies showed that up to 80% of glaucoma patients do not follow their
prescribed medication regimen. Further, although multiple eyedrops can add incremental effectiveness to a medication program, they may concurrently complicate the dosing regimen, reduce patient compliance, and exacerbate side effects including
damage to the ocular surface. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies have demonstrated that chronic use of glaucoma medication contributes to ocular
surface disease, an inflammation of the ocular surface, which is irritating and painful (further contributing to poor adherence) and can contribute to greater risk of surgical failure should traditional glaucoma surgery (such as trabeculectomy) be
required. It has also been reported that the long-term use of glaucoma medications is associated with increased expression of proinflammatory mediators in the conjunctiva, and that even preservative-free prostaglandin eyedrops have been shown to
promote macrophage infiltration in the eyelids with long-term use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sustained pharmaceutical delivery through an intraocular implant is
another method of drug administration. While intracameral sustained drug delivery mitigates issues relating to patient medication adherence, it could introduce new challenges associated with leaving an intracameral implant in the eye for several
months or years, or the procedural complexity and risks associated with implanting objects in the eye and potentially removing them. Durysta, the only intracameral implant for glaucoma that has been approved by the FDA, is a bioabsorbable
intracameral implant providing sustained release of a prostaglandin analog (bimatoprost) in a single administration that is designed to elute the drug for a period of four to six months. The FDA has approved Durysta with a label that warns that the
drug should be limited to a single implant per eye without retreatment. In the pivotal clinical trials, the IOP reduction associated with Durysta was <FONT STYLE="white-space:nowrap">non-inferior</FONT> to timolol (beta blocker), with a mean IOP
reduction of 5 to 8 mmHg in patients from a mean baseline IOP (washed out) of 24.5 mmHg. Durysta is procedurally appealing because it can be delivered at the slit lamp in an efficient <FONT STYLE="white-space:nowrap">in-office</FONT> procedure and
because it naturally biodegrades and is absorbed by the body over the course of its treatment duration. However, because the implant can freely move around the eye for several months, we believe long-term safety data on the risks of potential
complications such as corneal endothelial cell loss resulting from repeated implantations will be key to the long-term viability of this alternative. Another intracameral implant that has not been authorized for use by the FDA is reportedly in
Phase&nbsp;II and III clinical trials. This product features a sustained release implant that is surgically implanted and fixed into place within the sclera at the angle where the iris and cornea meet through an <I>ab interno</I> approach similar to
MIGS. Unlike Durysta, however, this titanium implant is not biodegradable and requires an initial operating room visit for skilled implantation, as well as potential <FONT STYLE="white-space:nowrap">follow-up</FONT> <I>ab interno</I> procedures to
remove or refill the existing implant or install a new implant at regular intervals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As POAG progresses to the Moderate stage and beyond,
or as medications prove ineffective, there are multiple procedures that can be performed, which range from <FONT STYLE="white-space:nowrap">non-invasive</FONT> SLT to minimally invasive MIGS to invasive conventional surgery. In an SLT procedure in
an ECP&#146;s office, laser energy is applied to the trabecular meshwork tissue in the eye&#146;s conventional outflow pathway which initiates a change in the tissue that results in better drainage of fluid out of the eye. SLT procedures can
eventually result in a lowering of IOP. SLT offers a <FONT STYLE="white-space:nowrap">non-invasive,</FONT> energy-based solution and short recovery times, with effectiveness similar to a prostaglandin analogue eyedrop but with a waning treatment
effect at less than one year for up to half of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common conventional surgical options are bleb-forming procedures,
including trabeculectomy (also called filtering surgery) and tube shunt implantation, and each has been in use for several decades. Blebs are permanent blisters on the outside of the eye intended to serve as drainage reservoirs. Conventional
surgeries are multi-step invasive procedures, and surgeons only turn to them when they need maximal reductions in IOP to prevent visual field loss or when treatment of the conventional outflow pathway has failed. Unfortunately, despite their success
at reducing IOP, serious complications or even surgical failure are not uncommon with conventional surgical procedures. In one prominent study, 34% of the 82 trabeculotomy procedures followed were considered failures after three years. Furthermore,
these conventional surgeries are considered as a last line of defense for Advanced/Severe stage patients because the procedures create a physiologically artificial pathway that can be difficult to control, carry a life-long risk of complications
(e.g.,&nbsp;hypotony, blebitis, bleb failure), and typically require longer recovery periods. Post-operative care can include a regimen of prescription antibiotic and steroid eyedrops to prevent infection and inflammation, wearing protective eye
shields when sleeping, avoiding strenuous activities and refraining from driving. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the observed benefits and safety data for
the MIGS category generally, and the problems typically associated with topical medications have created a paradigm shift towards earlier surgical intervention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prior to the introduction of implantable MIGS devices in 2012, there was a significant difference between the relatively low risk and moderate effectiveness of prescription eyedrops and laser
procedures and the high risk and high effectiveness of conventional surgical treatments. Trabecular bypass stents have steadily grown in usage among surgeons performing cataract procedures because the devices are relatively straightforward to
implant, involve minimal complications and have an established reimbursement pathway. Trabecular bypass stents have demonstrated modest reduction of IOP beyond the IOP-lowering benefits typically seen from Standalone cataract surgery. One RCT found
that the trabecular bypass stent plus Combination Cataract cohort had a mean reduction in IOP of 7.0 mmHg versus a mean reduction of 5.4 mmHg at 24 months in the cataract surgery only cohort. The attractive safety profile of MIGS has expanded the
intent of MIGS surgery beyond solely IOP lowering goals for patients with elevated IOP to also include medication reduction both in patients with elevated IOP and in patients whose IOP is controlled by medications. The FDA&#146;s authorization of
trabecular bypass stents has been limited to Mild-to-Moderate cases in Combination Cataract surgery, thereby restricting the use of procedures with such stents to the less than 15% of diagnosed POAG patients who undergo cataract surgery in a given
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our field research, we believe that the majority of surgeons who perform Combination Cataract procedures with MIGS stents
are primarily specialists whose practices rely on successful cataract procedures. For patients with Mild-to-Moderate POAG, we believe that cataract surgery creates an opportunity for early surgical intervention without adding significant risk to the
patient or to the success of the cataract surgery. In many Combination Cataract cases, the incremental effectiveness of a MIGS procedure in reducing IOP is secondary to the success of the cataract procedure, which can immediately and dramatically
improve the patient&#146;s vision and is the primary reason for the operating room visit. Given these dynamics and the IOP-lowering impact of cataract surgery by itself, for a Mild Combination Cataract patient, safety and efficiency can be as
important as the incremental effectiveness of the trabecular bypass stent procedure. Conversely, MIGS utilization in the Standalone market must be a deterministic, as opposed to an opportunistic, decision. A Standalone procedure is not a mere <FONT
STYLE="white-space:nowrap">add-on</FONT> to a cataract procedure that has already been scheduled, but is the only reason for the operating room visit and must deliver a very high consistency of efficacy and a very high degree of effectiveness to not
only justify the procedure, but also provide the surgeon with enough confidence to take the patient to the operating room for a singular reason. Among currently-available MIGS devices, we believe that OMNI is the only alternative that can deliver
consistent, significant IOP reductions in Standalone cases because of its ability to not only address all three points of resistance in the conventional outflow pathway through two sequential procedures &#151; canaloplasty and trabeculotomy &#151;
and distinct mechanisms of action (<I>high consistency of effectiveness</I>) but also do so in a complete, circumferential, <FONT STYLE="white-space:nowrap">360-degree</FONT> fashion (<I>high degree of effectiveness</I>). In contrast to OMNI&#146;s
ability to comprehensively address the entire conventional outflow pathway, currently-available trabecular bypass stents were, as their name implies, designed to address only one of the three sources of outflow resistance (<I>less expected</I>
<I>consistency of</I> <I>effectiveness</I>) and do so over just a single quadrant of the diseased outflow pathway (<I>less expected degree of effectiveness</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dry Eye Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although MGD is
the primary root cause of DED, we believe it is relatively &#147;new&#148; to eyecare research and product development. In contrast, we believe aqueous deficiency, which is a less prominent root cause of DED, has historically dominated the medical
community&#146;s mindshare regarding DED and has been synonymous with the disease. This has contributed to the current DED treatment market being characterized by an abundance of OTC artificial tears and lubricating eyedrops, and prescription DED
eyedrops. Given the relatively recent focus on and understanding of MGD, MGD procedures for DED have had limited commercial traction and represent a significant but underdeveloped market opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DED is treated by ophthalmologists and optometrists. OTC eyedrops, which are palliative, and prescription eyedrops, which aim to alleviate
inflammation and/or increase aqueous layer tear production, are the predominant current alternatives utilized to treat DED. Both AbbVie&#146;s Restasis and Novartis&#146; Xiidra DED prescription eyedrops have achieved commercial success, with 2019
global revenues of $1.1&nbsp;billion and approximately $400&nbsp;million, respectively. Restasis is believed to partially suppress an immune response that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prevents tear production while Xiidra blocks migration of activated T cells to the ocular surface, reducing cytokine release that can cause inflammation. While Restasis and Xiidra have
demonstrated the commercial viability of DED solutions, we believe both are limited in their ability to treat the substantial majority of DED sufferers. Neither medication is indicated to treat MGD, the primary underlying cause of evaporative DED,
which is associated with 86% of all DED cases. Furthermore, patient <FONT STYLE="white-space:nowrap">non-compliance,</FONT> the high rate of side effects, and high
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs further limit the ability of prescription eyedrops to treat DED effectively and with maximal patient access. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast, the market for solutions that treat MGD in a targeted manner is highly underdeveloped. MGD procedures represented less than
$100&nbsp;million of U.S. manufacturer revenues in 2020. We are marketing TearCare for its currently-authorized use and, as part of our long term market development plan, are seeking FDA clearance for an expanded indication to more specifically
reflect its effectiveness in the treatment of DED due to MGD. In general, currently available devices for the treatment of MGD can be difficult for providers to administer, which places significant time and oversight demands on the ECP and are
uncomfortable or <FONT STYLE="white-space:nowrap">ill-fitting</FONT> for patients. We believe that TearCare uniquely has the required physiological profile to liquefy hardened meibum within the diseased meibomian glands to allow an ECP to remove the
underlying obstructions from meibomian glands that cause MGD in a consistently effective manner. Further, we believe lack of patient access to reimbursed MGD procedures has been a major obstacle to widespread adoption and market development. Many
competing MGD procedures require high upfront capital equipment purchases for providers, as well as high costs of ongoing consumable supplies, which lowers the overall value proposition to providers, patients and third party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solutions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have designed OMNI and
TearCare to be interventional ophthalmology devices. We believe that both glaucoma and DED are significantly underserved by current treatment offerings and that there are large market opportunities for effective solutions that restore the natural
functionality of diseased eyes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Product Development Approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The past, current, and ongoing development of OMNI and TearCare follows our internal product development approach, which is governed by four
fundamental requirements that we believe are critical to delivering the most effective, safe and consistent clinical outcomes for patients with eye disease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Comprehensive Understanding of Disease Physiology.</B> We review and analyze all available clinical data,
science, and literature that is relevant to a disease to achieve a sound understanding of its underlying cause(s), which guides the development of our products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Treatment of Underlying Causes.</B> Healthy eyes are self-regulating marvels of evolution, biomechanics,
chemistry and physiology. We believe that restoring the natural functionality of diseased eyes by comprehensively treating underlying cause(s) of disease provides the optimal combination of effectiveness and safety. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Intuitive Design.</B> Our products are designed to transform complex, impractical or invasive treatment
approaches into intuitive, minimally invasive, user-friendly procedures. Our product development goals are focused on delivering a preferred &#147;go to&#148; treatment of choice for ophthalmologists and optometrists. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patient Access.</B> We seek to maximize availability and accessibility of our products for as many patients as
possible. We believe that our devices have the potential to offer differentiated clinical, experiential and economic value to all eyecare stakeholders. For conditions where patients lack optimal treatment access due to insurance coverage limitations
or difficult patient-pay economics, we plan to demonstrate the value proposition of our solutions through data from rigorous clinical trial data and real-world results to improve access. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We aim and expect to be a clinical leader in every eyecare segment we enter and seek to
achieve all four criteria in any of our product development projects. From device ideation to commercialization, we take into consideration the perspectives of patients, providers and third-party payors throughout our product development process.
When possible, we seek to streamline our product commercialization process by judiciously designing our products to achieve the most efficient routes for FDA clearance or authorization for each applicable indication and reimbursement coverage by
third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also actively seek to protect the intellectual property involving our products, technologies, and methods. As
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our patent portfolio consisted of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued patents and
patent applications for our Surgical Glaucoma segment and&nbsp;&nbsp;&nbsp;&nbsp;issued patents and patent applications for our Dry Eye segment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OMNI Surgical System </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Figure 4a. Canaloplasty using OMNI</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 4b. Trabeculotomy using OMNI</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g90195g22v10.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g90195g87x28.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OMNI is a handheld, single use, therapeutic device for minimally invasive glaucoma surgery, or MIGS. OMNI is
designed to restore the eye&#146;s natural drainage system without compromising the structural integrity of the eye or leaving implants behind post-surgery. We have received 510(k) clearance from the FDA in the U.S. and a CE Mark in the EU to market
OMNI. OMNI is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm&#146;s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce IOP in adult patients with POAG in the U.S. and with OAG in
the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In late 2017, OMNI received its initial 510(k) clearance from the FDA for delivery of small amounts of viscoelastic fluid and
cutting of the trabecular meshwork during trabeculotomy. In March 2021, OMNI received FDA clearance for its current expanded indication for use, which we believe reflects the capabilities of OMNI to reduce IOP in adult patients with POAG across the
spectrum of disease severity in both Combination Cataract and Standalone cases. In connection with this clearance, the FDA reviewed clinical data from our ROMEO multi-center study. We believe that ROMEO represents the first and only <I>ab
interno</I> clinical data reviewed by the FDA that has successfully resulted in a Standalone indication in Mild-to-Moderate glaucoma. Together with our clinical trial results, we believe our expanded indication for use will further bolster
confidence in the device among current and prospective surgeons, primary care ECPs, patients and third-party payors. We believe that OMNI is the first and only MIGS device that the FDA has indicated for <I>ab interno</I> procedures to lower IOP
across all severities of POAG, including Standalone procedures. We further believe that OMNI is also the first and only multi-procedure MIGS device dually indicated for canaloplasty followed by trabeculotomy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 5. The OMNI Surgical System </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g65f41.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B><U>OMNI Instructions for Use:</U></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">OMNI includes a stainless-steel cannula, polymeric microcatheter, removable priming lock, internal reservoir and plunger tube, a Luer fitting for direct
connection with an OVD cartridge to prime the internal reservoir, and two advancement wheels. A single advancement wheel is located on each side of the handle. This allows OMNI to be used in either eye (OD or OS) and in either hand of the surgeon
(left or right), by turning the device 180 degrees along its vertical axis. These wheels are used to advance and retract the microcatheter.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The stainless-steel cannula has a curved shape with a beveled tip for entry through the trabecular meshwork into Schlemm&#146;s canal. To perform the combined
and sequential canaloplasty/trabeculotomy procedures, the canaloplasty is performed first, followed by trabeculotomy as explained in further detail below.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Performing Canaloplasty First: </B>the microcatheter is advanced into Schlemm&#146;s canal up to 180 degrees (one hemisphere) by rotating the advancement
wheel forward until the wheel stops (about 20 mm). When the device is being used to deliver viscoelastic fluid, retraction of the microcatheter causes the plunger tube to advance into the viscoelastic fluid reservoir thereby automatically dispensing
viscoelastic fluid along the length of Schlemm&#146;s canal and collector channels. The microcatheter can be advanced/retracted up to 20 mm per cycle by manually rotating the advancement wheel. The microcatheter can be fully advanced/retracted
multiple times, however, viscoelastic fluid can only be dispensed during the first two advancement/retraction cycles in order to dispense viscoelastic fluid along each hemisphere of Schlemm&#146;s canal. Thus, OMNI is designed to be used twice
within Schlemm&#146;s canal to deliver a controlled volume of viscoelastic fluid along the first 180 degrees of the canal, followed by a second delivery of viscoelastic fluid along the other 180 degrees. OMNI delivers a total viscoelastic fluid
volume of 11 microliters throughout Schlemm&#146;s canal (approximately 5.5 microliters for each of the first two advancement/retraction cycles).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Performing Trabeculotomy Second:</B> the beveled tip of the curved stainless-steel cannula is re-positioned into the same Schlemm&#146;s canal location after
finishing canaloplasty. The polymeric microcatheter is re-advanced into Schlemm&#146;s canal up to 180 degrees (one hemisphere) by rotating the advancement wheel forward until the wheel stops (about 20 mm). With the microcatheter resting in the
canal, the cannula is removed from the corneal incision and out of the eye causing the microcatheter to cut through the trabecular meshwork. This process can be repeated in the second Schlemm&#146;s hemisphere.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surgeons have performed canaloplasty and trabeculotomy to treat glaucoma for decades using
conventional, invasive surgical methods. In a canaloplasty procedure, a surgeon advances a specialized microcatheter through the trabecular meshwork then into and around Schlemm&#146;s canal and injects viscoelastic fluid to dilate the drainage
canal and points of egress. Canaloplasty primarily addresses distal resistance (i.e., collapsed Schlemm&#146;s canal, blocked collector channel ostia) and has some presumed effects on the inner wall of Schlemm&#146;s canal and the trabecular
meshwork due to dilation and stretching. In a trabeculotomy procedure, a surgeon unroofs Schlemm&#146;s canal by cutting the trabecular meshwork to provide aqueous humor with direct access to the drainage points in the conventional outflow pathway.
Trabeculotomy addresses proximal resistance (i.e., outflow resistance in the trabecular meshwork and inner wall of Schlemm&#146;s canal). While there exists an abundance of clinical data supporting the effectiveness of canaloplasty and trabeculotomy
procedures generally in reducing IOP, we believe these procedures are difficult to perform, traumatize the eye, have higher risk of intraoperative and post-operative complications and require longer patient recovery times because they were
historically performed invasively through an <I>ab externo</I> approach which required deep scleral incisions to access the diseased conventional outflow pathway. During our initial research and development in the glaucoma space, we came to believe
that products that could combine the benefits of <I>ab externo</I> circumferential surgery with less invasive clear corneal MIGS access, would have a global impact on POAG by driving mainstream surgeon adoption of intuitive, effective, and
interventional surgical procedures to patients across the disease progression spectrum. We believe that the sequential combination of canaloplasty followed by trabeculotomy is uniquely capable of treating all three points of resistance in the
conventional outflow pathway of the eye. We believe treating all three points of resistance is critical to achieving the consistency and level of effectiveness in reducing IOP and medication requirements necessary to expand the use case for MIGS
procedures to the Standalone market and to all disease severities among adult POAG patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 6. Aqueous Humor Outflow through the Conventional
Outflow Pathway </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g14q53.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 7. Close Up on the Conventional Outflow Pathway </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g16d54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OMNI has roots from two handheld predicate devices, the VISCO360 and TRAB360. Both of these devices
received CE Marks for the reduction of IOP in patients with POAG in 2016. In the U.S. from 2013 to 2018, VISCO360 and TRAB360 each received FDA clearances to deliver small amounts of viscoelastic fluid during ophthalmic surgery and to cut the
trabecular meshwork during trabeculotomy procedures, respectively. After years of extensive development of the predicate devices with our physician advisors and other practicing surgeons across the U.S. and in Europe, we designed OMNI to combine
their functionality into a single device. OMNI received its CE Mark in 2015 and its initial FDA 510(k) clearance in December 2017 by demonstrating substantial equivalence to predicate devices. OMNI received 510(k) clearance in March 2021 for its
current expanded label. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied our medical expertise, as well as specialized design and engineering capabilities, to create a
complex device that is simple in appearance and intuitive to use. Each OMNI device consists of 29 separate precision-engineered parts that have been optimized for performance, effectiveness and usability. After inserting the cannula tip into the
corneal microincision and accessing Schlemm&#146;s canal, the surgeon can advance and retract the catheter with a fingertip dial up to 180 degrees. Upon retraction of the catheter, OMNI delivers viscoelastic fluid to complete the viscodilation of
Schlemm&#146;s canal. The surgeon can complete a full 360 degree canaloplasty by reinserting the catheter and advancing it in the opposite direction. To perform the trabeculotomy following the canaloplasty, the same microcatheter can be reinserted
into Schlemm&#146;s canal and used to deroof the trabecular meshwork in a titratable manner (90, 180, 270 or 360 degrees). OMNI&#146;s versatility and titratable functionality, which we believe are unmatched by other MIGS products currently on the
market, enable surgeons to perform sequential comprehensive outflow treatments, customized for an individual patient&#146;s disease severity and eye anatomy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that OMNI has the potential to offer the following benefits: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Effectiveness </B><B>and Safety</B>. We designed OMNI to set the standard for consistently effective IOP
reduction in adult- POAG patients by focusing on what we believe is a primary underlying cause of the disease: diseased conventional outflow pathway with increased resistance to the drainage of aqueous humor. OMNI facilitates two complementary and
sequential procedures, canaloplasty and trabeculotomy, which enable a surgeon to address the three main points of resistance in the conventional outflow pathway with a single device using a single clear corneal incision during a single outpatient
visit. Further, we believe that OMNI fits all of the criteria for a product to have a market leading safety profile: it restores natural functionality to the eyes, involves minimal complications and fast recovery times, and does not require
implants, which can carry longer term foreign body risks. We believe that the effectiveness and safety of OMNI is demonstrated by the clinical data from our four completed trials and five peer-reviewed publications to date (with several additional
publications planned). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Intuitive Design. </B>The intuitive, ergonomic, single-handed design of OMNI, coupled with surgeon familiarity
with the <I>ab interno </I>minimally invasive approach to glaucoma surgery, facilitates physician adoption and utilization. We believe that OMNI&#146;s intuitive design enables a steep learning curve and allows surgeons to become comfortable using
OMNI relatively quickly. In May 2020, we introduced a new version of the OMNI Surgical System called OMNI Next Gen that incorporated extensive user and ergonomic feedback from our surgeon team members, advisors, and customers and that we believe
improved upon the first-generation device. We designed OMNI Next Gen for improved ergonomics, enhanced canalicular access through modifications of the cannula tip and microcatheter tip, smoother deployment and retraction mechanism for the
microcatheter, and increased viscoelastic fluid volume. In the second half of 2020, OMNI Next Gen represented over 90% of our Surgical Glaucoma revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Versatility.</B> We believe that OMNI&#146;s broad FDA-cleared indication for use and comprehensive titratable
360 degree access to the diseased conventional outflow pathway make it a valuable option for all adult POAG patients and in either a Standalone or Combination Cataract setting. In practice, our field research indicates that surgeons utilize OMNI for
cases across the entire POAG disease severity continuum, as well as both on a Standalone basis and in Combination Cataract surgery. We believe that from a device effectiveness and an indication for use standpoint, OMNI should be the MIGS device of
choice for IOP reduction in the full range of adult POAG patients and supports transforming physicians&#146; approach to POAG by bridging the chasm between current first line treatment options, such as eyedrop medications and SLT, and higher risk
conventional surgical procedures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Market Access. </B>The procedure enabled by OMNI, canaloplasty followed by trabeculotomy, is covered and
reimbursed by all MACs and numerous private insurers, covering an estimated 67% of U.S. POAG sufferers. We believe that OMNI enables safe, fast healing and effective ambulatory care procedures that are attractive to all stakeholders, including
patients, surgeons, facilities and third-party payors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TearCare System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 8. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g91c96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TearCare has been commercially available since 2019 and is currently marketed as a 510(k)-exempt powered
heating pad for the application of localized heat when the current medical community recommends the application of a warm compress to the eyelids. Such applications would include Meibomian Gland Dysfunction (MGD), Dry Eye, or Blepharitis. Based on
our favorable randomized controlled trial results as well as over 10,000 cases of real-world evidence, we are seeking clearance of TearCare for the application of localized heat therapy in adult patients with evaporative DED due to MGD, when used in
conjunction with pressure to the eyelids to express the meibomian glands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to optimize the treatment of evaporative DED due to MGD, we custom designed
TearCare to facilitate what we believe is the optimal method for clearing meibomian gland obstructions based on numerous clinical studies: warming the glands to a minimum of 41 degrees Celsius for 15 minutes to melt congealed meibum followed by
manual, clinician customized and performed removal of the liquefied obstructions using forceps to help facilitate restoration of healthy meibum production to naturally fortify the tear&#146;s protective lipid layer. Tear film is a complex,
continuously renewed solution that is necessary for maintaining a healthy cornea and optical clarity. Tears consist of three layers: an inner mucous layer that nourishes the cornea and helps stabilize and anchor the tear film; a middle aqueous layer
that lubricates the eye, removes particles and prevents infection; and an outer lipid layer, or meibum, that prevents premature evaporation and maintains tear film stability. MGD occurs when meibum accumulates and hardens within the meibomian gland.
Over time, the glands can become blocked or clogged, which prevents meibum from reaching the tear, fortifying the outermost tear lipid layer, and protecting the integrity of the tear. As evidenced by our design of TearCare and desired indication for
use, we believe the most effective treatment for DED due to MGD requires the application of consistent therapeutic levels of heat to the meibomian glands for a prescribed period of time followed by a comprehensive clearance of obstructed meibomian
glands, thus restoring the eyelid&#146;s natural ability to produce healthy lipid secretions and recovering the integrity of the tear film. We believe that the <FONT STYLE="white-space:nowrap">open-eye</FONT> design of TearCare allows patients to
blink naturally throughout the thermal portion of the procedure, which has the potential to facilitate the natural flow of melted meibum. which can be further complemented by an ECP&#146;s manual expression of the previously obstructed glands using
forceps. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 9. The TearCare System </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g33u12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our TearCare System includes a pair of <FONT STYLE="white-space:nowrap">single-use</FONT> SmartLids, the
first wearable, highly conformant, precision heating device for the eyelids. SmartLids allow for eyes to be open and blink during the thermal portion of the process and are software-controlled, delivering precise heat to the tarsal plates of the
eyelids directly overlying the meibomian glands while continuously monitoring temperature and communicating 144 times per second with the SmartHub, a compact, finely calibrated power source and control unit which can make instantaneous adjustments
to ensure delivery of the desired amount of heat and therapeutic temperature level. Engineering SmartLids to remain comfortably adhered to virtually all shapes and sizes of eyelids while allowing freedom to blink and delivering precise therapeutic
heat is one of our most significant design accomplishments. Following therapeutic heat application by TearCare, ECPs can use commercially available forceps to manually express melted meibum from each gland. ECPs can tailor the amount of pressure
applied during expression to specific glands based on a desired full evacuation of the glands, thereby allowing the eyelids to resume the production of healthy, new meibum to coat and protect tears. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to patient and ECP feedback, treatments using TearCare are comfortable for
patients since they can keep their eyes open during the thermal portion of the procedure and have the freedom to blink naturally. Additionally, TearCare was designed to be administered during the course of a routine office visit to an ECP, which
makes it convenient for patients, and allows providers to maintain procedural throughput in their practices. We believe that these features of the patient and ECP experience with TearCare procedures offer a stark contrast to other available
alternatives which we believe are burdened by ineffective and suboptimal product design, including awkward and uncomfortable patient experiences through closed eye solutions and/or manual solutions that require extremely close patient proximity to
the ECP throughout the treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that TearCare has the potential to offer the following benefits: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Favorable Safety and Effectiveness</B> <B>Data. </B>We developed TearCare to address the underlying physiology
and root cause of MGD and we believe our clinical data will demonstrate that TearCare treats the signs and symptoms of DED due to MGD. In our OLYMPIA RCT we observed that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of TearCare in patients with DED was associated with improved symptoms as measured by patient-reported
symptom outcomes, such as Ocular Surface Disease Index, or OSDI, and Symptom Assessment in Dry Eye, or SANDE, as well as improved signs, such as tear break up time, or TBUT, and meibomian gland secretion score, or MGSS. TBUT is a measure of the rate
of evaporation of the tear film and is an indicator of tear film stability. MGSS is a measure of the quality and quantity of meibum secretion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A single TearCare procedure was associated with improvement in each of the signs and symptoms of DED within two
weeks of treatment in subjects with MGD, as measured by TBUT, MGSS, corneal and conjunctival staining, and OSDI; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The TearCare group had a statistically significantly higher proportion of subjects (72%) improving by at least
one OSDI category than the group receiving a competing treatment (59%); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TearCare procedures had favorable safety data, with only a few instances of minor adverse events that resolved on
their own. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ECP and Patient Experience.</B> We believe our straightforward and intuitive training process helps ECPs and
facilities integrate TearCare into their practices quickly. We have already developed the flexibility to train and certify new TearCare customers for the device&#146;s currently-authorized use either in person or remotely via videoconferences, and
we believe we could do so for an expanded indication as well. Additionally, TearCare has a compact design, which we believe makes it easy for providers to adopt and implement regardless of their clinic&#146;s physical footprint, as well as providing
portability for movement within an office or to other locations for multi-office eyecare practices. TearCare was designed to allow patients to keep their eyes open and blink naturally during the heating process, for a uniquely comfortable treatment
experience. <B></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Versatility</B>. We believe that TearCare has the potential to be a part of the optimal approach for reducing
the signs and symptoms of DED due to MGD across all degrees of meibomian gland obstruction and all severities of DED. Our OLYMPIA trial enrolled Moderate and Advanced/Severe dry eye patients and we observed clinically significant improvements in all
signs and symptoms of dry eye assessed across both severities of disease. We believe that TearCare can be used as part of a procedure to restore natural meibomian gland functionality and lead to higher quality tears with a fortified lipid layer.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Economics</B>. We believe TearCare already provides compelling value for all stakeholders, something that will
only increase as its clinical evidence, reimbursement coverage and authorized indications for use each expand. We believe we offer ECPs a thoughtful business model featuring minimal upfront cost, affordable
<FONT STYLE="white-space:nowrap">single-use</FONT> SmartLids, and an efficient patient flow that fits into existing practices and a recurring annual or semiannual procedure cycle. While our initial commercial success has proven that a significant <FONT
STYLE="white-space:nowrap">patient-pay</FONT> market exists for TearCare, we believe that improving access from Medicare </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and private payors will be the most effective way to meet the needs of the estimated 14&nbsp;million diagnosed, but underserved, MGD sufferers in the U.S. To that end, we are pursuing a
comprehensive long term market development plan that aims to improve patient awareness and insured access to TearCare. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Success
Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to transform eyecare by developing products that address the underlying causes of the world&#146;s most
prevalent eye diseases. We design our products to enable ECPs to perform safe and effective interventional procedures that can transform treatment paradigms. We believe the following success factors will drive the growth of our company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Large market opportunities in eyecare with flawed treatment paradigms.</B> We estimate the total addressable annual market opportunities in
the U.S. for OMNI and TearCare are approximately $6&nbsp;billion and approximately $10&nbsp;billion, respectively, yet combined 2020 U.S. manufacturer revenues in these markets implied less than 20% total addressable market penetration. We believe
that market leading MIGS alternatives do not consistently and comprehensively address the underlying causes of POAG and do not adequately treat a broad enough range of disease sufferers. In POAG, we estimate that over 85% of diagnosed sufferers can
only be treated with Standalone procedures because they do not require cataract surgery. Similarly, we believe that the market leading DED products do not address the primary underlying cause of the disease, MGD, while those that do attempt to treat
MGD lack user friendly design and do not provide broad patient access. Given the narrow historical product development focus on aqueous deficiency, DED patients are currently limited by a mismatched treatment set (typically prescription or OTC
eyedrops) which do not address the root causes of MGD, the predominant underlying cause of the condition. We believe patients suffering from many other eye diseases could also benefit from the transformation of stale treatment practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Continual development of </B><B>innovative </B><B>technologies</B>. Our ability to transform treatment paradigms in large, underserved
eyecare markets will depend on our ability to develop and commercialize products which are differentiated in how they treat underlying diseases, in their safety and effectiveness, in the breadth of their patient access and in their ease of use for
the ECP. We believe our product development approach is a key differentiator of our team and our company. We design and iterate our products with continual input from our advisor network, an elite group of ECPs who prioritize efficiency, safety and
effectiveness. Once our products are authorized by the FDA and launched, our customer feedback loop helps us further develop our products. This collaborative and iterative process led to the development of our first generation OMNI Surgical System
from two predicate devices, as well as our improved OMNI Next Gen which we launched in May 2020, our TearCare System, and new products that are in progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Consistent delivery of exceptional customer experience.</B> One of the key drivers of our success will be fully developing the potential
addressable markets for POAG and MGD, by maximizing the breadth of patients that our products can serve. We believe developing our target markets requires a consistent, exceptional customer experience, which is best accomplished through a
differentiated, highly involved commercial model. Our sales professionals provide ECPs with the necessary education, training and support to adopt and continue to use our products for their authorized uses. We devote significant resources to
onboarding our sales professionals and to continuously augmenting their knowledge and capabilities. Our management team and commercial organization are highly experienced in developing primary markets and commercializing disruptive products designed
to satisfy unmet patient needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Prioritization of clinical excellence and market education. </B>We are deeply committed to a robust
clinical trial program and are investing significant resources to generate additional scientific evidence regarding the safety and effectiveness of OMNI and TearCare through numerous clinical studies and the publication of our findings in leading
peer-reviewed journals. We believe OMNI is growing rapidly in adoption because of its superior effectiveness and comparable safety compared to alternative MIGS devices and that patients, surgeons </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other stakeholders will all benefit from our continued investment in clinical trials and our broader market education initiatives, which include actively engaging in scientific conventions,
presenting at conferences, and conducting educational and promotional activities, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> events. We also believe that treatment decisions should be
evidence-based and that rigorous clinical studies with high quality data are crucial to achieving and maintaining optimal patient access. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Focus on compelling economics and value creation for all eyecare stakeholders</B>. We focus on developing products to generate substantial
benefits for patients, providers and payors. We believe use of our devices will ultimately reduce the <FONT STYLE="white-space:nowrap">all-in</FONT> cost of treating these diseases for payors. For the sequential procedures using OMNI, surgeons and
facilities use the longstanding permanent Category I CPT code for canaloplasty which is broadly covered by Medicare and private payors. TearCare can provide ECP practices with an attractive recurring revenue business model with only a modest initial
investment. While there is a viable <FONT STYLE="white-space:nowrap">patient-pay</FONT> market for TearCare, we believe that improving access to treatments using TearCare through insurance coverage by Medicare and private payors will be the most
effective way to reach the largest number of patients. Leveraging the results from our OLYMPIA RCT, we are currently pursuing FDA clearance to expand TearCare&#146;s indication for use and plan to pursue further clearances for more robust
indications for use as we build out our library of clinical trial and real-world data regarding the benefits of TearCare treatments. DED is the most common reason for patient visits to an ECP and has major negative effects on patient health and
society. One study estimated the overall direct and indirect costs of DED in the U.S. to be $55.4&nbsp;billion per year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Scale culture
built on community, passion, courage and perseverance</B>. Our organization is designed to be nimble, innovative, adaptive and growth oriented. We have an entrepreneurial and creative foundation that is complemented with an experienced executive
team, who provide deep relationships throughout the eyecare community. We share a passion for improving the lives of people suffering from eye diseases and our success has engendered significant <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">esprit-de-corps</FONT></FONT> at all levels of our organization. We believe that our focus on thought leadership, high performance and collaboration, as well as our hiring and recruiting processes, have enabled us to
attract and retain a world class team that is prepared to transform eyecare for all stakeholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Growth Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fundamental objectives of our growth strategy are to establish robust clinical data to support the development of our target markets and
the continued commercialization of our products and to deliver an exceptional customer experience to the ECPs and patients who utilize our products. We believe that our expertise and product innovation process are applicable across many undertreated
and prevalent diseases within eyecare. Our current growth strategies include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Establish OMNI as the standard of care for Standalone interventional glaucoma treatment.</B> We believe
OMNI has the unique potential to transform the treatment paradigm for IOP reduction in adult POAG patients by greatly expanding the universe of patients who can be treated with MIGS treatment alternatives. We believe OMNI has distinct advantages
with respect to effectiveness, safety and its broad indication for use to reduce IOP across all adult POAG patients in both Standalone and Combination Cataract procedures. High-volume cataract surgeons who are familiar with MIGS procedures are our
highest priority customer acquisition targets and we have directed our initial commercial efforts towards them. We have successfully gained commercial traction with many of these surgeons. Based on our field research, we believe that after gaining
experience using OMNI and confidence in its consistency and effectiveness in familiar Combination Cataract cases, surgeons will often expand the use case for OMNI to include more proactive and interventional POAG cases. We believe many of these
cases will involve Mild-to-Moderate Standalone procedures for which we believe OMNI is the only MIGS device authorized by the FDA for lowering IOP via an <I>ab interno</I> approach. An internal field study of our user base has indicated that
Standalone procedures constituted greater than 20% of our customers&#146; total OMNI procedures in 2020. Given these strong initial results, we plan to invest additional resources to execute our interventional POAG market development plan,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
which includes educating surgeons, facility administrators, primary care ECP referral networks and patients on the clinical benefits of OMNI in both Combination Cataract and Standalone
procedures. Our planned clinical studies include head-to-head RCTs versus a leading trabecular bypass stent and leading prescription OAG medications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Develop the MGD treatment market through a patient <FONT STYLE="white-space:nowrap">access-led</FONT>
strategy. </B>We are executing a comprehensive long-term strategy to increase patient access to TearCare beyond its current patient pay market. Our long-term goal is for TearCare procedures to achieve broad reimbursement from private payors and
Medicare for effectively treating the signs and symptoms of DED due to MGD. We believe the MGD market is the most underserved in eyecare and that current treatment protocols either fail to directly address MGD&#146;s root cause, require
cost-prohibitive capital equipment purchases, lack elegant and user-friendly design, and/or lack the compelling clinical data required to transform treatment paradigms and properly develop the market. Key components of our strategy include: pursuing
clearance from the FDA to expand TearCare&#146;s indications for use to treat DED due to MGD; execution of our SAHARA RCT, which will compare treatments using TearCare to the leading prescription eyedrop treatment and assess the durability of
TearCare procedures over a 24 month period (SAHARA was designed specifically to provide key clinical data that could support potential reimbursement decisions by third-party payors); developing real-world prior authorization and reimbursement claims
evidence to educate payors on the benefits of TearCare for its authorized uses, facilitated by our market access team; and converting our temporary Category III CPT code for TearCare to a permanent Category I CPT code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Drive adoption and utilization of our products by leveraging additional clinical trials and market
education. </B>We believe our existing clinical data demonstrates the compelling safety and effectiveness of OMNI for its cleared indication, and we plan to continue delivering additional clinical evidence regarding its safety and effectiveness. In
our ROMEO study, we observed that use of OMNI was associated with controlled or reduced IOP and reduced medication burden in adult patients. Across several studies, we have observed a consistency of IOP reductions that we believe may appeal to
surgeons evaluating the utilization of OMNI in Standalone and Combination Cataract procedures. We intend to dedicate significant resources to further establish definitive clinical studies regarding the use of OMNI for IOP reduction and/or medication
reduction in adult patients. We are also pursuing clearance from the FDA for an expanded indication for TearCare for the treatment of DED due to MGD. We believe the effectiveness and safety data from our OLYMPIA RCT and other ongoing and planned
studies support the potential of TearCare for this use. In our OLYMPIA RCT, we observed that a single use of TearCare was associated with improvement in each of the signs and symptoms of DED within two weeks of treatment in subjects with MGD, as
measured by TBUT, MGSS, corneal and conjunctival staining, and patient-reported symptom outcomes.<B> </B>Leveraging the results from our OLYMPIA RCT, we are currently pursuing FDA clearance to expand TearCare&#146;s indication for use. We have three
additional ongoing and planned studies intended to evaluate the safety and effectiveness of TearCare and support potential clearances for expanded indications. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Deepen and broaden our commercial organization</B>. We plan to continue investing resources to grow our
commercial team, both in the U.S. and internationally. In addition to competing in the market for devices used for Combination Cataract MIGS procedures in adult POAG patients, we are investing significant resources in our Standalone market
development plan, which includes a team of representatives focused on educating ECPs, ophthalmic surgeons and patients on the broad utility and use cases for OMNI and on Standalone treatment alternatives generally. Through March&nbsp;31, 2021, we
had sold OMNI and its predicate devices to over 1,000 facilities in the U.S. There are over 10,000 ophthalmologists focused on performing cataract and glaucoma surgeries in the U.S. and over 3,000 are currently MIGS trained, a figure that is
expected to grow as MIGS utilization increases, in part driven by the benefits offered by OMNI. Our targeted and controlled launch of TearCare in the U.S. through a small, dedicated sales team has been successful, providing insights into the large
patient pay market. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
We plan to grow our commercial organization over time by matching its growth to the achievement of key milestones in our long-term plan to develop our target markets. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand international commercial efforts</B>. We believe there is a substantial market opportunity for
clinically effective glaucoma and DED products such as OMNI and TearCare outside of the U.S., or OUS, and over the next several years, we intend to increase our OUS investment. The number of U.S. POAG and DED sufferers represents a small fraction of
global sufferers &#151; approximately 6% and 5%, respectively &#151; yet the U.S. represents approximately 60% and approximately 40% of the global glaucoma surgical device and DED treatment markets, respectively. There are currently a number of
developed OUS markets with ECPs who have relevant ophthalmologic and optometric experience and existing reimbursement for MIGS devices, particularly in the EU where OMNI has a broad CE Mark to lower IOP for all adult OAG patients. Trabecular bypass
stents have established significant markets in Europe and other geographies. We also believe that a number of OUS market fundamentals are attractive with respect to potential OMNI adoption throughout Europe and Asia: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surgeons in certain OUS markets choose to intervene at a later stage of eye disease which places increased
criticality on highly robust and dependable effectiveness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Circumferential canal procedures are widely accepted and adopted in select large OUS markets. For example, <I>ab
externo</I> canaloplasty has been very successful in Germany and <I>ab externo</I> circumferential trabeculotomy has been a preferred glaucoma surgery for many years in Japan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surgeons in certain OUS markets are typically salaried and less specialized than U.S. peers which increases the
relative importance of clinical effectiveness over procedural efficiency and/or potential case volumes. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We believe that
OUS markets can be extremely compelling for clinically differentiated products. Our OMNI clinical trial program includes head-to-head RCTs against competing treatments in European markets that are designed to address the needs of regulatory bodies
and third-party payors in those markets. We believe the results of these trials will help OMNI penetrate and gain adoption in these geographies. We also plan to commercialize TearCare in OUS markets and believe MGD procedures have significant
potential. In 2020, we hired an experienced international commercial leader to develop our European expansion plans. In Europe, we currently rely on a combination of direct sales personnel and independent distributors to sell our products, and we
intend to grow our international sales through a combination of direct and distributor sales. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuously innovate premium product offerings in eyecare.</B> Over the course of our ten year operating
history, we have successfully brought to market multiple iterations of OMNI, its predicate devices and TearCare. Our product development approach, which targets underserved eyecare populations, and our ability to effectively navigate
commercialization pathways, has enabled us to launch our products in a highly capital efficient manner, which we believe is distinctive relative to other medical device technology companies and allows us to retain financial flexibility to continue
investing in further product enhancements or to explore other avenues of research and development for future pipeline products in eyecare, including drug therapies, sustained release drug delivery platforms and devices. Our internal and external
advisor and customer networks provide us with ongoing real-world feedback, which we use to rapidly implement improvements and further develop our products. Our product development roadmap focuses on improving our current products, seeking required
FDA authorizations, and disrupting other eyecare categories where stakeholders&#146; needs remain unmet. We believe our product development capabilities and process provide us with a competitive advantage. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that treatment decisions should be evidence-based and hold ourselves to the highest clinical and ethical standards to build and
maintain credibility in the medical community. We are deeply committed to conducting studies to evaluate the safety, effectiveness and durability of treatments using our products, and subjecting the results to the rigorous peer review process for
publication in leading journals. Our robust and growing libraries of evidence to support OMNI and TearCare are helping to drive their awareness and adoption, and ultimately advancing patient care in ophthalmology and optometry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently conducting active and robust clinical trial programs in both POAG and MGD, with two completed studies, 17 papers published in
peer-reviewed journals, and an additional eleven ongoing or planned studies that we expect to provide data for future publications. Our completed, ongoing, and planned clinical trials include several <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> RCTs against market leading treatments. We also support IIT programs, of which eight are completed and two are currently in progress. We plan to support other IITs in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OMNI Surgical System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>OMNI
Clinical Program Overview</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Building on a solid foundation of completed and ongoing clinical trials, we are investing significant
resources to further develop clinical data regarding the use of OMNI. Clinical trials for OMNI include a range of study designs including RCTs as well as retrospective real-world studies, based on our belief that each of these approaches has unique
strengths. RCTs provide high-level evidence in a strictly controlled setting minimizing confounding influences and extraneous variability. On the other hand, we believe that retrospective studies provide the best insight into the generalizability of
effectiveness in actual clinical practice. We believe the clinical evidence that we have generated to date demonstrates the substantial benefits of OMNI across a range of adult POAG patients with various backgrounds, degrees of disease severity, and
prior treatment histories. Since 2018, there have been 11 articles published in peer-reviewed journals for OMNI and its Sight Sciences predicate devices and procedures. Our robust clinical trial program for OMNI includes: one completed multi-center
study (ROMEO) that was used to support OMNI&#146;s indication expansion in March 2021 and resulted in two published articles in peer-reviewed journals; one RCT ongoing in Europe versus the leading trabecular bypass stent (TRIDENT); an ongoing
extension of our ROMEO multi-center study (ROMEO II); two separate RCTs that are scheduled to begin in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the U.S. versus the
leading trabecular bypass stent (PRECISION) and versus the leading glaucoma prescription medication eyedrop (JAEGER); and several additional studies currently in the planning phase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from our recently completed ROMEO multi-center retrospective study, and published data from single surgeon datasets show a remarkable
consistency in the IOP reduction observed with OMNI. Figure 10, below, presents data for mean IOP reduction from four clinical studies in five peer-reviewed publications. Where preoperative IOP was at least 20 mmHg, a mean 8.5 to 10 mmHg decrease in
IOP was observed in all four studies. Similarly, Figure 11 shows that, at the individual patient level, almost all patients (98 of 103, 95%) have an IOP decrease following treatment with OMNI, and three out of four (77 of 103, 75%) have at least a
20% decrease. These real-world patients also experienced substantial reductions in glaucoma medication usage following their OMNI procedures, a benefit not reflected in a number of &#147;medication washout&#148; trabecular bypass stent trials
designed to isolate and thereby maximize IOP reduction in a non-real world manner. We believe consistent therapeutic outcomes are important for patients and surgeons alike. For patients, we believe the anxiety that may accompany the need for ocular
surgery can be tempered with the knowledge that there is a high likelihood of success. For surgeons, consistent outcomes simplify the treatment choice and the decision to perform a procedure. We believe this is especially important for Standalone
MIGS procedures which must deliver a very high consistency of efficacy and a very high degree of effectiveness to not only justify the procedure, but also provide surgeons with enough confidence to take patients to the operating room for a singular
reason. We believe delivering consistently effective results will be crucial to unlocking the Standalone market, as well as capitalizing on the full potential of the Combination Cataract market.<B></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 10. IOP Reduction Across OMNI Clinical Studies </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g63l19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 11. <FONT STYLE="white-space:nowrap">Pre-operative</FONT> versus Post-operative IOP for Patients </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g45w97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vold et al., Hirsch et al., Brown et al., and Grabska-Liberek et al. A position below the diagonal reflects an IOP
decrease post-operatively. These data represent cross-study observations under different conditions. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, OMNI received FDA
510(k) clearance for an expanded indication for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm&#146;s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure (IOP) in adult
patients with POAG. As part of this process, the FDA reviewed our submission of clinical data from our ROMEO study that was collected through a real-world evidence approach evaluating use of OMNI for the reduction of IOP in adult POAG patients
during the general practice of medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that OMNI&#146;s recent clearance is one of few, if not the only, successful use of
retrospective real-world data to support an expansion of an indication for use of an ophthalmic medical device. We believe the FDA&#146;s reliance on this data to support the clearance speaks to the quality of the ROMEO clinical study data and that
the expanded indication for use differentiates OMNI&#146;s effectiveness and versatility from other MIGS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
devices. Specifically we believe that OMNI is the only device that has been authorized by the FDA specifically as an <I>ab interno procedure to: </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reduce IOP in adult patients with POAG across the spectrum of disease severity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Be used in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT>
Combination Cataract or Standalone procedures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Access 360 degrees of the diseased conventional outflow pathway through a single clear corneal incision; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Facilitate two consecutive procedures, canaloplasty and trabeculotomy, that can comprehensively treat all three
points of resistance in the conventional outflow pathway in a single operating room visit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Table 2 below summarizes our
completed, ongoing and planned clinical trials for OMNI. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 2: Sight Sciences OMNI Clinical Studies </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stage</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study <BR>Goals</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Design</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subjects</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patients</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status /<BR>Publication</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g31l94.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">ROMEO</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Real&nbsp;world effectiveness and safety of OMNI Standalone&nbsp;or in Combination Cataract surgery </TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Retrospective, real-world, multi-center, stratified, US study. 12 month</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">OMNI&nbsp;with Combination Cataract surgery;&nbsp;OMNI Standalone in pseudophakic eyes</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-</FONT></FONT><BR>Moderate OAG </TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">129 (81 in Combination Cataract, 48 Standalone)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Vold et al.<BR>Ophthalmology Glaucoma (2021).</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Hirsch et al. JCRS (2021).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g75o07.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">TRIDENT</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Effectiveness as Standalone procedure versus trabecular bypass stent</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Prospective, multi-center, randomized, active-controlled, EU/UK study. 12&nbsp;month</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Standalone in pseudophakic eyes: OMNI (canaloplasty + trabeculotomy) Standalone in Pseudophakic eyes; OMNI (canaloplasty only) Standalone in pseudophakic eyes; trabecular bypass stent in
pseudophakic eyes</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-</FONT></FONT><BR>Moderate OAG </TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">378</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiated Q4 2020. Study completion expected</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">ROMEO II</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Expand ROMEO database; collect longer-term data on original ROMEO cohort</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Retrospective, real-world, multi-center, US study. <FONT STYLE="white-space:nowrap">12-month</FONT> and longer <FONT STYLE="white-space:nowrap">follow-up</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">OMNI with cataract surgery; OMNI Standalone in pseudophakic. Preop IOP <BR>&gt;18 mmHg</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-</FONT></FONT><BR>Moderate OAG</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiated Q1 2021. Planned manuscript submission expected</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g83u54.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">TREY</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Effectiveness in eyes previously treated with trabecular bypass stent</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Retrospective, real-world, multi-center, US post-market study. Available <FONT STYLE="white-space:nowrap">follow-up</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">OMNI in eyes previously treated with trabecular bypass stent</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-</FONT></FONT><BR>Advanced OAG, previously treated with trabecular bypass stent</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">50</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiation expected</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">ARTEMIS</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Effectiveness in treating more advanced disease</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Prospective, real-world, multi-center, US post-market study. 12 month</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">OMNI in eyes with Moderate to Advanced / Severe glaucoma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Moderate-to-</FONT></FONT><BR>Severe POAG</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">50</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiation expected</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stage</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study <BR>Goals</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Design</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subjects</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patients</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status /<BR>Publication</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">ROMULUS</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Long-term safety and effectiveness of OMNI in Combination Cataract surgery</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Retrospective/ Prospective, multi-center, <FONT STYLE="white-space:nowrap">single-arm,</FONT> US post-market study; 24 month</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">OMNI with cataract surgery</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT> POAG in Combination Cataract surgery</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">130</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiation expected</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">HUNTER</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Long-term safety and effectiveness of OMNI Standalone</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Retrospective/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Prospective, multi-center, single-arm, observational; 24&nbsp;month </P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Pseudophakic eyes</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-moderate</FONT></FONT> POAG Standalone procedure; minimum of 150 days prior to enrollment</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">up to 100</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiation expected</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">JAEGER</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Safety and effectiveness of OMNI Standalone in OAG versus medications</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Prospective, multi-center, randomized, active-controlled, US IDE study. 36 month</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Standalone: OMNI (canaloplasty + trabeculotomy); OMNI (canaloplasty only); <BR>Glaucoma Medications</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT> OAG</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">378</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiation expected</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#d8d8d8"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">PRECISION</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Effectiveness in Combination Cataract surgery versus trabecular bypass stent</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Prospective, multi-center, randomized, triple arm active-controlled, US IDE study. 36 month</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Combination Cataract: OMNI (canaloplasty + trabeculotomy) with cataract surgery; OMNI (canaloplasty only) with cataract surgery; <BR>iStent inject with cataract surgery</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT> OAG, in Combination Cataract surgery</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">378</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Initiation expected</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial body of historical clinical evidence supporting the effectiveness of circumferential, <FONT
STYLE="white-space:nowrap">360-degree</FONT> surgical treatment of the conventional outflow pathway to reduce resistance to aqueous outflow and reduce intraocular pressure. Canaloplasty and trabeculotomy originated as invasive, <FONT
STYLE="white-space:nowrap">&#147;non-MIGS&#148;,</FONT> <I>ab externo</I> procedures requiring multiple conjunctival and scleral dissections to access the diseased outflow pathway. While the effectiveness of the invasive <I>ab externo</I> variants
of circumferential angle surgery were compelling, these procedures are difficult to perform, traumatize the eye, have higher risk of intraoperative and post-operative complications and require longer patient recovery times. Moreover, the
conjunctival and scleral dissections required during invasive surgery can limit future surgical options such as trabeculectomy or other filtering glaucoma procedures due to potential scarring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The VISCO360 and TRAB360 predicates to OMNI could each be used to deliver small, controlled amounts of viscoelastic fluid (VISCO360) or cut
the trabecular meshwork (TRAB360). Table 3 summarizes three IITs evaluating canaloplasty procedures performed using VISCO360 or OMNI. Table 4 summarizes two IITs evaluating trabeculotomy procedures using TRAB360. In one study, a series of 81 eyes
with Refractory glaucoma, was observed to have a 34% mean reduction in IOP at 12 months following trabeculotomy with TRAB360. In another study, VISCO360 was used to treat 72 eyes where IOP was poorly controlled in patients with Mild to Moderate OAG.
At 12 months, the mean IOP reduction was 41%. These <I>ab interno</I> canalaplasty and <I>ab interno</I> trabeculotomy single-center studies with open-label designs demonstrated substantial improvement in IOP control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 3: Published Sight Sciences </B><B><I>Ab Interno</I></B><B> Canaloplasty Investigator Initiated
Trials </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Reference</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mean<BR>Baseline<BR>IOP
and<BR>Range</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mean&nbsp;IOP&nbsp;and<BR>Range at
Last<BR><FONT STYLE="white-space:nowrap">Follow-up</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(length
of<BR><FONT STYLE="white-space:nowrap">follow-up)</FONT></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>Percent<BR>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000"><B>Medication<BR>Change</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Ondrejka and K&ouml;rber 2019*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">POAG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IOP&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>18&nbsp;mmHg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">72</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">24.6&plusmn;7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(12 month)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">14.6&plusmn;2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">-40.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000">-1.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IOP&nbsp;&lt;18&nbsp;mmHg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">34</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">14.9&plusmn;1.8</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">13.6&plusmn;2.3</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">-8.7</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">-1.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"><B>Tracer et al. 2019*</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">OAG</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IOP&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>18&nbsp;mmHg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">111</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">22.0&plusmn;5.5</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(12 month)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">17.2&plusmn;5.1</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">-21.8</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">no&nbsp;change</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IOP&nbsp;&lt;18&nbsp;mmHg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">69</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">14.3&plusmn;2.3</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">15.4&plusmn;4.1</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">+7.7</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">-0.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Hughes and Traynor 2020*</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">OAG</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">89</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">24.5&plusmn;8.3</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15.8 &plusmn; 2.5</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(18 month)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">-35.5</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">-0.8</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sight Sciences supported independent research. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 4: Published Sight Sciences </B><B><I>Ab Interno </I></B><B>Trabeculotomy Investigator Initiated Trials </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Reference</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>N</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>Baseline<BR>IOP and<BR>Range</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>Mean&nbsp;IOP&nbsp;at<BR><FONT STYLE="white-space:nowrap">Last&nbsp;Follow-up</FONT><BR>and Range</B><br><B>(length of<BR><FONT
STYLE="white-space:nowrap">follow-up)</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>Percent<BR>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000"><B>Medication<BR>Change</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Sarkisian et al. 2019*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">POAG&nbsp;(83%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">81</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">23.7&plusmn;6.0&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">15.7&plusmn;5.5&#134;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(12&nbsp;month)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">-33.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000">-0.6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Areaux et al. 2020**</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PCG</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JOAG</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GANASDS</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GANOA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GAAC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GFCS</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">21</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">8</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">2</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">4</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">5</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">Success&#134;&#134;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">81%</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6 83%</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">50%</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">0%</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">50%</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">60%</P></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">30.9</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">20.3</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">-34</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">-1.0</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PCG: primary congenital glaucoma; JOAG: juvenile OAG; GANASDS: glaucoma associated with a nonacquired systemic
disease or syndrome; GANOA: glaucoma associated with a nonacquired ocular anomaly; GAAC: glaucoma associated with an acquired condition; GFCS: glaucoma following cataract surgery. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Standard deviation estimated from error bars in published figure </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Success defined as post-operative IOP <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 24 mmHg with or without
medications and no additional surgery </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sight Sciences supported independent research </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Sight Sciences funding </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As much as these individual circumferential MIGS procedures had advantages over their more invasive,
<FONT STYLE="white-space:nowrap">non-MIGS</FONT> variants or the far less comprehensive trabecular bypass stents, neither procedure alone could completely and effectively address all sources of resistance to aqueous outflow that may be present in
the conventional outflow pathway in glaucoma patients. We believe that combining the two procedural mechanisms of action (<I>ab interno </I>canaloplasty and <I>ab interno </I>trabeculotomy) provides a comprehensive solution addressing all potential
points of resistance in the conventional outflow pathway. The clinical history described above and the focus on physically and procedurally optimizing the surgical treatment of the entire diseased conventional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outflow pathway in glaucoma (titratable up to 360 degrees of trabecular meshwork, 360 degrees of Schlemm&#146;s canal, 360 degrees of collector channels) is the genesis of OMNI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>ROMEO Study (Completed)</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ROMEO study was a multi-center retrospective study conducted from February 2018 through April 2020 and designed to assess safety and
effectiveness of OMNI in reducing IOP and hypotensive medication usage in Mild-to-Moderate OAG patients at 12 months post-operation. This study evaluated the clinical effect of <I>ab interno</I> canaloplasty and trabeculotomy performed using OMNI in
both Standalone and Combination Cataract procedures, the use of ocular hypotensive medications and safety in patients with OAG. Clinical data from ROMEO supported our March 2021 FDA 510(k) clearance for an expanded indication for use of OMNI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study evaluated two different groups of patients based on baseline IOP with different treatment goals: The Elevated IOP Group had a
preoperative IOP greater than 18 mmHg and its treatment goal was IOP reduction. The Controlled IOP Group had a preoperative IOP less than or equal to 18 mmHg, with a treatment goal of IOP maintenance and medication reduction. The primary endpoint
was defined as the proportion of subjects at 12 months post-operation with IOP between 6 mmHg and 18 mmHg or with a 20% or greater reduction from preoperative baseline IOP, on the same or fewer number of ocular hypotensive medications compared to
the preoperative baseline, and with no additional <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> surgery or laser treatment. IOP of 18 mmHg or below is a well-established benchmark by the clinical community for control of POAG progression and
is based on the belief that maintenance of IOP control should be considered a &#147;success&#148; for patients already controlled on medication. For patients not controlled on medication, a 20% reduction in IOP is the recommended primary efficacy
endpoint according to FDA guidance for implantable MIGS devices, which we have relied upon in designing our retrospective nonimplantable device study. Safety endpoints included ocular adverse events, and efficacy endpoints included secondary
surgical interventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proportion of subjects meeting the success criteria overall and stratified by type of procedure and baseline
IOP are presented below, in Table 5. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 5: Proportion of Subjects Meeting Success Criteria (Month 12) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Subjects<BR>Meeting Success<BR>Criteria</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proportion&nbsp;of<BR>Successes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>95%&nbsp;Confidence<BR>Interval</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Cataract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>80.2%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>71.4, 89.0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Standalone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>72.9%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>60.1, 85.7</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">p value Combination Cataract vs Standalone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">0.3855</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>129</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>77.5%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>70.1,&nbsp;84.9</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mean preoperative IOP and at months one, six and 12 post-operation and mean preoperative medication usage
preoperation and at month 12 post-operation for both the Elevated IOP Groups and the Controlled IPO Group of both Standalone and Combination Cataract cohorts are shown in Figures <FONT STYLE="white-space:nowrap">12-19.</FONT> Error bars are &plusmn;
95% confidence interval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Figure 12. Mean IOP Over Time. Standalone Use of OMNI (Elevated IOP Group)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 13. Mean <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> Medication Use. Standalone Use of OMNI (Elevated IOP Group)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g90195g70d74.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Figure 14. Mean IOP Over Time. Standalone Use of OMNI (Controlled IOP Group)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 15. Mean <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> Medication Use. Standalone Use of OMNI (Controlled IOP Group)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g90195g26x53.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Figure 16. Mean IOP Over Time. OMNI Combination Cataract Procedure (Elevated IOP Group)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 17. Mean <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> Medication Use. OMNI Combination Cataract Procedure (Elevated IOP Group)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g90195g94f87.jpg" ALT="LOGO">
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Figure 18. Mean IOP Over Time. OMNI Combination Cataract Procedure (Controlled IOP Group)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Figure 19. Mean <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> Medication Use. OMNI Combination Cataract Procedure (Controlled IOP Group)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g90195g39u22.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in Figures 12 and 16, mean IOP was significantly reduced from baseline at all <FONT
STYLE="white-space:nowrap">follow-up</FONT> timepoints for both Standalone and Combination Cataract cohorts in the Elevated IOP Group. As shown in Figures 14 and 18, in the Controlled IOP Group, statistically significant differences with respect to
mean IOP reductions from baseline were not observed either in the Standalone or Combination Cataract cohorts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all patients, in both
Standalone and Combination Cataract cohorts, statistically significant (P&lt;0.05) decreases in the mean number of medications compared to preoperative baseline were observed (Figures 13, 15, 17 and 19). In the Elevated IOP Group, mean medication
usage decreased from 1.71&plusmn; 1.31 to 1.17 &plusmn; 1.28 (P = .014), and from 2.04 &plusmn; 1.27 to 1.13 &plusmn; 1.09 (P = .002) for Standalone and Combination Cataract, respectively. Mean medication usage for Controlled IOP Group patients
decreased from 2.04 &plusmn; 1.31 to 1.32 &plusmn; 1.26 (P = .001) and from 1.61 &plusmn; 1.25 to 0.91 &plusmn; 1.17 (P &lt; .001), for Standalone and Combination Cataract, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse Events, or AEs, observed in this study were generally mild, <FONT STYLE="white-space:nowrap">non-serious,</FONT> transient in nature
and consistent with expected events for the population under study. The most frequent AEs observed were posterior capsule opacity (15%), mild anterior chamber inflammation (11%), a rise in IOP greater than 10 mmHg above the baseline IOP at or after
30 days post-operation (4.7%), corneal edema (4.7%), and hyphema (3.9%). The incidence of these AEs were comparable to rates reported in studies of trabecular bypass stents. All of these AEs were observed to be temporary and mild. Nine subjects
(7.0%) required a secondary surgical intervention for IOP control. BCVA was generally observed to have improved post-operatively overall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Additional Ongoing and Planned Sight Sciences OMNI Clinical Studies</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have two additional studies for OMNI ongoing. TRIDENT is a EU and UK <FONT STYLE="white-space:nowrap">12-month,</FONT> multi-center three
arm RCT evaluating Standalone procedure patients with pseudophakic eyes (post cataract surgery), treated with OMNI for canaloplasty and trabeculotomy, OMNI for canaloplasty alone, and a leading trabecular bypass stent. With ROMEO II, we plan to
expand our retrospective data from ROMEO and extend follow up periods beyond the 12 month endpoint for ROMEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have six studies in
the planning stages: TREY, ARTEMIS, ROMULUS, HUNTER, JAEGER and PRECISION, further demonstrating our ongoing commitment to developing complete and robust clinical data regarding OMNI. These studies will aim to evaluate the comparative effectiveness
and safety of OMNI versus current treatment alternatives, such as leading trabecular bypass stents and leading topical pharmaceuticals, in both the Combination Cataract and Standalone settings, across the full spectrum of POAG severity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Sight Sciences Supported OMNI Investigator Initiated Trial Program</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also several completed or ongoing IITs of OMNI. Although we provide financial support for many of these studies, they are
independent in conception, execution, and reporting. Investigators seeking support for their research submit a detailed study proposal, which is then reviewed by our IIT review committee for scientific merit and fit with company strategic goals, but
without consideration for their associated commercial opportunities. There are currently two recently completed OMNI IITs and two ongoing. These are summarized in Table 6 below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 6: Sight Sciences OMNI Investigator Initiated Trials </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Stage</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Investigator</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study <BR>Goals</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Design</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment<BR>Groups</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patients</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"><B>N</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status / Publication</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g31l94.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Matthew&nbsp;</B><B>Traynor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>MD</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Outcomes&nbsp;of canaloplasty as a Standalone or Combination Cataract surgery </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Retrospective, single center, case series. 18 months of <FONT STYLE="white-space:nowrap">follow-up</FONT></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Canaloplasty in Standalone or&nbsp;Combination Cataract surgery with either VISCO360 or OMNI</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT> OAG</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">89</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Hughes T, Traynor MP. Clin Ophthalmol</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">(2020)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Karsten Klabe MD</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Outcomes for OMNI as a Standalone procedure in medically uncontrolled OAG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Retrospective single center case series. 12 months of <FONT STYLE="white-space:nowrap">follow-up</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">OMNI Standalone in either pseudophakic or phakic eyes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT> OAG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">Submitted to Journal of Glaucoma</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g75o07.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><B>Daniel Terveen MD</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Safety and effectiveness of OMNI Standalone </FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Retrospective, multi- center, case series. 3 months of <FONT STYLE="white-space:nowrap">follow-up</FONT></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">OMNI standalone in </P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">pseudophakic eyes</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mild-to-Moderate</FONT></FONT> OAG</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">100</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT STYLE="font-size:8pt">Ongoing. Abstract submitted to ASCRS 2021</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Iwona Grabska-Liberek, MD</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Outcomes for OMNI as Standalone procedure or Combination Cataract surgery</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Prospective case-series; 24 months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Mild-to-Moderate OAG</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">17</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Ongoing 12-month results published: Grabska-Liberek, Eur J Ophthalmol (2021)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These IITs are retrospective case series in Mild-to-Moderate OAG patients, patients inadequately controlled on
maximum tolerated medical therapy, Standalone procedures in both pseudophakic and phakic eyes and Combination Cataract procedures. We believe the investigators plan to present their results at major ophthalmic congresses, such as the American
Academy of Ophthalmology and the American Society of Corneal and Refractive Surgery, and publish their results in peer-reviewed ophthalmology journals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TearCare System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>TearCare
Clinical Program Overview</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed TearCare to comprehensively address meibomian gland dysfunction, which we believe to be the
primary underlying cause of evaporative DED. We have developed robust clinical data evaluating TearCare. We have completed one RCT for TearCare and have three additional studies in the planning stage, as summarized in Table 7 below. In our completed
OLYMPIA RCT, we observed significant improvements in the signs and all symptoms of DED as assessed by an array of measures including both functional and biologic markers, and patient-reported symptom outcomes. We observed TearCare to be safe and
well tolerated, with only minor AEs that resolved without any further treatment. Leveraging the results from OLYMPIA, we are currently pursuing FDA clearance to expand TearCare&#146;s indication for use. We have three additional ongoing and planned
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies intended to evaluate the safety and effectiveness of TearCare in reducing signs and symptoms of DED due to MGD and plan to leverage the results of these studies to support FDA clearances
for more robust indications for use of TearCare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary and secondary endpoints we used in OLYMPIA and plan to use in our ongoing or
planned studies are homeostatic markers and patient-reported symptom outcomes used extensively in the study and diagnosis of DED. TBUT is a measure of the rate of evaporation of the tear film and is an indicator of tear film stability, according to
the American Academy of Ophthalmology, and measurements below ten seconds are considered abnormal. Longer TBUT is desirable as it indicates a lower rate of evaporative loss. Corneal and conjunctival staining allows detection of corneal erosions and
other ocular surface damage. MGSS is a measure of the quality and quantity of meibum secretion, which helps prevent evaporative loss of tears. Patient-reported symptom outcomes such as Ocular Surface Disease Index, or OSDI, Symptom Assessment in Dry
Eye, or SANDE, and Eye Dryness Severity, or EDS, are standard questionnaires designed to determine the severity of DED symptoms that are completed by patients and provide an overall score that increases with increased symptom severity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Table 7: Sight Sciences TearCare Clinical Studies </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Status</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Goals</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Design</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Groups</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patients</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;N&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt;border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status&nbsp;/<BR>Publication</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g31l94.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">OLYMPIA</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Safety and effectiveness of a single TearCare treatment compared to a single LipiFlow treatment to treat the signs and symptoms of DED in adult patients</FONT></TD>

<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Prospective, multi-center, randomized, active-controlled, US&nbsp;abbreviated IDE study, 1 month</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Single TearCare Tx vs Single LipiFlow Tx</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Patients with moderate to severe dry eye associated with MGD</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">135</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Pub1:</B> Submitted to Cornea <BR><B>Pub2:</B>
To be submitted to Ocular Surface <BR><B>Pub3:</B> Exploratory analysis&#151;to be submitted to Clin Ophthalmol</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g75o07.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">SAHARA</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Safety and effectiveness of TearCare treatments compared to Restasis to treat the signs and symptoms of DED in adult patients</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Prospective, multi-center, randomized, active-controlled, US abbreviated IDE study, 24 months</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">TearCare Tx vs Restasis Rx</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">Patients with moderate to severe dry eye associated with MGD</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">300</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Initiated Q4</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">2020. Study completion expected</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g90195g34p96.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">CRYSTAL</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Evaluate effect of <BR><FONT STYLE="white-space:nowrap">pre-cataract</FONT> surgery TearCare treatment on refractive accuracy post-surgery and signs and symptoms of DED</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Prospective, multi-center, randomized, placebo-controlled, US&nbsp;IDE study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">TearCare Tx before CE</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Patients with moderate to severe dry eye associated with MGD scheduled for CE</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">100</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Initiation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">expected &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Study</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">completion expected</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">RESTORE</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Safety and effectiveness of TearCare to treat the signs and symptoms of DED in patients previously treated with Restasis or Xiidra</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Retrospective, real-world, multi-center, US post-market study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">TearCare Tx</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Patients with moderate to severe dry eye associated with MGD and history of Restasis or Xiidra and are treated with TC at least 4 weeks prior to enrollment</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">300</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Initiation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">expected &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Study</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">completion expected</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tx = treatment, Rx = prescription eyedrop, MGD = meibomian gland dysfunction, TC = TearCare, CE = cataract extraction </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>OLYMPIA Study</U> (Completed) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our OLYMPIA study was a masked, multi-center RCT conducted at ten U.S. sites designed to study the safety and effectiveness of a single
treatment with TearCare in reducing the signs and symptoms of DED </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with MGD as compared to a single treatment with the LipiFlow Thermal Pulsation System (Johnson&nbsp;&amp; Johnson), or LipiFlow. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subjects with signs and symptoms of DED and MGD (N=135) were randomized 1:1 to a single treatment using either TearCare or LipiFlow. Key
inclusion criteria were regular use of lubricating drops, OSDI score between 23 to 79 (moderate to severe), MGSS <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 12, TBUT of <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 7 seconds, and at least 15
expressible glands in each lower eyelid. The primary endpoint for the study was <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of TearCare to LipiFlow, as measured by TBUT, and MGSS scores at one month. Secondary endpoints included corneal
and conjunctival staining and number of meibomian glands yielding clear liquid. To reduce potential bias in subjective endpoint assessments, the clinician performing the treatments did not perform the endpoint assessments and the clinician
performing the endpoint assessment was blinded to which treatment the patient had received. Symptoms were recorded using OSDI, SANDE, and EDS questionnaires. Any AEs, either patient reported, or observed by the investigators, were recorded to assess
safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In OLYMPIA, the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> primary endpoint was met for all endpoints and a greater
proportion of subjects in the TearCare group reported better symptomatic relief compared to the LipiFlow group assessed by OSDI; p&lt;0.05 (Figure 18). Use of TearCare was associated with a statistically significant improvement in all assessed signs
and symptoms of DED in subjects with MGD. While statistically significant superiority differences between the TearCare and LipiFlow groups were not observed, in a <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis, the TearCare group
demonstrated consistently greater improvements in most signs and symptoms assessed. Statistically significant improvements in the primary endpoints of mean TBUT and MGSS from baseline were observed in both the TearCare group (3.0 &plusmn; 4.4 and
11.2 &plusmn; 11.1, respectively) and the LipiFlow group (2.6 &plusmn; 3.3 and 11.09 &plusmn; 10.4, respectively (p&lt; .0001)). In the TearCare group, mean corneal and conjunctival staining were reduced from baseline by 0.3 &plusmn; 2.0 and 0.7
&plusmn; 2.3, respectively; the mean number of expressible glands and glands expressing clear liquid increased from baseline by 4.3 &plusmn; 3.6 and 1.8 &plusmn; 3.7, respectively. The TearCare group improved in mean SANDE (by 38.2 &plusmn; 31.0
from baseline), EDS (by 35.4 &plusmn; 34.1 from baseline), and OSDI scores (by 27.9 &plusmn; 20.5 from baseline). Although statistically significant differences between the TearCare and LipiFlow groups were not observed with respect to the primary
endpoints, in a <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis, the TearCare group had a statistically significantly higher proportion of subjects (72%) improving by at least one OSDI category than did the LipiFlow group (59%); p&lt;0.05.
Device related ocular AEs were reported in three subjects (loss of visual acuity) for the TearCare group and four subjects (loss of visual acuity, corneal abrasion and foreign body sensation) for the LipiFlow group. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 20. Change in OSDI at 1 month </B></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g90195g61n87.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statistically significantly higher proportion of subjects showed clinically meaningful improvement in TearCare
group compared with LipiFlow group </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">% Subjects improved at least by 1 OSDI category </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">% Subjects who had severe OSDI at baseline and who improved at least by 1 OSDI category </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">% Female subjects improved at least by 1 OSDI category </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statistically significantly higher proportion of female subjects in TearCare group improved by Miller
definition (7.4 point improvement in moderate OSDI and 10.4 point improvement in severe OSDI) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statistically significantly higher proportion of female subjects who had TBUT &lt;4.0 in TearCare group
improved at least by 1 OSDI category </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Additional Ongoing and Planned Clinical Studies</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above completed studies, we have three additional ongoing or planned studies to evaluate the safety and effectiveness of
TearCare for the reduction of signs and symptoms of DED. The SAHARA study is a multi-center RCT designed to compare TearCare treatments to Restasis, a current prescription eyedrop for DED, in 300 patients. We began recruiting subjects for SAHARA in
the first quarter of 2021. SAHARA was designed specifically to provide key clinical data that we believe could support potential reimbursement decisions by third-party payors. RESTORE is a planned retrospective, multi-center study of TearCare in 50
patients with a history of using prescription eyedrops such as Restasis or Xiidra. The CRYSTAL study is a planned multi-center RCT of up to 100 patients, to evaluate the impact on refractive outcomes post-cataract surgery when TearCare is used
preoperatively in patients with MGD. We plan to leverage the results of these studies to seek further premarket clearances from the FDA for more robust indications for use of TearCare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Sight Sciences TearCare Investigator Initiated Trials</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We actively support independent study of TearCare through our IIT program. Dr.&nbsp;Thomas Chester completed a study of 134 eyes (both eyes of
67 patients) treated in his clinic with TearCare. The study compares <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment <FONT STYLE="white-space:nowrap">(8-12</FONT> weeks) dry eye symptoms as measured by the Standardized Patient
Evaluation of Eye Dryness, or SPEED, questionnaire, and <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment meibomian gland expression scores. In this study, a single TearCare treatment was effective in reducing both the signs and
symptoms of dry eye. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 21. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g64r82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have built a world-class direct sales commercial organization that features professionals and executives
with substantial leadership experience from leading ophthalmic product companies. In particular, we have recruited professionals with track records that include launching new technologies, growing primary demand and changing treatment paradigms. We
believe this expertise is crucial to achieve our market development objectives for interventional Standalone MIGS and MGD treatment. Sales representatives typically have relevant experience across all facets of medical device and/or pharmaceutical
sales focused on eyecare to ensure the development of a trusted consultative relationship with our ECPs. As we have continued to develop additional clinical data and brand recognition, we believe our team has differentiated our product offerings and
gained commercial traction through exceptional, highly involved training, support and ongoing professional education. As of December&nbsp;31, 2020, our overall commercial team consisted of 82 professionals dedicated to sales, marketing, commercial
support, training and professional relations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We created distinct sales, marketing, and training teams to sell OMNI and TearCare because
the products are predominantly sold to different types of customers and require specialized product specific sales expertise and ECP training to integrate our products into their practices. We sell OMNI to facilities where ophthalmic surgeons
perform outpatient procedures, mainly ASCs and HOPDs. We sell TearCare to optometry and ophthalmology practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketing efforts
are centered around increasing awareness share of our products and presenting clinical study results through leading medical publications and at-large industry and scientific meetings, both directly and through our advisors. We have also partnered
with early-adopting ECPs to speak to peers on our behalf through educational forums either <FONT STYLE="white-space:nowrap">in-person</FONT> or via virtual meetings. Clinical data that demonstrate the benefits of OMNI and TearCare for their
authorized uses will continue to underpin our commercial efforts, and we will continue to devote significant resources to conduct new clinical studies and publish articles in peer-reviewed journals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OMNI </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the commercial launch of OMNI in February 2018, we have pursued a three-part strategy to gain rapid commercial adoption and
simultaneously expand its potential market: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Target and train the over 3,000 high volume
cataract surgeons who are already familiar with MIGS approaches (<I>ab interno</I> access techniques) and have a willingness to trial new technologies; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Leverage positive clinical experiences and outcomes to expand the utilization of OMNI among these
MIGS-trained surgeons and drive adoption from additional surgeons and facilities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Promote
interventional Standalone treatments with OMNI for the larger population of adult POAG patients for whom other leading MIGS devices are not indicated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our OMNI sales representatives cover dedicated geographic territories or specialized customer segments, such as academic or
government institutions, across the U.S. These sales representatives establish new accounts, train new surgeons and operating room personnel and nurture the continuing use of OMNI at existing accounts. In addition, we have positioned overlay sales
representatives in our highest density customer markets to educate existing users of OMNI and primary care ECPs regarding the potential benefits of OMNI in interventional Standalone procedures in adult patients with POAG. The general
ophthalmologists and optometrists who provide primary eyecare services are typically the first to diagnose POAG and deliver first line treatment. We aim to educate these primary ECPs regarding the clinical benefits and use cases for OMNI as they
often have referral relationships with ophthalmic surgeons for patients who require advanced treatment. We seek to increase usage of OMNI among the ophthalmic surgeons who have already been trained and convert those who are not. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our initial commercial efforts for OMNI have been successful and we plan to accelerate growth with the expansion of our team to
cover more geographic territories and provide increased support to accounts, as well as <FONT STYLE="white-space:nowrap">roll-out</FONT> large-scale marketing programs for the interventional Standalone opportunity in 2021. Although the vast majority
of our sales are in the U.S., we have also begun to sell OMNI in select European countries both on a direct basis and through distributors. We retained our first full time manager of European sales in 2020 and expect to scale up our efforts in
Europe and other regions over time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TearCare </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We implemented a controlled launch of TearCare in the U.S. in April 2019 with a limited sales effort. We have assembled a proprietary list of
over 5,000 practices that are prime targets for our device and, as of March&nbsp;31, 2021, we had sold TearCare to nearly 400 eyecare facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the success of our initial launch has shown that a significant <FONT STYLE="white-space:nowrap">patient-pay</FONT> market exists for
TearCare, market research indicates that improving access to TearCare through Medicare and private payors will accelerate adoption of the product. Currently, no third-party payors have formal policies establishing coverage for procedures using
TearCare, although we believe that some payors may agree to provide coverage outside of formal policy based on medical need. As an early step of a comprehensive long-term market development plan, our market access team is assisting key strategic
accounts and their patients in the pursuit of prior authorization approvals and reimbursement claims for TearCare on a case by case basis. Simultaneously, we are also continuing to support our customers with
<FONT STYLE="white-space:nowrap">patient-pay</FONT> models, which remains a significant growth opportunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our dedicated commercial team
for TearCare consists of sales representatives and leaders, marketing professionals, dedicated trainers, and independent sales representatives. We intend to scale up this team to the extent we achieve key market development and patient access
milestones, including completion of clinical trials and our pursuit of FDA clearances for more robust indications for use of TearCare. Our sales representatives collaborate with stakeholders across the practice to train doctors and staff, implement
workflow processes and monitor operations to ensure proper integration. As we help customers incorporate the use of TearCare, we have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gained insights that enable us to continually improve our selling model. We expect to add new accounts and increase utilization at existing accounts, as we methodically grow our commercial team
dedicated to TearCare. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are three primary aspects of reimbursement in the United States: coding, coverage and payment. Each aspect is an important determinant of
our customers&#146; ability to obtain reimbursement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Coding</B> refers to the availability of billing codes for use by healthcare providers to report the provision
of medical procedures, and the use of supplies and resources for specific patients, to insurance providers and organizations that make payments for healthcare, commonly referred to as third-party payors. The Healthcare Common Procedure Coding
System, or HCPCS, is a national, standardized code set used by providers to capture and report healthcare services and products. This code set consists of two subsystems: Level I, Current Procedural Terminology, or CPT, codes, representing
procedures performed, and Level II, commonly referred to as HCPCS codes, representing healthcare products (e.g. devices, drugs, durable medical equipment), supplies and services not captured in the CPT code set. CPT codes are published by the
American Medical Association, or AMA, and are used to report medical services and procedures performed in the outpatient setting of care by or under the direction of physicians. HCPCS codes are established and maintained by the Centers for Medicare
and Medicaid Services, or CMS, and identify items used in the course of care delivery. Health plans pay outpatient facilities and physicians for services based on submission of a claim using one or more CPT and/or HCPCS codes. CPT codes fall into
one of three categories. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Category I CPT codes have been approved by the AMA as permanent procedure codes based on a number of factors,
including the level of published clinical evidence. They are identified with a five-digit number and official code description. Approved Category I CPT codes have typically been endorsed by relevant medical specialty societies, are consistent with
contemporary medical practice, and represent procedures performed by many physicians in clinical practice in multiple locations. Category I codes are only available to procedures for the which the technology (e.g., device, drug, test) has been FDA
approved/cleared when such a regulatory requirement exists. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Category II CPT Codes are supplemental tracking codes used for performance measurement. They are intended to
facilitate data collection about quality of care by coding certain services and/or test results that support performance measures and that have been agreed upon as contributing to good patient care. Some codes in this category may relate to
compliance by health care professionals with state or federal law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Category III CPT codes are a temporary set of tracking codes for new and emerging technologies. These codes are
designed to facilitate data collection for the assessment of new procedures. Additionally, Category III codes provide a mechanism for payors to value a new procedure. Temporary codes are not automatically assigned Relative Value Units, or RVUs, or
weights and, therefore, do not typically have a widely accepted payment rate methodology. To achieve Category III status, a new procedure is required to have either an approved protocol for a study of procedures being performed, support from the
specialties that would use the procedure, availability of US peer-reviewed literature, or current clinical trials that outline the effectiveness of the procedure. Once granted, Category III CPT codes expire five years after the initial application
was approved, although they can be extended beyond the five-year limit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level II HCPCS codes are alpha-numeric codes governed by CMS that identify medical products and items or services
that are not appropriately designated by another code set (e.g., CPT). Criteria must be met in order to qualify for a HCPCS code, including such requirements as regulatory approval (if necessary), national programmatic need, and a distinct
difference from existing HCPCS codes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Coverage</B> refers to decisions made by third-party payors as to whether there is sufficient published
clinical evidence to support medical necessity, or to consider a healthcare item or service &#147;reasonable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and necessary&#148; (as per Medicare guidelines). Coverage can be established by explicit medical policies that outline specific procedures and/or technologies, and under what conditions coverage
is permitted, including specific diagnoses, clinical indications and therapeutic prerequisites. Coverage can also be implicit, as when payors are &#147;silent&#148; on a procedure or technology (i.e., no formal policy is developed). In the absence
of formal policy, coverage may be granted one of two ways: 1) with no required review, as with long-standing established healthcare items or services, or 2) on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis via review of each patient&#146;s circumstance, as may be the case with newer procedures/technologies. Each payor can make its own decision as to
which procedures or technologies warrant formal policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Payment</B> refers to the reimbursement rate for a healthcare item or service. The amount paid by third-party
payors to providers, including facilities and doctors, for specific procedures and items (e.g., medical devices, drugs, ancillary supplies) is determined by each payor. Payments for professional services under CPT coding are generally determined by
the RVUs of a specific billing code. These RVUs identify the time and intensity of the work required, the practice expense incurred and the level of risk related to the procedure. Payors can use their organization-specific formula or conversion
factor to translate RVUs into payment rates, or may establish payment by reference to a national Medicare payment amount. Likewise, facility payments are weighted based on the resources (e.g., operating suite time, devices and supplies) needed for
the procedure to be performed in the facility setting. Most payment rates are geographically adjusted, taking into account the cost of providing services in different wage index areas across the country. As with procedure payments, payments for
healthcare items (e.g., products reported using HCPCS coding) are determined by individual health plans, often based on some form of manufacturer&#146;s invoice or billed charges based on the provider&#146;s
<FONT STYLE="white-space:nowrap">mark-up</FONT> methodology, or based on established fee schedule rates. It is important to recognize that not all reportable codes are separately payable. Some codes are bundled with related items or services and do
not have a separate payment allowance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For further information regarding reimbursement, see &#147;Risk Factors&#151;We
may not be able to maintain adequate levels of third-party coverage and payment for procedures in which OMNI is used, and third parties may rescind or modify their coverage related to OMNI. We may not be able to secure any, or adequate levels of,
third-party coverage and payment for procedures in which TearCare is used, and even if third parties provide coverage they may rescind or modify their coverage related to TearCare&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, our commercial activities were substantially within the United States. We sell OMNI primarily to ASCs and HOPDs,
who in turn bill various third-party payors, such as Medicare and private health insurance plans for the healthcare services and resources rendered to treat a patient. TearCare is not currently covered or paid by Medicare or private payors under any
formal policy, although some payors may agree to provide case-based coverage outside of a formal policy. Our market access team facilitates patient access to the OMNI and TearCare systems by engaging payors on coverage, coding and payment matters,
and by providing support to patients and our customers as they seek reimbursement from payors that do not have positive coverage or those that do not have formal policies in place regarding our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement for Uses of the OMNI Surgical System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surgeons are able to use OMNI to sequentially perform two well-established glaucoma procedures, canaloplasty followed by trabeculotomy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canaloplasty and trabeculotomy are covered by Medicare outside of formal policy, based on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">claim-by-claim</FONT></FONT> adjudication. Widespread coverage is important for commercial adoption. Based on POAG prevalence, we estimate that currently over 70% of patients who receive glaucoma treatment using OMNI are
covered by Medicare, and that this percentage may decline modestly over time as usage of OMNI expands to include patients with a broader range of OAG progression. Private payor coverage policies for canaloplasty and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trabeculotomy vary. Some private payors, including Aetna and certain Blue Cross Blue Shield plans, have written policies that consider canaloplasty medically necessary for the treatment of
glaucoma, though specific criteria for coverage may vary depending on the payor. Where coverage is less consistent or is limited, as is the case with certain private payors, our market access team works with payers directly and with customers to
facilitate patient access to our solutions and verify that appropriate reimbursement can be obtained. We have established and continue to build a substantial library of clinical trial data and published articles to directly address the needs of some
payors. We believe that the results from our nine completed, in progress and planned clinical trials and subsequent accompanying peer-reviewed articles will help to expand coverage of the use of OMNI. We estimate that, as of March 2021, 38% of the
covered lives within the top nine national private payors (including commercial, Medicare Advantage and Medicaid Managed Care plans) cover the procedures performed using OMNI. The OMNI procedure is covered and reimbursed by all Medicare
Administrative Contractors and numerous private insurers, covering an estimated 67% of U.S. POAG sufferers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Virtually all sales of OMNI
in the U.S. are to ASCs and HOPDs. Surgeons may use OMNI to perform canaloplasty and trabeculotomy sequentially, with CPT code 66174 used to report the procedure. Per Medicare and many private payor payment policies, when certain procedures are
performed in the ASC setting, such as cataract surgery and canaloplasty, multiple procedure payment reduction rules apply. Therefore, when a canaloplasty is performed with cataract surgery are performed on the same patient on the same day, payment
of the lower-cost procedure (most commonly the cataract procedure) is reduced by 50%. Multiple procedure payment reduction rules also typically apply to professional services. Physician payments are likely to be paid at a reduced rate for lower
valued procedures when performed concomitantly. In the HOPD setting, Medicare procedures performed using OMNI as well as cataract procedures are paid under comprehensive ambulatory payment classifications
<FONT STYLE="white-space:nowrap">(C-APCs).</FONT> In this site of service, the highest valued code is paid at 100%, with payment for additional procedures performed during the same operative session bundled into the single highest payment rate. Many
commercial payers use a similar payment methodology, but payment rules can vary across health plans, particularly across plan types (e.g., HMO, PPO, POS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ASC setting, the 2021 Medicare national unadjusted average facility payment rate for CPT 66174 is $1,872.33. In the HOPD setting, the
2021 Medicare national unadjusted average facility payment rate for CPT 66174 is $3,917.74. These payments are classified as comprehensive C-APCs, therefore the highest valued code will be paid and other C-APC classified procedures will be bundled
into the highest paid procedure. Regardless of facility setting, the Medicare national unadjusted physician payment rate for CPT 66174 is $947.70. Based on customer feedback, we believe the rates for facility and physician reimbursement in both
settings reflect attractive and reasonable payments to cover all of our customers&#146; costs and economic needs related to glaucoma treatments using OMNI for both Standalone and Combination Cataract procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While commercialization of OMNI has primarily been focused on the U.S., we have also begun international commercialization efforts. Outside
the U.S., we have made the most progress in Germany where we have established and trained an ophthalmic distributor with successful experience commercializing the invasive form of canaloplasty. Although Germany employs a single-payor health system
and a national MIGS procedure code which includes canaloplasty and trabeculotomy, coverage decisions are decentralized. Our distributor is working, and will work, with the decentralized Physician&#146;s Associations
(<I>Kassen</I><I>&auml;</I><I>rztliche Vereinigung</I>) to facilitate access to OMNI for patients and ECPs. As we expand into other countries, we will establish reimbursement strategies that are appropriate for each local market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement for Uses of the TearCare System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TearCare is not currently covered by Medicare or private payors via formal medical policy, although some payors may agree to provide coverage
and subsequent payment outside of formal policy. We are seeking FDA clearance of TearCare for an expanded indication for use in adult patients with evaporative DED due to MGD, and specifically the application of localized heat therapy in adult
patients with evaporative DED due to MGD, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when used in conjunction with pressure to the eyelids to express the meibomian glands. We believe that the current standard of care, which primarily consists of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> artificial tears or lubricating eyedrops, and prescription eyedrops, does not treat the root cause of MGD. In 2019, the two leading prescription eyedrops for DED recognized combined estimated
sales of $1.5&nbsp;billion worldwide. We believe TearCare, if cleared by the FDA for its expanded indication for use, has the potential to offer a better standard of care for evaporative dry eye patients and reduced overall costs for payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the presence of a large and growing <FONT STYLE="white-space:nowrap">patient-pay</FONT> market for TearCare as shown in our controlled
launch, we believe that improving access to TearCare through positive coverage decisions by Medicare and private payors will help grow the market for the device. We are pursuing a vigorous market development plan to convince Medicare and private
payors to increase access to procedures using TearCare in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, we applied for a Category III CPT code the describes the
heating of meibomian glands using a wearable open-eye device and manual evacuation of meibomian glands. This new code, 0563T, was granted in 2019 and became effective January&nbsp;1, 2020, allowing providers to pursue reimbursement claims and payors
to establish payment rates for the procedure. Prior to formal coverage decisions or a permanent Category I code, third-party payors may cover procedures billed with temporary Category III codes that meet their coverage criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have already begun to generate clinical data to support positive coverage decisions from Medicare and private payors. In January 2021, an
article discussing results from our OLYMPIA RCT was submitted to <I>Cornea</I> <I>The Journal of Cornea and External Disease</I>. This randomized controlled trial compared treatment using TearCare to the leading alternative MGD treatment device on
the market. In the study, we observed that a single use of TearCare was associated with improvement in each of the signs and symptoms of DED within two weeks of treatment in subjects with MGD. In a <FONT STYLE="white-space:nowrap">post-hoc</FONT>
analysis we also observed that a greater proportion of subjects in the TearCare group reported better symptomatic relief relative to the comparator group as assessed by patient reported outcomes. We plan to submit additional articles discussing the
results from our OLYMPIA RCT to <I>The Ocular Surface</I> and <I>Clinical Ophthalmology</I> in the near future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our comprehensive long
term strategy to improve patient access to TearCare includes the following key initiatives: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Demonstrate the </B><B>effectiveness</B><B>, safety and durability of TearCare with rigorous clinical
data</B>. Building on supportive data from completed studies, our upcoming clinical program for TearCare, including the SAHARA, CRYSTAL and RESTORE studies, aims to advance the development of TearCare for the signs and symptoms of DED due to MGD
with comparative trial designs established to evaluate the effectiveness and durability of treatment with TearCare, which our research suggests would be the primary criteria for payors to decide coverage determinations. SAHARA, which will commence
in 2021 and features a trial design directly informed by a masked panel of medical directors from eight payors, is a RCT of TearCare versus the leading DED prescription eyedrop, and will compare effectiveness and safety, as well as assess durability
of effect through a <FONT STYLE="white-space:nowrap">24-month</FONT> follow up period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Augment library of published articles on TearCare</B>. We plan to facilitate publication of numerous articles
describing the results of our studies of TearCare in peer-reviewed journals. We collaborate with our advisors to design and conduct our studies, and ensure findings undergo the rigorous peer review process for publication in leading ophthalmology
and optometry journals, recognizing that third-party payors base coverage decisions on reviews of the published medical literature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Support coverage applications</B>. Our market access team assists key strategic accounts in their submission
of high quality reimbursement requests for uses of TearCare. Our market access team also works with customers and patients to navigate the reimbursement process with third-party payors, including prior authorization approvals and appeals for denial
of coverage or low payment. As more </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
claims for uses of TearCare are accepted, we will work with third-party payors to formalize coverage decisions to streamline the coverage and payment processes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Convert to permanent Category I CPT code</B>. We plan to leverage our clinical studies, peer-reviewed
publications, society and medical community support, and utilization / real world reimbursement claims data to support conversion of our Category III CPT code for TearCare to a permanent Category I CPT code. Although Medicare and private payors may
cover Category III CPT codes that meet their coverage criteria, we believe AMA approval of a permanent Category I CPT code for uses of TearCare, along with potential enhanced indications for use, will bolster our efforts to gain positive coverage
determinations from Medicare and private payors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device and pharmaceutical industries are intensely competitive, subject to rapid change and significantly affected by new product
introductions and other market activities of industry participants. We compete with medical device and pharmaceutical companies that develop and commercialize products for eye conditions. Notable competitors include Glaukos, Ivantis,
AbbVie/Allergan, Novartis, Alcon, and Johnson&nbsp;&amp; Johnson. Some of our competitors are larger, well-capitalized companies with greater market share and resources than us currently. Consequently, they are able to spend more on product
development, marketing, sales and other product initiatives than we can. We also compete with a number of smaller medical device companies that have single products or a limited range of products. Some of our competitors have: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Significantly greater name recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Broader or deeper relations with healthcare professionals, customers and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">More established distribution networks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional lines of products and the ability to offer rebates or bundle products to offer greater discounts or
other incentives to attract adoption; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Greater experience in conducting research and development, manufacturing, clinical trials, marketing and
obtaining regulatory clearance or approval for products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Greater financial and human resources for product development, sales and marketing and patent and other
intellectual property litigation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete primarily on the basis that our medical devices are able to treat patients
with prevalent eye diseases safely and effectively. Our continued success depends on our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop innovative, proprietary technology and products that can cost-effectively address significant clinical
needs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain and maintain regulatory clearances or approvals for the use of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain and maintain favorable reimbursement decisions relating to the use of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Demonstrate clinical safety and effectiveness in our sponsored and third-party trials and studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attract and retain skilled research and development and sales personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully market and sell products. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From its launch in early
2018 until February 2021, OMNI was solely assembled and produced by Second Source Medical LLC, or SSM, a contract manufacturer based in San Jose, California. SSM&#146;s manufacturing relationship with us is governed by the Supplier Quality Agreement
and Plan dated April&nbsp;5, 2018, or the Second Source Supplier Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;14, 2021, we entered into a Supply Agreement, or the Peter&#146;s Supply
Agreement, with Peter&#146;s Technology (Suzhou) CO LTD., or PTCS, a Chinese subsidiary of Peter&#146;s Co., Ltd., a Taiwan-based contract manufacturer. In February 2021, PTCS began to produce commercially saleable OMNI units for us at its Suzhou
City, China production facility. Our objective is to transition OMNI production from SSM to Peter&#146;s and an additional high-volume contract manufacturer with domestic U.S. production facilities by the end of the third quarter of 2021. The
Peter&#146;s Supply Agreement governs the assembly and supply of OMNI by PTCS, pursuant to which PTCS purchases components from our approved suppliers for assembly and we make purchases from PTCS on a purchase order basis. The initial term of the
three year Peter&#146;s Supply Agreement expires January&nbsp;14, 2024. The Peter&#146;s Supply Agreement automatically renews for additional one year periods if neither party provides notification that they intend to terminate the agreement within
90 days of the term ending. We have the right to terminate the agreement without cause during its term by providing 180 days&#146; advance written notice, or with 30 days&#146; written notice with any material agreement default by PTCS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the production of TearCare, we currently have supply arrangements with separate U.S. medical device manufacturers for the production of
each of TearCare&#146;s SmartLids and TearCare&#146;s SmartHubs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We directly engage with several third-party suppliers for key components
used in our products. We believe that third-party suppliers will be adequate to meet our current and anticipated manufacturing needs. We do not currently plan to manufacture our products or any related components ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing facilities that produce medical devices or their component parts intended for distribution world-wide are subject to regulation
and periodic unannounced inspection by the FDA and other domestic and international regulatory agencies. In the United States, any products we sell are required to be manufactured in compliance with the FDA&#146;s Quality System Regulation, which
covers the methods used in, and the facilities used for, the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of our products is handled directly through a third-party logistics provider. Our finished goods are shipped from our
contract manufacturers to Sterigenics for gamma sterilization in Hayward, California after which they are shipped to distribution facilities and are distributed from there to customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial
success depends in part on our ability to obtain and maintain proprietary protection for our current and future products and product candidates, novel discoveries, product development technologies and
<FONT STYLE="white-space:nowrap">know-how;</FONT> to operate without infringing on the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among
other methods, seeking to obtain or <FONT STYLE="white-space:nowrap">in-licensing</FONT> U.S. and foreign patents and patent applications related to our proprietary technology that are important to the development and implementation of our business.
We seek to obtain domestic and international patent protection, and endeavor to promptly file patent applications for new commercially valuable inventions. We file new patent applications as we conduct research and development, initiate new
programs, and monitor the activities of others. We also rely on other approaches to protecting our proprietary position, such as trademarks, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and/or continuing technological innovation
to develop and maintain our proprietary position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of medical device companies like us are generally uncertain and
involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent may be challenged in courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative
proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or at all, whether the claims
of any patent applications, should they issue, will cover our products or product candidates, or whether the claims of any issued patents will provide sufficient protection from competitors or otherwise provide any competitive advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain of the priority of inventions covered by our patents and pending patent
applications, in part because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature
often lags behind actual discoveries and patent application filings. Accordingly, we may not have been the first to invent the subject matter disclosed in some of our patents and patent applications or the first to file patent applications covering
such subject matter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, issued patents are granted a term of 20 years from the earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT>
filing date. In certain instances, U.S. patent term can be adjusted to recapture a portion of delay by the U.S. Patent&nbsp;&amp; Trademark Office, or USPTO, in examining the patent application (patent term adjustment) or extended to account for
term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. In some cases, the term of a U.S. patent may be shortened by terminal disclaimer, such that its term is reduced to end with that of an
earlier-expiring patent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely on or may in the future rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop
and maintain our competitive position. We typically rely on or may in the future rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. It is our policy to
protect trade secrets and/or <FONT STYLE="white-space:nowrap">know-how</FONT> by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These
agreements provide that all confidential information developed or made known during the course of an individual or entity&#146;s relationship with us must be kept confidential during and after the relationship. These agreements also provide that all
inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions,
such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we owned 25 issued U.S. patents, 29 issued patents outside the U.S., 17 pending U.S. patent applications, and
13&nbsp;pending foreign patent applications. Our patents include claims directed to devices and methods for canaloplasty and/or trabeculotomy, ocular implants, and related methods, as well as patents and applications that are directed to TearCare
and methods for its use, as well as individual components of TearCare, including the SmartLids and SmartHub devices. Subject to payment of required maintenance fees, annuities, and other charges, our issued U.S. patents have expiration dates between
2027 and 2037, with six of our issued U.S. patents having expiration dates before 2030, 18 having expiration dates between 2031 and 2035, and the remaining one expiring after 2035, in each case exclusive of possible patent extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we owned eight U.S. trademark registrations, one German trademark registration and no pending trademark
applications worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information regarding the risks related to our intellectual property, please see the section titled
&#147;Risk Factors&#151; Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products and our operations are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and other federal, state,
and local authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our products are subject to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its
implementing regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA regulates, among other things, the development, design, <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical testing,
manufacturing, safety, effectiveness, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export and
post-marketing surveillance of medical devices in the United States to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Premarket Clearance and Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless an exemption applies, each new or significantly modified medical device commercially distributed in the United States requires either
FDA clearance of a 510(k) premarket notification, or approval of a premarket approval, or PMA, application. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, medical devices are classified into one of three classes&#151;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&#151;depending on
the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&nbsp;I devices are those for which safety and effectiveness can be assured by adherence
to the FDA&#146;s general controls for medical devices, which include compliance with the applicable portions of FDA&#146;s current good manufacturing practices for devices, as reflected in the Quality System Regulation, or QSR, establishment
registration and device listing, reporting of adverse medical events, and truthful and <FONT STYLE="white-space:nowrap">non-misleading</FONT> labeling, advertising, and promotional materials. Some Class&nbsp;I devices, also called Class&nbsp;I
reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class&nbsp;I devices are exempt from the premarket notification requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;II devices are subject to the FDA&#146;s general controls, and any other special controls deemed necessary by the FDA to ensure the
safety and effectiveness of the device. These special controls can include performance standards, special labeling requirements, post-market surveillance, patient registries and FDA guidance documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most Class&nbsp;II devices are required to submit to the FDA a premarket notification under Section&nbsp;510(k) of the FDCA requesting
permission to commercially distribute the device. The FDA&#146;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;III devices include devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some
implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, requiring approval of a PMA. Due to the level of risk associated with Class&nbsp;III
devices, the FDA&#146;s general controls and special controls alone are insufficient to assure their safety and effectiveness. Devices placed in Class&nbsp;III general require the submission of a PMA application demonstrating the safety and
effectiveness of the device, which must be approved by the FDA prior to marketing, or the receipt of a 510(k) de novo classification, which provides for the reclassification of the device in Class&nbsp;I or II. The PMA approval process is generally
more costly and time consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the
FDA&#146;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data,
manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#146;s satisfaction a reasonable
assurance of the safety and effectiveness of the device for its intended use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a new medical device does not qualify for the 510(k)
premarket notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Class&nbsp;III. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into
Class&nbsp;III due to the absence of a predicate device, called the &#147;Request for Evaluation of Automatic Class&nbsp;III Designation,&#148; or the de novo classification process. This process allows a manufacturer whose novel device is
automatically classified into Class&nbsp;III to request down-classification of its medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a
PMA. If the manufacturer seeks reclassification into Class&nbsp;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The
FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk and requires PMA or that general controls would be
inadequate to control the risks and special controls cannot be developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining FDA marketing authorization, de novo
down-classification, or approval for medical devices is expensive and uncertain, and may take several years, and generally requires significant scientific and clinical data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some <FONT STYLE="white-space:nowrap">pre-amendment</FONT> devices are unclassified, but are subject to FDA&#146;s premarket notification and
clearance process in order to be commercially distributed. Our currently marketed OMNI products are regulated as Class&nbsp;II devices subject to 510(k) clearance. We currently market our TearCare product as a Class&nbsp;II, 501(k)-exempt powered
heating pad. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investigational Device Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. In the United States,
absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval or to determine safety and effectiveness of a device for an investigational use must be conducted in accordance with the FDA&#146;s
investigational device exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors
and study investigators. If the device presents a &#147;significant risk,&#148; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing
human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE
application must be approved in advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are
approved by appropriate institutional review boards at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA&#146;s approval of an IDE allows
clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#146;s safety and effectiveness, even if the trial meets its intended success criteria.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an
IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting such trials. A significant risk device is one that presents a potential for serious risk to the health,
safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise
presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is
scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an
IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the degree of risk presented by the medical device, clinical studies must be
approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the
study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a <FONT
STYLE="white-space:nowrap">non-significant</FONT> risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE
requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE
to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be
submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them.
The clinical investigators in the clinical study are also subject to FDA&#146;s regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational
device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a
clinical trial on hold; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients do not enroll in clinical trials at the rate expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients do not comply with trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patient <FONT STYLE="white-space:nowrap">follow-up</FONT> is not at the rate expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients experience adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients die during a clinical trial, even though their death may not be related to the products that are part of
the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Device malfunctions occur with unexpected frequency or potential adverse consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Side effects or device malfunctions of similar products already in the market that change the FDA&#146;s view
toward approval of new or similar PMAs or result in the imposition of new requirements or testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Institutional review boards and third-party clinical investigators may delay or reject the trial protocol;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated
schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other FDA or IRB requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third-party investigators are disqualified by the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate
manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records, and reports of sponsors of clinical investigations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third-party clinical investigators have significant financial interests related to us or our study such that the
FDA deems the study results unreliable, or the company or investigators fail to disclose such interests; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require
us to undertake corrective action or suspend or terminate our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in government regulations or administrative actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and effectiveness.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>510(k) Clearance Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the proposed device is
&#147;substantially equivalent,&#148; as defined in the FDCA, to a legally marketed predicate device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A predicate device is a legally
marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device) and for which a PMA is not required, a device that has
been reclassified from Class&nbsp;III to Class&nbsp;II or I, or a device that was found substantially equivalent through the 510(k) process. A device is considered to be substantially equivalent if, with respect to the predicate device, it has the
same intended use and has either (i)&nbsp;the same technological characteristics; or (ii)&nbsp;different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise different
questions of safety or effectiveness than the predicate device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before the FDA will accept a 510(k) premarket notification for
substantive review, the FDA will first assess whether the submission satisfies a minimum threshold of acceptability. If the FDA determines that the 510(k) submission lacks necessary information for substantive review, the FDA will issue a
&#147;Refuse to Accept&#148; letter which generally outlines the information the FDA believes is necessary to permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested
information before the FDA will proceed with additional review of the submission. If a 510(k) submission is accepted for substantive review, the Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k)
submission, but the review time can be delayed if FDA raises questions or requests addition information during the review process. As a practical matter, clearance often takes longer, and clearance is never assured. Thus, as a practical matter,
clearance often takes longer than 90 days. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence,
which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance to commercially market
the device. If the FDA determines that the device is &#147;not substantially equivalent&#148; to a previously cleared device, the device is automatically designated as a Class&nbsp;III device. The device sponsor must then fulfill more rigorous
requirements of the PMA approval process, or can request a <FONT STYLE="white-space:nowrap">risk-based</FONT> classification determination for the device in accordance with the &#147;<I>de novo</I>&#148; process, which is a route to market for
certain novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical devices
can only be marketed for the indications for use for which they are cleared or approved. After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <I>de novo </I>reclassification. The FDA requires each manufacturer to determine whether the proposed change requires
submission of a 510(k), <I>de novo </I>request or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a PMA in the first instance, but the FDA may review this determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing
and/or request the recall of the modified device until 510(k) marketing clearance or PMA approval is obtained or a <I>de novo </I>request is granted. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or
penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include
increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced steps that the
FDA intended to take to modernize the premarket notification pathway under Section&nbsp;510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use
of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of
demonstrated substantial equivalence to predicate devices that are more than 10 years old. These proposals have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More recently, in September 2019, the FDA issued revised final guidance describing an optional &#147;safety and performance based&#148;
premarket review pathway for manufacturers of &#147;certain, well-understood device types&#148; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria
established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a list device types
appropriate for the &#147;safety and performance based&#148; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where
feasible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PMA Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;III devices require PMA approval before they can be marketed, although some <FONT STYLE="white-space:nowrap">pre-amendment</FONT>
Class&nbsp;III devices for which FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is
safe and effective for its intended use, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, a full
description of the methods, facilities, and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a
substantive review. If it is not, the agency will refuse to file the PMA. If FDA accepts the application for substantive review, it has 180 days under the FDCA to complete its review of a filed PMA application, although in practice, the FDA&#146;s
review often takes significantly longer, and can take up to several years. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the
applicant, requesting the applicant&#146;s response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an applicant fails to respond to an FDA request for information (e.g., major
deficiency letter) within a total of 360 days. Before approving or denying a PMA application, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to
whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA may or may not accept the panel&#146;s recommendation. Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial
data and clinical trial sites, as well as conduct inspections of the applicant or its third-party manufacturers&#146; or suppliers&#146; manufacturing facility or facilities to, among other things, ensure compliance with the QSR. PMA applications
are also subject to the payment of user fees, which for fiscal year 2021 includes a standard application fee of $365,657. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overall, the FDA review of a PMA application generally takes between one and three years,
but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The device may not be shown safe or effective to the FDA&#146;s satisfaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and/or clinical trials may be found
unreliable or insufficient to support approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacturing process or facilities may not meet applicable requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in FDA approval policies or adoption of new regulations may require additional data.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the
latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter
authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of
the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> data from patients in the clinical study that supported PMA approval
or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and effectiveness
data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of
those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval. If the FDA&#146;s evaluation of a PMA application or manufacturing facilities is not
favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the
trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval
has been sought by other companies have never been approved by the FDA for marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain changes to an approved device, such as
changes in manufacturing facilities, methods, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials, or design of a device, or other changes which affect the safety or
effectiveness of the device that has been approved through the PMA process require submission of a new PMA or PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to
information needed to support any changes from the device covered by the original, approved PMA and may not require as extensive clinical data or the convening of an advisory panel, depending on the nature of the proposed change. Certain other
changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation
of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. None of our products are currently marketed pursuant to a
PMA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Regulation by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after the FDA permits a device to be marketed, numerous and pervasive regulatory requirements continue to apply. These include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establishment registration and device listing with the FDA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design,
testing, control, supplier/contractor selection, compliant handling, documentation and other quality assurance procedures during all aspects of the design and manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Labeling regulations, advertising and promotion requirements, restrictions on sale, distribution or sale of a
device, each including the FDA prohibition against the promotion of products for any uses other than those authorized by the FDA, which are commonly known as <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Medical Device Reporting, or MDR, regulations, which require that a manufacturer report to the FDA if a
device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to
recur; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medical device correction and removal reporting regulations, which require that manufacturers report to the FDA
field corrections or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recall requirements, including a mandatory recall if there is a reasonable probability that the device would
cause serious adverse health consequences or death; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An order of repair, replacement, or refund; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Device tracking requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Post-market study and surveillance requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device receives 510(k) clearance, any modification that could significantly affects its safety or effectiveness, or that would
constitute a major change in its intended use, will require a new 510(k) or possibly a PMA. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#146;s
determination. If the FDA disagrees with our determination not to seek a new 510(k) clearance, the FDA may retroactively require us to seek 510(k) clearance or possibly a PMA. The FDA could also require us to cease marketing and distribution and/or
recall the modified device until 510(k) clearance or a PMA is obtained. Also, in these circumstances, we may be subject to significant regulatory fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some changes to an approved PMA device, including changes in indications, labeling, or manufacturing processes or facilities, require
submission and FDA approval of a new PMA application or PMA supplement, as appropriate, before the change can be implemented. Supplements to a PMA often require the submission of the same type of information required for an original PMA application,
except that the supplement is generally limited to that information needed to support the proposed change from the device covered by the original PMA. The FDA uses the same procedures and actions in reviewing PMA supplements as it does in reviewing
original PMA applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations require us to register as a medical device manufacturer with the FDA. Additionally, some
states also require medical device manufacturers and/or distributors doing business within the state to register with the state or apply for a state license, which could subject our facility to state inspection as well as FDA inspection on a routine
basis for compliance with the QSR and any applicable state requirements. These regulations require that we manufacture our products and maintain related documentation in a prescribed manner with respect to manufacturing, testing and control
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing processes for medical devices are required to comply with the applicable portions of the QSR, which cover the
methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also
requires, among other things, maintenance of a device master file, device history file, and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inspections by the FDA. Failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, manufacturing operations and the recall or seizure of
marketed products, which would have a material adverse effect on our business. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency,
whether resulting from the use of the device within the scope of its clearance or <FONT STYLE="white-space:nowrap">off-label</FONT> by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the
product from the market or voluntary or mandatory device recalls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has broad regulatory compliance and enforcement powers. If the
FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recalls, withdrawals, or administrative detention or seizure of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refusing or delays in processing, clearing, or approving submissions or applications for new products or
modifications to existing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Suspension or withdrawal of 510(k) clearances or PMA approvals that have already been granted;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA refusal to issue certification to foreign governments needed to export our products for sale in other
countries; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our facilities, records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. Failure to comply with the
applicable United States medical device regulatory requirements could result in, among other things, warning letters, untitled letters, fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements, refunds,
recalls or seizures of products, operating restrictions, total or partial suspension of production, the FDA&#146;s refusal to issue certificates to foreign governments needed to export products for sale in other countries, the FDA&#146;s refusal to
grant future premarket clearances or approvals, withdrawals or suspensions of current product clearances or approvals and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Medical Devices in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Union, or EU, has adopted specific directives regulating the design, manufacture, clinical investigations, conformity assessment,
labeling and adverse event reporting for medical devices. EU directives must be implemented into the national laws of the EU member states and national laws may vary from one member state to another. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, there is currently no premarket government review of medical devices. However, the EU requires that all medical devices placed on
the market in the EU must meet the relevant essential requirements laid down in the Council Directive 93/42/EEC, or the Medical Devices Directive, and the Council Directive 90/385/EEC, or the Active Implantable Medical Devices Directive. The most
fundamental essential requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the
device must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices. These include standards
governing common requirements, such as sterilization and safety of medical electrical equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory,
compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical matter. Compliance with a standard developed to implement an essential requirement also creates a rebuttable presumption that the
device satisfies that essential requirement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To demonstrate compliance with the essential requirements laid down in Annex I to the
Medical Devices Directive, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Conformity assessment procedures require an assessment of
available clinical evidence, literature data for the product, and post-market experience in respect of similar products already marketed. Except for <FONT STYLE="white-space:nowrap">low-risk</FONT> medical devices (Class I <FONT
STYLE="white-space:nowrap">non-sterile,</FONT> <FONT STYLE="white-space:nowrap">non-measuring</FONT> devices), where the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate
to sterility or metrology), a conformity assessment procedure requires the intervention of a Notified Body. Notified Bodies are independent organizations designated by EU countries to assess the conformity of devices before being placed on the
market. A Notified Body would typically audit and examine a product&#146;s technical dossiers and the manufacturers&#146; quality system (which must, in particular, comply with ISO 13485:2016 related to Medical Devices Quality Management Systems).
If satisfied that the relevant product conforms to the relevant essential requirements, the Notified Body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then
apply the CE Mark to the device, which allows the device to be placed on the market throughout the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notified Body certificates of
conformity are valid for a fixed duration (which shall not exceed five years). Throughout the term of the certificate, the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements.
In particular, there will be a new audit by the Notified Body before it will renew the relevant certificate(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a general rule,
demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when
weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. All manufacturers placing medical devices into the market in the EU must comply
with the EU medical device vigilance system. Under this system, incidents must be reported to the relevant authorities of the EU member states, and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to reduce a risk of
death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device,
as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An
FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety
Notices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advertising and promotion of medical devices is subject to some general principles set forth by EU directives. According to
the Medical Devices Directive, only devices that are <FONT STYLE="white-space:nowrap">CE-marked</FONT> may be marketed and advertised in the EU in accordance with their intended purpose. Directive 2006/114/EC concerning misleading and comparative
advertising and Directive 2005/29/EC on unfair commercial practices, while not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example requiring that advertisements are evidenced,
balanced and not misleading. Specific requirements are defined at national level. EU member states laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising and
promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many EU
member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular <FONT STYLE="white-space:nowrap">vis-&agrave;</FONT> <FONT STYLE="white-space:nowrap">-vis</FONT> healthcare
professionals and organizations.&nbsp;Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities. In addition, many EU member states have adopted national
&#147;Sunshine Acts&#148; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on medical device manufacturers. Certain countries also mandate implementation of commercial
compliance programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;25, 2017, Regulation 2017/745, or the EU Medical Devices Regulation, entered
into force, which repeals and replaces the Medical Devices Directive and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly
applicable, without the need for adoption of EU member state laws implementing them, in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The Medical Devices
Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medical Devices Regulation was originally intended to become applicable three years after publication, but in April 2020 the transition
period was extended by the European Parliament and the Council of the EU by an additional year &#150; until May&nbsp;26, 2021. Devices lawfully placed on the market pursuant to the Medical Devices Directive and the Active Implantable Medical Devices
Directive prior to May&nbsp;26, 2021 may generally continue to be made available on the market or put into service until May&nbsp;26, 2025. Once applicable, the new regulations will among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthen the rules on placing devices on the market and reinforce surveillance once they are available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish explicit provisions on manufacturers&#146; responsibilities for the
<FONT STYLE="white-space:nowrap">follow-up</FONT> of the quality, performance and safety of devices placed on the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Improve the traceability of medical devices throughout the supply chain to the
<FONT STYLE="white-space:nowrap">end-user</FONT> or patient through a unique identification number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Set up a central database to provide patients, healthcare professionals and the public with comprehensive
information on products available in the European Union, or EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthen the rules for the assessment of certain high-risk devices, which may have to undergo an additional
check by experts before they are placed on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the
European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the marketing of medical devices that
meet EU requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">EU-UK</FONT> Trade and Cooperation Agreement, or TCA, came into effect on
January&nbsp;1, 2021. The TCA does not specifically refer to medical devices. However, as a result of Brexit, the Medical Devices Regulation will not be implemented in the UK, and previous legislation that mirrored the Medical Devices Regulation in
the UK law has been revoked. The regulatory regime for medical devices in the UK will continue to be based on the requirements derived from current EU legislation, and the UK may choose to retain regulatory flexibility or align with the Medical
Devices Regulation going forward. CE markings will continue to be recognized in the UK, and certificates issued by EU recognized Notified Bodies will be valid in the UK, until June&nbsp;30, 2023. For medical devices placed on the UK market after
this period, the UK Conformity Assessment, or UKCA, marking will be mandatory. In contrast, UKCA marking and certificates issued by UK Notified Bodies will not be recognized on the EU market. The TCA does provide for cooperation and exchange of
information in the area of product safety and compliance, including market surveillance, enforcement activities and measures, standardization related activities, exchanges of officials, and coordinated product recalls (or other similar actions). For
medical devices that are locally manufactured but use components from other countries, the &#147;rules of origin&#148; criteria will need to be reviewed. Depending on which countries products will ultimately be sold in, manufacturers may start
seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for placing medical devices on the Northern Ireland market will differ from those in the UK. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Fraud and Abuse Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we are subject to a number of federal and state healthcare regulatory laws that restrict business practices in the
healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, transparency and other healthcare fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or
service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value, including cash, improper discounts, and free or
reduced price items and services. Among other things, the Anti-Kickback Statute has been interpreted to apply to arrangements between medical device manufacturers on the one hand and prescribers and purchasers on the other. Although there are a
number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. The government can exercise enforcement discretion in taking action against
unprotected activities. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws, which establish
similar prohibitions, and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers <FONT STYLE="white-space:nowrap">and&nbsp;self-pay&nbsp;patients.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal false claims, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to
the federal government, or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S.
government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Moreover, a claim including items or services resulting from a violation of the
U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. In addition, various states have enacted false claim laws analogous to the federal False Claims Act, although many of
these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal
Health Insurance Portability and Accountability Act of 1996 created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute,
a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to payments or other transfers
of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership
and investment interests held by physicians and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Violations of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be punishable by criminal and
civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid), disgorgement and corporate integrity agreements, which impose, among other things,
rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States, our currently cleared products are not separately reimbursed by any third-party payors and if covered, are paid for as part of the procedure in which the product is used. Outside of the United States, there are many reimbursement
programs through private payors as well as government programs. In some countries, government reimbursement is the predominant program available to patients and hospitals. Our commercial success depends in part on the extent to which governmental
authorities, private health insurers and other third-party payors provide coverage for and establish adequate reimbursement levels for the procedures in which our products are used. Failure by physicians, hospitals, ambulatory surgery centers and
other users of our products to obtain coverage and adequate reimbursement from third-party payors for procedures in which our products are used, or adverse changes in government and private third-party payors&#146; coverage and reimbursement
policies, may adversely impact demand for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our experience to date, third-party payors generally reimburse for the
procedures in which our products are used only if the patient meets the established medical necessity criteria for surgery. Some payors are moving toward a managed care system and control their healthcare costs by establishing coverage policies that
categorically restrict coverage of certain procedures, or by limiting authorization for procedures, including elective procedures using our devices. No uniform policy of coverage and reimbursement among payors in the United States exists and
coverage and reimbursement for procedures can differ significantly from payor to payor. Third-party payors are increasingly auditing and challenging the prices charged for medical products and services with concern for upcoding, miscoding, using
inappropriate modifiers, or billing for inappropriate care settings. Some third-party payors must approve coverage for new or innovative devices or procedures before they will reimburse healthcare providers who use the products or therapies. Even
though a new product may have been cleared for commercial distribution by the FDA, we may find limited demand for our product unless reimbursement approval can be obtained and/or maintained from governmental and private third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payors regularly
update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes routine updates to payments to physicians, hospitals and ambulatory surgery centers for procedures during which
our products are used. These updates could directly impact the demand for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the overall escalating cost of medical
products and services being paid for by the government and private health insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products and services. Third-party
payors are developing increasingly sophisticated methods of controlling healthcare costs through prospective reimbursement and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective methods of delivering
healthcare. In the United States, some insured individuals enroll in managed care programs, which monitor and often require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of the services that a member will receive. Some managed care programs
pay their providers on a per capita (patient) basis, which puts the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member per month and, consequently, may limit the
willingness of these providers to use our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In international markets, reimbursement and healthcare payment systems vary significantly by
country, and many countries have instituted price ceilings on specific product lines and procedures. In the European Union, member states are facing increased pressure to limit public healthcare spending. There can be no assurance that procedures
using our products will be covered for a specific indication, that our products will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available or that the third-party payors&#146; reimbursement
policies will not adversely affect our ability to sell our products profitably. More and more, local, product specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additional layer of clearance
requirement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the
healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated
with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of the Affordable Care Act, or ACA, in the United States, for example, has changed healthcare financing and delivery by
both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA, among other things, provided incentives to programs that increase the federal government&#146;s comparative effectiveness
research, and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through
bundled payment models. Additionally, the ACA expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research. Since its enactment, there have been judicial, executive and political challenges to certain aspects of the ACA. The U.S. Supreme Court is currently reviewing the constitutionality of the ACA in its
entirety, although it remains unclear how the Supreme Court will rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and
adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the
statute, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through March&nbsp;31, 2021, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012,
among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access
and CHIP Reauthorization Act of 2015 repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that began in 2019 that are
based on various performance measures and physicians&#146; participation in alternative payment models, such as accountable care organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access
to, confidentiality and security of personal information, including health-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA,
and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the
operations of our partners. In addition, certain state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, such as the CCPA, the CPRA and the GDPR, govern the privacy and security of personal information, including health-related information
in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where
applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate
compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the GDPR went into effect on May&nbsp;25, 2018 and introduces strict requirements for processing the personal data of European
Union data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to
&#128;20&nbsp;million or 4% of the annual global revenues of the preceding financial year of the noncompliant company, whichever is greater. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to
provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States
agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, from January&nbsp;1, 2021, companies have to comply with the GDPR and also the United Kingdom General Data Protection Regulation, or
the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e.,&nbsp;fines up to the greater of &#128;20&nbsp;million (&pound;17.5 million) or 4% of
global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is also unclear how United Kingdom data protection laws and regulations will develop in
the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending
June&nbsp;30, 2021 at the latest, whilst the parties discuss an adequacy decision. The European Commission published a draft adequacy decision on February&nbsp;19, 2021. If adopted, the decision will enable data transfers from EU member states to
the United Kingdom for a four-year period, subject to subsequent extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Menlo Park, California, where we lease approximately 10,823 square feet of office, research and
development, engineering and laboratory space pursuant to a sublease agreement which was effective as of September&nbsp;17, 2019 and expires on July&nbsp;31, 2021. Effective August&nbsp;1, 2021, we will remain in the same space under a new lease
agreement with the direct landlord to that space which will extend through August&nbsp;31, 2024. We believe that our existing facilities are adequate to meet our business requirements for the near-term, and that additional space will be available on
commercially reasonable terms, if required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had 136 full-time employees. Our highly qualified and experienced team includes scientists, physicians and
professionals across sales, marketing, regulatory, finance and other important </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
functions that are critical to our success. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel. None of our employees are
represented by a labor union or are a party to a collective bargaining agreement and we believe that we have good relations with our employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase
stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a
party to any material legal proceedings. We may, however, in the ordinary course of business face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual
property rights as well as claims relating to employment matters and the safety or effectiveness of our products. Any of these claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover
many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen,
the payment of any such awards could have a material adverse effect on our business, financial condition and results of operations. Additionally, any such claims, whether or not successful, could damage our reputation and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers and directors as of the date of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jesse Selnick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn O&#146;Neil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Park</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeremy Hayden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Legal Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staffan Encrantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mack Hicks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erica Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valeska Schroeder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Badawi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Technology Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald Zurbay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paul Badawi</I> is a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of our Company and has served as our Chief Executive Officer and a member of our Board since the Company was founded in 2011. Mr.&nbsp;Badawi holds a M.B.A. from the University of California, Los Angeles
and a B.S. in Biological Sciences from the University of Chicago. We believe that Mr.&nbsp;Badawi&#146;s experience in the industry and knowledge of our Company qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jesse Selnick </I>has served as our Chief Financial Officer since January 2018. From March 2012 to March 2017, Mr.&nbsp;Selnick served as the Chief
Financial Officer and a member of the board of Electric Lightwave (previously known as Integra Telecom), a telecom infrastructure company, until its purchase by Zayo Group Holdings, Inc. in March 2017. Prior to that, Mr.&nbsp;Selnick worked at The
Blackstone Group from 2003 to February 2012, where he most recently served as Managing Director. Mr.&nbsp;Selnick holds a M.B.A. from Harvard Business School and a B.S. in Economics from the Wharton School at the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shawn O&#146;Neil </I>has served as our Chief Commercial Officer since October 2017. From October 2003 to October 2017, Mr.&nbsp;O&#146;Neil held various
leadership positions at Alcon, Inc., a global leader in eye care, where he most recently served as the Head of Sales and Marketing, Surgical Glaucoma. Mr.&nbsp;O&#146;Neil holds a B.A. in Economics from Princeton University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sam Park </I>has served as our Chief Operating Officer since March 2020. From March 2016 to May 2019, Mr.&nbsp;Park served as the founder and Chief
Executive Officer of Park Medical, a medical device company. Mr.&nbsp;Park holds a B.S. in Mechanical Engineering from the University of California, Irvine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jeremy Hayden </I>has served as our Chief Legal Officer since April 2020. From August 2017 to April 2020, Mr.&nbsp;Hayden served as General Counsel of
Endologix, Inc. Prior to that, Mr.&nbsp;Hayden served as General Counsel and Vice President, Business Development at Cytori Therapeutics, Inc. from July 2016 to August 2017 and from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
May 2012 to August 2017 he served as Assistant General Counsel at Volcano Corporation, publicly traded medical device company that was acquired by Royal Phillips in 2015. Mr.&nbsp;Hayden holds a
J.D. from the University of Michigan Law School and an A.B. in Politics from Princeton University. Endologix, Inc. filed for Chapter 11 bankruptcy in July 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staffan Encrantz</I> has served as a member
of our Board since 2017. Mr.&nbsp;Encrantz is the founder of Allegro Investment Fund, L.P. and has served as its chairman since 1997. Mr.&nbsp;Encrantz holds a law degree from Uppsala University, Sweden. We believe that Mr.&nbsp;Encrantz&#146;
financial and industry experience qualify him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mack Hicks </I>has served as a member of our Board since 2011. Since
2007, Mr.&nbsp;Hicks has been a Partner of Hicks Holdings LLC, an investment company. Prior to that, Mr.&nbsp;Hicks served as a research analyst at Halcyon Asset Management from 2005 to 2006 and worked at Credit Suisse in 2004. Mr.&nbsp;Hicks holds
a B.A. in History from the University of Texas at Austin. We believe that Mr.&nbsp;Hicks&#146; financial and industry experience qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Andrew Offer </I>has served as a member of our Board since September 2020. Since 2007, Mr.&nbsp;Offer has held various positions, and currently serves as
the Chief Executive Officer of Scientific Health Development, a healthcare investment company. From 2004 to 2007, Mr.&nbsp;Offer served as a senior analyst and associate at Value Management Group, a healthcare transaction advisory company.
Mr.&nbsp;Offer holds a B.B.A. in Finance from the Mays School of Business at Texas A&amp;M University. We believe that Mr.&nbsp;Offer&#146;s experience in the healthcare industry qualifies him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Erica Rogers </I>has served as a member of our Board since November 2019. Since October 2012, Ms.&nbsp;Rogers has served as President and Chief Executive
Officer and a member of the board of Silk Road Medical, a medical device company. Ms.&nbsp;Rogers is also a director of Lucira Health, a diagnostics company, and currently serves as an advisor to Alydia Health and Venture Investors. Ms.&nbsp;Rogers
holds a B.S. in Zoology from San Diego State University. We believe that Ms.&nbsp;Rogers&#146; experience in the medical device industry qualifies her to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Valeska Schroeder, Ph.D. </I>has served as a member of our Board since 2019. Since 2016, Dr.&nbsp;Schroeder has served as a Managing Director of KCK
Medical Technologies, a single family evergreen fund that invests in medical technologies. From March 2014 to July 2016, Dr.&nbsp;Schroeder served as Senior Vice President, Product Management of Vital Connect, Inc., a wearable biosensor technology
company. Dr.&nbsp;Schroeder holds a Ph.D., M.S. and B.S. in Materials Sciences and Engineering from the University of California at Berkeley. We believe that Dr.&nbsp;Schroeder&#146;s experience in the healthcare industry qualifies her to serve on
our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>David Badawi, M.D. </I>is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of our Company and has served as our Chief
Technology Officer and a member of our Board since the Company was founded in 2011. Since 2012, Dr.&nbsp;Badawi has also served as the president and a practicing ophthalmologist at Central Eye Care Ltd, an ophthalmology practice. Dr.&nbsp;Badawi
holds a M.D. from Georgetown University and a B.S. in Microbiology from the University of Maryland. We believe that Dr.&nbsp;Badawi&#146;s medical experience and knowledge of our Company qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Donald Zurbay </I>has served as a member of our Board since July 2020. Since June 2018, Mr.&nbsp;Zurbay has served as the Chief Financial Officer of
Patterson Companies, a global medical device company. Before that, from March 2004 to February 2017, Mr.&nbsp;Zurbay held various leadership positions at St. Jude Medical, Inc., where he most recently served as Vice President and Chief Financial
Officer from August 2012 to January 2017. Mr.&nbsp;Zurbay currently serves on the board of Silk Road Medical. Mr.&nbsp;Zurbay holds a B.S. in Business Accounting from the University of Minnesota. We believe that Mr.&nbsp;Zurbay&#146;s experience
with publicly-traded healthcare companies and financial expertise qualify him to serve on our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;members. Our board of directors has determined that, of our
directors,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that
each of these directors is &#147;independent&#148; as that term is defined under the rules of The Nasdaq Stock Market LLC, or the Nasdaq Rules. The Nasdaq Rules&#146; independence definition includes a series of objective tests, such as that the
director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by the Nasdaq
Rules, our board of directors has made a subjective determination as to each independent director that no relationships exist that, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out
the responsibilities of a director. In making these determinations, our board of directors reviewed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may
relate to us and our management. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Classified
Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our restated certificate of incorporation that will go into effect upon the closing of this
offering, our board of directors will be divided into three classes with staggered, three-year terms.&nbsp;At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election
and qualification until the third annual meeting following election. Effective upon the closing of this offering, our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;I directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual meeting of stockholders following this offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;II directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual meeting of stockholders following this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the third annual meeting of stockholders following this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation that will go into effect upon the closing of this offering will provide that the authorized number
of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will
consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our
company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding voting stock entitled to vote in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors were elected to and currently serve on the board pursuant to a voting agreement among us and several of our largest
stockholders. See &#147;Certain Relationships and Related Party Transactions&#151;Voting Agreement.&#148; This agreement will terminate upon the closing of this offering, after which there will be no further contractual obligations regarding the
election of our directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is currently chaired by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
Our corporate governance guidelines provide that, if the chairman of the board is a member of management or does not otherwise qualify as independent, the independent directors of the board may elect a lead director. The lead director&#146;s
responsibilities include, but are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not limited to: presiding over all meetings of the board of directors at which the chairman is not present, including any executive sessions of the independent directors; approving board meeting
schedules and agendas; and acting as the liaison between the independent directors and the chief executive officer and chairman of the board. Our corporate governance guidelines further provide the flexibility for our board of directors to modify
our leadership structure in the future as it deems appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their
respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and
the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee also monitors compliance with legal and
regulatory requirements. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our
compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain risks and overseeing the management
of such risks, our entire board of directors is regularly informed through committee reports about such risks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of
which operates under a charter that has been approved by our board of directors. Upon our listing on The Nasdaq Global Market, each committee&#146;s charter will be available under the Corporate Governance section of our website at
<I>www.sightsciences.com</I>. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit
committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Appointing, approving the compensation of, and assessing the independence of our registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overseeing the work of our registered public accounting firm, including through the receipt and consideration of
reports from such firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewing and discussing with management and the registered public accounting firm our annual and quarterly
financial statements and related disclosures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coordinating our board of directors&#146; oversight of our internal control over financial reporting, disclosure
controls and procedures and code of business conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discussing our risk management policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Meeting independently with our internal auditing staff, if any, registered public accounting firm and management;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewing and approving or ratifying any related person transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preparing the audit committee report required by Securities and Exchange Commission, or SEC, rules.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chairperson of the committee. All members
of our audit committee meet the requirements for financial literacy under the Nasdaq Rules. Our board of directors has determined
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; meet the independence requirements of Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and the applicable Nasdaq Rules. Our board of directors has determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is an
&#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq Rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewing and approving, or recommending for approval by the board of directors, the compensation of our CEO and
our other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewing and making recommendations to our board of directors with respect to director compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; to the
extent required; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preparing the annual compensation committee report required by SEC rules, to the extent required.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chairperson of the committee. Our board
of directors has determined that each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is independent under the applicable Nasdaq Rules, including the Nasdaq Rules specific to membership on the compensation committee, and is a <FONT
STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee&#146;s responsibilities include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identifying individuals qualified to become board members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recommending to our board of directors the persons to be nominated for election as directors and to each board
committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Developing and recommending to our board of directors corporate governance guidelines, and reviewing and
recommending to our board of directors proposed changes to our corporate governance guidelines from time to time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overseeing a periodic evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. Our board
of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are independent under the applicable Nasdaq Rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee Interlocks and Insider Participation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers served as a
director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation committee during the fiscal year ended
December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics and Code of Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon our listing on The Nasdaq Global Market, our code of business conduct and ethics will be available under the
Corporate Governance section of our website at <I>www.sightsciences.com</I>. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq Rules concerning any amendments to, or waivers from, any provision of
the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our named executive officers. We are an
&#147;emerging growth company,&#148; within the meaning of the JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act. For 2020, our named executive
officers and their positions were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paul Badawi, President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shawn O&#146;Neil, Chief Commercial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sam Park, Chief Operating Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations
regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently planned programs summarized in this discussion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth all of the compensation awarded to or earned by or paid to our named executive officers during 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity&nbsp;Incentive</FONT><BR>Plan<BR>Compensation&nbsp;
($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn O&#146;Neil</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">534,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Park<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">332,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">611,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Park served as a consultant to the Company from January&nbsp;1, 2020 until March&nbsp;13, 2020, the
date he commenced employment as our Chief Operating Officer. Amounts shown for Mr.&nbsp;Park include $93,672 in consulting fees and $238,654 in base salary earned as an employee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the full grant-date fair value of stock options granted during 2020 computed in accordance with
ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of the stock option awards made to named executive officers in Note 11 to the audited
consolidated financial statements included in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts represent bonuses earned by our named executive officers for 2020 under the Company&#146;s annual
incentive program. Refer to &#147;&#151;Annual Incentive Compensation&#148; below for additional information regarding the Company&#146;s annual incentive program for 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary
Elements of Our Executive Compensation Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For 2020, the primary elements of our named executive officers&#146; compensation
were base salary, annual cash incentive bonuses and long-term equity incentive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salaries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base salaries of our named executive officers are an important part of their total compensation package and are intended to reflect their
respective positions, duties and responsibilities. For 2020, the named executive officers&#146; annual base salaries were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual&nbsp;Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn O&#146;Neil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Park</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Park served as a consultant to the Company from January&nbsp;1, 2020 until March&nbsp;13, 2020, the
date he commenced employment as our Chief Operating Officer. While serving as a consultant, Mr.&nbsp;Park earned consulting fees at the rate of $325.00 per hour. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Incentive Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
maintain an annual bonus program for all employees who are not eligible for commissions, including our named executive officers. Participants in the bonus program may earn a performance-based cash bonus based on our achievement of specified
performance goals. Performance goals for the 2020 bonus program generally related to specified commercial (weighted 50%), clinical (weighted 25%), research and development (weighted 10%), regulatory (weighted 7.5%) and financial (weighted 7.5%)
objectives. For 2020, the named executive officers had the following target annual bonus amounts, expressed as a percentage of base salary received during the year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020&nbsp;Bonus&nbsp;Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn O&#146;Neil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Park</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, our board of directors determined the bonus payments with respect to 2020. The actual
amounts of the 2020 annual bonuses paid to our named executive officers are included in the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; column of the 2020 Summary Compensation Table, above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally offer
stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation program. Our stock options generally allow employees to purchase shares of our common stock at a price equal to the fair
market value of our common stock on the date of grant, as determined by the board of directors. Stock options granted upon an employee&#146;s commencing employment generally vest as to 25% of the underlying shares on the first anniversary of the
date of grant and in equal monthly installments over the following three years. Subsequent grants to employees generally vest as to 1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares underlying the stock option each month for
four years following the date of grant. Historically, our stock options have been intended to qualify as &#147;incentive stock options&#148; to the extent permitted under the Internal Revenue Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have granted equity awards under our 2011 Stock Incentive Plan, referred to below as the Existing Plan. We intend
to adopt a 2021 Incentive Award Plan, referred to below as the 2021 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and certain of
its affiliates and to enable our company and certain of its affiliates to obtain and retain services of these individuals. We expect that the 2021 Plan will be effective on the day prior to our first public trading date. Once the 2021 Plan becomes
effective, we will cease making grants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Existing Plan. However, the Existing Plan will continue to govern the terms and conditions of the outstanding awards granted under it. For additional information about the Existing Plan
and the 2021 Plan, please see the section titled &#147;Incentive Compensation Plans&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Plans and Other Employee Benefits
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our employee benefit plans and programs, including medical and dental
benefits and life insurance, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans. We also sponsor a&nbsp;401(k) defined contribution plan in which our named executive officers may
participate, subject to limits imposed by the Code, to the same extent as our other full-time employees. We did not make any employer contributions to the 401(k) plan for 2020. We have not typically provided our executive officers with any
perquisites, and none of the named executive officers received perquisites for 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment, Severance or Change in Control Agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment offer letter agreements with our named executive officers that set forth certain terms and
conditions of employment of each named executive officer, including initial base salary, annual bonus opportunity (for Messrs. O&#146;Neil and Park) and equity grants and employee benefits eligibility. None of our named executive officers is
currently entitled to any change in control or severance benefits. We expect to enter into new employment agreements with the named executive officers that supersede their existing agreements effective upon the effectiveness of the registration
statement relating to this offering. The terms of these new agreements are not yet known. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2020 Fiscal <FONT
STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information about outstanding equity awards held by each of
our named executive officers as of December&nbsp;31, 2020. All awards were granted under the Existing Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting&nbsp;Start<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)</B><br><B>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Exercise<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn O&#146;Neil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/18/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,563</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/28/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,625</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/16/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/30.2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,396</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/29/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Park</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/13/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/11/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,167</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/29/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The option vests as to 25% of the underlying shares on the first anniversary of the vesting start date and in
36 equal monthly installments thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The option vests in 48 equal monthly installments following the vesting start date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Badawi is a Company founder with significant beneficial ownership of our common stock. See the section
titled &#147;Principal Stockholders&#148; in this prospectus for more information regarding Mr.&nbsp;Badawi&#146;s beneficial ownership of our common stock. To date, our board of directors has elected not to grant equity incentive awards to
Mr.&nbsp;Badawi, but may approve grants of equity incentive awards in the future. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letter agreements with Ms. Rogers and Mr. Zurbay, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
who are not affiliated with a significant stockholder, that provide for certain terms and conditions of their service </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on our board of directors, including annual retainers and the grant of equity awards. In 2020, we paid Ms.&nbsp;Rogers and Mr.&nbsp;Zurbay annual cash retainers equal to $50,000, prorated in the
case or Mr.&nbsp;Zurbay for a partial year of service. In addition, in January 2020 and May 2020, Ms.&nbsp;Rogers received an option to purchase 15,000 shares and 20,000 shares, respectively, of our common stock, and in June 2020, Mr.&nbsp;Zurbay
received an option to purchase 30,000 shares of our common stock. Ms.&nbsp;Rogers&#146; January 2020 option has an exercise price of $4.13 per share and the other options granted to Ms. Rogers and Mr.&nbsp;Zurbay have an exercise price of $3.91 per
share, each of which our board of directors determined to be the fair market value per share of our common stock on the date of grant. All options granted to Ms.&nbsp;Rogers and Mr.&nbsp;Zurbay vest monthly in 48 equal installments and accelerate
upon a Corporate Transaction (as defined in the Existing Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our other <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors received compensation for their service on our board of directors during 2020. Mr.&nbsp;Badawi, our Chief Executive Officer, and Dr.&nbsp;Badawi, our Chief Technology Officer, both served on our board of directors during 2020 but have not
been included in the 2020 Director Compensation Table below because they did not receive any additional compensation for this service. Information regarding Mr.&nbsp;Badawi&#146;s 2020 compensation is included in the 2020 Summary Compensation Table,
Outstanding Equity Awards at 2020 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> table and associated narrative disclosure above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020
Director Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or&nbsp;Paid&nbsp;in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staffan Encrantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mack Hicks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carter Meyer<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erica Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valeska Schroeder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Don Zurbay<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the full grant-date fair value of stock options granted during 2020 computed in accordance with
ASC Topic&nbsp;718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of the option awards in Note to the consolidated financial statements included in
this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Meyer resigned from our board of directors on October&nbsp;2, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Zurbay joined our board of directors on June&nbsp;16, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) held as of December&nbsp;31, 2020 by each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director who was serving as of December&nbsp;31, 2020. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors did not hold any unvested stock awards as of December&nbsp;31, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options&nbsp;Outstanding&nbsp;at<BR>Fiscal Year End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staffan Encrantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mack Hicks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erica Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valeska Schroeder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Don Zurbay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt a compensation program for our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors that consists of annual retainer fees and long-term equity awards and that will become effective upon effectiveness of the registration statement relating to this offering. The terms of the program are not yet known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incentive Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the material terms of the 2021 Plan and the 2021 Employee Stock Purchase Plan, which will be the long-term incentive
compensation plans in which our directors and named executive officers will be eligible to participate following this offering, and the Existing Plan, under which we have historically made periodic grants of equity and equity-based awards to our
directors and named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective the day prior to the first public trading date of our common stock, we intend to adopt and ask our stockholders to approve the 2021
Plan under which we may grant cash and <FONT STYLE="white-space:nowrap">equity-based</FONT> incentive awards to eligible service providers in order to attract, retain and motivate the persons who make important contributions to the company. The
material terms of the 2021 Plan, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving and implementing the 2021 Plan and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility and Administration.</I> Our employees, consultants and directors, and employees and consultants of our subsidiaries will be
eligible to receive awards under the 2021 Plan. The 2021 Plan will be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to
other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to the limitations that may be imposed under the 2021
Plan, Section&nbsp;16 of the Exchange Act, stock exchange rules and other applicable laws, including Delaware law. The plan administrator will have the authority to take all actions and make all determinations under the 2021 Plan, to interpret the
2021 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2021 Plan as it deems advisable. The plan administrator will also have the authority to determine which eligible service providers receive awards,
grant awards and set the terms and conditions of all awards under the 2021 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Available.</I> An aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock will initially be available for issuance under the 2021 Plan. The number of shares initially available for issuance will be increased by an annual increase on January&nbsp;1 of each calendar year beginning in 2022 and
ending in and including 2031, equal to the lesser of (A)&nbsp;&nbsp;&nbsp;&nbsp; % of the shares outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;a smaller number of shares as determined by our board of directors.
No more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares available under the 2021 Plan
may be authorized but unissued shares, shares purchased on the open market or treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award under the 2021 Plan or the
Existing Plan expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, or canceled without having been fully exercised or forfeited, any unused shares subject to the award will, as applicable, become or again be available for
new grants under the 2021 Plan. Awards granted under the 2021 Plan in substitution for any options or other stock or <FONT STYLE="white-space:nowrap">stock-based</FONT> awards granted by an entity before the entity&#146;s merger or consolidation
with us or our acquisition of the entity&#146;s property or stock will not reduce the shares available for grant under the 2021 Plan, but will count against the maximum number of shares that may be issued upon the exercise of incentive stock
options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards.</I> The 2021 Plan provides for the grant of stock options, including incentive
stock options, or ISOs, and nonqualified stock options, or NSOs, stock appreciation rights, or SARs, restricted stock, dividend equivalents, restricted stock units, or RSUs, and other stock or cash based awards. Certain awards under the 2021 Plan
may constitute or provide for payment of &#147;nonqualified deferred compensation&#148; under Section&nbsp;409A of the Code. All awards under the 2021 Plan will be set forth in award agreements, which will detail the terms and conditions of awards,
including any applicable vesting and payment terms and <FONT STYLE="white-space:nowrap">post-termination</FONT> exercise limitations. A brief description of each award type follows. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Options and SARs. </I>Stock options provide for the purchase of shares of our common stock in the future
at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied.
SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The plan administrator will determine the number of shares covered by
each option and SAR, the exercise price of each option and SAR and the conditions and limitations applicable to the exercise of each option and SAR. The exercise price of a stock option or SAR will not be less than 100% of the fair market value of
the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock option or SAR
may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock and RSUs. </I>Restricted stock is an award of nontransferable shares of our common stock that
remain forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until
specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. The plan administrator may provide that the delivery of
the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the plan administrator, subject to the conditions and
limitations contained in the 2021 Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Stock or Cash Based Awards. </I>Other stock or cash based awards are awards of cash, fully vested shares
of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock or other property. Other stock or cash based awards may be granted to participants and may also be available as a
payment form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. The plan administrator will determine the terms and conditions of other stock or cash based
awards, which may include any purchase price, performance goal, transfer restrictions and vesting conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Criteria.</I> The plan administrator may select performance criteria for an award to establish performance goals for a
performance period. Performance criteria under the 2021 Plan may include, but are not limited to, the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and <FONT
STYLE="white-space:nowrap">non-cash</FONT> <FONT STYLE="white-space:nowrap">equity-based</FONT> compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income;
profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after
allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity;
total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in
or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth;
customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring
liquidity, activity, profitability or leverage); debt levels or reductions; <FONT STYLE="white-space:nowrap">sales-related</FONT> goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing
activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the company&#146;s performance or the
performance of a subsidiary, division, business segment or business unit of the company or a subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to
performance of other companies. When determining performance goals, the plan administrator may provide for exclusion of the impact of an event or occurrence which the plan administrator determines should appropriately be excluded, including, without
limitation, <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges or events, acquisitions or divestitures, changes in the corporate or capital structure, events unrelated to the business or outside of the control of management, foreign
exchange considerations, and legal, regulatory, tax or accounting changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions.</I> In connection with certain
corporate transactions and events affecting our common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2021 Plan to prevent the
dilution or enlargement of intended benefits, facilitate the transaction or event or give effect to the change in applicable laws or accounting principles. This includes canceling awards for cash or property, accelerating the vesting of awards,
providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares subject to outstanding awards and/or with respect to which awards may be granted under the 2021 Plan and replacing or terminating
awards under the 2021 Plan. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders, the plan administrator will make equitable adjustments to the 2021 Plan and outstanding
awards as it deems appropriate to reflect the transaction. In the event of a change in control of the company (as defined in the 2021 Plan), to the extent that the surviving entity declines to continue, convert, assume or replace outstanding awards,
then all such awards may become fully vested and exercisable in connection with the transaction. Individual award agreements may provide for additional accelerated vesting and payment provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Provisions of the 2021 Plan Relating to Director Compensation.</I> The 2021 Plan provides that the plan administrator may establish
compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors from time to time subject to the 2021 Plan&#146;s limitations. Prior to commencing this offering, we intend to approve and implement a compensation program for our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its
business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value of any equity
awards granted under the 2021 Plan as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any fiscal year may not exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, excluding cash and other compensation awarded prior to the commencement of this offering. The plan administrator may make exceptions to this limit for
individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the plan administrator may determine in its discretion, subject to the limitations in the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Foreign Participants, Claw</I><I><FONT STYLE="white-space:nowrap">-Back</FONT> Provisions, Transferability, and Participant Payments.</I>
The plan administrator may modify awards granted to participants who are foreign nationals or employed outside the United States or establish subplans or procedures to address differences in laws, rules, regulations or customs of such foreign
jurisdictions. All awards will be subject to any company <FONT STYLE="white-space:nowrap">claw-back</FONT> policy as set forth in such <FONT STYLE="white-space:nowrap">claw-back</FONT> policy or the applicable award agreement. Except as the plan
administrator may determine or provide in an award agreement, awards under the 2021 Plan are generally <FONT STYLE="white-space:nowrap">non-transferrable,</FONT> except by will or the laws of descent and distribution, or, subject to the plan
administrator&#146;s consent, pursuant to a domestic relations order and are generally exercisable only by the participant. With regard to tax withholding obligations arising in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with awards under the 2021 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2021 Plan, the plan administrator may, in its
discretion, accept cash, wire transfer or check, shares of our common stock that meet specified conditions, a promissory note, a &#147;market sell order,&#148; such other consideration as the plan administrator deems suitable or any combination of
the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment; Repricing and Termination.</I> Our board of directors may amend or terminate the 2021 Plan at any time;
however, no amendment, other than an amendment that increases the number of shares available under the 2021 Plan, may materially and adversely affect an award outstanding under the 2021 Plan without the consent of the affected participant and
stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws. Further, the plan administrator may, without the approval of our stockholders, amend any outstanding stock option or SAR to reduce its
exercise price per share. The 2021 Plan will remain in effect until the tenth anniversary of its effective date, unless earlier terminated by our board of directors. No awards may be granted under the 2021 Plan after its termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective the day prior to the first public trading date of our common stock, we intend to adopt and ask our stockholders to approve the 2021
Employee Stock Purchase Plan, or the 2021 ESPP, the material terms of which are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 ESPP is comprised of two
distinct components in order to provide increased flexibility to grant options to purchase shares under the 2021 ESPP to U.S. and to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> employees. Specifically, the 2021 ESPP authorizes (1)&nbsp;the
grant of options to U.S. employees that are intended to qualify for favorable U.S. federal tax treatment under Section&nbsp;423 of the Code, (the &#147;Section&nbsp;423 Component&#148;), and (2)&nbsp;the grant of options that are not intended to be <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> under Section&nbsp;423 of the Code to facilitate participation for employees located outside of the U.S. who do not benefit from favorable U.S. federal tax treatment and to provide flexibility to
comply with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law and other considerations (the <FONT STYLE="white-space:nowrap">&#147;Non-Section</FONT> 423 Component&#148;). Where permitted under local law and custom, we expect that the <FONT
STYLE="white-space:nowrap">Non-Section</FONT> 423 Component will generally be operated and administered on terms and conditions similar to the Section&nbsp;423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Available for Awards; Administration.</I><B><I> </I></B>A total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will initially be reserved for issuance under the 2021 ESPP. In addition, the number of shares available for issuance under
the 2021 ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2022 and ending in and including 2031, by an amount equal to the lesser of (A)&nbsp;&nbsp;&nbsp;&nbsp; % of the shares outstanding on the final day of the
immediately preceding calendar year and (B)&nbsp;such smaller number of shares as is determined by our board of directors, provided that no more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock may be issued under the Section&nbsp;423 Component. Our board of directors or a committee of our board of directors will administer and will have authority to interpret the terms of the 2021 ESPP and determine eligibility
of participants. We expect that the compensation committee will be the initial administrator of the 2021 ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility.</I><B><I>
</I></B>We expect that all of our employees will be eligible to participate in the 2021 ESPP. However, an employee may not be granted rights to purchase stock under our 2021 ESPP if the employee, immediately after the grant, would own (directly or
through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Grant of
Rights</I><B><I>. </I></B>Stock will be offered under the 2021 ESPP during offering periods. The length of the offering periods under the 2021 ESPP will be determined by the plan administrator and may be up to twenty-seven months long. Employee
payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering period will be the final trading day in the offering period. Offering periods under the 2021 ESPP will commence
when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. In <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions where participation in the 2021 ESPP through
payroll deductions is prohibited, the plan administrator may provide that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an eligible employee may elect to participate through contributions to the participant&#146;s account under the 2021 ESPP in a form acceptable to the 2021 ESPP administrator in lieu of or in
addition to payroll deductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 ESPP permits participants to purchase common stock through payroll deductions of up to a
specified percentage of their eligible compensation. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period. In addition, no employee will be permitted to accrue the right
to purchase stock under the Section&nbsp;423 Component at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the
first day of the offering period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each participant will automatically be granted an
option to purchase shares of our common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price
of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their
participation in the 2021 ESPP at any time during a specified period prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation
ends automatically upon a participant&#146;s termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the 2021
ESPP, other than by will or the laws of descent and distribution, and rights granted under the 2021 ESPP are generally exercisable only by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions.</I><B><I> </I></B>In the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions or
events affecting our common stock, the plan administrator will make equitable adjustments to the 2021 ESPP and outstanding rights. In the event of certain unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> events or transactions,
including a change in control, the plan administrator may provide for (1)&nbsp;either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (2)&nbsp;the assumption or
substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3)&nbsp;the adjustment in the number and type of shares of stock subject to outstanding rights, (4)&nbsp;the use of
participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (5)&nbsp;the termination of all outstanding rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment.</I><B><I> </I></B>The plan administrator may amend, suspend or terminate the 2021 ESPP at any time. However,
stockholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the 2021 ESPP or changes the corporations or classes of corporations whose employees
are eligible to participate in the 2021 ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors initially adopted, and our stockholders initially approved, the Existing Plan in September 2011. From and after the
effective date of the 2021 Plan, no additional awards will be made under the Existing Plan. However, the Existing Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Outstanding Awards</I>. As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, stock
options covering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares with a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share were outstanding under the Existing Plan. If an option granted under the Existing Plan expires, lapses or is terminated, exchanged for cash,
surrendered, repurchased, canceled without having been fully exercised or forfeited, in each case after effectiveness of the 2021 Plan, any unused shares subject to the option will become available for issuance under and in accordance with the terms
of the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors or a committee delegated by our board of directors administers the
Existing Plan. Subject to the terms of the Existing Plan, the administrator has the power to construe and interpret </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the plan and to take such actions are as the administrator determines are appropriate for the administration of the plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Options</I>. Options granted under the Existing Plan are subject to terms and conditions generally similar to those described above with
respect to options that may be granted under our 2020 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. Certain terms of awards outstanding
under the Existing Plan will be proportionately adjusted, as determined appropriate by the administrator, in the event of certain increases or decreases in or transactions affecting our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. In the event of certain corporate transaction or events, the administrator in its discretion may terminate awards
that are not assumed in transaction or event or provide for the full or partial vesting and exercisability of awards, which may be conditioned upon a subsequent termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. The Board may at any time amend the Existing Plan, subject to its terms. To the extent necessary to comply with applicable
laws, the Company will obtain stockholder approval of any plan amendment in such a manner and to such a degree as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2018 to which we have been a party in which the amount involved
exceeded or will exceed the lessor of (i) $120,000 or (ii)&nbsp;one percent of the average of our total assets at fiscal year end for our last two fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial
owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and
other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain other transactions with our directors, executive officers and stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series C
Preferred Stock Financing</I>. Between January 2018 and June 2018, we issued and sold to investors in private placements an aggregate of 1,288,761 shares of our Series C preferred stock at a purchase price of $9.4868 per share, for aggregate
consideration of approximately $12.23&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series D Preferred Stock Financing</I>. In August 2019, we issued and sold to
investors in private placements an aggregate of 2,447,818 shares of our Series D preferred stock at a purchase price of $12.5622 per share, for aggregate consideration of approximately $30.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series E Preferred Stock Financing</I>. In March 2020, we issued and sold to investors in private placements an aggregate of 1,899,847
shares of our Series E preferred stock at a purchase price of $15.8697 per share, for aggregate consideration of approximately $30.15&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series F Preferred Stock Financing</I>. In November 2020, we issued and sold to investors in private placements an aggregate of 1,062,716
shares of our Series F preferred stock at a purchase price of $21.8779 per share, for aggregate consideration of approximately $23.25&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate number of shares of our capital stock acquired by beneficial owners of more than 5% of our
capital stock in the financing transactions described above. Each share of our preferred stock identified in the following table will convert into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock immediately upon the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;C<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;E<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series F<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5%</B><B></B><B>&nbsp;or</B><B></B><B>&nbsp;Greater</B><B></B><B>&nbsp;Stockholders</B><SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allegro Investment Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D1 Capital Partners Master LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,890,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">685,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH Sight Partners, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH-IOP Partners, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KCK Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,388,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences Angels, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are provided in this prospectus under
the caption &#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our directors and officers are associated with our principal stockholders as
indicated in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Directors and Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal&nbsp;Stockholder</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staffan Encrantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allegro Investment Fund, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mack Hicks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH Sight Partners, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH-IOP Partners, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valeska Schroeder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KCK Ltd.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jesse Selnick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences Angels, LP</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a Third Amended and Restated Investors&#146; Rights Agreement on November&nbsp;23, 2020 with the holders of our preferred
stock, including entities with which certain of our directors are related. The agreement provides for certain rights relating to the registration of such holders&#146; common stock, including shares issuable upon conversion of preferred stock, and a
right of first refusal to purchase future securities sold by us. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a Third
Amended and Restated Voting Agreement by and among us and certain of our stockholders, pursuant to which the following directors were initially designated to serve as members on our board of directors: Erica Rogers, Don Zurbay, and David Badawi.
Paul Badawi was selected to serve on our board of directors in his capacity as our chief executive officer. Andrew Offer, Mack Hicks, Staffan Encrantz, and Valeska Schroeder were initially selected to serve on our board of directors as
representatives of holders of our preferred stock, as designated by entities affiliated with Scientific Health Development II, Ltd., HH Sight Partners, L.P., Allegro Investment Fund, L.P., and KCK Ltd., respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting agreement will terminate upon the closing of this offering, and directors previously elected to our board of directors pursuant to
this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board
Composition and Election of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a Third Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-sale</FONT> Agreement, or the First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, with certain holders of our common stock, or the Key Holders, and our redeemable convertible preferred stock, which includes certain of our directors and executive officers,
pursuant to which we have a right of first refusal in respect of certain sales of securities by our Key Holders. To the extent we do not exercise such right in full, the holders of our redeemable convertible preferred stock are granted certain
rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such sale. The First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement will terminate immediately prior to the consummation of this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into employment agreements with our named executive officers. For more information regarding the agreements with our named executive officers, see &#147;Executive and Director Compensation&#151;Executive Compensation Arrangements.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into an employment agreement with Dr.&nbsp;David Badawi, one of our directors and the brother of Paul Badawi, our
chief executive officer and a director, to serve as our Chief Technology Officer. In connection with serving as our Chief Technology Officer, we paid Dr.&nbsp;Badawi $162,000 in each of the years ended December&nbsp;31, 2018, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements, among other things,
require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146;
fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive
officer. For further information, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option
Grants to Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers and certain of our directors as
more fully described in the section entitled &#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering,
setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant,
where the amount involved exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities
in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts
and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the
transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock, as of by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by the Securities and Exchange Commission. Under
these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that
person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage
ownership of any other person. Unless noted otherwise, the address of all listed stockholders is 4040 Campbell Ave, Suite 100, Menlo Park CA 94025. Each of the stockholders listed has sole voting and investment power with respect to the shares
beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Prior&nbsp;to&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficially&nbsp;Owned<BR>After&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;Beneficial&nbsp;Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Allegro Investment Fund, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with D1 Capital Partners Master LP<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with HH Sight Partners,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KCK Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scientific Health Development II,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sight Sciences Angels, LP<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jesse Selnick<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Badawi, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shawn O&#146;Neil<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Park<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeremy Hayden<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staffan Encrantz<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mack Hicks<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Offer<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erica Rogers<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valeska Schroeder, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald Zurbay<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors (12 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description
summarizes some of the terms of our restated certificate of incorporation and restated bylaws, each of which will become effective upon the closing of this offering, the investors&#146; rights agreement and of the Delaware General Corporation Law.
Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our restated certificate of incorporation, restated bylaws and amended and restated investors&#146;
rights agreement, copies of which have been or will be filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. The description of our common
stock and preferred stock reflects changes to our capital structure that will occur upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the
closing of this offering, our authorized capital stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $0.001 per share, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, par value $0.001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, there
were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock in connection with this offering, held of record by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have
cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters
shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our restated certificate of incorporation and restated bylaws also
provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote
thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt
any provision inconsistent with, several of the provisions of our restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#151;Amendment of Charter
Provisions.&#148; Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and
issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately
our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption
or conversion rights. There are no sinking fund provisions applicable to our common stock. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and
nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our
restated certificate of incorporation that will become effective upon the closing of this offering, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of
directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing our board of directors to issue preferred stock and determine its
rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate
purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no
shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, options
to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock were outstanding under our Existing Plan, of which
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; were exercisable and of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; were unvested as of that
date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021, warrants to purchase an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock were outstanding, with a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. On January&nbsp;25, 2019, June&nbsp;28, 2019 and November&nbsp;23, 2020, we issued warrants to MidCap Funding XXVIII Trust, in connection
with a loan and security agreement between us and Midcap Financial Services. Pursuant to the terms of the warrants, the number of shares for which the warrant is exercisable is determined by the total principal amount of loans made under the loan
and security agreement. If unexercised, these warrants will expire on the tenth anniversary of their issuance dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will
neither expire nor be automatically exercised upon the closing of this offering. The warrants provide that the holder thereof may elect to exercise the warrant on a net &#147;cashless&#148; basis at any time prior to the expiration thereof. Assuming
the closing of this offering occurs, the fair market value of one share of our common stock in connection with any cashless exercise shall be the closing price or last sale price per share of our common stock on the or other public trading market on
which our common stock is traded on the business day immediately prior to the date the holder elects to exercise the warrants on a cashless basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock are entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act,
pursuant to an amended and restated investors&#146; rights agreement by and among us and certain of our stockholders, until the rights otherwise terminate pursuant to the terms of the investors&#146; rights agreement. The registration of shares of
common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any
time beginning 180 days after the closing date of this offering the holders of more than 50% of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities
then outstanding and having an anticipated aggregate offering price of at least $20,000,000, net of expenses, we may be required to register their shares. We are obligated to effect at most two registrations in response to these demand registration
rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the
marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time after this offering we propose to register any shares of our common stock under the Securities Act, subject to certain
exceptions, the holders of registrable securities will be entitled to notice of the registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to
limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses and Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any
registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for
the selling securityholders (not to exceed $25,000) and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any
untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or
alleged violation by the indemnifying party of securities laws, subject to certain exceptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the foregoing registration rights terminate upon the earlier of five years after the effective date of the registration statement of
which this prospectus is a part, the closing of a deemed liquidation event, as defined in our current certificate of incorporation, or as to any holder at such time as Rule 144 or another similar exemption under the Securities Act is available for
the sale of all of such holders registrable securities without limitation during a three-month period without registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of
Delaware Law and Our Certificate of Incorporation and Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our restated certificate of
incorporation and our restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and
directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which
provide for payment of a premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage
coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased
protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result
in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of our board of directors, without action by the stockholders, to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any
attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated
bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of
directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and
the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board Composition
and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for
stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders
except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote in the election
of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the
holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may
be entitled to elect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be
&#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or
the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and
associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or
other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated
certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding
brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&nbsp;any action to
interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine; provided that the exclusive forum provision will not apply to
suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. For instance, the provision would not apply to actions arising under federal
securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Our restated certificate of incorporation further provides that, unless we consent in
writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act. Our restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have
consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding
or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock
and the provision prohibiting cumulative voting, would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of discouraging others
from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the
effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to
apply to have our common stock listed on The Nasdaq Global Market under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in
the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
closing of this offering, we will have outstanding an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, assuming the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock offered by us in this offering. Of these shares, all shares sold in this offering will be freely tradable without restriction or
further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act, whose sales would be subject to the Rule 144 resale restrictions described
below, other than the holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted
securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. We expect that
substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below.
Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be available for sale in the
public market, subject in some cases to applicable volume limitations under Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, of the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock that were subject to stock options outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock were vested as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 and, upon exercise, these shares will be eligible for sale subject to the lock-up
agreements described below and Rules 144 and 701 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and each of our directors and executive officers and holders of substantially all of our outstanding capital stock, have agreed that,
without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and BofA Securities, Inc., we and they will not, subject to certain exceptions, during the period ending 180 days after the date of this prospectus, offer, pledge, sell, contract
to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any
securities convertible into or exercisable or exchangeable for common stock; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock, whether any
transaction described above is to be settled by delivery of our common stock or such other securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the
limitations discussed above. For a further description of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, please see &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted
Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a
part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s
transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on The Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also
subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of
$50,000, the seller must file a notice on Form 144 with the Securities and Exchange Commission and The Nasdaq Global Market concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an
affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any other Rule 144 restrictions, including
the <FONT STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701, any
of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement
under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement,
and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities and Exchange Commission has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes
subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or
more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our stock plans. We
expect to file the registration statement covering shares offered pursuant to our stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public
market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our preferred stock upon the closing
of this offering, or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully
tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional
information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership, and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the
U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in
effect as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These authorities may change or be subject to differing interpretations. Any such change or differing
interpretation may be applied retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There
can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership, and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital
asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income or the alternative minimum tax. In addition, it does not address consequences relevant to
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Persons holding our common stock as part of a hedge, straddle, or other risk reduction strategy or as part of a
conversion transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Brokers, dealers, or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and
investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S.
federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly,
partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS DISCUSSION IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX
LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP, AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL, OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common
stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of
which are subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal
income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the section of this prospectus titled &#147;Dividend Policy,&#148; we have never declared or paid cash dividends on our capital
stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S.
federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute
returns of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as
described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding effectively
connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income
tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not
timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable tax treaties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent
establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as
adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to
U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real
property holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point
above generally will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or
such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale
or other taxable disposition of our common stock, which may be offset by certain U.S.-source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United
States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the
determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there
can be no assurance that we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our common stock by a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market and such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should
consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock will not be subject to backup withholding, provided the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on
our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or
conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification described above or the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United States generally will not be subject to backup withholding or information reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns that are filed with the IRS may also be made available under
the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax
Compliance Act, or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax
may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT
STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the
diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertakes to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually reports certain information about such accounts, and withholds 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock. While, beginning on January&nbsp;1, 2019, withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our common stock, proposed Treasury Regulations eliminate FATCA
withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in
our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_19"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley&nbsp;&amp; Co. LLC, BofA Securities, Inc., Citigroup Global Markets, Inc. and Piper Sandler &amp; Co. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number
of shares indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; over-allotment option described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the
cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share under the public offering
price. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions.
The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each
underwriter will become obligated, subject to certain conditions, to purchase approximately the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the
total number of shares of common stock listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the
per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an
additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory
Authority up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary accounts to
exceed 5% of the total number of shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on the Nasdaq Global
Market under the trading symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all directors and officers and the holders of substantially all of our outstanding stock and stock options have agreed that, without
the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and BofA Securities, Inc. on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 180 days after the date of this
prospectus (the &#147;restricted period&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">File any registration statement with the Securities and Exchange Commission relating to the offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of common
stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and BofA Securities, Inc. on behalf of the underwriters, we or such other
person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph to do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale of shares to the underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issuance by the Company of shares of common stock upon the exercise of an option or a warrant or the
conversion of a security outstanding on the date of this prospectus of which the underwriters have been advised in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions by any person other than us relating to shares of common stock or other securities acquired from
the underwriters in this offering or open market transactions after the completion of the offering of the shares; provided that no filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), is
required or voluntarily made in connection with subsequent sales of the common stock or other securities acquired in this offering or such open market transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers by any person other than us of shares of common stock or other securities convertible into or
exercisable or exchangeable for common stock as a bona fide gift or for bona fide estate planning purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers by any person other than us of shares of common stock or any security convertible into common stock
to (i)&nbsp;a partnership, limited liability company or other entity which is controlled or managed by such person or the immediate family of such person or under common control of such person, (ii)&nbsp;to any trust for the direct or indirect
benefit of such person or the immediate family of the such person or, if such person is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust or (iii)&nbsp;if such person is a corporation, partnership,
limited liability company, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
trust or other business entity, transfers to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated
under the Securities Act of 1933, as amended) of such person, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with such person or affiliates of such person (including, for the
avoidance of doubt, where such person is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">distributions of shares of common stock or any security convertible into common stock to limited partners or
stockholders of such person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of common stock or other securities convertible into or exercisable or exchangeable for
common stock by operation of law, pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to a nominee or a custodian of a person or entity to whom a disposition or transfer would be
permissible under clauses (c) through (g) set forth above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to us by any person other than us of shares of common stock or any security convertible into or
exercisable or exchangeable for common stock in connection with the repurchase by the Company from such person of shares of common stock or any security convertible into or exercisable or exchangeable for common stock pursuant to a repurchase right
arising in connection with the termination of such person&#146;s employment with or provision of services to the Company, provided that (i)&nbsp;any such shares of common stock or any such security are held by such person pursuant to an agreement or
equity award granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the prospectus and (ii)&nbsp;any public announcement or filing under the Exchange Act shall clearly indicate in the
footnotes thereto that such transfer is being made pursuant to the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to us by any person other than us of shares of common stock or any security convertible into or
exercisable or exchangeable for common stock upon a vesting event of the Company&#146;s securities, the settlement of restricted stock units, or the exercise of options or warrants to purchase the Company&#146;s securities on a &#147;cashless&#148;
or &#147;net exercise&#148; basis to the extent permitted by the instruments representing such options, restricted stock units or warrants (and any transfer to the Company necessary to generate such amount of cash needed for the payment of taxes,
including estimated taxes, due as a result of such vesting, settlement or exercise whether by means of a &#147;net settlement&#148; or otherwise) so long as such &#147;cashless exercise&#148; or &#147;net exercise&#148; is effected solely by the
surrender of outstanding options, warrants or restricted stock units (or the common stock issuable upon the exercise or settlement thereof) to us and our cancellation of all or a portion thereof to pay the exercise price and/or withholding tax and
remittance obligations, provided that (i)&nbsp;any such shares of common stock received upon such exercise, vesting or settlement shall be subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (ii)&nbsp;any such
restricted stock units, options, warrants or rights are held by such person pursuant to an agreement or equity award granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in this prospectus,
and provided further that (iii)&nbsp;any public announcement or filing under the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers by any person than us of shares of common stock or any security convertible into or exercisable or
exchangeable for common stock pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the board of directors and made to all holders of our capital stock involving a change of control,
provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the common stock or securities convertible into or exercisable or exchangeable for common stock held by such person shall remain
subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">facilitating the establishment of a trading plan on behalf of a shareholder, officer or director of the Company
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
provided that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act,
if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the
restricted period, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that in the case of any transfer or distribution pursuant to clauses (d)&nbsp;through (h)
above, (i)&nbsp;each donee, distributee or transferee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of the agreement signed by the donor, distributor or transferor, (ii)&nbsp;such
transfer or distribution shall not involve a disposition for value and (iii)&nbsp;any filing under the Exchange Act reporting a reduction in beneficial ownership of shares of common stock that is required to be made or shall be voluntarily made
during the restricted period shall indicate by footnote disclosure or otherwise the nature of such transfer or disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan
Stanley&nbsp;&amp; Co. LLC and BofA Securities, Inc., in their sole discretion, may release the common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or
otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no
greater than the number of shares available for purchase by the underwriters under the over-allotment option described above. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the
open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters
may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if
the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this
offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels
or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters
and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the
accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates
may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities
and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price was determined by negotiations
between us and the representatives. Among the factors considered in determining the initial public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating
information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited
investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to,
the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to
each Member State of the European Economic Area (each, a &#147;Member State&#148;), no securities have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation
to the securities which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus
Regulation, except that offers of securities may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Regulation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation), subject to obtaining the prior consent of the representatives; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of
the representatives and us that it is a &#147;qualified investor&#148; as defined in the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares
being offered to a financial intermediary as that term is used in Article 5 of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have
not been acquired on a nondiscretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in
a Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any Member State
means the communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, the expression &#147;Prospectus Regulation&#148;<B> </B>means
Regulation (EU) 2017/1129, as amended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of the shares of our common stock
in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) (the
&#147;FIEL&#148;) has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or indirectly,
offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration
requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Qualified
Institutional Investors (&#147;QII&#148;) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph 2, Article 4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article <FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation,
as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock. The shares of common stock may only be transferred to QIIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the shares of common stock constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as described in Paragraph 4, Article
<FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock. The shares of
common stock may only be transferred en bloc without subdivision to a single investor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP. Certain legal matters
will be passed upon for the underwriters by Davis, Polk&nbsp;&amp; Wardwell, LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements included in this Registration Statement have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent
registered public accounting firm, as stated in their report appearing herein. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom90195_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under
the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits
and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the
contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other
document filed as an exhibit to the registration statement. Upon completion of this offering, we will be required to file periodic reports, proxy statements, and other information with the Securities and Exchange Commission pursuant to the
Securities Exchange Act of 1934. The Securities and Exchange Commission maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the Securities and Exchange
Commission. The address of that site is <I>www.sec.gov</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom90195_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin90195_1">Independent Registered Public Accountant&#146;s
Report</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin90195_2">Financial Statements as of and for the Years Ended December&nbsp;
31, 2018, 2019 and 2020</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin90195_3">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin90195_4">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin90195_5">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin90195_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin90195_7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin90195_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the shareholders and the Board of Directors of Sight Sciences, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Sight Sciences, Inc. and subsidiary (the &#147;Company&#148;) as of December&nbsp;31, 2020, 2019, and 2018, the related consolidated statements of operations and comprehensive loss, redeemable convertible
preferred stock and stockholders&#146; deficit, and cash flows for each of the three years in the period ended December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended
December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards&nbsp;of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to
obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;9, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s
auditor since 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin90195_2"></A>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin90195_3"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease ROU assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock, and Stockholders&#146;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred Stock, $0.001 par value; 7,413,965, 9,894,056, and 14,241,390 shares
authorized as of December&nbsp;31, 2018, 2019, and 2020, respectively; 7,356,822, 9,804,640, and 12,767,202 shares issued and outstanding as of December&nbsp;31, 2018, 2019 and 2020, respectively; aggregate liquidation preference of
$34.5&nbsp;million, $65.2&nbsp;million, and $118.6&nbsp;million as of December&nbsp;31, 2018, 2019, and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock par value of $0.001 per share&#151;16,000,000 shares authorized at December&nbsp;31,
2018, 17,000,000 shares authorized at December&nbsp;31, 2019, and 21,831,000 shares authorized at December&nbsp;31, 2020; 4,596,003 shares issued and outstanding at December&nbsp;31, 2018, 4,659,733 shares issued and outstanding as of
December&nbsp;31, 2019, and 4,754,591 shares issued and outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin90195_4"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general, and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share outstanding attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (3.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding used in computing net loss per share attributable to
common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,611,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,693,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,678,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and
diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:230pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin90195_5"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,068,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,541,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $46</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,288,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,356,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,596,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series D redeemable convertible preferred stock, net of issuance costs of $647</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,447,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,804,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,659,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series E redeemable convertible preferred stock, net of issuance costs of $106</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series F redeemable convertible preferred stock, net of issuance costs of $219</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,062,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock upon exercise of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,767,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,754,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin90195_6"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of debt discount and amortization of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Provision for doubtful accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Provision for excess and obsolete inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Noncash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from Paycheck Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(735</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the issuance of debt (Term Loan)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments of costs related to initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the issuance of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series C issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the issuance of Series&nbsp;D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series D issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the issuance of Series&nbsp;E redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series E issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the issuance of Series&nbsp;F redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series F issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from exercise of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net change in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">End of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental noncash disclosure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisition of property and equipment included in accounts payable and accrued liabilities</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unpaid initial public offering costs in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGHT SCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin90195_7"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. Company and Nature of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description
of Business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sight Sciences, Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware in 2010. The Company is an
ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company&#146;s surgical glaucoma product portfolio features the OMNI
Surgical System, a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. The Company&#146;s nonsurgical dry eye product portfolio consists of the TearCare<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is located and headquartered in Menlo Park, California. The other office operated by the Company is in Southlake, Texas. All of
the Company&#146;s current operations are conducted in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has incurred losses and negative cash flows from operations. As of December&nbsp;31, 2020, the Company had an
accumulated deficit of $90.0&nbsp;million and recorded a net loss of $34.7&nbsp;million for the year then ended and expects to incur future additional losses. If the Company&#146;s revenue levels from its products are not sufficient or if the
Company is unable to secure additional funding when desired, the Company may need to delay the development of its products and scale back its business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months
from the issuance of its financial statements. Failure to generate sufficient revenues, achieve planned gross margins, or control operating costs will require the Company to raise additional capital through equity or debt financing. Such additional
financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its
business, operating results, financial condition, and ability to achieve its intended business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2020, the
World Health Organization declared the coronavirus disease 2019 <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> outbreak a global pandemic recommending containment measures worldwide. On March&nbsp;16, 2020 the Company implemented
alternative work arrangements for its employees and limited its employees&#146; travel activities to protect its employees and to comply with the provisions described within the local shelter in place order. Certain U.S. federal, state and local
governmental authorities issued other orders and directives, including restrictions on elective procedures and therapies, aimed at minimizing the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> As such, the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacted and is expected to continue to impact demand for the Company&#146;s products, which are used in procedures and therapies that are considered elective. Although some of the
governmental restrictions have since been lifted or scaled back, recent and future surges of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may result in restrictions being <FONT STYLE="white-space:nowrap">re-implemented</FONT> in response to
efforts to reduce the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ultimate impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s operations is unknown and will depend on future developments which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak, the status of health and safety actions taken to contain its spread and any additional preventative and protective actions that governments, or the Company, may direct, any resurgence of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> that may occur and how quickly and to what extent economic and operating conditions normalize within the markets in which the Company operates. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
could disrupt the operations of the Company&#146;s third-party manufacturers and other suppliers. Although the Company has not experienced disruptions in its supply chain to date, it cannot predict how long the pandemic and measures
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intended to contain the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> will continue and what effect <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the associated containment
measures will have on our suppliers and vendors, in particular for any of the Company&#146;s suppliers and vendors that may not qualify as essential businesses and suffer more significant disruptions to their business operations. The Company is
working closely with its manufacturing partners and suppliers to help ensure the Company is able to source key components and maintain appropriate inventory levels to meet customer demand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP). The Company&#146;s consolidated financial statements include the accounts of the Company and
its wholly owned subsidiary, Sight Sciences UK, Ltd. All intercompany balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of
Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with US&nbsp;GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most
significant estimates related to inventory excess and obsolescence, the selection of useful lives of property and equipment, determination of the fair value of stock option grants, the fair value of the redeemable convertible preferred stock
warrants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when
facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Company&#146;s financial
position and results of operations.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share data has been computed to give effect to an adjustment to the denominator in the
pro forma basic and diluted net loss per share calculation for the conversion of the redeemable convertible preferred stock into shares of common stock as of the beginning of the period or the date of issuance, if later. The numerator in the pro
forma basic and diluted net loss per share calculation has been adjusted to remove gains or losses resulting from the remeasurement of the redeemable convertible preferred stock warrant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities,
redeemable convertible preferred stock, short-term and long-term debt and redeemable convertible preferred stock warrant liability. The Company states accounts receivable, accounts payable, and accrued and other current liabilities at their carrying
value, which approximates fair value due to the short time to the expected receipt or payment. The carrying amount of the Company&#146;s short-term debt approximates its fair value as the effective interest rate approximates market rates currently
available to the Company. The redeemable convertible preferred stock warrant liability associated with the Company&#146;s redeemable convertible preferred stock is carried at fair value based on unobservable market inputs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable.
The Company&#146;s cash and cash equivalents are deposited with a high-quality </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial institution. Deposits at this institution may, at times, exceed federally insured limits. Management believes that this financial institution is financially sound and, accordingly, that
minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies
on third-party contract manufacturers for the manufacture of all of our commercial products currently available for sale. Disruption in production would have a negative impact on the Company&#146;s financial position, results of operations and cash
flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes
historical bad debt trends, customer creditworthiness, current economic trends, and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s accounts receivable are due from a variety of health care organizations. At December&nbsp;31, 2018, 2019 and 2020, no
customer represented 10% or more of the Company&#146;s accounts receivable. For the years ended December&nbsp;31, 2018, 2019 and 2020, there were no customers that represented 10% or more of revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred
offering costs, consisting of legal, accounting and other fees and costs relating to the Company&#146;s planned IPO, are capitalized and recorded on the balance sheet. The deferred offering costs will be offset against the proceeds received upon the
closing of the planned IPO. In the event that the Company&#146;s plans for an IPO are terminated, all of the deferred offering costs will be written off within operating expenses in the Company&#146;s statements of operations and comprehensive loss.
As of December&nbsp;31, 2020, deferred offering costs of $0.4&nbsp;million were capitalized and are included in &#147;Other noncurrent assets&#148;. There were no deferred offering costs capitalized as of December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash and cash equivalents. Cash and cash equivalents are recorded at cost, which approximate fair value. As of December&nbsp;31,
2018, 2019 and 2020, cash consists primarily of checking and savings deposits. The Company&#146;s cash balances exceed those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable and Provision for Doubtful Accounts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable are stated at invoiced amounts, net of estimated provisions for doubtful accounts. The majority of customers are not
extended credit and, therefore, time to maturity for receivables is short. The Company makes estimates of the collectability of customer accounts and provisions based primarily on analysis of historical trends and experience and changes in
customers&#146; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records a provision against amounts due to reduce the receivable to the amount that is expected to be collected. These
specific provisions are reevaluated and adjusted as additional information is received that impacts the amount reserved. To date, the Company has not experienced material credit-related losses. The provision for doubtful accounts was
$0.1&nbsp;million, $0.1&nbsp;million and $0.3&nbsp;million as of December&nbsp;31, 2018, 2019 and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory represents finished goods purchased from a third-party manufacturer and is valued at the lower of cost or net realizable value. Cost
is determined using actual costs on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> basis for all inventory. Net realizable value is determined as the estimated selling prices in the ordinary
course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company regularly reviews </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inventory quantities in consideration of actual loss experiences, projected future demand, and remaining shelf life to record a provision for excess and obsolete inventory when appropriate. The
Company&#146;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected lower of cost or net realizable value, and inventory in excess of expected requirements. The estimate of excess
quantities is judgmental and primarily dependent on the Company&#146;s estimates of future demand for the particular product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and
Equipment, net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are recorded at cost, less accumulated depreciation. Repairs and maintenance costs are
expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, typically two to five years. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are
removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Construction-in-process</FONT></FONT> assets consist primarily of tools and equipment that have not yet been placed in service. These assets are stated at cost and are not depreciated. Once
the assets are placed into service, assets are reclassified to the appropriate asset class based on their nature and depreciated in accordance with the useful lives above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses long-lived assets, including property and equipment, whenever events or changes in business circumstances indicate that
the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the assets and their eventual
disposition are less than their carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived assets exceeds their fair value. Fair value is determined through various valuation techniques, including
discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. The Company did not record any impairment of long-lived assets for the years ended December&nbsp;31, 2018, 2019 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contractual arrangements
that meet the definition of a lease are classified as operating or finance leases and are recorded on the balance sheets as both a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset (&#147;ROU
asset&#148;) and lease liability, calculated by discounting fixed lease payments over the lease term at the Company&#146;s incremental borrowing rate (&#147;IBR&#148;). Lease ROU assets and lease obligations are recognized based on the present value
of the future minimum lease payments over the lease term at commencement date. The Company currently does not have any finance leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease ROU assets are adjusted for (i)&nbsp;payments made at or before the commencement date, (ii)&nbsp;initial direct costs
incurred, and (iii)&nbsp;tenant incentives under the lease. As the implicit rates for the operating leases are not determinable, the Company uses an IBR based on the information available at the respective lease commencement dates to determine the
present value of future payments. IBR represents the interest rate that the Company would expect to incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis with similar terms and payments, in an economic
environment where the leased asset is located. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably certain the Company will exercise any
option to extend the contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease costs for minimum lease payments for operating leases are recognized on a straight-line basis over
the lease term. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is amortized over the lease term. Variable lease payments that do not depend on an index or rate are recognized as lease costs when
incurred. In measuring the ROU assets and lease liabilities, the Company has elected to combine </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. The Company does not recognize ROU assets or lease liabilities for short-term leases, if any, having initial terms of 12
months or less at lease commencement as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term for these types of leases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred stock warrants require liability classification and accounting as the underlying redeemable
convertible preferred stock is considered contingently redeemable and may obligate the Company to transfer assets to the holders at a future date upon occurrence of a deemed liquidation event. The warrants are recorded at fair value upon issuance
and are subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized as other expense in the statements of operations. The warrants liability is recorded as other noncurrent liabilities in the balance
sheets. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise or expiration of the redeemable convertible preferred stock warrants, occurrence of a deemed liquidation event, or
conversion of redeemable convertible preferred stock into common stock. At that time, the liability associated with the redeemable convertible preferred stock warrants that are converted into warrants to purchase common stock will be reclassified to
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, while the liability associated with any expired warrants will be recognized as a gain within the statements of operations and comprehensive loss. As a result, the redeemable
convertible preferred stock warrant liability will be settled and will no longer be subject to remeasurement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred
Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance
costs. A redemption event will only occur upon the liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, a greater than 50% change in control, or sale of substantially all of the assets of the Company. In the event of a
change of control of the Company, proceeds received from the sale of such shares will be distributed in accordance with the liquidation preferences set forth in the Company&#146;s amended and restated certificate of incorporation, unless the holders
of redeemable convertible preferred stock otherwise agree or have converted their shares into shares of common stock. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#146; equity in the balance sheets as
events triggering the liquidation preferences are not solely within the Company&#146;s control. The Company is not required to adjust the carrying values of the redeemable convertible preferred stock to the redemption value of such shares since it
is uncertain whether or when a redemption event will occur. Subsequent adjustments to increase the carrying values to the redemption values will be made only when it becomes probable that such redemption will occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Warrant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s common stock warrant is classified in equity as it meets all criteria for equity classification. The fair value of the common stock warrant was calculated using the BackSolve Method and is recorded at fair value upon issuance in
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital in the consolidated balance sheets. The common stock warrant is not remeasured after the issuance date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its arrangements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify the contract with a customer, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify the performance obligations in the contract, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Determine the transaction price, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Allocate the transaction price to performance obligations in the contract, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recognize revenue as the performance obligations are satisfied. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenue is generated from the sale of its products from its surgical
glaucoma product portfolio and its nonsurgical dry eye product portfolio to hospitals and medical centers in the United States and elsewhere through sales representatives and distributors. The Company&#146;s contracts are in the form of a
combination of signed agreements and/or purchase orders. The Company accounts for a contract with a customer when there is approval and commitment from both parties, the rights and obligations of the parties are identified, payment terms are
identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it will be entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Company&#146;s surgical glaucoma and dry eye products specified in the contract represents a distinct good and is accounted for as
separate performance obligation. Revenue is recognized when control of promised goods is transferred to a customer in amount that reflects the consideration that the Company expects to receive in exchange for those goods. Control of the
Company&#146;s products are transferred to its customers at a point in time, either upon shipment or delivery of the product to the customer under the Company&#146;s standard terms and conditions. The customer is able to direct the use of, and
obtain substantially all of the benefits from, the product at the time the product shipped or delivered. The Company considers control to have transferred upon shipment or delivery because the Company has a present right to payment at that time, the
customer has legal title to the asset, the Company has transferred physical possession of the asset, the customer has accepted the asset, and the customer has significant risks and rewards of ownership of the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Company&#146;s contracts are typically due within 30 days of transfer of control of the Company&#146;s products to its
customers. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company does not accept product returns, unless the item is defective as manufactured. The Company
establishes provisions for estimated returns and warranties. In addition, the Company does not typically provide customers with the right to a refund. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Practical Expedients and Exemptions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s contracts all have an original duration of one year or less. As a practical expedient, the Company does not consider the
time value of money for such contracts. Further, because of the short duration of these contracts, the Company does not disclose the transaction price for the remaining performance obligations as of the end of each reporting period or the when the
Company expects to recognize this revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses shipping and handling costs as incurred and includes them in the cost of
goods sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a practical expedient, the Company recognizes the incremental costs of obtaining contracts, such as sales commissions, as an expense when
incurred since the amortization period of the asset the Company otherwise would have recognized is one year or less. Sales commissions are recorded within selling, general, and administrative expenses in the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Goods Sold </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
purchases its products from third-party manufacturers. Cost of goods sold consists primarily of costs related to materials, manufacturing overhead costs, reserves for excess, and obsolete and <FONT STYLE="white-space:nowrap">non-sellable</FONT>
inventories. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs, such as shipping and handling costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company expenses research and development costs as incurred. Research and development expenses consist primarily of product development, clinical studies to develop and support the Company&#146;s products,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory expenses, medical affairs, and other costs associated with products and technologies that are in development. Research and development expenses include employee compensation, including
stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation, and an allocation of facility overhead expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management,
finance administration, and human resources; facility costs (including rent); bad debt costs; professional service fees; and other general overhead costs, including depreciation to support the Company&#146;s operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advertising Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
expenses advertising costs as incurred. Advertising expenses for fiscal 2018, 2019 and 2020 were $1.0&nbsp;million, $1.8&nbsp;million and $0.8&nbsp;million, respectively, included in selling, general, and administrative expenses in the statements of
operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting for Payroll Protection Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, Congress established the Paycheck Protection Program (&#147;PPP&#148;) to provide relief to small businesses during <FONT
STYLE="white-space:nowrap">COVID-19</FONT> as part of the Coronavirus Aid, Relief, and Economic Security (&#147;CARES&#148;) Act. The legislation authorized the U.S. Treasury to use the Small Business Association&#146;s (&#147;SBA&#146;s&#148;)
small business lending program to fund forgivable loans that qualifying businesses could spend to cover payroll, mortgage interest, rent, and utilities during the &#147;Covered Period&#148; defined as the
<FONT STYLE="white-space:nowrap">8-week</FONT> period starting on the date the PPP loan proceeds are received. Upon meeting certain criteria as specified in the PPP program, the loans are eligible for partial or total forgiveness. In May 2020, the
Company applied for and received a PPP loan for the amount $2.2&nbsp;million from SBA. We believe we have satisfied all of the terms and conditions of the PPP loan and applied for loan forgiveness in September 2020. We expect a decision from the SBA
on loan forgiveness in the second quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. GAAP does not contain authoritative accounting standards for forgivable loans
provided by governmental entities to a <FONT STYLE="white-space:nowrap">for-profit</FONT> entity. Absent authoritative accounting standards, interpretative guidance issued and commonly applied by financial statement preparers allows for the
selection of accounting policies amongst acceptable alternatives. The Company determined it most appropriate to account for the PPP loan proceeds as an <FONT STYLE="white-space:nowrap">in-substance</FONT> government grant by analogy to International
Accounting Standards 20 (&#147;IAS 20&#148;) <I>Accounting for Government Grants and Disclosure of Government Assistance</I>. Under this guidance, a forgivable loan from government is treated as a government grant when there is reasonable assurance
that the entity will meet the terms for forgiveness of the loan. While IAS 20 does not define &#147;reasonable assurance&#148;, this concept in practice is analogous to &#147;probable&#148; as defined in Financial Accounting Standards Board
(&#147;FASB&#148;) ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">450-20-20</FONT></FONT> under U.S. GAAP, which is the definition the Company has applied to its expectations of PPP loan forgiveness. Under IAS 20, government
grants are recognized in earnings on a systematic basis over the periods in which the Company recognizes costs for which the grant is intended to compensate (i.e. qualified expenses). Further, IAS 20 permits for the recognition in earnings either
separately under a general heading such as other income, or as a reduction of the related expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has elected to recognize
this government grant income as a reduction of the related expenses, and recognized $0.1&nbsp;million, $0.3&nbsp;million and $1.8&nbsp;million as a reduction of cost of revenue, research and development and selling, general and administrative
expenses, respectively for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined on the
date of grant. The Company recognizes stock-based compensation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expense over the requisite service period of the individual grant, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation, and accounts for
forfeitures as they occur. The Company selected the Black-Scholes-Merton (&#147;Black-Scholes&#148;) option-pricing model as the method for determining the estimated fair value for stock options. The Black-Scholes option-pricing model requires the
use of highly subjective and complex assumptions, which determine the fair value of share-based awards, including the option&#146;s expected term, expected volatility of the underlying stock, risk-free interest rate and expected dividend yield. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
fair value of the Company&#146;s common stock is determined by the board of directors with assistance from management and, in part, on input from an independent third-party valuation firm. The board of directors determines the fair value of common
stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#146;s common
stock and the general and industry-specific economic outlook.<I> </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Currency Remeasurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign currency transaction gains and losses are recorded in other expense, net in the Company&#146;s statements of operations and such
amounts have not been material for all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method under ASC 740, <I>Income Taxes</I>, in accounting for income taxes. Deferred tax assets and
liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expenses or benefits are the result of changes in the deferred tax
assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to their net realizable value where it is more likely than not that the deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 740 clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit
from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon audit, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties related to unrecognized tax benefits within the benefit for income taxes line in the
accompanying statements of operations and comprehensive loss. Accrued interest and penalties are included within the related liability line in the balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive
loss represents all changes in stockholders&#146; deficit except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, there was no
difference between comprehensive loss and the Company&#146;s reported net loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net loss per share attributable to common stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the
<FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers all series of its redeemable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible preferred stock and restricted stock awards to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid
on common stock. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss attributable to common stockholders is not allocated to the redeemable convertible preferred stock or restricted stock awards as the holders of the
Company&#146;s redeemable convertible preferred stock and restricted stock awards do not have a contractual obligation to share in losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common
stockholders by the weighted-average number of common shares outstanding for the period without consideration of potentially dilutive securities. The Company&#146;s potentially dilutive shares, which consist of outstanding common stock options,
restricted stock awards, common stock warrants, redeemable convertible preferred stock and redeemable convertible preferred stock warrants were excluded in the computation of diluted net loss per share for the period as the result would be
anti-dilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging growth company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012. As such the Company is
eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards
for public business entities. The Company has elected to avail themselves of this exemption and, therefore, will not be subject to the timeline for adopting new or revised accounting standards for public business entities that are not emerging
growth companies, and will follow the transition guidance applicable to private companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09.</FONT> Subsequently, the FASB also issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2015-14,</FONT> <I>Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</I>, which adjusted the effective date of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09;</FONT> ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-08,</FONT> <I>Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)</I>, which amends the principal versus agent implementation guidance
and illustrations in ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09;</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-10,</FONT> <I>Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and
Licensing</I>, which clarifies identifying performance obligation and licensing implementation guidance and illustrations in ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09;</FONT> and ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2016-12,</FONT> <I>Revenue from Contracts with Customers (Topic</I><I></I><I>&nbsp;606): Narrow-Scope Improvements and Practical Expedients</I>, which addresses implementation issues and is intended to
reduce the cost and complexity of applying the new revenue standard in ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09</FONT> (collectively, the &#147;Revenue ASUs&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue ASUs provide an accounting standard for a single comprehensive model for use in accounting for revenue arising from contracts with
customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December&nbsp;15, 2019. The guidance permits two methods of adoption: retrospectively to each
prior reporting period presented (the full retrospective method) or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company
performed a detailed review of its revenue agreements and assessed the differences in accounting for such contracts under this guidance compared with previous revenue accounting standards. On January&nbsp;1, 2018, the Company early adopted ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2014-09</FONT> using the full retrospective method. The adoption of this standard did not have a material impact on the Company&#146;s financial statements. Results for all periods presented are under ASC 606.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued an ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Compensation&#151;Stock Compensation
(Topic</I><I></I><I>&nbsp;718): Improvements to Employee Share-Based Payment Accounting</I>, to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact and classification on the statements of
cash flows. The Company adopted this update on January&nbsp;1, 2018 and elected to record forfeitures as they occur. The adoption of this update was immaterial to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued an ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>, that expands the scope to include share-based payment transactions for
acquiring goods and services from nonemployees. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees,
with certain exceptions. This update is required to be applied through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. This guidance is effective for fiscal years beginning after
December&nbsp;15, 2018, including interim periods within that fiscal year. Early adoption is permitted for any entity in any interim or annual period for which financial statements have not been issued or made available for issuance, but not before
an entity adopts ASC 606. The Company early adopted the standard on January&nbsp;1, 2018, which did not result in a material impact on its financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842)</I>. In July 2018, the
FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-10,</FONT> <I>Codification Improvements to Topic 842, Leases</I>, which provides clarification to ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02.</FONT> These ASUs require an
entity to recognize a lease liability and a ROU asset in the balance sheets for leases with lease terms of more than 12&nbsp;months. Lessor accounting is largely unchanged, while lessees will no longer be provided with a source of <FONT
STYLE="white-space:nowrap">off-balance-sheet</FONT> financing. This guidance is effective for fiscal years beginning after December&nbsp;15, 2021, and for interim periods within fiscal years beginning after December&nbsp;15, 2022. In July 2018, the
FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT> <I>Leases (Topic 842): Targeted Improvements</I>, which allows entities to elect a modified retrospective transition method where entities may continue to apply the existing
lease guidance during the comparative periods and apply the new lease requirements through a cumulative effect adjustment in the period of adoptions rather than in the earliest period presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2019, the Company early adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02</FONT> and its associated amendments
using the modified retrospective transition method by applying the new update to all leases existing at the date of initial application and not restating comparative periods. There was no cumulative effect adjustment recorded to retained earnings
upon adoption. Under the update, a lessee is required to recognize a lease liability and ROU asset for all leases. The new guidance also modified the classification criteria and requires additional disclosures to enable users of financial statements
to understand the amount, timing, and uncertainty of cash flows arising from leases. Consistent with current guidance, a lessee&#146;s recognition, measurement, and presentation of expenses and cash flows arising from a lease continues to depend
primarily on its classification. The Company elected the package of practical expedients permitted under the transition guidance, which allowed the Company to carry forward its historical lease classification, its assessment on whether a contract
was or contains a lease, and its initial direct costs for any leases that existed prior to January&nbsp;1, 2019. In addition, the Company elected the short-term lease exception and combined lease and <FONT STYLE="white-space:nowrap">non-lease</FONT>
components as practical expedients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption of this guidance did not materially impact the Company&#146;s consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement
(Topic</I><I></I><I>&nbsp;820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I>, which changed the disclosure requirements for fair value measurements by removing, adding, and modifying certain
disclosures. The Company adopted this ASU beginning on January&nbsp;1, 2020 which did not result in a material impact on the disclosures related to fair value measurements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic
326): Measurement of Credit Losses on Financial Instruments</I>, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments,
including trade receivables and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities. The guidance is effective for the Company beginning in the first quarter of 2023. The Company is
evaluating the impact of adopting this guidance and does not expect to have a material impact on the Company&#146;s financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>, that simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for
intra-period tax allocation and modified the methodology for calculating income taxes in an interim period. It also clarifies and simplifies other aspects of the accounting for income taxes. The guidance is effective for the Company for fiscal years
beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022 with early adoption permitted. The Company is evaluating the effect this new guidance and does not expect it to have material
impact on the Company&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2020-04,</FONT> <I>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</I>. The new guidance provides optional expedients and exceptions for
applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The guidance also establishes
(1)&nbsp;a general contract modification principle that entities can apply in other areas that may be affected by reference rate reform and (2)&nbsp;certain elective hedge accounting expedients. The amendment is effective for all entities through
December&nbsp;31, 2022. LIBOR is used to calculate the interest on borrowings under the Company&#146;s term loan and revolving line of credit with MidCap Financial Services. The Company is evaluating the effect this new guidance and does not expect
it to have material impact on the Company&#146;s financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reports all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value
in the financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy
that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority
to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to
access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs are observable, unadjusted quoted prices in active markets for similar assets or
liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related
assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Inputs are unobservable inputs for the asset or liability. The level in the fair value hierarchy
within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of and for the years ended December&nbsp;31, 2018, 2019 and 2020, do not include any nonrecurring fair value
measurements relating to assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not have any assets and liabilities that are measured at fair value on a
recurring basis at December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value measurements of liabilities that are measured at fair value on a recurring basis at
December&nbsp;31, 2019 and 2020, are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As of December&nbsp;31, 2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>(Level&nbsp;1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>(Level&nbsp;2)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>(Level&nbsp;3)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrants liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As of December&nbsp;31, 2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>(Level&nbsp;1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>(Level&nbsp;2)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>(Level&nbsp;3)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrants liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the redeemable convertible preferred stock warrants using Level&nbsp;3 unobservable
inputs within the Black-Scholes option-pricing model. The key assumptions include the fair value of redeemable convertible preferred stock, volatility, the risk-free interest rate, expected term (remaining contractual term of the warrants) and
dividend yield. The Company has limited historical volatility information available, and the expected volatility was based on actual volatility for comparable public companies projected over the expected terms of the warrants. The Company did not
apply a forfeiture rate to the warrants as there is not enough historical information available to estimate such a rate. The risk-free interest rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the
warrants. Refer to Note 9 for the assumptions used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of outstanding debt for disclosure purposes on a
recurring basis. As of December&nbsp;31, 2019 and 2020, total debt of $12.9&nbsp;million and $31.9&nbsp;million is reported at amortized cost, respectively. This outstanding debt is classified as Level&nbsp;2 as it is not actively traded. The
amortized cost of the outstanding debt approximates the fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the fair value of the redeemable convertible
preferred stock warrants annually, with subsequent gains and losses from remeasurement of Level&nbsp;3 financial liabilities recorded through the other expense, net in statements of operations and other comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the changes in the fair value of the Company&#146;s Level&nbsp;3 financial
instruments at December&nbsp;31, 2019 and 2020, is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>convertible&nbsp;preferred<BR>stock&nbsp;warrant&nbsp;liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tools and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for fiscal 2018, 2019 and 2020 was $0.06&nbsp;million, $0.3&nbsp;million and
$0.5&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued and Other Current Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,767</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short term interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,086</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Noncurrent Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other noncurrent liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent portion of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable preferred stock warrants liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, the Company entered into a loan and security agreement with MidCap Financial Services, which provided a maximum of
$25.0&nbsp;million credit facility consisting of a $20.0&nbsp;million senior secured 2019 Term Loan and a $5.0&nbsp;million 2019 Revolver (collectively, the &#147;2019 MidCap Credit Facility&#148;). In November 2020, the Company entered into a loan
and security agreement with the same institution, which replaced the 2019 MidCap Credit Facility, and provided for a maximum of $40.0&nbsp;million credit facility consisting of a $35.0&nbsp;million senior secured 2020 Term Loan and a
$5.0&nbsp;million 2020 Revolver (collectively, the &#147;2020 MidCap Credit Facility&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2019 Term Loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Term Loan had a four-year term and had a stated floating interest rate which equates to reserve-adjusted LIBOR + 6.75%. The 2019 Term
Loan was split into three tranches as follows: (i)&nbsp;the Tranche One Loans provided for $12.0&nbsp;million in term loans, (ii)&nbsp;the Tranche Two Loans provided for up to $2.0&nbsp;million in term loans, and (iii)&nbsp;the Tranche Three Loans
provided for up to $6.0&nbsp;million in term loans. The Company borrowed $14.0&nbsp;million under the Tranche One Loans and Tranche Two Loans. While the conditions necessary to draw the Tranche Three Loans had been met as of December&nbsp;31, 2019,
the Company did not elect to draw the Tranche Three Term Loans. The 2019 Term Loan required 18 monthly <FONT STYLE="white-space:nowrap">interest-only</FONT> payments, which began on January&nbsp;31, 2019, followed by 30 equal monthly installments of
principal, plus interest. The interest-only period was extended by an additional six months upon achievement of the Tranche Three Milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Term Loan had an effective interest rate of 14.52% per year. The 2019 Term Loan interest expense for the year ended December&nbsp;31,
2019 and 2020 was $1.9&nbsp;million and $2.0&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the funding of Tranche 1 and Tranche 2 under
the 2019 Term Loan, the Company issued a <FONT STYLE="white-space:nowrap">10-year</FONT> warrant to the Lender to purchase 29,514&nbsp;shares of the Company&#146;s Series C redeemable convertible preferred stock (the &#147;2019 Initial
Warrant&#148;) at an exercise price of $9.49 per share (the &#147;Exercise Price&#148;). Further, depending on the funding of the Term Loan Tranche 3, the Company was obligated to issue an additional Warrant to the Lender to purchase up to 12,649
shares of Series C redeemable convertible preferred stock at the Exercise Price (the &#147;2019 Additional Warrant&#148; and together with &#147;2019 Initial Warrant&#148; the &#147;2019 Warrants&#148;) (see Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the 2019 Warrants of $0.2&nbsp;million upon draw down was based on the Black-Scholes option-pricing model and
probability of future draw downs. The 2019 Warrants were recorded at the fair value as a debt discount and as a warrant liability. The debt discount is being accreted using the effective interest method as interest expense over the contractual
period of four years for the Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred $1.5&nbsp;million of issuance costs in conjunction with the 2019 Term Loan.
The issuance costs have been netted against the borrowed funds in the consolidated balance sheet and is being accreted using the effective interest method as interest expense over the contractual period of four years for the 2019 Term Loan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company could voluntarily prepay the borrowings in full, with a prepayment premium
beginning at 3% in the first year from tranche funding and declining to 2% in the second year from tranche funding, to 1% in the third year from tranche funding thereafter. In addition, a final payment fee of 5% of the amounts borrowed is payable at
the end of the term or when the borrowings are repaid in full. A long-term liability was being accreted using the effective interest method for the final payment fee over the term of the loan agreement. The borrowings were collateralized by a
security interest in substantially all of the Company&#146;s assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrued $0.2&nbsp;million as of December&nbsp;31, 2019,
related to accretion of final payment due at maturity per agreement using the effective interest rate method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was subject to
financial covenants related to minimum trailing revenue targets that began on January&nbsp;1, 2019, and are tested on a monthly basis. If only Tranche One Loans were funded, the Company had to achieve minimum net revenue of $7&nbsp;million over a
trailing <FONT STYLE="white-space:nowrap">12-month</FONT> period increasing to a maximum net revenue covenant of $35&nbsp;million for the trailing <FONT STYLE="white-space:nowrap">12-month</FONT> period ending December&nbsp;31, 2022, and thereafter.
If only Tranche One Loans and Tranche Two Loans had been funded, the Company had to achieve minimum net revenue of $7&nbsp;million over a trailing <FONT STYLE="white-space:nowrap">12-month</FONT> period increasing to a maximum net revenue covenant
of $37.3&nbsp;million for the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending December&nbsp;31, 2022, and thereafter. If Tranche Three Loans had been funded regardless of whether Tranche Two Loans have been funded, the Company had to
achieve minimum net revenue of $15&nbsp;million over a trailing <FONT STYLE="white-space:nowrap">12-month</FONT> period increasing to a maximum net revenue covenant of $46.7&nbsp;million for the <FONT STYLE="white-space:nowrap">12-month</FONT>
period ending December&nbsp;31, 2022, and thereafter. As of December&nbsp;31, 2019, the Company was in compliance with the applicable financial covenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;23, 2020, the 2019 Term Loan was replaced with 2020 Term Loan (see below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2019 Revolver </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019
Revolver had a four-year term and has a stated floating interest rate which equates to reserve-adjusted LIBOR plus 4.25%. An unused line fee of 0.5% was payable monthly based on the average unused balance and a collateral management fee of 0.5% is
payable monthly based on the outstanding balance of the Revolver. The Company can request to increase the 2019 Revolver commitment amount to $10.0&nbsp;million under the term of the agreement. As of December&nbsp;31, 2019, $4.0&nbsp;million was
available to be drawn under the 2019 Revolver.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may voluntarily prepay the borrowings in full, with a
prepayment premium equal to an amount determined by multiplying the Revolver commitment amount by 3.0% in the first year, 2.0% in year 2, and 1.0% thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Revolver has not been drawn upon as of December&nbsp;31, 2019. On November&nbsp;23, 2020, the 2019 Revolver was replaced with the
2020 Revolver (see below). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2020 Term Loan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Term Loan has a five-year term and has a stated floating interest rate which equates to reserve-adjusted LIBOR + 7.00%. The 2020 Term
Loan is split into three tranches as follows: (i)&nbsp;the Tranche One Loans provide for $12.0&nbsp;million in term loans which are deemed to have been converted from Tranche One Loans that were drawn and outstanding under the 2019 Term Loan
immediately prior to entering into 2020 MidCap Credit Facility, (ii)&nbsp;the Tranche Two Loans provided for up to $2.0&nbsp;million in term loans which are deemed to have been converted from Tranche Two Loans that were drawn and outstanding under
the 2019 Term Loan immediately prior to entering into 2020 MidCap Credit Facility, and (iii)&nbsp;the Tranche Three Loans provided for up to $21.0&nbsp;million in new term loans. The Company borrowed $21.0&nbsp;million under the Tranche Three Loans
in November 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Term Loan requires 24 monthly <FONT STYLE="white-space:nowrap">interest-only</FONT>
payments, which began on December&nbsp;1, 2020, followed by 36 equal monthly installments of principal, plus interest. The interest-only period can be extended by an additional 12 months provided that the Company is in compliance with the minimum
trailing revenue targets (as described below), and has unrestricted cash and cash equivalents of at least 12 times of the amortization monthly cash burn amount, measured as defined in the 2020 Term Loan agreement (&#147;First IO Extension&#148;). If
the First IO Extension conditions are satisfied, the interest-only period can be further extended by an additional 12 months, provided that the Company is in compliance with the minimum trailing revenue targets (as described below), has unrestricted
cash and cash equivalents of at least 12 times of the amortization monthly cash burn amount, and has consummated an IPO in which the Company has received cash proceeds of at least $60.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Term Loan has an effective interest rate of 13.59% per year. The 2020 Term Loan interest expense for the year ended December&nbsp;31,
2020 was $0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the entering the 2020 MidCap Credit Facility, the Company issued a <FONT
STYLE="white-space:nowrap">10-year</FONT> warrant to the Lender to purchase 300,000&nbsp;shares of the Company&#146;s Series F redeemable convertible preferred stock (the &#147;2020 Warrant&#148;) at an exercise price of $21.88 per share (see Note
9). The estimated fair value at issuance of the 2020 Warrant of $1.8&nbsp;million was based on the Option-Pricing Method with Discounts for Lack of Marketability for each class of security. In addition, the Company incurred $0.5&nbsp;million of
issuance costs paid to the Lender in conjunction with the 2020 Term Loan which represents a debt discount. The Company concluded that the 2020 Term Loan represented a modification of the 2019 Term Loan and accounted for the 2020 Term Loan as debt
modification. The 2020 Warrants were recorded at the fair value as a debt discount and as a warrant liability. At each balance sheet date, the 2020 Warrants are remeasured to fair value with any changes in fair value recognized as other expense in
the statements of operations. The debt discount is being amortized using the effective interest method as interest expense over the contractual period of five years for the 2020 Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company can voluntarily prepay the borrowings in full, with a prepayment premium beginning at 3% in the first year from entering into the
2020 MidCap Credit facility and declining to 2% in the second year to 1% in the third year thereafter. In addition, a final payment fee of 6% of the amounts borrowed is payable at the end of the term or when the borrowings are repaid in full. A
long-term liability is being accreted using the effective interest method for the final payment fee over the term of the loan agreement. The borrowings are collateralized by a security interest in substantially all of the Company&#146;s assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrued $0.5&nbsp;million as of December&nbsp;31, 2020, related to accretion of final payment due at maturity per the agreement
using the effective interest rate method. The final payment accrual is recorded in &#147;Other noncurrent liabilities&#148; on the balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to financial covenants related to minimum trailing revenue targets that began on September&nbsp;30, 2020 and are tested
on a monthly basis. The Company has to achieve minimum net revenue of $20.0&nbsp;million over a trailing <FONT STYLE="white-space:nowrap">12-month</FONT> period increasing to a maximum net revenue covenant of $84.8&nbsp;million for the trailing <FONT
STYLE="white-space:nowrap">12-month</FONT> period ending October&nbsp;31, 2025. As of December&nbsp;31, 2020, the Company was in compliance with the applicable financial covenant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2020 Revolver </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020
Revolver has a four-year term and has a stated floating interest rate which equates to reserve-adjusted LIBOR plus 4.50%. An unused line fee of 0.5% is payable monthly based on the average unused balance and a collateral management fee of 0.5% is
payable monthly based on the outstanding balance of the 2020 Revolver. The Company can request to increase the 2020 Revolver commitment amount to $15.0&nbsp;million under the term of the agreement. As of December&nbsp;31, 2020, $4.8&nbsp;million was
available to be drawn under the 2020 Revolver.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2020 Revolver has not been drawn upon as of December&nbsp;31,
2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term and short-term debt was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total principal payments due</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: debt discount related to warrant liability and issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total amount outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The repayment schedule relating to the Company&#146;s debt as of December&nbsp;31, 2020, is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Lease Obligations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s leases mainly include facility leases and storage leases. In September 2019, the Company entered into a noncancelable operating lease for approximately 10,823 square feet of primary office space, which expires on July&nbsp;31, 2021,
without the option to extend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes rent expense on a straight-line basis over the noncancelable lease term. The
Company&#146;s rent expense was $0.2&nbsp;million, $0.3&nbsp;million and $0.7&nbsp;million for the years ended December&nbsp;31, 2018, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted Topic 842 as of January&nbsp;1, 2019. In determining the present value of lease payments, the Company uses its incremental
borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. At the date of adoption of Topic 842, the Company determined the amounts of lease liability using a
discount rate of 16.4%, which represents the Company&#146;s incremental borrowing rate, which is based on the Company&#146;s current borrowing rate adjusted for various factors including level of collateralization and term. As of December&nbsp;31,
2020, the remaining lease term for the lease was 3.4 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease expense recognized and supplemental cash flow information
related to operating leases for the year ended December&nbsp;31, 2019 and 2020 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New operating lease assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019 and 2020, the Company&#146;s costs related to
short-term lease arrangements and <FONT STYLE="white-space:nowrap">non-lease</FONT> variable payments were immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum
lease payments at December&nbsp;31, 2018, under the noncancelable operating lease were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aggregate future minimum lease payments at December&nbsp;31, 2019 and 2020, under these noncancelable
operating leases were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion of operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities&#151;noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to claims and assessments from time to time in the ordinary course of business. Accruals for litigation and
contingencies are reflected in the financial statements based on management&#146;s assessment, including the advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings, and/or the expected resolution of
contingencies. Liabilities for estimated losses are accrued if the potential losses from any claims or legal proceedings are considered probable and the amounts can be reasonably estimated. Significant judgment is required in both the determination
of probability of loss and the determination as to whether the amount can be reasonably estimated. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information
becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company&#146;s results of operations in a given period. As of
December&nbsp;31, 2018, 2019 and 2020, the Company was not involved in any material legal proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and
provide for general indemnifications. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any
claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company indemnifies each of its directors and officers for certain events or
occurrences, subject to certain limits, while the director is or was serving at the Company&#146;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the
indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company
currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company&#146;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these
indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December&nbsp;31, 2018, 2019, and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has the following redeemable convertible preferred stock issued and outstanding at December&nbsp;31, 2018 (in thousands, except
share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Issued and<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Original<BR>Issuance<BR>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Liquidation<BR>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Issuance<BR>Costs</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Carrying<BR>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,804,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,804,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,209,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,209,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,342,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7,413,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7,356,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">34,476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">34,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has the following redeemable convertible preferred stock issued and outstanding at
December&nbsp;31, 2019 (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Issued and<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Original<BR>Issuance<BR>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Liquidation<BR>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Issuance<BR>Costs</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Carrying<BR>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,804,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,804,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,209,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,209,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,372,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,342,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">22,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">22,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,507,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,447,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">12.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9,894,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9,804,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">65,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">64,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has the following redeemable convertible preferred stock issued and outstanding at
December&nbsp;31, 2020 (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Authorized</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Issued and<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Original<BR>Issuance<BR>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Liquidation<BR>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Issuance<BR>Costs</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Carrying<BR>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,804,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3,804,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,209,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,209,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,372,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,342,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">9.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">22,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">22,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,507,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,447,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">12.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">30,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">30,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,921,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,899,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">15.87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">30,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">30,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,425,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,062,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">23,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">219</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">23,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">14,241,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">12,767,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;118,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;117,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and preferences of holders of the redeemable convertible preferred stock are as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of each share of redeemable convertible preferred stock has the voting rights equal to an equivalent number of shares of common
stock into which it is convertible and votes together as a single class with common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Election of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of the Shares of Series A, Series B, Series C and Series D redeemable convertible preferred stock, voting separately
as a single class, are entitled to each elect one director of the Company. The holders of a majority of the shares of Series E and Series F redeemable convertible preferred stock, voting together as a single class, are entitled to elect one director
of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series A, Series B, Series C, Series D, Series E and Series F redeemable convertible preferred stock are entitled to receive
dividends declared by the board of directors in proportion to the numbers of shares of common stock, which are held by each holder if all shares of such series of redeemable convertible preferred stock were converted to common stock at the
then-effective conversion rate of each series of redeemable convertible preferred stock. No dividends shall be paid on any common stock (other than dividends on shares of common stock payable in shares of common stock) until dividends to the holders
of the redeemable convertible preferred stock have been paid. As of December&nbsp;31, 2020, no dividends have been declared to date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the event of any liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, either voluntary or involuntary, the holders of Series F, Series E and Series D redeemable convertible<B><I> </I></B>preferred stock
shall be entitled to receive on a pari passu basis among each other, prior to and in preference to any distribution of any of the assets to the holders of Series C redeemable convertible<B><I> </I></B>preferred stock, Series B redeemable
convertible<B><I> </I></B>preferred stock, Series A redeemable convertible<B><I> </I></B>preferred stock, and the common stock of the Company, an amount per share equal to the sum of the original issue price of the redeemable convertible preferred
stock and all declared and unpaid dividends on such shares of redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment of all
preferential amounts required to be paid to the holders of Series D redeemable convertible preferred stock, the holders of Series C redeemable convertible preferred stock<B><I> </I></B>shall be entitled to receive, prior to and in preference to any
distribution of any of the assets to the holders of Series&nbsp;B redeemable convertible<B><I> </I></B>preferred stock, Series A redeemable convertible<B><I> </I></B>preferred stock, and the common stock of the Company, an amount per share equal to
the sum of the original issue price of the redeemable convertible preferred stock and all declared and unpaid dividends on such shares of redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment of all preferential amounts required to be paid to the holders of Series C redeemable convertible<B><I> </I></B>preferred
stock, the holders of Series B shall be entitled to receive, prior to and in preference to any distribution of any of the assets to the holders of Series&nbsp;A redeemable convertible<B><I> </I></B>preferred stock and the common stock of the
Company, an amount per share equal to the sum of the original issue price of the redeemable convertible preferred stock and all declared and unpaid dividends on such shares of redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment of all preferential amounts required to be paid to the holders of Series B redeemable convertible<B><I> </I></B>preferred
stock, the holders of Series A shall be entitled to receive, prior to and in preference to any distribution of any of the assets to the holders of common stock of the Company, an amount per share equal to the sum of the original issue price of the
redeemable convertible preferred stock and all declared and unpaid dividends on such shares of redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If upon the occurrence of such an event, the assets and funds distributed among the holders
of the redeemable convertible preferred stock are insufficient to permit the payment to such holders of the redeemable convertible preferred stock, then the entire assets and funds of the Company legally available for distribution shall be
distributed ratably among the holders of the redeemable convertible preferred stock in proportion to the full preferential amount each such holders are otherwise entitled to have received pursuant to the entitlement as noted above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment in full to holders of the redeemable convertible preferred stock as noted above, the remaining assets, if any, shall be
distributed to the holders of the common and redeemable convertible<B><I> </I></B>preferred stock on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT>
basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conversion rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is convertible, at the option of the holder, at any time after the date of issuance of
such share for such redeemable convertible preferred stock. Each share of redeemable convertible preferred stock shall be convertible into the number of shares of common stock determined by dividing the original issuance price by the conversion
price. The initial conversion price for each share of redeemable convertible preferred stock is the original issuance price for such share of redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock automatically converts into the number of shares of common stock at the conversion price
on the earlier of (i)&nbsp;immediately prior to the closing of a firmly underwritten public offering in the aggregate gross proceeds received by the Company are not less than $75,000,000 and the Company&#146;s valuation, represented by fair market
value of the issued and outstanding shares of common stock (assuming conversion of all redeemable convertible preferred stock into common stock) immediately prior to giving effect to the issuance of any shares pursuant to such public offering,
calculated based on the price per share at which the underwriters propose to sell such common stock to the public, is at least $425,000,000 on or before the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the initial purchase date of
the Series F redeemable convertible preferred stock, and at least $475,000,000 after the twelve <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the initial purchase date of the Series F redeemable convertible preferred stock (a
&#147;Qualified IPO&#148;) or (ii)&nbsp;the date specified in a written request by the holders of a majority of the then outstanding shares of the Series E redeemable convertible preferred stock and the Series F redeemable convertible preferred
stock, voting together as a separate class on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2020, the conversion ratio for each series of redeemable convertible preferred stock was <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one.</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
redeemable convertible preferred stock is recorded in mezzanine equity because, while it is not mandatorily redeemable, it will become redeemable at the option of the stockholders upon the occurrence of certain deemed liquidation events that are
considered not solely within the Company&#146;s control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Common Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Company&#146;s Series A redeemable convertible preferred stock issuances in September 2011, the Company
issued a warrant to purchase 64,655 shares of common stock to an investor who purchased Series A redeemable convertible preferred stock at an exercise price of $0.10 per share. The common stock warrant was exercised in December 2020 and is no longer
outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Redeemable Convertible Preferred Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with
the funding of Tranche 1 and Tranche 2 under the 2019 Term Loan, the Company issued the 2019 Initial Warrant to purchase 29,514 shares of its Series C redeemable convertible preferred stock (see Note 5). The 2019 Initial Warrant is immediately
exercisable, at an exercise price per share of $9.49, and expires 10 years from their date of issuance. The 2019 Initial Warrant will be automatically exercised upon the consummation or effective date of a change of control of the Company. Further,
depending on the funding of the 2019 Term Loan Tranche 3, the Company was obligated to issue the 2019 Additional Warrant (together with the 2019 Initial Warrant to &#147;2019 Warrants&#148;) to the Lender to purchase up to 12,649 shares of Series C
redeemable convertible preferred stock at the respective exercise price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the 2019 Warrants on the date of
issuance was $0.2&nbsp;million. As of the issuance date, the fair value of the 2019 Warrants was calculated using the Black-Scholes option-pricing model and was based on a term of 10 years, a risk-free interest rate of 2.99%, expected volatility of
50.95%, and 0% expected dividend yield. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At initial recognition, the 2019 Warrants were recorded at their estimated fair values and were
subject to remeasurement at each balance sheet date, with changes in fair value recognized as a component of net income. As of December&nbsp;31, 2019 and 2020, the estimated fair values of the 2019 Warrants were $0.2&nbsp;million and
$0.3&nbsp;million, respectively. The fair value of the 2019 Warrants as of December&nbsp;31, 2019 and 2020 was calculated using the Black-Scholes option-pricing model with the following assumptions as of each reporting date: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9.1&#150;10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">8.1&#150;8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50.63%&#150;50.95%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42.18%&#150;42.63%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.33%&#150;2.49%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.33%&#150;2.49%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the 2019 Initial Warrant remained outstanding and the remaining term was 8.3
years. The 2019 Additional Warrant of 12,649 shares of series C redeemable convertible preferred stock was not legally issued and expired upon modification of the 2019 Term Loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with
entering the 2020 Term Loan agreement, the Company issued the 2020 Warrant to purchase 300,000 shares of its Series F redeemable convertible preferred stock (see Note 5). The 2020 Warrant is immediately exercisable, at an exercise price per share of
$21.88, and expire 10 years from their date of issuance. The warrant will be automatically exercised upon the consummation or effective date of a change of control of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the 2020 Warrant on the date of issuance was $1.8&nbsp;million. As of the issuance date, the fair value of the
2020 Warrant was calculated using an Option-Pricing Method with Discounts for Lack of Marketability for each class of security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
initial recognition, the 2020 Warrant was recorded at its estimated fair values and was subject to remeasurement at each balance sheet date, with changes in fair value recognized as a component of net income. As of December&nbsp;31, 2020, the
estimated fair values of the 2020 Warrant was $1.8&nbsp;million. The fair value of the 2020 Warrant as of December&nbsp;31, 2020 was calculated using the Black-Scholes option-pricing model and was based on an Option-Pricing Method with Discounts for
Lack of Marketability for each class of security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the 2020 Warrant remained outstanding and the remaining
term was 9.9 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2020, the Company&#146;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to
21,831,000 shares of common stock with $0.001 par value per share, of which 4,754,591 shares were issued and outstanding. The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared
by the board of directors. As of December&nbsp;31, 2020, no dividends have been declared to date. Each share of common stock is entitled to one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2018, 2019 and 2020, the Company had reserved common stock for future issuances as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series A redeemable convertible preferred stock and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,868,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,868,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,804,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series C redeemable convertible preferred stock and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,342,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,372,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,372,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,447,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,447,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series E redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series F redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,362,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of options under stock plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,596,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,659,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,754,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of options under plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">921,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,568,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,938,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,552,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,420,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Stock Option Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, the Company established its 2011 stock option plan (the &#147;2011 Plan&#148;) that provides for the granting of stock options to
employees and nonemployees of the Company. Under the 2011 Plan, the Company has the ability to issue incentive stock options (ISOs), nonqualified stock options (NSOs), stock appreciation rights, dividend equivalent rights, restricted stock awards,
and restricted stock unit awards. Options under the 2011 Plan may be granted for periods of up to 10 years. For incentive stock option granted to a grantee who, at the time the option is granted, owns stock representing more than 10% of the voting
power of all classes of stock of the Company or any parent or subsidiary of the Company, the term of the incentive stock option may be granted for periods of up to five years. The ISOs and NSOs will be granted at a price per share not less than the
fair value at the date of grant. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. Options granted to new
hires generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter; options granted as merit awards generally vest monthly over a four-year period. At December&nbsp;31, 2018, 2019 and
2020, there were 25,377 shares, 830,938 shares and 225,835 shares, respectively, of common stock available for issuance under the 2011 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s stock option activity for the years ended
December&nbsp;31, 2018, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Options Outstanding</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares<BR>Available<BR>for<BR>Grant</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Number of<BR>Options</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term (In<BR>years)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Aggregate<BR>Intrinsic<BR>Value (in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">92,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">827,967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional shares reserved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">80,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(164,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">164,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">16,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(16,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(54,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">25,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">921,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional shares reserved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">941,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(154,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">154,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">17,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(17,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(63,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">830,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">993,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(624,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">624,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">19,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(19,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(30,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">0.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;225,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,568,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1.87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">18,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">854,065</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">4.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&nbsp;&nbsp;11,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected to vest as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">714,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">3.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">7,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair values of options granted in the years ended December&nbsp;31, 2018, 2019
and 2020, were $0.1&nbsp;million, $0.2&nbsp;million and $2.9&nbsp;million, respectively. The aggregate intrinsic value of options exercised were $0.1&nbsp;million, $0.2&nbsp;million and $0.2&nbsp;million during the years ended December&nbsp;31,
2018, 2019 and 2020, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. As of December&nbsp;31,
2020, the unrecognized stock-based compensation of unvested options was $2.6&nbsp;million, which is expected to be recognized over a weighted-average period of 3.4 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of stock options using the Black-Scholes option-pricing model. The fair value of stock options is
recognized on a straight-line basis over the requisite service periods of the awards. The fair value of stock options was estimated using the following weighted-average assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.00&#150;6.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.85&#150;6.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">55.13%&#150;55.98%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">50.63%&#150;51.00%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">48.27%&#150;55.64%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2.80%&#150;2.85%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2.30%&#150;2.49%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.33%&#150;1.77%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected term is calculated using the simplified method, which is available if there is insufficient historical data about exercise
patterns and post vesting employment termination behavior. The simplified method </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is based on the vesting period and the contractual term for each grant or for each vesting tranche for awards with graded vesting. The midpoint of the vesting date and the maximum contractual
expiration date is used as the expected term under this method. For awards with multiple vesting tranches, the time from grant until the midpoints for each of the tranches may be averaged to provide an overall expected term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company used an average historical stock price volatility of a peer group of publicly traded companies to be representative of its expected future stock price volatility, as the Company did not have any trading history for its common stock. For
purposes of identifying these peer companies, the Company considered the industry, stage of development, size, and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period
equivalent to the expected term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free interest rate is based on the implied yield currently available on US Treasury
<FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues with remaining terms equivalent to the expected term of a stock award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend Rate </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not paid, and does not anticipate paying, any dividends in the near future. Accordingly, the Company has estimated the dividend
yield to be 0%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of stock-based compensation expense by function (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Tax Assets and Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities reflect the net tax effect of temporary differences between carrying value of assets and liabilities for
financial reporting purposes and the tax basis of these assets and liabilities as measured by income tax law. The income tax effect of temporary differences that give rise to deferred tax assets and (liabilities) consist of the following (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for excess and obsolete inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;7,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,797</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will continue to closely monitor the need for a valuation allowance against its existing deferred
tax assets (&#147;DTAs&#148;) and any additional DTAs that are generated in each subsequent reporting period. The need for a valuation allowance can be affected by actual operating results, forecasted financial performance, variances between the
two, and the rate at which future DTAs are generated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal Revenue Code (IRC) Section&nbsp;382 limits the use of federal net
operating losses and income tax credit carryforwards in certain situations where changes occur in stock ownership of a company. If the Company should have an ownership change of more than 50% of the value of the Company&#146;s capital stock,
utilization of the carryforwards could be restricted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s income tax provision for the years ended December&nbsp;31, 2018,
2019 and 2020, consists of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation of the statutory federal income tax rate to the Company&#146;s effective
tax rate is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax at statutory federal rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is recorded when it is more likely than not that some portion of the deferred tax assets
will not be realized. As of each reporting date, the Company&#146;s management considers all evidence, both positive and negative, that could affect management&#146;s view with regard to future realization of deferred tax assets. As of
December&nbsp;31, 2020, a full valuation allowance for deferred tax assets was recorded as management believes it is not more likely than not that all of the deferred tax assets will be realized. At December&nbsp;31, 2018, 2019 and 2020, the Company
has a net operating loss carryforward for federal income tax purposes of approximately $28.9&nbsp;million, $54.1&nbsp;million and $85.3&nbsp;million, respectively. At December&nbsp;31, 2018, 2019 and 2020, the Company has a net operating loss
carryforward for state income tax purposes of approximately $29.1&nbsp;million, $53.4&nbsp;million and $ 83.5&nbsp;million, respectively. Net operating losses prior to 2018 of $14.8&nbsp;million will expire, if not utilized, beginning in 2032 for
federal and state income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, 2019 and 2020, the Company has federal and state research and
development income tax credit carryforwards of approximately $0.3&nbsp;million, $0.6&nbsp;million and $0.8&nbsp;million, respectively. As of December&nbsp;31, 2018, 2019 and 2020, the Company has state research and development income tax credit
carryforwards of approximately $0.5&nbsp;million, $0.6&nbsp;million and $0.9&nbsp;million, respectively. The Federal income tax credits begin to expire in 2032. The Company has provided a valuation allowance of $0.4&nbsp;million as of
December&nbsp;31, 2020 for deferred tax assets related to research and development income tax credits that are not expected to be utilized. The Company does not expect any significant change to the UTP balances in the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity related to the unrecognized tax benefits (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions related to the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions for tax positions of prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not have any material uncertain tax positions as of December&nbsp;31, 2020 and does not
expect any significant change to such balances in the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company currently has no federal or state tax examinations
in progress nor has it had any federal or state tax examinations since its inception. Due to the history of net operating losses, the Company&#146;s federal and state tax returns remain open to examination by the tax authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13. Net loss per share attributable to common stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. As
the Company reported a net loss for 2018, 2019 and 2020, basic net loss per share is the same as diluted net loss per share as the inclusion of potentially dilutive shares would have been antidilutive if included in the calculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands,
except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,611,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,693,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,678,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per
share attributable to common stockholders for the period presented because including them would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,804,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,804,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,804,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,342,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,342,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,342,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,447,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,447,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,062,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">921,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,568,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable Convertible Preferred Stock Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">329,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;8,278,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,840,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,665,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Pro Forma Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted net loss per share were computed to give effect to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion of all outstanding shares of the Company&#146;s redeemable convertible preferred stock into shares of common stock in connection with the IPO, using the
<FONT STYLE="white-space:nowrap">as-converted</FONT> method as though the conversion had occurred as of the beginning of the period presented or the date of issuance, if later. Refer to Note 2 for further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted loss per share is computed as follows (in thousands,
except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Numerator:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: change in fair value of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding used in computing net loss per share
attributable to common stockholder&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: conversion of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14. Defined Contribution Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined contribution plan under Section&nbsp;401(k) of the IRC of 1986, as amended, covering substantially all of its
full-time US employees. Participating employees may contribute up to 100% of their eligible compensation up to the annual Internal Revenue Service&#146;s contribution limit. For fiscal 2018, 2019 and 2020, the Company did not match employee
contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15. Segment Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has two reportable operating segments which are determined on the basis of product portfolio: Surgical Glaucoma and Dry Eye. The
operating and reportable segments were determined based on how the Company&#146;s Chief Executive Officer, its Chief Operating Decision Maker (&#147;CODM&#148;), views and evaluates the Company&#146;s operations. The CODM allocates resources to and
evaluates the financial performance of each operating segment primarily based on gross profit and gross profit margin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma
segment includes sales of the Company&#146;s OMNI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Surgical System and its predicate devices for use in minimally invasive glaucoma procedures. Dry Eye segment includes sales of the
Company&#146;s TearCare<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> System and related components. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes select operating results information for each reportable segment (dollars in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 22,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 26,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost of goods sold</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gross profit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surgical Glaucoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dry Eye</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not allocate any income and expenses beyond revenue and cost of goods sold to the reportable
operating segments in its reporting to the CODM. No asset information is provided for reportable operating segments because they are not reviewed by the CODM on segment basis. Substantially all of the Company&#146;s revenue is generated from sales
in the United States, and none of its property and equipment is located outside the United States.<B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events through April 9, 2021, the date on which the consolidated financial statements were available for
issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Lease renewal </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2021, the Company entered into a lease to renew the corporate headquarters in Menlo Park, California. The lease commenced
on August&nbsp;1, 2021 and is for a term of 37&nbsp;months from the commencement date. Total base rent is approximately $1.6&nbsp;million under the lease agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g90195g01a31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>P R O S P E C
T U S </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>BofA Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><B>Piper Sandler</B></TD></TR>
</TABLE> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq
listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors
of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our restated certificate of incorporation provides that no director of the
Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law
of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party
to any threatened, pending or completed action, suit or proceeding (other than an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a
director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any
action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding
and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause
to believe his or her conduct was unlawful. Our restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favour by reason of
the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts
paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our
best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all
of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all
expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification agreements with each of our directors and officers. These indemnification agreements may require us,
among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as
one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of
claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection
with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, or
the Securities Act, against certain liabilities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of capital stock issued by us within the past three years. Also included is the consideration
received by us for such shares and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Capital Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2018, the registrant issued an aggregate of (i) 1,288,761 shares of Series C preferred stock for an aggregate
consideration of approximately $12.23&nbsp;million to accredited investors, (ii) 2,447,818 shares of Series D preferred stock at for an aggregate consideration of approximately $30.8&nbsp;million to accredited investors, (iii) 1,899,847 shares of
Series E preferred stock at for an aggregate consideration of approximately $30.15&nbsp;million to accredited investors and (vi) 1,062,716 shares of Series F preferred stock at for an aggregate consideration of approximately $23.25&nbsp;million to
accredited investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020, the registrant issued 64,655 shares of common stock in connection with the
exercise of a warrant to an accredited investor at an exercise price of $0.10 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each issuance was made pursuant to
Section&nbsp;4(a)(2) of the Securities Act and/or Rule 506 as a transaction not involving a public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Equity Grants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2018, the registrant granted stock options to purchase an aggregate of 2,809,807 shares of its common stock with exercise
prices ranging between $0.69 and $4.13 per share to employees, <FONT STYLE="white-space:nowrap">non-employees,</FONT> and directors in connection with services provided to the registrant by such parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuances of such stock options and the shares of common stock issuable upon the exercise of such options were issued pursuant to written
compensatory plans or arrangements with the registrant&#146;s employees, directors and consultants, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act,
relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2019, June&nbsp;28, 2019 and November&nbsp;23, 2020, the registrant issued (i)&nbsp;a warrant to purchase up to an
aggregate of 25,298 shares of Series C preferred stock at an exercise price of $9.4868 per share; (ii)&nbsp;two warrants to purchase up to an aggregate of 4,216 shares of Series C preferred stock at an exercise price of $9.4868 per share; and
(iii)&nbsp;a warrant to purchase up to an aggregate of 300,000 shares of Series F preferred stock at an exercise price of $21.8779 per share, respectively, to MidCap Funding XXVIII Trust, or its affiliates, pursuant to Section&nbsp;4(a)(2) of the
Securities Act or Rule 506 as a transaction not involving a public offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation of the Registrant, as amended (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of the Registrant (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Bylaws of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amended and Restated Investors&#146; Rights Agreement, dated as of November&nbsp;23, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Stock Certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant to Purchase Stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2011 Stock Incentive Plan, as amended, and form of option agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Incentive Award Plan and form of option agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement for Directors and Officers</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sublease, dated as of September&nbsp;17, 2019, between the Registrant and Cellular Research, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Multi-Tenant Space Lease, dated as of February&nbsp;5, 2021, between the Registrant and Deerfield Campbell LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Credit and Security Agreement (Term Loan Loan), dated as of November&nbsp;23, 2020, among the Registrant, Midcap Funding IV Trust</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Credit and Security Agreement (Revolving Loan), dated as of November&nbsp;23, 2020, among the Registrant, Midcap Funding IV Trust</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Supply Agreement, dated as of January&nbsp;14, 2021, between the Registrant and Peter&#146;s Technology (Suzhou) CO., LTD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> Item 601(b)(10)(iv). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Financial Statement Schedules.
Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the
form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SIGHT SCIENCES, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Badawi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned officers and directors of Sight Sciences, Inc., hereby severally constitute and appoint Paul Badawi and Jesse Selnick and
each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution
in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering
that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto
said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and
about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or
any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paul
Badawi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>President, Chief Executive Officer and Director<BR>(principal executive officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jesse
Selnick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>Chief Financial Officer (principal financial<BR>officer and principal accounting officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Staffan
Encrantz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David
Badawi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mack
Hicks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Andrew
Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Erica
Rogers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Valeska
Schroeder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Donald
Zurbay</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g90195g01a31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g01a31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1XT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'AB^=P0X0DE-! 0      #T< 5H  QLE1QP"   "(  < E  "')R,S4Y
M,#DS' (% !Q-:6-R;W-O9G0@5V]R9" M(%-I9VAT("T@4RTQ #A"24T$)0
M    $)Q15WNLT?-N(U&UXU@VQKXX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^
M-0 "  $X0DE-!"8       X             /X   #A"24T$#0      !
M %HX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              $;   "[P         !
M                  $              N\   $;
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   $;     %)G:'1L;VYG   "
M[P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !&P    !29VAT;&]N9P   N\    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     <X0DE-! P     $[
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MS\=F5A7,R*+/HVUN#FGQU;^ZN?/^+CZI?9_1^RO%FW;]H]:SU)B/5^GZ6_\
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M8;F78]C;:G>M<8>P[V.VON<UWN'YR=*., 'U:BQLH&0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ 6P#P P$1  (1 0,1 ?_$ !T   (#  ,! 0
M  D*  <(!08+ P3_Q !/$   !P ! P," @4'!0L- 0 ! @,$!08'"  )$0H2
M$Q0A%3$6(CE!=Q@W47BUMK<R.$)ULQ<9(UAA<967M-76&B0F-#5(4G*!AZ'%
MT=?_Q  = 0 !!0$! 0$            &  ,$!0<( @$)_\0 5A$  @$# P(#
M P4)"@D+!0$  0(#! 41 !(A!C$3(D$'46$4,C5Q@0@5(T)S=)&RLQ8S-%)B
M<I*AL;0D)394=<'1TM-#56."@Y.4HJ/A\"9$9(3"\?_:  P# 0 "$0,1 #\
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MB<?-^OF4U";XV5FVRL!5G3!!@]LCO3]9AW,PL1TP=*"[6C(2)9',50I!18H
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M^O5G+T7T=.ACGZ3Z:FC(VE);%:Y%(]VUJ4C'V:S+IG;=XC:6@MYS-"A2:A3
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M7!HTDS)32*R.OE+*0KJ2OH'1@&7M@D<YR?3.N\^C:^.MPM+=(R"%EQ2PV!!
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M(3Z9_@1;LKIU\YLZC!.Z_)[#7&]!Q:(E&HM9)7,BR;*>LEZ506#YT8ZZ3<7
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M\G.U2KH/J#@L!C@#>0!P,#&J1I?I5..\=(I+Z#RFV2UQA% .>/J=1I=&<K$
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MMWO^9';6KE,XG\L^+;F>J&5QB52K<?8X^?Q_68.M12AFS)FD_DHN4K5PBHE
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MZ;Z;XMB_EIOZV!TO'VW^<V$\!NYSS8U;D ZM3.I6I7><^BE:E75++(?I"^Y
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MB2U-,03F/=)&,GN3&< ^G)![>_.M8P7?$[JE>3318\OK<Z23   )VCY'95#
M'W %'%ASZ3=*C]_N91<QA_>;JN?I2P/DM;(QDGYLM3&/JPDRCT[?IU*6^711
MM%8Q..[)"S#X^:,_U_Z]?*S=[[NH6QLJSDN7UR9H*E$IOT9J&64UR4!_,4Y"
MI42%D4C?T&3=E$!^X" _?K['TM8(R"MMB;W"26ID&?JDF8'ZB#I/?+HX(-8X
M]252%#CGU6,8'^SOQK#MOTSDMRMN4:WN]YVKD1?'JID(5A/S]TU"R***F_\
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M&C"++."LVRL@Y>/#I@LX64\N'*RGE00]_CP ,SSS54TE142&6:5M\DC8!=L
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GM+4Z6EJ=+2U.EI:G2TM3I:6ITM+4Z6EJ=+2U.EI:G2TM3I:6O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g90195g14q53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g14q53.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Y2^8#8X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,S4Y
M.#DQ' (% "U-:6-R;W-O9G0@5V]R9" M(#DP,3DU7U-)1TA4(%,M,2!&24=5
M4D53+F1O8W@X0DE-!"4      !!;8TMFEL_,I9,4 0<C%H-W.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "E
M!18          0                         !              46   "
ME                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
ME     !29VAT;&]N9P  !18    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   I0     4F=H=&QO;F<
M  46     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M66,ES3'TO=L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$Z&QP? 4,M$'%2-"X?%2%B0T-5-4<G.2)3-B=*+2"$-5@I-$16/")K*S_]H
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M[*<-72(NH5XB4X3V"4LJ))V' SE0 5&B QD<K>ESW<-C!-4B*KMU(/5R?KK
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MRRJ.>R%=-,9A!J@IJFF']ZM)*B$K336%#E+$J4D?)'M!^QCVA_9]Q2CQG@/
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M@25*&5R6>%8B#1X:JJDZ!E @;W!(D@'&?<M>:.F>8T&=S/Y7:Z?U/!&KL?\
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M.-7RN>5GN(Y;+UZYHT*E1U%=6HM*EJ(DNH !4DN&CN,9ZW%9AQ6_J[ 52/\
M+) Z5"OM)Z:L$D=R?C?;C5JV:JU"0HJ"@9=+ ;CX#;;ICM^1X+E*--Z2::H$
MI 4Z2Q<2;]#$CIA@FY)XIZ5T*NJ'EN=[N]O4CRV]%ZE2I())N27;[Z1+ZZ6
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M!BHL%R8F3"C,0D-]27;8C_5VNE<I:G^H!$F/274EZO';ZDMME*4J00 @@DD
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MREH<0M3;[O6S"#JT.R7O%>*"TRX%K!C( $-'>W9^I#S@RZZTC\_Y6YE !GF
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M^O3&2<KL V]JJ.Y-3UB"B3E)I*A?AMO*Z72M:E=;_4X\\2I7OJ8*B:(XS51
M8SM>]Y#>1\\"R&9-5:U%1<^+2Z;7!MT9^C8Q>=E5Z[U'E<UX2E'(9!O'1F 2
ML1\;&4VU'AM*L@H8QS+:5%-!3BG75$DGC 02F?Y6\_H?2QWO)=97ODD%N8N6
MNY@/L 2PZ#O@K4\=R#KS!0X+LR <!CH$]IQAU;"XN1R<M]Y4UAP="D)^I1<>
MAI6Q2@@#W5$ V7)0M*TJ*%(5S)(+,0 RA,O +EBQU.!<6]UF: RF80FK3JH*
M*U*J.9%1"P04%)##F2TP9_,0PQNEH3F\]F-*35:^D1&',=%2Y,R8)8"H2GF8
MR'9K38Z69"7'FR5LI2TM 7)6AI*'%';N&^T2><(S2@E5,C^('D,(+EN9VVWV
MQPSVG_9'F$H/$_9X&K0Y2:O#BYJTB'(_#E8)JI+ J#.'8 B<9@WADY*.WD,%
M*8RN/DH#T>1&>:?0ZVL6%-.LJ4TZ :W;)20>]WQT;)\6I5TI=0*68$$L0& )
MEM>C7;'!L_PS,9.JNEFZ-3+U LCEJ(524%2Z5!1>#<V.F&UUB1%-.,NMJ3O2
MT*![^6P]>X!'KMQ9^]I*_F!!,\I(8'[\I\JPT2%$.".Y(AH(O?X!K'%6Y2".
MET@[^= @=N] D@=NQ]21P-=-"PR5CD+^%0!!!%E.Y 8G2Q&!\JTGP\R5"0M!
MY2&(E+&"(8@7 A\'LSGVB#%G36 ;H-2W4)[V:2ERO6MJ V\[X7_=^7J()71R
MRB7Y@JF):VFN'J'%^+Y4#W'$^(T4O &;K\AY7_D*N4L[!@)/HYM:DR[5(.8R
M)!%'WDK/3>]E:5'<[7N=S>^_"M7@>4()_!Y6=D1'F!(L,6/^57M,@,CC6> B
M?> ZC<$G#F-0.N))5-E*4KN2H @F@=P :%V*%^=7P-/!,JD'_-<O;^5  .T7
M?J"7UTP)?M3[2+_-QG//TJ%*B_5(#3ZDQK@5Z>MRNN5(6#M:GG.W:OM $C:K
M'PXG^ZJ*2 C+T0007* 1IJYV[NV$JO&.*Y@'W_$^(57T5FZI!(_Q#G9O+4D3
MAJ7X)-D(-$_:5U&SY[]7QO;\>+!%%-)( %-!&H 2PV@@.;DD=)@8KJBZU13K
M4JH2 _O%+43+F[]P=]L5:9=?I$=I:K55(1WL'<=(L>M4=NQX]4J4$25N=05$
MAK_EM=NN@Q--);)+,5 $\OAF0X#;=>YG#ZUI=11]8S+R(,-("UI<Z2^M/;_)
MDE+0.P!=4FU*% [@5N>XE1I45E*T(3_,3920'('>1 ?S;%MD.%YS-UT4,KEJ
ME?,**4H13"EKYB? " DA+E@]@)[1SS(]H56E,.]I?ENVAK)*AOMKU*OPGFXB
M@I*7&H+1*B[D$A94A]Y CM4GPD232D<^XCQY"TU*6366+\RA8$W ,".L><8[
MO[+_ +*5Y7,4.(>TR@@!5-:.%@*-1;^(*S!3X0 X(0]BY+P-*FT2=1Z:5F)2
MI$W*QLAD&)\^6\M^3.>A9"2\7W5.%;CZS!=:;DNK-JI/5[PVTLCG*E+=2E*)
M42[D^9,$&W]\=^4GW5"BFFD4J:$<M-%,\J$H( @ E/A #'0L&F'[E^\G((SV
MCEO,I:EXN1DX2'E$%IY*HL6<V@*ZB*;<AS4J 24KQSA2H>*HGQ"7 &B2XE@\
M3(Z&^Y-\-Y6N5T*@4?$)>-.I!N)/8:8PTN.:1RR)CWZO%.*1$FH4+4RVF:63
M)  -F'*ZY'31\1D/,GW'R#(4^4. WAT)L;];>387IYM":LJ(6>9AH6!G71]&
MU&Q<VLS*TKF''&$M'#K*7GH3A4I*\=(4%/MI2V0.EM95TJ -LRFT)4$K4GCP
M24AM!VM'R/2+7&(5:B342M#@\W*2+&RK!@"1V9CWQE^#UA_<9J133<D,:?U$
MPP\B<VE!8864)=8D#K!"VHY<:;DI4%!4)3CB.E^.#Q-!8["_GN3?S.,9A(J"
ME6YF*5,MRUS!G6(L=\2 WS"RC&HEXO)-,%MTH3')6M7B3%K*!#=6XHAD9!"W
M(;,T)6AB86P]<9U2T9]Y=[]=7ZS)TBXOL/EJH4.59Y%D$$R!=Y;R.TFSXSG-
MS<?E\3%G8K$B3%2T\ZZU%6(^09\,]$Y^"KQ6PN7 Z3]>QSS:%%MLNH<(2H((
ME8+L -=7823>!OT\\#J>]2'YDKIA;$%H5<@-&VHGS:,L5AQB,B[)CO-PC(EH
MG8V0V_*8FF4TL/1YYE..A^'.QDI12A(7U-M*MQ:VG&W56O#LXI 70*V35 *#
M(*5 N%#1)L"3<%BXQ3<;R&7S5(D4TK0NF454A((Y>4@@@@O#OJ;@[]H_8U]L
M:7S&R+O)?G(ZUC.9^*16DM024_4V.86):04KAS4K"&HFM<2I!;E1F^EG/1?!
MR4-*91EQSLN6SXYDT*R>6J$@%G91<VDV!!/=[6^:_:SV+K<)77S^02NMD2KG
MJ)"?%04N7(8>$EP+_E8D&_0C.X7&ZDQ$["9J&S/Q^18<BRXKR0I+K3B>A84G
M925IV*%)(4A24*0I*@D\6C#F"P6(9B#L7AC=V'9[XY\4<R2DI "AJ#(-R'?1
MR6B;6;3W(XK)Z)S?]R>9>?FQ74./Z4SSY"EY?'LCW\;.< 2G].8I!2AU1_SC
M"2B>%%Y$X-;APSB SB/=55<M9#/S1S@".4;M<=!%\:/QKA2LJLUJ2?X!)+)_
MD<R#H+$P][8O*@2!Y!0HG:^]_*N++M]C^V-?'I!9^Q']'P.%*[J  _,^A&][
M_+U]."I4& >>NY_J<#4D.229.G;M\OUP&[NM1 NQ0/8;WOO_ #1X;I*3RA))
M!!YK/K@=GB^_?[%IG I2?$W'>R?E6_G_ #?!T%)_*7 (#EA$??8/KA=9(5TC
MXD?J6V; Y LU5=5 ]C6][][^7W^?!I  #R3J2&8V('1P+[X4J)4"X2H)W-C_
M &]1Y/A!X7=$I(&]?'<W7Y_?\^,I! 8X 1 W$QNW5_C@8WYJ&]W8&_[#^?!J
M>OE]< 4"HGXAGZ2S-;IA ]]NXZJ]#Y7Y[;[;WP5*F8M>^XW&GQU'3$.4L082
M(T%R3+DV;[EXWYO?Z.-5;?\ U*,?_P!4@<)\7/-PW-<L\M(CS=1WM:;7P]P;
M_6F3_P":C_\ Z(Q]1/'(L==QS,YN)OF+K+<[9J2H#_JH_@?QXUS,$',5P"7%
M53_"-8;[&.G\(_U9DO\ D(^N(M)*3L-[*AZT?V=K/G\N%EW;H^OT[:P&OAY=
MOCY"_P!#M';"KIZD@^M&ZV[*OOZD@?@?3@B '2 U@;#;4=6P$W'R=M1\@#BP
M#K!/4115>WD2*'<7N;/[>,D$7U?"]0,L%@S@#ZZ?V(?4X2D ]9-;&J/RL'\^
M"I!  /W.%*B2&5H0WF"<(J%H![^5>HLFOQ\]N_W\2Q I)2.Y8O9I+?'O:-45
M]T]^_E7P]>#_ -F]/E^N )#@]P9\_O3%Q-I)[_+;L?B/W?+B0N.X[7QX@CF(
ML'$W=K0=X\]GQA7U-6N\ZY@4*']R6$D(&J) HHS63:+;S6FF7*(7 B^Z_GEH
M)#KBF<45D#((#"ZC!,L2\ Z!K2]K:/)Q6U5*42 (DEH+AFUD%SW#NYQL+'+2
M$);9"$-H;I*1TMMMMMI&YLI2VA"0256$("3U !) %SEG+/<SU]=W>S.;X4]U
M54H(2@J*E )2!S!2B82 +Z:1Y8Y#>U-[2^+YE.ZB@8N>H^S]RQR,=G-RX[KC
M1YS\QU2"WI[2N/<2I*Y>EXN40%%+82B68,[,N%4>%BRYJW$,\O,5AEZ:FHI6
M I@05$DAAJ6)+OTQ]'^P7L6CV>X>GC'$*"?WIFZ2O<(4 ^3I+#E24R?>*$/(
M$"6&-#QDG2W+GY\1LK.GRI,Y<1=HA.ZAG?JW9(C)(:2G%QRY%@M. Q88;<?2
ME2$*"I9E80U >)"!/4GTA]6:S:'&_P"52JE3-1+A:U !QS'E?>#)N27>PDXP
MS4F=9TAC7WY+QGRY[D=R2VA?09,N1[F,P6/2D]86^.CQE) ,7'Q77%4](;"J
MU?A?82T'H&#-O/KH3;TU*#.Q4H /  UO9^MQ =\0OK?-S,<PC3.0D?6<[FRU
MJ+74UE(08D!#2U8S3T9*:\)OPFD--HLI3%4 !_A*CP-P1N#W]/N7VQFIR.A
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M+K/9&/)QLS.,M,LQ(SSB8C@=>CPX[<<%04$I<*DLH4GKOHZE(3X8%\5B>/\
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MD%:)%:BU1*+-S!3&6(Q+N/YT^S]J1*?TA]<T[(64I\*=C);+8<( KQ8"\A&
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M.8\**\CH06DK>5[X4TXI "B4+!2!<)K45A*A5I<I!+\P$B#KH._U%6* H\R
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MRLVQ=O0-A92.53G>WU=[//PP$L6HT-CVO;:OCZ>?!4J OKM:'![=O08 NFH
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M#TJWY<Y^:X$A*3)D./%*/ZH3XA(2!9V2 2>_%!F*^:S-4U*U6I4<DJ\:P[V
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MTK(5=I6D@*0XA5H<;4$J:6E3:DI4DCC>TJ"T)4E14DAP>_R>;?VY\4%*U)6
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MJZF<K9U_>U5K3<)"B #I#>9W+]@ZG+IH2@)!);F.I;1GF!W OCT-#SR>MU1
M43:;*-R=NX]=N^Q!&QXKLPH)6 DBS-VW[S/],6-&D5@%4O$1;[G38X=X\5"B
MOK5T](KO]HT2-SO1KX6?/A9=<!B5#L))FWV0)G#2:" -9>?+2Q]1IIK:IIQ:
MNA#BJ"P!N02>U#]]GMQ$9E)+2.[?U^VNQ?PRQ>5,#8E[![R//ZPQ'AO,*(#R
ME"A8%D]NQVW^._D2:H\855!5H5" !_5R(VCO?'A3--_$2!_9C /JVQG%ZGU
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M'0.*(*$8O1L%Q28*FHY/2T_E"V)SW98CJC,.*5X!XH,PH9O,HI)42' 2 &!
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MLF;UH;"!TD*!W/N@6-AYCX]1)OM9XK:B>9:E*>&8@'4G2PN78'26Q84PQ2E
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ME0+L8<3'=OB&[2<&*C!*KAV:_2Y:_;#C'=66Z4H405A5^7Q)VKU]*XPJF'
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M>11]YS B>5P6M][7Z834L(\1W@3]^@V!MC($3H[S"3[J=CUGIL"@D6:KL"2
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M>[5UOY[5^/"')ROJ!.C%KZ%Q (^SC)4TWL>GF;8<$N=("=B>PHW\/05OOO\
M+@*D\W2>^) W?X%^^E_*(."T.H ":%[$$=R;\R3MM^?EQX4G!DN)9NA-I?\
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M[:Z!37S%PX (!,CU<::CI?&%L$DG0/V/D3^O3#_IB%'?5GC(*?$9T^YD8BE
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MY#(2CJ#SL1AZ6U$4#5)FJ9$3JWZ"^% **0#7(0%!26EB2&U [W=]9V;#Y47
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MP%YQJ/+ZNM+BW&IC(E-.N%-D.NM/(6XE?ZP$TZE*[ Q4IK)/,%.0[P7.A)!
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M5Q7X<DDA1I+*&+NPYF!<&P8_K?&@<:I>[SQ(A*T0S,]W;I,L-0^,(4J]R3=
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MVWC([##@0+(0#(?65T4@%))'<G3.*5!4S**20"62&+F0W8:SNS8WFI4 57S
MGW:'2[L5$:WL0>V--?;8U:WGN>S&CL8@C$\L]':9TEC4-I4#*GY.*=99*4M"
M@D?6&E:G@:=60!;6GH[:J4@A,.)E*32I()Y:=-(DSS+)422PE1@B[ #=X^S
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M5D)( ]X#XF_/U^))\N^_&%TEJ#0T>9\WC[ZX;16"?"/)W=FZ&_;H\8N=FI6
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M&22US(ZPQ.S@R)!&M1750A&A=0_\+$0=R2-W%^B+DKPD*4!L .FR2*%D4/(
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MS!A9YW'0X,FA5H4Q7SB&0DA2*0!"ZBA_*L*<4XAR#/3#PD!2BXC;K(% 4$A
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M'W@D$>=@<8I@\Z3HXGU_1L5U<M2JM<!9[2&MU&$\6GPHD9":'0VVFB.P2A(
M->=B^+=/YA<1'WL9QJGO5**5-8N+3,;7'HYQS&UC,&>]K#54IPA;&#G8B D*
M)(0SAL0U.= ^ 6\LJ%7U;C8<:1Q5?-Q-0U0DA[N9WL&(@]-I^POV84$Y3V"I
MU$CE5FEU5EYNJ)(W+M\<<P>6<AS/\U=3ZOD*V3FM<ZR>=4"L#ZNK(N0E*KI/
M2) BI'2=ST@#<<:2:QK<24HF*0?2[PU]/3#E<E'#ZBP/%5K*2FX\23M)(/*X
M9S)C;F"C7$76//.1KO5AD'%YWF2O/YAEI*%R6L-,U,9CT1A"!X9<8QB_J\?I
M(04MMGJ439-6JH!55J)="E*47@@%F>6;S,,SXNN'9?W=7*Y2@H<R#1R]-3L$
M\J0$E40.1U*+0?3&/HDN97(9>>^@AUW+Y);Z;5TI>=FNNJ32Z77ZQ)%[D&S?
M%95J(2>9*DD$.ECH7@:P/[VPQ4!_%UZ:DD&G5J(4_P"9TK4.93VYF>#+QL'1
M)]SI2*45$V.PNA9'G>W^\64@KE)7N6 ]/@?Z6,- 7!, ,W>7&NK3?X"YXI9:
M2CH2OIZWW+/]6.A3@2KJ\EJZ =QL:\APRDJ6Q,,V]H+=["=+",.<.2@5*M=G
M]PGG8EM(:[W9B0#>^ UMR$Q3X3:G@E23*>2%*1'CJ<0VXZXI(]T...M,!:J2
M77D >\4I)"0KF(>(<L##!Y<?;X716YU+K$@K\2QS0Q+@!P# "8(;6"<9)$I+
M20$I "4@ ;!*4@>Z3W-#X^F_%17)54;9TP>A(>"VLG?'J7-S*)9U%U$N\%OK
M'Z,SA'2T+( W!HDDU>]^=_?Z50X5(42>4")8WC8:/:YW@N<-(5R@!.H))-B2
MYZ_UT PB](>R)CI5*4F-$CN1$M-^X7V_K<B0!XJ0E:6DN27U%"2GK+E A(W8
M542$H2G\R0RDFX%QVDFY.'35IH10J-SUQ3+BZ4A]3O$Q;5\.4="6T)\,!*$C
MI2A.R4@;;>='8[\ 42HZ,S&[]OH3Z;X *G,HK%W)ES)[]^V'!,@C8*(V !\A
MM\?7L3Y;UMQ$)28.GP!\QH/.]SB:JBB"X8&YN[>4W^FD*&6X*"5[FA?2* \]
M[/Y_?QXTT2RCV;]=L8"RI@IN7N?*(;Z8<?KS"H,F',*TM=#LG'2$)ZS!RH:'
MAK6W8\6'DD--X[(H^TEM<><D%W'M)4]EP$I*5#PFUH4PGS8/I.K/A>H%$L0)
MCJSL]H+P&@->^,?_ $HZXDE)H>X?(42DFCL0=C1'KZ\$0D\Z@&"2'#]-&9G.
MC1<="L*Q!NVNVK#^FC7Q8SD' XI;FZ320 :LT?+S[^I(WV._#"T(6 DAVDD;
MZ&]G>6VZ8(BLIP;NWK87\M1UPZM2D. $)'<7N;3O\ /,CY]^$JE)O$8L&&MH
M)\GN]^A+2:A)"H<EM&:^S#M&^!7W1XH-U1%=-DG<B@>XVH[C>O,<#$$)'U_3
M[B)PRE:47=C#  [O<@1JSMZ.HSD7$*06STJ:4AQ"@=PM)L$>Z4DCXV-MTJ%@
ML(YT0&93JT;PC4$=6MB'O4<X*200^VNHF0!Z;/@5]Y'CA3*$QVE+==$-FTL,
MJ4H%"&_>*RPV0H,M*)"$A"#?@H)R?&@A+.2Y&H,0&DL23/GU.M2:/+4#*562
M>0*CD#CQ.\%7UZP2W-6EQ*FE=+A-%0)VOU%C?N.WE7 E4@!S*<$&.W6TN=L#
MIU.91#A];0?*XTGUQ9DI<M*$E*U*"AN018(ON!>Q/W"]][H^60.8J>[6<V[L
M--M.L"S  M>QM9MO32)Z8:&);I )%*O>O*ME=SM=]^_P!VXG53342X=R[DM?
ML#J'+[B7PO364#F2VK@WG;8,U[?#"#&6>5G7H940P(K#W03LXZP7D(<(']=E
MN;(;0K?I2^Y1M:N!U$)30"0?Y@3:S*$:&]OAN="R::5!@2HI>&# @CLX!?M%
M\9>"'60DBQ01U$W1'?8[@7ON>*P)()=O+J7OY_*<%YA4@W#F]RS!ND>;Z.!@
M-UEVK4:0% )[;>8K?<'??@U-@2#?Z@'IZ_# CSDD&$W!,;WZ6\]<->3@,9"$
M[&D)#C:DD'J\B18KS!%$GX[@@[\,4N8*)!$?E.O2&_N\@!\2544D$0M#^*F8
M! N+&_76QOC'XQRD'I@8QEW+1VVUNI8<=J8PS'3U.K5(4E8>C-(!*UO!"VD?
M:4L)!#!2E1)6[ER& />" S #H;XA2H_B4OE6IAR%(4KE""=1)!!(<]A@K&NS
M$Y2+D\UCV7\3!6]*_1)=1*_2$QJ,[^CVYQ2&V_J<>>J/)E,I),EJ.J.E2"YX
M@BFI0"FY64Y&\GH"_P 1!.#)RB\N%U5YFDM:7]W32'Y5!QS<S7N9$^0. YSR
M9\!ULNF*^H!8?;'0M#R%!33E)V!2L ]-U0%$U? Z?*BH4A /B<'FCM-W[,+R
MV%AFE!2C56I96/&&O)G;F8 ;1UAHBY'*XIYA61R3>5@/.(9< BHCN1'">EM]
M*FTIZT!1 6@W:;Z=QTG"J"*O,I"0E2002^\F"-V/PQ *I$*--50\H)(J,'&I
M#%3RT.->V,O<E(6J@019)3\#L*/<T!WVOT\^ %'(;\R@SNS[%G[@&TN!?'B>
M9 +AS(#MNUP1WG CA0RE/2314=J[*-*.UG8>5_'RJ_4SR\S""8!M>_4X76;!
MYO!MW^#>?F/+<3$:\=QP-MNNAI*RG9*W05-]1KW05)(2HFK-&MCP1(%91222
MD EA=(@A]'<=;B;X(E2?=J#ETJYT#J3X@9>4_EO-R&<*8IYE^9$$XE..:?:7
M/22OWXB%=3[ +8*PJ0VE4<+0#T!TK)!38+RH#%20I %I< 7# [ -ZW& 45*5
M4'*Q\3AXD/>\7[DQ AHGR"I)+K:46124J) %=D*  H#<>[1 N^ I3[Q12F &
M,P&#$;V<#SQ*H5*6:BSXBX(T !AWMY1&T8C_ #"O"ZU!6RB?P/D=[-#\/A?%
MA0ID* (MJ02S#L.GVV$JJB$DCM+;%XB[3MZ8V_\ 89RXG/\ /C03JPH9WEUC
M=6PVEJI/U_1N<<Q311N+=6C6ZD(23TJ05$I*D)4F^R[U,GGJ12%&G[HI)ZI*
M2P8RJ'-HZ#&K9VIR<6X95\)*UYC+J!NRA353+L'"2%'<$W\1QT$]C:2HZPYI
MZ;*J3GN7+\H-DWU2,',3)21WM26RL%0VHDW9W-PN:"T;2?A \V(M.-AR"A2X
MAT%>D2VRIBVAFP^#=E_8IRYD\K<_B%+%X/6>392@FRAJ>TQ.0E.PI)4ZX0-]
M[)() /1N"5>?((!#\I*6?4."=Y\B>V/F/]K>3&7]M.(5!"<U2I5]02[A[,)!
M8.S,^V)8YQ)2O!XQ\"C&RZ4DV3^KD1)*5 >5%2&[L^MT=N.@>R54CB"D@PJA
M4/=26O=X(;=F,3CA_M$@')H402U5-HE7,!,O*9LP,.<:Y+<K[)-$&D@T?S!^
M/E?SL<='2.:^@W;MO_3&FL\=F[X&6LD;CL-P>X W NJOOY'@U-/*2]]&(-K;
M/]8TQ%5,$$ZN\$$;RQ)N.@[VP XI1)!-#;8;#;[_ .>]<%3RWUMI!Z!A?[UP
M!@"?+M$1A%2R#N;4;KX#MO9^[;Y4!QGE! #P-0WWKB*UA%P_3?O\<1[S.<*M
M#:B^SNQ!'N[4/TK LG]FWD.W%?Q9/+PW.F6]R._YA/8@>O3#/#P3GLO"0ZTL
M [!R>@F0\;X^LSCD.-ZQS+YL?Z2=8_\ 3DG_ .#C5\T <S6!L:B@>SXZKPC_
M %5DO_+(^1Q&;ZJ705>P\AL/+RW^? B2DL#';7[G#0#/&K]^N+R2EH*55U=D
M7T@^5'O5=N^_PX(D,-;3YZ&S7/RZX@LM9@XFSF=?4VZX1H$*NS?5^!OM\P!^
M[SXF28 T;NX'ZD_73 C;3SMALSQ*<+D!W CE(![^\H)-=O(D&]M^&*:1S)V)
M&S,"Y#7N?2;8K<R0*%4BY21Y$F1YCKM@>(_2&K)H$>GSL;V/7[NW%D"RG9A^
MA;2.DVW:#J?(2E@08#]'ML+=8.^.3R)ZW>;_ #JS:B"Y&D:]DA7];_ \+)8;
M5?D0EJ@0=J\]N.>YXA?$\S,LJ;!@'^^L#'VG[))%#V X,@@@KIA3O_B4HZS_
M "B-@SC3GARA;4QIGF'DDE*'(O+S(S@XL%7N?I7&S)8 3[RBJ*U(30^T;"N_
M&FY!)7G,V0"Z4D)#7/-;39]V&LX]FE\F6X<2Q*\Y3<&WC4')Z.1IJS8XK8E?
MA%I"%K ;2VE"E4%%*.D)4HV3U! 3U$B^JP"3OPU625@NQ!!<-#D@V)W$;=<'
MH5JE&H"B%)4E*6,I4X +O+#F:(+.T8FC-8=S Y/&+<?:=;U3I7 ZN:4V/<!R
M+<F)*:(.Y>C3L=(CR?(N()&Q215KRQI(  '*4@AF)"3(#]'9MWDNV+_B&83F
M,\,Q3!'XBDA=0#6H@<BB?^(L2+&"&T28*DN)-=0(N[ [C:MC>XO\MS?"%4E*
M0D,2_,#LT6W?'@IST) ,;=_CVTDX:L[(6W$E.,[K$*4L =@6O!<5N>]I2?@=
MP-CPY0"B$@D=; @%)UT!&L? X:RK^XS_ "PH9?F!NZ@2 -1MH;B,"8G4\W*E
M<?&,.PX!BI:RKRS_ ,;0)$>2W%Z;Z5-"5'CO$*/47&D*M/A@GU12:7. 9).K
M@!HL1J-!J,)Y<U#26I5-G]V@%5WGF[@@WL&-L94Q.2EM06"F@02G<$#;O1 -
M$#R^'%:1S5"I,$EVT?>]A+_IB040 [,+_$G;UMN,(JRR'E?4H:5JD'_**) :
MBMF_UCJ@3[U*)0@%2E$60E ),_<BDD*7/,P^/3L[7Z%QABC_ !%!9=*$%V#@
M+-VFX+,=6=K8/;>:8Z6D[]( VH ^[Y6;]!7J/AP!: M7,FS /(/<MOI:VF#K
MJ@J4H!G/30,0'-MQO(UP:V^5)ZNHB[% F]N_X[4;_?Q%5,L"! 8DEC(T<ZZD
M]VQ.G4!<227U;L=(:6\NF'5ET*0-[(\ST^@-]^U_,;U>_$2DB^OQ9IQ/FY@0
MUH$?/S=]?,RMM=FK\O7^;/Y\8[8\"D$"S,.][/V[6UQ9(=*8Z]]D[^?=)]W_
M -XT-^Q-59)8H+)A1C7]0?+5NLQB"2^80 S%33=K:;^?DV&]#+Z6DVWW2#9'
MD D=S=[=_EY]^&Q4D0"XL2US'D.NKSA-2&4MV("U)':XOYZ;VU163U>74+ 2
M#?PNOF3==]OB>& KPB&Z7G62X%^IZ@8BB>8&XV83 %AOTGU9Y8J@CJ("Q?8#
MM1[^MCR-_=?"U9_RAHD_'Z? XL*?*$@L_F;!Q#:MMH\'"RF2%!5!=D=JL[;
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M!-W('6\1H\]-L176*4MRR3RCS!#BP D#9I,.RA;#$1J8ZZTY-RHDOLMH(<5
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MV8>6HF3VQ'(U2E5;,+2!R)9"%)'.5%_RI4)@ONQQE;CX4?$4Z2X4VH]14I9
M_K7NHDA/VB=A\-D2%%@ 2.SS)EW;:3O&F/)J DJ+<RC*B6(M +^%,63'IBL2
M6AL]3BMSW"C0^UVW\B?(V//8]HB@I14XB]F+>5Y'EH\8)[XA8(7REP I)(48
MAR+M!D,P:V'E3S:@.A1 )! "CZ5Y&N_XC<<+%PL@ B UYZ:[=MVU=3FZR4 G
M,5IVJ+'P!#6QCN5FH\%\-JZ'4I*>HFKZKL+I6Z4D!2D^:;![\-9:FM50E04S
M.Q#)C0L(W;?$TYZLHFFNIS(6"W.7/,0+DR'F'TM&,99R;4E*'0?#64GQ6Q_4
M<02EQLJ"B%%*PI(.U]QYTRNB7!8&("7?M&K;$:QBJYV)2P3RJ4((N9G5^OD<
M%,R2M1*2$@G?>R-JV"B-SYF_C7 UT.:.5N9E-J")8@RSBVK3@B:S/X@-'U^)
M^3=",#29GA@I!I:CUD#:TI%@ V=B>_K6_ 1245,HP2)+/\@7VEK:@8PI80DG
M?6"7AGTM9K69QAG<GK64DDD &OCN?(GRH_$]^&44!S-8 &QZC2WQ]<)JK6TB
M9;L;G]0>MD6Y 6"2I5V2"LG:AVH;&MB/6OQ*:;F P@6 Z'K,NQ(E[V FHI1+
MGL-&[,WW82YL:62H;]P15_ @7WVH['R\MKX%5H\KRXTO>S3L_P!WP=%2SJ8V
M+N06W/P.ORP8T^AP+!OK40E!)30 L D5>]DW9)L=APLA"@0IB)=R(VV;I_6\
MZA2LI#@<H(&ADO$^CCRPA!<:\-WK-J;?<0#\$[)!V)V'[/0\'J<Q4 "8 !B^
MS0WZ88S:DI6D%(YO=H#NS, YN 7?;2V[9D'$E16@@[WL=JO;RK;TV\^_#%%)
M /-#OYQ]LV^*VHJ1RD%H,B2S3/VSG&#:GD^!'*QTDI3VO;??OY&P ?@-C=\.
M92DKF!8@!5AI#_&]V.K!W5S2Q[E140X9@^LZ&6T G6\8FKV&@N=[26BEHH&/
M'SKI!!*2B5B9.*<!(OI"?TFE9600 *XM%K520M7+X5(*'$N2S$'])Z&<:_42
M*U,)< G,) .B? N2;  C4P2P+L_87V98R5<_(<L;"!B=7S%*!'33<&01ON3L
M=S7<#S[(<&(-7,&Z02'-HVN+[?.,;53_ -+H_P O\%($N234IKCNY@];OCIS
M[)N9&/3S"> '^$96 DJLBNF.LCTOUK\ -^-]X-533RBB!"ZBSJ9*GYKO:1 '
M3'(/VJY;\9[2CF4XIY2@D$,6/*[1 8D]B_7$_<Q=3?7L*Q&)]UV>T5 D4?";
M==NK59]P=MZWH&^.C^Q"C4XNMG>GEJQ:Y\7(QDN+$1U@MC@?MIDTY/A25!0)
MJYBF K8,OF'J 7N(F9@]V2%#W5I%]A=*K[[Z;^%=N.NI2"9#,W:?B9#W.V.4
ML$I!!#M$WUF==',3@%3V]E0%[=P=]_YVX* &  /5KL^UNLZX"9=^QAK]L(K=
M15=2*NC2AU$?=O\ #S^(XDE+NX(V+=]_*S?$X&02[/!AWZAP26?7I#' JG$D
MD%5B_=H[T+K<;BOD?F."A(3VUE_@")]-=L>+:7$':X-E09W(-S.,'YB.(&C,
MX >Z,?5FS?Z6@"MZ[^E'BNXR0.%YUH>B019]]3\QZMAO()?-Y>8%2& N$J+L
M'&USOTQ]=_'&,;CCB1[06ODX[G+S%@F1TF+J:8ST]9!'2EO:@1M]W?[^->S2
M7KUB+\Y<L(M]/N"W2.&+ X9DGTHIW&I%[6DG2-\0ZGF6@=1^LFP/]<]K\[/K
M^_@5)!$@DL=O7?S^#7PZ*@.H ,7)?TBSXL=YEHL'ZS=CL5GXU?R/Y??P0@D@
MD@MH0&^ 'RO+:8PNHD!(<@.Y()^ \_UPF.9B+-21LFS2E C<V/M;_*_[<A 4
M3 MV;^NQ$^F!*JI:Y(!DN_S ]+S;"4WF0AV'*:$H6['>;^U=E;:D 'U^U_;P
M5((Y01 !VG7JUNN%ZJPJE4#@.@S>6VE_N<8E%YH*6TPHOV5(1W)L>Z!Y$#\3
MZ^G#F-6YT@D,(403(-V<7'7]=><NH=9)Q?M&ZS84Z UE<DAU5D@*1F\6([A(
M&Y22L[ &P#8!/&G\2I-Q $!^8@'L]HZ >8TQ]._L]XF:OL.*!4>:BNL@)!$,
MLJ0&@LW6S.^.=VG-4/X]CF1AD.J#J=.:MAEH>]U+PN1;GAHIH]0*,<H=(KNH
M)(!(.GT<O[O/YM,@J2]X<J)$..CNSZXL\QGN;*958+^YKDD,Q=)/A$%GT80=
M)&.*V/S"HLI31<LL.*05=@HH]TJ'< J(OM0[#W>D"TJ98+0X )(L0YOW$:09
M;H^$J6>Y:[K6?"6=P 0!XB6W;9@VF)$C:G^L)0V7ND!(/2'!V K?;S\A\['F
M*Y>6--23REQ=@;V.QE]_.<6PXD%@<JX2S26(?0WTV9K8<6<XL*'ZQ2DC8DJV
M%&]SV&UT1M7GY<9-!*@Y1(ZL>O\ <"<23GR2&7RVNKZ,.H;Z8'3K+)G+ID8R
M6[&8AH?CNO,NJ0J8),=V)*CDMJ25Q7&9#S3S9*D/!:T.I6V2DQ3E4("'#*4_
MA_P@[GKI (=^F+&AQ%=,^_\ >*A'NVYB!46#&H<"7#%V;!0DQGTA;T6$KJI2
MDNL DG?NM)2NAMYD5Y7P!=+W2B$KJ"2TZ_??4X*>+UR4JJ4LDM+\RZ:LO2#D
M[+0$K<"[DLQ-B<*YE:,(UB<_AYB7L7E@J!E\6#T/8+.1E$(; 4M1?@3X28\R
M%-0 DK7,@/=+T)2G&495%:GRJ8K#*"VL\6?O>XV9BIG<]RUQG*(4BE5Y4+0%
M<PIU F&( #$#:]]\-#FIW%K2%&@"* -D@ V"0*W)/<CM5;\27DP*1Y0#(<64
M3NSEM/+ #Q-5PJ7!8&\VU#GX&[ZN\;--K;ZBI*=K 4=SZBZW^!V!\N*I67JH
MJ'E!()L=GWZZDCZ8>I\020ZE$N S2Q>TZSMY QA)S4!OK;0X\VV>ETLJ05("
MJZ3X:EI=<W !+*' @;KZ019QE5$A9*0&M8G1QIITC7:7XVI4(]TA522_*4DV
M<.[/;:+$8/C:B2DAUB0XW25)44K4A82NTK;<1M[JP:<:6*4DT4D <$]R$OX=
M-1#]W:3Z[O./(XDJF0I!4A22R@6< "RDD0>H;7?!#>58*E>"IV*M5=2XCW@H
M7?<JCE#C/59/OMH;5N22> FB%&5.8\)0S>;L-&9-YP?]ZY98>K1(6#!R]15-
MSJ2D)/,27<<R1+],.4/)1&F\@T\VZ_+DLH5CIJICC;T2<T\VMIU\+2XW)C+9
M$F*]&(9H2OK#;B%LA+DQ10!R\KF[LXVZ2W;<F 1Y'$45@J@FDB@%D<E0\REJ
M4(3S$J(3J>9@/_")./(U IU 7U41[JTK*NI*P:<;5= +;<M*A0HCIW(-9_#%
MR4AA9C&DSYEH\],(G.*2KE62"DEY$'=)UL2X9C%C@YG/(*2E2Z-&J/VNWP/Q
M!KTW/$%92HH*(8  1?3YRUR+Q&&!G0P\0TO?KZ>7ZE-YT!225I\][\Q7K='?
MT/IY\+*RRR+'33Z_T/U$SQ!/*Q,[WM>/+=NCX5D9Q+Q0L2?J\ENRS(3[S=4>
MIJ2UL78[E#K _6(4E#C9L=*I)RI(/,&>!%NTCZ,\W?!OWG2J(%"I44FF66BJ
MQ9"DN&)#*Y3/-, 'S;W=0K=2[UD,O-6AUH+\1!5MTK:<'3UMN)'4A0 V-&E
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MMB/0]]NWG>_&%9=8$!IG<QU-I#L2.FPD9[F#E4RY)L'CK8#ZX,&?6V-W+'8
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MD =CY#S.I9FD$\14J1[Q#@:$L""=R]B]R7><;)4S1.5JTW8TLQS .7!)!<7
M+O8.&8SCD5KIY.&UYK&"TH)9C:ES28R4F@(R\C(=BA*!T@ 1W&Q0  K85L+H
M9?F0B/"4(9M6$R'U'TQ3*XF!5J.L,I:EI#D !1*@&T #,(W?#"N;+"4RX;Y=
M!2"\PDJ#C*DFJZ.K]8D !06BQ[Q2=TT()H4^;DJ) D\JB(/_ -VEM6;#!S&8
M-(9C*K%4  U*04U5$20EQSHU=RP)<1#A'R&3F%!D2'&V30*4J4DJ3WHC?OV(
MKS^[B%6G22X0@.-2!?RM_6#&&:68KD(7F5\B2'2A)(6I]%"S6$[SC,X612RA
M"$4E*!2-R-A7?L+)WV\SVXK:M$.23)+LWG#;;_KBT3Q)1($A*0 @.62P: ;.
MY?3Z./Z;)_K!(] 0;[_$@[^7QX65ETJ+O-I?0CSZ]]\3/$2!^8B=7O&CC <O
M-(>9DQU.;/,I(WNG&G4.)6$WL02H"NP4JNY'#5'+E!<2&8N/,!Y&D=^I<B.(
M!67S=%1'+42E8>>56A&H5<O83.&0Y)(4FG-AN*5M8JMB2*V._8^M\'%$*?PW
M^+VL]B0&(Z8K1G"%)'.;A@22_*1>^NCR[AH<QG.* H+L"SYBK^1 '3Y?/?A9
M>52%#PR.P;76Y&NF&!Q%B0.4S/GUO'Z]\5_3'ABP03= ]JL[[W8W^'_5O8^&
M6!L-#L_R]/UQ/]X,D*!(.A<N_K]&WC#TK4R94)!>0E&2@H#;3S;:$#(P0M2E
M1Y9;"2N9%ZNN',=MQ44+A/*(:B='OPH/@=A:TI_H3!A[.9."C/U*KJ=UL#<\
MR@D%P[N2T@DD:-@9G4P3TKM/:TFP1MZ>\#V/?U[[6.!'(R0"8;16OFQ\OCK
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M\Y_MU_#],>_X!WL@?^(/0W_J,C_M#C/N:5^0;X\<]FS'OU_#],>_X!WL?_\
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MXJ/H:_HOP21[&'*&SW/U7/V?O_3G'CPO(%@<K3BWYA\E8D/:?CXMQ3,^J/\
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M^1_7&?\ *CV@D_O7-2[RC6_\F+O[S9]%_O\ _0PY0[]_\%SW^W.('A?#S_\
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M;+4_0_KB!]H^-F_$LP9>Z+_]'IMIA(_0L_18GO[$_)T_^BZ@_P!O<2_ 9/\
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8;^VIQY-&DDA24)!%BTB"/KC>'A/!<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g90195g16d54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g16d54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %SZ^65 X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,S4Y
M.#DQ' (% "U-:6-R;W-O9G0@5V]R9" M(#DP,3DU7U-)1TA4(%,M,2!&24=5
M4D53+F1O8W@X0DE-!"4      !!;8TMFEL_,I9,4 0<C%H-W.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "B
M!1,          0                         !              43   "
MB                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MB     !29VAT;&]N9P  !1,    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   H@     4F=H=&QO;F<
M  43     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M2>P>>!_:6 S"Z@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" #/ : # 1$  A$! Q$!_\0 '@   @(# 0$! 0
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MB@7=\37&I53-OMW+OTL=ZX0@.EIM2PG?*B9(GBO,G31E:8L.[][6FWWC4PF
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MZ??PR*LQ@I26H 3>O3PC:D#+)!,'^&Q.\?Z\,18_K]CZ'SM"RE)3F:H86=W
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M34:QK++"!.5),G[8!B-#$[;#:)GA;FC/R\83N;;ORU_?9H"?J $E+8F0)C0
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M_CQ(JD$&]Q]/U-=G$3;06U>OO3PC:E(DITB9D$SI\M!^!_,T:G^_O](7-[I
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M;P#=6U#6)'E!!/W?#KH/PG@\.Y"AH 3Y #RMY^5:<C."4BU2-T@%SN]1T'G
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M20D)(8U90&C#733J8Q)TG"<'EXG&X?"K6IGF)E*9*0HNZ:/+0@AYK%0"0S
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M$4(87;>]W\VCT@6E24KEJ"DJ2"E0^522 H*2]P7N:UC65$1!W$GKKK.\_=Q
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M22Z7S9JZAJ]6#5+;::EZ<P9@20Y*:4-[/2A;9G.\ *!&802-CH?U/3X'UXL
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M)C0#76#'W"#_ )<6D*2L)4YT<$6 LX=ZMM'*%'H VE&W]78U^D+G?K$D221
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M3%&=*2J;@53'*TF2#VF%[[D9T9BE%"%A56[L<A<RK2Q37%BXTP0FGNC:G2E
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M).26 0F;*2E!KWBI,Q!!*;)>FVCX^(_AWPC&SA-XBM$[$*229<E*UK*2:A(
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M\V?PR4H%+E#L0I%=Z%P.=+<HCU<K&322*:XVJN4!H'T.T%0K0F?KDKIU*_\
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M/@-'9+F\-Q$O%*2 Z)<V62.8#-4VS+Z"\(_VNX9Q((ER,=P^8A(*P$8F69I
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M$4K+0B)>J"I7P*6TQ(C7Q1KI/#I9)+,#7ZO^PHS;PA<O#)5WITPZ]Q"DN0[
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MQT;U(@E.$4$@BVO. 3XJNH7\3*!W?SD?YJ7B,2NBIH(\5/5JDJ&P\(65RA4
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M#9"]6.',4,(0)/B6XVG;S2,QU]!Z#7@P:$A(8UJ6NVEWYA^99H9V3@!2C<6
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M5KF, %1GH9D ZSN#OQ:2<J?]5B[TY]7'.GC D! ;YB;DZ7M;P^T&MDE4>?\
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M"ZF)2$N">?B 8H^YTEW4MSOK6XR,VBE(<B>A^QIIJ"2)\N/:X>3)("DSL_(
M"V[UMIMXF/SSQ;%\12J9VO#5R02>\H+;:I"6T_>$3>'JRI4%*;(!/[J=/@04
MF/YGC22@ 4<DMLXZULV[-3<MY1?:+K0'8&GKTV&E!6)3:L$5+JTCN%;C4I49
MTV$_D -_6>"RCF>H/T=Z79@:ARU87V:P"V45YUYT!\@ /I%Q8:Y:5+RD%5/!
MD $I)C8D$$#7IKY^8XX);5G%7;DP )O3V8((F!F(%:L ["]WZM5KQU!@SEH6
MTM?U>(RR0B20/.1.FA)D09@@<&RB17NFE14BUF!+GF(L T9R!0'4]='L;D:
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MS7^)>*R."X5/#\'.4K$J 7B<2%CM%+8I *LQ)2G,0$CY0 :JK'Z5^&?@WAG
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MW&G!'(VIYT?QV'AT>L25IJQMLUR]-;$7WOJ(C]0C*2.FQ(U,ZF3M^.WEH."
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M.\/SJ9W)NWFS5:K':L*G6E%DJ#:5-MJ3[NVHR5U#FB7G"/%WC@!,*GNT>22
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MDZ':#,3,SIL9TX<RPGN@]U]*$"NAY>(-ZPT2!927(9B:#U!#'IHQB24UA#B
ME2)5,I4-!O)D#P]#UZ]#IP2)4Y3#L5G.I@EB_4=:$%ZLUS#D86611+*N]MNF
MFI;8://,(<J<1XPO5%9L/VMZZ7&M4$-4[:"@(02 NIJGS#=+2LA0+K[Q2E$:
MDD1Q]%^&_A>04#B7$U]CA9?>RS P6GNL.\78G,$A(*EDLD!ZX''>)8+@>%7B
ML:M"$)"A*25#M)LPI)3+E(?,I9"5-3**DE(!;O\ PYR$Y5<AK?0XLYJ7>AO&
M(FP*BAH'&U/4C56AL*[NQX?25/WBH9=*0FNK&U,-.A+F6C(#G'L4<3Q&*3^
MX#A?P>#3W)F) $I900SF8G_ %Z2RJ:;%:7RQ\,QW$?BCXUGS,%PO#S<-@5J
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MS QKRIO=!BC"EAL]^<O2;FW?J.]VY58FNI[K6M5"D*=:=:?8<=880U[PM3B
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MXC#$!/:! /?J"X8FNKOZZW,%_%7BZ?B-7 Q\.<7,@8I6$_F*U+$I"49@J<I
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MM1,F2"+:$E(%*LP#>>K)O4UO2D9$R=,6^91427*B7)?[6;7T@=Y#M>"I1 6
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M(43J2.&)3=+O<YF!<;-87N[\HK*4#\I*3O6P:C$G<78]:QJJ**E><SJ8IR8
M(4TDJ U)*53^24JZ!4<$*."337K4Z&U>K](%*E#NYF8_,2+FMR]O.IA<]24R
M"I3=,@>$)E*52 -#!!5 .\ ^6_2740&5I<N=K>&]QYP6=6AZ4#1''E--N*<*
M ,BBE*",P#AT!.FJD@$](_*6?KR%>5"^[5W-GB'<N?&SQ]RMH$!6^;-'12HE
M1ZJDC;]T"!$ZN0"D%_6_4[=/I'*)9J.FC>_(:!AXB/+;1/B!2)DD1,#37R'G
M(\M)X-RWL;:>'ZPKF?FHPUJ>= [E@78;M1/<:A ;2$D$*222,NT)T'E)F?YB
M.%3%!F<?O7:M-=:\HMI^4=/I$/J*ILK49 .4^9DB0$Z'IK_I'%<$E0Z@TV+>
M+,*^O-Y<)[O(<Z\M7Z>L(JEU*C(,B(4"/*!!]!Y[?'BZR2 P;NU>E:@FNO1X
M$/JIJV(9ZO1R*'6T1^L2A4R0#N"!IL=SZZ SN>HGCA53,>9:GATKL!$$DC\M
M"["I%[W#1&GD?:&T"=-A(\NNNG^6\J8$[#[" $1^L\)VWG7K(V.T1K$[SOY<
M0Q504YM:&H7D)! (<@^]J5WA'5*3),CU!(W,3M_.?QX=V: S%Z/0#*36GC3S
MMK$A2B[@NQ8^C5%VM>%+JM8'E&_0??O)X*%JS.Z@7.X: 7%&#Y=/Q@_#\/SX
MZ!A-4KU^)  UUB0)_P _B.#2"SNST+[>_P"\$ [EV8!^E/L#IR+O"QT@KT\O
MG(!)!]1U'IP$&*)/)[BGI<?O"I]841(  5H3KL--YZ:DZZZ</2H@4!!:X%P=
M U/"A@%2W#O6ALS:EK-RI340L=7"(5&<D[:'?0SKI&WW1Q(+UWW^\ '-14%]
M*Z"O2OI"EY86H   G1.FT;SU,1KZ<%4EVIR!;T_7Q$<2Q L7#$BU7M<NP?2H
M>%;VI,F!E(Z[B =1Z1&@ZQPQ" 'J*LSAF^_(_2Y"U ,/\Q+'G4@D=3Y4A<XH
M!!C23I&DZ;QZ'KT(\^'  @EW+$Z4)'HW,L-&@ @FM3=^5;;TN Y:AO%J=G+_
M +9OLO\ _P!Y?D%/I/-7"Y$^7&7QC,.'S!1LR,SD.?F9J[-:"0EEO9DEGUKY
MO?QKH8]=>TVG^WWFF9@_M34QU&M-3'^/'R3$E\3.2WYC]OUCZMP=3<+P0:G8
MC4@_,HWTBEV5 H ZZSO]\_".$I8@AZIHS7;]6MO2+ZG8[M^WGZ_6-X49,&9.
MH]?Y\%TTKLWC].<('E^WND-6",IG:0>IB " ?6-?Y\/:E_6H<G?SY=(KK92B
MP RJ!(KIOU##[O$=Q-BVUX:IBNI<#M6L'W>C:5]<XO4"0-4#S)$F($Z<2+%G
M)8L +^+^?+G2.1AUXF8$)% 1F4: >EZV=]1'/]YO]?=ZD5]T5WM0HYJ*W%7]
M6HD'[#CS>RG-"0%@[Z3OPS.)(S,.V_(EW" =2/S$Z. ?,MM2,,B2G*E@ 220
M""I[L7--:6<G4O&ZAUX.IJ5>,06EJ"<N9$E0R#4  J4(Z@^8!X3-FJGA*EEU
MI#&@ :M= Y+6&O01<2@*0P!H7L[:7]!1O&D,FGV'4MI;4G,0 )  3IU(VC>)
M$G7J>$MWFY@5_1_OY0MB 7!!Z.&ZZ=12W6&Z&TI1)*2I.98DQH"1G6!/V004
M),1N-YXL !@7>G(;;NXJ6 >GIR?F$#4UO9<9"W$I2M*<ZU)"LY6H2@ ZYE04
MDC628(T/$\A?5JFHT&UZ@UY4ARYJLZA1B2& ',7TK<GKK7: XU4FBK%AYO*I
M04@_:S#-*B(U$*26TF"K*-0".. -:@&^W*]A4LW5[0!EI*.U3=V8U9FWO>I;
M>'E/0LY0 A*-4@%: 2DDJ620 "91$ Z[R(X:D 5J?'5A?0@ZU\:"%K6LJ9J@
M"@H[T (^HM:UB>$4[_>,-4R5NELI[R &FY&4.EX$@0/W4ZE4)B=.# !LPI5S
MLQ?U:S4-[Q"<Z#F+$<P".5PV[^O+;;*-VTU)J'U(=:"5-%10I>5+F4H="%)
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MV'Z6H0+KBG%]"KPE+%%<7'V$K3$'.13H2,P'A;7F@F!TX,*EN'*\PHP<AQ8
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M(826JA-16+<+L',II@J9M;J'LP2ZMQ117I)IT20H'NBO1*A2D) J=KN2-JV
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MD)#%99U3 V4V#CCM*\ML VRHI.7#-INMYK!"ZUEAY%LH\I(2_5U52AJLNCR
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M'320G_/II/!LY!J03H:V)(J?"K[Q(2"68D6J6!+6+@4&NNL!O8LHR0I;D;R
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M"4@OE"DAK=[7<MN2U6TALGF55,D%-;594C[3=8Z%.)R@%!*5%0:A(!Z*  F
M.&)2&I9OII16M+^8,+)2002:C8T +N-+W+4;>-!YE5*P5N5_<I6$Y=5*<0MT
M%)253J%I 0OS2 E1(TXG(FC.7Z$7W'F'/@;1V=)26403>C!G8@4+GTO&Q',*
MI9">[KBEI F?>20D*)*PDJ7"<RA/A,B-1KQP2QU8 L2-3RY/RJ_. 5,J*DEK
M%):G,.^A\:Q]I^8U0'RLU[C14$K*0\L%92$I2H+!A.;(@$2#E0 ) D.9S?DX
M<[#F3RL#H1$F9W;UH+/Z5:S/7;6#7^:QIR5N7)Y3BT!:@FH4KO'4A(2M20HC
MO$A"(<C. E "@$ #BXHX\*DG]:D,>='+E:5J))+4%'!;P<"NE"[BP$!GF[6.
M.%QIUQ;BH5WE0\EP$G*%%:7<R79R)G.A0(2C-*D((@M[Z>(KK5WT#1Q(<J-2
M78:7JS$'WL(W)YIU:5A\/%IXK4O/2OED$J.OU;(;2DZJ3.GA6H;&..M[Y;C>
MMO$[ 9A)HI1"6<9?&IW;F?!X/I.:3[#J7_I"I;=5[P)[]:@E-2F'E)(4K(MS
M,HJ<0$.&=3,DV$RPX((M4$.>3<M_+0 "I="_1F+G]/.EB]X*;YF4ZEYGK@V2
M=5DJR%6H))*@"22-5=3/0\-!.K,'KS#^5'U,")AMH ]1I37S'GR@M7-"W!((
MK4**2H 9T;'I)(@CIM.F_!;N/7S<-]# $K<=[4,=N=26Y;^3B+YPTK<I36-)
MRB$I"TJ &D1E"I,1U.W'.UR0.6_F/V@20Q.9S9@6UVU%=SK"]SG#3'PJK%$
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M>9ZCSCA!FI8IS%B]JBMJNWZ6>CP3#3IS#UN2^M=:TC0K&2@(4Z!(T!5/QV
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M+]C9[0,%):PWRX2H C.>9-H&7U2D4\ C]:\$<+.+=U-!N+M]/?(]_M%@F/\
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M_P"6?U?UC)'L=/:%F<]DY=)$'0<QK/,DQH13::>?IKY- U86#@;WW;I]8/\
MGN$U5,\)>GF-6\''7;_P./M 2/%8>7BCECQ<R+3!Z;!@#3?[]-AQ(2*@FA+V
MMY,^@]3K$'CN$.LQJ_\ ED4IL;DOH8"<]C3[0%2B1AWETH'0@\RK2/F)8/\
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MC4S\/+AIXKAM#,LSE%=MVMR\&A78KLXOH2WK7EJ?*H;GL5O:%+/_ &-<M(Z
M\S+1^/\ 5_C^&_$#BN&U*V<&B"+>+']SR;NP7NGU_3UC2?8H^T(,_P#%CEH2
M?/F;:8GT I]OB9Z_'OYKAA8K-[H)/(W\_3:)[!6I3X/^@\/M R_8F^T+421A
MGEH/)(YFV?[P33_KY\&GB^% 8F8?_86\GL=8CL%;@^)!]0T!K]B-[0Y1TPSR
MT]9YFV8  ^0#'YC7Y<3_ #C#.[K_ .SIY/J ;VO'=BMF!'1S7P;W2T:E>Q#]
MHCTPSRS.PD<SK-,>>M/OO]YCB1QC"6.=O^GY/WK#Q--8@R9@ME_[B-.GG;E
MZO8@>T5F4X:Y: __ &GV80!Z>[G<::$1^<*XK@E&IF,P<]G9G.X/]S!I3/3^
M8#89B:59W%2--*CFVM7L0?:,&!^R_+& -?[4+-J1L?\ K:==?AP"N)X,A@9E
M&9Y9_P#^M+<^<.0N<D$*"5;$$AAL10/NU(U*]AY[154A6%>61GRYH67I\6!^
M7 GBF%S."OQ0?L=Z]:PX+&H(]??A&I7L./:+';"O+(>IYH66=NOU'X]..5Q3
M#D76#_REN3]+^WB<P-W'A^A-7J#I&K_@-?:+_P#R5Y8CSCFC9A(\M&/U' ?S
M.3JI1_\ :K]XXK&_I^K1@KV&?M&"/#A7EA_[T;,?S8C[^)_F6%-25.:GN:[Z
M1!4'<:=:TI2S/?=M8&7["WVC"I/[*\L)W_Y4;+O\.XC76/Q]6#BN%  =>Q[A
M']_UB<XV/H.NL:%>PJ]HV=L*\L/_ 'HV6.H.G<=1_F..5Q7#%@"NVJ/3I6(*
MP:#74AV\/(B\7IV5?8R=O7E3VH.SMS1QOAKEU3X,Y<<Z^6V.<4OV_F/:*^N8
ML&&,5VR\71VCH&F4NUE2W24CBF:9LA;RP$((41Q5QN/D3\.J6@JS%22Q2PH^
0K\]OVA2@7\/,>#VZ?8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g90195g22v10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g22v10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (QB^B80X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!X\
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              JH   2\          $
M                 0             $O    JH
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   JH     4F=H=&QO;F<   2\
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *J     %)G:'1L;VYG   $O     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      9 0
M  $   "@    6@   >   *C    8Y0 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M"!4B<8&1T? RL<'A"2-"4F(D,_$6HB4T-4.2&%-R@L3B_\0 ' $  04! 0$
M              $" P0%!@<(_\0 11$  @$"! ,%!@0#!P(%!0$  0(1 R$
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MU/7 Z7;?9=O?M_;A-+;P?OPWP0HY#K>,'T6(V]/<!V^_RX72W3Y8#IVD =)
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MIF/'!<TC>>VWGWW_ );_ -.$*&]Q;<;^_P!/+UVPH8="+ 2#>WH-^?IC+A5
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MNW<[_#\>#L_'X?OA=9YQZ?(W\-[QTO@NAW\^W;OM[O3S[?#SX.S\?A^^$U^
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M$,=;_P#41XKZL2#*MJ77U>3 UI9YY_K>[A;XAO1EE2.HLE54?H-)*)*M:-C
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MT<EIEL+T72.VG)Q9-4NC")(C1%HO Y7(.\DDXBT!*3QHJ5B[ZU8RYD:F)=;
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MP_KZ^[@ZD1-QZ^)^8^.#$M^&?@[J+Q'N(U:"2IA(F)M9250D?30@2"N\ICA
M0=IK,SI5K;$R.S 1'$S_ !0TZU/A_#LNW$.+5CI3*45+A-7\U9UM3@0>^54
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M&4,].>9'7DD2:RTJ6%,WM;;LHKU:R.Q):5(![DB2=[S! 'C^SE7L&!HHHJ&
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MX6"/CN/^-L&!T5_>_P"O!!Y[1T^/E]S@P?17N??N?(^_<D=_@>$((@#<<CS
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M03RXN1'B4NJRV8JRV"BRDJZO<R*LZ'G6RPVC6$)F$5H"(CD7$!MHW,DG<P"
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M6/XCB53\)D*8ERVK75TF66Q)"L(&H2[,3H!MCH<WFJ@#)07768 7)55)YZ@
MNQ!WB=Q;#O;%=4+_ -/''&@81<J=U1F4L SEBC2E$:0DLS\L:.\B00B/5XO[
M6/6RW]T<(5N'<*0%&6D>SJ9M8(_B:0NBFPWI@$U9_B,065JU+AP6H<Q7/;9E
M@ 6:(10)**#RD22!!('AA(L4 NX**-SY;'X[D=QON=CW]>_?TY16IJ+$"8)
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M=_\ @$ B%N(!8[[+(VWQ4&<I:J2D@=JI().Q!B(^_A?J)]#S2^4O^!V2\/\
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MNEXL=*L!O)@"!CBS])'Z/.0\(,^^3Q4-BWH?+6&^K;)YI),18D+2'%7I!O\
M9 !-"R['VF(&.0FQ$SR[WLO[1CC-'L,SI3B672:R3"YBF+?B*0,'>S*-C,"
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M$8D&GA@J_;4$[]SMVV.PW)/,200!V[G9>8CE!!F,W7S(TU*C%!&FG/=$ "P
M'QVCKABHM,%0L$W)YDGJ?"9'NV.%%J(4%/-@>[$$;]_+ON/(#L.Y]22.*@))
MB]NNUC N3]SOOAWW]GI^^TX0;F.!W#<@;N!YGW]_+[([]QV\_?VX?N3).QO:
MX%[WO[SMTV69W,P?#P&P(GS!.WKAN/66-N1E<F0B-%C22621^Y5(H84DFED;
MOM'%&\C#R4D=M3AG!>)<7JFCD,NU5E_S*DA*5 "8>M5)"T1 )4N0QC2JDD*:
M]7-T**RS$&Y"]S43L(!9>;#O$PMBQ51.()\0!?T/XA#/25@^"U+7CI:@HR/
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MJ7U*;6N"5DW6#><2@U1F&X!!&_GMN?=\OCW[[<<_K$Q(//8Q'/D;SRZ$7Q<
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M-% '<[GR_B9F)9V[LSDLV[$D\;4JU:]1ZU>HU6M4,U*KG4[F3<L9,7,+,*#
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'O/"XDQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g90195g26x53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g26x53.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '[*^@10X0DE-!"4      !                      .$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $( <@!O '0 : !E '(
M( !- $8 0P M $P ,@ W #4 , !$ %< ( !S &4 <@!I &4 <P      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     <,   6=          $                          0
M   %G0   <,                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   <,     4F=H=&QO;F<   6=    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   '#     %)G
M:'1L;VYG   %G0    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M #A"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M       $    !CA"24T$#      5@P    $   "@    ,@   >   %W    5
M9P 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@
M6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M   !  #VU@ !     -,M2% @(
M                            $6-P<G0   %0    ,V1E<V,   &$
M;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M  -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E
M8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (
M#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#
M;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M    $G-21T(@245#-C$Y-C8M,BXQ
M                                  !865H@        \U$  0    $6
MS%A96B                      6%E:(        &^B   X]0   Y!865H@
M        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M   6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z
M+R]W=W<N:65C+F-H
M                 &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #
M7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M               "CP    )S:6<@     $-25"!C=7)V        !      %
M  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '(
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M6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP;
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M&E$:=QJ>&L4:[!L4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4G$:)"4S-T-5=C5686)RE]/7&28V1%-UA/_$ !P! 0 !!0$!
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MPEH91%8L=UF<(F!W4HHCD&/=X^L5]KUH WP_RS*G!N<=2U@ L$@,S TJ4]J
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M(O-+>!;>9@07$1T>UISZ V>T*OHE)D36M?;E8U]N?=&^^0\S$UV,B&/F&-Y
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MH%W(,1Y;CP:2UBC./>HVIP9AS:FD%*E+")A$PBX^4B(J<#=CIJ,CY>/?UV>
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MRBM6'EO\V(OD2/Y$1'+N@*E&/1W'8?#;%3/+W7O./TY?"\3 <4/@)(;E7*O
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M*TG;FY%?0)!Y.IZA7/A/ID4@/QP7C@#O.Z21S R<"#-K#/=4:<WGAO/C'_\
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MOK7YA^]H/]!QVH?!:OT;_P"8G /OT_SQ]E/=$]]:_,/WM!_H..TCX-5^C?\
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M8'7&<UY!C\9&3GN:.(YQY-AF)$;L=JPS1D\SX#TSTFC/ZCP ,9+CN!HR3+$
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MQ9$!>C_W\N]V2]O]YGR][(<+63GMDN]O\5Y&3*'B;F;(L/=K.GM8#N^1@#<
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M(9/,^ \^[$\9SG!QC&0<LP1GBQ8XK/S;B I;U&(U',L]G(1A*$0[+'J=CO\
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MW[6#ZP+SK<[EG /<>O+D>>,=W3KR\_QKF"8[\<SS^YP?$D'GZ,\\HF2<9&"
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M)AFYS+J_7E7)F>:OY&WG.6QN49$CKQ]<QRQC!./= @M><<MR,C<,3 ,-CW.
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M=K")VU\VOW:PBQRB^ISCZ7-CHP2+MBY0^_<J\>+C&H<<R0"E^)(FQ3LR60&
M>6^\#/14 DNJ-Q[9DG+)EXU#D<&ZB21'D5P4SG&#NDGQ^ )5[5%L<F4)KD&J
MR,JBN^J(B?8]<F3&# 8VPR4R"Y&MVB,CC) B-3!:F=JC&)9]]^/\\49S]_-G
M[_)U4V]M?-K]VL*4[:^;7[M81.VOFU^[6$6N$3"*.YWBFBV6SO7":AUFSA-5
M72BG5R$D@,FM.E&%/1Q$8T6B.=V_J2DA'BE"[,<C9$Z.41L,EQG9,=_W^_\
MY\5S]2J,%2*\%5Z\,^Q$ *.<:;,.-E"WGY,\J4DBC9"2?*..+/D3BS"B2R'G
MGGR'%+5OOVT3 Z8Y>"YOR(7T,7[.S^#")Y$'Z&+\_P#J[/R_/_<PB>1"^AB_
M9V?P81/(@_0Q?L[/X,(M/( _0A/L[/Z_E_V/UX1:*CH]>O"L$-6OE[*%85KO
M\_;:-Z_7O"8'AYOB\%M^R8K_ ,,C_L0W_P!/)R?$_*HP.N!GQPK"(OW#8DD3
M"E77C(:8#E&X0N)(L=59DA9IY*ULQ!(+AB2F)1U+;BFP'6DEK2VO:6MZ2K>F
M3XGY2F .X#I_X_\ "KAK9Q89 $6L2R\?E580@<0JRC3-=?@!BC%A-B#$3+1*
MHYD@I<E'('9<)2X^L\)+25;*8TXR?$_*4P/ ?(%K7[5Q;;3"8ZJV2@V:0#':
M++!K\Q79HP41]D0A@HD:-()>8'>8D 'VGG4);<9-$<0K:"65+9/B?E*8'3 Q
MX85W>R8K_P ,C_L0W_T\9/B?E*8'@%NZ !UK6M!":UK6M:UH=G6M:U\FM?H?
M)K]6LA2M?(@_0Q?L[/\ P_W/F^&$3R(7T,7[.S^#")Y 'Z&)]G9_!A$\@#]#
M$^SL_@PB>1!^AB_/_J[/R_/_ ',(GD ?H8GR]_\ 5V?E^?\ N?+A%IY '?RA
M";__ ,[/X,(M?( _0Q/L[/X,(GD0?H8OV=G_ (?[GS?#"+3R /T(3[,S^#")
ML '>NVPA-Z^&^VQF=Z[Z^.M_%'ZM_)A%\^S(WX?]'A?#Y/\ FC'P[=NW;^S_
M %>%/[M?-K&3X_?[D_*HP/ >/3O\58%FOW&M,LM=J5F,CHB:M4-;IZ#;(BW?
M*%1E$!"D[.\Y(M"+!$<C8TMH_0Y1#+Y(@Y;HC;R0B/5DP/ <O-X>"XUCE+BX
MF%XWGV'=O <LL:(H:6:I,OGS#7YL'6_NY&,1#LA&JU!QI#NFY,81Q1JA(E"%
M2IH8;Y.7FP?D/+U!7-4;#4[J))%0T>XTN'E7(28 EX B&E(N40 !*^3.CY(0
M<AEUR,EHT]'Z"D['.:\2DN^M:;9/BF!X!77[,C?_  \']?\ ^T8_7W[_ /=_
MK\2N_P#\6_GWC)\?O]P$P/ +[\@#]#$^SL_@PI3R(7T,7[.S^#"+3R /R^2$
M[_/Y=G\&$6OD0OH8OV=G\&$3R(7T,7[.S^#"+5(0:%)4@09"D[TI*DL-)4E2
M=]]*3O2-;UO6_CK>M]];^3"*IPB81,(F$3")A%#M^X*X]Y/G=S-Z!DIX55:3
M6'JXN;EH^N%BM3&IP8V0C8DP!,E(@R"6R8Q^0<*1$E,L2$6T')-(,T1<M'<.
M<:15@D[0%5 TS$PAQ$BM\J2-CWUO#PXKY*80TTB$'/(8@8I),B-',GD*'<=?
M)<=+,603_561&],'$$19HNR@0LJVJ)"B!1H=ZT68Z&>>KAM9-JYDB*?+$N2N
MZJJH5]JL1TD^5"0.H]I^,C!B];(PHP/O_#Y.[P^-9!X4IA$PB81,(F$5AV_C
M&BWV0A)2VP#,R?7-;U#/NF20WDDJL%7M#B=-!&C,OH>FJ97""$$MO((&!=C'
MTN1<E*!&DQZOE536./:?3=Q^ZU#)C-Q54AJ0!X39(KR]7K[YI,1%Z\Z83ZQ(
M;T@8O1;WK#WO7;204\E#:4$5YX1,(F$3")A$PBXN;AHRQPLO7IH71L//1<A#
M2P>W7V-%QDH(Z">+M\9UDEG1 K[K6W1WFGV]+\;3K;FDKT11!_HV<*I\*F:8
MH-YM^7):+CK+;HP]@B>:/&F'AY&/GACAUR(<I(QY.V2&_'&&D1GPCW%#;)A3
M6((* (* $PT*$$.P((*PA+; PHS261V&6TZTEMIEI"&VT)UI*4)TG6NVL(JC
M")A$PB81,(F$44Q'"'%L#8E6N)J; =@5-$V)4BB3FW%*FC![P(5(*'>DW1%/
M/B\CW$=U.V-M+9DQF]M^&%@=1A%5U#B#C^ARB9BJ1!\4<FMUNH)[V>UGA)K5
M0C=Q5:ATQ<E-F1FA(@19"A=:#TYYXZ2E77')24D3"B=%)>$3")A$PB81,(F$
M3")A$PB81,(F$3"+'-'395#K9NX6B:G;"<%:.0I^N1VEB1,17P^2P'XRSP[;
M0(^I&11(B.#+)/D)-XEHP 9V(U#C.&AEDQU\_P#]*IA.FCC>OUO5?C-2S!3<
MW5; ):$Z@6K('*4IZK/5MYMT:!8AR4@:IT$RXB1AC=2# [C<ELOUR]X1;O$G
M3[7>))%^0CIR;F/+IL@5;#D/)-"5Z&M;M0+GA4[%';*E9"6D*3!GGR<F2\E#
M[+C4.##B/DCOD4_81,(F$3")A$PB81,(F$3")A$PB81,(HFY"X8IG)LY6+#9
MM2FY"I,'"17D#4",J$E9RJS4N*6C8SRWAY=JI#0,FTEQI!=<EIZ+=UM,CIU@
MBJ!>)*V!4^.ZA'F380/%WDU5(YDL1<H,^!4YNG!DEO$ /"%O,1<\8^G2PDLJ
M/;&><96RVL=TBYGCNA1G&U8'JT3(2LJ*P48:Y(SNXMZ:/.D7MER,A+GQD7%;
MF)62/<(D9.9DVBIB3D"R2Y \EUS2DD5\81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%UF>D5HGI";J=TXKZ#[]'
M4<.$Y"D3>>T2$K5HS<[1EO5?8 0^K+!3:BG&VA[%K;<9L$G7F$Z4\K:VMM[!
MH4VAPMOC68'3.? T4BULCMR;\)O$\.1F,YCYN#ARZ#FL3JD>IR&K[72",-E)
MLY<P;T>68 WVNST?TP>?52U[0ZL)Z[RJ:XH^+IP5_P"1(\DJU1E C@'(:''L
M"..TU5I(+]J+J\A(CQ@UVE9D-R;,25&%4HE,;[8/;U]97G]_CY=/1]^MQP"^
MJS7'>US[0Z[5NT5'S#3**"W>$51950_/740IDQWC%Z0;;5<%0;LML;L$D)DD
M=^0:9),*5]=/4OU'RTO);YC%,&  8FXV4U(1U1C8U=A#=JJ8-5%U )3.'Q2A
ME6[=FD[%ZV.+DM1&ZB0_&))<V4#/?]_1YO3SY]RRTPI3")A$PB818&$<7=5\
M@9U'B3?(9SE9MNG@>&6Z_<QF)ZL"2G(L[-J,"*'JE/<BSH>F2,7&H*+F25,-
M !U$,.2>K$AR;RODK<M!]6HRM$666M;VE^XYH<6PQL/,S2 [TC7OPUHSDR%S
M1(VM6L:\=MMBPZ>0.@<3P&AX):#(]PR!%&1AA:TY<[H& .+'332;Q=5>;B6^
M5B^3Y*8AY&Y5FIB02(:RA%C5R8C8FPPDPY4T)*D1H-\M+4%-DE*%:2_+2#KV
ME/."*VSC5?#/?U\RI>&JGRK'6NKF78*[Q(E=XEKE<G3):^!VV*O=[*JO'R)V
M7)CM6^45#-U<ZOR,7&O#0FB[#/2USL!A[(1H1-C*!Y^O?Z5EAA2F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g90195g31l94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g31l94.jpg
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M  (# 0$!  $$ P        4& P0' @$("0 2%183%"3_Q  7 0$! 0$
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K#"RLK(1+L;&<N04J560F;*WK7%&C1'020CZ-.K!@ @UJJFIFIE^/8#7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g90195g31y24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g31y24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M 4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "W   !,H          0
M                   !              3*   "W
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "W     !29VAT;&]N9P
M!,H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   MP     4F=H=&QO;F<   3*     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !@ * # 2(  A$! Q$!_]T !  *_\0!/P
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MU?#7]5HV_HW5O98SP)H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ Z@&( P$1  (1 0,1 ?_$ !X
M   & P$!              ,$!0<("0 "!@$*_\0 7Q   0,# @0$ P0' P<&
M"0<- 0(#! 4&$2$Q  <200@346$B<8$)%)&A%18C,K'!\$+1\0H7&"0F4N$9
M)2<S-J0X1E-45F)E=K0H-#5#16:C-T159')T=8*&E+/#TO_$ !L!  (# 0$!
M              (#  $$!08'_\0 /Q$  @$"! 0$!0,# P,#!0$! 1$A C$
M T%1$F%Q@00BD:$%$['!\#+1X084\2-"4C-38G)SLA5#8X*2-=+_V@ , P$
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M/&+K_MM;HQO_ +$T'(__  /Y<7\NE_[?6KWVQ7S3S]*7=6O>.N,_Y4#QC?\
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M(: #<>^>+%B>;-YA=GK(>C-SI7$ "Z2$.*2^2@S<2A%C!-]L$]0SJ23GMC3
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M%O66OMBMU1.=01C(';T]M1]!D=^+:(W+^E\+ )J#"'$GSJ('<+D.KG +BN@
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MF-QK_AP5-*7\_P"/;]RNNLU7) =@+$0()@HSI[H=+"M0$G0YTU['.,^PWXN
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MJ546G8SC964"&6SJ6DG@.-9B'Z0 !9<0MV,/8VF0[CKSZ7F'BJ1,G])3N@3
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MT&H5+2HZ3,<_:)YXSUTJUA]6N?:<32\%&MRWL?\ V-3?_C'^/-_U'_T?#?\
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M7M_6>( X%_KR'/%$KN5TYS@4-YU4<=78Z$''T!V_K/$DMM_=@+T?IB-70VG
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MS_Q "FJBASP;ZV5TF)O=-QA^K==*9K;#O4J.\HI<;!("RD*Z.K.Y"B2"!L"
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M[<0(5"(<?3F^H/[877PU4P)5A9\X&)H>"H%-U7P.KJ'Z$I9R!IDS9!_'?/\
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MTB^J*)Y&TZ[_ %(%*J$ ]''+_"C=XV\G;X@<^Q[C;OKW&=3G;@:20P1))YH
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MC <@8]-_7??W_AP[ $$$O4_Q&JZWP"H84H>_\?\ CGAM%1+>GWPBJ\6N(4'
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M15H0,D@#I22,8Q@G &VA]?QS47-2U,B;R$38VDV TQ/F@5!KB"1#%^HG6_;
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M:\FKB"!K=)V"  Y,N1&XQGS*K$ATP #8B0 >^AQ$CF\X_ YO7L6'769$"O\
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M:O"HTVO)'F*U3@8&F21CN-/ZQP#!?E$(FS(<Z>LXN@$D\)2#?,#_ "L*C:%
MC.-$X]=<C4Z : :]M2/G)#.AD3PC51?L#,7T=&O$22! 9YO2?MS6#;:<CK.,
M@G3I2 <#V['!V^O<\*!!0+J!%R6>G_&.>OK@LP$ U4D@ -! &9YO\>!T@J V
MUR!@;$'?Y ;8UW],\. I%=2B!TTMW-M]W&>HU5 .22?:/;Z7M*W$0DE60,)
M[#.-M]-?YXQKQ5@40 T3+<-#778] ,:.&04$*>)'4Q;H3;:>O4L-C3I&#@;
M:E1W)T/?U.YT/:] 03* :4Z6Y"?P*H\U551E"-()F F@RGA8C-*RG"2<G!.
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MJ5$)4OS#DJ4L@=14H*402=\;D\9?#T&F@$!DJHFYF43'0GE?&3QE0JSZI/!
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M.0=-\'U[D""26"PNH(',0%R?<#!9=!8!!0G0(S?9OG&R9Z2"VCH"2  3KG?
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M\P!(8)@K53CL;[YXVG>3U-JS-1Y@I12I]F3U6P_;MIB@LNV\8#;[:J^PV*Z
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MBJ-[LR9Y/3U[6Q-#P2'-U7QG.E#I8SZYFR#_ '?UCC@_U*!\KPQ"#S:X&H%
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MY%&33\_,\M-,T"&2H/[1[E&H3FU?#M3>FS'75+22LI2#U*5OA*0/B*UJ(2D
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MM\7.\IV"Y8"T.A2D/UFI)1C(/E%EIM>%C4842,C'22,$</\ "'_3J*:J"8L
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M9F>(.7GTY1'EJI8*CBD$$74"VXN,:LGPN7G>%IS*#5\^JLTU 334:0Q0E%1
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M.Y_+XFQX("573?*B-Z'2\'74??9)_N]_SXY7]1$G(\*_^[63R)H&FWYOCK?
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M, $#K*C@D:Y2<ZG<8X,LD@%!(A$Z::#U%L%1P_[@R240F$=6B9Z\^2@TWDH
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MS>*)^3$4_,!6C *G4]=.48G.BN.2Z;24*<4M"*334)22  !"C@!*  E"1DX
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M&Z^_WP I9)L2 &K\WS4GIO@OE2E%.I"3OI_/7OZG'#0#);TT5R@-8EM]<(S
M:#YH=E/8K8?FQ5U6#T]*E#7! ! )[DC;USN/QXNJDE@R%!4!:B)O?2%B4 &F
MHQ/[%'^<%'3A.F1[@ Z#?3\.%Y89MT)Y-^FN%5$_I&HDZ(@E=T\39\#Q/ZT7
MRG.U$I?_ ,=)_K^[CD?U&0<CPO/-K/;@"^^.Q\%G.\0=\NCZO_.*@?M4"1XP
M+F .GZG6?II_YK*&-<_/CRM(<M(C\OCOU%+42QND?S[VQ78DY'I@9QC?3?&^
M?XY[<%:JS,EC1N%#]6>V%&1-C83$@VTO^7 I.@W( [C7UVW]!_ ;\$2@(<K\
MC"S2R!8 =;]V(5]H&,!P0<$_A_/_ !^O$!)#2Y8H <2=K1^6.T[*XV)P,Z$J
M.0>XVT^FWMPQ&H;<($&Q,R=GNCBR5.M1;4BT!W5M,&(QPL9 &.PW[8S[G^AP
ML6"/XK.^Q9G%AA,"3W:308Z\SI?"TVH*Z0,C((SZ8TP?G[$X[\2Y 3;'>R^O
MX<'A2!Z"5:J&$@)3G(UUT. >PP-,#.F_ BH$D(Q;G8&''^;:SS4HN[(3*W>Y
MFR@@#1X/-GJZ2="H# UQGN2 ._U/H=,<.IFD N-=B?R5$SOBC5Q52@2( )YR
M;:)/:$<+,4%20K3;&=O[\@>Y]_E674*F0T-PY#?22>MNLKH-( <77%<%&RBU
M^I-B<*#9PDY.,$[#.@QCZX)/SVUVL_KX&9 +,P"3WUN.6"H(%'$0Q3473JC<
M,H@@75YP=:3JDC8()Z>YP/3MG7Y=\\"*SQ54GBOP@RA>4-[@:*#@:J 1\RF
MGPH%*+N9$QUPKQ2.E)'[JB0D#MD#Z=B,=L\$2:9(=W$E0@2+;;M8O+IA/]0%
M5K<OH=.F%A*#T#73&1Z?/?&HSDZ^O -R'2S;6]E';M@33-0-M.1#E/>3]]#C
M#9)3KC!)VT(/IM]/77Y<,IJ)JJ0(#$G8/U:[/!_+-*)(@5=^($0.^%5I)"T@
M  $9 &^^F!CT'X'T'%O5ZS&@#1#.YYOMBZ.'B EL'H.4J]AR[8-MD]1P,Z9P
M-?J<#4YP=-,YV/$4#29DC?<@P.1* %L0%&";+0=I:!U]2[848Z%*7G&FN#L-
MA^&OKQ1I9@[/N_L!UOJ\ 622T93F(_Q;[8Z"*ORSA1)T['!],D^WR&>_%U4M
M2D?5[3I='M@Z2!U5S.[.E]ATPN,2@KH_>!"M<XSC; U&NO<=COQ;9Z::/0N_
MMTD!U,HL*8(C7?E]R&4[O(JAQ+FYIN5!51K,=SEK2V:FJG,L>51*K-NMF9 @
M_?IH<S)?IK$>3(;IWEN-!QQJ2X4K2C,S":<@GAH/SJN$$EUT?+(-2"CB/#)
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MXLJ4\]1^E"ID$K(*EI@N*#T=)R4LK6A/P(  ^#JJIH%&8"6Q22_*$!KZ ,=
M5AF?2*QQ"] F-B(6IT&E^>+EO CSTATHU+E'<M6I=.9FRD52QD2$)C2)U6EJ
M=56*9YP2EM]UU+34F+YJO-)\QI&?A T>(ROF4"NFFLYM (S22Z1E!"DHEQQ$
M$60>XPC(KDT$B3!YF"&YN]&Y86+*9]16L@9+BNKX4_$H[^@R00=@-CC3&^$#
MA"-7>/0-XT@5&$5KIJ!T?N\5[?:%(E57DO2*;3VGJC4D\Q;7EJIE/:=GSFXS
M)E%V0Y&CI<<;;;!3U*4 D=2<D#7CO_TQXC)H^*9AKS<O+I'@_$CBKJ%-)J(I
MX1Q$@/\ 4@V>IQ7C<HC(  )/S*732&A_D\@#=(XDJQS)@0Z93U-4B7(4Q!IS
M69#[<<J/W1L+PE =*2DIQA12= --N/*YWBSQUFFGRG,J,G0U$[3=*QOC=2,N
MFFGRFM\():N (\K3WZ(7QV55Y@V93.6<SF;7IK=N4.B3E4^LJJ+J>E$SH;=C
M,,.(^*2J8'VDM(:3YI6H@I'2<.R*JO$CARZ#76 3&VIZ!7*41NJHT#,9/#3Y
M004A)19T[6EV?S)\T/$?=M9Y[<P*E>M*IM3HE7KI>#4!EJG2J522RV*8["DA
MM"9 C4TQP\9J5+D+"R7D*4.(?$5T9GD-1RJ3PTTU&0%>\,LIW=UC9F9= J.5
M7ET*F1F4A5 $!$J*DY9O>Q..VAR*55*;&N^S:JBL40R@E$F./+E0);9"C$J$
M<D.1)*0$E*7!T.I(<:4I)XZ%&=EYU/EJ$B049V1A/?1;L8:@<JNDTU$BDNFL
M$BVJ11&WK$8$KPJ5!E_YR*!F7:]?D(B7Y0%$ENCUN2V&7):4Z^32+D;STDE*
M(5; Z2@/-<<NND^$SQF$>2NJ5_M,DF3K$A7:6/5> S:_B?A,_P 'G9HJH(JK
MRZ:B#5EUTBU!)!56HCS(JY%XOA"YAN<Y.0UZ\NZ37%4_F5#LXTJV[C0M/WNK
M0($;[W9]4<3U)4NIP_(%#GGJ"E);6TM2O+ &S,/%2*Q%-Q#.I'^9^N/*598R
M?$'+S@0*,SAS BT#)&IB0==</+]G7]HLB[;A?\.//=AZTN:-)EKATV74F%08
MEPMMN+BH>") ;7&E)ELKC2FE)*$.N-GJ&%].OP.8/-06..*0:I!8DFW"0P$$
M"XQF^+_#SEU49V4>.@T<>6BS5EU )H!D-$7!$V9O$!QGYGJ!(&#K@:X^N^WM
MQVJ"#3J%$N94'WQYDT4FDU%BHE=P?VW1P"ZL)"EJPG3 )T&<9 ZL?GPT*%*+
M@&;/^+:7)A=+!W!ON)*^[&DNV$_S"D]0 *2/BP<J!UWS@8WP==_Q<*B+%/"L
MRCY@DFDM@FRVYB>0"O. _,!*NE 2"==@==OAQ@[_ -^G%$N^L;Z&_I]IOBA2
M*:4Y,-':().YO',X*K!P2K!QE1P20-3D>V1H<C7WX90.$%4[<N[-\*S*:@/*
M$  $)2;F#9*'"#OB;/@;6575?0(_^PJ6?^_2/GD^ORX\]_47_2\-,?,K5TN$
M(W+UG5.V.I\#_P"IXC_T4?\ R.*AOM4<?Z8%R^OZG6?I[?=9>OT/\N/+4&2-
MT=[3^_Y&/05W%[';6-3TV4]J[$ $$YU]??VT.XQJ??;@[U&HF!IT'\O>9EX6
M00J1%R"QJ>XE?S;&P.-,$X&<^N!G<Z:[#<^QXL&-8%R%I^#4];X"H JWZAM.
MGKZV6-L9SC7_ (_W?+'!U! %&95]D1]=^^%HDE?D$K38BP'3&P&2 K(!T!.F
M/EG\.*!.A(!$B)^XZ1<<QBTHJ[%R$ 5ML/P8.-L]*\=62>YWWT_OQV&O%,C0
M<IW*&GK?OBT"0&7=D@^BU,'D)W&%5O"4@!0)R3D8[^Q_QSQ*8 ES?>>N\=<,
M-@;S9%\CZSR^AUM16L!)Z58^>@P-/F2-]!P-1X4@&3^W3ZXL!D#?"@P>DI)U
MQC377!^6 --1V'#J6X9W#6T\_P#$XKA #VJ-/-ZE]1^#'1-)Z0!E72<'3OH<
M=] "<X/L.^. 0H*IIB6P3YBOM!*0T+#Q#7Q,I&PNB+L!HF+A1>"$?C1WY3C<
M6.R](D2'$,L,,-J=?>>6I*6VFFD)*W'7%E*4(0DJ45 )220.*S":<P&E JZ@
MML]->K.*% -%3)'#48'019LL3TQTTNV+FHK\2/6;;KM'>EX:ALU.DSX#LM9/
M2$16Y3#:WU%?2D(:"U%1&F=VD@@H@RV"(,'>8VT0WQ*'\P!%"D@L(2Y5D2NN
M%NG6O<\IFHR(MM5V7'HZEMU=^/2)[S5+<1GS&Z@XW'4F&XV 2XB06U-C)4
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MNPF?1Z:Q5)U'9+BY+<.H24Q8[TI24]#0??(#<=QQ*UIRX&R@$E.7GT55'A3
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MY(ETME,%"?T+1%5B5(7)CK:90W&AH0A46)EE@J:3J%#Q5 J&7PJ@G1 '1^S
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M%2X&)\AU2FW*BXI<)L!#05C/%<-1I-)J"((@3,,EW%X 9VQ.*CB!1,@MQ')
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MAJ,E"4X=?^+C^+\5PTFFE$F% &DEW(>HT5H'9\)E _Z^?2Z*1_ITD/BK4"\
M#]4VMOAE>7-5J5I<C+WYPW*\J5<%\U>154R)'5YTMB&IRD4"*TC&?*=JS\QY
MJ.@%ORX+72G  3BR^*C)JSB5574J=S L(A)*>>-^57Q9E6=F$$T UJ4P.&@
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M*%-&3!FP#Y;/EQUI\L(0AU'04D\NLTI"#4!PDR7N%,"SE<X':\+FTYCIJ6<
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MFHS !(0T/2!TGGCE9E?"*BR.$@*W(FS6U^DC$%K]\5$45)Z)98J-R7"PZ"S
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M!"@$%R #() M&S*@QKR9HD01!)2(DAH@[85F00"1KD8[ #W]/?'% (+[<\:
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M<^AQS]'2Y""66'F^ET".\%.M>9DI+J@#@8XU>$KO32C#&U[D&/0!_3-X[*K
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M@??UP<2ML'10(QJ<C(]NQSOIC?'H>!))@"&6K/WY"-\09@DL,!3K.EN9.D#
MZ9K37]K3 P"0<X_ ?AK\N(-6%R) (M*N1]C@QF $U,%(H%A:VL;W]#J&]5&T
M J"REO *B#@#&I)5GI WW( U^?$IDH$,"Q&A<GIWN-,+XS5Q"D$"JQGN1UDI
M3RT:N[>?_*6Q K]:N8UH41:<C[M,KD!<U1SLF#'>?F+5V 2P5*.FASPT<P&$
MEIR?V&G7$&7FFD4@E![OE/XIOAMXOBR@7<]]RY1\M.<'-R2I00Q(M6R9T"A+
M)QA2KCK_ .CH"6L8PXD*'2>H C@Z<C.K+IRR6=1H8Z3R/L\6:,N^9F"DH03;
MT?8ESR.+4?!-8WB<NRPKAN:HT'EORQ?KUSRH*&:A44WC>-!I])998_0U6_1,
M=B*9OWHNSC!7*<8BK?Z1U*)5Q,_P]8&5EUTU91%/&14S34:R552'PCRJEAN9
M6-62,H4&J@FI[  P.8:)L\3PB^%TU(MN\S.8%[WHHD+=I3,S]4:"HD:H,"BE
MJ2\SN.AZ5DI_>U&>!IR**!/F(<*?X"3;'5R[C(7#2@$=#4^I!,0V1OB''CT\
M7G+CP*VG;W)[D'1+&A>)_F_Y%)L6-*53H-/L6G51Y4$\P[WKE26I;$**L*53
M&YTDIDR&C)=!C,$*]#\"^#CQU57B,[+J'@/#.K-JII-56;52'\K+09)M419H
M'B,9,_.(  K'%5 +X4#N"A>!(U)P]/V?GALY?^%_E?5;H9O*B<ZN=_-]]5Q\
MY>?+%5BW*]=%P35IF2*-1JTQ(E!%NTN0X4QV$.H,M]/WR0VDEI#:?C/Q'.\9
MX@9?RJ_"^%\-Y/#>%JI-'!2&.*NE!UU"&HI@7+/)RJ::3(JJJ_54"^PNKA[W
M+<2]J=[1HZ%#STE:204I7G7_ 'B0?RUR3\^.0B6R5!!,#T/LL.%*4 (([N/6
M1.WUI\\8O,9BS>9\B>:G0H5*N:W(%5;@LI8A5%JI1Y$J%5*C4@@-_>Q4"ACR
M9;BEONNMNM*SY8)Z_AJZ!X:D9AJ>761QDN@TGS4T!DJJD2:0D)! *QCSZ3\W
MRKS#B1 94,J>G,%$X@:N\K_YAR%1;$M^;/;<5TJK=3+E*MYAO(!<$IU'GRB,
MY#<9@]0R$N;<5F>/HII(RQQ$DAF$23O(,OEC.J*#Q9E8DH@7)&B!*E]SMCKZ
M'X9H-4=:J/-:XI][2,I=%L0')%%M!EP8(;DMQ76ZG64(4!_\[?896!AQA:=%
M8*\RO,1J.K-(@:WF;SJI$QA=7B<RJH4Y5 HIL,PD55/4A!#WN %B3M$MN#2(
M$>DT>F0*-2XB4MQ:52H;%/@,IW(:BQ&VF$Y(&5]'6LY*U*))X!TJPO,,LRY:
M>BZ76$U9)J%559-=19=3/4A\^Q/7'1MPT-@X2">Y[ '?7T]-\]O<B.0)#>L:
M_P ^^"IHI X2 >%?3;UQXXA*1E*0<9QGW]]1C(P3MM]+&Q,;<2$'IWB\R3@S
M32.0B! E*-K66^$60"GXB2%94"-P,:]M]<C'MZG/%0$@M;Z.%$)8I!%T@7T!
MC?7'-S0"3U#.^-M2HYUP-,#0;G4[<-&9P@7("7N+,+5_<(G/5E4U2="@HO\
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MH+/2VW_9;2HJ6=F95FT4BG)HJJ "-7"U80PX0Y3><5X+(\&*ZLWQ6=3EM<-
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M;X&C@\+XRO*H-1J.7ES0:C!*J'"RO,-P\!7ET5EU4@PFRU.R]8/MBH&ET?\
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M!524Y7IKKTY_WL@G?.FI([:@\""6$;$:EK2W/[X(,U)#ROERW_@!X(/N)4C
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M@TN?&I+2T1G:M,DRG5EYU;KCKS;70R7%N**M$=*=$ =(&->7E49=' *ZCSJ
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MB+H[?4PBIQ)4DCXFX#OWQU1).GEQ ]A0(P,J3G."1IP&9XS+I"X@P#Q0"(3
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M$X.>K)[[]C[YR>WMQ9)AFSU?K?ILL,I .C@=OI[/6UL*04>^#H3GTR/D1G7
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MC7UQ7 =QV)B=+3C3R5 D#T'XZ^G8^F?XD\#523K9IZL/7T]VPL6&(1!*)L@
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M<B+NWYH 10V;WB^LBSNQ@N6.E1Q\61L2,C.^ASG\\YXGF0  "AQO_G0;:3<
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MNFG;XMO8_P"%G/H(I>924R)]&PG^<S8RR0N"I-V)9YKDOQ'"(_X*/%6XHYY
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3Y^0_GQ,3&J=S\U#Z93IQ,3'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g90195g33u12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g33u12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13T4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "^@  !H0          0
M                   !              :$   "^@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "^@    !29VAT;&]N9P
M!H0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   OH     4F=H=&QO;F<   :$     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P
M 04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !
M  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$  @(! @0$ P0%
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,T*2P?!30X+A\0H8)30U-V)C<I33.$955E=89&AU=X.8M+?'TM?_Q  ; 0$
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M[NZ[+6>J:EID5K!I^G:5<)J*_P 5TFZGU&&X>S@:Y5)(YR##.(E4NGR\2N7
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M"]T=ML0ZF81/Q^P<QWJ[GC?4K.(:+ZY:=L\N:M:6[$R/,:EIDUS*9]!6."!
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M'O\ ,6]G+= \!8 \<N]U&^U%U:\N7F$8(BAR%AB7H!% @6&%!D@+%&JJ-@,
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MJX59(B5$JL3D#<!JQ13)MH=9)?0;F3!=E!"&U/O.!E 3GM=:U*W"Q6[I)EE
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M"Y#-E!1*KD36TEV"N2F4V.]I(YM:?+!!=P27*"6%&)D5EX]R"(V,;'#!'P_
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MJQ-D6E0C$*"VXB4E]*FG&G$'L++J%!94$=JBH VB$S2QBW,AF8CE"(-S./\
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MCGDDE88"M*[2.%4!5!9B3LH  [@ HV %7AMX+=2D$,4*Y8\,,:Q(2S%B>!
M"226/4L2QW)K(DCM2!]A_P!@>_@?3E*S5VXI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI47=:
M;J3CG2;J7D$982[1X'EMJC?C3D.BGO-_0^RD@C_Z/Y\4K^2Y==*K%Y4BP?9_
MVB?(DV+SBT$^H]/DNRWE#14HJ<<?425:.SY(^D#.._ZD9Z_;[>E6ZGNWVV'Z
M8SY#I^=9?\+?1Z1EOQ/]"\5EP2N+;]3\.B26U("VW8Z[V ) 6%$!#?H!WO4?
M8 Z!.@9_2H_Q]?0D$>9&W=CKG^E'T\E(O;OJ7DS24F(_E[&)TQ2D#T:7!J2%
M51F6DC0#)EORW.U  [R/&P>03T&=SCS]^O=45G-C)EB<TB-.>C+0N%Z-6FL<
MFLWC,ATMV D690&JE$)HJ=:45H=6H!(2\ET<FE8IGG4:%T^;J)MA6/2ZF?;5
ME78V:;6JK4U MYYJH#C$6Q?9E7\QZP4A*ZBH0]9)BH<E)964I8=C]MN[QQUZ
M;8[OO2I$>0II:VE'3C:UH5HD$EM10K>]>.[8\>>[8^G'AU\/$C[9Z]Y)I7CW
MJ3LZ<6=I2E#8*W%K6H)2VA (*EN$]B$C]Y2@GZ\FJLW",^_R-8]=Y9B]UT'Z
MT9OT]R^@R6^Q7$^J<!C(*&?#N(>*YS@]19L6%.T6P_"%WC-S'^6M4?UKD>>T
MJ,X.]! =!U_4].NPQ^N>ZL;/Q;8([\^G=W?L16 =-^LN)5OP<_#UUDZQ74UN
MTS3&^CE'/RZ/62)LJ5F_4ZQK,8HY-^*YD,QZJRR2SBQK*RE);AUZ)*7G76O'
M'AYY^PQ[S5DW)QW ;;]^=B<X)QW8\.\U-Z@I+CK2T%MUEQQEU"BDE+K2U-N#
M8\ !:"$@$@#6B0>/?K^U9*:W]OY@?XGBE>$I<A$1XQ2!)'9Z![$.J[RM();9
M=<::?<2DE:&%N-I=(TM02.*5:*E,SYZ2I4ZRF02VL%5JBJ8>>E=R=NQHE6A2
M(;#:"6W&W9;I"B-!)!Y&WWW]?/WY>5!Z8K6_X?H95_I,OB LFP?2:Z!=/(+J
MTI(2EYP4#^@KZGTT+TG9( !/DC<^_O2OKH#L?3W(\?D2/Y_?\_;?%*YXI3BE
M.*4XI7!\@C[@\4K#\RQ.)FF.V&.67K-1YQBNID1U)2_&EU\UBQKY;?<KL4N)
M.B19*6W4N-.^D6W4+;4I*LUI<2V<\=Q&%,B<:D,/E*.I1EVW!*,0&&"I^;J!
M6M>VL=[;R6TA94?@8,A^99$8/&P!&"$=0S*?E<9!!!-8!1]%*VHOJ7*9-S:6
MV20,EN\LL[.0W CIN[B[Q!&%NNR8D1EF)$9C5#4=##%>S';]2.'5I6IQPJZ$
MVKRS6\UJL$45O);0VB(&D<PPPWAO%57=BS%IB<L_$W">'( %<Z#188;B&[>>
M>>YCNI[MY&$:<^>>T%BS2)&JHJI !PK&% 8<1SO7E;]$*VUS0Y<JZM66G,IQ
MW,GJ)+-:Y!<O\:IK&BAR?F'HZYJ&78%B?5C-O!L/,-.H2A1<*IAUB:&R6S6&
M%F6UN;(7#&02"WN9XKAU"*PC+!XAPN5X@"1FJRZ'!-?->M-, ;NVO6M@L9B>
MXM;>2W1N(KS &CDPP# <0R,&L$G_  EX/8VL.TDRY[JVIMN]8,/M0I#-E"M,
MXR'/6Z\EUON@MP;;))K+$F"&I2HK49#KBUM]W-Z/M1?)#)"(XU0Q1QQE2Z/$
MT5E!8<Q2&PY>&!2ZR\2L[.=L[Z$O9+3Y9HYFDF9UEG>0$(RRI<:C<:D8G##Y
M!'+.T:N@#F,*"Q89J1<ZZ/-9Y<PK&PR*SBP(SM8^[4,0ZAY"W:N6F:R8%G*B
M/6U*MY]M F+JY4;YMI/IO=R%*!YUCJLEC$\<=M#)(PE"RR--\HE1HSQPK((9
MR S%.8C<!P5X3@UTM1T==1E1GO)XH5,1>"-(#Q-#)S%:.9XS/!Q%563DR*7&
M0V1D5BBOALQA6,P\9_:-LF/"Z;9KTR3*"8 DKJ\WDUDN=9'^H+8L(;U<#%4D
M>E_7OK<0M79V[2]HKP737/*C#G4['5, L%$UBLJ1J/F),3K+\ZG!7A 4<)P=
M4]FK,VJVAEFY:Z7>Z467@!:"_,32R%2 %EC,?\L@D;DD$G(QU/PEXVNTR*SE
M91DDM>05\BK=3)%>XIJ$_>UU^6W)"F5/32W+KDL,&67?1A.B.D:::*=ENU-V
M8[9%M;9?A9.9'PF15+?#O;CY0P" JV6X1NVY)RU:W^D[4RW4CW=Y(+I#$5<Q
M$QQFX@N.'BX29,20@ OD!"5"C"!<KR;H%^W,ADY)4YE=XO+D9;C^;-,0:VAG
MQX>0X_C=ABC,II-G"DE;$BGGJ:>BN%4=#K#3S#;;A43IVVM_#V\=M+86]RBV
MMQ9N3)<1M)#<7<5V58QRIO'+'@, "5;!R%&-RZT 7%R]W#?SVSM=VU\$$4#A
M9[:UFL^(<R-SB2&7A*$E5*@@ DU[2.A+DZQ>R:?FMW*S=:<64QDXK*",Y&E8
MF[F*(,I-0Q"13N&169I85<EIR*II34>+)0A,H+=5*:V(XTMHM/@CLPUXS6YD
MG8.MZ+0R1M*91+\CV4<BE6!RQ4G@P!#:!S)6NY;^XDU I9!;HQVZ\N2Q-\(I
M$A6/DY>*_EBD5D92,-CB (M6*?#73XE<XS;P\CO'EX[(F2UI+-7'=MI,M^QD
M'Y^9%C,R?E$JLGT_(M+3&6I#2E();!-[OM%<W<5W"UO$%N(UC4$R<$(3EX**
MSL&8\I278<0W (!K':]F;6UFLYTN)RUK(\K'$8:=Y.9_S&6-"$4RL2BGA.Q8
M$C(V)9A-L'N1':0H)*0IM#2%=O8V@)3V@:VEII)_X2&T#0#:.>?+-N/YA )(
M'%D,V2V<$X&3(^^V_$3L:]&%4'944DJ"P0 \) ##(W(' H \ -@*N* 0-'_I
M_(:/D#V!.CX]M:Y/L>E6KMQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H@Z^05VG
M1'JY5MH4M<_IUF41*/'<LR:&>T D#\7E2P!X&O[PI7\_RYZ#)$)E"8"AV1&0
M0&=;(0 1^'N)(/V)'Y[\\>_?7]/TJ?Q]<_H:NWPQ]%UX]\2_2S(TPPRJAR.#
M9AST5 (7#<6\A:MI.P' @[UX^WOM568*"3MX=<#KM@=Q-?L/Z#H'^JW'I:E+
M]:TDW]F^OR.Z187M@\Z5GM/<0$)3W@'02 G>AN"._8X![O'WX&L7.7OV\>_\
MAN*D!RQGHGH(>K%P%3'ZM<1,N0,A:>;CF69[L%MKY9%..T,)><?$KU'6W OT
MRI($;'\NF=L8K(KJV>$YQ]/8K3+XXD_.)^&Z/WMEY?Q+=-O1!4D%QAJ7/>=2
MDJ/:5I;(/<D+<]-04D;*5!O@@=0/QQU][5:M^9DE!D25'O\ Q2721L;'<LZ*
MO?[@@@)V5;UO?(\3L!Y==B<DX_+?S[Q4$X&<9\>[]ZMDR1)$62*T]E@&U"$5
M!)2F:4D0U$K':D)D^FLK)T@)V=@%)G/3S^FWW'KY#/C6,_S-NF#Q Y\-O#SK
MYS_ _D5<Y_HB6V*E'JY/BW2#XBL?ZF5J4.OY#%ZRP;_/TY_!NHR$KFJR*9?2
MU35MR4&7)9EPWDI4VXT>6SL-L>\D^O0=X_"HY/S$ELC.WCY=P^_X5<,O5K_1
MQ?"E\/,MEUCJ-UY@?#/T]QRB<8'[5A(ILDQ3J+F^4O5RRF9&KL(Q3%+*QLK-
M3;;-?-<A,NNHD2&4+C)V^W48 WP>[OZ[]_E5@H0EBQW'3!\@3MGKL,=_X5]'
MGY3<F7,=;]3MD2I,IOU!^)+;S[BT)6 3M:$N!#@'_E$J/ORI[]B,^& ?>P^]
M6#*Q(!R1UV/[5XA2C^$*/UWY.M']23_</X^_)Z;DX]<?IXU:O"Q=D" I,=2V
MGEK:;#[<,6"X[3CB$.R6Z\/Q3/6PE14F+\TT5[VDE0UR:5;*CYWYN4VN69\%
M3;;K<MVEG8])^:WV.,/PI=A9"0H("G?586EI'^[0@D$\C[G'G]?3/F=_$TJ,
M?@^JS=_%;\86?I6'84"]QCI[7R@"IIUK':*L;E>@ZK:2A$IE]EQ*2>U39WH\
M#\O'K[/7'IM2OIVD:  ]@ /.M^WY>/Y>.32N>*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE62_@M6M3
M8UC[96S8U\Z"ZD>ZFY49;2@1_P"?H#[_ &XI7Y(,IZ9M5=K=4LF)Z<BFM[6K
M>;4WI2%U]A)B=I\ _P#DM_IH_7D;?;S^OOPI7?I'TXAHZ@5DEM@>JE>D[024
M;[B""/8^0#[?;Z<FL4HRN/\ Q#WWU]L.ASP9Z8XY'5W?[*[<PG1W'3:XUQ+(
M&OH2%[ \'1!/OY>_?TW^E:_"<9 \L''O.<CQ\ .E2))ES(TQI]BL;>KOG(E/
M/L?F(C<R/)G)4Y%8$9Y(F2F5(0%.J0L(;20OM6E"M3@^'A^N/Q%9(F"!LGKX
M8/3J<^>0/7SK".J>%8OG&-2JRWQ";D6:QLCH[KI?<M]K%?@V0U[3;;.2N3BZ
MAN([5K5+?D-/L24SFPU#:9+CJ-5'AX;>_9K*)5/3/V^M2Q(65=Q6H+6K\1<
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M6M[\_3\N2>OO]/Q\_"J@8_'/KGKX_?.V-_'E*0DA7=L'Q^$G?O\ ;W/C?^/
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MI5A-%1,#P$Q:JOBL  'L*MDTN-?OI(S;6BPZ99=!:Z?&( XQ@\^91\1.Q/\
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MADDA5V'+SR_ZL@\&3C(P#OC-2FW"0TTAIOM2VTA"&VP@);;2A(2A*$)(2E*
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MO;QK\H&<==]QG'3TSU'GWT)_MY]3]^O4_6IQQK%5(2VM;9&U [ VI1/: E(
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M;D;[],]WZ#WXU'L?O^/F.E5#C#$T=\CH'FM<AP$A0$=MU"1K8+3%FI>SL'8
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MR^0_!FM8=936X<E<B.X_*:C*=4ZT\RIQQAQM06E3;IT%;'<D*UW *#?Z_?\
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M>AR!]>NVWKBBH6WXF )WWS]B-OT[CBO4%?\ ;&OR2?\ _?DUD$(!SQ'/F*K
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M_P#;WW[_ &K+Y^.^]2A2=*(<5;+US+?LGFEI=1'(1&@=Z'._;D6*@^JV"/\
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M\K_IR]_[YH/_ )FT3_U]6_U%9C__ !M9_P#+FN'\["NP^)?"$@ 85\0>A_\
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MY1 LD:D'A);;)QL<#O/K7$G[)Z',\TLT=W*KW'%';QSM%&T8&ZG!! R02/+
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MF$?O]KCZ$=F_(0G9!(2=Z3HD_0>_ .,8^X[L>\;4Y+>([NO3;TS^/C6,N91
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MSJY__;^^YV.S7_O)H7_\UI/_ /=@KC=HO^P=<_\ X;5/_P"E+4STW_P/5?\
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M"XZP9U02NJ>7S9F+RL&Z=]0H^'+Q5%).CY)80%XMAUR]80L@1<269MFA[))
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MR'F+"M^3;4_\W 7(PMV8O9;R6W@: (LL\'$TTC\%Q%=+:):L3"F))9)(RA9
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MDG' CQA0=VP3OX[EGV5LK1;Z/FS2IJ&E0Z3.K!0!!%;R6W&,#/%(DA8@# 8
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ME'>[8([@KHP=J9(I69[))4>:\F;C:WE<?%SK.B1_%V=W'&(&7 ;E2$@Y3ED
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H23ZFLV,?MW#  P/M7KQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g90195g34p96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g34p96.jpg
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M 0$! 0$! 0$! ?_  !$( "L $0,!$0 "$0$#$0'_Q  8  $! 0$!
M       )!P@$"O_$ "00  (" P$  @(" P        0% P8"!P@!  D1%!(3
M%5&1_\0 %P$! 0$!                 @,! /_$ "@1  (!! $#! $%
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AP.]&\,D@)Q'GGE@&$C@X # KI2E+ND9+#+56[YM&O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g90195g39u22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g39u22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $UR^258X0DE-! 0      "L< 5H  QLE1QP"   "   < E  %TQA=2P@
M5F%L97)I92 H0F%Y($%R96$I #A"24T$)0      $,F+7V44!.4P$<"*7-LD
M=DHX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q ;0S$H         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          'K   %G0         !                          $
M        !9T   'K                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   'K     %)G:'1L;VYG   %G0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !ZP
M  !29VAT;&]N9P  !9T    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M @4'!@@% PP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MG1BDX<,=Z6.V989(9HJ.HF@Z2,QGFR8ALK0/*8P[9,.QFJ"\_P#$TM"<DV"
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M65U/<;&5F=LU8U9[4Q!U<VREIBJA:M#!H%@#;,S$3,F[$*!K\N9$A^I: FW
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M+'M)!(.'-/,$@]02""NJH7ZFITJNHT9FST[L$=FM,T$"2&5H<QP#@'#D1D$
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M5)Q6*N3CXJ91-6.(+CQ9"N""2:9,5TR1D(UQ)[3<>0Z L1^(/9+0^/W'-T"
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MXSI:!Y1@N,=4DT9]E&L?HVIQ-TZ2:K+''JV!0>]NULV9#",./+F\<@>>TM<
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M"E"I"1/IUMC'8QX2,K4K$![B#H1B3D"+*S:XEN&2 R0L@L@8%+:BRFV=;/\
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M[Z:L$C0^&JZP8(W,:61 9"L2]D] GFMS3472=_[R;==URZ:$S[D9AM3NTWO
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MW+VE._%>!A;X<5SMQR<#DW 'LR[V^(V5Z2ORDOIUYCM4=2>HOCF3Z<)"6(8
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M5:.38QR(KF&I\';%?K<H(7(7>X(J#T:Y%"FL"D&UP<2YQL@98TMHB]QH<G)
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M3II[C!QD734'78<!(X38XV]!^>IG9;Y3[S]5M?\ ^[YOK*_XBGX9TS_M+?\
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M'QK%FR?_ *)[1_6=-%C'+F<.)^C.>N?!7MKEOKZD%[3']&W"T,C>]:0];NL
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M8MQPATGCTE#WJ=E%E$OFR4UHA1T])2,O8?5WF\WBKB''(GF0<;L9\D-'2V,
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M2W-%;CB?-B@2=??WPLOX1,(F$3")A$PBP3U&R?4#$\9%D],D)2)[E9R>K(@
MO(@3\G51( J;#9M4L;&BWSC8F0?C(%1I0 8]NCGGC$,Z2@O6E"ND4MT\63GV
MS5NW$]0]$AZ#: ^0;$!5(Z"U#Z DN/6F8UZMRREP_)G)^BC'''Y (J0/-JA\
MBL'1KE$K#3S(SI/?W]G^JS_A$PB818KB?\=G(/\ Y7\/?_FKG++KS_)HQ_\
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MUTE^@1AO"BR,ES(7?(YGXNL1DF!^YKM^UQ+I]S7O+W3<1SKG&2D<20@X+72
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M4@%D$DY@@R#9>#'DR70XQ\MIP5+@[,B6P^* Z\E""R&'F6%..M+2DBXERL2
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MWN[YUGZZZZ.6^J< <W5\DX&.?EC'AY_.M%^KU'^M8'+&&RM 'K_FR<^TJ/\
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*(F$3")A$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g90195g45w97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g45w97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'XB^@'(X0DE-! 0      $,< 5H  QLE1QP!6@ #&R5'' (   +43!P"
M4  (<G(R,S W,C@< @4 &DUI8W)O<V]F="!7;W)D("T@1DE'55)%(#$Q #A"
M24T$)0      $#5!!*CKT3=O9'S[_E@A.N$X0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T#\@
M    "@  ________   X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           #W   !+L          0                         !
M          2[   #W                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   #W     !29VAT;&]N9P  !+L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ]P
M    4F=H=&QO;F<   2[     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !40     0   *    "#   !X
M]:   !3T !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M;655^]QW?I /8PM'%KM_[_\ @V?I%GY.3F8'5JW96S]EY#=<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MEK*TTA<D,G%R=)3$)3-A)D)BH<5$15)39(&%-4-E\/'_Q  < 0$  @,! 0$
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M></$M3.X9_87O;\@\5:.>F@XD78O'BIR&.X,LN)S"C])ZZW:;?/I2*IJU#M
MCY5_$& +"NOUCF-7,W<G#_@Z?12%0OY(1YF.7PF*3F 8_P"-Q)'VW:_,T1ZZ
M7_"\QL_ _+ZQ';=K\S1'KI?\+QL_ _+ZQ';=K\S1'KI?\+QL_ _+ZQ';=K\S
M1'KI?\+QL_ _+ZQ/'(3-EC63I^XA8L46B)UE02F%C*"0@<Q @&C2@)O@YB 8
MV?@?^=?X)B>HCZTJ$*<L-$]$Y2F#G,K@( 8 'D(=S!\(<_AQL_ _\$?Y(_\
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M)S (@B69B(Q$8B,1([;?)F;]'K_NXB9IKXNC^C3_ '"XB>C$1B(Q$8B1J?\
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MC^C3_<+B)Z,1&(C$1B)&I_QZK>GP^R93,'WK^O\ @Q)+F8C$1B(Q$8B1J/\
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M\R;NIFSV!^\<$;D2AJY%(NYB0(@8X*/'"#0S9D@4Z[I9),HCDOQ7!<IS1O\
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MKR7..N3ECS1AKYQ,)?P54)*66^XLXV.X [=@&'0$)B<   *JX      EHSD
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M5UO;:]KFV^^^PV77VD &RQB= Z 4!0 J@#R1L]H.[,[\E7'K:,^?_F#D-O\
M(G]O\D3>CNS._)5QZVC/O,;/P/R^L1W9G?DJX];1GWF-_D?E]8GGJBJZZ]C5
M<M3,UCSAQ.V,JDL9,>YT<  *B(F3-T@ #>Y$>7/D/A <S$F&(FN>S_*@?1[3
MZUL1+PK_ (DX]+37VJ[Q$SF(C$3X8I3E,0Y2G(8HE,4P 8IBF#D8IBCS 2B
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M&%(H$%2^=)?9_P OU?C9F9AWXF+CXM@H5\IG_KY/8+#4@K5BH564M8P[06
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M #F/@ ,S$XR]D4>Q_%V^J?"AHGNE?=IUBZLK5<'D,N0-=4"+28/8YQ_2%/\
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M8%/<3O8ZFKYUL#"&$;F< ??1AEA:UO8@!'ID.:N_OV$.MD%AV@3 [PA>/$W
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M,0'C]H].F^S8W$23XB:Y[/\ *@?1[3ZUL1+PK_B3CTM-?:KO$3.8B,1/@B
M(B(   (B(^\ !X1$?^@!B)6+[=>H(VMS%Q?[-HC6J5^:5KDU8UK3#$A8RP(F
M2(K"/)(7G:B,JD9=(%&!E0=$$X<TO?'$2Q&#]C*LFDE&O&LA'OVR+QD^9+I.
MF;QJY3*LW<M7*!CHN&ZZ1R*(K)'.FHF8IR&$H@.(E?:V0=D"XKJOA6:K7BS
MU9=KI)E9=7(JE6$'!/RK@7"G-4>M\"7]@@=$>>(_G\_GB69B(Q$8B,1([;?)
MF;]'K_NXB9IKXNC^C3_<+B)Z,1&(@?>'\V(G$G:G!_QDV7C\B]RURY+(ZO);
M*U.,;*%Q.V2K-2BT6))6GC4>VB*N!==2^0!!!HJPD@>F=/5B'%<"=PXGK'HS
M&^SZWA<K$#<I]SRJ+,3[EW'+S+6L]',^^!2H"]R/WO8MM7IA44@+N@YG"<Y;
MU$N;5>1C>O78EXN %-"]G=2:BP;W*R=JJ4?8=B"3.P-SE8R"0A9J:D&43$14
MHJ^DY.2=(LF#!FWAI51=T\=N#D0;H)% 1.JJ<I"AX.?O!G$JJ;LBVJBBI[KK
M7"54U*UEEKML*B(H+,S$^% W+V[I4C66,J5H"SNY"JJCWEF.@!^9.OP]YG/"
M>W!N'C<F)'7_  QOI36G#\S=+1E[XEW#-5K+6PB9C(OZ_IIFZ*@LJ"@ =%>W
MF $4/"+8R0BF#GJ%'#<-T-17R/5*5<IU"ZB[C^F%8/3B;TU>1S#KW+X\,N+Y
M+#P5<[9*G;G9W/N^+Q)?%XU6*9'*$,KW ;#UXBD*?/XN""->2H/:V\6DM#ZS
MX?*:VI6M(!*)8%.+J4DUS"[GK)*J<Q<S-CF%N;R6DW1S&.HNY4,! -U:!$DB
ME(%%YSG^3ZBS6SN3R#;9KLIJ4=F/BTC^VC&I'L4U*- !1MM=SEF))L/'\=B<
M;0*,6H(/?8Y]JVY_Q>US[3L?S\+[E $D.R]JZ^T]6'=PV1:8NJP+003!Q(+#
MVP^='_Y$=$QZ)57\O*.C>X:1L:V=/7*GN$4#CSY:_%\3R/-9:87&8MN7D/Y*
MUCV:T_&RZUM5TU*/+VVNB*/)8>)Z9>9C8-)ORKDIK'XMLLQ_[4107L<CW(BL
MQ^$CMW97^^UU@\UG<F54C)VGV;K#R5>=FFEGU@KHITV28N5UV;FOK0DHNG(2
M"+J.<N%DP[5%)LJF)PV,"SCN/RK$Y7!LS+,?.Q !5DH*%3&R@<ZJQ52Q,E<B
ME6JK9+452>[N8'4\LA<G*I5L.]:4MQ[O^I4_J%KJ?_KNI)5J36Y#-M2=>.T$
M>.978UN$?BAX>]C;7L^Z)!&/KMEC"LCQQ;.C9EKE:$Y(CDMS<'166,@9NS!T
M@1S(&3DG02!DE$BIH".=.^TWJ_I7J+B^*Q.%K:W(QKO46PXK8JX.(:BAPE#J
MO=WOZ9[*@U:FH$-L@2J]+<+RO&Y>7=FGTZK*RAK]86^O:; PN]EF_L'>.YR&
M/>=+KS-+^$"Q6UUV3NQ-'F]%)INK:=E(/I)25F7$5LAFS*_!I58]DX'M7K8[
MW#AJFJ1)JS+!. C#JAU/67?K'&PT^R^ATX(4,N)QC54BFE;>+=S47RK'7V@'
MVR6%=O8;P;0/;[8'A+;FZJ8-R'J WY2M9WN5RU46=M:@@>"0&0-[*BL]I+=H
M/^@V8U5I26V3#7^<I5!>[5CFP=Q+)(1D0I;4D&P= BS1=8@OE!9@(E;N2@=1
MF',J"J0<PS\\4\MSE/&7\?1G<A7Q-C:OQJ[;AAEG.RK@'TQZA\LFP'/EE,Z2
M^%Q]F6F39CXS9JC:6,J&[2^YAOVB4_VMHE?P(EMY$?AKW_K^/ZS>C$30#LD&
MIMO[?X?3P.G[,W@9*-LL=-6)BZLR-/;V.NM4'::T8K873IDS:E1>+-7P-WSM
MNS>&;@FLH!BI@/0?LUY?A^'ZB]?F,9KZ[<2RG&M3%?,;%R6=&%JX]:66,6K5
MZ^ZM&>L,3KM8ZK75.'FYG'!,.T5FNY;+D:U:1;4%8=IL=D0!6(8AV"G7O! E
M&P/"AOVQ=C8F= V6V1=@VC,H+RT F[L))V,;QB5A:3L34!M8+.4')#MVAT$9
M$BR[%FH[3025.T;%/D[D=6]/XWVF4]08V);C\73JC)9<9J+6N;&LQKLW[H51
MU*LX+5E1;8M9<KZC]LCZN'Y*WI9^.LN6S+L/JU!K18BH+5M2D7 E2&"GM()1
M2X7?8"1ANQN<)&\]':IWDI=56-&M6T6R#*G-6L@SF7<"ZBHJ7CVMA?KQRSAD
M0PR#]-1LU2546*BS%942&5(F'I]I'673_4'*=/GCP_)87%V-;F6&NRBO(2VZ
MAWQJUN5'(].E@[LH7N<*-Z8S'3/"<EQV'R2Y&L6_+05T+W*[5NB6JM[FLLH]
MJP$ $OX).O9WY>QQ<*'%CHC:FRK-O">63JDQ#JQA8U6YFM@6^QFDTG25L(EV
MTY!@"#8CDO;#L&\@X%^+=1 $T1Y>OVD]6])<_P 3QF+PE ?,IN6WU1A'$^Y8
MPJ9&Q"2B=_>Q3V*^^I?3#!M]N_CI?AN8X[-R;LYRE#ULG8;Q=Z]I=2MN@[:[
M0']I].0X&O+2W-8]C'UUK+B>=\1;&\V.101GIRU5RD.6K5-O$3]A[;%ZLZFD
MU1=R;)L9^\,Q9J(("'6I@Y7< D'2B.4^U#D>4Z63IRS QJG;'HQ,G/1V)NQ\
M?L[ F.5[*K'%:"QP[ :)15)\;N)TIC8G*GDER+61;'NJQRH!2VPL3W6]VW12
MS=J]@/N#,VCOIQG+Y;(Q$C-Q\FY/]&C_ !".(FG79"=,[KWEH%:G:-F%&-D3
ML45*2T,E-=[Q[7 -4G974($OUS=-$>V%6KT&SE=)J\%KU*R@") -?/L[YOA.
M!Z@&9SM(?&;&MJIR#2<D8>0S(5O]$*[-M%>ON16=._8!&]5WJ; S^0X[T<!R
M+!:KV5!_3]:L*P[.XD#PY5^UB W;HF9_@+U)M_2G#K7*/NR;/+7!O*3+]%D>
M7-/GK4(^<@K&UTTR914'PLP!5<>J55;M1="S;*'1;D,.OU]R_#\YU'D9W"4^
MEAM336UGI>@,J^M2+,D4Z4H'VJ^TJN_9WL 6,]>G</-P.,KQ\]^ZX.[!.\6>
MC6Q';5W@D'1!;0)"]W:"=3;^2D6,/'/I:3=),HV,9N7[]XN8"(-6;1$[ARX6
M./@*FBBF=0YOS%*(Y3JJK+K*Z:D:RVUUKK11MG=V"HJC\2S$ #XF3;NM:L[L
M%1%9W8^ JJ"68G\  "3^4U'X>N.G0'$W<;+1=934RM8*XU6DRH3<(ZB$YR%0
M=$9K3$&HN)@=,TUU4.F14&[LB3A!8S<$C](+?U%T)U!TOA8N?RE- QLEQ46H
MO6XX][*76C(  [78*VBI="5(#D^)"\9U#QW+7VX^*UGJUAG MK[!96I"EZSL
M[ +#:L%< [*^#K<7*;)R<0>)GA(XO[]QS539U"N:S:@&DJG(0<X6WJ1A*##5
MXL<-EB35LKE-1X#Y4CIR"3-NX0F1?BD_.GT%.CW#ICK+HSCNALCB.0PU;DC3
MF)?BG#]4\E=<;#1:,KL*IV*U:%K'1J17M ?&Z#RO!\YD\ZF;C7'[N+*&JN]8
M*,6M.SO4UENX^T'<!%(M[M-^(';P@"4I0,/2,   FY<N8@'A'D'@#G\&</E^
MG]8B,1&(C$2,0'C]H].F^S8W$23XB:Y[/\J!]'M/K6Q$O"O^)./2TU]JN\1,
MYB(Q$_E0.9#@!0/S*8.@;P%-S 0Z(B("'(?>'F AR]\,1.3S/A@XA2=WIH==
MZ<;KQG$_9=[5>AKWA\\J]D@[CKR2U\XA)9RE0VZ,%*UX[AM8V#H(B6:NU^N:
M=6T5*F\,B;[Z-U;*:HT1KO4SJ?%Q,4ZEQ=<<S\>D I@^;-P!9:.1>D4 &C=4
MQT6";@AA*U31*H7I )01(8VLL1K2OR,W=MCR4+%2VVDJ+'N7#!BJ5W:K=;6]
M8KS0I6L:LH5Q.SD@S:],Q2-455RF,9!$IA*B0Y/BWT$KM(-0$WA(C;#VP=?I
M/QJ\B6C.-AE$Q3Z\;;'&MA1'%Y35(=L>KHV$\L5^FI&BW[I)G:%1/WT]Q6:.
MWO<I.@ZVW'.2=ICD+$[;QTK4)2LDL,?4; I5+3*5!]8ZW%L+=&5ZQ)#$3#VN
MN9%&/=J(%<F33<(**(U^/\_]3T/.*;1$=:J92I#?)6-DV%MNX:*I[!Y'%;DF
MML4-B$A9J8@\4ABLTI-FW,0K<7"Z3>1<J),X]9RZ532,B>"S\6VB*G76ME?[
MGFY!O(WV[ZRAX:M5"5M5MG+IK:8?0=]B82GUVM25DE4ZG(1KTDY),XU6+8))
M%77>%17;G61_//C_ ,R+2_&1P^N[HCI_^E^Q%N<^C4F#!K+T2QQ%=--[#@2V
M2D525MC^JM*_"6JT1!B+1-;EI1A-.5SI,2M ?+)-SOP^O^?=$EVI^*74&Y(J
MVS=%V1>'%9HD-*3<];9G7%DJ]/-%0+M_'R[R%LUCJL;#SZ$>ZBI BXPSQ\8J
M;8RP 9(Q%#(F,>\9'#RTU;JS<C?>,M-T;=2:Z^L'-7J$Q:9RVMF*2KB9=Q]4
MK]8D;.1I76Z"RUD<NHE!& (GT94[50Z9#HDB3XE]6.MQ!HF,V!?IK82:-:</
MV\)K6RRU=A$[A$*SU;[X;BQJ:U6@3RD0B=ZBE*RS54B0I]<1,ZJ9#(FRG<*6
M^5<M_IHOV/$2IMS;1I>@Z6^O>SMGO("%:CU#5$S:,<2TW(G*/:T1 Q*+,SV7
ME'9N1$&;-)0X\^F<2)%,H66X7@^3Z@SDX_BL5\F]O:=O[*<>K>FNR+F_ITU)
M[RSD;]R[8@'2S^0Q>-H;(R[!6@\*OO>U];%=:^]W/P'N&R2%!(T0:ZOW7QN2
M->L_$,-BU?PVKSK=>DZ*,HBRN=[319O'3*Q;5>,TT!9,%^U^FA502 PH+\EP
M((%<*WV[E.&Z"I?!Z=LHYCJEU:K-ZB=%LP^,+ BS'XBI@R66*/9.22P[AY+>
M:UKR8F=U#8F1R2OA<2A#8_'!B+LL=WBS+=2I52!W*O:#H^R /:;IE#4=&KP[
M&#KTL>OP,0U3:1L1$Q<)'QD<S0)T4V[1HW8)HH(ID#P%(4/SF-S$1$>8WWWY
M5UF1DW69&1<Y>VZUVLMML8^6=V)9F8_$D^X"6NNNNFM:ZD2JJM>U$10B(H_!
M5&@ )$I.6L4Q57DWJ.TQ.Q9%M+I11&PS\*TA15:2Z#"Q(KS4;&2I$7\.U[=5
M%D*/3.];$9+&;BJ)R[E6$E.971S/WSC:FI:TM]T9K]/2UF,RT6FDM7<_8OJ!
M@ C%QW:U-=\AK*&LP/0RW6P(!ZX%6PZK:#:G> U:ECVZ)+ *0-^,+<=*ZX>V
MR,W+L!^@ZGJ'!NV\58K4I&J0M38 L+UW*M6,DF$#%R1! 0/8NUDY!%J HE=I
MI#RSWPN5YFO#MX3CK[UQ^0O5KL;$KUD9EA45K2UM2_>;:B#XQ@YK9O:["T^+
M\/ :]>0RJJFMQJR$MO8FNE02QL".WI*X)/\ 5*]X'@,!XDPI<_7]BPQ;#0MK
M-;A!F75;!*UMY7I=B#E >2S<[ABBLFFNF(@)T3F*H4IBF$O1,41T\[C\[C+S
MC<CAY.%D!5?T<FFRFSM8;5@MBJ64_@PV"01O8(GOCY./EU^KC7U7U;*]]3JZ
M]P]ZDJ3HC\0?.B#[B)+>X,M\JY40_. M8L0'X0$.T_" _G#\^:<]YHKK/L>N
MC-<<0E@W367%I1M:"SB:BF;IZQ<P,'+VD)$LP_C(\S$IBJ*%.X*U376628E=
M*@W*'N!+>^3^T7J/E> KZ>RGQ1BA*:K\FNEDR\JG'*FJNU^\U@ HGJ%$4V=H
M[O>97L7IGC,/D#R-0M-G<[UU.X:JE[-]S5^SW'89M!F(4G8\ZFK>XN GB?NO
M'%#[NK^R4$Z"6R56>1M+B?7:V"H1,"DR*^K3"NI%*BZ(Y[6=$:@VZ$<Z(_4-
M)E XK@K<^$Z^Z8P.@[>!RL"QN0&+EXS8JXR/1G79!L*9=F1[D(+HSEP;4-8%
M0("]L'G].\KD]0KR%5ZC'-U-JWFPBS'2L+W5+7O;:[2%5?88$%V!)G8\8*6$
M>??5*EY_]T&T7R+_ - _J?O![WUYQ >X?C^O_N7V?.X4M\JY;_31?L>9B:']
MD*X8]S<1&E8^HZKN!W<O%VME.257F)!K QUKC4FKEMVDO(H(HH%58.%TY!L@
M_P";)<Y#]88BR;<P=!^S?J3B.F><MS.8I=J;\-\>K*KJ]>S#M+J_>M8!?MM5
M36[5^V 1K8+ UOJCC,SE,"NG#8=]=XM>DOV"].QE[>XD+M&(<*Y"G1\[ DQX
M&>'K:^A.'RO:^V7=W"ED;RTU*]RHQRWF(ZLL)-R55K7F<D]05%TDUZ"CI06_
M0:)N'BZ+8#(ID.?2Z_YWC.H^I,CDN)H:G%-%%/J/6M-F7;4&[\JRL>59@RH.
M[VRE:EM$]J^_3G'Y?&<8F-F6![?4LL[%8NM*MK5:M[B 07(7V07(78&S?ZQ+
M+#ZXE9^!?2\O*Q5>G)*)KK9&. 9618(O5V<8D<6AE ,^<HIH /,3\U?<^'EE
M4PZ:;\O%HON&-1?DTU79##8HKMM5;+2#XTBL6\^/'GQ)B]WJHNLKK-ME=5CI
M4/?8ZJ65!KSMB OCSY\3E]V/#BZXHN)3:.PZCMAHHSKD'!JRI9B,J)*_WJSI
M)-%HG57JCQL<KI9PV4<&(W7Z,@@9@HLIS34'EU[[2>BNF.F^)XW+X?)L7*MR
M%I]&S+&2<W'-+N<L ':!&5=NFJF]4* " )3.F.=Y7D\S*IS:T:E$9_46KTO0
ML%BJ*CH:(8%M*Q+CMWL@&=@>X4M\JY;_ $T7['G&)>([A2WRKEO]-%^QXB.X
M4M\JY;_31?L>(D?M,-)HP,@HI99-P0J:?214;QQ2'YKI  "*;4I@Y"(#X!#W
ML1,^$%+" ?\ :N6\(>]VM%\O[O$_>Q$^]PI;Y5RW^FB_8\1(];J-+6>J6:M]
M]\BD-@@)B%!9=C%KI(FE(]PR!91'M0H*D2%?IF3$0 Y0$O,.?,-K!R!AYN)E
ME2XQ<K'R"@8J7%-J6% P\KW!>WN'D;W/')J]?'OHV%-U-M08C84V(RAM?CK>
M]3DCV/KL>F\.'+<MNO\ L::K<7%H5B0J-?&MO$9AY8"OY%DY&5,1PU (9FDA
M'D-VLN O5%U@2,4J*9CG[%]HWVA<)U-P>'QG%IEM<^73F9#7U&E<<55V*:=]
MQ%SNUFBP'IA5V#W'0I/3/3>?Q?(7967Z*HM-E-01Q8;38R[?W;0 (#HZ;; :
M.C.Q_<*6^5<M_IHOV/.)R^3 /(:2+8H9(;))&4492QB+BWC@42 G:G2*4 :@
M004YEZ72*(AT Z(AS'FB9_N%+?*N6_TT7['B([A2WRKEO]-%^QXB.X4M\JY;
M_31?L>(CN%+?*N6_TT7['B([A2WRKEO]-%^QXB>>JH*MU[&BLZ5>JDG#@9RL
M5(BJO..CA 3E1(1,.0"!0Z!2\P* B',1Q$F&(FN>S_*@?1[3ZUL1+PK_ (DX
M]+37VJ[Q$SF(C$1B(Q$8B:)[GU7;=DT-LPI#-68EF'%MJ2]2D>\F$&;-G6=>
M[HKEDLKYB5\JFW25;P<:[>&:-Q%Q(N$RIHD474(4<?Y/\]P^'^!N)J/&<-_$
MLMI^I<%LEJ9NSJU6XF8_:3[B;2O544KDEKN"X@EM],I>.JJ;L=@EVI,D*VJ<
MC%.X1M$-)9Q(3Y;2ZCRH-W#^?S]?^?Q]QCQY^GQ&OE^_N\2_.![@OD=/,J_L
MO;TO<Y;;<&KNZ%JE7FK-#3%+U74MF[>G+F^94AA Q[9N5>SQR%9<R<A+OYF5
M0103BDW+5%)9N;/\_G\_SM-=;'P$[2VA9E(>X0Z==K3[B"XT-C1]SC9V'<3=
M&/LF/I[O1VQX!!-P9TE88RU5].6;(MR@]BU&(D?@BBZ'I(_G\_68+AQT!QDZ
M&?:?W[?M*QFR=CL7O%Y6MKZOHU\I323B_P"G/>;?9T!LZ@RUEDX>K/64N2%(
MA8*ZYF(J9814S&@4'+B(=QYD>/P\#^? 3,;#X3^(.S;VN7$P^@YQ.OJ;ZX7=
MH.>'*3N]1>46VU^G:]C:Q;[#)"R(54-B:?L;@EOJJZDZ2!G7].9H)14@+AB[
M21_[_P#Y_/G(-JWA=XJ67"G;.&*.IFWJ#;]AS\96+5L79.U:/LC4=;H,EL^;
MG;?,ZVI,/=QFV;)Y2U19&K!T(1R[--HM!73%BN)7\_G\_P Q_/Q_G\_#Q/;/
M<(W$[3*C=Z,XH$]L^TU7;]QVQPI[XX=[K1] 3&GYG:E7;NK!7RT^UV=ZU)KI
M"^)S 6ZNOU++%3\-,MS!69 6J7:+^?"9.O'Z>=_SW:U+RTYICB)I'&-8MG;2
MIFU;&-ZK6AFTO>]7[/J$#HIS9:SJAQ5=A2EQU7)6=A9I#M6RJKJQ"K2 ?G.T
M4CU6Q"@QZ!4Q]3_/Y\YMYQ&<6=6TBM%T:MPS_:>];> (4;3]3,#F>D%E0,!)
M.?62*J2M5ML(=:[EI$J912*?M<A^1E$[=TWTCE\ZMN?DW5\5P&'ML_F<L=M%
M:K[ZL96*_><EO[5K0D D!CLJIA>4YJGCRN/2AS.1NTN/A5'=A9AL-:0&-5>O
M:)(V1LJ- LM8Z9X3;39;HRX@^+R98[&W$3^LU"CMBBMK'3+9004185:)6,LU
MDY]$ +VY971#K&< 8S;F8I7)I3FNKL3%P;.G>CJ;.-X4^SF9SG7)\TX&FLRK
M@ ]>.WD)CJ0"GA@$/IS4P.&NMO7DN;L7*S=;IQ] XN$"![-:;*NXT"6.P&]H
M=SZ>;K69<&ZU?4324<J-I918K1OT#.5A3A9<Q$4B&.0HJ+&)U20&,0ICB "8
MH<Q#GP4%D!(0,X7O;^Q=^"S:\]J@]S:!('G4LA.@Q +%0257WG0\#]3X W^4
MJ^YT0.(W6E<C["]V;JN*F'#*7M-4C9-&KVF3C").DG%+LS^+4>N6,>\4424D
MRPDDW<KIHD;E>@BJL09_"SSTURN59C)Q7+74+91B9EE396)5:2A3/Q*[16ME
MB $5&^ME4L6[.Y1J-R,8<KATI:<S#2PK9=0KBFYTTP./<R%BJL2"X1]G0'=H
MF6A1Z'3M:UF-IU#KD35*Q$)BE'PL,S29LD.D(F55$B10,LX<*"*KETN91PY6
M,99=510QC#%9V?F<GE6YN?DW9>5<0;+KG+NVAI0-^%51I410%10%4  ";F/C
M48E*48U24TH-*B  #?DD_B6)\LQV6/DDF59Q1Z25XBM%W[4#>Q+55U;8U!!I
M-)I'<I-G;%^UD6R;]JFJB=W&NE6A6T@W*J0RC950"B)@ HRW2O.#IOGN/YEL
M9<M,.QR]!8*S)96]3-6Y5@EJ!^ZMB/# ;T"9J<O@'D^/R,);32UH7M?1(#(Z
MNH< @E&*@,!^!WHZU-?^Q_<&\[P?T:Y0MGN;.USMVL#29=-X1L[:5V(2CF1V
M#9-BF]-UZ[QV0XK/W9TF_3Z*"!4S%0ZP]@^T'K/'ZQSL*[$PK,3'P<>RE'O*
M-DWM:X=S9V;5:T[0*T#/Y+MOV@!&]-\';PN/>E]ZW67V(Q%?=Z:"L,!HMHLS
M=Q+'M70"KYUN= ,Y]+)(U'^4U@_R4+]<CB))<1&(C$1B(Q$C50\FXS_ X_C'
M&(F<;LF;,RQFC1JU,Y4%9P9NW20,NL/@%584B%%500]\Y^D8?SCGVUCOV][N
M_:.U>YBW:O\ VKLG0_(:$P%5=]JA=G9T -GXG7O/YGS/3GQ,QB(Q$C-Q\FY/
M]&C_ !".(DE+[P?W!]6(GW$1B(Q$8B1E]Y4P/H^:_P!CB))L1&(C$1B(Q$C$
M!X_:/3IOLV-Q$D^(FN>S_*@?1[3ZUL1+PK_B3CTM-?:KO$3.8B,1&(C$1_?B
M)5NM$(PBMW<-A;]TW%WL020)K]-QT4GZI68N$.L-U'- 0ZL>K3ZPON_=?VLQ
MK7\_>):69B,1&(C$2.VWR9F_1Z_[N(F::^+H_HT_W"XB?N8Q2@)C& I0 1$Q
MA    #F(B(\@  #PB(^\&/?[HG/#;/%5=]E7.3X?N#./87'8#0_:5_W$^*9Q
MJ[3J"@]6X.O()E.UL]M2(81:0#!58$EB_P!9ZPZ:J*?1N(Z3P>,PJ^H>M;+,
M+CG]OC^&K/9RG,L/*@5[6S&Q3X[[G"DJ?!4%2U7S>9R,N]N-X)5OR![.1G$;
MQ<,;T?:/LV6C9T%[@&&M.0RBZN'3A4I.@D)2PKOY#86W[<(.M@;?MY@?VVRO
M5.1E4$%UA5-#0:1P C*%8J%;I)D3!45U"%.6#ZDZLSNH35C"NKCN&P_9X_A\
M,>GB8R :#.JA1=D$;[[G79)/:%!(,AQ?#8_&A[2S9.;>>[)S;MM;:Q]X4DDH
MGP4$D@#N)T-6P]M:UVAMCP.L)UK&WBJN'E7+)S]>E7$/"6LT6TD&:R[-;N9W
M>8-T9!HLJ:,>G;+&$[8'152*%+$)B+@W\9D<KCV6X&8J9?I8V12MV1ABUZG5
M;%]7[M8QK=5%J!QX;MT1-QKCDUYE6':J9-!:COMJ<UUWFM74E2%%J@.I/82I
M]V]@B59J_1HZG?-;#8;W;=G;+NTXQ&ZW>T2"P)/A814R9I'5ZLMU @ZK L#+
MK QC8QL"@%.)W;IRL8QQW>=Y\\O]VQL; P^*XO":S[C@8M:[K]0#OLR<IAZ^
M7D6!1ZEMK:_!$43PX_CON7JVVY-V9EY 7[QD7'0;LV56JH$I36I)[57S\6,V
MAROR3C$1B(Q$8B1J/\IK!_DH7ZY'$22XB,1&(C$1B)&J?Y.1G^!Q_&.,1)+B
M(Q$8B,1(S<?)N3_1H_Q".(DE+[P?W!]6(GW$1B(Q$8B1E]Y4P/H^:_V.(DFQ
M$8B,1&(C$2,0'C]H].F^S8W$23XB:Y[/\J!]'M/K6Q$O"O\ B3CTM-?:KO$3
M.8B,1&(C$1B)5^M31@GN@-A8C)EN]D[I AU';P%&15%GV\!/RX *'+M;K_ *
M7_+YEQ$M#$1B(Q$8B1VV^3,WZ/7_ '<1/QG[76Z16']IMTW&5RN0C SZ6FI=
MX@QCV#1%(#*+.'+@Y$R!R#D0O,3J'$J:93',4H[&+B9.=D58F'1;DY-[A*:*
M4:RRQB= *J@G\R3H  L2 "1Y7758]3W7V)556I9['8*J@?B2?D/>3X )G-A[
M=-S\?C]S7]4NK'I3A+3<*L[#ML[=>*V%N9ND<4G<3KQJY(DYK]6= !D'%D5)
MU[I/IE0Y\SM1Z?7A<)]GM:9/+IC<YU>5#XW$!A;QW"L?*7<BZ[2_*7PRXX/L
MG1\>S;*HU^?U(S589MP.%!*6YA!3(S@/#)CJP#)4?*ECX(_N)/=5-[]5:]U%
MHZ$B=0:TCJ]5TV,8>6;UMJZ:]WI%J1<C1W8Y(BB@RTJHL].1)[-.BK"=RH1$
MZQ1ZM,.?\MR/,<[?;S')V9.6SV"@Y+(PQJG*ETQ:B!Z-(" LE"%=*"W:?+2Q
MX>-A<>B86*M=6D-GI!@;7785KGV>]]L0IL;?G2[\ 2OJ54^(BS;,/?\ :EQC
M:32Z^]F6=/TU0U$Y-G,LE068M;%L6V/FB;J5>K-A!\P@(AK'Q\2L=(5W+UPD
M?)+.R^G,;BUX[B<*W.S<A*'S>;Y &JREU(L?'XW#1BM*!OZ=F1<SV6KW (JD
M$:F/1REV7]ZS+UQ\>IK%HP,8]RNIVBVY5Q']0D>VM:A50Z.PP(FSX%*41$I2
ME$P\S"   F'D <Q$ \(\@ .8_F /@RK28D<G_'JMZ?#[)E,P?>OZ_P"#$DN9
MB,1&(C$1B)&H_P IK!_DH7ZY'$22XB,1&(C$1B)&J?Y.1G^!Q_&.,1)+B(Q$
M8B,1(S<?)N3_ $:/\0CB))2^\']P?5B)]Q$8B,1&(D9?>5,#Z/FO]CB))L1&
M(C$1B(Q$C$!X_:/3IOLV-Q$D^(FN>S_*@?1[3ZUL1+PK_B3CTM-?:KO$3.8B
M,1&(FI7%ON;9^D:M7;70*RQF(%*0EW6R["^KLU;DZ/3HF#>2:UA&MUZ>@)>0
M0*Z020=J-'+@S-N<[CM1<2 0439&)LT5)5.+MZ3Y-W#R,%'SJ,BT;.NI<L7S
M)%ZD[;M!(J\!-9)8JJ2!B'<%*8"' 5 '$2M]<6VM=KVA1-90JJ]SL;@Z@1,B
M115%>05.V,HIVD!C""7O$.(G1#W!RD'W.(EC]]T#\;7]727LF(CON@?C:_JZ
M2]DQ$=]T#\;7]727LF(CON@?C:_JZ2]DQ$HGB&XE-2:7U[*3-UL!T7,FW5CZ
MU6F;)VO9[=,+ !6T16X<R)'4B[75$B8G3(+=MTNL<*$('AG. Z=Y3J3-&'QM
M/=V#OR<JTFO#PJ!_??E7D=E:*NR%WWOK2*3[H_D>3Q.+I];*<CN/;52@[KKG
M_!*T'DDG0+:[4WMB!-/JQJR_\6\]$[,XNR/:;JF+<(2>O.%AD64.V.#8Y#L+
M%N%ZV;)A.2RI0!=&NBF1DT(<A5B$YJ(*W3*Y_B.C<>[B>CW3-Y>Q#3R?5;H.
MX;V+<;AU8$4T@C1R%9F;6U+GML6"IX[,YRQ,SF@:,($/B\2K$>/]EN6P[2SG
M9_IL =:!"@E3LA>=D[;7N$?J?1-&C*15()O".)_<5TA'(TV.B#"F?O:U[3HL
M&SRS3?:B9VJZBRL5#P8F 51<*@FF-;P<;@$PGYCJ#DKL[+R6O7&X7 =CG6W#
M:_>>2S;5=,2GO86*H%EV1X(TO=)/(MY)KQ@\;BIC44BOU,[(5?01"-BK%H4@
MW-H%3_:E>COSVF;' _HYII"RJLV:ED1BSPQ)X:^Z[K$BU7!':\<E("Q,[3CU
M7:9'1V95NH,N0BIB&4(!@K/WB\4-C"ZT8S6B\X_J-Z)N52BVM6"$-JH2@L*]
MP4D @'4EO2K]07&M#<$]/U>P>IV$]Q0-Y8(6]KMWK?GWS,]]T#\;7]727LF>
M,]([[H'XVOZNDO9,1(_-6B%6>5PR;E82H377*\V#\H@0(N2)S #-BB8>F<@=
M$G2-X>?+D B&#^'Y'_U_F)(.^Z!^-K^KI+V3,Q'?= _&U_5TE[)B([[H'XVO
MZNDO9,1'?= _&U_5TE[)B([[H'XVOZNDO9,1, RM$*2PS:YG*P)K-(@J8@P?
MB(BGV_T^9 :B<H!TR\A,4 -S]R(\AY(F?[[H'XVOZNDO9,1'?= _&U_5TE[)
MB([[H'XVOZNDO9,1'?= _&U_5TE[)B([[H'XVOZNDO9,1(_5K/"MH&/15=+
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M _=3WH[6%[47M[[&)+N.[P9>J:::29$DB%333*4B:9"@4A"%#D4A"E "E*4
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M*DU*?H'#D;HB,H8 'E[PB4>7P8B>DD%L,A"D"\QO(I2E#_LBV]XH  <_^*_
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M(Q$QLP]<QL5(R#.-<S#MFR<.6T4S5:HNI!=%(QTF;=9ZLW:)*N#E!(BCE=)
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M)%T^2A"B")7=UX6]/;!:[+:V>#?O?Z5I^H6NS.$YAZ@Z;66AL&4?5)N 63.
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&0Y<\1/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g90195g49i05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g49i05.jpg
M_]C_X0Y:17AI9@  24DJ  @    ,   ! P !    - ,   $! P !    + 0
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ ?
M    M    #(! @ 4    TP   &F'!  !    Z    " !   (  @ " " _ H
M$"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P(#(R+C,@*%=I;F1O=W,I #(P
M,C$Z,#0Z,#4@,3(Z,#,Z-#0   0  ) '  0    P,C,Q : #  $   #__P
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0%(            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              Q@   )@
M!@!G #0 .0!I #  -0    $                          0
M   "8    Q@                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   Q@     4F=H=&QO;F<   )@    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   ,8     %)G
M:'1L;VYG   "8     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1
M ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M_\  $0@#& )@ P$1  (1 0,1 ?_=  0 3/_$ :(    & @,!
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M3_FZPU:8L0M-701:!QK",9&E?A(H42TDLTAX"K]3_A[I<1VH35<*M*TX>?R
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M'LMGC$]TEH!6(#6]/EP'R^?RZ,8?\5MI+H@:V[4^?J?RZ>]+'^S^+^FP%OH
M!_4>S+23I6F2?\F!TD$B\2P_U>?3=&369-W))I\6OBC(Y#UTJCR,/\88S;_
M^TBDW%ZQ.8(!0>A<Y_.@Z<>D%HJC^UFR?]*.'[>G9K@:F.D*"68_V%4,22?H
M %'Y]KF(HY8]O$_9Y](E ) &&Q3[>FG&1M(M3D)!9Z^6\:\76CANL"@7N-=M
M1_%_:&R7Q1+=NO=*<5\E&%_S]++U_#9+93VHN?\ 3')ZR9-WIZ)_$"*B8K30
M!;W\TYT(2>?T*2?I^+^W+UC';L4%)6[5^T_YAGKUJ5GE7Q!V+D^E!_L]<X:,
M4L,--'_FX8U6_P!;V'K8_P!2TA))_%_=8[9(E2)00JJ/]GK4KB?Q)0/B/KP
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MIBC/\Z\$^8/'IZ,F*)IR.XX4>?H6^P''4]?5Y2%%HRBBUA=2NDE5_LHG ]O
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M4J]9+)20,R0Q^C(5*&^D\%J2GD_2)V7_ #A!NBFWU]I9/\88PH2(Q36PP?\
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M1&HC]@]>L!CDG9LE6V\LBC[:G(X@B8:EN&-SJ^H_-^3S[2+"\NJ]N?C;*+Y
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MY'-AJU6X'X'M1! EO$D:@?;Z_,_GTQ/,]Q*96QZ < /(#J22+#58  G7>V@
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MGR8^OY=/L:AM)-B;$+;\@D?G@D_6WLTB4@$GHOD<'/3=%;(U[5)YI* Z*=;
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M+ ?10!;B_ M_3Z>S+Q$J:$#_ (KHN,16FIN)R?\ +TQUK_?Y*CQH)\*-'6Y
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MV>IUG)/'CQZAU12MJ(J4W:F@5:S)E0?W%O>CHS8V/E<>0K_J5]L2GZB58/\
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M%F5452[.2 J(HU,['\!1]?:PD*"Q:@ J3Z <3^7GZ=)A5B M=1X9_EU%IO\
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MTC&1Y6YFFDXU2S-SJ8V^G  X''MV)1&FE"3FI)XGYD^?^3IB61G8LZ]HP .
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M9=.SWLQMH6I;+\;4XGT^SRZ,X:641N95K<L.P>@\R0?/_!T\PEXT$:NBK&+
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M;^,B6\9[JGXS_"!Y@<3^SHRMIELT$VAWN'%% 'PBOQ?GP'RSU*.T<>MW?<=
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MQ&:ZLGJ1)4215BTU(-=74:?&M^(Q<WED/UO;Z7_U_;[2O%="&W%9G./E\_\
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M9O4TCM<EW=N2#^?\/>X0L<:*H[1^VOG4]5D<RLSM36<#TIPQ\J=.%36.BK%
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MM=O3_2C'2TT@LA7^TF;AZ(/\YSTH%<&]F4#TCDZ@.1?Z<\?7_6]F(8_#7/\
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MF/\ @'\J]9\A-]K054@L)?"(X=+7.NH(CB(_HVM_IP1[=NI/"MY7'Q4Q]K8
M_:>M6Z"25$(HH/\ (9_P=3:*!J:GIJ:RZ:6". 606)5;N\A!NY9[^[PH(HHX
ME&% '[./\^J2G5+)*QRQ_8/+J%-JJ,K2+JM'00M62@LH"3U-X*52>22J:F_P
M'MEZR7D4?X(@7/S8BBC\LGIU6T6LA [I"%'V U;_ "#]O3DH4:B6&IN-5[1J
M #ZF+<BP]J=(&">/'_5Z=,>8IP_R],6/U2)5U[<?Q"I+1!@6(I:35#36_%I"
M&>W^/M';GQ%ENBM#(_;\D7 '^;]OET_.K(([=&%$4$_Z9LD_ZN'764K6Q]*:
MH ,[KIIDL;RS3,(80>;B\K7M];#WZYD-O 9:]V /F3@=;@B6:54)[ *M\@,D
M_L_V.HJ1#'Q14LFI32V$Z!3Y:BX:28LUP-4LK$B_Z;W]MHHMXXXV;X1D#S/$
MY^T]>=FED>33@G^7!13I-9!_N7AH RTQJY1(Y9FJ)(J5&5Y@=-G)<V0"UW)-
MO99=GQ#';\/$-3Q)"C)/S]*#CTOLPJ![A03H&,4J3BG^6O4F9W(D9GIR"XC
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M/(;N<\11!Z#U^WHRGDC@A%I"]?-F]6]/L]?V=.X%@+@<\@GD_2_-N1P?S[,
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MCC:8_P"4U+-5U%SR)9_7:_Y*1V'MFRC:* %_[5SJ;\\@?D.KWLHEFHI'AH-
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M&?IXHK 2U#VN> ;#^OM+=S,BK;PYGDP/D.#']G2BTC1W,\@I#'G/FWD.IE/
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M6\,8'!!_@KTQ,=<LSX%6/^;K%$/-FJN55!CQV-IH"P8662NE,EM/ZM3)&/\
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M%G+G+GS_ ,OV]-58RU,RTVD'TJ]5);2RQ#F.*X_M3D?ZX7VDF G*6X&*5?\
MTODI]-7^#I9;MX$;7(&:T3YMYM\POE\^LR6+*$) YN#] +!2MEM86X_/M2,
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M(H.+_P"(9AR?\/\ 7]I;J5W=;. CQ&^+^B//I5:Q+&K7=POZ2UTC^(_YNG*
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MJN?S[9^J2)$C0G2JT_9T[X#RN9&'<V?V])K+5TLD:4X<^6LF6$?6XB!O._U
M'I%K?X^R?<;MWB6!/[21@/RXG^71QM=FBRRSR+V1)J^1;R_G^WK.IN%0+=0
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M3%S>IDT&[ !84&J=@/H %6W^-_99*[.5BUDER!3Y<3_+'1C:HD1DN0M!&/\
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M2WHL?'!%%#&@6.) BBU@0HM=K6LQ-S_K^Q%;6<<:(H7M44'1!=7;N[,[\?\
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M!R!<*Q!!L6_I]?9MQ.>->D'D1YUZ@XR8%\G5/I+3Y6I^B?MZ8E1%55O^E2"
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MX$!X'FFL\S @V(5 %_US[$6V*&N7>HI&H4?:<G\Z8/0>W#MM8U!.J4EC\U&
M/L)S^70N43#2" +_ $-Q<?33?\\J#<_ZWL=6]*(1T"KDA;AF(Q4=8<9,)6J:
MSZFJ8B/Z@_:4[&&'2/\ :V#-?\W]M6C!C+<&G><?Z5<+^TUZO=J4\*#'8*G_
M $S9/3R:L0P5$S@:8$+$_1GTCTJ/J2S'VO$XC225LJH)_P W[>'2../Q72-1
MDX^SJ3CRU/21K+83O>HFN>3/.?)*7(XNMPOYL![W:H4B2O%A4_Z8FI_9PZO.
M0\SE?A&!]BX'V=8<I72)2N(2?/5.M'37L2)IO2SWX&F&+4VK_#W6[E,4-(V'
MBN=*_(L:5_(5/6[= TJL^40%F^=!@?F?Y=-K-'&B0QM:*!!%&&&GTJH%^!RS
MVO[3@!$6-?@44'6R999&<G]0FN?+_5Z=,U>_E:"A5OVZEVFJ#>UJ*FL\P//!
MJ)=*?XDFWM'<N)#':^3Y8^01:5_::#I=;QB,-<4%4%!_IF_S<?V=?__7UIJ+
M'-2HQE'DJIP7J&'-N;^+4>=(MZB/J?>=EI9_3J=8_P 88=WI3T!_G\SPZP]N
MMQCG951:0J:*/7'&G^K''/3HM/J"C1<?@6'IO]+?X>UL,-%]*]%TES2NEJ#_
M  ]=SHE-&\TG"H+6"W+L;Z4'JY)/^VM[W,BPQF20<.'S^77H))9Y$A0]Q/[!
MTW8K%R/5G(U0O43@&)"+>&&_T _#E/I_0?Z_M)86+O<&\N!65N'R'KTMW._C
M2W^AMZ:%&3_$?3_+]O2GH((UR4$CQ>2)2=4;>D"X;268 V&KD?ZWL]MX%CNU
M?150*4_R]$%Q,7M2@:A)Z?)$@IHGGELJ1 Z](Y^MU34?JY-A?\\^UT@$2/*_
MP#-/7_9Z0H6E98DH6Q\L_/TZ@XZC>9VR=4G[LH9:2/Z+#3VL& )N"X%@?]<_
MGVEL[5YG>\F!#$=H]%^W_42,^?2F[N(XXUM(O[-3W?,^A_/CT[^%&4AH^.0"
M18V''!^HM_L/9@8"3@8^72!9B*EFSU'G-/1T[RRI94'"\7:0\J@/TNQ_VP]M
M2@6\;3291?VD^0'^7IR'5/(D25J?Y#U_S5\^H./QSG76U:DU-3ZP+<10DW5;
M'Z:A_O%A[2V=F]'N)O[>3Y<%/E_GZ4W-T*1VT34A3!]"?,_ZO/ATX_:Q$\@W
MYTWO;2.?H1:_)]KC$U*TSTD$U#QZ@9*3[>DBA76U4Q\=,O!L[6!9?K<*&_V_
MT]I+R0PPJJ?[DMA1\SY_[/KTHM%$L[,YI"N2?\GY]9Z"@%'3+$?5.W[DS'ZO
M*>&.H?4+>PY]WM;+Z:%8R*N35CZGJMU=&XD=ZT POR'4X0G25TK9OJ!:]N+\
M_P!3_L+^U7A U4 ])2[4U%A7IMJXOXA5Q8Q 3%"JS5[+QH"D:8K\\V(/^N?:
M*XB-S/'9IA%[F/\ DZ6P/]/ ]W)\1-$'^$_Y1T[FGTV,:* -* :!;0JE5'T&
MFPXY]F1@0*%5.D/C.2=5*G/6%XX8D9Y$TQH#)*W!!5!ZN0 =1_'MET"([L,
M5_U?;Y=.*Y=@BU+UP/\ 5Z<>FW'TTCR2Y*="LM0=,"GDQ4J<*B_B[@?[8>T5
MG;2.TE[(HUR?#_17Y?;TINYEC"6<355!5OFW^QT\1QMSI%KMR>23<\\_UO\
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MH*=O#I.9J/[RHH\6M_&Y^[K0.1]M"=4:,/I^X_X_(]D^X)X\L%BOPDZW^0'
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MSTM,2 0&$TXU #BXT*?9\(?T/# R[*O[3G^71&TM)"[<$4G^70IT4>BW TH
M.!Q9;!/]B;?CV,H4X"N.'\N@A,X9F<DU)_XO_#U(A35F)VL#]OCH5N>?7/*9
M#Q8?V5_U_;HH;^3T2)0,>IK_ +'5G;3:(NH=TA/Y*/\ 9Z<I"8H*B1CZ5BE:
MWU'IC8W/)_(_V'MZ5],4C:>"D_L'2= &=1YDC_#U'QL2IC*)2!J>E1R?H0TE
MW+ ?0_J]TLU"6MNM/P#IRX):ZN"QQK/4>9'_ (KC8RNK1!6SC4%T@E4CN/\
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M[> ZR8[%-0T=/3,#Y%#23L5!,D\MGE<M8WLQM_L/>[2U^GMTB'&E3\R<U/\
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M3-Y)+(FC5XXU,CZ5OZ?]@/;=A;R-"\GADL[DCSQ6@Q_/IR_G1)$C+*%1 *U
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MZ 54#DEG^O/O4T3-=6*E"0"QX>@I_EZ]%*/I[PXIV ^N6_V.G!*=R2KPZ[7
M;2%"M^/J#?GZ?X_7VL\(@T*?\7TF:4G25)!]/+K#0T-08*V6DC(AJ<A.:B4
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MA72&5<91\UE<=+GZ?;TYY=[CE-8^O]$N?Z>TUY.^H6<'^Y#\2.*K_DKT_;P
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M?VAO[ME"6L.;B4T'R4X)/\QTMLK="3<S+^@@R/4^0'V]3:;QTL$=-$P\<((
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MTMIO_MO>WE)MY$7XGTK_ +V1TVJ#QXY#\*5;]@/2T@J"L8$?Z% 4C](!C
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MK$2H,=#U&K\_4TE.2%0S3'P4RJHU&5Q;5_B4^H_QM[9NMUEAA)4UE;M7_/\
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M9ZZ7);1[)Q]#UIN*6OSG4>X:E8JK)-2H#+582K5<I0PW<?=0H\XQHWGVSO\
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M-'<>@RR)'JD)!#,RKR?;3;E<37T78!$D34'S8@'^73Z[;##8RN')F:5:G&0
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MP=+J*E81JIM<$<'GZ@?D#BWL2PPZ44 5Z#DMQWL3G'4:AIV8U\UP2^0D6QU
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M !&H'H>ENX^^6TQPR#;-HG>?('BE47!I7M+E@.-*K7A4=:H?R?\ DKW=\O\
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MEZ*%EE H.)^+UZ'4?N9SW;QV\9W[4^FK%HHB<^5=./MZ&_K[_A23_,8V3F*
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M>M0WQH:E6C<C!9&!4D8-,8/6/6^[->;#N^X[)>Z?K+:0JQ7(84!#K7.EU(8
MY%:'AT :)?+9@'_E6H5'X%M#_P"P_/M9&/\ &[T_T$Z02@FWM03P9S_@ZA3
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M>DEG29:.KC\=28BID@T?7_=B@1VX/U][;P([JZ1HV(8*V#ZC_.*].$,\%L0
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MI9DIXWFF.F*)/(Q4$D ?0"]@68\#_'VMDD2*-Y)#11Q^SY?;TBC1I&"+Q/\
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M18W!N(?T$\G\_7V@C)-WN KYI_@Z4RJ!;V@KFC'^?6"JU6GX/$<BC\D>AO\
M"Q-S[<E(H ?G_+IO"Z2.&/\ #TF<4;XRA/X$%N>/H[ _[S[*+(GZ.V!'!?\
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M[64H6/J3TS\O+IKEEC;-X_5&5,=!7.29+K8R(+GB]^+?GVE<J;ZV!6K!&/\
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M 7,7N"),:O M8Z)[?GZVU<^R\-_C^#@Q?MHW^'I>P_Q-B#E9JT_VHZ=XX]?
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MMQ=K<>W1V_22>0DI_O6.F78.+M#YQUIYU4UZ6; J!]5) ^O^L!;Z?U'L1*
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M)_U_:J.&.*-(E T@4_9Y_;TPTKRR-*Y[F-?V_P";IN>GC8^G6K GTAV74?\
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ME00;\_[#VAGFK=6"EL:R?V#I;$E+:]9A^$#_ (T!TH15,=-SK!YN/JPM:_\
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MG;(BYLB"UK78DD7)(TVM>_\ MO?1=IT\W'6!BPM0L$->NEKQ>QC7UFW!-_\
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MJ"32&CC9 HY " G\>Q3M_@3VT=PJ ZLC]G#]O0<NO%@F>)B:*2/Y_P"7_!U
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M]),>G#ICR%\ADJ?%7O3TQ%97E0/I:\<)_J;$#_7/^'LON@]W=PV*G]-!J?\
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MC!!_EZ]1J0L]96NQ;1YX*=O& 91&B_NLB$JKL > 2/\ 7]L0,[SW;^0<+C)
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M2Q'/&E*=0,!1UDE%"KT[*JR3)Y#=+@5#@%&3ZN ?I[2;9;SM;QAX]*@G/YG
M_P O2C<;F!9VTR:C04'Y#CZ >O7#)@BDR$4;.X6GJ02X%R0K7 7ZC2?R??KM
M0(+E1BBGJUG5I;9B*$D=>II&\%.;D@P07_H1XTL#_A[W$:Q1'^B/\'7I /$D
M_P!,?\/7JUF"4DG!\>0I''-K:G*'D"WT;VW<DJL#C\,JG]N.K0T!EI_OMO\
M/TH5)YU"_P!;@$ <W '/-S_A[.1CXCT5OD*P'4;[EXLQ261E2IQ]1$QU!B7B
ME1PW-KA5)_P]IQ,4W& !:*\3#]AZN(?$L)B6)99 :</+RZ=Y9X*1FU291'U>
M1A%(GV]@H*A8"1P1S^?:UY$B>CR2A^.*4^SI%'$TT5(TB(H1Y@_ZOLZ2$M=2
MT^0JIFK<M*J5GW20KXVA*5$2R6D1G'T)(8?3V2-<PQ7,[&XG;OU:12E&S_*G
M1SX$DEO$/ A#:*5-:U&/+S^?3/N!J2\\225L[UL+U'D:=5@\<\9*QHHY]+*
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MV_UV_P /?IQ]5=PV8/Z2]S^GV?Y.G(/T+>2Y([SA/\IZ5ZQJ%]*%5!/I/%E
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MS&U3#'+'554?D=T*H'X52;CT"PO^;_3V=PM&]B095#!F%2>'1-*C)=!EC:A
M-*9)IP'22>@A3/12_P 3H6IJK#5=*]+%.34M)&0_J;2JJI;U?X#V3&UB7=49
M;N/PI+5DTU[B10U^S[.C9)W;;'B^E<2I<*^HC%"#@?Y.H?V%2**NITJ:-4E:
M&42)4ET5HR=/E5N4NGI ^A]M"VF\"XB6:/2S BC5&/GPKT]]1&T]LY@<NH8<
M,Y\^DK$LN*CRZR&)I#.HC191-=:F(:Y/2+"["PM:WLDA1K)=P#LI):H -<,.
M/^QT;S2+=_N^05[4H213@3BG[,],LD(DBD0CAHV5A:][K:P%A>U^/9;)&&C:
M)A4E3_,=&$<A@D656((8'I3[/=602,ZQMX(8V!4EM<8:)M0']IK?6]K^SK8)
M T<<FH!@BKPX$8/^KCT4[Y&RR21A*KK) KY-GCTI<P0(L?4C2&HZM9@2225,
MPCDL%N6]#$G^@]FNXG]*TEK4QOJX>5:'^7159 ![I%;#K3^5>LI7_+(W)-AC
M9;*.2!]QP;@<W7Z>W67]92<?HG[?BZ;!+1M&/]^#\Q3J-%*4RR (B??4?B(D
M<!1/2,9$<D"R_LO]?K^/;,<JK>KVC3)'0UX:E_SCCTH=&-B3J):-JX]#BGS'
MSZ=:WQ^"50L3%J>H$C6U*WIN^D@#5Z>![77!01E:*:J:TR"*>OIY=%T ?6KI
MPU+2M1GH.\-4Q*GVA66+Q5#0@WL&CUAX2]C<$JUA_7V$]NF"(T(4@HQ7\B:K
M_+^70MW"$M(DNI3XBAL<*\"/MKT+N""_99*9759:2:EK:=F=4+-179T(-C=X
M"18>QK89M[I@PUJRL*G/;QI^70,O&+3VX<&C*R\/4]+ZKJ(*J2!X&62)J=9U
M<.K#3,H=5:U]+JOU_K[/6<2!&0@J5J*9X_/AT4*A2JNN0?\ !_JX=0J:N&/J
MJ70"%RU ]/,3(- KJ8F2FD']HZZ<LO']/;&L17$51VR BO\ 2&1^9%:=*-&N
M.0$_ :_[4_YC3K)557F@>.H ,11U"E2"RR^F0.W+'4I_V!]O,0P*,.UL'[#Q
M!Z:742I0Y!Q]O2*HI)%B-%*UGH:L4KBX):$ R4KDW-]<+ 7']/91 [^&UNQJ
MT3Z3]GX3]A'^7HPN5!=9T_LY%U#Y&M&'[?Y'KV2#K#'5QJ6GQ\GG"BYUP,-%
M3%>]K20F_P#2X]^NU(C2915XFU#UIP8?LZU:L"[PM\$BZ?S\B?SQU__1UUK
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M9N&S7T!]/F>O7ER*+#%B!?(9KY'_ %>?&O3@4%G -])+'@AB;B_-A_3Z^U;
MZJ4Z2BFFJX'7$*S,  ?Z6)%A>X%Q^3?_ (CW4C&16O\ @ZT&);!-!TP,@R%8
M*0$M14,C25!U$K-*3S'<_P"/I_UK^RLJ+VX$"G]",U;YG_*/+[.C1#]);M*W
M]LX[1Z ?Y3Y]*)1P01Q].. +< #^J@#CV<: QJ,#^71.'T@KQKUD06;Z?GZ\
M\V/'T_//MWAD=4ZP2R_>5]-C;EH*<_=5O)(T@76/_"P(%OZM[2R2>/=PVFH^
M"IU.!TI2/P;9[L@:R*+^?^3H1J*O*Z!>P(%K'G2/TJ M@MK>Q=#<F@H1]GET
M%)83'D5)_GTH(\BOU+J6X*_07/X!4^FP_P!Y]K1,O'ATQX84L#2G29K:PY3,
M14Q/^28N\]0 =225)_1%<_4AK#_;^RN:47.X)#7]&++>FKTZ,8T^FLFFH?%D
M-%^SS_U>?3A+5W!:X!;D\@D D \_@W'T]K6F)-!P\ATA,9';3/4)ZAB;7/X
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M%-84.D>GY=.'W-^ #P?KP1:P' X ^OM8+C)%>'3'@,/*HZ:<Q7FEH9G2_FG
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MQX^IC@72%C$"GD,SS$1W(O<WN?\ 7]I]QE"VK)'PII'S)/2BQCK<*QXUU'Y
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M )!]E[UGO@E:QP#/^F].ERK]/:%]/?,<?(?[/3BY)Y_ X)/U^EQ_A:WM;TG
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M&U,01_+JFI>!'\^O3S"GB::0Z(UL>+78C@*H/U9A_3VT^F!#)*]$'^K'J?\
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MP(^I_P!C[N]M0U4>?7DN0>X^G$=1LE.:3'R%?7-4$4M,JJ+F2:X(6P_L)?\
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M(_['3@6-;*9RO>[!1Y&G2EBJB+,"O-KMY0#;ZGCB_P#3V="?30XI]O14\(.
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M_-O?K,&;<I:*:I"/+UZU= 1;?&"P.N4^?ICI84Q4ZM1^G(-K_P" %OZM[/$
MTT^?1*:U/H.HF196K,-"6L/X@TK?6VF*)B"1_KFUA[8NEU2[>G\4I/\ O(/2
MNU%(KV0_"(Z?M-.G<R*2W(_WKD_[#^OLQ#5 (%:]%^D^0QTU9ET_AE5^G7)X
MDX-KJ\J#FUK\'GVCW/\ W!GQQI_A'2ZQ!%W"?2O^ ]3HR#K!((6*,+8G^RJ@
MCZ@>I1;V[2OP^5.DI^)P>&?\..FRM*BFJY/02*68@W)%S$UN+_V;^TEU189\
M?@;^0Z46YK)"-1KK4?S'4?&1QQXW'IXQ<4D)N..674;CB_+>VK( 6EJ"G^AC
M^8Z<O&<W=V58Z0Y'3Y"$Y-E 53<WY)L1_4:1<>UX51^'I&34'ATW89%_AT1\
M8-Y:DWYY'E<_UL;7]I;#2+2,4'%O\/2N]5C=28Q0?X!TYN]E%OH3I_J0Q(('
M];>UH)JOGGI$0-)].DUBFO!57L2,G6J0.;'R\#_8_P"/LIL=7A35_P!_/_AZ
M7WU?%AJ,^$G^#IRE6Q"LRAF/Y.HL?Z64G@<^UG @&E?MZ8SI4@9X9QY=,>.X
M&0IR_I3*5%A<*#J"DW4F['_;V]EUH<7*$X$Q%/MST8W([H9#6IB7^73B%-P0
M/5<$"X!/-A?Z?T]K@.ZG28M1=5:#IOQ*(IR:,;LF4G-K\#RJCD"]N03[160
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M;@ /,#R_S]'-HD5L@NKG)XJOG7UZFP8N*CA6&%65%-W:P+.UK:R0+7-O]:W
M]J8+..WC$,2?IC]I^9Z327DLSZY "?Y >@^7KUE, Y^HN?H0>2 ;_P"O?VX5
M_;TV)SCM%.L:T4\H.B,L+ 6 !0WOP2?]?W7P&DKI!/3HN%6A'^;I*U<<E?5G
M#T]_!&VK(SI^E2IL8E8\,5/'^+?ZWLDGC-W/^[X7I"#60CACB*_X/GT:P2BW
MB%Y+4RD40''^JOF?3I31TL$,,,<$130F@I]55%_0$X!)_)_J3[.5@BC5%C
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MC[5.0>K7C>(\,_G(@/YC!^7ETZM3K)#5PR#5%/YU9?J2CK:RBW!YO_3CVI9
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M_P"!M[06+BEYZ>.W2^^4Z[3N&8%/V>73F:E%)(8 <>C^AO\ 2]R2#_O'M?K
MXX/2+2WD*]-U+*/XCE06%[TCFQX_S)!! )) ]HK=@+S<%ICL_P '2V=&^CL6
MTX.O^1Z=A+>PNMC]238 <_2_UX]K=0Z1<*'2>F^.H-/GWD#7OC802I/J5)FX
ML/QI/^/M&C:-U<@TU0#^3'I6\8?;$8_$)B/LQCI0O)&X/Z5U-K3GU L.1?\
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MUL/*E70-R;>HF9 2>"68$6_V/MR<Z+_;9&':^J,_GW#]E,=-0H7LKV,'*E9
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M)?4W(X!^GMBR<V]I%$0-5*FOJ<]*[Y5N+N61!6/5I'V#'65LB#^!<DFQ)/\
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M;PZZ[RZS=2?R'E]GY<!3Y]+=P$1TVT I;H?]Z/\ EIY?/IR;(*/[7X_%^/\
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MX8Z])N#&H;292@0@\#[VF!8C\ >2Y)]JC<O4UK4^F>FQM:@9%,>=.NX\U33
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M*_YND*G0Z2C3J4U'Y?ZL]<L17&:BA#NPF@!IY/06O)3DH1_47 'NMI.6MT)
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M"_S:@Z-5LO\ X3T_S<=ZU<=97= ; V%0K$J4\F^^\]D05*O(/6\F.VTNXZI
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MI4Z>+!D(/ _!O[8GN%+O$::2I'[1TIAL3X","<4.?MZQ8K(QM04H64:D5XY
M;CU1.R$ &^G\>ZV%^BVL \2C@4/Y'JM]M#27,U4JK9'YCI]CR<(TG[B/4-(*
MD$7)X;_D'GV?1[N@XRKQ_ET&)N79&+!;5P/E3CY'K)09A!%) )XK4\\T///!
M;6OJ87(L?]@/>]MW2$0&)IUJKL./E6H'[.F]TV.Y-PLZ6['Q(T)QG4!0_ETZ
MC)%O5%,EU!(]98 _[Q]+?[#V<+N"89)E-.B)]KG4E+BW8#@<9IUAHLG/"U1
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MJU_;3HPM-2TU%!'2T=/!24T*A(:>EAC@@B0?1(X8E6-%'] ![+22Q)8DGI8
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MO65\)+6)F/<!I;[5QTQNFU-!>3B,'PB=0^QL_P N'Y=?_];7-EK ?TL56W)
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M)-QUXJBPOY%=6!^EA[!-_P Y\T[GJ%WOEP4/DK:!^Q-(Z$5KL.SV=/I]NB!
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M]Y&V*[9WCC>&0_PM4?L;5CY5'53?=7_"4_Y#;<%=6_'?Y7=;=ET<4?DHMO\
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M2X;9W5&WJFJ@@-N!49[,U<SC@:Y"?J2??NO=;.__  GLZNH>J_Y:_P >L9%
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MX/4.F2CRFY<?'6Q3114LU+-)DFDACIX*2D8U<TTC.$J:*GCIS(SN&,4XC*R
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MIS(BX#8<?]UZ01L2##49&BFJ-Q5B?\M:U0?RON:>7O8_:;7PWGM_%E\R_?\
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M^K_!U%MYS'N&X2$1EW)QC )^W _;TS-2U4K%JZMCI[KS% 1/(OYTM)S$IXY
MN?:TSQ1"D29^? ^G^K'17]-=7!K<3A13@N3^9X?LZQ@45.08*=97L09ZEQ,X
M/T-E?]M"QY%A[3RWI"G7)2GD,?SX]*K?:A5=%O5ABK9/\Z_X.H5=E5CI*UIY
MB(A1U7I2_P!!!(6!"FUR!^/9>=P42Q",$L648^T>?GT<KMI6*1IY-*!&J/(X
M^76VM\8=XU+_ !EZ&1]0,766W8T!.JT:4@6-F3ZBZ@'U6^OOFISFX;G/F]UP
MC;G<4_YR&OY5!ZZ3\H)IY/Y24FM-LMQ]H\-2.EEG.S:6@9U>O\E3]3!2:)F
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MIY\3-W]/34^"2)921_'/[H3MN/)US6!BAIJ>GI5L?-(2UA*NV<H1O*1OUVT
M%%G6U&J0\0F@R$( ?Q:F/''2"7<O<)+6Q=.5-I\>:.AM_K6I&!G6L_@UDE;.
MJ,JJJH4AC7HU&&DWFG;V"HL+18JJV#6=<T8WS-7/5C,Q9-*BN_NXN.I1 V)E
MQ4M/+4BJ>25:D,(@B,C.5#AK5@P 8$\#7'D?M/F/(]"X@AJ>0_G\^A$H^I-M
MT^87)3R5N1H*2HDJL/@*Z19L3B)YSKG--#I'EA9S=4DN!]#J_&NO="DJJBJB
M*J*H"JJ@*H '      _ ]^Z]UV?]>W/^^'^Q]^Z]UX_T_P"*^_=>Z]P/\/\
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MI\?F/\'^KUZ4+]Q[-Q\21#<%$U74?Q">BP^-HLA5[BRE/B8O/F:_"[7IJ/\
MC^<H<)2@S5TU'!,E) /++I2Q*?:9HM^MXKS:',UFXQ(4DBC +E!J:5$"G4K
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L^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g90195g56a28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g56a28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2"R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ():^@T(X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,S4Y
M.#DQ' (% "U-:6-R;W-O9G0@5V]R9" M(#DP,3DU7U-)1TA4(%,M,2!&24=5
M4D53+F1O8W@X0DE-!"4      !!;8TMFEL_,I9,4 0<C%H-W.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $60
M!V0          0                         !              =D   $
M60                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
M60    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !%D     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MM_-GM/YUJLDY+VN+70QP]]A$1 AVQOYZ620.@78.7F/5*@XE
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)2<T-E)7LL'P"AE'9I;1UC=&5H*&U>'Q0T5B975V=[;&.(6BHZ7%_\0 '0$
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MH7FU7Y>HU)XLP+R+Y<&"@A?^B=SV&V_C6KIAF(-(<F18?-Q?CUM+BC?;A)Z
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M),[TJ*1PS/+=[.?D8[=FUR^&\GFH\],MPQ5_M _-39JQQJ\DZ6^BR%BP.ZQ
M]%VW^8%5[$L!R[;]I(Z>YN6TP9);T9,*/3G69;LJQXM?*)^"]Z-D@*&8=*P'
M8DYIEMS4#]Y:;MV5KBPO[)OS5^:75/G?U'TLZS^93JUUBZ=Y#RLZXZB4\'U3
MCT+(^+U5I_JUTGTUB\IB[6D]#:0LQ'\$:HS-:Q%-):K6%LI)P#PQLG9]%,\G
M<Z1/F=A0H1EHD!,+JD+3J$5*U*U%<6)4%(9B-W&/G+TX^C;H[Z.9SH[+]'IC
M-)A&:RD_'FCF<S+S"DKE8TM#A]29>3E E)$9>H*"R62015_3M3S]>T?R4Z2
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M;H_%0N+,I0P2F&C2D,P&I3FFY)WK1ML>>=-82T0))2M?SD19UJ#:B$IU .U
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M947(#"E>WN>_/F[G+IQULU-TDL4X-149M2UMXQ/0>9GR=&!P1"?B&)4I&FY
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M:*ZG1TVR5G(Y/(16'>K)%E<E<V<)&MNU<EL&+TJUBO%)6C58+#V5>QZSPJA
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MF@+IAPR7_P X@,6'9QQY?Z3)2)*2^6!82RHT=(*0 [(0; !F#;GX8F7Y<O\
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M3>9Q8B5"HZH @48N30C9K@@WVX]-EN6R4(P(9AP^LG8\0BCD%*0HL0& 8_1
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MAQR?KR0AM]EY21>BI[M\NQ\7$"720!H!+LP2>3&G-C:EL5F83:I5]44$:00
MI+-6C!S<&O??#_J5]5S8P0RZ+TYBZ4JA_CM2WWV@D7O%ZE2B%9I-QM&RJ0K>
MX ._BWEY,ECH-;^RH7X6(8'EX8YQ72!(?7$.D$DU<&M6IM4FC-NS@QMZMR6J
M.,G,75# G,P3&2/#U\%?./B"[<DAO39"+<D*?>%B-@0 3XV19)2G2F@<[._
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M,0.&S;+EH"BY85#<MSXEO!^//[07(V[?EXT-$[&>LGFJ\I[K(KR68HR>NFC
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M'BDG\HAPYA,14)#, W5BG( AR;&];%J''3Y1TIF?5E2\*9CE_:4CK5=IHX!
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MJT=4RBSWJ&/-FKOZT0JL\8-5F"(K>F>_<@DG?<$@;AAXQGI"%/)7$6ZE%V8
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M+^NBQQ\6*,.*!%"^%-2HA%"XITL0:U)#T>O'?E8@4KCG@F8"E2R0HA.E3:0
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M1=RI)J2 0;/0/+C%]<,3K/45C ,:M+ 9">M;QV3:O$C7))=*XC.KBTO&(22
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M15AX 8V/+YC<OB?.KCZF50DOY;.I-NM.ZH)YDM=6ND;R^N(]E#QR@A=U#<&
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M$=4'<=F W[=]EV2HAA"W!/5I5S*B0';:[[5HS._E>=](UKZU*%*3\XI+EBR
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MLM/*#REG53)Q5W#1CY0 I]C[[>+F%.]2E"DJ(J'9W>U7#;;-4#%.T5,P=2"
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M041QUH2F#K=]7LQ(H?V!$(HR6]E@.=,</F,_$@@1%%46(7^D"H@*J6>M@.+
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M1V5L,R&)IW,H3\1NJ0H I;4H[)2R:_Y))%KD@5!+5$&1$S#EXJDI1ZS#5*L
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M2*%J <3:2D5(0ITZ@"Q(Y-RX;4IWDTK]4LC^$-3VI#()(U<B([L2J-W*'?\
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M*5]2Q*[>G$8$9@/D*AI"Q&^Q Y;CQA,1T04*3%!)%;BH^%*]G"V+V3E5+TK
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M4;>-Y!7]4GK8X%5+A )'-R#O<N'+U9QQQOA- RE"TIZR% S",M*V8I,&)+S
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MR$.GLQ7JUH(ZT2&_CP97$<0"\I)HF+,=R>Q.WL-$-]1XZC>S-LS[>!VQFGZ
M)=W(VV)[W!VX4&*?R?EWVV.X[']1_D^[Q(P\<@=P#]XW\8DEP&H=^XT^O&0
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M+[XSAQG) 60 /:8UW:QJ1MO48C1J7H>,-!//?Q]<U\Y<9Z/PM,F>5$9MF%=
MKK+!,[35YY?1:589>9,*%AE"B1HJ E*: D7>U*[OL!]1IL4N&DDF)$! L5D%
MMZ-V=MC3#\T!IH3)E:.'QG*%\<QHV984BF8I;7C!)Z\Y:E9DLL)Z\%N5/7BD
MCD$2B5)Y9@ECK0J/5V )'T:ARP:H)?E:U<0HLT0IDEZU )+MLYHYWN7K6QW=
M)T+FE\K7EU#C[5F+)SW\/9C:NU>@T$61BND6,9.MEHKD368K<4I>LJ0>HZ0R
M1I$5LU(AQ(>@,:!BP#$.'9ZFO<",5JEQ!$*@Z25;$D7L_P .'#CPU56QN0DR
M-&M"D+036J;VZ<*1^E48/+3D*^EPAG@$J;(CA0DI'$(X+U:84&#%>)[1)9V-
MFNU0[D<.(HQQ9=9$B("4J]D<@23S#[-:C7+TP@8#HCG,SFL77%Q52=UDR$GJ
M'\ES;@ SJ>'J,H18W5@2'5 O(^-H,/4I25(1+P]761%D)*?SCI'YS!FXUQ<9
M=(S$Y'A0X4&+$CK^BF&C4"2K355Q9QR+$M4V,=$?+[0EMS:K8F#!8/(0Z?Q]
M.YBY;#SU-5XV+XG+Q\I_3ITK6-]>2E.]8R6(B/B'I6$4KYAF$SZW.19E"F@1
MIA<""FJ@$(2?GE"PU$,G4&]IBU,?1V59.K+,OA2,S!$6-!DXLR# &IXJ.J!A
M)4;F'UCQ3=*DL'"GQ,SJYTN@RFF:<62I5I=9:#IT:^F-7_"VH(Z=N"YIB/!9
MNC#&\)L1U9)<L)X$E8)'?M+/.+"D)43"E0H:@1J9@E3*<U% Y(HY:I=SM3%Y
M @0(PDRE4.&=(6J$EE+4M(7JZQV8EQ5C4.'%,#;HWT]QM0ZHP=RMZF.T=HQM
M(25<SD),;-%D+.5R&5-V!F@(RIF6G@K%&Q'$XLQ6I?2LL4X148$),2/%C%#&
M" RU$*<!5 /:%38M4UK1^K@*B"1D):47%1$A3,6$E4" J.E!B*_=(YHF&@!5
M&+$))(#8 /F]TW'K9])V:56A5RJY6EE)*XM"A92.3$6*T\-*85T@1GKSO:9D
MKI')5B#R>I8+OXTQ(T,%.@)250P6!+_1L"1<L[@>.+(2,S%$*#,K]91*9CK7
M%(*>L6ID+4'460#[0WN'N\=NI6*S65Z>8:N+?!-(R8>O4NJ&%G*+\?GLC\1(
M\+^E3CFG=*\AB#F>A54$1O+(@EKF%&#+PTD?-I+DN"2HDD,"P)85'<+8TS^1
MHC)CS@AD14E,9 :T.$H!8)V!0#J3P=J8&_132=BSJ86<<D[VM+8+':OJ1F0>
ME-+)&M&QC[,C$F63)8N"Y4%<N\L-N0LZJ%=3,EDIUA2RP$,DE@')->=:TK6W
M*BDT)G<NS:5A0V$..%)%289&7*20![+ZC!AH=ZFAP=>C=S3N;Z\>5K/XK*&U
M;M7O,%"N.>JU=\?1BZ<8ZFT[%N'*7)38V.>W^2!^(C9)9'GBD5>XZ&0TA4[$
M!JI*$Z>"0M1!?=R2] 7';CY^],$=4?*>C)6GYV&N:@QHA^DN)!A0H9"J4(TD
M\W.[/Z2_+E_RBK_&'^A/'>8\$QY[_+%D[V$\N/1G4..YV!B=(0?A.G%LTEG&
M_A&\TX2,=V:NQ$@&Q.V_T\?-?3.*I&>YI%023"G(@+ DABD-QM7@U;''Z8>B
M>2$SZ.>B*%@:5Y%*%R=V4S.;BA%-V +XEG%U4P.6FDRR4+D*2X^&7&W+D;B"
M>W&6+0"1%)1&8H!R((92 /H*F%-&)&"T%P"%$DD?1Y&H'<6M6C]ZKH]&3 ZC
MK(:]9.ID@$((()#L^E+N'V>N)*]$_6M:ALZMU'B:=:YJB.*Q0R<4PEBCFKPE
M9JL4K[NC2( _%BB,0RKWV4=G+1PJ$(@(U1&JUDL$M6@-"3VWQQG3&$(<E DY
M-1(E$Z(L!)8Q6;YX@4)2"5 DZFKNV)?8J]#B;-< >O!<H/9:5!LA7FR%-P=F
M/%RZDCGOOXDJ+NH52!<5]SWX\+EG./)X\LN.E14!JA!QJ+.>3[BGQWQJ7ZLD
M-XRUHUXV8IXZ-R2-EABE]19)*L@WY&.8D.3V7DOT(!.(K4%@ [V Q+AZ?55P
MS%]M&DJ0X) )%*4+$62YY5;&E2T[?O?&%9C7FJS2?$UXY "8QQXSQMLPDAE)
M9PR*"H7CN.)/B5+A8=E$DG:CT#CML7WXD6BYA%EH100A,1.EU$IL6)#T>EB"
M-L-[4FDK5*A\0RF.I)* MS:,2B9P"69CN?391Z6Q"KL0"3N-[J%,Q(21K70T
M)>KBP]SEP[\WQS$62@9C$4$Z#%424(&G4JY8U/\ YG-*5Q'')X*0ZB^%N+/&
MLM"62(R<"A:-U6+T4C&RC;D"K@E=D;W?;Q-AQTJ510)9^1-*DCBV['D&IC,9
M>N%EITI)0B/U<3<I4$N12KOVUH^'&-,U/@/BA'RAEB$.P$3-$0#N[KL)$D]Q
MLV[#?W&PVG)BLER=CSLW#E8<^#XY2-):O9TL7<I8#V>PU:^]'[&"N?TGZF>6
M&-Q/0G*3*@+*_JQ1"-^>['>/DW,,X55*D!C]%#F25WHF@-'MS'8UKXG&2AIR
MXQ$00(J  FE1JJ?\X AQWT:N%JIB8L;/'9:O5FFK!%%>:..6)XT4J@DC4;,(
M_F.S?*S<6[[=[!,VPH7XD!_KY@.;XXV+ED5<:'$ZNBUD_F\Z;D#?[!9OV-(P
MS2/=*'TY0TJ<_P U'D9F*@=N"C?>- W(<0I 4;G,33W4 U*_KK3C;$2-DZ^N
M65)4EU&@9JU^!+V#ENUK7=+"U;]$<7#*)(2-N4GS!@ "O$*=^)4@@[#?OV\'
MK/,/\=@*&IYD[CAC1$R98"2$$O?Z)H>3U=GL6\<<L;H2*.8RSA>0W$:+LB(W
MYBK*68KW]@0!N22-MCOH$PD*B$J#FSNY&D;@>' T;$N'DJHF@HAE1#,Q'BQJ
M*\0.+;X<&F]"TQ;FQ4;R6K_KAZT=>/UP'G)80!P69W4?*X&Y=!OV(!\1S,JB
M*4$%1TOLQ]^WP\<6Z<E0@(B1DB&G2-16&8@$V%VY/RKAV:KIXWI]/)@LQ 1G
M'J>J^(K2)RKF92(9<C. 5@:0DR.A/J)] -CXK)N.A+E44!WOVEZ<CWEC2^.G
MR>!&ZQ!E8"8@9(U! +I HJK4+)8U=[%P\=M2Y*1PD7+U)&7U%CC(C@0C92GI
MDGUI.0'&60,S$JPXD;'C<PG%Q5E"%:H=:@D !SS',"[VL1CU?+LFB+3*Q)GY
MN(DDE)*2P(#.02*.Q+V'(L.HL0V6LQ L*ADD:%1)$T<G8$2$3,R@2G;8(=P3
MV4[';Q6P8!*W"[@N>=Z#:[<=[X[:5@+DTZ4IUO2IW)>^JM&#6N&X=TNEOQ=1
M-0+8L9"M7G*2U+J!DL^HRQ%5DW$D+1ABX)Y1\5*CL?&45"4*%3I<.]FL6(V<
MAJ6X#%]))]9(08?M:J@LX<OV%NUWP=17IXC$TS@JY42UX5EC4RM-%9F022R%
M@6Y(Q<H/F 1%78??NFUM"2(+$%.S$O=G+TVH_P!>*N/">:C(F%,F"72"0002
M0VS;$OV<#C?Q#WXHB$L-6MR,O.Y$QBG@Y)Q*P.-G#2,P#*.0*[?>=HL'K"')
M*"SN&!9Q2C$.UKXKIA$)SIAI4BC."0:N#>EFN[[V9[X-# S%K3/"C1B6PX*^
ME(Y*.JLNY<@CY00!^80 #OXW0H*C$ZP**U %P3M]99V]^*V,C0E+#2ZOHLS!
MVJW*OW8W'U#0P3Y3*-(TKX.BM^"!8X9Z5B_(SC$T[2RMZ;5[EI4$U<LYDACE
MV1N!7Q*]<@RZ"IP5@$)<%@IBU>(-ZM\,5<S*+FHL.%HU0U$"(UTH((*CR8CG
MJ8<'@OH?,YG4?GTIY[/Y*QD\KE?+=U0O7+,[%N5BQU>Z1R2&/N0J MP4#95C
M2.-0 J@=3Z.51(B,\C17UQ9B JI>G5Q6['!=K[;8\+_"!@RTK'Z&RTJA*(<&
M1S,#2D)J9F4X "U7 JXW?'H0\M?]VK?QHO\ 0OCT['SAN.P_%.+<]/\ [F5O
M\$G^UX,/%/'3O("KY[OM,8 0)9.KWEQE4D [(GE2Z8AAL0?N]P">_P!P[TT]
M$T3LN'8&&23M],BKM2O$>_';=%X!BR<T4@E28X">#F&DVWMX;C>3>6ZB8G$1
M9-K-A!,TM6K%" H*J\,9DG!/LH+,2>^Q_@V\3C%2N"6+D&C,32QJ*]@;:C5Q
MT<+*YB,L@@AQ5S0/3E]U[/C0Q&O\9>-BG0BL9JT&IJDT :".%9^2R-*=UY1C
ML6*DG8$H?KXC=<H"I) )\]HXMQLQQE,Y N$A2C$2.6H#@X!?GM[G;#W+1687
M@M6E8(@,<D(G]%V8[/ )7;@K*"=G??OL&W/A%944\-R>RMWI?XXH3*F&LI7$
M"B*) 4Y^M^!V-S3#2NB&,3\)?5$<+Q!-RQB38[HY8$.Y'NZ?*1OWW&QV-#=B
M"[;$V=G L/)YB9# X;;4[#4^#U<O3:O/S@::&8Z=Y6"G7G,4%69F6 R;!N4Q
M)8\N[;%=OKML/N PBPH<6560^L)+/0[T[&;:X:F)"U"&@:&*@6#L:A[@\#QV
MW._F6MTO1S65J/:GA%:XLHA:1T>*9IN#DG?<<TXEE/8@#OW\>:3D!2(RP0:D
ML:@U._)^+TO>M5UBXBE:@&23L^]:\>&"9<PE?4NBM4:<JU4EMU[/I-<G7TI9
M+%:N;:0U0G'UT/RAR0Q!]^WBEF9):(R%D%BD$%F#<>=O#9A6SD9^$RH:C4 A
M@P=E4?L>SWO4G%!_7W1F3P^I[TF1A,1-@!G921W!.VR]@S$'8;;CW![GQZ/T
M:G4)ETP /;  *;UXWLUSS>HM3YW)HBI$PD'3^<JK/6@/$DAG-#V-B^?_ ,G:
M\WOEP\G-/S8:UZY=2=,Z'RUG :2BT?C<W+>CMZF'Q\\5N+&PU*MNS<_!\DBS
M7(HHRZP$N6 !([)"M22H"M.YW?W-OORQQ,:&H* 2"4 D]KV#[$U%-VQ5[]KG
MYE-"^;+SD:QZU=/LA2R6G\_@].TOBL;%>AHMD,76GK7143(QQ6_0YK&\;2(O
M)2#Q[]\$!M6SJ.S<//#WDA# =G%^[SN]<5C=R.Q]_8[?3?[OX/&>%CM"KL-_
MN!/O]?;P8,<&V!.WMV([;COM]_\ G^[Z]O&"M6UN5_/9]F&&;F_<WN[ZCB-\
M.32V&O9W+TL92K36[-R>.*&")2SR,S[]M@6 "[D>_;Q$GIJ'+RRX@4 0EB32
M] &X5IQKBQR^75%C!.DFM>RAJ0_:!OSMCT$^6KIE$N!Q;8_#O'+C*];?U7E,
MD4JK&)U+._)EY[[*2P78\1MN/'B,Y.0XDRO4HZU%XCU()+N .)  8<2<>G2D
MF40PL/I!&EA0G3;DVY;@^)OW<3*%EKR*:B;CU"W<.1MOV;\WWWV4^XW'ML<H
M4=$-)%$E2=(?XCM I85;?&WU=432HNK37B]P+UH:]S8>GE\T[#+JN[/#*+4<
M<JDR <V4#YB=COV(!&^Q]R?U^-TFEX@(#AB:6N6]YYO2^+.1AJUI!VH01P<-
M6H KLU6Q<%H*+(6L=56 5EJPHJ$(4:?GMLH:,[D+MONVPV(V)\=/*]<0;5L[
M%RS@F]+<JUI3'5+2B%"04/UE#2H=Q0FM:\:/WX/F,TV&59;,2%C&60M*D0&P
M[_(2"Q!]SMMV[CN/&$=4-)^=<D$U!8.[N:-V?&F,-$S%8PUD$FH&HT/  @ $
MG;G3;#=OR(KVJ\LT -4<Y$:92.##=.T1X'<;;D+R/;EXB19R4@I,1+ZP[:B^
MU&I7MV%:XGP\JGRJ$H74H,6+FQ%W)L[-;A7 /U/F:$RWH*UE)[<=64QU4(.R
MM8XL^X)) !W'UV]^QW\4\3.T1U$.G5P>S4IN+W[*.V.JC]&9DRT*,I*@%%"E
M$)(I<M8,U3VEJ5P-MC#*CM\R*3OV VW! WV._P!QW/MV&_C0N;2 I1(OL7)M
M4TL+U?9^<F7RU$,:$I(-*D;;CM8?"@Q$?SM/$_3/ID5"\SYH_*_[ [@?LRZ4
MW[[G8';L#_(?%QT2FA%S^50-X4T2.R LOV^%';'$^E&4$+H5F"P#28R\DD<9
MV$+FUZ_>^+#.@O[IU?\ #)_VQX]BQ\J8I$H=,K6I,!UZSD=6*6&3S6^;BI-,
MK*T\$?[8WJBI9HQ\\*R+$Z&TGY9HT:$LD3<9?">FL-8S[-(@'LJ$HE^9DX <
M6:Q!N:!Z6_3S\'"- F?1/T4D(RH@4A6?+AH43U*R<_S%96*%.I!4FE":UNS
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ML4$MW\(0ST8J$Z5UDDHP<)JS$R!+2!S 8S"55>9G5)]8"X8" ^K11@"" FQ
M <"U@U<>MY%E<6- $&;BKBF($ Q.K2D!2$I3$45I2ZJ@G6JI?E4?X;3%S7^#
MN8[)8V+$8KT<"D34B\B\JUAH9/AG,:.J.MR;Y0%<!4=CN.*SX""M"S$8!*X0
MN2P42];WL>1!Q<S66PX4:#"0H1$*E9F$4T.K4@ARU0=+CD.&W3TFT!8HZZUC
MBH!+$N0TQIJQ-*:Y6>8R9',VK4AC4*RS+8OSU&4J1_8)?FRL2UC$*@=$,N^F
MUZ N SOMQ-.=/+NCJ4R\3,5K0$I$:(A8(?4H1EH26(N$.ERP8N6-,,K0.FDT
M?YQ.CVF$=#'AM6^8R2K&"JF.EG^FN"SL(BB5OR=5I;5B54*#:>:9MR68^.\Z
M&JB"/-H4-*4P83.#4E2B6<,SUH3SX#YE]- 2B#)0DT*,ZS134#(7#@*2&'^4
MI1.Q=QL,>D3RY?\ **O\8?Z$\>@8^?\ %)ODDTWCI?+9T4FR%2S*,CI%!'Z#
M*ZN'NY%6#*1NO([!@=U]_'SOTGAJ1G^:K5#"H42=BD!P7) J1VL7[G%A^D_H
MMFUCT==$$(5I$/))-)/ IU&H%;T=[.]JNC(X>7IOJ+(1V:,]O2=^27UZ4KB2
M7#33R,ZR1*JA149BK!H2&A??W7;QP1B1I6*I:0#"+@@D!K<:-[Q[Q[!#B>OR
MVN'%,*.')2"> )('+D*LU0HD3.Z8ZIQN;P.)PEG&20W*R&Q1RE=8VJ68XRH2
MW$%;BEY9"HGJ[,_%6D 97[=?EF9")!3#5I2K_)8N&O5G)W\7&WG.>99,R\U&
MGO6#%1%20N&I)8)-P7V9F)[..#=CLW9QEM:$AGDLI#;=?4C66D[*&L;0,5V(
M9MW:+Y'1&9 =P-[Q,72*FIL#;>W:??RQQTU(08Z!&8I!8J0DL[L2X'WTP5J%
MSXRI36VZE5?YV9E_(M-"$21"JKL)' V+[&,\.1)((G0XFN&4@7 J=J U+7<%
MF\:XX^/"$M,QE0X2AJ T.0Q]IB-)-" ;W+6H^&QK34V4T7AS:QU6.[:?*XVE
MB9+#"O'!8R-H5WCR3H.4=5N>ZR<3'*DG$\"01%B3"H)]FX(2.'M*%2>!9P]#
MO?%GE.62^=S:H4=9"8<&-%BI _1H)&FCD[EA3F^$JR^M<K7DCR&6Q\%>0JXQ
MM;&,(%*R\_1JO/.RN&8$R; D\>VP;8HQXBO;5$-?S:EC2U78;;MP=\2$R61R
M<;5 DU*B)U?/J4 5;%T/0EC4 6#7 P,;.G\C+G[64R=E D5=Z0CJ&:)X8HXI
MF:=H'5B$:4Q2F"+<12!G+NC >)LM,+27U$C2'N.PW;?=CM1\3XT*1B2:X$O
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MQ]V++?(UT$SFH-1TM<Y*BM:D\<D.!^( !>9&"6,@Z2 \8:ZLWI.X"R\CPW"
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M26KI!%G8GJR4A"@M4-2R1I]FA(%B[[T^N(CH!+9/(Q<T6E,Q!2F!$EY0%8F
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MH$*:)2 "=*3#(!"B1S<$D6<,QHZ:&E)<%)'48SQ5I5,6->Y&99%9WYR0&0L
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M$V5D(LWU4PI<4B*2R1=+.P40KD#0.PYX4XK$F#PT65M1HV(M7OA:\E90\QL
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M^F&K-*9IES6,F:I-;5"T+S3%(GCV8!D=OS6XCY>^V_U/?QZ#E$PE:DJ,1+D
MD%0!K0AB/JW[CY/TAR6) AQ%)0%$$D,'(#@L!L]=AB1$E1;E*>=(UNBS(UR2
M--@&EC3FDBLPV"P\1)M_TNX[DGQU("%_06DD[)(8.+?2K6O/' 1H46""HPB.
M12SD=W!K%F<TPM8I1>HTS$4EM20,UJVZ<A*Z2/&!MN"I2-53Z#MV&P[RH$ 7
M4-3$."'YD7XA^#[[XI9R8"% V8/V&H\'HUCPWP/NIO3BOK/!Y+'WJ_..6F_P
MRJBL47B5/_2))<.1Q ]]O?;Q,B *3I*07% 1P!:@I3F=ZBN(J)L1/9<.'W\
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MI5)K<^ZO\KN8U"]RP4=O%+'S.$DJ(.YL=Q8,]S8T%.\XO)/(YS6G4" % FA
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MOP/8R^/L%D<F&XJ-) G$%'"A$1B0[\AOT"8BI>%#1#@(0J$MQ%6 RP[.!6K
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MV\7\',XB($"%!2J'IUKBDJ*@HDN&(%/9!H]*;%C23'1R7$:=G,SAPLPG9B%
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ME/&I8J!HI[,%*!JSQ6%EFL(:_I!4JB!FA_*K(UJB5BJ2LQ%!"8IU+8D)<!G
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M8?Z$\=;CPC$ /LU<!4F\K'0-\KCI)L7;Z?U);%VO+$SB1KN3$,,]*?8RPQ;
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M-!+5OQV:<\4<,7-EX<X92O!21LA60 %7)8.#L?FCV B-&@*TL$I+#4'!4"S
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ME=XK<>,@TWCUDBO7JD5I(((LS((:UN>"=X.4"AS91B88!26!!9MQQW/!SX@
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MR1L#M-+;"R." 1$>Q[][KU"7$-X@ ((:C$G=N.Y 8%R'+$8ARTV%N%J-C4J
ML]"U&L+$BM*G#?FPMVIF\HTK&15R"*8D4DN"_'A&JDD\CR4%01V.Y]SXJ3+G
M6HA@'!J":<36U_ \:2S,0"&U$$$M0LW@3O9Z_#[F,7>N9"C2AB:.'(V34J5I
MT*BO#<DBB>2PA.[1%"SHIV!('?8>,?41->RMD@$M??Q'<&#G:F,(DZ(,-2X;
M W<5)2EZ5M>I\+T?EG0&FL!F\3I_$V)LME,4\5:2Y*0M91+M+8B6-?DBCA.P
M!.^^X[[C?QE"R*%#C)TJ"J@FAJ>--KC@"7 XTZLXBQ$U!0%5TT?2-3.;U%2'
MH2UC@DPXVOD#:OY6I)CDX2R,M4^NEJ:M^3/I5-C^0C"CXMQN-SV)/;Q;HAI@
MQ=!0'IPN&#=NY(- 30XBQ9U2H1(*@7TU+T%7XO4A()>E6>IHTZ<=+A,52HK7
MHV[R4:D]F*DPJU.#>M<EJN0.332>F"H^90"6;Y>U[ 4C0R0 2@!^\59W#\68
M!V??DYV9C"(I52A"E%(!8EPP<6(2!0]^V'S8KQU+]*S#'0QV+M6S0LO+";$L
MD#0QK$UFMMR(]9%C V)5@"_U\-" 5WTBSD; ;@7-JBA(/ 8IXTW%6 G4M:Q[
M3NU:T!I4"EWJ3B!OVFIC/EVP,)$1DB\W'E%N1$1B(A)NN^C*[-%'OR&X"AR=
M^S@?P=-T>@($^E:2Y2E>P J@I/ VL&M=\</TYB+.1J"B0%*@IN2[1D*8T.[$
M'F6P_>@O[IU?\,G_ &QX[S'B>(N= +T]WI;E=(UO3&2M^;;SHY"DXKLJ&K;\
MX76"I\/:>5F,SV,CCZYA>'A RP")D,U5C)RF>1")B#"0X4I:'+/0A_L:AH.6
M/I/T40$(R&+F$=24R\-,S#4HEV*8D0Z& >RU%15]$+!L1B5F?SL^F:MVUC\3
M3GH86KKG&3X0M65)K<F'P6BX<V\$K6%,(RE.6>R$1Y8[]W:.-TE#P1O65(0O
M6E*@F'$2020#5*7-.]F/*N.KE\K1F"X21'7U\W,24S"BAPJ%"ZR:FNK30.DI
MB%*78%*0%'^$'NLT6,R^B.G,V&TVF.S4JY++Y*Y'//(]7!6,N:5;UGE9GC-F
M]'M!%'-+*M>*2].JM<E=M.8F&)*6,-*0= ULY(U'[RPY#L/1]&$3,IFF<P(\
MY%BPH&B#!$1* E<5$( I8,'(]I19@HTL!@29W2^834\>5K2I7PF$P-&W=@'J
M"62<>A!=6N%?E88HPR*\PO):TXB9I7BC:EBPE3#+22!! 4S.5%P:^YJ.6-*T
MO43\)$!:8Q2J/,3"T&(X&D$*%6I0/5F=W).'2(LKJ'-/KS4\4?PEU:F LX]V
MCHV;%*>#X91D09^3MD JM9BQ6\E6,5(9Y3!'(DDI$O'BGUN9TJHF" P=*27>
MA<%V%]@W/G%Q)>"@2,*(L*UJCH6MG*D^VZ02Q)+"K #"5J30<>DY:F1P5UK&
M-QZV<5>H2PQ4\MCI)Y&GCCA:!IY+E.U!'%;AG>-8Z\;STIW]?\K;D1I0067+
M%P"RDD * =]FN&VY;OBVR_/E3B(DK-(*%KT]2I)44**&3J.I#!1)9G)(2&8&
M@IR^ ^(R\38YX*=3(2Q6C+86V&JRJ\2W:]BMP=B.(DG#UDFD:&:Q7C0,KJ_.
MSR(JIA"=(,,LHJK0FX:U!X.;X["0S%8E%I6E42*DE 0D(!4@."U07(9B6YF^
M'#IJCD4PV=Q5NI7<09.:(F.2,0SVT-7TIH3%Z*)'>KI3>.S;4%8S+%90M%+&
ML=, *2N&4@)"Q5JT +@T.X8LW)WQ$$XA$9$6'%,.*A;JAJHN&Q(<LX=WIP;B
M#C;;IX<1')J&!;;XBS6I7),C'8^$&.J78WCC&9B@FEDQ\5FS5DD,?Y6"I&N/
MI6FK6J[QDB9=%A(,1"-4)G<*(4>UK5>W82,39'I%"FHRO6H\-$XHK'5Q0H!8
MAJ("H9*0 2/S2;V<4PV:^CVD1\I5D"P:G=S8I6G1'HXZ9G@PL]&PLK7:ZVJS
M5K+Y%)RL=R_Z4Z25"Z^((D.M(C(2&B!UI42Z15F9V+ =CG8G%K!SH:M<4Q8<
M:!$URL5&G2P#*2J&P1$2^H@J<LS-3":^CLUD8GPL5[(0R8RK+4NTLC)7D*3+
M-**=ALI6D>J('5D>*V&CK)-''-ZDJ3PN8QRU:E!/7*AB$022D$,"34N['E;;
M%A"SN%U<>)$@]9!CNH1H"SJ<I/YJP@I(410.=F#'&CH.3-4M/9B[:GQN:,&I
MM74WK45MU!+=EU'D+=F[62SZ#Q#(69(KD-=H(V6D\5A.?Q?R3(DG#4%1 M,4
M*1H4A#I!*2^L\U7O4;-B%D41,9H2Q&AB!,1#+ZE)6M(5J4LK0IPH+%"'4 ;E
MG)%6.M]2\WJJYCL@]C(T8\CC[FGYXU^.MX:*A')9FJ6(;HAG857!5,:TOPZ-
MLZJ*5V:1^?@&,9J+ B@Q(:6ZHBNA+MI+U+'8OQ%\=1TCRK*E96C-I 0Y7,)1
M),6&&0J>"P-4,)0:+)HX)]HU#8DGHZ9=6Z.GKVI8.4,*UA<(L%J<[1F4.M>S
M$DM>I2O-:PE,DGX>O0#ATXR*.B@08,4-%910D!))/LAJ4>C;!VH!RQP&6YE&
M3$3%@),NJ#I3$EE)2E86HM$AK4EBI8;2H_G*#D81TZ;6,Q0RZ5,C:Q6H*VUZ
MAF;\BRTFM1Q*DEFY18L\KSJXKRV:3RS6(2R7%LPQQK'LE9&'$$4ICJ*@K4-0
M  "0730DUY.Y!+7>7G.8!!A]3#AP$J0H:(8*HVM;DK469W!U) 2!0!W]G[TR
MIODM&V#E*,>/O0R9?3V>I^MN:U_$7KU-TQQ:&O9CQD,<=8T;*L:LBRQ_#$2/
M92'?#)ANR0Z04\'[&#\.1V;&I.8+BP4#K"F(D)"E*3J40FSA1+/5P&+,YH&D
M-B'"X2L6ACCN)&4BFL$K*U:Q"&L1&8^B63U]F@+&3;U9@0XC0"4%+7#&L A3
ML"..WWLYJU<4LTN&9M3+!AKA@*2"-*%@#VT@&]+4 +,:4T_P9IW"Z<&/6*M8
MN9#+X^_*4,GKL5RE.U(K&$J[+P@<<FY,.P &X'C%$K*2D A* %*(5>Y!"MP3
M<<W;$*;FLPGYA.N)$3+0H:8:26JFUBP%&+]K@G':DN0NULK/#6M226YH:\:(
M"L1C,@LVQ$SD,[)Z-6)RH9S\2%8D@[ZX85%$10?YQ1*:.S7YW;9R3V#&Y1A0
MUP(8TI3""HD5:@' * $,+ O<O1K$4#=QV)OW)K-6>K)#!#'7],O8!EFDDMQQ
M!&&WRA(/4=]@&''<\">^MU.8922S FMR""&Y$%SX[OE%FDJ3!6(@45:R" D4
M2"$LQ-^\X-6BNG^)QR69KZQ R.[PO+ZEAHY614B)>5F$<6[L1Q)V91LHV\29
M>#!A$E8!*CJ!-2Y-C<%A79Q5]L5D[F$Q%T""2PT@@485N0_>:DX.]'$068(,
M72A1Q7B=GG61)'<<MF) V*Q>F$V4MR0C8*0=Q.6KK4=7#*0P9M0%*U'>>7/'
M/1XBI8JF(D0*435+\7N:5??ZV?E/7LZ=@>NI>JMOBL4@8/"[L>2<T?\ -F)7
ML >Z@@;#<>(G619=TA0)5?L%&)J?+\L8PU0YY0B%)(8CVJ,6?ML;WJ.+BMSS
M>3I:\R7DBF&QD:WYE4FV7@!+'TRP D(3<[<R"WL/NV\=-T2B*B1YW4&*8<,7
M.ZB79FWV-6MN?)O3)"ZJ2R5*0R/6YLHV=(@0G/;J"@>+/5\6'^7+_E%7^,/]
M">.XQX'B%_V=]6(^2SR\S/**]A.FU"2O&%9C<,F1R)#12 ^F)T(XO _;AR8-
MNI4^;YMJ3F$TH/\ NRJ4;84+.>^['LQ]:="HL3]C71X!'K,$2,%$2&X=&D%-
MJ4=R]B!??$UX$-2..2"1SD9H+T-VX06CDISR(WP[3*'=*\<9$3PLL1F+%NR\
M6%+[14K2Y4007W20Y%WM<\2>-.MBA,<QX9*$!2TQ)9   "D$%) )92DD."#3
M2U:C [R$EFEJ6S=P)FEAM58*U3'L\48^)DC7U;2POP'S-R!GE"14P@A#B:1"
M8J8*A,*7 )2 C1I=TU <;4-7JS'LQU,!$"8RV6@9F(:HD%06E024J)20$N2]
M0 DM<E^[JHZL73T$.=E5Z>7QD584(H);$T4UVO,[R+8M;B6O"\9?UA%Z:/N8
M@I:0%M,Q.& !$('60BZ- HHN&27)H 2;W84KC7.909Y$645%09*.%0XIBZ3U
M,,I "H8(*7!2/I/3L&")I^_;ZA:]P&J;.$+8O*U*U'+4<M/;DAS4[23*DD,*
M.&J8Z">PWP.),CRNL >3A).9'SAJBS<:7CD(4@D&(B*DD,;MNG30@$%B*A[<
MA-RB>CF09I(IG5*F81,QEL65AI$Q "5)45$_161""M9(/LLS #!DRU;2.L-<
MZ:TUIJMDYPE2V;]U*4E.V;>*JSO7PN-@L%(8:C6@DMR>[*:\0@@KQ0<B\@O.
MIDYN<1+2R%Q!"3J4ZO:U) )2DEF020*N2P#T+<1(1L[R+H[FN9YK-2H3$5!B
M0  52Z?7%I"\PG- 5$*DP5:=*!J,2I ! '+66B=)&7-9S,3V=/93#X2WE,=6
MH6(,M+:RE*0FTCB)IFN/ IF6_"WPBX^-*X!>!5<X3LI*:XT2+$4F/#EU*A0D
M44%@L%*H=27<D<6))&-V1]*\Z@R\K+P!#GI*;GQ+1XDRF) TP%#2B- "PC3#
M4HCJB%+"T!3I!+AK=/\ I%JK45B'.99,=6H(T5ZQ%:R=*"Z^+F,<\\JQEY(P
M DLCO,WII"5D3LR=XF59+-1HD*:C+3#AH>+$U#\PA@Q<!RX)-1NUQB\Z3]/\
MGR>&K*H'K/K<81($*)#A%83,I089^<%T=8!I;Z0(JQ!P1]3IHW5ZY?'XC"4%
MM:<TQ)9BN5<B*&*H8NK,$J6K,<4$L=S),DH@"^H([31F0SA2>-A,Q)/,4QX8
MAI)@$C4 4NY(#$,3RKN.6.0R-?2+H^<ICSV9QU)S3,$0HD*)+Q%Q7F-2@A U
M?-I=*6*@Z0% !\1)STOX1R-.GHW!6;-O'5JD2[!K%C)V[\8I&>:!5F@I?V5)
M+.GIS2M7KQM*Y4\E7GS+15M!E800M#^TM)4DAC<.*@;@][N3[5(1O4<KBS6>
M9C#B=>J9ZJ&D&%[,#4O0@DA2B$C0O8J4 S&JQGZ4-7!8\292&YK#U[6/R1M6
MX1AI?P4CM>R-_+1RV+5>7*R\*V,I-"EB[)!)'7 $D;!19?YH$!1C)6(2EZ@8
M)BD!500"200R0IZC%7)3\>%/1H$*6,'+#!E9F6(U*GHAG E240X*4!*T0$$Q
M(JP6"0S 5#HTETP@-ZA4RU^33F9R.-5\3D[-,QZ9M:AM)-.,)=KWBJTW;'RI
M8FG$KGUO1* 3*Z-8P<O@Q$F%,K1!C&&GJ8R0!!,8@ZD+2HEU!+%G=F8$7K<W
MZ6S4.5FX^62D;-I26F4JFI5,00\P^3DK"5S<#2"E2%10I*4_2 2=0%CHZ@Z9
M9/09LW<IE<;>J6+P1[V&M'*TH+LE6)V@85FX02RAN.[<!,\84-RX@Z)O*HDB
M$QE+@3*4:=42$#H 6'*6!42I-0:ARX%B<6.5=,9#I$N7@RDE'E9E0*X4"<@]
M3&BP4"ABA1.HH(]E8#:6+!V/9KC!0'%:"QG3U;.8.H<-C8<_8QHJ03X/U[GJ
M92OD]IQ,N0D=S2QC"M)/6E>%G!"ER3TO#5!DE29ZU$124Q(:&UH"E'5UA=R:
M@/LE@S8I<GS:;]9SR-TAU2T24F8\23C3$"*J$J71"U0U2X=((!3L2**8$G"#
MKWI[!IK)3XJOB)<?0BJSUJK^I%<2 UIPUV!K*HDMJY6FDD%^5"X:TLDQ=5!V
M@YG((@QU(3!6F%"22&4"1I#$.S.Y8L!8GECH^BO21&824.=1-IF(ZXP3'&A2
M EW"5E!/L]>P3"!<N0[O4,9%K6DM+9J+UL'(F/FKW:XE8PYJ:S>:+'8W%T50
M-%=COV[BRV0A::,0//+Z<0V,+4H24103!ZJ&Q6%!YBS: QL"?X)?@PKV$2/"
MF\TDX@@Y@F/'2J%I0QEDI2 M41:M#I6@(*-3Z2HD %3 =.$Q^;EAGDEBJP\L
M?/+/D+!>"J&K5F,GJ1H3L]EU>- JHDKL@(0;'QA)(4$%"@A (-2[NU'[2U&!
M)I3:=.QY:!I$41HB]:4 ) 4VI025,:E*7=3#Z(-S?:U1BLIIW%XJIG6HQV<I
MI\:AQE.O8BR#6,5,JL+$"5GFBIV)(^4EBM.4F 0O(JMQ8;YJ 8$.$B+'A%:H
M9B%/$I!]D#434CM-GWQ&RG,<LS*<C1)%,10@3T7+XZH\O$ETB/!HI21% U0V
MH#458$MAAW</@;VGL')C[5*MFEJ6)+=-OB*MFND;/&M.\25262Y$&LPF)N4$
M;IN_)N!B+@0(TLA2 A,5B2$L"EJC4'I5V-*.#BSDIF=]=FD196.B7$3JY>84
M-4&-JH%0@*I8NDZFL0 S8#E6U\)D*\&4]4XR:46+M*G:$UNQ6B9T:.)]I%CR
M$<3S1K/*']-6$C)N=C3I!A1&56&I0$1(H2&JVP+$AB7=Z7&.JB)BQ($14#0)
MHH"$F*G5"224DJ6@:210!@H%P'+##'U)9-FU-526:."6'E5BD#%):\>YIR2S
M%@9980@AD*A.1V8KR]XLPA*U*"4EK/<\JML;_'AM3(]4F',08R"M#>L(-4DD
M#5H2&9BS5V9Q8HE)9J]"G:Y#O)&S_E-IPDC JY5OF,2, "Q[$+L=M]O$-<NJ
M'#$4J8 @,!5B=[CQKM;%F8HF2E( 4 D@@_1*DBC\">!K5ACOS6>@SC/CY+!G
M@J1M!\6TC^JL;LC0M&DF_P"1BLKOZ88!4:65>Y(+$81/8B!3)9C1PH4#NY9S
MMMOC6F45*'UA"!#=0!2EPC2Q)(=B2Q9R34CD<!/157X3SJ:,56+1OY7NJG$G
M8GFO5_HWZHY#LPW*E3W^4[_WP\>T>C6&42>:*-EQ)<@[L$1!_P"H5^!<8^//
MPJXR(F<=#@@'V<OS/43L53,F> _@]K'>X] 'EK_NU;^-%_H7QZ?CY*W'8?BG
M%N>G_P!S*W^"3_:\&'CS ]9\ V9^U%\Z^0"%_P 5]?\ 1S+0IN>+7+OE7Z38
MBNVP!WECAMW#$!W+$@$;DCRCIV"<ZRT["067_P"\+#>]^['T/Z'XFCH_G(>I
MS1%!_JD*OU>\6Q([(8F)JU2VI$==6A18TB5Y K@<7"G8[%=C(?96) W\529C
M3!9]J;OXT=R;ECW./3Y:,T17 E^5+;=@>@L,1+UKBILYJK'TJJO'/J&?-IGX
M%<P24<2EZK1JV\>RJ2+<\,0,5<"/BOKV0_Y%P>8F(CS!4"/:4'WIJH6Y@.S$
M?$W*XK0R >RN[4IR.^UGP5>FN@)L/I>"OQA)DN97*RA@ZR7FN3R688<@(5$5
MRVE5*U"WD2BO>2O#-M&-QXZ"7C%,L2BX#D"P"GIL^U1M7;%7%CJ!)#/J:_-B
MVW=6IP*.MN<N5=&29-KS0ZRR.;JZ>QD$):6M\9D7?%X_&7+*  05/B/C?B)$
M*1PUI('CD5F!HIJ=BJB)*G"M3&I.S5(VJ]C0D 4)Q:0(,.9@J2N@T,.+T (X
M'>XL26?"\-1Y?):72K?P\>4K:1)TEIC4DN'C^&H7:5*-\B)8BLM5L!3#)6J4
MWB6I&BR*\C6KLKC<9F.J"%:"H)<!1(+&I46(%* 4 %J'$%.62Z8Y2@ %;$TJ
M22&>M20&-:.. &&OT-UOB<'AM47>J>.?6>0R^.BP&GTSQ::.ICL,[4<)4IUH
MV?X[)7*C(S0;I#LQ!94.Y)#,NJ6H14:G.G<Z6:C 7J!6C X)O)U0TPU0XA@Z
M5E:SI!ZQ)2ITEP2 5-4,20PYEV3JMK;1^A]7U<+I; =/H\K@))HLI(/5S8?X
MNE9L5JV'Q\%/%B>63T984LV995A22+?;<GI(V8P"D$PPRD)220?:+T#%B[-V
M>['-S.1QYM04%DF&K6FHV!%7X@W)NU#5BIBNI]72FA-/54T)I;,ZNOQU:C7\
MI3:6_<RV4B5+4\A!88^AC:BNLM.!Q!.:Y?:-Y"WB1#GI,P$]9# +L Q)=P[\
M .%J$UQ"A9)/PXY/K"QJ#:0I(2 5.!=G) KV7P*]&:]TG<U[J/5^KQ4GQG3B
M=,5IB<4\=3P-O)UVDFS=-J52,S3U[+A*E-@+$D]J)!(_'<BN3F670HX4M"62
ML'Z)9F))MW6[;UM)C(9Z-"#+(2H%*U!0+ @C=P"Y#V8C<OAV=1HZ75;5MCKM
M/IF"CAO1T_7PFG/C[4N1Q\L 5(=2IB(6_!]Z6BDUALA$RB3'HD2UA+(93XV3
M\>7G(HF)5 2D!("10N[NS!J%FKQ&^(669?'RZ#ZG&6J(HE9UEJ J;22#52G<
M4JQ<T#N+&]2<YU,AJP:AM8[/8ZM%>Q&FLE8@:LT*F%WBS$E:%HZSY")H)*SV
M[@#5_62/@9%;>1#G!I]HBB--F(<5!(;=V<VH-GW(RI,*(N)#2Q6HQ% $EU!G
M <G2&L$L&%!<G=Z78K#47ET/EM05*^D:T^2S]P56>5[>9LUA%#6%N5$DXK((
MS,R*\<XA(_)B4[:9,I)7_!.HDWKI(!&]:>;[9N%$ 0J"@*B^REB6]DD%5VL"
M3L06;"5!JB\NN9-4<(IKRS04:,=*JJD0U-XUL4HY(RJY)X%6*42)*7@+C<@D
M#*77#A3)4M6E)2P)=BX/!C5P^W98SHDOKD]# N'-2X<<30EW:M&IA_\ 5J1>
MH..Q%V:S!+?TS'+8JP-5@BOSH_IO:IY&2H$A%!-MI*'I\G=4=F!/?">$..X4
MH%B2.PT8EK$&O8*8C91+IEHZB'3UAXJ(*@+AR6/$TP$\?HG$3+#G\K'%3JSB
M>6C*H:"4VF>.,6(H1R=DQY!9) 0&/%0.QWK8$M*P0J(0E*DNIV#@EK#WFKU)
MQV46:BJ>63J(9G)):CMWNQ\7.-&UD</>U!O5%G54$D!NWVQ%:>K<+,YVDMHJ
MLD4DI_*2&21 JGGN0P KYV;$583!.L$W2?&E&I5CN[\<90( AI*HI$)0<@*%
MWL!4GM:_&CX<^GLGZEZ+.7IOP/+16-*6/DC6U)!"9G)$J DS21H_&1GW920/
MIL0.D)I[6EFO;CVDN;\-WQ@0*BX-CQ&Q_6QY8VKJ9[46J\=3HP)CJ]@AWL\5
MY6@D8'%1Q_)"0D@,".'(MMN!XDP(86HI!8EGK4.]JD/8N>[CC7$.E)(>@OX/
MSMVDL<$.?#X[$W(H)2T5GTU:T\9-BR)$]Z0?<%HWVW]?D#L=BIV'B<DB"0[,
M*<VJ-N-]_=BGBJ*E/6I>K"A-[^[:@;#CNW[63HU9G3\$0PM+CJD;PB.(*85<
M26IWV1(I=B0_)]Y#QV!]M:@8L4JJ Q#C@]:<7H:UO4FNA0 2K<GVF?>CBHL-
MZ?'!<K3PT;FFZZ10Q\Z*6Z]HO#'6H320<IA;JF0%Y9NX1N1^=MU&X[VTM!(4
M P<Z2 ;<P>?$F]N..?FG6(K@^RI22-RQ:C"S&G+GAXVZ4IT[9R<_J(+4R6(5
M#^D\1:9#$(20>+\R.78;K]"?:X$D6<I'#MV)V/&C;6Q2!:=>@#40./:.^A%;
M &@ O7S]IDB2>6CIY<<0O;G\U?E-BF?9C84Q==]'_G2*=I%V&VSC;N' ! \6
MV1P1"G46]H+9KADFM S&CO?C[-.2Z;@_(4RS@)B2YX@O'AN!2C5[>38(O07]
MTZO^&3_MCQVN/$L1=\HV'MV]*=0;D4=_\EYMO.1;22F09BF'\TG6"U#Q*JTQ
MAAMN66OZ;1FQ(TH]61XTCX[- 5YA% <Z%0R-M+0H9U!OX)Y$5\/I?T?3:8'0
MZ2!7!TZ)Y"H<1(977STPE050N5(0$ZKA-'%<25RN BFTW?T_!'/DM26,]?\
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MLC%3R=CX"*19L:U&&Q'^$6FQMVHD<L^-@$D-6..:0F@P<YZ04QD)B_-F'J"
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M!:O4RX6.-!%1]1&C2+2F05$BK0F(5U<)9G8<@S[/2^SX<Q.R<NE*HJH4)41
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M&8W.-9:RU/)6:#P2T\'3J,^/PM"JDEBW'M\8DQ8SBNF,[5$5&3+:4 E(*S"
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M.&MV)ZF'#YQI PL+/.IDK4?4CD)DAF!C:^\<H!0A&8  **4QT2RV@K5$2"5
M%96E9# %C8EB2DB]>&.URZ&M2DB:@@1+CV4I6YJ4N RF<#@6IA[=-,T^JHK\
M^1.0%3#066FBQ:6VNY.:"E-9ABA@B :".VR?V9;F9*4$8XN>857O\KA^N)5'
MC%02D*+(U)!(#@>S<\78=[8J.E,,99$@PI00U3,VN&B$9PI@I0%J92@%AEE
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MZ;]+$*U)SZ?"O:#]8E_:?4[HJ[EWXGCC;?RR=3I%"R>;OSGRJ%XA9>JFD95
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M6(U<8L935>FJ(K3842POQQOC^DOI?,0$R\3,H!@I).D9=(I<[$D2KEN9-:W
M.-K):-\XF7CEAR/G<ZEV(IFED*'HEY=56.>9>$EFN$Z;**MDIN!/7$<H+-LP
MW[.+T;R>,#ULJ5\'BQJ$6(:("".(X8URGI(Z72"@N4S*# 6&"UHD90+BI3]%
M$=7JY,9 -0B(5)>K4&$).E/FM2*.']NKU/9(D$:>IT;\ODC*@VV4,_3IFV[?
M4GP?L;R?3I]5HQ'[K%=B79];TV?%B?2[T\*@KY9A!0JXRZ0'M<0TH&.[W!J"
M^/D72CS5PBT(_.EU,'Q:\)>71GR]N NP!$0;IT1#R4<6,7 LNZG<$@ZAT6R0
M)4GU.BKDQ8Q/<>LH>88L2'PE^EOIW$$,*SB">J68B",ND =:KJ61*@Q#S7J;
M';^Q?YM!!)6'G=ZK"O*W.2 =(>@(@=^/ 2&+]CSAZBKV5P ZCL&'C$=%<ETK
MAF664+ !3ZS,M1C0&*0DTN*D$AVI@_;:Z<]8B-\K2_7(<"*<KR[K&=])7ZGJ
M4GBE1(]V$)^A?F9D$BR><WJ@XE(,@;I!T"/,A@P+;]/22>0!)[;D=_&(Z(Y$
M$E(E" 0!^[Q[ 4KUC^_$Y/IL](R D)SR7 024OE66%B=W,D[LV-%?+SYC5!7
M]N1U1:-[+7)(9.DO0=X)K;((_B)H#H'TII1& BO(C%% "[ >-2>AG1])I*+;
M<>M35:<XU.36%CC8?3CZ2"=1SR6*M)2%')\J*@DERD*]1U <6(??GK#RW>8@
M7)+X\Y'506Y:TE-Y?V*>A7>M*"KPA?Q"XJFQV55 "=N.VW@A]"^CT.(8B9->
MLI*2HS4THZ35AJC%B^X8\&QM_;X])O4I@'/I8PTQ!$"3DV4%EAF+^H.2&%RW
M*I=#G\I?6^S9AMS>;WJFTU>&.O ?V+.AJI%#$>2(L:Z$5!L=_FVY'V8GZXJZ
M%='EJU+E(JBS.9R<L+ #KV '!OJ:8G\(;TKI24#I%*D%15[61Y*H@EG(4<N*
MDV%B-N&'#7\N?F$K5:U2/S>=1>-.Y+=KSOT:\O\ );CEFB$3QBW)T]>P:Q4
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M:/S_ +BVXV]V/IZO^4, %NJN-4'VY:7UJ-_;VWTUW]_;W\+]G'1>O]E44O\
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M &,?_P"GX\!4X^#JKY26WVZIXL[$ _VMZR]S[#_FY[GZ#Z^#]L7H?_RPAO\
M5)]^\&5#6^''&P=)LD5:=2]*=5'%[/\ -W-AQ-!7'T=5/*46XCJGBRW?Y?Q;
MUCOV]^WXN;]OK]WU\(^D;H:+YPG^9S_C^2M[\;1T@RE5IL'LA1__ *=<??V4
MO*9W/[*.,XC?=OQ<UAL-M]]S^+OT(V/_ -T>%^V/T,;]^4 TH9/, 0Y8/^*T
M)-&OR>AVC.LM(<3+[4A1K\'ZMGI9\?1U1\I9.PZI8S?Z@:;UD2/X0-.;C^;^
M#?P?MD="_P#EJ&_ 2L^3OL)5Q8W /B'V#-)%3M'M=X<7WL@MC[^RCY3._P#Q
MI8O=3L1^+>L21_#MISM_+XQ_;*Z%5'RT@D582>8$MS_% V].19\;1/2IM%![
M$JX/ND'O;WX^KU2\IBD$]4<;^K^UK6/_ ,.?]X/\A\!])70L,?EI#'<R69/X
M>IO]1I7&P3$$V6.;@^?U'!!TGU^\I6"G27]E2@G$C=AIC6C,-N^P"Z;8GV/Z
MAXQ/I+Z$C^_:6JX]2S#>N\H.?;OSW)4%4!!/(CMX\/KP?1YT_**,=\$>K%3\
MS@/[5=;_ '; ?\VOX?8^WA_MF]"/^6D]OJ68/;_569^_GC((6IB*]_.MSPI4
M7J&P!-6^8#RDYZ9Y1U5Q[\B3N=+ZUW.^^^X.FOK]_M_WX_MF]"'89TBEQZGF
M%&M_<GUCO:FX2T8_F>]/OJ_NP/6ZH^4QCN.J6,[]^^FM9#_^&_\ ,?YO"_;/
MZ#O^_:?YEF/_ +3GWTQF)&:4?9A%7!E(/_JW[BQMCY^R?Y3OIU1QA_@TWK'_
M .'/"/I0Z#"^>)_F68_^T\UX'&T97/*'LRZCR"H?]9O X^_LG>4[_K1Q@W&^
MQTUK+Z>__P V_P#Q[>_C ^E+H.*_+:6YR&9_$29&-R<FS%0I*K)K_;( %.+Q
M'^'UXS]DWRG>_P"RAC/_ &:UE_\ #G;^7;?Z;^'^VET&9_EQ%;#U',W[WDA]
M=*XS&09LIFE#O>- #-VQ<?/V3O*?_P!:&-_]FM8__#GA?MI=!@Y.>(_F69?^
MR.-O[&LZ+-)&O_/2_P#]7W8^_LG>4_\ ZT,;[[?\VM9#O]W?3GOX#Z4^@H;^
MSL/NDLS)[?R*U./AC8.BN?*H)!1>WSTO7L^>Q\_9/\IW_6AC?_9K6/T_^QSQ
ME^VGT#9_EY/)Y#,1_P#*6Y[8VIZ'=(E%AEQ=G_*)7_ZS_5[L?/V4/*;_ -:.
M-_\ 9K67^;^USO\ R>,3Z5.@@_OZC^8YE]4F<;1T)Z3&V6GA^42H^,;GCY^R
MCY3?^M'&_P#LUK+_ .'/&!]*W00?W]0.V0S3_P!D,;1T#Z4FV5J-6I-2'N>:
M'O&/IZH>4T;;]4<9W]MM-ZQ/^C3A[_J]_#_;7Z!;YZD/;\0S3_V0QF/1[TO5
M]'*%'_O<A\/6L?/V4?*;_P!:.-_]FM9?]^G/ ?2OT"VSY)'.0S,>[U(_'&T>
MCCIDKZ.3*.WY9(#XS0QG[*/E,WV_91QF_P#^K6LC_HTYX7[:_0/_ )=1_,<T
M_P#8XVI]&/3=3MDBJ<9[+1_\YCY^REY2^^_5'&C;W_M9UE_)_P#-S_1X0]+'
M0(_W^A[VD<S-K_W%MOPQL'HLZ=JMD:C_ -^RUO$SF,_93\I?_6GC/X/Q9UG_
M *?Q;V_S^#]MGT?M7/TBW]P9FWCZF/AX8V#T3]/U%DY H\?Q_+/_ 'F/G[*?
ME+_ZT<=W]MM,:T/^C39_\?R^,3Z6_1_MGZ#_ -QS,?\ R7GXYCT1^D(O_P 7
MET_ZPRNW?.B_?RQG[*?E+_ZTL:/U'3&M ?\ ]VO"_;<]'X+'/T=TAFA_^1QM
M3Z'/2,H..CJB./REE+#_ //X^?LJ^4H$@]4L:-MO_FSK/Z_P:;)_A[> ^EST
M>AO^,"'.WR?FH/\ _ UQM'H7])2@XZ-1"]FS'*37@?Q\?7C/V5O*0/\ TIX[
M_P!E]:?YO[6^_P!?_=X7[;WH]#C]D$.[#\0S2_ _B3@MP!^O&Q/H2])RK=&(
MFS/F64!W_P"__''']E?RC_\ 6IC=_P#]6-9_Y_[6^Q_5X/VWO1X 2>D"7&WR
M?FA':_J5O);&8]!OI2)8=%XG?F>3BG$?C]0<<3U;\HH_]*N-[?\ JOK3;^<:
M;(\ ]+WH[9STBACA^(9HUN)DAO0TIVTQN'H']*IMT5B5_P"M,F'QS#'S]ESR
MB?3JKC3_ /8OK7?^8::/@/I@]'0OTC0W'Y/S/_V?G9ZMF/0'Z5RW_%5=?^M,
ME?WYB/<YY8^IUA\H43<CU5QXVV]M*ZV^\[=_Q9^\=_NV[_3Q@?3#Z.O\8D<_
MQ#,^/^I[[BM-[XV#\'WTMJ^CT3B*X?V5R7EQS%M_O."KH[S0>3W3LD;GJW00
M+L24TGKIB=O;VTOL/K]3W\9?MP>CH._2-'_AV:=PK) =^-@_!X],!+#H?%?G
MFV1C9]\S'FE\&/(^>GR=V\<:@ZO55 4J"VD=<[=MQW(TQV[?7;]0'MX/VXO1
MR2W[(D "Q^3\TKW>IUYEKAML9)_!S],1_P#N>MS?^S&0L#PIF>^VJIVJ:Q@U
M9Y@_*'GK$DT75C'RAV)+#2NM@-B=QN&TT.Y^X_3<^P)\(^F#T<@M^R-#6)]0
MS/X"3)IW5\<;?^#?Z9C0=#5G_P#;/1\<..:CC@>MU;\HP(WZIX[YOS=]+:T'
M+?Z@?BW_ *#L?Y1X/VX?1U5ND<(M<^HYG0"]I(NW=MVG,?@V>FA5NAD2G_7.
M0-X_*C&XL<</V7O*+OM^RIC@?8;Z7UH"?_J_BYN/X#X#Z8/1T*_LBAMQ]0S-
MN]I,]E'#XV#\&?TV*#CH6LBM?EKH^U'=WS7D?+XP]7O*(.QZJ8[?Z[:6UK_\
M-G_Q_!OX#Z8?1U<=(D$<?D_,V[OQ.N,A^#)Z;E,4]"HA!W&=='K[C]]J'D:\
ML<?V8O*%W_XU<=V[G^U;6NX_A'XM>%^W%Z.O\845M^(9G7_\GC8/P7_3@;="
M8G_C71_W?V4K^O@<=?[,WD_[D=5\;L!N=M*ZW.V_L21IK8?YO&7[<'H[_P 8
M4O\ _#\S \3)\.6,_P#@M^G0D#]@\2O'.NCP[;YJ';<!SNS X^?LS^3[_K7Q
MQ_6-*ZW_ -'XLD^ ^F#T= L>D2 =GD,R'C^*4QD?P6/3J/\ [CQ*\<[Z.#O+
MYOC@W6OR>*=FZKX]?N+:4UQMV_\ L9!/ACTO>CQ5ND":7_L?F=/_ ,I6WEQC
M,?@K>G=7T>@ZRS.V>]&G#]N< #O(I7&?LU^3L?\ I8Q_MOVTGKD]OO[:7]OU
M^#]M[T>_XP)_F&9_^SP_^"GZ>;_L$7=OW^Z,WM_RSC@>MWDZ! _97Q_<;_\
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M;KX_R?\ -8<?Y1_H\,>E?H"?[_(_F.9[7_N/&0_!'_" +?\ $2__ /D71?\
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MLPV_5\WT^[PC])/?\,3H).L!Z,:8^M[-_"/]"^-.+:#] =IQP7\X?^/IXPB
M:E4'D(^T^.+*6_.[!\!CDG=EW[[D@_P;#MX% :30>'/%Q" !H&JGXX[F[$?R
M_P#:;QI-FV=/Q&+&%M_G?9CZH&S=OI_[_ P%@/#$]%N_[,<5]Q_"/]/C$_0/
M:?Z6+*'9/;]>.#?WO\8?]_C(6[S\3BX@_0!WT&N^.7C!=C_G#^B,6,+\WO\
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M_)N!M_-V\:%?3[Q[V?QQ90[([$_5C3D]S_&<?R<O;^#PT@.:"ZO=IQ90K_Q
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M\E2]1OQH(_C7KV8)?B&C<T"I-*>G^:PS+($$9'F\RA'4)$'JST2F%PXZ4Z-
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MWGF02L_GN6G+IN( $UTB<@Z$E,ZB7/SDLF,](,38:T'JE(&/R_\ 3YT'Z"]
M/2%F60= NDJ.D650M428@ &,OH_.F+$3$R.+F229?,ERJ4H*H\$]9"*C+38,
MW!BJ5,&.A%&=P%'\ ]OX/'7X\6QO*H4; ;?Z3_"?!@Q2QU*^R6R_4'J)KO7:
M];,;BTUEJ_4>J$QKZ'M6GH)G<O;R:4VLKJ>!;#5ELB)IA#$)&0N(T!"CS>?]
M'WKT]-SIS3J_6IB-'ZL2FK1UL12].KU@:M.IGTA\?->=>@"8S;.<VS4=)X,
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MC%]!V8QX,I C]+(<2#(PHD"4AG*2!!@Q8\69B(21/)40J/'BQ25%2@5D Z0
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M (.D!\;DY:I(2DQ@4H?2-%G8G?<AR[_'"(/L@+HVVZYU.W_J'./;_P"RD_\
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MT6=*,OE_593ITF%#]8F)I).02BXL*8FBDQXTO,1(ZX\"(LI2=4&)#*5)!0Q
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M<3I=<GIS1+4[*EU=Y=;:XEDE.W9Q#+J:0)P(XD<3N2-QX?J<NS=73AKB<O\
M+Y>:N?*N8?X0?]B']:#Y.(OX[H3TO7UK%_!9.2O:C5:8&>U8!7LML@1C'F58
MH3\X]3<;[CEMMX/4Y=R=!K_EQ!_Z\'RMF'^$$?Q(7UH.&YK+H+HS%8TV:6.N
M)*460-7U#J641*J[GU#-F)/F;8[+QV[]OIX1DY8WAG_;B'_U88S6?)'S]?\
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M$88!@G+B$"UT"7A11%7$3J5ZQ& .I88!9 %% 4VQ>SD[-2QEH<"*8:3)2RB
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M=H0&&S)Z^1E+ C8'U>6WOL0/&)DI<VA^*XE.SVN-:\ZC&7RM/_I__P .&_\
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M^.(Q8BA@"), E-/PGG*$%^IJ"U&8XZ5I)S\.,;3FE%BQ.D*2!XI9E'!E?N
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MU[S7S7&;@EW;=GM46LQ>O$T+%R,1SU5I/56#B@CJK>K.DG&81^LB,(#NB@@
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MS3D:4L9 ].:.!Z6Y34%_5.J6M4[IC2MBXXS#+;EL+)!#)RD4H(X8@_J$\^+
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MW<;4-]W:P?I?Y9/P/9POX0I)'9N^C)$)(4D/IHK-ZA)9B%;L1N=Y%.ZKMXR
M8,_:VY[?KN<8E3@L[;]A;M;=K#A6UG>@>C]+34^+MS15(?2K?$OM&J,R$"0Q
MH%.Q(9 I4?-[[[]SX?U4QA@M6M7QW9[-'3>.6S76H'DR5I!%3IO!(L82&/YF
MLV027"+Q50O=B?E!@P/,=8R-ZS)4R,GQ"Q_V/ TA:.-'W,LLQ3GR8*>+N[$
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MW"0EAQ"D*5[#D00=R=O#W\?KK<\A1KONP" :@5M6[T8.]ZT->#X0J8M-E,I
M[AJSL'23L5*MQV8J   -MV4'8#8#N-_!N7'FO)_UL!<G+;C:]Z>YW_73'?<J
M00PAD<L6)41@\ %!));?8JC @*SG<CV^5? ;&C\K>>WW4JB1ML0>0K>E[/4L
M7>UA_F#,9<$@C(@36^BB&"[(H_&;%*H!]BQ[@GW/8[>_B)-_N/+7!(N!^Z)9
MG-*.X:U7&T_+F]9'^AF*C?YB)=@U?MYX]Y'E!_=F'_&O]M/$S%2JQ[#\,4-=
M+NGM;6>K?.(<UI^'+8=O/#YI:T4[4$MR+8770::)MXY&:,)(A"G;B6W4J7/B
M)*?0C5_NB/W>V?OQ99G^ZRU?[@E/Z*Z8!W4[R#=)=03RY/'Z5;"6B"ZW<;5D
MQ]])96(6=0AC8A'4KL&5AN>P7;Q*Y]EM[]O'$ *-0[O=_MO8-?$=V\JGF8Z8
M\<ITKZB9>YCD($.,RMB65/3Y\8XOB5DC=>R*HY%BI4\M]^Y]^!QP84??WT(X
M[U[3@@:;\X7FMZ*\<+U+T?J2U29P'RF-@L9:L8@WS;\$>:/8*Y[H2O+W/OX/
M+^;?#Q;#9)LH=C'ZZMQNV^+!^A7VFO3G*4AB-6Y7%XZ22.534U!!:K)'8E&T
M5EHGC6=+%>58V0LK?4%2#OX''D_'SPQBQX'S3$_M+=;M&=6<?@L=HJIBM2Y>
MPTR)!IG-5LAD;MPS?$--#BHI#=KF>-BOHB!F**S;<AOX>$W$8[-?' XB&]FI
M*^2Q>KLE;EIS:>RU-Z?X'C2(0U4$=H&>1FFY<ICQ]E8*!L?!@Q&:%;]&C>CL
M"-[LUMK<%B,+-^#R(5,BPA1NJ)(0Y!E#-SY@]^(.SSY/;@P'\WG9ZU"_5RRF
M6>RJS22*DL44[(#*T\"N [+\@,@[AF_-V(\'GOP8W=%:NP\F%EU88%2Q (:E
M!8BW*>UZ*K"JR-\VYCW>63;BJJ0=B/!@PU\IJ24.<J'6-Q9]2*.NS0I%S :6
MT2OS/(&;B[JW'BO<D'L8,).8U!^'$>PLK9 A(UC"@O$I=>+@ABQW)#<V#;;]
MB3MMX,/;SS^W &UA:LZ?K16EG$4.3^/@EQY5E-:K$87:Q"8S\I:8F!AW5@[
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M/'()@U8JCHA9@X#1LRH.3 [J23NRCP_/U^]\/S[^_P \,1NBTMC9DEDM>F&
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M*$FI%0.8X\*,!4W. %E9K"VHIHXV]%)!*L"EV17>3YQL H8C96;=2=QL[ ;
MI@0;<GJ'+'<;D[7N*G&1<&Q;=A\;<!79F-#A7@S\X1(K'$0W$W!B;=-XU 1G
M<=]QV.PV(V8$'??PW>H9JU>E'\[C?8.;!S>G>:M4>X\ &PYL>XLJ)A*[1%0O
MRML)0C %B2A(&PV5"3N&/<G8^"O>*5H#:M'[N\8*BA/>:#EVD[A[7YN"Q!Z]
M (J -,^[2DE67;N(F/=G '=3Q4 ^XW&_@[[V[>SW^."ZFX5WJ'=Z4I9CVUMC
M2S&F9*VB(,J\118=?=-XEW8%N<FM</&S>_<.'WW&XW/;;8@QIIA (X+A"O\
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MP]1W8CAQK5VW\M6L0,YY*^LM:PN0T-KH7(897C6ME:SR2<#NWIS6#.%VXCD
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M=]]VW4; <2"/?;P8,5<>?;+83+?:#>1R?"_"NC=*O,;--/6*$S":GI7T3*5
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MF:XP6.1MP$:4"9G W[';DH^H]A[[>#!B'^L;%6S9G:O*\:)(7_/"1D*P;8@
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M3\S'N!X,&*0?,K<_"/VBOE/O&2-VM](NO<W&-0JI&T>G_2'R]@2HWVW)'O\
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MB1 $+INNW E5/@#[L^[;8"!L[-ON=V[/.V.,VM<50^$LXNTD=VA8CO+#;0O
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MQN@:P#S9@-F V[,!L>_#Q#_J%U/M3I'EM57+5RI15X--8RQ.9++58Y&$<\K
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M+!_*9G_LO@KSX\3BPFA^(Y<"+B:JYK\ZFG+[^>)(:BT]IO'XF7*2!;<MGG'
MAF,<T>PD<!%([MON^PWV4"/EWW\23]_EZ;?JQ7XBQF=&V=5VH/C*3U\2L[Q_
M$@"251OL47BC2%';:0,5/$$J1N/#P8:NJ.FNEL;6L0+3>*FM?DDI %R:Q6=(
MY)%@)7BQW'J"3CNA+;[C8GD8,5KZYT)<U#U#9XJL=;$1S;5Z^.GCE,T!<GE,
M&4Q+8!0'B !NQ"MN?!@=OA@3==NC]6W6;#96CB;6/OHL4<V3PD%VG8A8&-8K
M,DZ2BI:#?DBJL$8 2+W[>#ZO=@MW^?/ABM[J)]GCI*>E;U#IFW+HV[ TD\<F
M L2R0,%W(48J5MOF4AP("@91N#L=P88(W'$4YAO/.YQ&>#IGYL-!U[,^CLE-
MJ[#XR79)6,U"V(U')2D-B1HV< #FJRED( V'A;FA'-[N7-+7[^S&3L#4*?8W
MX \>!:]3N"<=5?SA]:]%68JFM-.Y>BL!,=DM3F,;[H$W>S&DD4J_*H"\@$)W
M^O@\UNS5-J&HI\'P4W! ' N.56/(.^UL&70WGT@8V4N7%KPWN]FM*BAE?B =
MI" T;EAL#&!N"Q /?P\##8MQ-6[-P30'@3;8 RR>;;3VKZC?A?)QL9C$E#"H
MT/X,@2*8O&_IHOJ HZ*YG=_4?N#[D>,00;>#AP_&OFS8-![1OQOMW5]P?"7I
MGJ/5S]^62NM/*6[<TI2S)Z+"ND;O+&H[J=V[E#O[$ [@]W7@/'QVXX"+7 (K
M8NV[ [ U['K4X?UC(:9%,VLM+I^G))'Z=@RRP&UZA#!EBAB+,'8!R=@ '.Q'
M@Y\MJ_KQBQ=@_ ?9[ZCG7 VR>N\1#2-?!TY<BIE9!9FKM2A:%N18(V[RE]RY
M9XB@* =R?E+QF 7N''/MX5^%WK4884]K*9^":L7B2K,^XK+((8)(T*E8FY<I
M)%C78\I"QD(V[ [>,;&EM^3U^SL#DW?#H!:O8W&H>V[6)V#-C[6T[7_!TJU+
M*<W+M.Z,BQHT<'!4_)/NOY0@?,%;<#N=NS<\+F]VX$^6YX3C?^#:P8LX%27:
MEQ7:YPG3::)H0)D)Q&M?C%&KE&$\P'+U7&^_#D?E+@G8L1L0-RPN[4KQY]N'
MJNP-MJMM2X+-Q O1[Z-FGHO&TVDS%ZHEBL  GJ!I9)%VX\%[!8T'8L 5]N._
MOX#2K.WN['_6:#L'+[6#!G!;>]&\.#T)%.1ZS:?P%B>OA5;+2;N72NIFYGU"
M%5%16X'CL"2%)X@=O?P7_5RI?AV7IQ!3V:IJ[&C$GA8VJ1S.%G"X+KWUBI*V
M&PYT=IIP7?+VF9+#)N6 @B<<P\@ V!9 P&P/+N4U#3NI2G._(5 +"P? 2 >!
MXU);A6HOQ!H^XQ,;H/Y [MRY%F-34[&I+5R*.:M>R#/9C:5RK[B%R0H)!V8
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M+J#]GMTNRFG&SHTGC<?+-9E5K,(6F\D<D@2)E$"H4(93R 8DD^P\)O/G;S?
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MK(/'?9VZ]6O0S>OLOF<C4OS1A(ZLLLBNDBHR/)Z1+1QN#\I;BOMON/8:];\
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M&_&&6T2C1*8?6'9!*40%0"I[]QR/AXQPR^LO3F+$YS$9O#IZ<4]?\%01QH2
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MQXG8&#8>;5IXUOMC8Z_YG(:HLZ1"V)1A[NJTKSUKC\;47H2@++ 5)")R38
M@#[QW![_ #]6"G93SW-3MY.SDZNYVM:T.].-I;!HV,;1G8,DB(D4B<U5@YX[
M; >JH4D#\WMX/U;^>_"\U/ZGQLZZZFU,=H[!5:$EJI7IR8</$Z&3U8$1$D)D
MX?DH#])%.S=@VX]C#9[/X>>?AAI:YU/6G>A*UN5KDID99HDBD1Z<B+*(D^9X
M_G "AB.6X(&W+B3"Y[>?MP#YLUA,$V<EQ&'N4H\HD#UX)Y&EK2W/462>:2-3
MQ21@'V WXG8CZ &##6U!KNMC<DNHZYJ8-#B?@[\DHAKACN.<CNNQ8;CD"WY0
M;CCVV\'G[,.I[!Y\_=B('4/S1Z,5LNN,LV-0Y/'U><KTT,E664$1L@E#-'(X
M)Y D[!5^I[>$X-.+@.'!^IFYXR 8ER*5)N;L;B[M7OL^(2:LU7?ZGO\ $SZQ
MG_ D[JGX XM0NXN:1BL<;)R]"[7Y'=G>11NVVRL-@JB]7( \MM4]@&^&SL+"
MM"X(+^^K"YJ3;9IZ.Q-S3O5/2F$R<)2S7U/IIZTH*N)JDF8HO#)S0N#R0D;%
MCM^H@;1ILO )_P"<@\?TJ.+>+?=/RS\K8BT"9X.WJ\1AW=I]V/T??*#^[,/^
M-?[:>)>*M5CV'X8_/=\_Q7]O!YK@0Q)\Q77'A]5Y_LIZN )!.W;VV]R?N[DQ
M90#1%I_=$?\ WAQ:YC^ZRK_X!+7=J)4U-Z/3>V(?$LY#%CL'8LS*J]P!L"!V
M!V! ![=SW'B5BL+D^YS3L?G0U)^&.')%3LBESL68[]VY J/?;V^@'U_D\&!Q
MP%O?]5.&XX.,=ID)+#<[,2Y(VY;#< DD=MOS1Q.Y [^_<QD;GL-BY86>XV H
M0>+O7=5RB>FJL7],JHV!:0'8L6.^^P&X4#W [^##+@ DDT85&]7-W?ZKFYX(
M[LS+L% [CN3W[$!CW( WW/?8'< =O!@W4P/=X>(J2Q9QR?&Y"R.C+*7X[[ED
M((613N78$J& [D+N.X'T\+L;L^'9X' +/9[5:O/:YN[6H';"Q6JT)]XQD'B+
M_,S35W"J&"DG="VQ/N#R/<_KV!7X?>;_ &6PNT,3ON]QL]]ZO6[4+=1L'I_I
M_;CM2',T]69C'U,P8H?2L8[$XXS&.Y1+\F2S'?E2S"Y7:1*DD8&TC'P=MZ4!
MWN=^RGVG#/*@=G8V#AS6X/8268;8&F:BR^EK+XVS*OX/O5XY:N6I(R5,_C+*
MAX+;2$<I(9U">I 2(TF1E9%=#X&J#XB_AW^/<&5>(:[U (-6+4 K8\:7KWZ9
MS,F+N)) (IZ\T9BMTYV9J=VG( ):UE!V,4Z@#?\ .0@,I5@/#\^?/U8"2"&V
M'<:=@V+W+/?#XU5/,NEL3C\89)\5!=G:R$G,D^)PF5FBO4\1D%C&R5KMZE*\
M$[$1SQPD$"20EL0]7!X\N0#<.P\=\,V 38[;U)&_.EP]0[8^Q:EN9_!W]-R3
MVX<Q%!:ET[-67A 19CC2[I^1056'&7XH8)84.Z16J<!(')F\,?J&[C:[;6##
M"N*\ZGBV_=:I+MP; =EQ-JFR4\I%-!:I$Q35;')36G4*KQ>GRV7B?<$?-R!.
M^WAX +/3F:6Y%WV =KV(MJA.',)"0OJD,"I5>17EN-B0>WM\VX.Q(V\![6P/
M4M6A:EC2W"A N_$.P.MZO.PH]@I78N3W/+<\.Y [#L1W]QV\&!P6<. S4+FM
M68MQ8;6 PK_$SA/25S&"I+>D.!< ]@Y $FQ!(')R&[[>#&+VO3CS8T%A[WX<
M%"GD3655$<,\6P,L4X+Q2%3W+ GM[[=B".^QW!)3/]7+RSU>N,K@;4!JS ,Q
M#@[GOJ;5?@\K2@LJ)'&Y=_30?* 7+*O?EL$W*C<DD>[?7P"Y?ZGX;'=GL,%V
M(/%[4L;$6!:M:N20Y..==%< EBO(G= .6X''8?J/?W('8_P['"W(OY?[GHPP
M6HU6XD,]GX$6N*%L;44:QE7/)_9U(._'BW?;OV*[^VW?;P5L+\;#ZW?E8/5V
MPB;U+/9R;=H%.VN-EDY2J=MP7+$*#R)*DASMN!W[E1MO[\=R/ '?S2WCO6K-
MVX0L:EV[BYJ/>#XXVD'%!NVRCL0I.S#?V)V[,?N[#?P#[+MPY=H\*7PL6)?9
M;A!YR-#\1[Z<UVQ.^Y.^F;6V^W_O^G?OOXB1/RN6X:(S<Z#Q;;D<64#][9ZO
M]ME*?QE_#Z\?H$^4G]QG_P 4E_U,GB4;+[_Z(Q6X_*SU_P#\^-6'_P#/MS_-
MZ?\ [_&B3_)X8X:@?]H_JQ99O^7QO\V#_N8>&B!V_7WVW/8@?SDGQ(J^S>]\
M5N,'9@0>)!!W'N-OKV]]O#P87JV0IRD)?J&R&7TR4V$H78;%6WWWWW/??Z;=
M_";?]7G[-JXR<$<W-:?77W^-L.3%5-#R2A+M75'S-LH@%3B/[X]V'(J..P[;
MC?8G?V?F_G[^/ ]G=P#]]CW-7CRP9,)U!Z;Z=K0WDZ>Q7L] R3X[(Y"".Y=%
MN$J()982X@"*B @JIXL 1NVWA7]_W_8Q[=JMP*-9JT?M\-P>%:OCH&N-8ZDS
M5W5A6MC,I+)O7U/JV]/(N(@?<1P8:M+,4K-%N?2-:M+(N^VX7;PN -2[THW&
MYY^^@IAAS8 4%ZW!9MN=G<GB<';2?5/K!8.(T-H/462S,]W(T[.H-=:J:66E
M#%("\L&%C1UD6FTJ%4D=&FGY <44[J587VXO<7NW.I)KPP,#5@*U[ +@4H>-
M_J.=KS/YO&:[P6CM$X"YK&H*D&/SVIV1ZM27.U9'BSLU>59%@BJ490JN92."
MCD"V^WAOW^7V'"W'&+5>PNXHW*N^S/0]C8ESI[JAI+5T61BI:P:U5Q%J.I;S
M5D6Z.+EM15$L78<;;MLJ6Z]*9I*DEM (9'B81,ZD$/"TGA]?P?"AA.ONAM,W
MY;."ZGZ>LW*!9@!EHI9(I "&5ECEY-Q(.W'\T#^]V.R<"F_#?PPV4=B1SV-'
MWX_7PHDZD\URY.&OJG)=2J5T7<BF"H66LV['KWY"GIT*2@L[R?E4V2/=4W!)
MV.X>#2=P1YVXGE?LPVD\U-K-U<VT.IFM4=%3V:V=MVH+<5&E)79_6C:[:$5:
M62-HS&T<#R$.  "2 42>WSR<\-C]@$@[\O<"3M;<4;B30LW#><?3VJX#6IX>
M7+5&G]*OD;&.>C2M7F?:)*TEJS"UF0L/SX86$7YTK1C8D=K_ &UP!+U!!\0_
MP\[C AM^>N;+:HFTSCL++1H)-+0GSK-Z&.]>)FB?Y5L&S-75XVC>=8SL%:0@
M( 2/1Z-=[4VIY^K P<"K]E*<*OL:MW!L#/4WFAZD9;(38C%XW'HTS2&K))>M
M2K#CX*]AQ:OPK9YU[=GTEL5:VWR4W1Y2K.J!.UWN:4.[485:Y%QOMC)@0PJ2
M!4UVL:'32WQQ"_*]9NK.K\G3;/:FOKC@\8FH8>Q8Q\%B%W'.%S'*7<LG8,SA
MD.S=MAN^+7O<GW=VW-L8A]P&:K 58;D D59^'+#X\P&C=*XR# '1]:U+CM2Y
M*75>3LW&BEMP9*UC*<-S"/+'^8M2<23)%-RG+69"3LN_@X]PKQ[?"K>.S(>K
M-4D\1;BW;R?; JR]#%U,-IN''P;R1I?GL<D5&:TTD<+./?DD?IB- =C\K'8;
MD> 7-N!K6Y;Q%?MV&H/$/8<0UQLUP2W$X3'L&2! H 8 CB-E!7<=AV(W7ON3
MV/N!MV+\^:^>(P7?F10<KBHN :5 [F!^0N^Q'+L5)&Q*$D@@^Y(^G<;=]_U[
M>$6OP\^>_B<-W+4KW&UC136M=VQM0HPDV#A2N[$^W+<?-Q(&VVV_N2/?^'P.
M+V[?@W'R,(A@7#U=P*&E.0OL[FG;NE/39I3LRD +L-R5)WWV^IVV[C;8#<^#
MD">.S>3[V-7<G$EVY#G;%D7V5#%O.'H_<; :3U\%V.X_<&7<#N?I_P"/OB1/
MRR7_ -'&VM1+'D_CRKBQ@_O;.C_G94VXE7GW[X_08\H/[EUOXB_ZM/$S%6;G
M^)_2.+&8O[DG\4>#&6/S+O\ RC=2?M6.OC ]A0Z4[@__ +'- ;;?S?S[>(<$
M_C4SR$('P)^O%G,_O=EW;,_TTU^WEIQ16!W'<]ON]MOX/N'T\3,5F.:J&*\M
M^)^X [GOMVW[CV/\G@P=N-YO0BX!7L>HH9>2[)[[ @#EV .Y&Y&^P)]_!AT&
MYY&G'M+\JX[8+TD&XJW,A7+$+*8YE57!([D!E&XVW&[$;_RGP>?MP<*GM[Z-
M6C#G?QP_]!=6M7]-\K%DL!ELC8AY OBKEB5L?. >3#C%-&\)9^Y>%E9MR"6!
M()]>!V[*L#7P<-?=O'$UM ?:2=1])S(N2PHGH\RR0TLC,!'L%/%ZUM)89HB0
MP.\BON3\VX\&"E7</9N%>Q^&WU8FCHK[4/IAJ5*M366'R>!OM&8'N1':!!)\
MK-Z:K)"%)/S;3@G8[!=^RKO]W9L>=N_ PV/C0_9[\2_Q?6OI%J3#X-L)JS#1
MU(YWD6"Y;@H6#+,P,3$EPKDJP=&+-&3\H<^WAX"D\#X>?K[<,F>E(FH,WJQ;
M]7(&,VS2D2>"=T@*$1/"X:3NH95!5MPR[*=M@3!M<;T\TVXX:W4'7$*IIB-X
MWOIB;=>Y?^%BD99)46.9UD7D/5*L0CDIL\@8@GL2B6\^-=N_  [_ &<^ V[!
M3 PUGK'$ZITMD(%7*U[^8S<,TD2!W1D!E.TD;[R+Q4!$93PXJ/E^;P=WU>>S
MN+5PQ1[,.(H]J#>KUX/3;!WPNML%IG3>EL/+:N>E@*+3J?62"=+DD/#T58AP
MJ[R/LO'?;N-]N)>%<]O?AH:,ZL86OI?4TF7FRCI+J!YJ$4$K"]))8/.2220J
MIDBC 5&Y* R%OS020GMS[,!'P\^-+M<6QK::U[C\'U6O:C_+V,;E<.4+O))$
MIFDB'#U#$SLS*PXD,=C\R[#Z/!L;T+]@^TT\,*NL^I./S=?!%*AL6<7G!/+&
MGQ*%XD<D1PG9DBBE!8MLH;?B220-U;W;\2WGCAM9W :FXL^W>6V''"MD=7PY
MO&V\/CH[E*&Y(EB2JLYD0R;^HO,S)NS(X#*05!4$'V'AX6PIW\OU[]V&]F]0
MO#IX4M9ZCQN-@GB2*B]J[4$SI%L49HF;UC] $79=UV W/@O@W</\2]/KM2N(
MT:I\Q?1O2&+FIVM;6-49-;.P3"M+;EC>(L'C#1\A$ %$95B%!._@\\/## J'
MIM6M:\+UX[$.XQ$_5?G>U18LBOHW2D-7#12'>SFK+37IX_9V2)0$KNP]W,DF
MS;_*/S?!W^?/QP,!<'O(&[6JW>14>+]P^I.FO5/$W<IE=:ZK^(FC1KN M"M.
M^-D$<9G IQ!/BZ"-OPL1J5X_*W$@[+G7G6G;W5[MK-E6P8L*7!//G7>H+\SB
M/^K*&@H,JC:>SVF,E0C!AFKVJ-S#RS<&8<I'JC8NI0>S'OW(.Y\)JW+.]3VT
M[!2_B<!;@ 6((84.U0+T-+FE-P@871FE\B;4LN0PM&6Q+O":NH$1?AW#,\'"
MU$O(,0H0.0RN/KWW.5VY7(-+AO?S#8&2=PYYN^]J$<&#'B^%W#=.\)C-0Z7U
M10UE!E+E35^D\=-B6EKV9V+ZBH1*T<D<YD6.M$RN2\>S@$*1XC3?[@U/W2%R
MM%011N%VWIBPRP?C8X]3, [7@1 ]GJ3=B][8_0K\H/[LP_XU_MIXEXJE6/8?
MAC\][[0)Q^W9\V"-Q('F,ZWMLP[C_C4U;W!_7W&Q/W]B-QXBRGT(O^L1_P#>
M'%KF19<M8_B,K3=P%=WG>HQ#^5OF)C 6([(3LK%@"-V(V(([C8@#<GV\2L5I
MVX#D"*$AQ1C>YW/AKMPY!=]QQ#+LO'YO;=F[$J"#[[']7@P..3,-MVW-#?GC
ML64  #9=R.>_<[;[[@[=@>XV'W?R@P MV$U#=G8#NP:G@<=H8B03L"0VX'$\
M0-AMN"Q[ #B-CMV!)^[P8.!M^LW>W"KNQ?GVQV)9C\O#;W^FW%#W &P WW/?
MM[=O!@!>P:UCLX<#OK4L/?C829F5_EW^<#DH  (&Y!]CV';W'U[_ 'F,GV>H
M>[]O8.UWYL*[,;QIL"S%W525#'91N-EV) (*['??ON 1[^#"VW<]MW!V-35P
M;<G.'A8S4M.O+BY((WKV\)B%:-B=X)8;-Z=9HB"0)B79'/$JR;KM['QC<TJQ
M.YI3A[MZU%VPS0TI8V%0[M0O]K <'W:.H\9?QT>F=31238N,M^#;\(,EW!.Q
MYR"M$W#UZ$S$-+2+!5),L)#_ "LV/'W<^WM!/9PP6H13M+BK'8/Q9JW-\(][
M"5\!-)<-^&UCHF#4_1+QRWTW)C6-#^4A+@ 2F9"L?<#ELNXY:@K7AL;&_G<8
M5GK2KTV+!QOVO[-F!88[].ZBR42YB>>UQFR->*U;KS5_7J712F1H*<L2D(*B
M0,T8C8*$4#@58J0-V<N7W_;XI^)+F_.Y;LM8AW:U0Z*]?$Y^&VNF;M;&9NWM
M&V#OS20Q-&75^."RLHX!I66,+3R#Q/"-XXK5CD3X*[^YN5:GPIQ<&F,@ U Q
MYNS&K48%^"B#QHV-?4];)9Y9K%NE+1UKIZF(,]B;2M%/G\?6"I%E:K<3&^0I
M5O32ZHD<7((Q:C)D$B^#A3]=_)XM@(WN;5W%@2XH=[AP"0;X&D<R3UP(92%8
MDM'NPX2!0IW!&_+;^^^N_P!V_AXQM4&_"E+<"W&^XI083I(GWCXD+WXC<@D#
MU!\RC^0C;;<;D@GZ&&=A85YD 'QH' #6>MV49E5"-]B0%8-R(W9!L =OO4_F
MGMN.QV\&$[/5V(8M3AN]QW!J8VUC$BH2@Y,O<;@;$C<;;D @_K^J[ ^$?/U]
M[6PV:]B.6]BSCCN[-0\.Z,<8V4J48 %3O[L" RD[;; ;N-_;V'N? ]1N[]S?
M?MV\,%K 68L]R'=]PP!(LW;C<JMQ)(8%G4@+MW#@#;8;=R=M_<#PB/C7LK2@
MK>U^^N$>%K4I<T.]!3NHX&-V.6*+U%D16^1ECY-Q"NS^Y"GL/8 ';8'?]7AL
M*>YZWYUVYVPMC3AMV5<<C4<P:FW8LY5">*J>RON0 NQ[D'8 [C[O?L 3X/#F
MU3Q;N>E"_ 8&^[S\>&.^.1>*A1\O$;;^[EMR%)/NW?OW'8'?OL/!M8#9MN'@
M>RO#"Q8G]EN0?.1H<@<=M-ZZ4J-MAMIJX>PV[=CW!)VV\0U_E<M_F1_>VU*\
M:8LH-<NGJ-\[*_TE^>W'Z!'E)_<9_P#%)?\ 4R>)9LOO_HC%;C\K37W;7&K#
MOL?P[=V!&^_]S_F_\=_$>2_)T?QO<HXLLW_+XO\ FP?]S#PT=]]SM_[NY.^_
M\AV'B5BMQ\]_IW/Z_P#W]_YSX5>+]U?L]V#'-%8D!>0<GMMRWVVW[;=OJ#X>
M&'>CORO@A:;S/X#IWKUQ1(Q@>O0BF195ELOQXEN:OQ$:ACN -_8GOX.'O\#]
M;8RL*T+$[\0SW&QIXL<(2Y>S-,T\EUA,5=5$:<>/+N% 4$_+MV[;#N0/" H*
M#C2E?/NPA[V#!GJ.79N;586;LM/+Z$<\TK6O3.^\\K!4[C?=)6[\=S^:/K[^
MVX/#9K<Z=O;]>&7:M;7OWV+UH]+\0YFZ>Z^LX#%9'+V+TICABCQ>%KJLD4)R
M5@%(6]5E8N*:[V#[*OMON0/ Q<?$U;W[\ W;0# #>A+A@'VML*@,:O\ 6<*M
M7J?J)-(Q8L9!=,XK'Y*Y-JB;'0!\M>K950\445@*727)312F0ILJ;<W #'<'
M:Y(\1QH7&[58$VVP]19Q87[VL^[W?E=RXEUAU,S^I[YB@NV\9IJ&G#0QV$HW
M)H*:5XAL\EA$*+8N67)FLRR+NSD#\Q5 ?;C%1<\F#"W#SVMP;"5IT1T+\5A)
M9(Z[K+$\\0'K0-,O'F4__"E=S]VXWWV)W*(?Q'/D:=A/W7PPP--@7L:!F/!P
M?A;C*RA+IS3&C]!#+Y+XM-.9/4^<HQ1Q(C6\GEZ<-*G8$DRRHD]#T1+ S(XC
MDXNFQ7<EJM]O+?L?QHS8RL YH]+V#W/8:"U SX%FKNK&I=57*>@-/Q)^+>-M
M@_@-8D^"NY*5Q/8EO#9#DI7MLUBU:NO)\3,=R5CCC53G47IQ[1\-_AC$U+-R
M)Y[#F:<@3V XZ)\G%C,Y1Q-O(RY'+P8^Q;RSQNT5/&S)6=Z6(QJ0<8HH5G6&
M*Q\. M@[1EO1!5@G@];=]>5@-V[7P4>IX$^#T.[EJ <0*784^7GTO1B2[ 9-
M39257>=W5DQ&.$K.'2) 8_B+TI&ZG<QQQ%77\J0"_,;>7[>%*,UTY%KU%FW;
M@.':&O4C"[I;/Q7M1TILK>:"S8$M)LDB\S9DR%>2K&]\=C(R&8*+'9E155OE
M7P-:U]]NSGVU<N^Q;U.K@ X/&O?3NIWX0L57EP?QHR,$$F1PCNL=2*6&9I;M
M0G@\Z<^T"E"\BC?U"H3OR/@W:U_-1S!?DV 6!=N%')K;BQ8\+W+G&U7UY>FQ
M>-Q5]8\C6L"[#9^/Y,D.4M6/B(;\4BE7BMJ9GB]4. (MN1XJ #8^ZENP81/>
M6J3?;[&IL>+XZY,5/;Q<5?&J;67Q5V:22MN1;>K.JI<KR%CZ$C5ID$R2Q'\H
M9G8 COX-^[SY\=L,T9G!<]M>T7X!R0XN^$N.-1&OQ7"JT;LCAR&EW8#^]0GG
MMWV'T.^P/;P5>G?O[G!V^XU(;@"@.U784>N]:V/(-CMB,1W$0$BCN"05+@,!
MN23\A]]@/N]MCV"[>-@_91NXV%36V ER-J7I2X/ %V\+#AV!BA5BNP.^VYYL
M%'('?W[#?8@#;^?PAO5N-31ZF]C^M@Y&#Z0-*C>E3PIRX'?L.-A0>+*/N&P)
M!Y D[L-_8$;;#NH]OKOX?Z_/?7CC WVM5MN WM2W9SQ9#]E0K+YQ=(JWYWXI
MZ][]MB#@)B#L.P/;8]@=P3['Q%6_K<N#M#C>/L[L'H1RW9\6,'][)W;YZ6IW
MJW->Y^&/T&?*#^Y=;^(O^K3Q+Q5FY_B?TCBQF+^Y)_%'@QEC\R[_ ,HW.WVK
M'7[OV_!_2HG^3HWT^V!]OY/?^?Q$@_E4SV0O@K%G,_O?EU+&9KVQ$M\#BB9#
ML>YW[[$D_3W"[?=OW)]_O[>TO%9CNYE=MOH1[;=M_K_XV]_!@QC2,YW8-OL.
MY'O]/O\ ?VW]AMWW[>#!C-NV^Y!WWVWV]A]^^W\GU/@P8V3,KE2Z\]DXA@2I
MV ._?<C<;;;@??V\&&_&O-R_GN]U,=B^BZMS#]EW7B>1Y'L>1[ ?3^4_?X,%
M.;>/V;MYOW+#51>4\O==MU4;GCL23O[ ;=NY[D[_ %V)AD ;@M=JN*<+,[5-
M>6.VO//8!^'M7(*:NG!)+4D9^4C@_I(W8H .!V 7<'WW ,#.[6Y]A.VX^]F=
MBKIWJWU&TY%(N"UOEL/1H,3+7:[-8#(8P9I6:TTWK/\ +Z42<557D!CC]R%:
MP[MNSD_(=N&YH]0[%[CC];?:,/S37FKZUTYXK65SRY7'2VXY6J9"A5EF^!:0
M<X([*(DBRO'W#L6XLPVV&X\/SY? UR0&)IQ[ S^!I[S@E8SS>:UQNK%J9#%Z
M4R^%CMUY!>CQ]FM8;$SLC)86-IW5IZZLRRHR<6EC90P&Q&(<#PH!W$-3Q)H+
MVJ4)/!J%S8/Q=^8X@L1@M7?-SJ$WLGC[.A],6VK4,M;I3K:L)'E9,5\/:C2G
M^2;@+F#L?A&)G!)]&2)260^&_A5^[F]/-L  =JBXN*G@*!W<<+X2\#YI-4ZH
MQV<K8OIWI[\)XW#3Y?'8^.U;DFOO1E22_69EB!>3\'/+>JA4VE-:2 CF\>YV
M"G.C#L;;FV$SDW<<#J=K68BHX<+4PV\;YN>H$M*[D<7HO2-B#&&"QD8@UPVJ
M^(GVB^+0-(-_A+6T5K9'$:/'(R* 2 > ["/N^U^561>Y:I!-6>IIR XL"+T9
M"N^:'J>;HDAS^)QV(SGQ5C#78=/PV BQ!.6/L#UC)%?IS\Z]D%2O:.=$:&16
M\'EJ;F_V<N>!F:@-'=CMWD=M&<UI@=ZVZN]1-2TJF5BUUF\:P*4<YC\=8^!@
M2RI*5\I5>#C(*MT[131ERT$X&S&.10 /OV[<G%-@]_N<8&P&U.>SEF+O44V&
MV'?I/J9HO5&GX=,]9:5[,G&'EA-2Q6K4>=JR(%*LMZ)V=I5)+%+$,R2<%)&^
MX)5]O';:C>)X]@P.X849B7'(-6M:4L_;3#5UQTLQ&1GK97ICE8LXV43FN%N&
MO3RF2902UC&V/46CD;@"D6*BM!:D=69(#(6'@?WVH??Y'?@(?8.>8'(,W"M+
M<R1@ W:UVG)8I7J-JE;JN\5BG=@EKV*\H;<K-!(JRQM[;AE ]B"00?!Y'9[L
M!<_K!#ER1RVWHSUOCG3MVJ4\%['V):=N!089Z[&-U('L2&!*GN"I)4[D%3[>
M!J,YKO1^ZF 4KN+5!ISJ&:@VVIA]1Y; ZK,B:IA.%R?HD+J#$0+\+:L$?DY,
MOCUX[!GV66Q3$;D'=D?OX5B34@\+<NTFP [WOAL* "O;>X.X+<3NUF&-3(Z.
MS.'HI>"09+$.0(LMC'%RA)L00&DC'*O)N3O',(W!'$C<$^#MN:7%JT W;G5C
MW8&9N >H=AQ?<%Z\K<2-C00VZB:0(0J6U1IAW;N.>^9I <N_?8@;;K^=M^KQ
M&G".IM7K83=T1#_9[L3\K_*@U?F)E^/[A%I5VH!85WVQ^C_Y0?W9A_QK_;3Q
M+Q5JL>P_#'Y[?V@7;SN>; G\T>8KKAN.Y!/[*FK=AV('OW[_ /=XBRGT(O\
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MM^P[?38'8$CZ'POJ-*6[/MP^TBP+,;%F%+L; [&XVVED95X;[!F4GC[D@[;
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MOC?YL'_<P\-/<;]SMVVV[=M_K]0?I_!]?$O%;CD"#W'?_P ?^.Q\&#')G9@
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M:QYXUVZ-=3,N93FND?4BI;?D5RF.Z<ZXY2';Y1;H?BY'7D???E-"T3GF25)
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MF.7K<(_7C4_:W=>1O_Q0]23_ /8)JS_[3?\ C[_#]:1^CC_R*L+Y+C_II/\
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M[0NK0>_O_P#B;]7_ +O!ZVC]%,?R"_LPODN./[=)]TW!_K>_PQ\_:W]>2?\
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M)M^!_P";;;P>M(_1Q_Y")_5P?)DQ^DD_YW!_K8S]K?UZ^O2#J4?X="ZK^_\
M_0__ -_P>M0_X$?^0B_U</Y,F/TDGR_&X/\ 6I[\9^UOZ]?]3_4KW_\ H+JO
M_P"TXV/\_@]:AO\ N<?MZB)_5\\<+Y,F/TDG_.X/VX^'RW]>_P#J?ZE#8_\
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MI]!^Q'NK[?YP ?X/K[>#SPP8E'T2Z$SZ-MQS/&R!"#N5( VVW]_O_5[]_O\
M!X?&UO.QP>?/9B0_4O1<^I,(]*/F282@0$G<;;#8;]]B3V^[;????P&O+L\?
MNX\.6/T;[W/.@KP^'93%=V>\IEZ[?FG]*4AW8G=7/OWVW^G;;Z?38#;V//GO
MPP>8/9A$_:?W/T$G^3)_N^##QG[3^Y^@D_R9/]WP8,9^T_N?H)/\F3_=\&#&
M?M/[GZ"3_)D_W?!@QG[3^Y^@D_R9/]WP8,9^T_N?H)/\F3_=\&#&?M/[GZ"3
M_)D_W?!@QG[3^Y^@D_R9/]WP8,9^T_N?H)/\F3_=\&#&?M/[GZ"3_)D_W?!@
MQG[3^Y^@D_R9/]WP8,9^T_N?H)/\F3_=\&#&?M/[GZ"3_)D_W?!@QG[3^Y^@
MD_R9/]WP8,9^T_N?H)/\F3_=\&#&?M/[GZ"3_)D_W?!@QG[3^Y^@D_R9/]WP
M8,9^T_N?H)/\F3_=\&#&?M/[GZ"3_)D_W?!@QG[3^Y^@D_R9/]WP8,9^T_N?
MH)/\F3_=\&#&S5\H=V*:-O0?Y6# %7]P1[;C_1_)[]SSY\_7@Q._HGTQFT94
M2-XRA50H!4J3L-O8]P!]_8_3P"CE^[MH?->7)7;<7OX=OP]V'%U?T%8U?BWK
MIS8\"I4$DC<?G ;@]AVV^A/WCP5V\M@>O(B_/AR[=[8KWROE(O6K<TIBD8.[
M'?B__2W^X[=_U_S^$*W#?4>VQ[N_#PF_M/[GZ"3_ "9/]WP\&,_:?W/T$G^3
M)_N^#!C/VG]S]!)_DR?[O@P8S]I_<_02?Y,G^[X,&,_:?W/T$G^3)_N^#!C/
MVG]S]!)_DR?[O@P8S]I_<_02?Y,G^[X,&,_:?W/T$G^3)_N^#!C/VG]S]!)_
MDR?[O@P8S]I_<_02?Y,G^[X,&,_:?W/T$G^3)_N^#!C/VG]S]!)_DR?[O@P8
MS]I_<_02?Y,G^[X,&,_:?W/T$G^3)_N^#!C/VG]S]!)_DR?[O@P8S]I_<_02
M?Y,G^[X,&,_:?W/T$G^3)_N^#!C/VG]S]!)_DR?[O@P8S]I_<_02?Y,G^[X,
M&,_:?W/T$G^3)_N^#!C/VG]S]!)_DR?[O@P8VZ?E$N13QN87V5@VQ5CW!&W8
M@'O]"!O[[$?4Y5X\M_%OKP8GCT4Z9S:,IQQ21E"J@ <=B=PHW^FP ]CL?N]N
M_@\^?/UX5RUVOPIMVNQ:^_;*.->**O?L![^_\'\GMX,/&/&D@V=0P_7X,&$\
MTJS,2T8)!_5^H_=]Y^FW@P8SX&K^B'\Y\&$PX#P&,^!J_HA_.?!@8<!X#&?
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&-CP8,?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g90195g61n87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g61n87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &D*^9R(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&H@,2         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !X@
M _@          0                         !              /X   !
MX@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MX@    !29VAT;&]N9P   _@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   >(     4F=H=&QO;F<
M  /X     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M_P">[^]+T&_O/_SG?WKG3_SF!(%F0[31VR@#=IY?1^DK&">O?M*D7FXXGO\
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MOH=(Q[ZF746FVJQH?78RPN:YI$M>Q[7;7-<IBEH,[G_YSO[U,  0.$ZC7O\
M_]#TF[%SGY(MIS357N:30:VN:6C;N9N/Z3])^D]V_P#]2V',L+B180.P@(B2
M2GANI_6_H6/U+(JO'43;CW%EHJ%0K<ZLBIXVNM;OIL;7MV6?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4]O7?'=1<'7ZUQ^F[%94[KOW:A@0QKG :A@1UP\/EZ,7U;X56M#*]*)]*]=
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M $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ (
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M]4\3M],,X5M1=1VZJ=\;"F4AM>9*C<:'J^JJ;)=5;TKG:$50.IK&4V+E(JP
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M]2H6'R(FY*4C2R'+%9IZM4;*027*8I5''*#YPF-.-,,FFG$#DH 0 @! " $
M( 0 @! " $ ( 0 @"J;MM>%9>[[\)OS8W?X_W1Z.%3]KN515MV#.CA3'BMQ:
M4LX3,*['G.K/E=KU=Q^OZCZZD%EM";;T_;A5638EJ-*#%=Z<5*=E+89*S3/9
M:M4V35P+YDI5-:LP&TRF)VR28:Q1%-\ZD7"4M,'\-;8K;3>Q56??.[4M:78;
M'8HNU['%MEBHU@]ZJK:=O)WU.,T]+Z>>SB'=S!UV%5JJ\8A&(!F<.XUAZ]AF
MITL=:R]6E6DAFI8L(S_IERPX:>K$(C"</5)=*5]>NQ["8L;*@871W4,;\0W.
MQ<Y4R1YVA;GJYT9ZYM43&H3%K([(UQ,\AA:@4#@C7$3=B4)S9^65;8=/E2UE
M<"I:BZ'#O"B:;514LLQLJFZ?FF3,KG]9T3 *^AH^!BHMY!1S$/%,JRKJ,K^I
M7JN7CZ&>*VX5_!1;E^RTRTP\VB(<Q#M=@\=MM?F7L]D6ES8I']+2;552BE^S
M=J&&J'>LK1HW^2HWTA ;6CW33_5%4R^3Z;)9%2EOIEY4"F7&#VT2M,ARA(01
M7RHTB*TK-O[YIE&7EB,I;L$:1EE+%P(K28<'[[ J_!_"47"Q,$S'.I7"S-Y+
M%>+"0,UBYQ2;F/28Q[#A9Q'2V832:(C^7,03UY#RV,>*Z?-+V4[A&6WCIWZK
M'NDJ!-61;-55)TC5TMS+:.:E>LJ5GI5M66Q:S:Y"O6QK<'I:A3O#.<Y+*-4K
M*32&+'&H&U&2*9I<RD*HJ3E\G[VUEMMA&&\&Q5I4>JC&UJJ(BV+8C7OL&QPX
M<**?S1<2CAU-V8.9RN439*CIN)>1#Z90<KAGM-0S4\2>PT-$1K]P[BX5N)?2
M9X^E3IM]$S"'<L;5"Q+#AZPGZJ%FE0J+@+;?U?1U'5#4U0T_4=&KEU:TW2\Z
M&W:2LZO0O[(K7.KDC(:5TQJ:EW-72*PXEY>::()4I6Y>W*1)4\-K:C"-LM-(
MPRTRTFP;:M;5AE;4L1I515V2;-+41I<:68/K)&D</)Z_D,VD\GF$RCX"8R9^
M_G$ME:N*?=3B;.(^">OXJ(<L0C]6W<KB7LI>MNXR,EKMEX[AXB'>[!YS%PJA
MIVHK=5^2F=V^GZ(;7JI5]HV>GKCH)S:C,=;NJ7)$SU/9].X*'-JD04H[/;DD
MJ)>SLI*0ID9DGDU68M1)%'##"LO&+4M>*RRCQ6G:IL;':6JR\V-BVM(B;%E5
M5;5P)H_5/IA 3"GYZP[BX> DL/&3%_2D'+JA<*W,&HFK7L0YA)G2#$2\BH5E
MS*HN.B7,Q?0<$PZ9@H)TCY\T_AW+S\.P)X7=F?52I?B/4\<QG:KW@95%TJFS
M91+>#%@WL&E/C<,SK4CWS,=2S(M+1YXTO$ ( 0 @! " $ ( 0 @! " .">:I
MIFG#FE-4-1,3$H?EL[<QIWEW;VLYY<"TQRTQ TE+E!!CBM+1IE"N=*CE./D3
M$''S%@45//*!SL ( 0 @! " $ ( ZG)Z\N7;U37_ ,Z-C61S\$ZXMCS4,LWW
MPKWC&_.4XR/H?,MY]2^>9';*^^.Q_P";+HQ4*^A[<HWO:>>EE9:^]I[6K#CY
M'Z.:EAR_UQ[AT"[V99[=JJ*6O=T[LTM;I+2E3TT]N2QS;)Q6UA<BH$%0M=:,
M*9@EHFS])U_52:1Q87E.\/[4R4_Y(2*'M+(950M MMF#KU_6:0?1S;3;>[NC
M0\6%;P7401L[U-==I%B?*:>:,27KJF[-)O%J:935G63&3=VLJ=<[;-J2E[D6
MS.?J<N.YUHRM]*T"KE+5*R0P[WM]GC-_-FZ]#;?^SU)7/;U2 XVH4GDER1MK
M35C,E95RF61P*99$U;L]/U&N+0M:YM!-4BEC:4%8HC$U7L3>D87UL(D')G2
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MW()D5(M2VU#A3R54.3:NW516'M-0M*VUH!:33]$T0RHJ<I9A(15.J3,K&VE
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MVGM6L./DGHYH:@;2RM,OVC]H!>C- Y(MO9=56F- )Y0-3J:[?CB# D,EEGD
MPJ>6< GEDGER 32@.0"S="Y$4;S5I[5$&9PW4<YET3GU5W3]GY@N'JEF),"V
M&$_<W^UT![7P^Y'JCPOM^G!X_'T$Q_(S52P4I>*[:I_7RMZ=5;1$G3F"G5J.
MR'2U0V&#)UJ1.?/+@N2:89IY99<!CKLZ16.^?R:IM?\ CC[QP#[V%U+R7+2L
M="?:NXZ/LK"]!8E[\=M_1)*/B:GP>;F;!YPUZ0YPBE9I(BHN(=^.V_HED_!;
MWT_[MZ!]R M3=W?%^I>A1WX[;\:DE#QM3X&-<:Y;-!SIC?G(<!P%J=>CRX.$
M=^.V_HDE'Q-3X/3P;-=! <\P@.X0R%J;J=)A/:7NW;U7LX;0"5/44AAZFR5U
M4Y,G:UYD"<X^A7XHJ09YVZ623KS)@E":>:64!^RF  $0[VE\IJ=Y=E&L(<Z6
MIE3[7*@P_P#DDU]1B$\N ZQB-2S,H0!<WZF]KRDZ5V1;U(7YVE0*C]HYU5E%
M"C<%(S)Y[96U)E,&9&D422!,:2;*$L\TLP]9,/6];K%);YG+&1K_ #9<ZTFA
M<R]QR0G/.1]JR5EASOQVW]$DOB[5/F> ;NUF=1$ #34= UBN)8.U-U.OZTZ0
M-X[;AOJ27&_/:I[QNSH/:W Z:Z#J A_M!D+472@[\=M_1)+^"GL<<-?U-TW#
MOYIO]D<#FU-WKU1>@=^.V^[NDESNQVJ?,B.@8 .UF1U$ TXB <8'%J;J=/7=
M3I 7CMN/[92PW8&9L>I0'.X &9M !$=X  B(AKC&L!:FZG2AD-"M2N2)(X(3
MI5"-<F)5I#Y0GEE.3J"Y323999Y99PE,+GEF )Y99@ =0 =(')QE44TS5G3-
M0T?4:4Q=3U5,;M3CZB)6KVTU8S/: ]L<TA;BU*D3FAG4(E)Y,JQO6)%J89P.
M2J2#Y)#)0,?/-B;8OR^D5KDRNTQ%!H61!25/HJTKEJHIFEICR4-,+RJ!:JD1
M40H?J9-5BJINI%M/J:A8%R-H<&AS1K6-F4( /%$6$M);>I!JRB*-34\]A2R&
MBRC4CF^&($E.H$E/()4J!D5N:AC;EBY%2-)I7MY0MR=ZJ(BEZ<+?W%RE8VP$
MH&7X 0 @"'':UY;O95V-K\5CL\W.M[M!OU:42FIE4ZNE"4M;ASI=075=+L]6
MMX-ZRH+K4P[&SDMSVE(6@I94DI:TM061,H(E+4FS'25Q"JZRD,'44KF%/.(*
M.:BF73J/BYDZBF5A(I]!O-L8AY3%.41IZX;:8V#]NUA65:V+2JPS$=579Z7I
M">1<@F4!/W\9!,PS3U[ PLN>PS214,YBG>UMQ$UAGJJR[?,LM[)RQ8VC2,[)
ME$:76_\ Z2WL+>E-M9?B/9__ )ZQZ3W-%=_RM27]/G'^0GG?=&T1_)55?T&4
M?YX;);)/+<[*NV7?BD=GJV-OMH)AK.M$E3+&MTKREK<ME,)RJ5IEVJIPE7K*
M?NM4[J48<WLRDE&"=E52F+3""SYDY$QB@KS=6W$:KHR0QE0S284\_@H)N&8>
MNH"+F3V*:6+BG,([VMB(E,*Z5&7CYEIO9/V%1A&E91II$97T5*W9Z7J^>0D@
MEL!/W$9&,Q+;I['0LN=0S*0L,]BGFV-P\UB7J*KMRTRQL7+=K:LHTK+*JTDQ
MD0X2X( 0 @! " $ ( @_O[R^>Q_LZ7GN18VMK:[2;K5EKJI<:1?W&EJ0M>MI
MU8Y-DTLAY[.K=KPLCDH0SC,'83%K2WGS!GKTQ>Z)PD%P*L:CDLMGL#,J:=0D
MTA'<9#NXJ,FC$2PZ>I:RR^8<R9^Z9>)_XD8?/&4T-*0O/;NE)4_.)C)(V75&
M]BI9%/(1^\A826-P[;QTMC33EM[-W+QIA="MNG;6ZRAB'_I+>PMZ4VUE^(]G
M_P#GK';^YHKO^5J2_I\X_P A.I]T;1'\E55_091_GAM]L3\L1LT;>-X%UE+1
M4+?2FZI;Z)>J\.<+CTU0#33\S0Q.;$U*TQ2JF;F5>XBY&**A13IB9VJ1+.24
MJF-6$SR%%G>0K:X[4U!R=W.YO'2*)A7D<Y@&7<MBI@^B$?/W3]ZPTK$5*X-W
MM2,P[:--(]5I&E91&%155GUE&W6Z;KB;/)-*8*=P\4[@GT<T\F,- .7"N7#U
MPZ;91J&F46\VQ6HAA645TC*LHTJMHJ(C4L$1.2D( 0 @! " $ ( ZN;:[\+'
M:?\ 9#WJ^4FI8U&I#)*E^;LDU9"F9U5Y4U+R_.-8Q)KQ'HCH"S9U,=X0>TOZ
MS=-_'9-%9+YS)ZF>68GU%HLA>V_']1\CP_KK!<TBF1< 0 @! " $ ( 0!U.3
MUY<NWJFO_G1L:R.?@G7%L>:AEF^^%>\8WYRG&1]#YEO/J7SS([97WQV/_-ET
M8J%?0]N4;WM//2RLM?>T]K5AQ\C]'-31_:CQ]$SM%<1[^MW0P&\<U_4&G$=P
M8SS9'Q6;H7(BC>:M/:H@S.&ZC@NF71%T_;U5WAMJ"8<*XDP[V'1@P7D,]/BQ
MG'PXCU1X8FOY$4?KU7D#B%KD.>8?UV-?3\.N!BL=\_DU37+C[U!\74O)<M*Q
MM_!=QK6%Q%E**5FD@@! " ,&;4'@T[0_K&7:^(-01WM+Y34[R[*-80YTE39.
M5!R)-?4(@ZM*-2S,H0!=FZF<\#N]_LEG?Y+K8Q26^9RRD?-EQK6:%S+W')"<
M\Y'^JY62VW*VF'FC-HI-:$4*9CHY#3%CUKU6ZZE3:L+65;M%W)N3:VVU.)R4
M5P:2=69.54UNI4[HZ(:9KH@!JAN.>0I!H;U3VIKB6$W37"K-L_:,H2F5EUSZ
M)MM<*RR"Z=WJ)2U)3S4Y48^50S6OD86 '%M97>Z-5NB1&Y5:P7U>I*J9&>O&
MDJW-NVBK7EIIRE7ETK1C'"VZ+%6W3:B=-B^3R$BEHJ[37*MQ2U8D."5S/<4:
MA$\J4; _TJFDJA@7JZ=JY"5355#-4C'*V50U.[:+8]3FN*29()2DXZ>439QR
M9(@! " $ ( 0 @! " .O>Y>#ST#:"]2+,_(G;Z-";A&:ZG>-G6O)B4(NX9RY
M_P 5)]30!$!$OD3$PG(.>>?6$]0[R_(U7<0]=YS83_CY-KF ):N'YRI#Q,XU
M/''8.1GP7V$ ( 0 @! " $ =:SRIGGB.V!Z]U6?RQ4:57+,W='\AP?FJ9TW3
M<X%6\M1?G(:"Q[X\*3\=3@>'_4WL;[B_'*V,0#?(9OX7G)+O4IH3M>\Y=Q/-
MV8>N2PO4114NT( 0 @! " $ ( ZN;:[\+':?]D/>KY2:EC4:D,DJ7YNR35D*
M9G57E34O+\XUC$FO$>B.@+-G4QWA![2_K-TW\=DT5DOG,GJ9Y9B?46BR%[;\
M?U'R/#^NL%S2*9%P! " $ ( 0 @! '4Y/7EP[>J:_P#G1L:R.?@G7%L>:AEF
M^^%>\8WYRG&1]#YEO/J7SS([97WQV/\ S9=&*A7T/;E&][3STLK+7WM/:U8<
M?)/1S0T@VHQ_9,[17KZW<\7F_J#YZ\X<\6;H7(BC>:M/:H@S.&ZBO[IET7>K
MJK?S@F'7PF"@QO#IQKG'OXQH&@?TQZH\-UP]?)@)K^1%^W5>/UKD/BTJQK#_
M !"*QWS^35-<N/O4'Q=2\ERTK'FNYUM"EE**5FD@@! " ,&;4'@T[0_K&7:^
M(-01WM+Y34[R[*-80YTE39.5!R)-?4(@ZM*-2S,H0!=FZF<\#N]_LEG?Y+K8
MQ26^9RRD?-EQK6:%S+W')"<\Y'^JY63/.]Z]C-UJ9CJM]NWLQN58TB"]/352
M.]>VJ65-3 .$O8'0AC>%CJ8Z,H+I) )7E(%*;R3++V-1+.$N AI*&K9I$:9H
M^J595$5%2GYLJ*BI:BHJ0EBHJ845,"H26U=/N:LM-,M70Z&9:9566F6JMD"-
M,M(MBLM(LP145%145%2U%P*>2KY[&B=N:&@B\6S(2TT^C/;F%K*N#:LMN9$"
MI :TJ4+0BD=Y4S:C4-9Y[:>F1E$DG(#C49DDR<R<N;G[1:W_  .JK_EZ;_H9
MQ]U&YG_ZB4+_ ,W2#_,#)-JZSLI4+,-.V2JNUKY3U&)&UO%BM6^TFYLU*(54
MJJ5H1"V4DJ/0L211*@6RMJ;L"4DZ5&J!+),"<X).JF<BG<EVC[,R::RGLG;.
MQOLG+XN [(VG:]NVCLIRZVW:MM=;9M>RV&V.]E9LV;>]DM44S4O9/VNU%(I_
MV%M/9GV%F\OFO8G9.V]C]D]@Q#_:-OVA_M.V[#;=I>[#9;6WL<I1U1WH@! "
M $ ( 0 @! '7O<N_YZ!M!>I%F?D3M]&A-PC-=3O&SK7DQ*$7<,Y<_P"*D^IH
M B B7R)B83D'///K">H=Y?D:KN(>N\YL)_Q\FUS $M7#\Y4AXF<:GCB]O?FH
M+M4S;L]SLE3C55=P)JEHI E9G=.TKB9Z><:N9D5:N"-M?+DVC;'5U9:..?7E
MJ:U-P:>!>O0$)RS51D\J%3GP7V- 7[;9VAE;W;<JV%O:;K-CO0TJ4EH5+E;Z
MJJ8*K0U'LQ5K>I?<U553Q<]+1U'MK7<NB5MGU]D:I<V^J"9US95ZBZJ2FW!*
MXF@;#;(.U6Y;0T]3,]7(FBF:UI5DHLQ?2;=3E6HP.5+:58GRI*I150YGKZ0>
M*>>%55L2BE6*DWVJ53-2*JFJI?JI<0N TMK(!N[ " $ ( 0!UK/*F>>([8'K
MW59_+%1I5<LS=T?R'!^:IG3=-S@5;RU%^<AH+'OCPI/QU.!X?]3>QON+\<K8
MQ -\AF_A><DN]2FA.U[SEW$\W9AZY+"]1%%2[0@! " $ ( 0 @#JYMKOPL=I
M_P!D/>KY2:EC4:D,DJ7YNR35D*9G57E34O+\XUC$FO$>B.@+-G4QWA![2_K-
MTW\=DT5DOG,GJ9Y9B?46BR%[;\?U'R/#^NL%PNIJYHFBA:I:RK"EJ2%]6BVL
M85-4#2PB\N(%]E% U ZJT@N*T"O\H*5)V8\"_JQ+ZW6*9%P#YLZ]=FDZYX;%
M%VK9$.5.JBD-0-YU>4J4N8UI[H+(0C>$D[K*>V*CGH!:"DZTL@TQT 4$DDRL
M.Q0!D!$Y-SE*IF;EZ)?*C6JFU9,B5$*I4CBB,$I:@4B088!"U(: E*DIHR'I
MS &0TN2;2 /VP @! " $ =3D]>7+MZIK_P"=&QK(Y^"=<6QYJ&6;[X5[QC?G
M*<9'T/F6\^I?/,CME??'8_\ -ET8J%?0]N4;WM//2RLM?>T]K5AQ\D]'-#2#
M:BUVF=HKU];N8'_\P*@TWY\>X-(LW0N1%&\U:>U1!F<-U##=,NB\^JNP_C!,
M,&.WAQ)@,$[AWXUW8WZ<-<<!'GW .[$>J/"]>''P\..W=)L.1$^W3>/._O7(
M1'VZL:\;]>C7FBL=\_DU37+C[U!\74O),M*QYKN5PX[%FT+9;Y"RE%*S240
M@! &#-J#P:=H?UC+M?$&H([VE\IJ=Y=E&L(<Z2ILG*@Y$FOJ$0=6E&I9F4(
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M1IXM=(J+?36;*AMVRIK?_P ^OT]<)?V\:P?=0_$G^UO7ZB?^*DE_! " $ (
M0 @! " .O>Y>#ST#:"]2+,_(G;Z-";A&:^GN-G6O)B4(NX9RY_Q4GU- $0$2
M^1,3"<@YYY]83U#O+\C5=Q#UWG-A/^/DVN8 EJX?G*D/$SC4\<3*<M1X5=%^
ML-2?B\WMSO@WB&\= CH+V;(*:<[)AJF1D;7Z.=22\PY3K^I^#PZ?$1"C@-^
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M2O[6]?J)_P"*D%_! " /DZ[KBF+:T?45>UFX&M5*THV*'A\<$[8[/2A*@3
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MR5'D>/#!+YAM?6_\NP]'P_X0-?&YNEY=E?F19:>\^SOIS7G?I( M810@U2$
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M>O+EV]4U_P#.C8UD<_!.N+8\U#+-]\*]XQOSE.,CZ'S+>?4OGF2VROOCL?\
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M'4%T5B2F712CMS2SHG97ZMUA)$QB6F$#JL=&9&@%Y42EHE"A8Y)T<B0Y1Y+
M].)B8X"-%%9:]H4]:]N0H+DK*FJFV?>^KQQJ-M5S)+0,CW5EWW.K7RU%6N-U
MY'VDZPHQKK@IEHPE^I6ME%:4G2MK*=F6T\<+P^TT!FC8VH_:1MY6-4TY>%H=
MG&E5U&LZZGJF=Z@,<2J02I)FM93-L68@*H=TJD&_NGK=)4'6M$CBPN-)HTT]
M=U]23U0R6C1PG7Q^&W=M]IO;42:K5)">6DGNG613*;.*LVHJ7<ZH(/)&4 D+
M3D-E7T@8E-EGS-.<:I623RB$@$2"'7B.3Y,6F\_"O;8;N-HZKW\?W;-W1[\
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M/ YVP2NFUU;C_P#O,40-?&YNEY=E?F19:>\]PW7F5W:7G?I( M810@U2$ (
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MD+_L=J+^-93Q[KLAGWN =/&*C7T^.A>"IO+3Y?V\:_C0_$G^UI/_ !4@OX(
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MG2PS&V-['$SLD557&60^^.M]+&YO-Y44_P#VG]_=TQ3&S@Z4]IHSLTQ[%O\
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M8S>UM[-VU@V2X++5-=_I8>VCZ4L_-I4+!N#./]81['W1=SCY2=_-?_<$>>Y
MNP?(4TF"SX\3%_1-%OL5<!O)R>VR%M(;->T)+<FY=JGLJF9:(J5@&9C7,#LN
M%>Z&MDZ0 2 [IQ[",J4[LA@F!U@A+]2/7!B+;K]UVD*UI!9+)&YDU&K,X*+L
MBH'L=UM4.R_1Y^R;:W[[]D9V+-F%+<*66$X7OMP"Z#<VN@)4M2NI.S+4D<R@
M%6!F21;_ +(BFX5IRFU;0[]Y8Y;V36RP6I@55)T^^.MSCO97-_!#!CXS</\
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M(S=C.D+.-DE,EF"4R< "81R?J@#\QB-&:>"DU*F,4RDSII5!A!4Y\J<T<F$
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K$Q,Y;B!B4M"8"Z2:09583HB24<_D@#.N2E%IQR47+( 'ZX 0 @! " /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g90195g63l19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g63l19.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #$ 5L# 1$  A$! Q$!_\0
M'P !  $$ P$! 0            4&!P@) P0+"@(!_\0 4Q   0,# @$%" P+
M!0@# 0$ !0,$!@$"!P ("1$2&5B7$Q48&E?4U=84%B$Y559U=Y.8M-<7,354
MD925M;;3V HB(S-3)SA!87%TEK$D)5$R@?_$ !X! 0$  @(# 0$
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MRUK"7ED@*0K;OMKVV0\N^+L8JQ-LW(&&;;V1.QJ&(#!I$[/Y8J59/63"*,P
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MY[RG[E":&Z[\1G</1/X'/O3.QOYFTOXHD>AJ-^.U^)KE4VM:&(T T T T T
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M*?</?D'=-1S7!,G"L@Z0._0;X6&?K[7^;I]BEGHDI]P]^0=TU'-<$R<*R#I
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M==%A';2']_Z*A:"6\.$[/-N&'MODJSD%43PDO.F\6DH;$#IBT-QZ28UE4"
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MW36BE<NCKJ)U<(7HTOK;3'MM;J65OYU;>=3EY.3EIR\NB6:).BHO<^^J6/\
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M%<NRW%<S66@Q7'\4+P,MBN.8HBJ#.!.PN.6:+&.38)AV,#9S%SS20@'@M_)
M<?'QL$8N&("1CA1%PX8X_7BC43NU;91!-GPJV.8KR+EA]%%DP-QF,3!_ BHV
M1$8G@3;KMTBA@HZ&8]"&T'\>@>VZ.NV284L(&N9%-\@O2H\B.<Q 3#058XD3
M<CE5<:KE^";<=&W]I_R?'L2XIVC2>2MBSH>ODS)0BQ,,W:NG='3N(!G*=]R;
MQ\P2HC1-DK2^^B];Z753I1.ZE;KK?2Z=T=EU)IE=3=-[R2NG[$O<2I6I6\>N
MW6ANW,I=M(C3IR_:NU:?,P2X1%1&HM(J(B]HK4>S/1:P79.G&F5+Y%/LOFN5
M4/G28';FCTED$LEZ2R6SI,DM=/&W4XSG-3A),RZFU^R\;24M/$;:=(RZ;9::
M:8^//PW\1_ T^_8X+UFUQ!>?I/Z7,F^I;U<?233(+!>MJRGP%17MJ/#?Q'\#
M3[]C@O6;2\_2?TN9-]2WJX:9!8+UM64^ J*]M1X;^(_@:??L<%ZS:7GZ3^ES
M)OJ6]7#3(+!>MJRGP%17MJ/#?Q'\#3[]C@O6;2\_2?TN9-]2WJX:9!8+UM64
M^ J*]M1X;^(_@:??L<%ZS:7GZ3^ES)OJ6]7#3(+!>MJRGP%17MJ/#?Q'\#3[
M]C@O6;2\_2?TN9-]2WJX:9!8+UM64^ J*]M1X;^(_@:??L<%ZS:7GZ3^ES)O
MJ6]7#3(+!>MJRGP%17MJ/#?Q'\#3[]C@O6;2\_2?TN9-]2WJX:9!8+UM64^
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M;:E>D]E&W WCO'N+#<-D9N'XH"$H_CJPWEC,!F31$<1?@RB5PF>E)Z[GJ9(
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MJWC^0C;/];/*7]%F@JRKF3G'MJWC^0C;/];/*7]%F@JRKF3G'MJWC^0C;/\
M6SRE_19H*LJYDYSIL)!O'8LFS3\!>V=7V.E:GW3PL<I6<_DY?=YG@77\W\?X
MN=7_ *Z"K*N9.<[GMJWC^0C;/];/*7]%F@JRKF3G'MJWC^0C;/\ 6SRE_19H
M*LJYDYQ[:MX_D(VS_6SRE_19H*LJYDYQ[:MX_D(VS_6SRE_19H*LJYDYSIM)
M!O':W/+OP%[9[_93Q1UR>%CE*WN?/213[G_N77<[D[ESN=_=Y>=R<VG)RU""
M5UK6L<"9$3RMH[GMJWC^0C;/];/*7]%F@JRKF3G'MJWC^0C;/];/*7]%F@JR
MKF3G'MJWC^0C;/\ 6SRE_19H*LJYDYQ[:MX_D(VS_6SRE_19H*LJYDYSIV2#
M>/8_<OOP%[9Z^R&;%KW+PL<I4YGL-8@MW3G^!=7G=T]G4MYO-IS.Y<O.NY_)
M:%65<R<YRN9!N]>66).]O^U]TFFX;.DTW.ZW)R]ECIDX3=LW-EBNRJZVUPT=
M(HN6RUM**(.$DUDKK%$[;J!5E7,G.<_MJWC^0C;/];/*7]%F@JRKF3G'MJWC
M^0C;/];/*7]%F@JRKF3G'MJWC^0C;/\ 6SRE_19H*LJYDYRLH$_SL5D-[C*N
M.\20L,S#ODASK'V:)CDTF])NW@NZC=Z,D> \2-1S&QJU<*U?H&";BYQ1%O0;
M1-6]TC8U0VT7-'G(J)%%15P*E:0PPVUR%YM0'DK<;GWV#?/\]Y3]RA-#==^(
MSN'HG\#GWIG8W\S:7\42/0U&_':_$URJ;6M#$: : : : : : : : P-S%O0)
M8NW4P+;PRQHQD( RC@6Z<3=S-7 <X!6W*3+.<"QM2'PQ*(%FDR0$G\#2%SD%
M0A+8G>  FPQ,8D<6L=LK185*L<L,>"$8Y,-2XUJJ,\M"#0#0#0&)N[[<)-]N
M4)A4H@6.HME@_+<H0G'3+'I7(16#S*6.I@8;C;1F+1XS'L]LF,P9,;B4F>B2
MZL0CP:(1V32R12P0" D7: J)'-'^^UGW#++0@T T T!CCNRW'1G:C@B9YIDU
MH=S0'4.%C0D_)Q\)!GIO+C+&,0T*;F15%T.B$?>2 HQNDLL>,W[>+1Q(M(5A
M[],9<S7%1(K JG;KF!AN"P#A3.HUHP',\PXJ@.2K!0PVC(V05::1<7('8)$\
MW:L4BU0;M^N(5?48L;G"S)2]1BS5K>V2!4@JID54S%Y="#0#0%M,T9.%82P[
MEG,QY@_*@\1XTG>3C(L71.I,D*@,6*RHBP'45K1*K]XS$K-VE%*T3JX43I?6
MEO+70)6J)E+9;3-P=^Y7$:&07X49%I*QDA^)3&'C%9\K2(R0&NE>N!>J9+QK
MB65*/T1ST8\567A3!@Z2>H.QCAXR<(K5%5(+_;]%7E,F-"#0#0#0& &R#>X2
MW?FL\BB6+VV-;<02Q@*!*V2]Y)59O%3!V>@@LR9)OH=$VSR-&%( _<@9O"WD
MWQE+%%2@R(SDV0B$FL9BJF#''Z^N2$(Y_P"A!H!H!7\5?<Y?^7_[_P M :@Z
M<3Z8MU<;,RVWL$/)ELLY/QYE@<CF%V0K#A<!X@\.X?#$GCYU;BUK9DPX4F<V
M93\@$(HP%H- #5@C,R6*EQBVAE#D1<[*M9=J'QJP&WS0Q&@&@&@-9.<-]V4,
M5A-V;D!@J"2:4;;\D8YA,.A9?-9T&;SREDR!,)9#0,%0"87F#A+,$XD)8-"(
M5C>C8B*>.RZ1HU.PR# @/3&2,HL*\,8U8(5KCP(E<?@;+VJBJS9NLNWO:+JH
M)*+-%%$E;VJMZ=MRC>]5"Z]%2]&^MR=RB-]Z5];:W)W765I6HQ/)=XW/OL&^
M?Y[RG[E":&Z[\1G</1/X'/O3.QOYFTOXHD>AJ-^.U^)KE4VM:&(T T T T T
M T T T!;\UB;%DDGD5RE(<:P$]DV"-7[&$9$,P^/$YS#V15%RW)M(O+'HY<\
M ;$&[QX@]0%/VB3I%X[26MOL<KVWA%<$:LA<#0#0#0#0%KLGX/PMFUJ#8YGQ
M!B[+K*,DE3,;9Y/@$3GS6/%UFU[)8J#;RL261$DE6:E[15\PL;NE&U]Z%RM4
MKJV5"*I@6!='0#0#0#0'$N@@Z06;.44G#9PDH@X;KIV+(+H+65351624I<FJ
MDJG==8HG?;=9?9=6VZE;:UIH"/! @D7"!HS&0XN.QR.BAX*/Q\&/:"0@(((:
M(CQ0<.*8(MV(P6,8-V[(>/9((-&31!%LV1313LLM E= - - =0@/8%F#X458
MLR8LFS<CR0T@V1>L"#!ZC>V>,7S-S8HW=LW;=11!RV7341714O25LOLONMJ!
M2N/L;8[Q+%6$&Q7 X9C2%"U7BPR(0&,!(?&!ZQ%VL_(+,@,>9#Q;55^^<.'K
MQ1!K9>Z=KK.%[KUE+[[@557"L=TK70#0"M:4_'6E/=I3W?<]VM>2E/\ K6M:
M4I_^UKR: : MQC_#F(\3*R5;%F+<=8U6FA:X],%8#"HW#U)4<O4<JW&)'?'A
MH^XV3JJ]>*U?$JN7/=';J_NO.<+5O N/H!2M*TI6E:5I6G+2M/=I6E?Q5I7_
M (TKH!H!^/\ 'H#'>.;0MIT/5BR\1VP[>8JM!Y64GD+5C>%L;@E(C.#=H:PU
M,HS<+C;6H*5%[8Y':$Y ,JU+/^\ 2KIVK42/JW%BN5<YD1H0: : : QODNS?
M:'-"$F+S':MMOEA6:R-C,9D3DN#L8G2$MEPQL69C93)GI2+NG)Z1CVAXXU8G
M"JKLFT;&2R"#I-(B\M603(6*Y5SF0[-FS',VH\>U;,&#!L@S8L6:"35FS9M4
MK4&S5JV0LL1;MFZ-EB*""-EB2*5EJ:=EMEM*4$/)?XW/OL&^?Y[RG[E":&Z[
M\1G</1/X'/O3.QOYFTOXHD>AJ-^.U^)KE4VM:&(T T T T T T T T T T T
M T T T T T!T2B;A8812:<[V4JP=IMN9?1._V1>W4M1YBE;K*)W=TK;S;ZWV
MTLKR75NMI3EH!\OV"=G7%;@D;VF1PM[8U$-J R%2F#J2O-(P[[<\A9[VV&)'
MG!CFNC::/74G";=MR0ISCR+HWOY Q*PS*2CN(MWHD!:[%/KZ^MPS546ZA"M:
MUAB18I<Y(XXPP8C)2+ON,TVCFWM JQRN:D2V;@)?*Q,\ALJ -1.+T9)MB8SJ
M$9!!Q]P:K*@[T&ON:/PN=XMD$&D8I%!I&7D0D3JW'\RT"W%>Y5A6NO<ABJKW
M2NK<;\3F8[2-^..\M')I-<CY1V/MTL"I+D<"0XR!W,3$=NBBTXQW#9!BMM"6
MX@2*!B]MY<4>FQ-TFV.RLP]939;N9ED !%91IE<"(U7A7P4A!?775M8,MOL<
M8>XI.#Y+C;&,+?GQV*1^X_+Q><R:)M\53*$FHB8RCAH_C^T)!\T97D&2L98$
M>8;=9-CCJ&Q[(AW($1R<UG1I!^69NL7T?SX?K@_M](/!K7<A&,<"QK1(1C"N
M$%PX8E%8KB_%R@TJF&;Y' <ORW),S0VZQ'*H9X5V7V725*)XCX@ V6CL-L1L
MG QH5AB"[C,H[<)A&BD[(!<P%($V>=^GDG'LC,?<TL6(0JJ5I45;JNMF$=M4
M14J2&UC+CR:)<5*<0(NVFI[=3&<@QK).RV8,+<$F]D,>ADAQA'".W%]GL3&7
MDC1OEI',/?>[/QN71>>.6>$)0V ,(NU:'8*7$Q23B>#&J"I!K#';A^D/B4K'
M8;Q@\=!14)A2,Q;U A)U=%W35ELU;XS-)$#^Z8J<-9:03'C)<WS(<(/-OQC'
M:.-!(?%]SHE8I-!C9M7)C9J'@;E>W'_=JR98_"-1?Q] .) \PF]#2=V6R9E6
M%;O,<S#&\MEP_;>B?5Q#7;%C^0R@K>UC86-0)M6';F9%E*'1Z_O PF5@ $+Y
M5#02Y"0EQBL*H>M*X(L5JRX(*OKW$[C;&G$,D^T?.^.\L&YE/\M.\F;49#BJ
M0$">%8?*G,;N![69WG\$D_Q.W@<3: (5E5OGL &3+LVY\C&!:8RPK,&"X4F5
M%BD8HD*EJ2*UUHF&*Y#"";;.M^,GATM"17&V78QFQ6%;FPFX#,$ASM'"$#W4
MF<@9JB)K"GX/PH[-KDRT&1F(LB1P?[9XWAYQB^'-GF*H\M2TZN.H*BHF-(84
M1&:TJ7&J8O7%8*IGC.]ON2\!X8V68U?S@WE]D W[-YM/BK<9(4P($1-TL^2?
M"\/ !Y9+<BR 5C3%&?I1@:.0EO+9M)U P^,@7+PJW;-4&[ 2,55<%7,BX$PJ
MD8U;>V8SMHOQPX[C5R=0R5/YQDU_A8C;;$Y&)V4- P7+<GX>\VEBZH]6/PJ-
M6K*P3?T)@./8C81.$8XI&SA5:2TEL/4<RX<+X$<B8U\*M+K%_P#;7^B+AFLH
MX2XLAU.7P1OEK(V0XD4GZRD5D<N:;8@B\888NWP[(IMB"<U1Q8(P\>,J'\%.
MMU;R<QAZ4;#)'&\?!8PX$Q^2$Q5DM!%9A6B(L<"1K2"QPJN.&3"N+!:B_(6_
M+;GN:PK@O(>0\C,HIE+=/E.<SJ5PF#8E.L,@P6?;FXF#B%C>'S1?(\E90HW"
M5B[<_&,6R=&58!@AHOE><-$0D='UM"I8Y8)ACB9RY:L>&%1M[X<(X^)V/[<Q
MY]B2%VMX+?2*"C#5TQ)B<8*'C*V(!+U@]L2>CUQ>*U(:PN'NTD73#V/1HX12
M51O3M&+6%?CNX\%6')49M:$&@&@&@&@&@&@&@&@/)6XW/OL&^?Y[RG[E":&Z
M[\1G</1/X'/O3.QOYFTOXHD>AJ-^.U^)KE4VM:&(T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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=[%#_  +%;[:*<^ZE:4NYM!8JQX*8$P1P_"!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g90195g64r82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g64r82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1P"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &^:^<4(X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,S4Y
M.#DQ' (% "U-:6-R;W-O9G0@5V]R9" M(#DP,3DU7U-)1TA4(%,M,2!&24=5
M4D53+F1O8W@X0DE-!"4      !!;8TMFEL_,I9,4 0<C%H-W.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #WP
M!<H          0                         !              7*   #
MWP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MWP    !29VAT;&]N9P  !<H    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ]\     4F=H=&QO;F<
M  7*     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M=3PJ'TN<'$2>(0G"^B6N9ND^TSV0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /_A0/YH='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @
M/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3YR<C,U.3@Y,3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(#DP
M,3DU7U-)1TA4(%,M,2!&24=54D53+F1O8W@\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M
M,#0M,#-4,#DZ-3DZ-3<K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#(Q+3 T+3 S5#$P.C(X.C Y*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP-"TP,U0Q,#HR.#HP.2LP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS
M+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@
M,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/GAM<"YD:60Z,$(Q,C<W0C@S.#DT14(Q,3@Q-D)$131!
M1#<Q03<U0T,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z,$0Q,C<W0C@S.#DT14(Q,3@Q-D)$131!1#<Q
M03<U0T,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C!",3(W-T(X,S@Y-$5",3$X,39"1$4T040W,4$W-4-#/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 T+3 S5#$P.C(W.C4U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,$,Q,C<W
M0C@S.#DT14(Q,3@Q-D)$131!1#<Q03<U0T,\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#0M,#-4,3 Z
M,C@Z,#DK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C!$,3(W-T(X,S@Y-$5",3$X,39"1$4T040W,4$W-4-#/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(Q+3 T+3 S5#$P.C(X.C Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z.&,V.6,Q,#@M,F,W9BTT,CEB
M+3ED-F,M,F8Q9C@V9&)C-V)D/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI
M:60Z,$,Q,C<W0C@S.#DT14(Q,3@Q-D)$131!1#<Q03<U0T,\+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z,$(Q,C<W0C@S.#DT14(Q,3@Q-D)$131!1#<Q03<U0T,\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#HX8S8Y8S$P."TR8S=F+30R.6(M.60V8RTR9C%F.#9D8F,W8F0\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!/0': P$1  (1
M 0,1 ?_$ !\   $$ P # 0            8$!0<( @,) 0H+ /_$ &<0  $#
M @0$ P4$!@4&!@D1"0$" Q$$(04&$C$ !T%1$R)A"!0R<8$)(Y&A%21"4K'!
M"C-#T? 6%S1BX?$8-4138W(:)28G*%1S@L(9-D555F1E=X.$AI*3I;+&UCA8
M9G24HJ;2U/_$ !T!  $% 0$! 0            ,! @0%!@ '" G_Q !8$0 !
M P($! ,& @4'!P@(!@,! A$A S$ !$%1!1)A<2*!D083H;'!\#+1%"-"X?$'
M%18S4F)R)#1#8X*2TC535'2#D[.T1$55<W6BH],7)624LL.$PN+_V@ , P$
M A$#$0 _ /:-YU<[.;V7>:N><&P;/&/89A%!C]538?1L*8#%/3H2@H;9\2G4
MK0))'F5O8G;BPIT:9IH44!RD%R\Z%IGRQ09G,UT5ZR4UE)2E<)!TB 6C[L,1
M@/:'YV]>8^83_P#*4P^A_5O[N'^XI?V!ZG\\ .<S),55C1G!GTQY/M#<[8('
M,;,,QOXM-^/^C'\=N%%"D2!R"2-_SQWZ7FC_ *9>U[D^7VV]ZG\\O:V]IO+V
M'U3N!<Y,XX8XVDE*J:HHDD7&Q-&ON1U)CZ</J9>B$*(IAVAGOHP=O*QUPJ<Y
MF>8/660X>0U^@^6*A\MO;X]L'$L:J*7$_: S[6MH> #=15T)2$SI@?J(,&">
MPCN>/-^.YW.Y5Q0S-2DQ5*3J"6OH1H/IC><(HT:Q:M334#IE0\C+LQ9VU!?%
MU\.]K;VCWZ5AQ7-[-BU+;22HOT9DD03:DB/I;\^,0>/\:"B/YQS  + .E[F_
MA?MY[#&G/#<@$ALI2<B['ONTA\/*/:M]HHIG_.SFHF K_2*0B!!_\4&^WU[3
MQW](.,_^T<Q_O)_X<#_F[(S_ )-2W,&/C ^'0XV(]JSVB"1/-K-9FT>\4I/X
M>Z=NO^WCOZ0<9_\ :.8_WD_\.%_FW(_]&I6:Q_._6^%I]JCVA=!/^=?-4QN'
MZ29VM^J1O].._I!QG_VAF'WYDV[<OQQW\W9'_HM+T/T+X;5^U=[105'^=O-2
M9W_6*,Q,Q;W06)L#<])CAI]H>,@SQ&NW^)+VVY=X\CN,$3PO(,"<K2+S8^GX
MOX6PK8]JKVAU0#S9S4H$'=^DGK_[TL>]Y!MPH]H>,FW$<P?-/_#\^N$7PS(
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MS,;##D>TG&2D?Y?6)%R>2;L7Y.W>9TQ#C'VF/VD[SJY]K?F\VA"R#JQ/#@2
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M=*#*22"[NY$D'5F!GI<C48K@U]FCRR95;!&2+6+3-K6W9(CO)/X;-",N2!R
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M_+9Y.G5K%*0DDD)>"2'U83#MMICRW/&G24H@M)9B.L'<:Q9HP<\QO:0RYD3
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M$:SP;:QUUE_3!$HY78 DB8)UM8'O<;#:1499*:<AD@:T%#R4ZA,B-0T@7B%
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M,_F:)JI8 DL0SPQ;2^G088\H8BYE?,*GO%2A+CH6#*P+[B=$=R!8R"('7?\
M#^-44!(4M)"@$J=0#<NX,[2QBUIQV>X2M14I"2X> )(+.T:W  ^0..@.3N;N
M&IPQM%14L:M*0=2H,IZ$* OO?KU(,<7_ .FY6H.9-1)#Q(O!,B<5'Z+F*7A*
M%$C8$N-'!#'[8-.'JKYSX,PJ34TOE/[R?K>#MN1,#TFY*=6FLPI#18OKK+GN
M YWC J@J)#E+Z&&(GM_#S./+//;+U@*RECJH. ?AY=-NY(-^+&FE(!*2'(G4
M-U#_ 'UQ$J5R"S1 T WF-=3Z]<W^?.6TI.K$*1.K:7$@R-MA$R+ ;_6>%5RJ
M@R.A3]3VTTPT5E069M'MYLY&TZ#; _6\SL.QUI:*2LIU2# 20J00"!\/XD3^
M$<1*M)(+E4 AM!ZA_1_B,/%59#)3?5G<@7T%G%HB7Q$N,UU3552M3[:6PL'X
ME #M)"._?I!VX&M82(G0 ,_I(ZMMVP2E365 J+.8+%WUT[]8B^,*,I=2YI<0
M?,!,J),2G5 1!])ZB>G%8H$J.I^-GM]?/7$TWNXT[.>DX<T8([4B?&;03 V4
M0(@7\H[;P(_@TN;%NP'RP@]?OIC2[E!;H@U:1-[)58[>O3O<WZ'A""9O9WL;
MO?7:</*A$,W7UT^[W;#?4<O4NH_TD+,6U)/2=D@'>=_E\^&BF-2==O(=?+TP
MA6[-MWOU;Y7PSM\K&B\"XXI8FWQC:XF !'S@@6OP.I2!20' )<F(_CTZX)36
M09:&AV?1NUO7!QA_+2@;0)"3 N25QW-RDV[0?EUXBBD7#ZD>?4AW)GRUQ/-0
M<ETV> 7&A<R#^[#XUD+#6R(;9L0+ZY^H(5/X6,7VXEI06O(C[V;S/G>"IR8(
MUF9?T;U>[6PM3D_#VE)4&V)!D6N(VW1N.G\HOW*0'M_&[Z2_7UPV1,6$NI7F
M!;[DS@XPC#Z6E2+M), ")D7VF/0C:YVM$O0" 7#3^6$9,/JYLSL+P(#3?N'?
M!@PBB7$.LB0/VM.UY%ND=/X<2*9+&=M.EIN-Q;OHU24*9F[DM^_RZ]"SNEC#
M-!"JAD;3YE*W'IV V%CZ6@P6>AG7[_<,-]S38>*1.AF3 W^VP+8[AN#5+"D)
M?84H=C,=]0[]"=X/IP9*E1)'0EQU_+RC %TT$N&!TN2YUA[CIMOB':C L.%7
M)6R4A6X\W_HGN; F^\V 0@$NT/.I];WZ'KA$%5,^%3E[RT?-HV$>KRQAV"-L
MNH*V-901,7B+V(B!)M%C ^14(0X  +L&UTVEY]8W&#G-UT@_K"#+,]Y,%F'P
M.UG%=.9."88\S4!+[#:"5RLJT@ ZI,A&\7'6P-N-#PSV>1Q>L$*0I*'!)"22
MVC&$Z-=VM$B!G..YC*H)-0$L1):;/:;O(EK6QS8YJ<R*#*#SV$8'B=.<327%
M)2TZ5&4ILE02DDDW!($R=]N/=/9SV#X1D<OS+R9J I'];/,II)L6Z$M^(!KX
M\]XE[19[-U@E-?E 4RBG2;?AF>D==.1>.9\S1CO-+'$U6*@..LJ4^ IT63V'
MAE0 ),&=A([\:.FFEE*ZLIEZ1I4J:'2$MNTAWTOKV$H$FM3IU:JQ4*B0YYB8
M2X8\MQ&HU<G6*,Q8[4O+J0[6M+*5N)W=DZ21(EK>#WL9V@D S%98!<&Y(=M_
M\1ECH3 ['!J=,.EE)<!HYF#Z,$B-/*3H:_9@J@\MP^\L 21*E.QWF[774=NU
MX'&:S=9R00I]0>7;J?FY.KF,:')9=* F4N022 7;TAH:-(?$9OI54OAANI8&
MI:4GS.0 2)@^$8F\6L 3Q2U%%2F8M+"SG8ML= 6M;2WY0A!+A[[=6#@3# !K
MM-\6GY+82AFJI=#C,)(),.^;8"#X(%M[6,SVC5\&I\J 6-@=()U))_/?KC)<
M17[RJ25IBP#B6C1^D[=(O4VALAL*<84L-  @K,"(M#9(V V$Q>X,W222H^%3
M&!:VD/=B]]3OBL( 'XDN Y$Z]>6?BVCXD7*[KU-ASQ14,Z %%(\Y*%$0"/((
M@3! D ")MQ)=V=*A)9FZWG4?;/B,:8)/B3#.Y5L'N&9]-#H,4VYYUVJLJ5+J
MVROS"5+<-R?]9$R #,G:\$F]9GU$.X5^$Z#<]09<-L+EL6>5IADI=(<I!_%T
M=O#'1AN)UI<</]XK]1J&3*[&7+D'8?=QO)_GUXS"DE=8EBS]&-VL>X^.AQI"
ML(HLZ0PU<2S#30::?.RF0<(134(>+C)4\4M_VL@&$Q'@Q^TJ]K09WG2\/ID)
MYF,F"-A+?B!$W'?N<UF5\RB.=,FWBMWY2#'J7VQ>GE?1)_13B&ZE@A28A/B3
MYM/=JXA4FWT,D\7!+-X5$-HP<>MM+.>UJNJP6_,&#0Z@-2]F@CX>I'F##Z=E
MM1#[,I3I!^\A2C$G^K@2;".X-B1P>B3;E(UTF[:_.6%YD12#RD$!X_:(NS2'
MB-!:()& != PDA2G6@.GF=N23*AY"DR!!'573?B<E;Z.>PMYD:[Z1)G U(&I
M$P\EC;MZ27!&^-&)U^'X#2JJZRLIP F6TE2]1CH!X0G>!\X@[%RE@)=22&<B
MP=^C@N( 'K9L-%,JNL'0RKYD!N_YX@=RJJ<\8L7G7DIPQATAM$OA"]),$CPR
MDWOJ["!O/$8DUE?A4)T8AO5R>^[D[E"  1SI"0;SXB;-!<])8/%\3;A& L4K
M+6EUA0"4R/O ;0(_J00( F_F%O7B2D%(Y0E47LY@29ON>K88HA4E8:#KU+6<
M= )=XLQ.6"A 0EUDD!6DPZ0 I, ?U?:!N8';A"A1_95IH/7OKUMA I#_ (@V
MEV+; #Y2PT; \NG14US%*NH:+JG4DI!=*7 W<W+=@E()/0P=I!XBJ"N8#E+.
M[D ,-KMIJ,2 ID$N+,[GUD7[[O9\*QA*7L0-3XS 4VI7AD^(?*0 H)^[M,$Q
M)%S!G8JF"0.53M?O?OIUL]FP$;\PON7!VM>VID]L/+U*W3MI4I]A*E)E1 <!
M,3<@H,S(,D#RQ';@(4[NDP2T#4WE[GO+Q&'!W/B#&]P\]4_+>1&!!=0XJH64
MU#*]2DM@+4LA!0J/^:F%#5$ Q$FQ@\I9L$J&HL'E@TV:?AAX0\\P$1?Y<K,;
MM$1A.TRJK07G%LH\ZB%I4Z83J-S*+R+@G:01%I8%,?PGS;\SA5  ,"D.^X$?
M[+'U'F'P4TM7AE.E@O5S#2VDE*4ZEPI94H3&@04Q!L8"9V/#N<V (UT# :,Y
MZ;W; 54R7 (=]C:"S\KL\^8&V/H'\AU!?([DRL$$+Y4\NU C8A64,'((]#,\
M?#/'/^6N+_\ Q3B'_FZV/HW(?YCDO^J9;_P48I#S=RTZKF/G'$J<)*7L:?<>
M04A4DH1*[Q!( !WMU%N+;)K_ ,EH)_N "6/4B#;<=(C&<S]/_*ZZH8U)</H-
M[/OT&(\;PIEK[Q-*E4))5 DSU('J?IZ[<2.=3,_GKB(PV$]!A91TM*Z5&$H)
MW2NQ  ,V-P+?.>\\)),GU^GWZ#"@"P 'WT_)\+$4+8)4P ILDA03&\GJ/RL)
M^O'28NUOW"[1CL->/90I<P4*V5-(\1*2MI4)D*$2 8FQZDSN(ZEP6475!;4Q
M#BX:WY/A%4S4!@ B!:>X(;[<.;Q;A^%_H92Z%]D*2%E"VUHA*A<3!%AV,]=S
MP5035!"F*2#!D$/;KY]F P%!-)0DA0,$!B-R&MJQM+6.(KYD<HSB++^/9>8"
M'D@N5%*VD0[$J,) C5^ZJ %$03?CR?VP]C$UQ4S_  RFE%9(*ZN70&349R5)
M$^(N&8.?PD!W'HOL[[3&ER93/**J9)2BJHDE!(\-W+:$:20"7&*J+:=8>6T\
MVIIUM>AQM8*5I4DPI*P1((,@VN.G'C"DJ0HI6DI4DD*2H,I)%P09!&HQZ0E0
M6 M)"DJ *2+$&0?,,W[\/+ &@FU@1%OQV!D"W:?GP5-A]_?WV U!C\?G]_#J
M4KJ@#/\ >9Z]A'7>+$>L#403'W]E]2]\$27 ]/3]V-C4"#&\V'K('I;;<V N
M>.'XA%R_2^G:?N_*_"?NTX<64$@F^PWW\NQ@BXV'>0>W&EX2'!) (#$:P_7^
M#6Q29^[#N^DZ=R]NNV,'G_!L+&XVZ$Q(F; 028]3-R+;,U#38@LWS$[>O348
M@TD<Y:>G4]>SWC#954#-2GQ$K4E84#)Z3,6Z7V)@W':3$5GZE-)+DCXCYQ]M
MB2,HA; B;"'/46=O6,;\-54H(IVB\X=@ LB2"=Q(!BX,28G@-+V@S"5<B5+(
M,,E:@QT8 Z[ %^IPZIPF@4N4H$"Z!YRUOXOAVK,K9PK*=:Z3"ZIU)!(5XBC
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M\U4J*42I0<EI<DB>CF\SI:,'?^;;#$P4T-/8 #4A,Q?K O\ G'YW-&F D )
MV@VTB8G<AR\8KJBAS$N7N7!^YL7E\(*KEI@[P!70TQ@1=H'I>?Y=?Y2!29G
M;2_J"W:?G@2@2S3J+2YGZ=/,X483D#":58T4U.BX^%*4]^I&_P"=C%P.%6"V
MP'FPAF&AAH&H=YP$(2DF._?T+O/[L%-3DC#G:96EEL^3L 9@@ 3Z#L)(^7 \
M%8$<W*P<V/Y[=Y.*I<U\J,X8T\ZRC2023 FUR/P,&_?O((JJ0SL'MZC[GUW
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M%,% N\P"P\HWG3;88I*RSSJF2=G'T :^\.]FUX!E2U0T4!06XD %*KRHR/B
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M3W5---*E<RRY (<I3!<1#D6VP;*)]X22A(9Y(9C?<M<7WB&P$L$.TJ' PWK
M22-"AY3I!C[R1<$V%R(N>*@)) +FUHB):-YDR-0SXF\Z1H[;/&VH'IB=,HU;
M>!8.UB+S3 A*EDE*M4$!)2?O 9W@$= .Q-[E4"E0"E$B>8DM8ST:/+N^(%51
M6LA*0SPSRV_B:#]'G$MY5QK*)IU/TKE&BH?7XCBJB XMU9E0!+@)TDVZV] >
M+3+5Z$<E6#!)(?4R2&86U:78XK*]*L5%Z;I%@ >KEGU$RY[@/@[>Q2A;:4XM
M^B80AM2W'=02$M@ ZI#EY@VW%CO(XF+4DH)]X0 Y)< ,)N W4/\ 7$5*3S!/
M+)+,Q+#S^9?9]Z(<T\V468<SN.4B*>IIZ9TT[#ZDJ6I2&C!(\\!&HG24B3)(
M,7XQ?$ZU.O6'(HJ ( 4"0S06<=MCC2Y)"J=)E("72X@R#(UZ'>#TB=^2V)CP
MZ=*&F5GPU)"0%3UD$>(8,%,3(N!WXMLD'ITF42.4"6+6M .Q9XMBOS9!YG"0
MRGL1>UM6MHQQ9-C0XRZ]4,,^[TZ@ZI*@L)+B9\)NZKB8DC8D1,D<6Q( $JL>
MO2 UCYV((UQ5E1=F!U#!WU>_GOZOABI5.U>,/5]:Q3A*$%;(1K"&T!*M*5(*
MP#!!.HF200$D">&*)2F%'J"S$OH&[;6?!A+0FW5]SK^^-FP+YBS&FIJDH#+1
M2ATI4#-@!I!3"P1*9!)DZ057MP$N3<];3Z@[?+!TA@_(G3J\QK)ZM=[896%.
M5#172M,N+*E!5.X="QI*KH4E42?*(5-],WX:4DN75Y'X6 %O7MA0KE_92 9,
M$ ]3JWTLV&ZKJEH=]W=;99J%D2PZIQ,H*2"I*UJ@D%,6&D*N;\#4\CF5?I(T
M^V\\%!29 3WE^WIUT'F&8S7N>"MAQ%,I#:B-)2M3B3)TH "]1DZAJV,DC:#R
M$S=5G![Z/TMZ[81:N5)\*2-BY?HS[D?48!15L4SPJ'&&/*I!4V4NRM)6$ I(
M=@*F9!2$^:QDIAA!)?F5?0P?A;#0O7D1U@BS&SGR_($GZ7_LZ%*O9\Y$J3=*
MN37+ I-[I.2<#(W).T;DGUX^(^-?\L<6_P#B>?\ _-5<?0>2_P SRG_5J'_A
M(Q77/V,OT6?,TMZRI",6>AI386F(2?*2X#MV C:+#BQRJ7RU'_ -6>>WU(Z2
M<9_.5"C-UQ_?V!T&I_*";Q@3J,;J5)74)/CTRAI=8\!(4P( !"@X"4@]=-I[
M7X/RBT!6FQWT[G=R\:1RMYDI[ ,8?5SII]2?&'5+5E)65(< F4)W%HLXJ"2?
MG8[\*H$D/?Z7>0D6ZM.F%<%(,O+Q?K<MK9W;#K4II5( 67$:@"DZ$P+VOKD7
M&_\ LAKDDW)9H)^R-6_>ZGET<=&MYOWTPUZT-2VMQ;K,Q)0#I!VOXFPZ[WO(
MCA3S$['RO#Z7,-8-$OA  -3\_F>WW?\ )9;;4'&G%+0HS!2% $SL?$V!/TZC
MCB8(($"\C0&S7+=(##'  /)]'U/6/+"MQBGJ6BT]J*#MY!,FXW6(-OQBT@'A
M 6F'>_4-L+&Q:3NQ+\0#%]W#?4X;WGFVE"D3K;0D #[L7 ['Q(_#\KR\?VA.
M\GZI?JSG2[#"!20H)((L;!CT$MT^VQ^J\-H\5I7*5\!;+J"AQ*FT*W$3!7N#
MU&_4[R)24U$E"TA84&Y52&(F+,1Y8(A10H*2I25 N"!(8OOKK^;''/KGCR47
MEFIJ,>P@/N8:\LNOLLTR%AF9)6V/'3'0+18;D=N/%?;/V/.274XED4DY=2BJ
MM12ES2YOQ5$LWA)=PP9W&/2/9SV@&82C)YH@54I"::B3XF/X5G132#)+-<C%
M8$(IALZ^>I_5T6CH1[UTZ_PX\T@$R00/[(G356KZ;6QM@2U@)&I+]_4PTX=$
M&G $.OFP_P"3HW^7O)G:XD7) D">+7(*'."YZ,-+[@FX+-ZXAYL!B0QU:7>S
MPP(TL",?BJG)/WKP,7 IV_42"*D?SB3Z3:YQE(DDQL"X<$2^[[QL^*_+GE6[
M :,#J6+&(@:7\YP?4P6TD//QN?N$&8!D6J1-[VG87MQ4LA0EQ>0F7<L_B]?E
MBS%1:;$6D%1&P$M8.?D-<:L(=IV,4I7?&?E+[:I\!%S,08J>HM8QV$\.R"A1
MSU)25*=-0'\*;#9U=?G.!YQ)JY6J" Q00SDZ6D6<>K,V.NG(_$&:S"Z$I=<D
MM-D^1()D)(D!T@&#, VVFU_H_AE3WF4I*$CE3KN _D)._K'C&<3RUJB9#$O
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M4>88*!YB.R1\05#N98OA+@='1^\.@.O'2\+^[-@0%#_WS D0)M':W$7.),.
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M4M2E43.HJ-Y,XC)^EOG<<5AJ54$J9+&22LF7<DN@O9X!+^>-/4RU-7*E)+
M,$@@ :?CB^Q8&<!6-YV>#JD4U?6H81( 11,20.LC$(^HC801,<1JN:S%G\-H
M60WERZM/GTQ,H\-RJ4NI)*R9\ =_6?JYQTJY+(;I.3#6-OU-3X=0QXBE*I&
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M>"WNT N]G]X_Q=O7$8E%#[T"FJK5P1_R)F9%K'](7F.I DP18S7DKYA"2/\
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M(Y:(47\0?\*G(F;1V=IC&-XBHKS"PZ?"6#K2-QHJP+[SO(Q/F5WDH#;276#
M2#^M4Q /?^L,=)$?A'&@2I)$.XNR2P?R[XK@CE)D$G^\DF+ZR-;>N)PP9EM>
M(88M533$I7KT"IIB;))L X>EIFQ), ;FILX;F)-P$GZCMYO+8:M)*2(:7\27
M\I;UZ:XB7FSBJWL3JFVW&U'640FI8L$R";N'8 R>I,Q?@ZE!(4P4X  '*>IB
M-G[::# Q3/*E+H!=4\R3),&3)T^9Q"%#AJGZDK=T2D%4!]DZX)O/B"?IN?E!
MB<H)*B% AYY5/8OMIKVZ8,JIX4TT*0Q =E(AHCQ ,&[,"TVQQRL70T#K.MM/
MB60/>:?4H=+%V^TDSM-K":[B&:%&@4#F!J0/"JVMV/W,8F93+%=1*B$LF?Q)
M9FZ:!X-_667+=$DI<J75,E2R;%^GDS/_ $L[JWDV,^O%3EV(*I'-8D%YN+.7
MVC\Y]>2$.D!(U4((#"'VGIN;$AI*(JKTJ*VBA)E(-33B2"8N78,GTB)MQ,HI
M>HG\421RJ:)9]R"_IKB*I) ,IL6/,ENFK>1PX8XBIK*FFH=5.AMIH+M4TZ5$
M08_M!<B#'6W0#@N?65J13 ( 3S$,H26AR!!;M!Z,F70Q))2Y+%E(D![,8+'8
MQ?#'AN'NIJ=4-!*%J2%&IIS,:N[AF+&)@GU-ZZFGE)<$;%CJ=2T:6+=M9+'=
M+$P0M)C1V.[0]^V&K'D+0M9):4H@$P^P9O%X<V)Z2.OU2LH!P0;1!()N+"S_
M "/08:BFHKDIU)\2>H@.=+7;R<"%*VX7TR6A*@#^L4\F]]G-[#Z6BQ'$5*@5
M@,078.#N#J(O;371I*DLDR+-<:" [[G^(,R9E^F<=<TI<9 :;4M(]X8D*@]2
MY(W(2!:1MWO<L04@2>40&40_I(MK.N*Q22[N'))_$D;:E5^NKDZ8DV@I7@RE
M&EH>(0H@OL#4;$)*@N4^4BQ,&T"83Q+20&_$XOX3J;LS&WYWP-:3+<I=F 4E
MK]P?L1,OI0&$Z$>[B4I(5[RP?,;DG[P#]X WV-QP\+8W4S[*$/L 6\NV!%!G
M\(<.Q4E].O=CU(+:#U94N^.4*73*!7"FQ4L01J"DJ2KQ(0B04Z2#< 3*R>'>
M\#D,= /"KLYAW^,-AI06+\O8+3-XE0/1_5L*VJA]M3;(;I%H +J5>^-(<"5
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M<.UOMYP7WBNPMUN!$<SOT'?$:9_>4V#KW#0-]YC>#T\O<]]MY+IHTS<"YL!
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M:1MUQ0YO_.J^HYS'EOYAMNV 6KHR8=:MJF8M&XCZ_P 1N.DA)(+&PO#LVOW
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M?,""4B^XWDQ;@],I#!PY+&_U!$-K&TSARBI*07 Y1O\ #O'K,V!H[SQP%E*
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M,@&XZ6OL-^&+K.D(!: XF&:2=-/C)QWNU"P8.0[^KSMYWZX8:QWQ%Z5$J&P
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MTI! TI&E*2D_$+"2%2DP/A"=_-+17%K!R+@#?S_=H&PI0-FC1M1>W7Y;8D'
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ML D3H Z=/3R&(Z2@&$(=)C^LD>2V^3=R!@;KJNEI*@%NA94%2&VGUUJB4+$
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MW[QK/PV$$8=:%*5I=;DZ3YI(M>?];O$_3AN'IGF3N'\_MGCSC##B= /%U(5
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M>V+$54(8<SD.W@  ??Q!SYC\W'31T:FZ>EJ704I"%*12).I9( L'R#^-R!
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MRF?K9"LBK26I)2IV22Q8@EV+:/.QWQSAQOE3BN3\8J**LI7',/>4I-/4Z%0
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M'!*10\%):'!&K/,W_=I@:POE/A,D$$ NX[6U-IP^\R:QS!\ 6P$N%U]HR0%
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M@8N%[+_-+!:.I:#>+4J6G7$D(\=N$K) F-=IO)$7'7JS+Y9-%!2EK0( CI+
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M*&&X!S!I' \FK9SEEMD8+C554J\!MA)QIZB&/L(94I(I,6IX$;)^E4:9*%U
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MTG%35R_(_*D@]=1,/J6=O@<:*7F8^G%*FC-2X2:=&(4R?& )\%T-5;:-294
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M4+L?=U"H,$"@;?3[\[3@Z%)J-RER9:0H=P0",0Z6$$VKJ:.OEK 23(W]T/\
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M44+91*;!_")(?8SZCI/GK!,(QC*@J<,J*%*/ 'G;14B#H(*B$4INLVD[:=[
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M%P@"K"E$&QCW8F 0#!O'YY#/5R4BB 0%*<ETRUG\701U:7&-+DZ+?K1425
M LM@X8W0'<0+"]C;10X8T&V_UNE)! ,BK!@&Q_T0Q$]AZ$'@%*F0!S)-A?EM
M:_-YWVVDZU $^-+FT+V;^S#SK?>'38Z66RQAZ:UD)64ONI*:PI $@)_T2VH@
MV)!M>XNS.5&Y:02992B"DM?PRKH21=FF8?EZ8/-5YT$AP"RM3>4Z7ZZ0<,;M
M/2MME2JUB8,>2L 2"3L/=YN>A["QF!%4R4RE3L-4Q+FRG;UZXD@$F%)+F85-
MH?D;MWPOR'A"*_-3+OO5*6</:-2J45FE) )20/=")N;R1M!._$K@],UN((7R
MJ*:"344/"[V!D@,[!@=+8%Q)0IY,H]XD*JJY!^.  Y<!)V+N 7+0,'N/8JPB
MIJ''*VF/F*@8JQ!/33[I)!!DD;D6$$S9YW-#WBU*2I@8_"&9M.:9^48J\OE>
M9*0%CR"VCJ4:=?R(B?&<<34N@IQ"F*$)5 TU6F]DS^JB+[=Y'47H,QG"I3)2
MI@(8I;X&)DMI&+G+Y,(2T3L%C:'(M\HP#OXND.+<56TX("B/+6A,7%II@3M$
M0;"#(CB JLIR2DVTY?65/T_/$\4$@!(4-K$^<!];STQ"^9'JFMJEU1Q!A3:R
M0A&BLA(O CW2\P#V/K?BKS-2JHE:0HB0WA\F/8VAOE:4*:$H"?"2 [L9M%AT
M^[B*FD3*JVGFUM-9U&Y/NGTBT1Z<5BEJ?Q EB-OJ0^C3VOB2W4?'\L;6VV2H
M174UDD#RUGS/_)+6_"(F>'I7/7HVW4WPD$L_G(WM#^GR.'^@4VRF/?J8:H/P
MUD DVM[I:3U)OMN9XGTEEA!!8!W3K NKYZR[XCU*8N"!JY!L+O&G4#;KA74K
M;"936TP)DD!%9!).Q_5;A0V/S^I2L@. J3,BYB/%:?0!I&%2D6"A#W"@-S^S
M^Z+X^OQ[('_[)?LNW!_\'7DG<3!_[VF6;B0#!W$@'N!MQX#G_P#/L[_UO,_^
M,O&M1^!&OA3/D,(\VLMKS%C!4C>L<DB9(@"?\#8#BRRJFHTAIRZMN;&.E_+%
M!FA_E%7_ !D_ ?*V!15&D"&]2=MQJ^>XO\R)X/S P6=S-AZ@QY._G@# W?Z>
MEC][8\!E;8LD*,W()!]1IG^^/QX5)2 1M-Q/:SVPK$V?T-M">F-J5)L%H4D]
MRF1_#\3\K7X<XW'T]<(4$Z?"?B\>7G./+C**AM:" ;0D7DJBVF+VGK';O'.#
MJ/(_?\<)R$!@#+N_8W])9MPV!M=$P[XC3C?@OH284@%(<3L"$P4A1M(B ;BT
MQT_$^DMW^SA"G\HB(C5_X=\)Q0U-.3H476]]"A"X,QH,D*/R-^@$<<XNX;Z]
M^[8X BQ<3#2TZZ]>FV-<.()4$J2/VD$$$';4G8BUB(CL+<<;.W<1T$^7DU\+
M+@@]Q$]7O'TQDFJ4F05$#:""1\B"#N/D?E/" OHPT8COIZMWQS[G74_=[XC[
MF2JBK,L8I1)46JYUCQ*5;1C14M_>-**0"N5$%N$CRI62I0&\#B%5 HU*3%51
M28%N4B4G?]S;S-R5)7OZ=9O A7BMX@8,]/S.D\[ZQW%/&=;J?'2ZE2D+(;4%
M:A*20D@BY)(MY3,$B_& S.:73*@7202&+N[6)@V[26QZID<A3K)0I(204@@"
M00SB+'7!CE'+IHVUY@K,;JZE+""XU@[#BV0IX@)0R]K&K25?UBD+  &D $D@
M='/4D4#7-8K6F/<\VN@4#^RY<W9@)T=F,CF*F9&33ETH0H\IS"D@I"1)4E@S
M@ @ L'>0':7:K"_TWAKV&8HRR^W6T98KJ5(*Z=;=2V6W&O\ 72$J*=1.XU""
M!P+-\;0NFNDI:5+*2E:$0 X)(N2+MJ2&<[ER7!C1KHK(2JF$5"JFM891Y2X)
M#2[<Q8,?/$(^QKS8H.8%)S#R?6NES'N4/-O/W*''O%(UU57DK&7:.@Q( $A:
M<9P%S"L37I3#5155%."2P2?*>-9S-<-XHG++*O<9JE1S>56Y)51KCF2#$<E1
M-2F38\CB^/5LIELMQ/APSU&F.>DNKELT@ -3S%!02HI, A:2FHD6":B4FQ5B
MYF/<NZA]+#^',E937M.>4&?=WDK!0%0(TK58:C*9$;SI.#<8J45(+EF9+&Y,
M2SW$&_F&QFN(\,RV;"Z:^5R"&+..4BVD$V8:R&.)5R'[-&)FEJW\8K$,46(X
M4IZC::6"^QB+#R7: O(4(2AQ*]+A1?0@!205#C=I1Q+-T^<+%%%3+U5(J!1Y
MTUD\II)(/*Z5ZFX B\^>YA?!LK7Y!3.9J4LU2IU I(Y%4%!0KE"YE # $,HE
MW(! GC".1.3\*]RJZ-#J:EO$&<3++SI<:;0[3I:Q*C" $ZJ:JJ5.582N?#><
M*4$-Z0DXX:NM2RZSF5^^*\O64EV *4I3F$#E+%"U@J!8<J@ Y%H(XLFDO,)3
ME:*::J5:B%) YBHK*LO5\4<]-#(9_$)+'#YFCE;D[-+ZJ!_!Z:CJ4TPJ,-Q6
MA3[O6452E2XTE)"7&9@J96E2"";)/F!<U31F,TO(+0E*5Y45J%5 92*G-RD*
MD!0+ M#S:^ 97-U<M21F@HK*:WNZM)7X5H(!!#,RA(!>-I+MM!RUK:7!$IJ'
M2O$*,:4I U!Y+=B=4V4M(*@(,;3Q6T>#9E&5J&H0*Z%***:6(4D'0];AY]<6
M.8XME*V:2*:2:%1(!68*2KI(8%GW(?28IS/A>,T_B>[T;CT V;U!>T7V  @_
M+BL17S%);<RJ922#)!?J" ()V\VN:ME<O50_(E85^%@X)CS!>[:3)Q N.,8^
MEQ?O&'.I&HG4L()$R?B2C4)$=;6WF>+_ "6=K+9-125I:"Z7F( TO8[:XR>>
MR%-!/*A21?\ "K33Q/?;>18X&O$?_:0H$6*2")/4&;_Q[1Q<)6"U@8L8L-Q]
MS<8HETB";C:+#KWOYO@8Q+$W:8DM^(F)$:5$$DP((^(7VZCH9$%"N5F(CN'N
M6L[[6:;X9R%K/=[@#0"X+]8\RV(,YH8!RTYO9=J\D<X,@94YC93K0MJJP+-V
M"4F,4@\5"F55%&JJ9748;6H0I09KZ!ZEK&#*FGT* (.BJ\AXZ)+@]W!#.^^
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M_ 7[!J4N4N"23.IZ?!M0=,*$)?JGV:6F;6\_4NML,,M@J6XZZH(;;0!NI2B
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MX^T'$O0C3K:0N"XXXI7E_M]PBCP:OD..<#J#)ISBET,W1RY2*-3,(3[U%<(
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M:W''7:E#CKKBSJ<<<6MDJ6M9,K4HDJ-S)D\6=,AF<-TZN\/IY-KJ<$(2S :
MQ&XB#YAX9[N<;U5;)!'AU$1-G6YM> /![?[HX(LJY7/:=7Z0UP7&!\J00P+
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MHU*/@>5"$A2W%'RI0E2C8$\)PZGF,[FJ&5R[+JYBHFFE( B74HW'*E(*E%F
M23IA,Q4I4*-2O4\**2"M9U+;1<E@+EV&+PY>Y=4&-O8;D-BLQ##\(PVB]XQ2
MLHA3NU(;*@IZKJ-;6A#V)52EMT+?AN/OK!#;2:5AQU'O7#>"BI[CA=.J:66R
MU+];40@%3$@JJK)(\5:H%<@8J)_"DH2<87,\5&3HU>(KIBIF*]4II4UK(2\@
M4Z;(/,FD@!557A2FQ65JY<?5S]E^BIL.]FGV>,/HO'-'0<C.4M%2&I4E52::
MER#E]ACWA2$-H4_X3:/%4E"$ES44H2( ^6^+H33XMQ2F@DHI\1SJ$E7XBE&9
MJI!/5@'ZX]*RJU5,MEZBF"ET*2U<KMS*II46>6<EGEL1!GQMQW.>8=2_*G$W
M0E)4-@$:1&JP[6'7ZS\M_F]+3]7>>L_,_P <4>:2^9K.8YS#ENA-MK?'#$RP
M!$!)BUU)DGL+B=_KL9X,)DVN!T>YW.VU[G @&8>5Q\QW^YP[LM:++(\VY"T6
M-@/VNGU&]N$43</Y@M%QT<&]HZ84;-)@;S\-.E\.+;24F!I,CX@M)/\ M^5A
MN8Z\ 6HD/(U9CK%Q;U>V")3H6+2&.Q.D6.^[8_+.LP"!! ,J3UD_O6FW;\.$
M3 GX _EWWO?#TR1H##P6.EMVN#WQBGR@ E,@W&I)ZGL3PK%W!,PS6ZL2/EY8
M(D$!RYN&$M-_A\<9!Q1) B9L)3?T].G7Z\(4IZAKEC_#NP],/2Q<C?L\78[]
M/F<;V]=U*( W(*D[QMOZ1^? E,'9VW8_E@R+22S^@Z?>F%(<0KR+TB3^\FT]
M=Q!_C_$19R0;FS'SEF]1ZXE)!_" _4@C?0M'GANJ$++FEJ%"9W3/83?KO:YO
MP,ER01LW7L^S!AV>,2 &%]NWEC%-,I0AP)_\XH%B )WL=]_R/ 3S\QY7 %A)
M[/8@; C#P$J@L 8+R#J>PTW[SC!6%ZTZ4G2#L$K3MZW/U@_7A4UZR8DRY!L?
M6[ZL9PQ65R]1W"7W!8WT(!/9]\4VY@>QS1YMS!4YB1CM4Y45U:Y65XJRV^XZ
MIYPK<#:E&$&^A";-MM@(;0$I 3EN*^SM#BE6I7JE7/4*E*YO$"I4NUQH!L(T
MQZ#[/>VN9X#1I9:G3IIHT0E-/W?,@A* +C]MRY42Q<DDESBS'*CV=^267LGU
M^&9OPZFQE.+8?783B>"8HZ[44K^'5K*Z.JIZJE96A%6:QAQQ*T:2V&W(@K\R
M<WE?8[V>X=F5YW-9*HNM3J)71/Z[D"DL4U$BFM*2H*'AL$D/)M?\;_E ]JO:
M&E2R.1S"!EC3'O2E%#G5S E=-1JA2DT@'"B96Z@_*2#+'LZ^S_AO*SE9@G+S
M'\SXOS+5E8U."8)F'-2$MXY290H*EYK)N!5+E-4K#C^!Y9.&4+]8%,N5M4V_
M5*IZ4.(IF;Q' N$<4.8S6?R5/,U:M7E K/ST*-,?J:--2% H0RC6 !YDJJJ2
M20D-ALUQKB.350HY*NO*T444J(ID*37K'PUZRN=#+)J(-,*((4BFE9=2E$SD
MQD/*S-+44R,.:<0\LK\5PERI9, )2Q4J)?:2B)0$KW)*BJ3+Z7LIP&EEZV73
MD::Z=515S+)J5J9*0 *58DU4!+.D!>IYN9R\2I[0\876IUE9NHE5-(3R)\-)
M8=S[RD/ LJ/XCR_X688K%S%RT]E',^"YE:65-X4]X&(O @&MRKB*RQ6..@QJ
M<PAY3>)*3!.FEJ$H0HOH''A_MEP)? .-9'BM,NG)5.7,5#R@YC@^94JE74H>
M%UY-9%=0@@45^[E8!]8]F.+(XWPC/<*6 %9JG[S+(/-_D_%\L/>T DN $YVF
ME66!=@:U,J(%)1P=TE,</KA7H *74AM\C3.B24FYO!,&.AVZ\6E/+JRF;.<2
M!RU$\E24RF"E5WB7C]K&?K5QG,K^C*40I!*Z8D390M,0-A$NV#4J&E+S9!;4
MD'<&%=OI:;7Z@<7^RDRA0<%TN/\ YF'6S7AYH6)*D*?F!U';U_>V^-+J]:29
M@7,@@=+1<3WZVGK<L67$=7\0^AGHV'TTE)(,S9O4F(^#%I9\#]4VIV4-!2W%
M'2E 25+4J; )3)4HVT@#_; JTU+6E" I:U%DH3*E$P E()4=F )(TQ8T%BF"
MI9"4@.5*+  "Y)@ #=@0/70CE=C6.*!JRUA5(JY6]#]2H'<MTK:DWBT/NM%)
M&RMN)V6]A>)\06%YHHX?04SFH/>9@B[IH)4 D]*BT$2Z;.9?M=D,@DIH!><K
M,6%,"G22K^]56"__ &:*@.XC KB'+7E]EW$U/OT@QZMI%I4EW&%-/T[50CS%
M3="E"*8E"KH+R'EH(!2H$2/1^ ^PO!>%BG7-%6;S#\R:V;(J!)WIT4@44MHI
M25K#D<XOC'<9]MN,\1"LNFLG*9<CE52RH*%+!NE=<DU"&(<)*4GE_",1SSHY
MST?+;(&9\X/@.M8#ACM0S3(<;;#K]FJ.F1*DI;\>I6TTE1\J N=DQQZK[-\#
M7QWC7#N#T2$*SN8%-51B?=TTA2ZM1@_,44T*4$B2T,3CROVL]H*?LS[.\7X_
MF![Q'#LJJLFGS!/OLPHII9>B5K+)]Y77305%PEW8Z^KOSCS[GGG;G56.9NQ?
MWVOQ?$C28=2&O8-#AB5N4U904=#2A\(9IU,>,P$@:GE%2WE*<6M9^WN%\(X7
M[,<(5E.&Y7W&7RF7J5:BA25[RLNG34JI5K5>5UU%E))59(9( 2 G'Y^YKB_&
M?;3V@3G^-9WW^8SV:H4@#6IFCE<OF<TK*#+Y6G[PBE3RZJB%)2E(*FYU<RU$
MGV*\U4J,'RO@N!8866F\%P/#<+HV0ZA""WA]$W3L-)*E@)!2T$IF$DP)X_)'
MBG&*V8XSGLVM3'-YW,YI;D2K,5EU52#+E:C=^^O[.<+X)0R_#,G00@^[RN5H
M99 "2P10I(I) #. R!!F,<W>8?-A.#UM33XPNHP1]EU2":]O33JTD@:*II2V
M8D2D.*1T.\S94LPJHE/C27,$$%_0W.K,3#M@5>AEZ+NEI%PIA:\:F-YU+XJ!
MS7]L?EEDC \P8)FC,M)7-8]A3E$]A6%UM)48NKQ0"A;=,V^C0DV5K><;;@$D
MF;Z#A?LQQGC9!R5!9HDL<Q5/)EQ+*YJDB#HD+() ;7&6XU[3<$X&#^EYJFFJ
M$A2:"&5F"2!R\M($*8Z$LD] ,40PSVQ^5F9\#>PW,S^,X748=C2U82ZJDI*I
M#^!-,M)I69H*EWPJM;J5J>2Z%)3(T+@D<:]?L+Q_)JIBG4RV;0:20H(J"F*2
MP2"D>]2@K2S,NZBWA)QB*/MW[.9Y-4U4YG)+355RFI3%3WU,@-4!I5%!).J"
MQ2 % D$XG[EVSAF?>7^,Y_P2I;J4XY6.HPZE=J:-JKH<-P]]=.Z]44R*E:V$
MN.MG0I>DK!!"9L<KFD9OAW%:F2SJ0A=/E<I)534I2 H!*N4.0E0);47F=92&
M1XCPFCG>'J*TU$J(YD\BPU12%**>93!120)D $/  XS58C@.!XIBGB)2JH=5
M1T1-6Q+CU@HH)=%HF8)F)F0.)X6DI)!!+1T.[ F_F/CBAJ4F6E)!@DJ=VU=^
MD,]S,7Q)W*_F_7Y<724==4A+JR%!"ZMC=1\I_KO*D $Q<$C@=1P 0"26<]9Z
M>H[,S812 LV# %C+EKOT#:XZ>9+YMIJ<-P^DJJMEMZMI4MT].\^REYQE]QM;
M]6X@N:D,A"/!I]83XA45 %"0HLIUUTB)8']D]2'+$B2Q$V<L,05TPLJY6@R0
MQ,.P^>K]+-8RF#=;3MO,+:6A29LZV8D=!JDB#%I&P/<W-.LFH@$,2-'E)$&T
M_G>(:*JF0[>AO^77$&\X<+KZO <2IZ"H8IJ]RDJD4%0Z6G6V*IQE:6'7&=:?
M%;:=*'%-%2=821J23/%A1Y JE44DD(6E2DI("E)!\0"BZ02+%B =VQ$)4!5I
MVYDE+]PP)'0L3Z/&/3&]I'VO_;.PO..*Y-QGFS696;IZW$L'?H,L-9<P%='B
M>&5+])5TR<1I&/TP-%0TM"2,0*BD(\Q-^/::W >#T!EJF7H\]#.4*=6A5JJJ
M+*A4IBH@RR7*3LUM\9RA5-05 M*?>T*BJ=4%0 '*2"6!9K$$_4$\P.8><.9&
M;*Q;V=L\YES74^+)7F3.%7C1"YF4C$<3J @3=(2 E(LD <>=<?RJLEF4@.D$
ME2 ' +%@R;):>Q]<:?(FFM!9*4PQ("1<NY8RYOOKAKH'':FC#973$Z8O6T8Z
M;?U]]I([@1/&LX1Q(9W("DHO4IHY%.)/*G8W#%YAB[WQ S-'W54D0"2H%XZ@
MWZL18=AA.RP^G4G72@!4$^^T>QFX/CV$ F=NMN(^3S)IBI242R5:BV@[V#!M
M=<=605<J@0' )F"-1M;?3N<;U4[Z@//3;2?UVB':)_6-MK?3KQ8&LX!)+::-
MM<]FVC7$;W9<)$F;D=XN!-Q-F</C'W=XV*Z8=R*VBN.W]?$WWFW3:.!^^22Q
ML-8LS?34@;/<O-)3:.;MK?>U[_#0*6V%IB7*:3T]]H[21_T\?GUWXETJB4L"
MJYM,=1TAWLV!$$O8#H0P/J&-@<*DLO@PE5,1'6MHQ\[E^P_#KWXE)J$A@2VQ
M23TLQNV."01*@+Z@_7[?$^<IL,J:)M^K6:9(?< !]\H[ITC>'SN8 M,WCOH.
M$@TDE<@J+?A,@C<#> >^*GB0YT\H8D,?Q)L'T)[CL/2RV')4A<>/3I, !!K*
M, DB9!#V]QL?7<@G5Y>N H,5#NE0:;?A&\:EFN3C-9BDI28Y2-^=+C>ZF&KA
MOE$JX+6(0V&G':;3H4 1649)*@D&4E_81%@)[WOI\OF4$!BH[,A5]_PM^;ZG
M%!7RRBHET0Y?WB&GNH#O9],,.*T2TN?%30%$R*VCLD](]XCI,P!)@6-CUJB2
M 3S--D*LIYD6O)U(P/+TJCK#HD""M!!(,.>8C4M=_FA>HDK82A:Z=/E*M9K*
M(S,D  O[#<F9!/6T0*Z4*00I*VN"4*_X8[/LYUQ+HA843S4X+_UE.#8_M3Z"
M-"^(]QC!W4(7X;E*XT0H ^^TD@$Q!^^'R$"]_3C-YE "5 <Q!) 9*B0SW#1W
M;ZG%YE:A,'E!O^-!D= 29V? Q^C5L-L!*V$E)48]]I DR09*?'%]Q,1L022#
MQ"8)33;G<.6Y%,Y(E@')@O>P86.+,**N=^60!^)),0PEKL=G)C"/$F5H>0M3
ME+<),>^4?6Y,^\"95.QN)(Z#@==0YP9+_P!U3SOX1\X?3#Z2"I)$ AP3S D.
M!U9@-X?S=JQS#W<4PMW[RG2MIO4@"LHPH@;Q+XDF"23] 1  ZS5:9$P/[*K6
M_LRS/L[Z8-02:-2.4\SO*5,[;EAL&VG%?*Q;[:U-@L@ D!2JRC!)DVO4;$=0
M#\SQ0K6Q9B):4F;BS-.TMY8MA1)<DI>[!20P\S;T/E.-!8*:9Q:U4Q*R;FMH
MY&HC:7]Y@7,=9.Y:5@@EC-G"F#3#CU$-T=AW*5+ '+#L.9.@??2/3O@1J67%
MK(2NFZS^NT=[DV_6!>/X;VXJ,S6!4P!!): 2'<R20-'WQ* (80PO(D-IU]?,
MOAL>IG;)UTND G_3:/KN?Z\FW]PW$\46=JN @EPD&R1<L3TV9XWN#B313<AI
M&JA9_HQ?R=GC]AF6,<S!6)H,'HDU]4OS>&S5T6EMM)\SK[JJA+3#*=UNO+;;
M3-U<4U'A^>XGF!ELAEZN8J$$LD$)2G_G%K4R::0+J4H"TN1@]6O1RU/WE:JA
M"1J5!R=$I#NHZ !],3_R_P G(RGB]+38<[AV9N8F*A>'X71TM=2.83@JZA*@
M_4+J2^GWI]AA+A??A%*PSXMW4$N<>E^R_L_1X+70KG&?XUF$FA2132HY7*^\
M_&I"R$FJL)!"JJ@*:4.R5 /C/\2K*SE!2\P?T/AE!0JU5*4D5Z_)^%'*Y"$*
M40 F5J4P\)8BV9IO\BL,>P:BQ6B>JM9KLQYA=JJ-53BV(+46E*8;-0VMELZ4
M4N%T\LMMTX*RVHBI=5Z<:B.&T?T:E4>HWO<YFE4U*J5:I+,@,"'A-(.E*4E1
M 8+5C&BDKBE=-:K1_5!J.3RJ%H"*--+E)6L$\S.5UE,I14X<.A ^HS[+3A=]
MF/V<W3,N<B.4+AE6HROE_EY1E04L*,GX@I4[ZC,GXYXJ>;BG$E?VL_G#-YS%
M0R^/9: Y:-%/]FE3$0(0! 8-Z#MB,\ZM%6<,P$#?$G2;':$ [7OU.WUXL,L.
M:A2<0$!AN0;G\N^*/,_YQ6_QG#0Q3*L8OL#T'2T[F#<_AZG4H)=YU;8?<M)^
M@0"6#?/U[87"F4/BV[;=KS/\OX\,-0Z CJ 2!WC#N7JDG0/?XCOK;&1/@I(W
M@6G_ %N@([?6-IX$64\M+GHQU!T[X5RDF')V>X'QDS.YPA\8 :1*E$DV!)O%
MR/I\N'=XPY*6,F+:F.WR'?&'BJ"KFP)D;SOW_P!G'8.G4"&+;SN7TAH;R>-X
M?0D$Q)(MTB9'^W\._ U*(+-]0WRN&W8V$X(@.T-NX^;L[^IOCRJJ41<@"/4^
MM[]-Y^0M8\"40$&Y,AM -_O\L&2X W#VC7RQJ56(%D[VO)O>3^9.U^G$=5C]
M_?3KB8AW.VOT^_W8S:JE)6#,@_QO8>GSOZ=HZU,()#"&F_EWLSVZXETTA36>
M=3<#7[ZC#TQ4H< "@/D23![6V^HZ_/@1JJCQD6MKUD'\L'%(%WGH-G]=K?'"
MKW=+IELE!@[7$P9/7\?\!4Y@V+*9[@ GMH[;B7+C8:Z*0[$@B&<&?N_TPB==
M?IE%#H@195P+>MK#<B_3@Z$I4Q3!LX>1:WP-OD, ?D)<3WAM[?'"4K0Z0L :
M@9!ZB#8?2U^_"&DX(4D$$R-Q+.]W'SM&")K*0RD+*5/=)(:=#H8$B<%.#9OQ
M#!*:JID(#Z*EUAWQ%+*76BU*7=  A2GFR&]2CY=*57/$<<-I@*32"J(6L+/(
M5!U:%]'# L"XT< X+F,_5K^[57*5JHH4A"E)2_(_, I@.8I+D$M)F^)CPS.>
M U.&:VJUH5"6=3M,\OPG&E" 0X7#"4)48*Y*3)()Z@KBME**BJBLE((0$A2D
MK(8  A+@$,2[D/.!TT#,50$K202'+@$""622"3)8"_3$8Y]QC#\S4J&Z1E2C
M0^\LU2W4E(6'4)0XTA"@%.,@@*#J@D+!\J=)GCR?VQS]#BZ*=%.5K4U9;WJ*
MYK(*.<54@+0A);GIND*%3P\XLD&3Z'[,Y/,<+K%=6JDC,"FNB*:DJY2A14E2
ME LFHQ*2A)41+EX'[+;J*_!J4+(6I# 87)!)73GP%$^JM&KUD&;\4_"5#,Y&
MBA;*6BE[E1-RNC^J<S!5R\[D75MA_$T*RV?K\L#WIJ(#,.6J!42!>$N4O>)<
MOAUHEK:6[1.$Z3)0#-AO:3^&YZSVF4"I!506?#^SI'PYK,]G@-?$+,)"DHKI
M8&.9GN/K%BWQPOP_#:K%*E5*PH)0WYG7ESI;23$@ @K5T2D&21<@7XLN'\-K
M\1KFC19"$35JK!Y::':PE2G9DCS($B+FLW2RE(5*CE2H2A/XE%GN8 #R3:8)
M@GU)38#EYO4I]CQ],.5#JDK>5,2$@ ^&G_40 (^*8GCT#(<,X?PM(]V$FL1X
M\Q4Y355J6+-32Y8(0PD/S%CC-UZ^>SY_"OW3NFD@$(&KEVYS_>4YB&M@>QSF
M5@6&T[Z:=;M34AM8:0VRL(\0IA!*U! T:B-13) F)-N+--:FI0 6EH<DBURP
M)#EOX-@)R.8"25(*2!:Y_(;Z]0,5/QK,514U#[SSBB75J<4>ZE'5$F\F]AM;
MIQ<)S=-@ I+    DEA8Z1#?+$(\.J.24$EWZ.9>-B>MF8VQ '.7+#7,_EWFK
M)+M4FD<QO#5M4E2Z2$,5U.XW54+K@!U*:35,M!X"_AE42=]+[*^TB?9WV@X7
MQD)%1.2S 76I@I*ET*B54:Z4O 7[JHLI/]KEZXR/MM[)*]JO9;C7L\:AH5.(
MY-5.C5*5!%',TJB,QEEK"024"O2IE:0'*7@QCUU.8.6<Q\O,SG#,P8=48-CF
M"8K0U:6ZE"DI<.'*<2S5T;I3X=52/)TEJH94MIQL$ Z@4I^Y>'<8X1[0\+_2
MN'9RCG,GFZ*D+--:24BJDBI2K(!YJ51(40JG4"5!K,03^<F;X/Q_V-XRK(<8
MX?F.'9_)5%*0*U-0I5"FLBI2K9>IR^[S% KI<].M3="K@OCM+2>T+E+F1RGP
M;F%AV)4SM-5X.PWC='XS?O&%8HTPE.(4-6TE96Q44=6'&U(,*4V&WF]3:T$_
MD=[=^S.?]E/:GBG!N(454ZF5SE5-%124IS&4744K*YBDI02%TZM'E4E0<.Z2
M>9) _;/^3OVBR/MA[,<*XYPZJBK0SV3I5E)21S4,R*:4YK+54AN1="L%TU).
M@"@"E22>.OM'>T^S5,8IA>#UJ<3IZ%M]QZI12IJ:JG8"BG1XZ1K*4K4E#2Z@
M%8*DI#@"AP_@V6.<KY?*T!S9BLM*$(Y@E+F7)L D.I3FP):SS?:"E2R%#,Y[
M-I-/*T$&K45REU !F2)<K40$A@"I0#@XXRXGE/,G,?,U5CSU'4NKQC$F*2G2
M$K4$N5#J*6CIRN+$)*/%<LVA16XXI#=^/HC)<4X9[,<)R^1K9RFDY6CS5 D*
M745462M:^1(41S+4>4&687?'RMQ7(9_VFXQF.((RM04\U5"*0)2BG3I( ITD
M&HIDEDI!6H N256+@NSQRFRGR9P;"L7YBYD4V]C%0NDP_!,KX6O&\5==:;+C
MBG3B-9E^@98:1(6_[X[!@-H=F /A/M)Q#VGS-;+< X>:ON$>\K9OB6;3D,JA
M)+ #]'H9^NM:I9 HI-G*6?$W^B?"N&4T5>,\4.7*W2C+\/R"^(9A2@Q(?,9C
MA^70D7*S747=D&!CH7[..2N5V#Y0KLX\J,_5>::?-F"G!,41B&'/X0O ZMMV
MFK*BEKL)=:+C>(4A/ARS4UE(^%K71U%0PI+ZO(_:GBGME4XQ5X7[0\#R?"49
M!1KY:I0S"LX<VFH5(16I9E!"%T5I02$JHTJJ5 )JHIGPGV?@W /8GA?!Z'$.
M!\<S_%J^>2*>9HUZ%/)IRR4)"U4UY;Q+IUA5*4%ZU1"T\_NUK )P6YDPBOS#
MB6'X=14HH,L8$RE%,:QT4[^*UT?>UE2$:EL,$E:DH"5NN;!*$WX'D%UZ@ Y%
M .!S*  5$J8EV<1#"YDXHN(JRU-U!04O9+D %X!>[P3&KLSG9@V$LY=JUXC2
MT*,QYD6?U6KK&2,*PLW"3149,U#J)&EZJU0?,EM,QQ?TZ:N4\Q=1@.X )MZ=
M;SWQG:RU+\/,:=,72#XE[NH@,YN ):2^)9R;1YK;Q+].5U945&(.N>(XX^M9
M3$B$(2D0E*$V2A*="0   D1P.IEGN);R/YGL-! =@J*A2D)01RI);>?.;7GN
M2V+^<L.8U:R&*?$7+ !!!(@%-O*3^)M)$]I Z?/16XZ.#;4$'0/O<-YX;4 4
M'9B7.A'5I$[B-+8E#.V+X;B^%>)3.)\4%.M%Y2"#/XWB(!CZ\765J\[@N(L9
M8].D,^C=SBLS"9) (@A4@ Z=1Y^NK^K9]MC[-S.6<+R-[1N5Z!NEH,P8\[E+
M.8I6=#2,TTU(O$L%Q9TH2$"HQO!45=*_ 'B/9=55.E=36.K7Z7P7C%:OP2OD
M*BRJMPE2,WE"H^+]%]X/>4@6<HH+(Y 2636Y  E"6HS12C.^\ #9I/)5&ZPD
MA"VLYLHQ^$.[EO7NS@&*^AP[%&8E]I*7PF+/(A*IW@[VO.XZ\$]JT(S?#LEQ
M&DR@KE"F$LL. 6>R@QT!-\3>&%5*O4H*)%VFS'3RGMH,!F'5)8>T3"5"QDV)
M&F_3??TF+\9/@^=5E<PE/,R*GA.P)U^G5]&Q:9NB*B"PD $.YLX&A^]\/&H!
MY22++ /RN;S])&]N-"I?)G:@!#5 % ]2]NFD]=1B!R\U$.)!([@6]0/E?&XJ
M('<W@V/7IMW["_2]I2JS >*]I>U[_F8;5\#2DEXD0; G;TU=K8UI61.HDS,;
M@B.NYM\[@]+QP!%6=^WRV(\^N'*0PN3V@CKC>@D]Y!C>#V^A/\9^7%A2620.
M@;279A^]XOB,H .(:Q[-<[09ZO@FP3#:C$ZRGIFTDJ=4 ;$P)N3'01WG^/%[
MDZ*ZJDI5<D21H^TRUX]'?$1:@@$]"SFYNVGG_#%L\M8&FAHJ>GTQI2!('4 $
MS8]C$_(=(VF5RX132-G VC68#=(UC&?S-?F40Y\[G]WG:T7=#B[8J7$A8&E1
M; %B=/E]+DCO/H3(X49AJBI9BS0>CD;0SQ#:G CEB4A300_29&FW:,'>#XPG
M2@*4000 3<JU?C! W,2/F+7>3S92QW+&Y,_(:BWPQ49K+.24B#<"+,VS= .K
M&2YDXKWQ*'&_.-/F@WU=H!)V @V%OQTB%"LAP>8%@9=]K/!M:+;8IOZE9*^8
M.0Q8@&X]79_7&#Z2*923!D:?*9B),R#$3I$&T23<B.K)YD*!L8?;6^@LYEP>
MN$I+!JDI+!R7(:2X;?\ :=]8 <!B#XDV0#$PJ!$RDV,F(D;B?D+GC-9A#$@/
MRO#ZF_=G\V.ADW>54Q8R;O8OH-B3ON3%L"]6!'Q09.F>I @ &;@7.P/IM-?4
M#"8-P[!VB&U_BY)#V](N7T(>#I=^Y?<MZX#L5>(6@$@*$!0)'>$R8B!TZ08Z
MW@5E,=7 TO8_0L/GIB?22):=7$,3]ZEW&,J2I2ZTII9CQ 4$22=*P1Y5=A(@
MF1 !FW'4U\P8@22%?)P^G4B<<I)2H%X#$!FD-!OMWDBV(U<R#F?-&8T8'E7!
M*W&,0?.I#%&T"AII1TE^JJ'"BGI*9*B Y553K+"%$:W!(!AIX?F\YF1E\GEZ
ME>J7/(@" X!4LEDTT#55124C53MB54SV5RN7]_FJR*-,02I0!4K1*4@%2U_W
M4I*KQKB]/+#V",,QO :X<Q,YU-'F2MHU(PF@RVJG7AV$5@<2":VIK*9:L3<0
M DN(;:HZ0)=TMOO:VZA&TR?L&@98JXEF:GZ1420$Y0I]WER0X)540374"&("
M::6=(*W"\8K.>VBTY@?H&70:*%#F7F@HU*S."$H0I(I"00>=1L2  4FE7/3V
M7N:')"KJ*G%Z!6.93#DT^:\(9<<HD-K<TLC&*=)==P=]9*$??K=HG'5I:IJ^
MI6=(\T]I?97C/!%FNM)SG#BHD9S+H444PYY1F:;<V7401)*Z14>5-92B -EP
M7VAX=Q9(134*&;(G+5E)"E&ZO=*!Y:@$DMRK !*J8$X&\N9%R#^AJ'',>QZK
MQ1]]@/NX10)%&RRX=F'JA154.J01"U-):!(4 0(47</]G^"U,O1SF=S>8S:Z
MM/WBLM1_4TD\P)2@UG544VK<H)<-B35SO$C6J4,OEZ=%"5,FM5/O%*&JA3 "
M0=$N201(.$6)YN8H&JC#,M4+.!X4] 734B(<J E.@+J:A:E5#ZB!,NNJ -P!
M<&<K,4,HA5')4*>4RY()I44!(41 4M4J63R@E2R9TO@]+*@J14S*SF*Z7:I4
M (2221R) "4[.G2 HZ3)R^P;%\GY47G"FPEVMS'F%HII:D!>C L%4"I*(T*4
M*O%C%0X 4!%$RP$NCQ7FCH^&4*^1R7\X)HJJ9K-I)14Y2?T3+N6@ _K*WXB'
M9*$IEUD8HL[6R_$\^,C5S*:66R9!72*@%9K,,00"X'NJ /([*>HI3ICF#,E/
M,W-#A.%Y:QS$4)JU!9PO"J^L0NKA("77*5EQL*:0I"4-J(2V#XJ4ZW%+6%-/
MBN;!51RF9K(]Y*J5&HM*JD..:FDIY@"D!+^$$%@27L2O@V0(35S63HJ]V&36
MS%%"Q2<ETBHI*B%$$E;$J(8DA( ^M#[*;54Q[+OLVL5K3C%:SR#Y.M5;+J2E
MUFJ;Y>9=14-.)))2XVZ%H6DDD*!!)(X^7.*)4CB?$4K!2M.?SB5I(8I4,Q4"
M@1H0001H<;BBI*J-)2"%(530I"A8I*04D="&(Z8%\VTTYHQM9)A5>X;$BYTQ
M^$C\/GQ-RZC[BF!'A >2;Z3MU%HTQ2YGE_2*A$GG):UAT[.US%I=H2D)@ R1
M:"?QM_C8=N"\NI!/5KQ!V [;G$<K)Z#[UOC9J/<_4G^1_P 'AP &Q#7<1Y'Y
M,3J)C",&O.S?7[MA*ZI*BI+@.G8'>_4F2#'3K]>&EB2;6:UNHL_YEF?!D(/*
M^AZM?0>OKZ8UFE2H H6?Q)_]*)'6>&ML _IUV.N'=&(/37R)W&FNF$+S"TFZ
MC !WGZCYV-K=.W'7?Y'[L<%2^_:YL==NHNT01AO6\6Q8W[7/X1_$;<!6!I:U
M]>H@D=[]FP\&"-^K;W)ANGQC"4N53A.A#ADDQ*A^?^!/46X:P( ,CX?#39^E
M\'2S";-(_/8;R>AQL9HJU=R%(VB3\KD$_..MNO 3JWV-,2T+2()%[3J.G9_S
MPZL8<^H)"EP)!F>H&YD]3OZ_/@2Z?,#H_P"[IJ)UO@R:J4EX-]]=+=^^ML/+
M-"EOS..GH=][;")W[_3KP+]'<R0?*?C@HS*KI9Q$^EHOI\GLM0^AFZ50!U)B
M3>X%I/>/J.ZIRQ,)YH+L&8BTEO.?G9%5RQ*V$N2[!MF_?A#78DPXV4FYCXI
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M,[D>=K;8K*[>_K1/.=9/Y7 Z]6PRB!8;D"^XWCKZW_Q'!P&C;SM'VV(Y<R;
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M"7PV*Q,N*DF$SL=A;M/^P\34Y)(%P#TL/*7C$)6>4Y ;N!UL]^MNF,5U"WK
MP-HV^?2W\=HX.C+H1( /E/:X8];/J6P&IF55 '46&@>=;-_'#;5OHIDE3IZ@
MZ;3/H3UZ_CUW.BFY#"T/W^?W;$:I5"0[N3NXAKO'3RP(XAB!J04A)2G8"?QW
M_NW/$RG2 :2YG:WKY0^_2(JJ5/'4R/+YL>T;89%!6XO%P-O]_P!>'&BH6(/2
MQ;O^[ 2IST!!$??SQ^;6J1J'61Z[;1'02)C\^&%"A!B[/J=6WMAR5.9[/ZMV
MNWG>)4A0485ML.\3M\^T<-!*2X@]FUT].F'D W#X\*; 3*52>UIV[#_'3KP_
MG))>UWU_)W,Z7PTH$L_3;"FCJZRE<2IA2T$$#4"0+6V&\S$=H/?@-?+Y;,H-
M.O3140I+%*TA0T[LVNL>9D9?,YC*K34HU%H6DABE1%MV(??N=,/3ZJ7%T^%B
M%15TZS +M$\AI1C]XK:< N!-IO;TP7&/Y/. <06:ARJD*))/N%^Z*G<M^$C6
MXF&.-QPSV[XSE:8I"NA>B360*FTB0Y9[QMC*ERSEEEUK]416:G$!QW$'EUJD
MH6I(6L-5"ELI*1YO(TFX@=.(^5]CO9_A04NAPC+KKA)(7F@K-+) )'+^DJJ(
M3>Z G#LS[3\=XBM-.OQ.L**EI!1EE)RZ6)#DF@*9(%V45=G$6ZJL*HF:)BCI
M6&:>BI64,TS-.A#;+3#:0&D-); 2E 0$@   S<3/&-XGED5'$(2@,E*$A"4I
M=P$I2P U# #<3B^R>86A8)4I2U%RI9*BI5CS%3J)ZDDZXC[%Z5EH$)A(%YM(
M)O/U,R>X]+T!6BBP#)$DB1J[W^/6TL-3E%JJN%$J<Q#MMT8';NVT0X_7,-I<
M;\0%Q$DR9M<P)D7$V$W@B\QR>*44D#WC$78@R3N.SVW@%L6@X34J)"Q3<$1'
M=@6D18:C=L09CN-I2M80I0 5)-B#<R(!F#,E1]>FUC0XHA3,IXN==KWT\SBO
MS'!ZB00P[2'CM\SVB\4YDS(6*52O$-Q'E5L($D7 %]R9O-N+)&<%1@\Q&C/#
M]AL)/?%35X>I#E2+:-V9GW_-R,4YSGGA"*VK2[5)(<&B'%R- !L5;"=( @@B
M>G6SRZP)!G4.-H,L+WW$:XI\Q0,I"(%B!+ZVMVZS)Q%1S(W6/NU*:AI*% )3
M<>9* $@3O=-P29VO!XGN2 0_DQB=P"2\7]<5U2FP8@P]]+ _=HM<X4MOT=>@
M@0LW*@0DF!NJ4D0#)/8]".'I23 DF7:XW/03BO4GE+783ZD:$A_@]\,%;2X;
MXOAH4V'#(U B4R1\0F; 6OO?@WO.34%3,02SZQ;\L,,B >H+.VNXWZ-UP_4V
M!X7E2C;Q3%6S78WB(C \!0DFI6%#RU3[7Q(;7N@K2)2 I727#,I2'4/$_A0#
M*MNPZSV+,8Y2:I**9(2G\:Y9V+@0Q(@%NHP2Y=Y7YFS'4C%,Q0V'2%LX<P0&
MF&[%*5& "H#XAM/PW'#1F Y-50<D  6&H:'?N1TM"*"4 !"01$Z\TCS.I9KA
MHM-C>1?T51A#=-I 094$#>"3,]KW$S'0C@PJTRP"I.X(_<;C %*+R"-G&CL/
MLMBOO,VO3A=*\P@PM.K:)V(B!*HM'K;8QP3#T%C+M\.C_&=_/%2,#P1_&LPB
MI*%K>?=2V!$E6I?P &0 /K> 3(DN"8),#Y_QWPM3,!-R& #DL0 !K\^F.K.0
M%-TV5<,P@J\^'TJ&G08)*S)600)(!4!)$RD@]."TZG*DI+!BX/G+XH*ZQ4JJ
M6-26/0S;]YQZ9_VNOL'YR]F3GQF/G9AM(UB?([G_ )TS'C> 8S04RV&LIYWQ
M=RJQ_'<@XTSJ<135*RNNQG+52A2:?%\%%2AA#=7@V)T[&U]G,RBI6K4E$/5R
M_(L&'Y4L%MJ"4WT42"]R<U!4RZ 'YZ/*#N0&"3N'#.+N'9FQQ<IVQ[TN=DK,
M6MOMO/\ CY<4^4I-G%!H145?1B9?8?1M<7%5;T4?X0\[AI[0>N%KQ!=C]U.T
MGKWVZ'I^1XL,Y5?,AOV$"&9OX;[R1B/2!"9N23ZW],803)G;>3^%SP)-7Q.I
MRXT%M;=&O&[#!,*6A(!.]X&Y-_7YB.O;B=ET\RWTCTB-H:V(E8CF8-$Z?>[^
M6)VY69%<Q.H:Q?$&2*-"OU="DG[U8@A>Q) FW>QC;CTCV>X4I;9BJ&!_"#H)
M)5O-^UP'?&>XCG4H!0@@JUZ1!.D38RSZ$8N7AM S3L-I"$A0TI0B+P+^:0('
M3H(Z 7X]"I4@E  8- 'F^L6T%SC&5ZIJ*)*C)G8OU&@VF>MH<YJYEAQ.$L.R
MI"I<"2("@=*4]C %K;@"-SQ1<8S0YO<@_A+J:9(+#H0&;2<7?"LN0@YA8E08
M$@_A%XZF#V)@-B&6:APK@+*=^L64+?3S;FY^<GBE"M0;??;2?+1L7)"0)TF9
M?1I[6&TL,$%)6N(+4J*BF\G82)B;VM$VW!&Q/!4JL))W_A\ST.N!J ?U'E,=
MO-X?7$N96S'I\)+JC.H  F2;&(U=#?O(MU/%WD<WR$!1U$Z?%HW G2Q#TV?R
M04%*2+@EMC$1$7%B[N['$X45535=$VXZL!BF5[R_J!GPDP5-B#J4IP@-BPTE
M16=.E1&SI9A%3+A9(Y4NI0:S!R&#N"Q'F6Z99=%=.L0!)\(;53L"[1+'ZNPQ
M+W+OFD:,5E3CSF&IP2E+CCR%8=1$L,H;C2PVTRUYD) #:7%%'B!I("BLJ3*R
MO$DFFM=7D"*;OX4ADAR(#$M8ZRVN(V9R"O>(IT14*Z@2 .9;E1)V?\0U8, 6
M +#$H97YC\K.:C2RUDO#7F/'JJ5BJQ?!\#?15/-N )4E*VGWFP '7&DJA*@D
M#Q%.+;0;')5N'\40JH,O3J)"RA)KT*2N8),D N0^Q%N^(F=R?$>$U?=+S*T5
M"A-0II5JB>7G#A)8@$@0IG#]'(>7^6O+3%Z=VG1DW":&B=JJA_5AJZ["-:DA
MJD4ZK]&/T::AQ3J$AM*PMIG2M++86X5KFGA/#^0I3ET)2I14I-%Z*5+-RH4E
M()8" 7;1G.(Z.+<1I5 O]*6M:4A(5533K$)'B"1[Y%3EDERDNH&28PU57LI<
MOZNE778#79CP*OI]:M**]O$*)]PI*I?:Q-E50I1)+P4S6,(6U @J*@NM5P+)
MIJ<])5:B7*O#4*Q),$5 LP=B"3!)#C%F/:CB'*:=>GE<PE20)I<BD@6(-)5,
M2X!)20 1R@$!H%Q[D_B.7ZEU/Z=;Q.FI:=YWQWF_T94*0V#J)9\1]D.@F-7C
MI2 0VRAL*(27^8:R4"L,T:R4),* IU P-F=)8$^)PP\*4A)#+_2"A4*J8R::
M"JBTLQ%9*@XB0E8_P\JG)YU+48(=@N9*&B?1[I4E04TM,*4& 2VX&TC1XI;3
MX9F$D>$T214*>64%,/+9[+H4$HJ704L1R!P0 D D ,W^%(_$5**2).:X?F2E
M2ETB_O$EPZE,H.25)',7.LJ7= 2 7L]DOF)2*!\:KAQ+U,K2'E J#Z T$Z7@
M75>(M.HK*_>77]2WO!82V@WM.NBH/"I)@<UQ^*U^6]@X!>XU.?JY:H@CP%W6
M [&4WL6_"02'(V)Q9'#\9PW.^$+PJL?0ZIVD6U2J4K6=;;D);B4I24J$$MJ2
M5.AQ2"6PD B2:53G0&8N7 VU/F+O%^L.H@@&((D"]BQ#VO:"V +$<IX9F+"U
MY(SAA=+B;;#3HP]=4AVGJJ6$J"%T5<@IKZ!X,RTE=,\E*&0AM0(22M<YE<KG
M4%=6DE:%.%!O$@J#*6A264@R3S I4^I>%RF;S.36#0JJIJ!!'B)0M*2X2M"G
M2L.SH4"F'V.*!9[]CS,F'U3^&\J<>+5%4(>=JL,QY;E/5UK[3JUK;J<<I4+1
M5);24BB154%#3ADZG%EY:WW<5G?8VLBFM7"<XE--8=="N5I75=14'KH"A4((
M9*5H2E( =9/,H;_A_MOEU+0>+Y-2JJ7",QEPE:*0Y1(H5.55,&ZU)J5%*+@)
M2D)2(+H\G\Z^7K%=29DY?YM<H&!K]]I<-J<9PQD:M1/Z0PL5N'I\0 .,+74#
M1N4H.A0H$9;C7#@NGF,GF?=@%RE)KT88DA5(KINT@\S.Y)2SC2U,SP+BYIKH
M9[*"KL5HHUE B 45>2J0+%(2YL2P(/U;?91=4_[+?LUO*0MM3W('DXZIMP%+
MC:G.7>7%E"P4-D+224J!0@A0(T)V'R;Q0D\3XB2""<]FR00Q!.8J00P8BQ#!
MCH+8]#I "E3 ((%- !%B D $28-[GO@+SJE*LTXY*BDBO=(($WA/K_*W$W+*
M:C3$'PV,M?T=YWQ39A+5ZEW*R7VL>OEH=K$#J*@L66LK3.Y$F+=9/6_>8^A3
M-H^/G]S=B,"$VC<-]SI?RMA5XX>2 E4#H($QTV-[7GI/?;OL_N\\+S<CL#,D
MCKUT[;CMC'4D" 22($P(_P#Q7X[!2H,  \"]L8ET*,:C?L(L.GQ?7;I/'8Y)
M#L SG;3UCXC5IQK)3$G5OV@C>#\0CTX["EBEY#,VXF]_F>N/R5I$#S$[2I(Z
M_P#G?W\(0_;R])!CSQP4($G1S_'&9(/I\D@?^EP@2!/G]LWI;!(W/H/SPFJJ
MMNG191*[0D#<Q?90_$R9].#TZ*JA<CPO)\X[;_+? JE5*=7-IT%M8[2V!QQ\
MN+"EJ629,1:(VC4#_&_0;<6=.D$@0 WKWLWP#ZXK:E8J=B[>0DGK;=_,XV(6
MD[%=N@0GK?\ >_E;@I!>]]S>-N5OG@ (-[PQF&>Y=_WGMA0*E"-B9VL.W7<_
M*YGT'",XA.NYF-.86-G=]9;"A>YW_9!Z:'S^1PU8E4-NB2I0@;:09/RU7/T[
M]CP:DEK"==_0?P$WP*JH%W,"UA.E]]>EV<# PHME<ZB!,SH!GO\ M>N_I8C@
M\LVAL_E8^4X$""G]IRX V=M'L?XRV-+ZVDV!.W[@C\0J+=/D>"4P3YV)TO:#
M<Z;M%L-46+%R3$WVF8_<<8,K23]X2 )@Z1,=/VQVZ[C?CEI42P A]>URS?9[
M81*N62\EK %C$!WCUGOAR:;:4 2I1'Q60+[;RK>=_EQ%6.4GN3^[:/K@R5!1
M+%B   1;6SO9NS85%AG3(4H$@Q*4V]!Y@>O8S_%I4[P&.\D%](@8XEBY4[,X
M C43+/Z6MC4TVD*,ZDVBZ1N.LZ^H[?SX3#G"@VA'2'$OU^QKCRM/AJ@$QO=(
M@&(CXI[[]OE"\Q(EB\Z>H@>>[GOCN8 B9%B?(WMMC8%A:;+6AQ-@=NW^M!$0
M#,QWX"NDE<<J6ZN^L6^7PP>E74DW,3M;J[@Z!VW#WQ(N#\T\7P?#T4%;1_I9
MIEL-4RO$%/5(;0(0@N*UMOI3$(UA"PD!)<4  G'<9]EAG!4J9.L,O46Y4BH@
MKIJ47<I(*2@D,_X@[D 6QJ>'<>ITC3&;0I: ?ZZD1[P" RT*(2H@/RETEF?F
M,F/L<YX,.OJIW\MY@IW!((+=&MLB3\#@JQJ3M>!/47CCR+B?LOQNE64A=3+(
M,\I*JR>8%V(!INWFXA\>K\*XGPA5$5$5:U4%B6I4R4DBQ:J0X(FX^.([Q'.?
MZ55-/A->DK@ />$DF?\ R;[DDB9BUK;<5%+V+XI44Z\[E4/JGWM0]F4*8;0R
M[R6>-*/:OAV60 G+9FJ0/VDTZ8.Q<&H0]MR&+G GB% NK07GE"CD2$N'6;#8
MPXE/2P_(20+6E[&9^DDD\4H "W-3J)<NY;QENEYQ%J>VN0J*8<+KJ)+JY5TU
M  %B?PC22X;YXB3-65ZW$V%,4=2"N")*5(09FY)(@"9M(@=>)V6]F>+)(Y,Q
MEZJ22Q"ZHZV-,L1K<=6Q!S/M'P=0//0KTC8A2*:Q$,Z5#=P\[XJ7G+D+F>LJ
M'G??&G0H^(DBI;2203*1K<;\PD@ZC%Q&W%[1X/QFB?ZBE4 MRUTN2VG,4R9N
M0V*.KQ+@E?\ #F*E)1T.7J0-262MQHX9P)&N(4Q/E/G3"U*31L5]1H*DE%.T
MFHOIU1#+[AND$P!,"20!9F:J9OA])>8SV6K9:A2'-5KJ(500'"0550>1(<@>
M(B"]CAM')9;/5$T<IF*.9K5733HI)%99#DI2A03440 2R03H'(.'#+8K\,K:
M?"Z[#<2J<0K4J;:;9I25MH0E1<?>0IU)0RU!\11%K $D@$.6]I>'52A-',4\
MPJH0E/N5I4QO,MR@-UD%KM!XA[+<2I"K6J4%9:G3!4OWU-:0089)#DE3P"SC
MJ,%V5LCU6#NU.8*]+F+9FK'5JPVAJ&DJPO 6"J6G'F_&(K:U(.I6L^$TJ E!
M4-1O*25UASD$J586"1)$6:UYD[8R.:$^Z3X4(#*6F%K5JQND.>L Q@\P+)2*
M>N>Q[&L0?Q3':DZG*I]L?<@Q]U3M>*4LMIF $ 0 ))N3.1EDI#W7_:58 Z=A
M\-]<1369 II3R(2PY08B')W:#NY<E\%U?G*BRFT''J[0X("4**=1L3! =]+#
MTZ]&5* "2HF0UM3\(Z7ZZ%4$U">8. TC>=8([>N&&H]H7#Z9@MUZDEAQ)3XB
MFT@W%B9<WDWL#?IOQ$_6(4'"BFZ9'DVKWU+]</710L?B(Z&1ZW^9Z&YK-S$S
M3A^8ZX.4%4IYE\RCPT(4(4?1X01-MIL1-N+*BKFI@F]M=.MCUP(I8,Y< @V%
MC$SI%M3OB0.5^1VJ-AO&ZI+B7%@^ZI6RF3JC4X0728-PD]"/F.)8(*9MJ\3]
M!V_=BFS=0%7(#8^(CX"XV#]\60RW5MTM8WYW AU804E";D$23][8E6__ %CW
M/ 3L]C%I_-_EV#07!=O)B'+3#$^8ZX/>;OLQ\K?:_P"0^?\ D5S<HJ^KR?FI
M&&52:_"7*>CQ_+F.895(KL)S)EVOJ&:QNBQ?"ZA"5-+>I:FEJZ5=7AF(4M7A
MM=5TCT[+9RIDZ].O28J0]R>525 I4E0$D$/8@A3*$C!4.RN4][2+,0^_H==O
M2&]LO['?VM_9+S;GW$\-Y:9ZYK\A\"QL-Y=YT9.R]2XS0UN!5E(S74E9FG+V
M!8MBF.Y/?PU-0<)QRKQK#J/ F\8I:A.'XI5T;]$^_?<-KT:]92_>4T5:BE*3
M24L A1+$ E@9+@AR1($'%BO,4_=)',?"EE @_LO#N!V )F+XYZ<P>6+V0*#
MG\5?J$UV,4HJ5TYI&PI@%*50H^]3^V!VM,6CB_XQPVCDLM3KI5SU5D"HM_"8
M=3.+6%RWJ\/)9VIF,PNFH<B0'0EI(,I<N6) >URP:,12A-,LB'JC_P#IV_\
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M8=#CZ%/LWXBG&/9WY"XLA!;1BG)?E;B*&U?$VFNR/@52E"H)ND.A)N;C<\?
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MAS+8WI2' )+9W AQOTO\5C_MZ'A'[^AQQ2[EP(ER/C+;'4F&9L>%( 'Q)_\
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M9G&A@D^>CP,6\Y<./TF7ZZIJ ELU(#;8+K5R0EE $."RBH 1^U-KCA%*9+[
M ".K #73;;$RD/#838/Y]H:9\\3]EVO4FMJZ$%M3+R7U+;*VU Z%MJ)4-6RC
M4$6!,@;;\#-0"HE+M<L'+M8OT>S'N8P=*3(!AR8[!GO'?5B2V.2'MN?95>QG
M[16)O8AF[E6K+.-KHZ_&J?-'*_&!DC%U5*ZNEI,48JZ5AFMRU7/%>(TN)4B\
M2R_5N&H;>;#G@K=;<OJ?&<Y5H)RM6N:U/PH0FJ2LI ?E*22XA/+>V@(<0:B3
ME:IK4F22.8P"&<\P+[D\P8BU\<-L9_HWM-4OXEC7+WVKZ6IR^_7OJP# \V<M
M(Q*FH-6IO#\<S/@><UTU1B-,D^'45M#E.D9J2D5#>'TJ5J89M^&9K)TJ@5F:
M-6HD-S)IJ 4+/RNSZV:-=2VOQ*M40Z$TTZ<W.3),^'E+:$2IH+S@)Q+[$;VK
M,A4IILF.\I\[8>P"X@9?SI4X?7UKD$CQ&LU8)@%*T\NWE57K;!('C<>G<.]K
MN 4$4Z*:>:RB!^(KH!8<W<T5K6SZ\FLQ(HJR,Q4*EKY:BK)*%I #C0*4E3F1
M81IH%_*S[(;VKN8-6\SGVGRUR7P*FJ54SU7F;&L.S#C%8EM2FW7<'P/*-=B;
M56A*@2ES$\9P5FH1]Y3//(4A1F<1]M^$44<N555SJU!VI(722 9\=2JE)!)(
M?E0L@.[,V(='*U2HE24I(EUJ#.)AB3S=6Y2T$O-T*?["+D=BF EG-/._FI5X
ME3JT/8I@5/DS+F%+=(A26L'Q#"\T5B25&VO&G?+ MOQCZ_MGFZRF1E,O2IMX
M4%=2HOJ2L"F"=O & 9W.+.E350YB%).I)3V9,J=Q)!#.#(N< .)?T>[DO5:C
M@GM$\R:$$$(&)8%E#%HN3Y_=E8*5QV!1;ZG@']**X_%E:1'0K U=W<VM/<7P
M85:C2:9M'*0V\^]/Q'EM&&/_ -'CJD,N*RC[5%*^\F5-4>8N5K3+2EB0D+Q#
M#.8+ZVPJ8*DX:X0?,$;#@J/:H?Z3)G_9K=MZ7=K#?'>]7JE"H(A?*]MRK4;M
MTP0Y/_H^.7ZC)B\.SO[16(X=S8Q158QE_%, RIA]9ROH,2+BAA.&8TW75[6:
M*S])Z6TKQ)I_!VZ:H?52L45:\S3IQ*EXE[>9S(9VER<)14X:LI2:YKGWQ61X
MDJ 9-$F>1T54J FHA2N43,NA-9*GJ!-0%DTPTC3Q.!J'("6#!M30_-'V,GMO
M<I1F;,6<\D93K\K9+JZBJJWLMYXP7%:K,^!T3CTXSEW#E.4M<YA;S;"'WT8J
MQ@V*L4+KJEX:*AAYAK7\$]K> \1SV1ROZ0NBK-5$I;,(]TE%12710JU2?=(4
MNH!3"PLT^8N%,03&SPS&7HUBFFHE*?"H$$,S%:1^-7*"5ADDND.!BJF,\LL^
MU-14/_H^C:\5Y9<4<;P=U(4M6I6DMUS@7$R4@I,KE/A@!/'K-3@_$JBE+%#E
MYCS'QI+\SMRL[LQ# 0\ "!F\OQ'A]!*4JJ\S#1)%@+FPEYEF'XC.(SSGAV*9
M=R;F!C$7Z )?<8I7$IQ&C.@N!\. J=?;;A29!4A,@Q,&RZG/TUY/)YG](4$)
M'A6X4D)<*YB5$)#=02TOH#<9+W.<XAE*M(.$4JE1WIRW*$NE"E&"JRCN 3#8
M^RTNI7@.9J1EUDKH,;HJE01B.'A"FJ^D+/EUU&F2O#0)FZ3(&Y$#V!SR5T,W
M30I2Q2S22%!*BE:5TTI'(X((_5W:?V=S&]L<L3F,K4(0 O+J0.8I!"D5%+<C
MF%@N0'+WQTBR67ET:7%KIPE13J2[74;RVTH\,L)"4O!.IQU8=*)LH1YB$:/:
M\G52M ++[%*HV<A+"']2QOCS:O24%$> LX#+0Q+ARX5\_IBQ65Z=QEI*5U#+
ME0E)TEVIH5N.MH&IQ:_"?3(\58"(U*!2DB6E:$R*BP;!3"_@6&+D)N)+">^\
MXB<BK.D"6'-3;NW,8L-.N!KFWA*S0FK:4TGQ:=Q)FIH0E;P00EM2#4^61HDM
MJ"2%*@I(XD92H#SI942!RK<:_P!GNSW. J06#%-V)]XAB"''XE: $3YG'(#F
M5B>9<.S;F"@I,2PUJF:Q&H4AMQ>":DIJ2:EKSZ_'(<;>#I6LJU+6@E<(0I'E
M'',WF:?%,]22H)2,S4('N4@\M0E8\7+S2%NY=S(L#CV3@&3RE;A?#ZRD*6I6
M6IA2A6JJ#TVIE@*BJ:0%4RD)2'#$<OB(,4(Q'':9Q;R\0HBXM2M4U6&$*45&
M"4*>T:57($02(5/FFC&86DNI1<N[H)$ZRGY0\XT9H4EI"2@<J0!"B"(L"% E
MK;M;3&MS',="BH5U(G63)%9AMC)42!X_E5=0"DZ3H4I /AE0+#FERQ4'<0DG
MX!)T?\R^%&5H,![L$"SJ(N(U\R)#@&" </.&9QS3AY:72XVBF6RE 0XS78:A
M2"A04V$:'D%"6U'4B5)\,@^'I!),FCQ+,TB%4LQ5IE@Q2%"QC]G0R@Z=-8M?
MA>1KQ5RU*HY*CS$ER0RB2Y_$  1^U',\8D=[G+S2Q>E%%7YWQ2IH5*5-,WCE
M)2L*&G0LK;I:EK7((;"%Z_(=RBW$RIQWBE<$5,[F% ACRCW14'=BJFA!5(U)
MZXK4^SO"*!YJ.1RZ5 NZ@:I!Z"JI7*XN0$@ECUP%XEB-740:RN;<=4HE*JC%
M*1;BED$K4%.5*E0  DF20 (F!-;6S:EEZBZA48YE\ZR2VY))AHEH?$VEET4H
MIH13$>% 2E+ GE#!@P,]29$S]9?V33/LK^S01L?9^Y-&Y"C?ESEO=0)!^8)!
MWD\?,?$O^4<^UOTW--_W]3&RI_U:/\"?D-HQ%/,"M\+..8DS=&)/ ;;D)C\#
M/2T3UXLLLE)R](D70/F?G_#%)F5*_2*H']HAO+[/S<8!',7<U0#$R!)Z=>T?
M0Q]>#<J ; //YDZ>N ^,C7N&\MCW+SH^N*L1<(!"K6ZR3/UVOPUQ+&^[?+EM
ML''0;KRFYTL _J[B3KOC8WBZTV4L&.F^WS(OW_APSD"CIZD.WWK^>'2##'N=
M7[&-OKA:WCC9LJ!]?Y?CTX?R?WAT:7^(GIA_,Q?E$#1[]M7GK886(Q9A<!2P
M!.\CM<?*?3KP]E,R6'K)VU^)P(KNX)\NFKMUTMA0*QE8)0H*4>\=#:!W,=_7
MIP=%(G\1!)>Q+1Z-Y"[3@*J@<\K;B!'F)O\ 8PD>7,K)D_/:8_/IT )GMQ.I
MH"0'_*=S].F^(E11T+O<B?@/LV&$J"3)F;6&T]1_CUX,0S=GLS?>^  N;,Q,
MD[!ODW1@=L:ZA,ID&]OY3U^GX=^%9G8NXZ6<;$MYZ=X:5 W#Q\=! %G/J9+#
M#1 F8C?K,]?[A/IPXMJSEX()/3L68.0Y9YPH)81#@N[!GE_B6T<86L$$">_R
MDB/\6C^]SP^TDC5K])^(PQV):'L#UM&L;OC2\D %5[=;3O>WY]@3TX:Q> 0T
M." \O'?:P,0TJ2G<ES8Z09>;?8)8X97JDZE(&P,6VC?_ !^!]%/-IJQ<$6V
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MXMI]+CYX82^W6XTD[3T&FNJYW$=*0"6EID$Z@5"?4F+R2!N3TO'#PA]V^]"
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M!A2UZ2!)CKQ19G(UZ!)J)Y1_:_$@_P"T /4L!ZM=96K3KH*<N0LW4 22'#M
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M",7Q)US6:O%GFT$@0AF@;;H2@0 +OT[[I-S+AC?BHX HUD9O,J))JYE20_\
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M;_;PX.&H$DZOQ/63.]CTOQW*2(+2YD GI<'H^P;#<>%"02"+#;O$W'>)X4)
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M.TRR5>9:H""3.DDCS&1)@3*2#,2"=^!*3</()8B_V>^$,N+>=MOW'IB3LO5
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M#SYY,Q40YA:G/1W9M-&TEXQ=Y=2?=(+GQ6?9U2+!KV)^>/7C^VS=I/\ +'E
MI[$6*52ZSF#3IIJA1;9?9>I\H//.%U12VTII;;:0I3K<^(H#6"4'V_\ D8KH
M2OC%-2T(34I9$\RRP/*K.CE)L'<$$D,'WBEXVA90DH0JH4U%*9#DA12@ \H?
MF L0Q()TA2>*;>7]-(EQYB%PM"5*.I90 E;#J'0H)J&5!8 TZE%6A)*BIU0^
MC$Y)T!12'8@3S%@ 4J"@0*B2#8.7"7?Q'&-5G_UQ0FIX202&"0"2H+24L336
MX<V\+F $ X.O.4M.LITI+* \E2W D-O)U7\B5%3@< U&;JTDD%4B+6!2A40
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M)!D'">OP2J2LJ;"DF"E('E42M1 *P-2P20D*( 6Z1I1+80I8ZN0J'Q()=B
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M;#;H@SUDV_#AI!_:#];.^L:  "W5V&"<R3>6L0XT#P)#:OU;8*D$$?$D6O\
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M?X6(<D/J (9WZZ_+>3BKM8K-?,%52K#L?QG"J1I#CB3X;VC4D2DDS%X&Z1
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M?%WF*^5SU(+RZA34TTU*II4I_$0DE3<Q!)8%*I<D @BBIT<UDJBD9@<X<D*
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M;/ WWBZ5+G-C*>&,X'A ]ZQ%UM**M]IM?A,6@T[)"5:B-E*L 9DD\,1E13!
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M"F#$" ?I_&['$>5/-/$&J52"PY55.HA:$,$D)"0 1#<&201U!VVLJEA@Y=C
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ML*4A#CT9&5I@E2U)(+FX!!<\R2"2"ZF(:8AR 52*E>MR\B::R1 =',( *%.
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MH4+*WG0K2:;#A3,#P@)(7I)"UD_57"34X5P[*<*0I*!E*":2E)O46IZE2HY
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MS_P>>0\@ _YF>5\A)D _Y$8'8$;@=#U%^/A'CG_+7&/_ (IQ#_S=;'T?DO\
M,LI_U7+WO_5(OCGOSD::/-C/RE%"E?Y0U9@I22+-V)*;_(DF/3BPRB0<M1T\
M%VN7^7I.^*3-J;-56;\6PF.M^NCZ'6,"4(6 $H$3LVB]O5,7M_O XGTZ;M.]
MS,6$ 6DP_P \0JE5G ,Q=NXW+"9V<X4E_P @"0G_ %B&TCT_=&\D&T$0!,'B
MPII8C0#R\[3U[Q.(=5<&>Q@S/?Z0[C&;52TWYG5(2D;DH;  $G]T?XFW$P(<
MP[L1!/K)/35K8@+4YN"/(R>XO.C_ $QX?S7A;(4TEUDJ (( ;F0.@TDD$=HW
M-Q/!4Y>H9EH(OYBX$=CUN#AAS"0X D.P<#X_(?&8CC&\ZUK[QI\,1J4J070V
MG2D&;CRP>LR#UWF>+++Y5"0%U"P@L\]B']0+VZ"!4KE1(3O!#:Z"/OHV,*#$
M&*5)JL:?:<?@G2XEN>EDIT=Y^4#<VXDDK40B@%)28</+[AVWD;/OB,R0.:HQ
M:6@EQWT?>2]Q@WP'F(W4N&FI6TM-)\H.A ) @7\MK7 @" ;[<(O(D!*EGF)T
M?SDZ^;;0)#T9LI"@D !VL'%FTZ$F//<AQ#&]2)44DG8%*(,]; D=?GP^E2#P
MDAGU-WE[#L;VL<,J55&2Q).P=IL6CRU.L8&3B14NX;,S^PV3]"1!]1;;TXD"
MFX@ZM=7V/NV!<Y>1#^?V.V,FJY2'-4) )D_=MB_>R=^&J0)!)?=S'Q^^^.]X
M7,">@AO(O:7$]HP\+Q5M;12=),7TI029D3\,?._3KMQ&50,@!W DF-[1IK^[
M!14 (<I\@#L]A\#&&VVL+\D$[Z&Q^(*8'^ 3W@J1RDI+OW5^?RCKB6"%,I+;
MD$![SN;_ +G?! *HJI?"3H@I ,(;/3U2+6ZCZ< ]UXG+Z %S9^YDS>!8]2E9
M;E@;. )[B=9F9O.$V$T?WQ<(1)48\C<?]:Z>VPVB0>G#UD -(L"7.MA?5^F]
MWPP N\&0T"9DQJ/,P=\%%2$A@P&[)V\-%^Y^'Y].]K6B!N;>; ^C3]?/!PHB
M"'EA @0W28UB"]L#3++]0Z0V@$$D? C8=9"3:3WF_6(XY:PD, 1K<Z,S3LUQ
M&F$2E2O1_P (GR8#[ZXD7 Z9-,E*G- (!).A!.X@S F!_NX@U%\Q9]'@P3!
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MEXXDF[7>POZ?NPVX@GQ4:@EN3:0RT>\ ^2\&/I)W'$BFIR4R[0"5 M&KG<_
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MX3*K7WSI^X($_P#):81;_P CL!Y9,0!)FPX$5<Y9U1,DP9G7L")'6V"!DAV
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MN^CNUC-I:9OV;I@=JZHMKA.U_0_QCY[7^?$NF@*2YN-P\3]WWZ8C$L[PVGS
M<RWW.&Y>)+4OPU7)B+>I$_,;;[<&%)(#AF<W,G\Q/>=!AA4H^0<= Y\IDM(U
M$XWJJ-393)GU((GN#OL#L+7^J!#*>&/QT8]NIQRE>%KG>&,W#7MM&LX!,:5^
ML)(@R"/SF3?UCTC@A#:>=Q(%OG?#-!]^?74>6&U8344;E,B%.) 6"0"04S
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M-BFXWAV[-VQE\K4.7JTUE@!!&Z502-]_(OBIN:\H./Y46Z[Y7&'"ELJF;&%
M&TG5('8"TC?-9_*<V5(46)@2Q'F>S]V8XNJ.; S0*#%W$.X=C,ABTC70&*Y8
MAEFL:1XJ4EQ W(OU-[2((GJ-^,+Q#@:JB>=!YB UWMU+/,]]=])0SX20%"#
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M[VGC0J2C+4W(#M #-&N_W&PICS557#&&D@#T#:N]]\2W4^[X!A2:1M]OWA2
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M.G028&I13"ALLE[3"HR:U,H>0H*!%V\5@+$V)&IQE\UP'D)52JI(!9E)+N)
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MNQ<]]1\0&#XETZ(0&2 $,Q$P'GF%@HD]B22TOAO0BI63Y2Y"BI*B%@D$SJ!
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M01(D$*N84G?BIS?]),M45^B\-743%^6JA6X* 06.I#$!B""QQ-H_H-5 Y\R
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MOLZ:;M+:[&WZ8!,,M2-Q]Y(O ))<D& (O>;GMQ4 .PM$,3VA_C$MAD$P!/\
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M1_J:6OZNG._A&*Q<Q_L[,L<P^9.<>9#W,K&\*K<X8U48U48<QEZ@JF*-RH"
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M5D*=-22"BHFNHE.A#&F((N'$L=,6?#N!#AREE.;J545!XJ:J:4CF#LH$*+$
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M*]IOPE^VSS'=3%BKD]E@*$;7&=B?GU/<;\31[?YL!CD*)_[=8W_U<R7_ (G
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M(;\*=;M-MA88*6OZ*GRN:0&T^V3S$A*0D3RFRT#I!) D9Q!L5$V(Z=1/!?\
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@I2"X2:BU+*08<#F9V#XOT)Y$)0[\J4I>S\H ?S;'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g90195g65f41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g65f41.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2/\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (^"^D80X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,S4Y
M.#DQ' (% "U-:6-R;W-O9G0@5V]R9" M(#DP,3DU7U-)1TA4(%,M,2!&24=5
M4D53+F1O8W@X0DE-!"4      !!;8TMFEL_,I9,4 0<C%H-W.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #=@
M!V0          0                         !              =D   #
M=@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M=@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   W8     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   $.$))300,     !ES     0   *    !+   !X   C*   !E7 !@  ?_8
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M45!1FU'F4@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML5IEV$->S#-3=I8S!8GDA4]TD49[_P!FS<=I[>5!/=W*,J3"1'959>QF4AP
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MX+V/_P E9_W6/Y0:'_#>H_RE2_WV/Y1=OO\ ESA_^,M-_P"-T_4^V_P7L?\
MY*S_ +K'\H-#_AO4?Y2I?[["[C;?(BJN=8?PG=?_ .):;_QNGZGVW^"]C_\
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M:8R!]S_#?M9O#N/M!N?N!3.O[S9)<[=AM6>T$W&)G[B40F/WS[ZCL #(+5\
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M!_Q.QW_R[3]>[O\ PSM?\HV_]]C^3G3W^ M-_DNC_N,?R4[7?T;8#_B=CO\
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M!KWFU[7N<@)KWEB)"0]TBVP;38U:TM.M?MP59^\RP16)(XG]5!%*2B,%!EB
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MJ(;+3.U:X;R&2I\+)%#(769!W"218XXQYE:,9:;D( /VB>'+* .8Q&0'[^6
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M,>0VF5!7V0X_OF%AVQ90;)J_+-QMF;+#]RB=U=U<MJ&)!!-CQ>(T=A1@W P
MM!<7-,)D0 PC;BD:Z<[2"IK]!L*,%*2J+L7ZRWT)?UJ6IW%<5(J6EJ3'N86(
M9;C6IZSRRSU(K<52:222O.1%.E9K>TWK;*U?CNQ:^@^JT-AH_1N;C46[KSS[
MVS!PJF"Q\!!2K6HXXX;TE.S>@BB@L0 ^C&\.^NU>QHV/.S_("QK?,3B:O"<.
MQS'\AS?/<VLPQT+-!Q#!L.J[S*\ADKQ50FREKJF42K'='/9$BQ2QO=YG3U]N
M^9!6C4I"H>>:62.O6@1CPK36)VCAB[C]E [@NWA03GITKQ1\=QX+'A54$LQ
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ML$EF:8J99K#!F[W8J&X 6-6+LJ!G<G)'$L0X5G*\ *';N"JO/"J.   #Q]2
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MOLGY)_HU%\F6<Z8QIC(CW-VBQ_<,"?SHH@[=8^(CFLX;*K&KY;2FL3EW0O\
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M.A<O[,CNVF./X_0_/[OZ_GY_',AAL)&?-55%[_5/Q_=S\NWXJNF4X]_N]\R
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MRN:WJX]G(O?3D?,?O'C^CV_J_'*GQ\^/Q/@^?J>?/O\ N]Q[<0GOKEPH@6
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M[5^6>M)'8JUVC]!T5DA5)Q.&?OP5^BJU6.%Z]YJVQK74NU=C3U>CI/&R5+-
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MLY'NA/\ D1T?_BQH?]%U<FG4<R5Y OB5_P""F;^L+93_ +:=O]2CH[_WZO\
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M.5%5\<-<9!!RB/-<B=6J_G\_Z\K[<@C\/?P.?O\ ES[?/D^3[@W@"X$.:^0
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MJA/'YY_JQG.JXQIC'MIC.MTL;&];GM:W_"<O2B<]DY5>..57MS[ZIR/Z_O\
M;W]L9SUL_P )-"0/?&<M>QZN1KD<K%Z7(B\JU>$7A4]T7A47O\M5QGUIC&F,
M:8QIC&F,:8QIC&F,^7-:]%:YK7-<G#FN1%1R*G"HJ*BHJ*G;A?EIC(ORO9O
M,OCD2QHQAR'HO!0#&"R-<J?M>6UJP=7/=7I$V1?\-/?5.///Y^1_/_KRS5C,
M/"-8C^:5A]M&6Q.7-!+3RID]U1C'22JU41.$5ZD/<O/W8=5QFH64;17V)'OC
M.IK&AL'-?*I%2D@["&H[AQ4P*QJ$>C7+PA-A6DHWJX:]O.GY_/Y_'*^./O\
M]7C\^WG,*YO@5:U[1;N!J*CWQ]-7:-1O*(B0R.DK#IWKPKW>II(&(BJV->S=
M,H?S^>3S^.?<%Y7S21C3NEKC)G+'&#:1.!(ED3GE@WG<0'JB(J]8$Q4:IW1Z
MIWTRO'_'Y<>_C\_AE]C1K515:B+S\T3G]WMW_P!??\F/P'O^\GS\O'^SGS^
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M*US%5JKRJ+SPY%=&].E['OC<URV,J2 ]Z@CV/CD<_0@^/;Y<_/GSSXRJ\T#
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MS<3"OM.O%1B+8HBLU$RL:)$;Y.4T=98R.:B(G$EA"*+:2.7CN]YSG*O=5YU
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MQ2QO>BK(>GJVOLOMAL:MBVD&FMV8$K65K2I/#) 1(K-7L@LL;2<!HV5?+,K
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M1[H6G#1DMB<]$:CG1ME1BN1J(Y6JJ(B+QKSNQ":]B>N6#&":6$L!P&,3LA8
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MWCV!)]_/OY^5T;!"X;C@H5\^" ?)XXY_G %?GR&Y'L,QN19)KH\MSG.BJ!V
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MA:Y>9;BW>D08+5_:5HS'(/\ A L$BHG':XN(D!(Y8\'C_G2-QX\<G@> ? \
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M&5-BG=5;#"2Z6:J*7CA.MTU0U5[)$G/">GZ?]+2_9CVU9XSP 9HOVD9]AR0
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M.YKY7UF3M%8(Q8V):E22-:FIO?T6["%I;?2\IWU!>6-,=J;NHO)^Q+2YYN!
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M/541JJO;4:V/Z0>D],[1W=[3$T?(>&NTEV1&!\K(E*.P8V'CE7[2..3G=H]
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M1MA^JXH7"2Z_9O8L7*E&IK8JD(V LV=79VHBL,][X5>:]69FD>:&* @),_\
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M>QLJM\#9SILD5O611Z:2"/6RTJFDZMIO++/Z%R>4Q]3M4JW(5M1SK\97LTY
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MHUK6HJN<Y5X1$1.ZJJ]D1.ZKV37T&2%!)( 'DD^!X\Y\D $D  DD\  <DGZ
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M&035G) =! 6+-+ R,B)S[WBEB[#)%)&)4$L1D1D$D;$A9(^X#O0E6 =>5)!
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MR_I<23)@N)183C@]&P\FV(<==7-I:%Q#P3V5YDMW8Y'?'J,(R,42,NYM3IX
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M;O\ 5]>.6I7U.P%ZN+=#94]OL4LQU;4,-J86Z]&]#KX;$EFC'\15D65;W/\
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M[*9U+6R9,N0V4;'<O8=/5ZNFMVHZMM+=&S/';DGM.:\8CVLFO5:4BZQ:.VB
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M(>M?86%,8PB"2.6$D>RIR@;(0F-\3%:0*7#,B)T=?0JM7)6M3U9EGA9>]%9
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+C3&-,8TQC3&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g90195g68f91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g68f91.jpg
M_]C_X1)_17AI9@  24DJ  @    ,   ! P !    - ,   $! P !    + 0
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ >
M    M    #(! @ 4    T@   &F'!  !    Z    " !   (  @ " " _ H
M$"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M,3HP-#HP.2 P,#HP,CHT,     0  ) '  0    P,C(Q : #  $   #__P
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 $@    !  $ 2     $  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #20    8
M     Q@   )@    "@!S '0 80!M '  -  S &X 90!W     0
M               !              )@   #&                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   #&     !29VAT;&]N9P   F
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    !.$))300,     !$5
M 0   'L   "@   !=   Z(   !#Y !@  ?_8_^T #$%D;V)E7T--  +_[@ .
M061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8
M$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .
M#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,
M# P,# P,# P,# S_P  1" "@ 'L# 2(  A$! Q$!_]T !  (_\0!/P   04!
M 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#
M! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84
MD:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E
M\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>W
MQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(C
MP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#
MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M+=Q_PKUT/U^S/7ZKBX(/Z/%J-[Q_+N/I5S_4IJL_[=6+A8]E_J,9#2[Z1G2
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ML:'6&XR+6P?@TMVC^UM1OV@R?H^<S^;'T$N(4KA-O__7N_XE_P"@=4_X^O\
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M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
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M(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1      ?_; (0
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MX4C_ $CGZ%CRQ_US[]U[K+[]U[KWOW7NN#R)&+N;#FW]387L!^??NO=1[RU
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MJ68V _VY_P  /J3[]UX"N.HX22>QD_;COQ&/JP_&H\$?ZWOW6^'#J2
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M\< #^1[.8/;;8(Z>-/<R'_3!?\ '0:NO>WF^6OTUK8PJ?Z!<_P#&B>@5SO\
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MZPRSI$+?J<_I0?4GZ?[#GW[K=">L(ADG(><V3^S"+@?\A?U]^Z]6@QQZE@
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M>5(R 3=F_2BB[-_K >_=>ZQA9I#=SXX_PBGUG^FIA]!_@/?NMXQZ]9E54%E
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M474Q  Y_U[<D#Z7/OW7NHMI*GZWCA_I_:?\ Z1/OW6\=2E14&E0% _ _WO\
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M&IT@EW_U" LW^\<#W[K=#CK@/N9/KI@7_8/(01^>=*^_=>]>NUIH@=3 R/\
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MW,D;OIX#TZ+=PBM89E16K4YKU__7TH/>4_01ZZ/T/^L?]Z]^'7NOKR_R%O\
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MW[KW718*"6( 'U)-A[]U[J)=ZDD"Z0#ZM]&E_P!;^@]^ZWP^WJ4JA5"J
M /\ #W[K77+W[KW6*29(P+W+']*BY9O]8>_=>IUPCB8OYI3=S^A?[,:G\ ?E
MO\??NMD^0X=2/?NM==$@ DFP N3_ $'OW7NHUC4\FZP@@@<@RV_K]"%]^ZWP
MZE 6X' 'OW6NO7_WCD^_=>ZC$M.=*FT(-F;\N1^%O_9/]??NM\,]2 H4
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M?S'GTLL4@=VK="&W!(:4_&WR \OE3CT.F6[_ .E.K:!</U;@:7+U\*"%JF&
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M_=:ZS>_=>ZZ9E4%F( '))]^Z]U&"M4'4]Q"/TI]/)_M3?FW]![]U[J4!;@<
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M;1T&%HH-2T. VWC$9J+"X+#0MXZ.B@ BIU%SKE9W,_1I9;39Q;9M4"Q6T8H
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MUDC^D296HI4X^9ZC>[CD^ID@D4EQ(,YX <>@)R6YHZJI@Q4-TCA+5$S&Y L
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M];'\>_=;)K3K/[]UKKWOW7NNF8*"6-A_C_OOS[]U[C@=1/74W',<(N/]J?\
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MD1?T/^U^_57^(=>\&;_?3?L/7U[OY"W_ &YV_E]?^*^X'_W;9KWCOS0ROO\
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MZV!7[.NHX3J\DQ#R<6_HG^"_CCW[K5:<.I'OW7NO>_=>ZXLP0%F( '))-O\
M?'W[KW44:ZDW8%(0>!R&D_Q/]![]U8T ^?4M550%4  ?0#W[JO7?OW7NNB0
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MAN?/_/T)N7^6Y]UN(YKWML?(GS^712L5MO.;WD.X=X5,[MYF$4<C/I5&!:S
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MDD_U/OW7B:]9/?NM=8I9!& !8NW"+SR?]AS8>_=>ZZBB*W=^97Y8_@?[2O\
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M_P"*>_=>ZQ1Q,[":;]7U5/P@_ L?S[]U[J5[]U[KWOW7NN+NJ*68V _WUO\
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M8_U)]^ZV<GK+[]UKKB[K&I9C8#_;DGZ #ZDGW[KW6&)"Q$T@]1'H4_V%)O\
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MV:TF"O(-4C_[[C!R6/\ )?4]6_5.,Q51)_"=H4K4G7VVI$QZO&NE\_E*<!3
M7 M-"K#6["X(X'U]G4<LT:+)>.#N4HJ!Y1H?EY'R \N/0>EA@D<P[=&1M$+:
M2?.5QY$^><D\/+JO'YF?)!H'AZKV/6B:KD44F[LA1MKCIYHF(7"Q2(=*^!"#
M+;B_I_LGVBO+P[?'X$6;N3B>)13_ ,_-_@^WI=M]A^]91<W&+&+('E(P^7FJ
M_L+?+HBV+Q^)BQ KJ^G%56I(4F96M40,_JCD4D%3KY(N#<BWM%#' +822)5Z
MFOJ.C&ZN+DW9@@ET1XIZ>E/^*X=,Z0Y6@KXLC3R_<T4S%8[*QBD0FTE/4PF]
MG9/2RG\&XX]IM,\,JRHQ,1./L]#TL+6D\+02T68<?D1^)3]O0IIMT08^/(TD
M4CXFN91/3"[RXRK%F9%8\ZHQZHVXUIP?9V+6D0FC'Z#>7FIZ#/UI>X:"1O\
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M^ZUUTQ"@L38 7)]^Z]U@0&4B5ULHYB3ZG^HD/^U'\>_=>ZD>_=>ZZ) !)(
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M:NP($--I/ZQ[$W*VQOS#O-MMN? !U2GS$:D:J?-JA5^9^70+Y[YICY1Y<O\
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M0/?NO==0Q: 2WJD<ZG;Z\_T'^"_CW[KW6;W[KW6&:0H J"\DATK_ (?[4?\
M!??NMTXGKE%&(UTWN3RS'ZLQ^I_V)]^ZUUD]^Z]U$F9I6-/&=-Q^ZXYTJ>"H
M_P!J(]^Z]UE*K%&J(+*!_O0OS^3<^_4KCK3?">FF9S<F_%K_ -+6!(_WCW=Z
M"B^0Z;(I0]);)U;JW@I_54/R+FZ1(P_SKVOR+7 ]J$4T /#JC-IH >X]$0^?
M?R-7XJ?&'?F_,35HG8FYPG775@D:]14]@[MAGIZ7)Q1\,T>V,:)\@Q'"-#'?
M]0]BOD_8SS#OME8LM;13KEI_OM/+[6-%SZD] +W$YG7E#E;<MT5P+XCPH/\
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MN"L6>C%<C".H@=DD7ZE9D]6D D61RMQ^+&WL?VT>AC$1VGJ+;J0N@DK1QQZ
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M?_B%O] /?NO=9O?NO=>]^Z]U%D+3-XHR506+R+]#_M"GZ7/OW6^'4A5"*%4
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M=U-Q(PB"*8U/Y_9T(+Y Y&2))<@PA=UA@@=&*A2UF9E/I'LT\77H#2]I-.B
M0F$.1'0C)('^'H^W2O5SKC*?+TN8QZ-&D=0E*E2M+6322"\:(K>-2S!;Z0Q)
M'X]BNW6/;X8TTL=8X@5 ^WTZ!DYFW*=Y=:KX9P-0#?8*]#U5S)1TU1+DXC'D
M(8V\572*L%>E1]$::FNL-8B&Q;39^/K[?4%V'A-^F3P.1^1XC_!TV[!$=I5I
M(!@KAJ^I%,T_;U,ZKQ64R>1DBEDCRJ5,S,,E3$EH2;LWWM.]I8'%K>L?[$CV
MSNL\<$&IFTLOD?\ )THV2"6YN OQ*U"&&2#YU'$=&]PNUL9C9(*B" 1UT;QM
M]W'Z7:Q!-U T^K^OU/L#W-]/,KJS?ID<.I%L]NMX9$D5/UAFHQ4])3LOHRDW
MZGWN,D^VKI6=Y4B<Q2:FNS%!J ECN;\68?X^U>V<P&P4PS@F+@/^+Z2;WRJN
MXNL]H0)N-/.OV?ZCT67)]8=E]:R)/ F0FI(SS,@GEIYHS:ZOP5*6X*M[%EMN
MFU;BN@.I;T)S_J^8Z EWLF^;,YD,;A0?($@_(])#+;$PG8T<LL5$F(W/8^6.
MG0(]1,H!+0Q>E*Q6^ICXE7FQ;Z>W)J0:?&.J'R?S'I7_ %4/3,2?4DF$:+@<
M4\C]@\_LX] TV/WEL3(/A:^F7)40D!..JU:6DG!L$DI&;2]/(5-[II<$<^WH
MA)16C;6A\P:'I).JJS13(%D'$'@?G]G^H]"'2]=;=['I2M"TVW\\J7^UR*E8
MIF X45:J$?D<,P4V^O\ 7W2Z<(H::&L1_$O$?EY]/6</CG1;2Z9O)6KI/V-P
M_;CH*M_=6;AVSBA!EH(\I D\Z/ C RJB ,L\7UD5HP?2RW!'UX]L.D4\#"-C
M(@R1Z?[(_P"+Z<3Q[.Y4RJ(I,C' _(_(_P#%=%[Q>':@R!J<-.DT;ZHJO'2L
M(IY:>0Z98I(2=$I8?0J;WYL/95! 8Y@]N:@BA4X)!X@UX_+HYGNEEMS'<QZ3
MQ5UR-0X$$</G\NG":@HHI:W;N4*KC:PO44OG4L<?4V!BJH66SQ,FK3+IL2/Z
MV]N&&-3+9S$>$V17\)\B#_A]1TVLT[1QWL"_K(*-0_$H\CZ@\1Y@] AFXGV[
MDGIJH2QRTTR24T\3:_+XCY(I()0 K_U7Z$^P]<$VLICD4@@U!'^2G0LLE%]!
MXL)4JRT(/^ @_G4\*]"3M7L2#<F9BE$02L%X:V!6T3SQ.%#U,=N)FX!DB^H(
MU+Q<>S:RW1;J<,!1^!IY_P!+YGU^?#HAW/8GL+9@7K$3536H'R/I\J>7'H2:
M//Y;9^Y9L:T[K!4RK5XZ=F.AV:TT+ ?I:&=#H8?@V_I[-%N9;.Z:W8]C96O^
MKSX=$S6D-[8K=P_VJ"CTXBG^;HW&$R.%[1QK12O%C\S-#'$]03H'WD5C3M*3
M9@?*.&_ :Q]F <)$)(P6AXD>8Z+PHN)-$NE)R,'R/ITD(*?,8+*3X^OAD@R-
M,\D,VH:5K8U)&F;BS3:?TM_:'U]K(R)%!#!D([3_ *O/HOD#Q2,I!6130CHQ
MW4O9N1V7G\3D8)Y#1RNL4\>L\TY8+*CC_6^G'X]DN][1#N=I<0N@+4J#\_+H
M4<N;_<;-N%M=Q2'145H>(\^K9,5-C-\8NDR\,R&LACBD2HCL?N8A8JSV))<#
MCCCGW ]S]1L]P]LXK;L2*'\)/64EE]%S+9PWJ-2[C R/Q#Y_/KNDR5/4O48#
M)LJ154CQP2R?[HJ2&"%F/T2<64C^OOTUM)$(MPMAE!4CU7S_ -YXCJMO?13&
M?:+X@)(2%)_"WE^3#!Z*;VM)4X"KBKU1A48JHDH:R,_2:E8MH67B[(\19?<A
M['HO(O#U=DBZ@?0\<?GY=0_S,KV$WBE2'B8HP/F!6@/RH<=$G[.<8VJJ:B@(
M..R].M13E6%AK!D6,@>E7C?5&WY!_P!?V/\ ;"7A E'ZL9H?R_U8ZBW>:12L
MT)_2D%13Y_Y1Y]$OW)FGE2LI]9=9+NB\'1(MRMA^"WT/^O[W=SMWCB.DMK#1
MHR!GI![:S219-*21M*UD4JGGT^212J6 X'((_P ?9;:7 \4(< CHXO[,B%Y@
M:Z:?L_XOH.,3.V/W=*/T>"N64:B "8)3J_Y*0FY/LJB)CO?F&_R]'MPGB[<U
M.#1_X1T9;:=)!#G<M#]%8R3H#P#'+(E3&R\<E0W^M[%EFH6>8?ZOET!KMV:"
M$MQI3]G_ !77_]!(^^I'7%?KWOW7NO>_=>ZGXC_B][?_ /#CV[^+_P#+[H+?
M[&_MN?\ W'NO^:3_ /'&Z>M_]RK/_FO%_P!7%Z^@;'#J82R^I]*:5/Z4]*_C
MZ:M0]\N_MX]=HS3%.I7OW6NO>_=>Z][]U[K#-,L0'!9VX5!R3_B;?0>_=; K
MBO7"*$FTDWJ<\A2!I3ZVXM]0#_L/?NO?+J3[]UKKWOW7NO>_=>ZBO*TC&*'F
MP]<G]E>;6!MR??NM\,GK-'$D2Z5'UY)/))_Q/OW7B234]9/?NM=>]^Z]UAEE
M\8L '=N%0'D_XG\V]^ZV!7SZXQ0E29)#JE;ZG\*/Z+^/?NO=2/?NM=>]^Z]U
MAEE$=@!J=OTJ/S_B?R!?W[KW74,3+=Y#JD<W)_U(X](_UO?NMFGEUG]^ZUU[
MW[KW4:5W=O#'Q<7>3\(/Z V(U'W[K8]>LT<:QJ$06 _VY_Q/^)]^ZT34D]<_
M?NO=<))%C4LU[#\#DD_@ ?DGW[KW''6.)"6,TGZF T+;_-K]=/\ K_U]^ZV>
ML_OW6NNB0!<D #ZD\ ?['W[KW491]PXD8'Q)_FU-QJ;C]PC\@?CW[K?V=2O?
MNM=>)MR> .23^/?NO=14'G<2L/VT)\2G^TPX\A'^]>_=>ZE>_=>ZXNP12Q_
M_P!N?P/]<^_=>ZPPH26F<>N3Z#D%(_PO^O\ U]^Z]UG)M_OO\1_Q7W[K1-!7
MIBR%3XU"@:W)M'$HY=_Q<?T!_P /;J*M*GSZ:QQZ87C\>IY#JGEOY'!O^0=
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M<@M48[*N%"2E 2/3R-0],J?X\>QM%:(EM' #D $ _P P?\GV=1U)?2/<RW+
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MEK9]H _QAD$LGJ7?NH?VT_VO6$F^;M_6;G3F3?\ 56T24P0^GAQ=M1]M"?\
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ML3N'"U-"&DNM732%EC8VO410M<1,?J=!LW]/='F\.33XFD_,5!_/KT42/'F
M%/D>'V#UZ5E3NZ"*BIF3))F,2MDH,A)''45-&O\ 9IZI)E+-%QPILR_@GVXB
MQZ?% TUXZ3C\O]GJCRRJRQEM0\BP[A]ORZ%C8_>+8:DAHF3&TWED(BKZ=2M!
M6*P4""I;U+!*AY 8"U_Q[*+[98KQA*)69*<*\/L]?GT>[=S%<6*>"L:JWJ!@
M_;Y8Z.)UOV_BZV6&FS$4B/)I,+0/%'*[?6])4 B&46Y )L?8+WC8)HT9K=A3
MSK4C\QQZDCE[FFUDF5;Q#]H(!_VIX?D>CO;8W3@LI2P@5[,HTHLT\(5XGX A
MK$4EXI%_J?21]#[B/==LOH9&98!PX \?FOD1]G4_[)OFUW4,:?4-04%6%"/D
MPX@_/@?(]"[0T@"1O&5=7 (D0AE<&W*E>#_A[!-Q*2Q#@@CR/$?;U(=M  %*
M$$'S!Q^72UQJ,E@RW5N#$5#7)()N&!7@#V1715B*?$//H2VD;(*&I6G C_(>
MF'>W2FR.S:*5<K1QT&4="$R--&@#26]+S(MK/<\LOX^H]F.S<Z[SRY(H@E\6
MT!^!C_@/^3HHYB]NN7.;X9&O(!!?D8D0#)^8]?GQZJ%^0'PUR6U,C69/&8R6
M5%=Y34T"^*=X_P!7F"K>GJD86OITM_4>\G.3_<>PWR&-6G"R4 H3P/H?3\ZC
MY]88^X/M!NW+=Q,\5L7M]5=2@]P_BQ@_E0]$7S.TL@M-4XJNIAEZ 7$M-/$1
M6TK+RLL44@\D<B$GE&(/T]R8LT$X!(&?LH>H8:VNK=F746 /^V'^ST77>G6-
M36PSRP0+*(8F\5D/J@0W--4Q-^XA"#TWY4_0^T5YMZSJ2AJP&/\ -TNL-QDM
M64-703GY?,>GSZ"&C%70QK0)^W543O-BWE-VC<-KEQDKL-1#Z=437MJN/S[*
M(O$C A!_44U4GY?A^7J#T=3""=C,QK"XH]/Y./4CSZ,5@.P<9W+M>'96[Q'!
MO+!0-!M;-,/'4RPQ+J&'J7N&D1&'[8;GZ@'\>UMI)#=-(!VR,:LOJW\:^A/X
MAP(Z1WT$]J(R_?&@_3?^C_OMO4>:D] O65>1@BRVS<I%X)HVEDI6L2B3P!O6
MC']=/4(;.G]D^H?GVV\DRI-8R]K>7I7R/YCJL440,&Y1=T8/<.)'^KRZ"O9^
M],]UYN9:JDGE@\-0#(FHE&56Y5@2%>-@;?0@@^R2VNY;&X8-4QL<CRZ$UY80
M[C:B2(TE7*D<?^*/1WJ^?"=H[>CW9@3'#E88KY.@C(,BN$_<T+^IUN"P-@;?
MXCV+8F2XA4HU4\CYCU!Z!$Z/!,VI-,HIJ7R^T=2.K>T*W 5$^-JJF2)RL<98
MD@EXR5I:ME-N23XW_P "/>G2.\01S?VJXX>75H)I+!C)"2(6_D?ETLMY[BCR
MU%4M!,J_<J:F(@BT-6G&D#\+(P*-;@<>U4$+0J:G('$^GE^SI+=72SM7R8@T
M]/7\NBS9#>RY"BK,!D7_ ,YY/MG=O\S5:2%%R>$D_21_K'V@EO4<20R4#$4K
M\^EL5C,H2= 3&IK3Y=%$SFX#25%?CJMR(Y#*A5R+(5;_ !Y5E?U#\W]@BXN0
MCR0L>I)L[+Q%BN5XUK\J=%WW+NA,>TT/E5@LK%R3Z;,!PIX#,5Y%O8;N+I8R
M1JX'H:V5DTU&9<=(1-_1:9J=IQZF!1KBX9?6C?6Q-^/I[+QN"94GHT.TECK"
MUQTL,)V92T](\+U" G]RWD &L$'D7]-Q[6P;FJ(5J*=%UWL;R.&"=PZ__]-(
M^^I'7%?KWOW7NO>_=>Z<,1_Q>]O_ /AQ[=_]WE![;G_W'N?^:3_\<;IZW_W*
ML_\ FO%_U<7KZ"H-E!/T %_\!;Z_[#WR\/$]=HNHAE>=BD/$8X>3D'_D'WKK
M8I0^O4B.-(ETK^3R?R3_ %-O?NM=9/?NO=>]^Z]UT2%!9B !]2??NO=0[O5'
M@E(!]>+,Y_I_2P_WOW[K9QCSZF!0H 46 ^@'T'OW6NN_?NO=>]^Z]U@FET *
M@U2M^E1_O+&WT ]^ZV!Z\.O0P^.[,=4C<LY^O]; _P!/?NO$_LZS^_=:Z][]
MU[K%+*L2W/+'A5'U8_T ]^Z]UPAC:_EEYD;D CB,'Z*/Z'W[KW4CW[KW7O?N
MO=8990EE6S2-PB_7G^IMR%]^Z]UZ&+0-3'5(W+L?\>=(_P ![]ULFOEUF]^Z
MUU[W[KW45F,[E$/[:\2,#]3_ *D<'D?GW[K?IU) "@ "P L!_0#W[K77?OW7
MNL,TNC2J\R.;(O\ O9/^TCW[K8%>NXHA&#SJ9CJ9C]2?^*#W[K767W[KW6.2
M01J6/^LH^I+'@ #ZGGW[KW7&%& +R<R/R>/T@\A ?Z+[]U[K-[]U[K%+)XU_
MJS<(OY9OZ#Z^_=>I7KJ&/0"6YD<EG)^M_P"@/'"C@>_=>ZS>_=>Z@5;NY%+$
M;/(/W&'^ZX_R>/RWT][&""1CJK'R'428+$BQ)Z54*H_)'Y+$CZL?J?\ 'W9J
ME QX]-],E6Y)(#6'T_K^?K_B#[=B4BA\SU[\NB)_/GNA^D_B;WEV#0U8ILG2
M[4EV=M617TR5&\]^R#:V)%.203]BE?-4DC]/@U>Q7REMG[XYCVFQ=:Q&4,_^
MDC[V_D*?GT"?<#?_ .KW)O,6ZHVFX6 I%Z^)*?#7[?BK^77SZ%;^^&_G8.9Z
M&CJ8Z2)Q<K]CBE$,3DGF\K1LQ/Y+>\AF/UVYR.!^F&QZ4!QUAVB#:ME2&OZY
M2I_TS#/1A*^6*BP=75D^.:H9*>EL--P;1P@6%](8W]G\G9;NU<DTZ"L(9[E(
MZDK\1Z4E/C:[!;>H5BC9I9:<2 BQO)+=F)%[EK'GVK$3V]NE/B(_P]%QFBO;
MR57'8K8KPH.F:E?(A)154DLZR$V# ZD'T])M_7_&UO;"&2G>M0>EC+%^!PI^
M70G]90)B\E45Q"R0("SQ2 ,/I<*;<!@;<C\^SC9U\"5I3D#H/<Q$W$*6RX<_
MZJ_9TL):Z7(Y&NS%#(9&B#+'12L!*C7(#1$BTT?'U'-O:YI3-))-&WV#HH2%
M+>".WE&*4U>7VGT^SI-2R568=Z?(TTJ%BQ6;Q,##JXNP*B\9_(O[2-XD]8YD
M(%>/2^,I;:98)/+@.ECLB@JML5O\0,SQ-&#]O+&2!QRLB,.!R;?ZWM?MT1M)
M#(7(QCHLWJ;Z^+P@JL]<CB?]7^H=")D]X8?><38+*LM"&N@RD*:D\Y](GJ($
MY OP2OU%[CCV:27T%\IMY6*C^+RK\^B6';KO;"+Z(!Z<5\Z?+\NDM'L/.;0A
MJ:@Q_<TDSJ\-?2L*BDGA +1LL\=U",#?G2P^GM$-ON+$,U.RM01PZ7MNMGN)
M59#D8(/D?3_5CH3=F;S:-TQ>4D95<!*>I\C*\3,;K'(X.H1ACZ6',;"XXO[-
M;&_ I#,W;Y'_ "?9T1[CM^FD\-"!FG&G2USDT;+X]QX\Y7&2$+%EJ;1'D*6X
MX\NG]N6P_M&VKZ@GVNGQ42QZH?(CB.D$!SJC;3,.(]>F[&X9:$"LP.7@R.)J
M;1RT]3JC4@G2*>J1R!#,IX&K2?R"?=880IK#*#&?(_ZO/K<TK,/UXZ./,=+>
MDV%N%HVR.VHVK8)DU5>)<K4Q\CE3&AM*J_V'%G'UO?W9U$+$K(%^1X'\^O1B
M29/[(M0>7']G2VV=D<OMVNCI_+48TEQY\'FA/]DS7Y^UK2NJ&_\ 9+:6!_M'
MVY+"D\9UI6@P5H2#_EZ];W$EM.N@TSD-45_E@]6'=8=FOC9**+,Q2U.,J(TB
M^]CE22MI%;AJ>J=3XZR!+>DMZ@+$$'CW'6];*+A9#;$+.#6A&#\QYCY^74M\
MM\Q_220B\#/;'%0:L!Y@^3 >0/Y9Z/\ [2S-1_#8GIJG^(8:M37C<C S,(YM
M.LT\X^L$X7@J?J.1[A;>+&![DB2,1WR?&I\UX:A_$/GUDEL&Y3"R1HYC-MKC
M].0>3#\+?PMZ@TKQZ%C:>]*.IJ%H,G(JDD1QU-P60FX D^EUXY(Y'L'[QL$\
M,;7%JN.)'^'H>[!S+;3RI:7C@-6@:N:^5>AKT")$"LMBH=70@JRO^EE8<,&]
M@8DOJ]0<XX=2+30 %&"*\?\  ?/UZ3>Y(J:MQ[P5].E3"+ZTJ$5@JNO^ZSIU
M(Y(_'/LQVZ2:WN%E@E*2'@1_E'GT5;O%;W=JT5S"'C/$-3^7H>B!]L?&;;6]
M*B?)[81:+*@M(:5=,0D:[<Q.H :2_P!5XO[GCEKW!O=OC2VW8ZK<X#C/[1Y#
MY]8Q\X>U&W[M/+=[%V7>28S05/\ 1-./R\_+HCV]/CMG<8LT60Q<\,T8915Q
MPL-:C@"=0!K4#^U]>?<M;=S99W8#P7"LA\J@T^S/4"[OR'N-@7BN[1UD'F0?
MYX_GT0OLSI*KHZF6HAIS'R!(\:EHW&HWNP'T!L0;"Q]B<"UW$!T($A_G_L]
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MX?ZLCZ:B??NO=2??NO=>]^Z]U&;]]S&.8D/K/^J<$64&_P!!?W[KW4D"W X
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MH/4JVOMUR[- EY97[*#G54>'7R ;XE/R8?+I]GH,)M9XCF=OU616G*^/*K!
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M/0/3SX-_F/1>-S]EUV(JG2BJ9X(A+K-%+,UE8&Y>GG%OI^. ?8GMMKBE0&5
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M42$\>-/\_21VC10M4-*T$.L677X(58EB+@$1\'_'^OM9>/1**V.B_;XPS:F
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M>C5O5'QS_:(N+_T-K?7_ &_M++;*PJE.E]M?,G;)7CY=-QI#<^@$WY(TF_\
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MJ5[]UKKWOW7NNB0 238 7)_ ]^Z]U%4?<L'((A1O0OTUD?VF_P!I']/?NK'
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MU%_JW_((Y]^Z]UP6(00!!R0"S'\LYY9O]?CWM?B7[>J-0 "OGTSRD@O;^O\
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M_*/SZ#VI^6VP,DQ3<74^##'EYL8TV/D!^A(\3!02.1Z;>W4VUH*>#OEPO^G
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M3_9^HN3P+<<_7W[K?7__UDC[ZD=<5^O>_=>Z][]U[J?B/^+WM_\ QW'MT?\
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M0/4\#TG:K,PJ%62BCTE[ QEHW()L3>YLP/M,TZ\&C%.E4=JS'MD[NH^:QO\
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MZH*0AHL9#/.6+#_.ZE>$(3]2.?;@;;6J9UD!]%<_ZATVW[Y4TMRC)Y,R ?\
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M?3<%5D0W8G\+?Z^RF[YDLK2JK<H3Z='UAR?N5\5<V3C^E0_RQ_@Z''!_&6J
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M1 _Y3V&[ W#_ ,)U/YL^'ZOAR=1O.MR?:8HZ3#>8Y6LQ$'2/6E5NVBH$I_\
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M@]S'":PV;G-81_+'6.DRD7.X1<"+AOYBO1=,L[)N+<:AUC)FA?3=B;$_1K7
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MU-X3\ED /^'H>ML]+=4XUHYI,%0H%L2:C,4,NJQOPB$6^@/UM[*)]WW,BD)
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M4>?G3K7#WG22XO=&YZ!XPOCSN1ATM<,JF9I%;_6*O[Q;W%##?WD7I(W^&O\
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MU/OW7NIGOW7NO>_=>Z][]U[J)(QF;Q1'T VE<?C\Z01^3;W[K8H*GSZDJJJ
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M& "11R"1IU:3;D>SVU\*(*Q4!N@G>M-,[!G+#[<="GC-R&6RTCK4+J2P8LC
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MKN&+QBY)9VY9CR;D"XO_ $%O?NO=9O?NO=>]^Z]U'GD(TQQ\R2<#_:1^6/\
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MN5@L%N ?5C4_L_PXZ'_;?3F:RD4-5NG.STU,X1UHZ.CE\D@-C^S3?L+I_H6
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MZ[1==^]=>ZZ)"@DFP'))_'OW7NH?-4W(*P(>!]/(;$7O_0>_=;Q0>O4P
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MBYX^GM= SB042JGHJN50Q.IDH>%1_LUZ<7JI?XE.D&-'-B6D,D:<KRQ+%5L
M?I?VX6/B-IASTV$_20-,3]GR_ET\TLD_Z9:VGA 8>.*D0.>+'EE6Q_PY-O;\
M9<&C2@=)9$C^(6Y:OF?]GATN,8]I(SJN"%YL%)X!YT@<@_7V:PMD4Z()5R5H
M0/MK^SH8=N27,5OH!;C@6U@<<>H\_GV<6YR!T27"T#9ST->&G:H6* 4P:,$*
MSRL @Y(+! "6:X_/N\HI5Z];MG\0! GH*GH1EP,M3 IBGBI(06,C/%&S,/\
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M=>ZE^_=>Z][]U[K#-(8ULHU2,=*+^23^;?6R^_=>Z[AC\:6/+-ZG/Y+'Z_[
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MPXC)9,?\!Z>21OLJ=CR9:@V(G>,BP3].KZW''M9;PP1DGZA6>GKTCN9YIO\
MB.53]E>C7=<5V0J2'J=Q8^I<&P'\02P4"RJB#2%11]   /I[U?"(1G]$DGS
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MXXJ:'2>2;D?7W9.4[?*VUD*>;O0_L!K7[>'5).>;TYN]R:O\$=:#[2* ?SZ
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M5%!%>O_02/OJ1UQ7Z][]U[KWOW7NG#$?\7O #^NXMNCZV^N;H/K_ (>VY_\
M<>Z_YI/_ ,<;IZW_ -RK,_\ #XO^KB]?02B0(HL!<A=1_J0H7_>A[Y=TICKM
M&23UD]^ZUU[W[KW7K@?4_3D_X#^OOW7NH5S5/Z21 AY/TUM_0?X>_=>_P]3
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M#Z<!\NJ7,T-DP>!R)2*T]?M^WI\H8<3MNH(QU)'-7*Y5ZN4:XXN/4L(-A?\
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MU&Q=A_84FWU_!]^ZV/7J0B*BA5' _P!Y/Y)_Q/OW6NN7OW7NO>_=>ZC3N21
MG^<D')_")_:)_P!A[]UZF*^76:-%C0(OT'^W)_)/^)]^Z]US]^Z]U[W[KW46
M0>=_$+B-+&0CZ$_71[]UL?SZE    < < ?X#W[K77O?NO=<'<(I9OH!_M_\
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M4\!?Q[3;E*RE887"P_(\?M_R=+=I@CD5YKB-GF]*5 ]?LZ;MNTU)*FJLKRP
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MV<'AJJM/J)/Z5L![],_B:$C%(E%%_P Y^9ZK;1&$222'5<.06/\ @4?(=,+
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MM]%!/_$ ?[$GW[K8%33K% A"F1_URG4WTX%O2O\ L![]UKJ1[]U[KHD*"2;
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M\G0(O+5+:R2W3,SL"U.-3P'V>O03[HRL.SL!+0TS(*ZM'V\KPD:M1L9(8O\
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M 5FC:S1$?0$'\'^OLI(,;_9_A\^A$I$\5!Z"G0J8C-QM0K4 *TB*;QGDM8
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M%C-*22!]#<CV,[:&B4 "PI^SJ.[N<O*S$EYW/VDD_P"3_!T?#:$%-B*)8C-
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M56?5#*3(')^^:&79KN2B$UA;^%OX/L/%?G4=0[[C\JF99.8]OAK*BTN$'XT
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MM_\ \./;O_N\H/;<_P#N/<_\TG_XXW3UM_N795X>/%_U<7KZ!LTC66*/];@
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M9&IJY6<F[1I)XXP6YOZRQ!]@RXNFF();N=R3_DZDBVL4MU*JO9%&%'VFA/\
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M_7/OW7NL%.A-YI/UR7('^I4VM;^E[>_=;/E3J5[]UKKWOW7NNB0 238 7/\
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M^3Y_+X3Z0K\>L"S_ .U$YC-C2>.1Z?>/'-/_ "L.Z_\ -3_(.A1;T\!/7/\
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MCUCITT1+?ZMZS_KMS;_8#W[KW6?W[KW4>I),81?U2.J ?U!(+6_V'OW7NLX
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M4PX78.\*V1VGJZ_J'*53BCZ_W/6,S,V&J67"U<AM U,QTD8[/S0\*K;;HQ>
M8$G%E]*_Q#Y\0.HUYBY$CNVEO]A"QW9J6BX(_J5\D8^GPD^G6IAN+$;KZ^W3
MN'9&^]OY[9^\MHY*3#;IVING%56#W'MW*PL5?'YS#UT<=312@J=#V:&9?5&[
M*03(,%RC1I-%*K1L*AER#U#]U9/%-+;SQ-'<(:,K"A4^=?\ 5GKA1Y22G/DC
M=7'U$#D%3<_6)KW%C^/:R*X*]P((].BV6U1@ !0?Q?YQTL*#<(EA9(I6AE=M
M#4\Q #$7X"GTVL?I]?9A#=!UTJU&]#Y]%<UBR-J=*K_$/+IQQN9GQE8M9!--
MCYHGU>AV5)2#Z572;D$_[ #Z^W8IC&_B E6'SP>D\]NDT1B=0RG]HZ&_;?;P
MD1DW,FF6<^*&M@^H&FQ=PO!TFUK >SRVW>HI<>?GT&KO82I'T9[?X>G[)5=)
M74"S4M1!6P69ED) F#./4RV-S<6'M1)(DB*8W!'^7I';Q2PRZ)%*M3[1T#V:
MR02>*F21H_"H&ESI-R=7J/TMJ_IS[)YY1J5*F@K_ #Z$5M =+.5X]9J6J"P^
M>=5U/98 Q&F[#_.,/Z ?3WX,*5I4^76G5M>E. X]91).T@6*65I&THH5R39B
M+!5O8CD<^]AG+"A.H]4Q3(&GIUJZV>F:.B6;R?; BH<>H/42G5*$:Y]"<*/]
M;V[)*RD1@UIQ/3$:*U9"E"WE\NL4^2EGIX:8G]J,$D D:I"Q+2$#@'\#W4SL
M55/P =76)%=G [CU!J*IEI3&?IIF3R7TN(I64R1 ?0:F')^I'NFOM" 8Z=51
MK!\S^>?+IQHZ!Y<1#3Q*!45LKU\D5[.::*\-,+ 7(X9K\_7V\D=80%XL:_YN
MF))0MPY8U55TU^?$G_)3I6XZ@EQ."8J&2:KFT_0@Z5!/%[<7/M7$C10&OQ,>
MD$LJ7%V!Q51Z]+K9V$>)#D:M3'3L1JF?C]0NXCOR[Z 0 /S_ *WLPLX"!XCX
M7&>BK<;P,1%$:R9H/\-?0?\ %=)3<N\))\KD7@=D1RT"(IN%B2\<8C%_PHM]
M;^TEU>DRR4-.EUCMH2"(MEN/[<]9MLS28N%JR6ZB6-W4,""00;,R\&Q/ M[W
M:L8AJSPZU> 3LB#@/]5.HL^XI9Z@R([6#&S@7TF_^OS_ $_I[H9R3\6>G$LU
M5:'CTVTN3E_O#0R:R?)4*CWO=EE.AOI]%4-]#[;64_41YXG/3\D2FTE6G 8Z
M<,I+Y=PX2<&X8Q0M?\>&8Q?7_5 (/]O[O*2;F!O*O^#IF%:6=TM,BO7_UM*#
MWE/T$>NC]#_K'_>O?AU[KZ\O\A;_ +<[_P OK_Q7W _^[;->\>.:O^5AW7_F
MI_D'0GM_[%/S_P )ZMS]A_I_K')((U+'\?1?RQ_ 'OW7NL%-&W,TGZY.1?ZA
M3]/]X_VP]^ZV:>7#J7[]UKKWOW7NO>_=>ZBU$A)$$9_<DX)!_0OUN?\ 7'OW
M7NL\:"- @_'Y/U)_)/\ K^_=>ZY^_=>Z][]U[K@[B-2QM8#_ %N?Q_MSQ[]U
M[J/3J6+3R?J<V3_!/H+?TO[]UL^E>I?OW6NO>_=>ZZ)L"?Z"_/T]^Z]U$B_?
MF:8WTIZ(P?H?\;?['W[K? 4IU,]^ZUU[W[KW7B;<G@#DD_CW[KW42&\LC3D<
M E([C\?0D?X?\5]^Z]U+]^Z]U[W[KW7!W"*S'\?3_$_@?[?W[KW6."/0ESR[
MG4W^N>0/]A?W[KW6?W[KW7O?NO=19KR21PCZ7UR?\%']G_7-_?NO=2OI_OOI
M[]U[KWOW7NN$CB-&<_@?[<_@?[$^_=>ZQTZ%4U,/7(=3?UY^@-^?I[]U[K/[
M]U[KWOW7NHT5I)))N2 ?&A_%A^HK_K^_=>ZD^_=>Z][]U[J*O[E2S?5(ETK_
M (.3R?\ '@>_=>ZE>_=>Z][]U[J,@UU#R7!$8\:_GGZM[]U[J3[]U[KWOW7N
MH]/<AY&^LCDC_@HX'^PX]^Z]U(]^Z]UAG8K$]OU$:5_UVX_W@'W[KW7.-0B*
MH%M*@6^O/YY_//OW7NN?OW7NH;#76I];0Q,?\ SFW/\ L/I[]UJF0>I#1A@?
M]AQQ;@W_ *>_=:*U^WIFKHO'!.X_XYD"_!)-EM]1];^[ZA\5#K_ETWPXC/3:
M*55@1/H0BW'%P2 2/K8W)][$G"HZ]7IMGIK<6!'T/T^@_K]1]/;Z,#]AZ]TD
MFH1-5UTA060I""/S8:C_ *YX]O@TX'/2<J7+$ 4ZKY^=G\M;XV?/?;:4W;.
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MK77+W[KW7O?NO=1:AR2($OJDM<C^RM^>?Z^_=; \SPZD(H10J_118?\ %?\
M7)]^ZUUR]^Z]U[W[KW45R)IA#SHCL[V^A-^%)O\ CW[KW4KW[KW7O?NO==,0
MH+$V %S?CW[KW4>G!8O,WUD;T_6P0<"WX]^Z]U)]^Z]U[W[KW46:\DL<(/ /
MDDY^JCZ#^O)]^Z]Y'J5[]U[KWOW7NL,[Z(S879B%4 7Y;C_#\>_=>&>N42".
M-$'X'^\_4^_=>ZR>_=>ZQROXXW?ZZ5)'^O\ 0?[S[]U[KC3K:,$_J:['BW)]
M^Z]UF]^Z]UPD<(C.?[*D_6WT'OW7NL=.MH@3]7]9XM^KD7_Q ]^Z]UG]^Z]U
MAG8K$VG]361?]=N!Q^??NMC/7.-="*O^I4#_ &/Y_P!Y]^ZT37/7/W[KW4>;
MU20QC_5^0G_!/P?]>_OW7NI'OW7NO>_=>ZC079II#^7*#_%4^G/^Q]^Z]U)]
M^Z]TW9% \<<0',LR*>+_ $-R3_CQ[V#_ #ZH_ ?;UU+3< @?3\6Y^EC;_#GZ
M?GW;54:. ]>J$$8/#ILEB^H(^OY YX^OX-O>Q5",]IZ]Y])^"E/A>33<RSNQ
M^ESZ@.#^;>WP?(Y ZT !6@R>H511@@^FQ-_K]#^+_P"^^OMP..JLFKH/\]MS
M%Y^+,;>S^&Q6X]N9G#RXS.[<W!C*+-X#.8ZK]%1C<QALE#48[)T4T;6:.:-E
M-^+'GVZKE""I(<&H(-"/L/29T5E:.104(H0<@CYCSZUIOG;_ ,)X]B;X;-=D
M_!;+8SJK=;B>OK?CUO.OJ!U1G:AB\TT77.[9ON\IUI7S27\5#6"KP^IM*M3K
M]!?MG-4L(2'<E,D0_&/C'V^1 ^6?EU'F]\@6UP9+K9)!!<$5,9_LV/R.2A/I
ME?LZU3.UNH^XOC?V!D.K^[>N=W=5=@8LR-/M+>N,?%UE73ZK)E-NU\;S8K<>
M$J1ZHZW&SU%,ZFY(^GL=6=Y#<1I<6<RR1GT_RCB/SZB?<MMN;2:2TW"U:&<>
MO _,'@1^=.D]C,Q!6.JR!HIE:U^(J@'Z7*D^.91_46;V;0W"N:OAO7S_ -G_
M  ]$-Q9O"M5S%^T?Y^GJJF:53Y88\A /U.%O,@!^CJ0)(V4?X?7V_(=0JZZQ
MTDA&@T#>&_IY=10D,BA*6H(1; T\XUZ0M[*6X86_'NH(8 1R?D>KL"I)ECJ?
M4'^=.IC3U4<<21!UC0,KO QMP2?5I]0 _P!;VX6?M !ITT$1F:M,^1_R'IUB
MSU4\"PDI.NH7( CGLO%[_0W(^GMQ;B2@ (/29K6,.6I1NI\.7D0-)#,8Y+$+
M%,+,&/)(#<:@!P1[>68Y8$UZ;>V1A0J/M'3G2;B#*4KHG4?V7#6):Q4\D'\?
M[?W=+A<^)QZ:>S(IX;UZ5-#5TT8CK4=2?&QB4D7$IN.=)YT#GC\^U<;(#XM?
ML'2"57.J,KPZ?MITJU6;AGF8LE/_ )5*Q^@$9U -]0 6/M^S4R3ZV.!GI'?N
M([9U49.!T*4=<L^<69G1CJ86!!-W5A8'Z6]FP?5<*U>B+P]%OI(Z#O+0U$[U
MUE<^2<C_ %0TJQ9@2;&U_9=*';73C7HZMV0+$3P Z1]7&'1\>ATR2(#&I)N9
M$.LH?^#BX^OM&PP8O/HP0Y26F!UEH8;82>CED2!GJXJAF=O2$C#1M8 '45#7
MM^?I[W&M+=DK1JUS^?\ J'59F!N%< D!:?MZ65'E($V_]E11F*42H\<@ 6>>
M&-_&[R$7MKD:]AP!Q[6QR 6_AQCT^WHMEMW-T)),KZ>G3KG4>K2@ACY6&B19
M0IN#4$7G?@VN6X)_P]NS@NJ@#@!TS:%8VF<T'=TP+3"&B2(V!>JU"P(OH4 G
M2!<6)_K[8T=E"?/I7JU3'->VF?GU_]#2@]Y3]!'KH_0_ZQ_WKWX=>Z^O+_(6
M_P"W._\ +Z_\5]P/_NVS7O'CFK_E8=U_YJ?Y!T)[?^Q3\_\ ">K9YW:1A!&;
M7_SA']D<&UQ_A]?8?Z4?/J2B+&JHOT46_P!?^I/^)]^ZT37)ZY^_=>Z][]U[
MKWOW7NH0O4S7(_:B(TB_ZB>0W^(X_P!M[]UOAU-]^ZUU[W[KW7O?NO=1ZB0H
MH5>9)#I0?Z_U/^P]^Z]USAC\2!?JQY8_U/\ QKW[KW67W[KW7O?NO=<78(K,
M?H!?_B@_V)]^Z]U'ID)U3/R\E[?X+>X'OW6SU*]^ZUU[W[KW7%F"JS-] "3_
M ,4_US[]U[K! NHM.?K)^D?ZE.+?7\FWOW7NI/OW7NO>_=>ZQRN(T9OZ?0?U
M)^@]^Z]UPIT*)=K:W]3'G_>;^_=>/6?W[KW7O?NO=1:@ZVC@4\L=3#_:!_7_
M  ]^Z\.I(   '  L/]8>_=>Z[]^Z]UT2 "3]!S[]U[J-3 L'F;]4C&U_P@-@
M!_A[]U['EU*]^Z]U[W[KW45OW9U2QT1#6W]-1_3S_4>_=>ZE>_=>Z][]U[J-
M/9WBB(N&8LW^LOOW7NI(]^Z]U[W[KW4:HNWCB%O6XU$\^D?7C\DW]^Z]U)]^
MZ]U[W[KW4:7US0Q_@$RM_3TW _WGW[KW4GW[KW7O?NO=1D&JHE?\(%0?Z]KG
MW[KWSZD^_=>ZXNVE&8VX4GGZ?3B_OW7NL<"Z8DX )&HVYY;G_B??NO=9O?NO
M=0Y0)*J!?^.0:4C_ !_2I_V'OW7NI9%_^(]^ZT0#QZ;ZR,+3S.;>F)K6O];6
M'U_Q/NZF@"_/JFDCIKB@\=/$IY'C#'TDF['5_MR3_K^[,K8(.?/JM#QZBRTH
M:Y4'Z'G_ (C@_FWNRN5(#8;K5?7I,+1ZJJND(N2\4(N?H(T^O^O]/;^NHQQZ
MKH&HL?3J'4X_5SIM8\V%_P#7_P!<>W%/J.FVCIE3^71:_D-\:>COE'M'_1?\
MANK]K]L;(:GJ9*:@W%2%<K@:F7TKD=H[FHC3[DVEEX2H9)Z&IA(8#4'%U]J;
M:[N+.7QK24QR^H\_M' CI!>V-GN,/T]];++#Y!AP^8/$'[.M6?YE?\)TNS]E
M39;?/P=WJW;NU(EGJO\ 07VADJ##=LXN !I!1[*W^RT>V=_1P* D4&3&/R+\
M#RRL;D:;?S9&^F/<DT2?QJ.W\QQ7\JCJ,MY]O)T#S;)+XD7'PW(U#_2MP;[#
M0]:Z>ZL#OGJS>>4V!V=M+=G6V_<!*U/E]E;\P.1VONG'2(VEF./R<,,]32-;
MT3P&>F?ZJY'L:6UV'5)(9E>+U!K_ (.HSO=MD@>2"ZM6CG'D001^1'4F&NH:
MV/R5E/IDTV^ZIBL-2I_U3$?LS&_];-[,EEAE%9$[O4<1_D/1(\,\!I$]5]#D
M'K,*:I2-VQ]8M:H'*_\  >MC'U"M&_$O!Y(^ON^EU4F*34/3SZ;#Q%AXT6@U
M^T'_ #=0HJXI*$GATR_DZ?%-Q_@;*RC_  Y]M+-FCKD?MZ>>WJM8V!7B/,?M
MZ6&,EIZY2LVEU4W)=!J\?Y/TO>_U]F$3)(*-D#HKFCDCR@HW4ZLB"A5@(\3#
MA7421E1]/KZE_P ;>W9%."G#T\NF8WK7Q!G^?3%65+B0>+RQ)& @\#%TX'U"
M6N+W/T]IG=@>/2J-.T:@,GI=83/G&42Q"H#35;CRDGD0Q\A&7Z^IN;#VO@N?
M#0"N3T67-H9Y"='8O#I5T.>D>=:A6OI8$%2=08<\@WO?_6]JTNLUI^SI#):@
M@H3C[.I>1W/+4R") D*%@7TJ5\DC?5VL+W-C^?=I;LN<#'3<-DD7<34@?LZ3
M%941/52NS$.K!E9;@ZN--KW^C#VE<DR%AZ]+(U(510TZEY60-*%C)7]F-V"D
M+ZW168_0CEC]/=YC5Z>@'5(JA-5*FIZ[CJ9::2G,1*^.%$++8W+'45(((.J]
M_?O$*,ORX]>*!E8.!D_G\NA3HJJ*DHL9Y= DJB7EU .Q61O2MFN0"?K_ %]F
MZ,%2*O$G/1!*C22S,%[5]/ETT9001UOH8&&G$LA%S:Z7=E(/T_%OZ^V9=(<T
M^$=*H-;1 MQ; KZ=?__1TH/>4_01ZZ/T/^L?]Z]^'7NOKO\ \AV7Q_R=/Y?6
MGES\?<"%')_Y>V9%[#^GO'CFK_E8=U_YJ?Y!T*+;^Q3\_P#">K<H(O&I)Y=[
M%S_C_3\>P_T_7AUG]^ZUU[W[KW7O?NO=0ZEV8B",^I[:C?Z*?Q_L??NMCU(Q
MU)1!&H5?H!_L2?R3_B??NM<37KG[]U[KWOW7NNB0H)/T )/^P]^Z]U$A7RR-
M4,#;],0)'T^A;CZ?\;]^ZWY4ZF>_=:Z][]U[KWOW7NH<A,THB%]$=G<VX)!!
M _J?];W[KW4SW[KW7O?NO=>]^Z]U#F(ED6 &_.I^?H!^./Z _P"]>_=;H:5Z
ME@6X'    _I;W[K77?OW7NO>_=>ZAO\ OSJ@_1#9G_H6O]!;FX]^Z]U,]^Z]
MU[W[KW71( )/  N?]8>_=>ZC4X+-).U[N;*"+606M;@?6WOW7O3J5[]U[KWO
MW7NHM22P6%;WE(N1^%!]7OW7NI*@* HX4  ?[#W[KW7?OW7NN+L%5F/T47_V
MW_%??NO=8*93H,C<M*=9/^']D'@?3W[KW4GW[KW7O?NO=18;R32R_P!GB-!_
MP7ZG_8^_=>ZE>_=>Z][]U[J-&1)42O>XC C'] QY:QOS]/?NO=2??NO=>]^Z
M]U&AL\LTMK^H1JW^"#FW]!<_[?W[KW4GW[KW71-@3_0$_P"V%_?NO=8*5;1!
MC]9"TAO]?421_O'OW7NI'OW7NHU2;H$!YD=4M_47NP_VP]^Z]CSZDCC@?0>_
M=>Z][]U[J-'ZJB=^?2$C%_\ DHV_PO[]U[J3[]U[J'7\TY3_ (Z.B?[=A_Q3
MW[K1%12O64Q#3;ZKI T_ZP %A;_#W[/D>JE?,<>H$E.=5P".?H/Z7NQY_P /
M=OBXGAZ]4/S\NF2G@1DD;@F6>5A;^ER!_0<W]V#G%11>O5/GU&FI=()L;6 L
M+%OZ\WN!:WM]) 14#'7NDW-1>3)2G0+)21J+?EG:Y%^0+#VZ&P"3GIHJ&D(/
M"G4"IQH-[ #@?@E;?TL>?I[L#Z]-LI7)%5Z*_P#)GXJ?'SY9;8H-A_([J#:'
M:^$B::/&UF>H6I]T[<1DL9MJ;VQCT>Z-MSH3=335*QA@+HPX]J[2\N+)_%M9
MV1O0'!^T<#T@OMOLMSB$-[;)*GSXC[&&1UK3?*W_ (3<[MPAR>Z/@MW%#N.B
M#2UE)TCW[6QX[.)&"6&)VOV[CZ7^%9,H"5A7.4D#MZ0U03<^Q?8<W4TQ[A%I
M/\29'VE>/[*]1UNWMR'+R;5<!A_ON3C3T#\#_MJ?;UKM]W=,][_%O=']R_DG
MT[V!TKN(R&*D?>&$FI]OY=@;"3 [MHWK-IYR!_JC4=<Y8'E1]/8QM-RMKM1)
M;SJR_P!$Y_,'(_9U&^X[%>[?+X5Y;M&W"CBG[&^$_D>D!#E_NT".T-:EA^H@
ML ?H1J D%K_@\>S'QRXH]&Z)&M#&U4JA_E_FZYFJ6$!*>9X6')#7D6ZFQ%VM
M(H'O?B!3I1J=>\$R F6,,/E@_P";IXIMU5M,!%+%!6*!8C4-9 _%[ACQ^/;R
M7\BBC)J'V]))-LB<DJY1CZC_ %#J=#G-NY&H19S68B>_J;07@4C\W7\?Z_MY
M;JTD8!M2-\^F7L;Z%2ZA9(_D<].DM!553I)C<CC\FBCT!72.H07_ *#23IO[
M=:-G(:*17'\^DPE2(%9871C_ (>H"Y?,XVI\!I)/MU-F"$.S6N6;_$'_ 'CW
M3QKB)PAB.GY'I\VMK-&7\<:SU.HMW1+*HK(YXA< %XF4-;Z>H^FP)X_K[O'?
M(6HZD?;TS-MC 5C93]AZ4*9J@J:I]$B,I92;NIMI'#,IYN?Z#VJ$\;GXAGI$
MUK,J D&OV=3ZC(4[5#V<,+*+BQ!&D"PO_OK>W'D!=LBF!_+IF.%Q%33TYP-'
M45%.JNA\AC0"_&DE5^H_%_=UJSKZUZ:;M#$CAT_Y;+1G)1)$P$5&8X4]0LWB
MTAOQZ2"./Z^U4TX\50,@=)+:"D/>*EJGAZ]97KDDERA+C2T#.ES>Y+J#?C@<
M_CWLN#XG=BG51$56"G#Y_GU__]+2@]Y3]!'KH_I;_6/^]'_BOO8\_LZ]U]=_
M^0O&&_D^_P OF4\Z?CU@$4?XC,9N[?[#CWCMS1_RL&Z_\U?\@Z%%L3X"#[?\
M)ZMY]D'3W7O?NO=>]^Z]UBFD$4;,>3:P']3_ $^A]^Z]0GAUCIXBMY7'[DG)
M_-AQ8#C\^_=;-. X=2??NM=>]^Z]U[W[KW42<F5U@2]OK*1] +_0GW[K8-,]
M2E4* JBP L![]UKKOW[KW7O?NO=89Y1$E_JQ]*#Z^H_0G_ >_=>ZZ@CT)S^I
MO4W^O^!_L/?NMGK/[]UKKWOW7NN#N(T9S] "?]<_@#_$^_=>ZP4RG297%GE)
M8\6LO]D>_=;/RZE>_=:Z][]U[K%-)XXV;\_11>UV/ ]^Z]UQ@C*1^KEG]3D\
MW)]^ZV:>7#K/[]UKKWOW7NHE2Q;1 I]4AY_X*/K_ $X_XI[]U[J4JA5"CZ*
M!_K#W[KW7?OW7NO>_=>ZBPWEE>?G3_FX_P#%1]3S_C[]U[J5[]U[KWOW7NHM
M1=RD(OZVN;?A5M^K\6O_ +U[]U[J4!8 #Z#@?[#W[KW7O?NO=89W\<3,+WMI
M%OK<\#_;7]^Z]UW"GCC5?R!<_P"N>3_O/OW7N/'K+[]U[KA(^A&?_4B_^Q_'
M]/S[]U[K'3(4B75^IKNW^NQO_O7OW7NL_OW7NN$KZ(W?_4J3_L?P/]B??NO=
M<(%T1(#:Y&HVXY8ZO]OS[]U[K-[]U[J/4DB(@?5V5!_R$?\ >./?NO=9U 4
M#BP X_P%O^(]^Z]UW[]U[J,YU5,2CZ(K.?ZBXTCW[KW4GW[KW7O?NO=1J:YC
M+G^W)(_^P+6%OZ?3W[KW4GW[KW46?U2TRW^DFLC\^D<>_=>ZE>_=>ZPSC]J0
M_D(WU^GT/^]>_=585'SZ;::F_P DBO<L5)N?R6)(/T^OMS4/A/P]4H?3'6*6
M$K]1<?5B?KR/P1]>/>M().D_9U6GITRK2B2IK7 !.I$X-C8+^0>01_7W<OI
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M2"BA3P_-G^<""V:;XA&;$K^^<>_3._(G\%M6E8QNE<NP"?D(6]ES^TGW7O\
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M.&*&GQ>-AIZ)9%EGT>:>5F!U]O<^_P#,%IN$\$<;F2,404&&&2>+$DY)SP'
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M=\M0MON21W=K2A#K1R/],!0G_3*WSZ"M]R7MEQ6:RD:WN"=0TG4NJF"0?+T
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MNX B%58!@H8HQ%%?20:TX<"16H!(Z7[Y:37NW2V\*:B>*UIJ!!'&H%02& )
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MT9)7!J"*J&SA@/3I//N8:UW^ZLYAIK$*FHPSNQ7!# L#I-""&;&1UL,_'?\
MD7_R^?CCV#\;^].B=I;YZ[[9Z(HGGE['V+VCNW'5??CYK;L>.RM3WFL^0R$6
M_L7F*F9Z]J96I8))I-#AZ8+  '?\X[YN$-_9WDB/:S-72R#].AQHI2A QFO"
MOQ9Z$UOL5C ]G/%K$L0P=1S6A.#4*"1P32*57X33K7X^*7Q"Z:^4_P#,/_F
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M\]D2D39/<6Y<S5U%?D*DJ@FJZB1@J*0HB7<MQNMVOKG<;V35<RM4G^0 ^0%
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M:Y-^&:WT_P 1?C_8>_=;!I7J;[]UKKWOW7NO>_=>ZQROXT9OJ0.!^23P./\
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MZMD'^4S7_P!TQ'C_ &IKWO\ G@V_VWL/]*"* =3_ '[K77O?NO=>]^Z]UT2
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M)50JA1]  /\ ;>_=:Z[]^Z]U[W[KW42H.MHX!<ZCJ:WT"C^O^V/^V]^Z]U+
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K/,Z_ZF9_]YL??NMD4IU(]^ZUU'3_ ($3#^JQ'_;!A_O'OW7NI'OW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g90195g70d74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g70d74.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1.&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $VJ^27 X0DE-! 0      "L< 5H  QLE1QP"   "   < E  %TQA=2P@
M5F%L97)I92 H0F%Y($%R96$I #A"24T$)0      $,F+7V44!.4P$<"*7-LD
M=DHX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q ;0S$H         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          ''   %G0         !                          $
M        !9T   ''                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   ''     %)G:'1L;VYG   %G0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !QP
M  !29VAT;&]N9P  !9T    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     <X0DE-! P     "10    !    H    #,   '@  !?
MH   "/@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M #, H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" "\ E(# 1$  A$! Q$!_\0 'P !  $#!0$!
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MG7R&6%]0LLSFPUDXMV&RVQ*QCQ,'-R=?8Z#=&++K3Y--DZRU<9>DGCU/58;
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M;)HU>F*I &':+?'X?'X816\OL:3)\H=8C.:9MZPSG)Q?(\\4F)L+$<GST+6
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M")A$PB81,(H?=+B-28P65+B9B78)EHV(\"$3%N&-ORI&A!'-,2DM%;,\0M;
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MTH(8^&'.BC,CNX%V"YV23Q<XGMSS7'R6;$QWS322')QN>7<3V  D#)/FM
MY\./9'LH>ZV=N#LF6R&DH'FBY<AT5@P94YQ9RI8).ZTR9B4$(=-"!<GGY&4J
M!9325-MR]6)CR67%(<):.80H5S!U'HYI>HL<V6JRM,1XMFNQL9:<$;G%F X9
MP2'9 X<1QQD5=2MU'#9,[:,9B>2^(M[@TDAO+SFD'B<\E[_NQ%VQ>,^W/V?Z
MMSUQEMX 64<(A;94CR62IFB76*2SN<JLL\PEMHAP5)(AT=(-LL-2T(?&2K;
MZ3/+L^.ZIIEC2;DE.S@N:=T<C>#)8CYCVCOYAP[#P[%W-&[%=@$S,MX[9&..
M2QXY@G.,'@6\N!X\>"[<9KUFIA$PB81,(F$3")A$PB81,(F$3")A$PB81669
MKD#8?1NYR(CY;</((EHE1XK1*HV4;&)#1(!*<2I0Q:1#"Q=/L[0YY<HAG:O#
M><2HBKCH"#B"3S(N)CX\N4V-N1*$$98?.\FA;8OFG6T)6_Y=#KNFM.*5I&W7
M5)Z*=<VHBN^$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB818AYQ-K\90?25IG]5> "N7
M&^Y2<<M!E.&"!.Y"K$4;HZ>#DXA0H189Y 1*'S6QWFR-MN)5M2-:J8Q\C@R-
MCWO<?%8QI>XXXG#6@D\ 2<#@,GAC*I>]C&E[WM8QO%SGN#6@<N+G$ <2 .(R
M<#MPHGS!QH;R"=Q</%Q-?DH"O33$M*SDE.FILD2( ?7Y2,U3-O@2T8F5E2(E
MIJ1MY>UV"+@F9*+K1 $C:G[%"T$@$@\"#C!X>-RQQ[?0./-2./$<1@'(&>![
M3CL]/ >GBHS-\(V=SBZP<>Q6XXMJ7Y<D>0.]*V$Z1<?@B.50[UJ)?.LT-:62
M9 H#S276)Z)L$#IYE,.0$1'$I)#<^[GZ^7Y_@I6=^,:Y)T_C>@U*9?')EJQ3
M:U7Y(@0@PP9XV'APX\AQ@R02@XMM3HZMI++;9()U^_NL,+<VRB44YPB81,(H
MA.<?4.S+0Y9*54[ XVK:VUS=<AY53:]ZWK:D*/"(4E7KWZ];UOU[RL22-X"1
MX'8 X@#V'M5!CC))+&DGF2 HJCA>B"O[?AA;)6?9I =3OEXJL0QI/7IH: K]
MBCX!E&NO^A3%Z97TUIQM6O5JX;,O#.Q^,#QH87X Q\]A.!VXXGTE6^HCP0&O
M9G.=LCVGCVC:[&>//@1V=BY&^/)UC\6+Y:Y)CV=:WM KVJ!.,(7KUZTX38J)
M+3+K>^FDK1J50K:.O<<0O?B:I$P&=U:!Y(/$F5N"3^Z(I8FY[?&:6CD!R3J2
M" R:9@!R0.K>"!V%TL4AQZG ^E4[BN8A-)\"X<?2[;>U:2Q(<?S\880C733:
MB94#D4L1!&]:Z/.#5UMAQ6^^T*.A/A;'P9P&8IF.&<ELS',YX:&QNA#F@#.<
MRNSD#(QP8L!QQ)$YG# =$YK^W.7B7:[CRQ&W [\K8;GN8P5N[D^.:A)BM].Z
M]5^1C'Y(E&DZZ[1$V6E5H 9[:M[TEARR/-:UZU&ZWU2DYM?(+9GM QC?#V'@
MXY9*[ERP&\L<BFZ=IP8F.!!XMEQQQP&'1CGC).3CT\U^=CVJ-/\ :D[:?NA_
M+O*$O.5P?C&1Y,LS@3 XATVRQ6.6*CP'QG4B$(?DA6@((RTU+=C>C5F[>AH*
M6;BG4DEC%M>U42--TK1H(&LD=8,,6\M W!S)K,CL$C!<00TDCQB#M=YJ\^L$
MV;-R=S=KP7N(SNY2&-K2> P YN?1Z]PFF_<V* =&<I3<=SM90-47CB'M$96+
MAQG7ZO>'[@=0><^4G:'8JB]RF^1'V!_C_AN%LX58KI=HNL;&\J58BS5J#9@;
M0Z':=KDS7P-?4@<Z9P87Q32NK-!FKP!P/4  ==,]@<\L83 >K>0YFZ16B/7.
M$A!C8'!KV-87>3EE.U@DW AC&X()(+P"#@A<0SL&<*V2;X9UP]R#RE>*=RYR
M%7:2[=9.O5^M1U2&N\;!P5*GGX"<]'7^8AIOD"Y59!Y4C1Z>F)JA(!*M% \@
M\:VFQ2W6+;19?:KUH9*T+[(A:^1[IH82#, X;F =7UK1XQ)D QDQR,%'@\;S
M$('N<)'MC+G-# V5P>YK=I>7$8:'GAY@)R-S2?J!^"\\E66.YE[3O"+I*W:K
M,\<5WDE8FO$=%!LU3M(E26\*K2MLL.R,?<-M&;0G2CD1<?M2UI 1TT'3^NP5
MJ%EP:)63NKYS@['QESFGOZM\9P>7CY''(6XZ-O=U]B$<6/@,I',!\;PT=YY/
M=GO+0.) 7L^UT^#X?7_7\.>9 ^D9R>[EG@NR^.W\_P N"UR5&1WA,*4PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$Z_P".F\C('QD^
MP(F3GM_(_AS1,(F$3")A$PBTWO6O;_LW_+D9 SD\OCV>GDBQ=>N<N%.+R1PN
M3.8.+N.S"VT.BB7J_P!4J))+3JMH;<'8GY:/=>0XI*DH6VA25J2K2=[WK?3(
M@JVK+2ZM6L6&MXN=!#+,UH[W&-K@!Z3@*Q+:K0.#9K$,+G>:V65D9=_=#W#/
M/LRIG7+75[C$CS]1LD#:H(OO:$FJW+Q\[$D]S?1?EY*+(*#>[F_4OPWE=W?3
M2NG766Y(Y(G%DK'QO' MD:YC@>XM< 1]85QDD<C=T;V2-/)S'->T_6TD?>K]
MK>MZZZ_Q^CVY0JUKA$PB81,(F$3")A$PB81,(F$3")A$PB816J;FXNNQA,Q,
ME:#CA/"\=_PGR%:4^\V,PVV.*T^20\^0\TPRP.RZ\ZZXA#:%*5K6$47;Y0X_
M>A):R,VR'>@H,QF/E)1@GQQ!S"7QQ16$.,I<\RLLLM@,78FGTDF+4&RI9+;C
M2"*=H6AQ"'&UI6VXE*T+0K2D+0K6E)6E6M[TI*D[UM*M;WK>MZWK?3"*K")A
M$PBQ)S?"0MEX_(KUDK.KE79>R48>?K3M6+N84M L76 /FQY.O"1LMN0C$Q(9
MCIS+X+X[K#:F%H6MYMM=3'R1/9)%(^*1CMS)(R6O:X X+7 M((SS#@1Z>1HD
M8V1CF/:U[7##FO +2.T$$$>T'ZC@CJFKL537%RV)_L4<U6?LZLIULMSABT@2
M/*W9LFDN='D@ZXLMDL%8N*FEJTEKN<.VWCT8#JYLB .<2XPO:_*C+ VZG4BN
MD@@V6D07>.>)L-:X2X)Y3QR @8)R25K_ ).,))HSOJC=NZHYFKGB,@1/(ZO(
M!&8W#SCP[%4KMD<@<)DMQ/;+X(L'&L2TG6GN?N'M3/,O9U[NM=WSMFDXZ% Y
M(XH9=7^,XY?J.W6(]*VT.7<K:TKW TZ&SEVG6FRD9(JV2VO;P>.QK23#.1R!
MBD)<,$LC)+!)NR5\"Y Y@. 9X?*P!V&Y)(Q(P$DG+XP!@X<X8<>Z](O]&Y,K
M<=<>.KC6+W4I=I+\59J?/15E@))E6M;TX#+PQ9L>4G776E;9(7W-_BJZ;UO6
MM9+%- \QSQ20R-.',D8YKAQQQ! Q]>.''D1G.CECE:'QO:]AQAS2"#G!'$=^
M0I=E&>7IY?BKF?=ZDPB81,(F$3")A%2K6]ZZ:Z?I^+UZW\&_@]F01G(]!]O9
M[%!SD8["#^.<?=_IS_/O]V-X&YC["_;JYDY*H+Q]<XU[5XUPLL!:!(H,^+E&
M;R2-*\I4=]4J%( "S<!<746.*?$2/-US3M.M5;*C)B.!/ ]DZ,W*NKZ15KRE
MKK&F]4)6EQ#FF!SQ%(T#B6.C<&N["=S"T@X/ ZO5DJ6Y\-Q%.7RL.WQ7,?QD
MCR>&YK^>,'S79!XKY+SG:2[1=E3.:L?/W-D]JSU]BHV7TURM>I?WR50;<DXS
M5YY4A//*E:ZT1,2Y34*=YB.:(E)%U(^UG%*=Z%FG4HMH;2JQAC][ RO$PAP8
M&[@X,!:XD EP\8$#<YW)8#IK#P0Z>9X+=K@Z1YW-'(')P1Z#RSXV>2X=4Y\Y
MGI$OZ=K'(]JC9%4J'.J2[)*EXUV>C8$JL0T^Y S2)"!=L5=@2WP*I878Y4S4
M4Z&(K9T6:"(4U7-2K3-Q)7801LR =Q87->YN>>QY:-XSM<W@[/$NLMW,P6$@
M@Y&,@;L. <.PD!S@".0)Q@G)]=/X.CV$I*L<,<B]J3DP"TUXWFQZ(KW%@\99
M;G1I-[C>MN%DR5F=>K<Q!EF15RL3XVHELS;PSP=5'F!/&$EA7]^;=-M6;-:A
MTZ!T;FU7&6QXL<K#*X!K&^,TX<QH<7@$ E^TYP2>KZ/T'".6U*TMZQO50$.>
MP[ ?*.X$9:XAF#WM) &5Z0WN-;"SM"(+F'DN$#9VG;$:[NC6D7>D]=^&7(72
MDV&U&,K_ !4N^)9DD]W6_!*97M2U<.96.QO@A.!Q+=[,\<\6M=CCVGGW871]
M4X9VS2C))&XM?C@.1+0>!!P.STK?U$<R"ZWH>[\?2;2-=$-27'<Z"4YK6]^I
MV0CN0UC(4K736UM0O=2KJM+>]=&],UB.,,H('#;,W:#_ '70D[>P#?V<2>:C
M98!X31EO<Z%Q=CD/&$H&>\AH&>.WL6FYOF ']\.X_I4J,UU2Y[W>1Y)4L0G6
M^FG1HN?H,%%MK<U^-M@BS:2UOHC1+VNKF06PG :^1I)_?8W:.[):\G';P;P/
M#B.*JS,.+F1D#YKW;CZ@6 =W[W+)SV+:<Y/E 5HU-\3<HQ;*M[THP6.J]I'3
MK6M[VO3%,MEBEE(UTWKIN+2]M736F=Z4G:JA""2&SP'^\\Q@_P#\I6L;ZANR
M>[&529BT9=#-SQXK!(>?<QSCCMSC [2"MW7-/'+7XTQ-'U%K?322N0*Q:N.P
MG5;WTTV.=>H2O!DN=>FMMCONN)WM.MIUM2=;CP>4@EH:\#&=DD<A&?0Q[CZ^
M'!/"(LX.]IX^?&]@X9SQ<T ?6599WM*]GZLR5)B9WF7C:--Y'GW*K1DD7"#\
M"RV5 +\BF#C3$&K#<E"!1GMA!K?;>/(2D()+YCK([E;*5R1DDC*MAS(6[Y'"
M)^&L./&)QYO'B1D#!)X E0ZW686!\\372$A@+VDN(.,<"<'/#CCCPY\%FW6^
MNM;U[-ZUO77V^OU^O,;GR60M<(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(M-]>GJWTWA%CL^!Y)1(%E05_@T!$$+>8C;/1=S6@6EK[WDQC(&T4]Y8
M[2?Q&%F)+)3K?>(?)WK67&F'AOB=GAES) UQ[_.9(/5P''T<%:<V7)+)&CGA
MKV%P'=YKV'VD^K/%<13_ #.#U;3%<9V;6]*WYSWPVFC[3OU=$>C=UCD+3G>]
M>]N[EFM(Z:UII6E;VFK%8EW&=@_=!ZN;// )\CCL!(!SC.%3^L#&>I?QXD!\
M?#T F7)]9'K[50N^7 !O>Y7B&X/+:]3SU:F:+-!;Z=>JQTR%HK\R0WZM=-:A
M$/[WO_0:UZ\C9&1PGCSQ\1PD#@!VD["WCR'C9/<%/6/!PZ&3UMV%N?K<#CTX
MPM&N7ZSI*/2<-R' N;Z>.F7XROJ1 M;UM6U&3@-?/KC++>M;VZ3J86*WKIM;
MR=;3O=7@[R0&NB>7 $!LT1/$9Q@O!SWC&1VIU[!G<)&8SG=&_'#N(:<Y/+O[
M.85RC^6N+99[RT9R-1CRNFM[$$MD"06GKON]%#-2"WT*[W5.TJ;UO2M=W>M;
M]64]1/Q(AE<!S+6%P''!)(!  /;R4]?#PS+&W/(.<&D^@!Q!)]"GZ'6W6T.M
M*2XVXE*VUMJTM"TJUK:5)6G>T[3O6];TK6^F]>O6]Y9)P<$'/:,'(^KG]8!5
MP$$ @@@\B#D'U=ZJZ^K?JWZO@]77?\GKZ8R.'9DXR<C\4SSX'A\<,+RM^[G^
MZ_WK@ZT2'8[[+%G76;ZS% E<T\K0[R/3M,1.#I,CJ)33$;4J(LK\2Z-*62P-
MIV?"@R<<#"/"32S2HOT'HGT:BMQ_*>H1E\._%>!P(#P.!F>.&Z(.! 9Q#@'.
MY;<\OK.JN8YU6J_:6@=?(W@YKC@[ >/$-(+\8/';G((/C4F9R;LDM(3]@F9*
M<G98ITZ6FI<PJ1EI,QW?5TR2DS'72S"'?:X24\\[OVJ5OX?3FM;&W9'LC:.#
M6LCZL 9X<6M :WG^[@ <0>*Y7=DDN(+C^]QR2>TG&<D\SGV+.O9L[5W: [(]
M]!Y%X"Y(L%%FF"Q2)6, -6_6[<.,YI>XJW5AU[T/98Q]O2VG!I,93K"5J? *
M!,;9*;P[^FT]2A=!;K12AP+0[:PS-/SXG@@AS>8R6CGDY*N069ZKVO@>8W9
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M2VVVVE*$(3K24I3I.M:UK,0DDDDDDDDD\R3Q)/I)XE9(         &  .
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M*61X0%CO*ULA>HV\MU*IU<AS^N:<UL4NXC ,M9_ZO, >+MAA>0, Y6 :ENL
MZE8WMR/U:X72,QG.(YV^48[&0 _K&DD<1C)LM/[57/D5*\A"6;W/KM+$V#5T
M'W,IX^N/9HM]2&-:HM*$\.'LE@YRH4I,!$L#L20A9=4A2/*'#MF "'ME"#P-
M,JO\>/6-/$;B=O7"S#, . ZV,0RAKCCDUS@.'$CB9^4+#3MDTRZ7@>-U74RQ
MYXGR;S)'D<?W@#SSZ)YKM>\O_P#V>/;+^F]D[U__ +HOCWO)^2H/]\Z7]NU_
M]KV_GV=D?*,W^Z]1_P JO_\ =*G?;%Y1:WW2O<^NVDPO?K2EH?LSGZ4GU_C;
M=CNTD6RC>]ZW^(MQ+G^MM&DJ3O;Y)A/+6M)QZ7VA^-9I^Y/E*8?^Z]1/_P J
M'\IW#[_N&5I_ED\D?]@'MK?5'9W_ /\ 1&/DF+_?.D_;L_\ 03Y2E_W7J/\
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M#"^C@LQ[W7YP)Q.E!R;'><[^#J/2C5M28Z)\P@A<,.BKC8'#&,.?QD(/'(W
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M,(F$7S_EI3W1XSF+D/5'CNS()P@!S+Q[$U)/)07(*KV=PZU4(TWE.;C'*I*
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M@%C1+!:SR(*$-G9:':$T9Q8SP<1PQYN_))+> !;CC@DXSM+@T!K#R1Y%O$M
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M*%B_*_\ ,L7'04.FOTVF\7TDDL<<..3(,Y<1G%PD><0" 22=SB0"7.)D>][
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MVJ507J:<+\VM,T])/6#WR\INRKW,7(/,:\TML0@@#$3FC Q@"1PV_P!E$3L
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HK^/)1.FOBU_5^?K_ +?7_+A%KA$PB81,(F$3")A$PB81,(F$3"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g90195g75o07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g75o07.jpg
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M<-O,#H7M#C<56KR#7B!":5/TY55W*(.0&$/# RB;#&U-E83Y]Z,<YRJS@2<
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MLK[Z:_9M2UX3K839RY,T+,M):</3O\UN/UW\ZXYU6P8H&%? [S7DY$_R&)Z
MR]?G=,_TL_M6]><[2[2+(XU%TD?B?UKFV],=<M&KQU#<\+W45OT[;NFMG\KM
:[_NN8C?Y9<V^5>&H?*[.:L#^*IUGS5J__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g90195g83u54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g83u54.jpg
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M P$1  (1 0,1 ?_$ !@  0 # 0                <$!@D(_\0 (1   @,
M P # 0$!        !08#! <! @@)%!43$A;_Q  7 0 # 0
M     0(#_\0 *1$!  $# P,"!@,          1$  B$Q05$#$F$RH2)"<8&Q
MX9'!T?_:  P# 0 "$0,1 #\ VC^1I8U=:#C-^3?1GHO/U!7Y5E1RRO&-'\[Y
MC"3$W;K=UG;@IGT"K75XJ_WCYU*"Q KK>OUB"^)LUPM0DRS4:=O6^3,NQ QS
M[U'31>UMM5E%+WC$6NFNVKJ%="^$H=/AP&AVUDEJQ%FG<] DK=]P<<Z=M;IA
M.C5?K#Q3\2R:K7S\<?$]Z]D?,N@.]G\""O -)]ZAB$@+'NV8SSNRGAJ;X[L
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MTOI7JS,=PPW$L-?R&0IV;7D#0]8W?6\W-(KF%TEV8G$,L*:#5*KY(,YK?_-
MW:ZQ#.W8^%M< N_W:8_F&L7#(A,1[*\E59=:676W77'<LA:(D!F<R9CAS6BG
MG@MOYE![7/2RMGZ;J'!XO#: Y>>(LR77!Q=JWX<XLV8K4#%Z6U4[?W(\DAHZ
=:$CWM5X*OT8JD\]$[ZS[5G=VS\"I&KAGS^J__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g90195g87x28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g87x28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1984&AO=&]S:&]P(#,N,  X0DE-! 0
M    %CR^5I(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!X\
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              JH   2\          $
M                 0             $O    JH
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   JH     4F=H=&QO;F<   2\
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *J     %)G:'1L;VYG   $O     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      ,)@
M  $   "@    6@   >   *C    ,"@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MEN]Q;2SO980$#(#<I$2=@P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"14C,L'1,U/A\18D0E)B0Y(7)28T<H(UD[+_Q  < 0 !!0$! 0
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M!^]._P":YX SJ.OK90M;_4]N#LI5/X:/T)ITIMR@SS/YUV>JE6MO!>\O&_\
M%<_]ZKB^HO\ [?CP=G+_ *:/T)^T*9DRG?7^M1K4.*^NA:#]Y=M_BN$=B7%:
MC?4DGQ_:UN#LY?\ 31^A/VA,\S12_P!2NF_-O&![R];_ !7+W_[U?CKO]OIW
M.RE?TY?Z$WWM>#M)G\Z_U*WZ[_&![R]I_%<O<D?&K^_W(MIXX.SE_P!-'/NI
M^T)G7_.O]1Z[[U@>].Z?Q5ZWTZBO/8WUTT_'@[.7_31^E/VA<\S^9=/[E4IU
MI3X0/>7=@XX1;NXJYOW-C]/6V_!V4O\ IHV]Q-MK0=I,_G70ZJ-_.\>0^M
M0M2$I2E( 4H )&@2+$ )3K8#0>!?@[.7_31O[B;[V@[28?SK+Z9E?)X/WEW_
M #7 ;V_G78Z?_EOWTU[7TU.SE-_QH_0FWEK]-=#/,_G7O[RM":WW>![R]OU'
M/6RU?(G>X.PO?2WV.RE_TT?H3]H,\P_G7^HZ^.OQ@>].]W7-1_F*%_6_G;8^
MH'!V4K^FC]">FVWV@"YE64MQ0]Y3U\=_C!^].[=5S8;.*&]P-R;_ -_IP=G+
M/_KE^*$_;P^P>#/,_F7M[QTKOXP/>7CLXO;4YU'^OS\\'92OZ:.7<3Y6'*#M
M)FJU[>\KQ%X'O+NHZKFFA_B*OKML1Y&WKWV.SE_TT?I3]H,\S^==:CO*TUOH
MWR,#WEW;J.=S_B*^G?Y_;3N.#LY?]-'Z4_:#M)E\Z_U*^_JF\%[T[_FN=]UJ
M&]K>-KC[]NQV<O\ IH_2G[09E_S*\%$[['D8/WET7 <<'R<5IW)\:W[^IX.S
ME_R(_2G[09YG\RZG^95?C6"]Y>_S5_\ ]BNU[]]_)]-N#LI3?\4NY/N)Y<N4
M&>8?SK_4K6VNOQ@_>7=?XK@__=1\CR-;_P"VFIV<O^FC]*?M!GF6SK;;,KJ=
M=JQY2\MM.5"U(2"2$I44I%S?86&I)).Y/>YOP=G+_IH_0GX4I"9UD^\LG_L2
M?G!^\N[=5VY&EW%$VMWU'?N1KL>#LY?]-'Z$_;I"YYG\ZV%/?+?.O0=;0#)>
M[N+-C<74O0ZC37?6PMK]^#LY?]-'Z$_:#M)G]1?ZS]_C&TW6*E'3D9J$UA!.
M8H:E2&TE1 !5E0XD7( %[7L +Z#A#(PY+JD2U'<H0_1RDO\ #I#DS)[=V9,
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MZ7W%MQKMI_7A0 6K6M&LW.UO6H'%35_3'DW+<LPI!=6WCR; G3L=][7/RU'
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M8C_;SJ? \\&8,[$;WM1P1\?/2QE55P?N*V=GLU/HT'[QZC?7;[[6_'2UK[<
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M6D'TY^?TZZP"[I\^ZO[]]C;TU&_"I-W)##34._S.N[;P?#IZ\8'6U[:$Z$Z
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M]2?=)V/G40&6""4.H&X-]A36V@>GC"!G!^]O[GZ?KO:>(QR.I?6Y-MJ_N'>
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MYP>C SD=]=M.]OZ;6WT!].%)<-=G8TV>NY =VU:Y@@=0WO;;ON>POMVW%_\
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MOAI:'XLB),IX? 0S=#J6Q<F3F# D*#@E0 + 4!_*HBI!"=]HD$T9U$+&=LP
MJE5!0@A(>E0D-<.[1M47$U1=@3)4@.LIAR7TU.-42VB5-0U&(5#<6J.''7HH
M?@+8D-HDJZ#(6P\I9(%9:)<M20R2&I5B]^\U"QH_[.IFXH%$L 94DY" P2%
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M2ISW0X8@&I3W27J[ Z.:1)>#L>4_.D5IEVGU%ARS,@*4C(NXZK?4D,O(DQ5
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MR\MGJK;97%8>?BF\4D2PF9*4A84: 9@P8^#L:@U !B:?*&)4"XESF"5A0 S
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M^HX85-L>G7=]K@ ^4#':]J7Z074\=M_7\[?+7@"P>O,L/B?D/"\(QV@=2VX
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MIN*FJR5K7!9+<*"%/-*;NJ5E0I<='+8#'I(9ES9A2#[B@X) />(90"GJ&)T
M#Q0F2Y.%6F8L+*DN&2RE*&H!(H="6S%S7\L)[/+>BX0B*F.8SK',BK*7[PMY
MNGU"E879J*(KB0N&\(44RD1(R5HZ[;3S:'7QFD)7EZ>S+0J8 I0[Q4Z@FV5J
M E@_1M0'B";Q&;,S2LB):2SI!*IA1H"22IGH035O=840,2RJO46WF&NM%>4R
MTN&EMAT"&R7"&&VGY+4@.!+*49I)2TQG;<4DK:4E/$I7)112<Q4X%59@-DL
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MNM)FQ(TL(,CW2H/S8,5V.I++@95(#J6W601Z][/8#LL%+G3U2YTV:%%*DI
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MCX&<BS(50B2'Y# 44SJ&TWU04Z.,4VF1W4J"%!5W)<<-V(5U%.)+B<''X/\
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MA8#U?(HN27->;@WAOPO9 JE'D-]48*A%EQ++,&FL8@H:Y<=C.ZJ\IMQ]2D%
M!Z4YV6D!H+<<6HJ!E"D)(%@:U"0LEF8S "2Q)N'!?:')Q$V6HYS-$QJF8<V]
M<JP ;%SF3M71PRL+BCPW(D: R@LJ3%FEZ2]59K&1]&=V*!392'3-!;)=DN(:
MCL)5THA44NIK3$KEJ65:AT@K!-:DDLY(8!A2[E[:6%Q/; $D+(!J$LD,^F<
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M2(SZS="R0T5J-@<K:D1P+)-]0+QSU@I2#V+O5\UKELS4WK<:TC-2F:MTK(2
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M!6,(-$30**QC+#X$)TL/252)*9+#BU*;9:3&2D/('2C9DJ+BTOR'BEH-TU8
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M:ID&IT>(RN2)3>'HRZA2I 5G"VZHW'<J],?8 '\=,HDNI;3!=;6XPSQ; E)
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M0#8M>EC0/<-6C[/0U%-_::Y!43G)@>I8<GMMQJDR')V'JP&@M^CUEMM88?!
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M9&5*'"A >;3?^&^ "XG6QR@JSME0NMI2%VLL<0STF3-4AB0"0D_S)JSU)!J
MH62:$T>$4G*2-K=-/'<:&-E4?,-KV-_0?E;[GB!ST=W ^+ $N+4_:$C2>C!0
ML18BY%_37\O2^WU>E5"0!X:"U*[MK]P0A.H*5GYVUT(T[\/74.]JMN]OV@A$
MFQ\X*T:W TWTN=?D>_>]M"1JB2!0C459JD6;34?(7,(7H=-7T9F/AZY,JHQ,
M^90 ^(#,+BX4+7(ML/GIOJ-.'\WI?1B&WA,PU.I N/-[G=[0R9\0_$D@%)&Y
ML=?F+]R+^!M>W"$:V+?;I;2PWH\.%&L1IL1Z^\,&IPP>HC+<HS$;ZI\:[BP(
MOV/ROPU0"T:.U.1]:><3H4Q;;1]#8#=M^C/>(EJ>'T.RW%A*0#VL=#F43V];
M_7Q;BH9;DND%B14!]]>K^,:,N>R14UK<C9[ B[Q9(ME)N=#_ %L=[V_#?[<7
MXY^-1XD#47!5:]M !>Y)T[ B]N]NXO&LZ4+%_G0BH)%+[^;T2W()H 7%"3^S
MJ;J*-"2]F2HJ!_F[VM<?$/E;>_$<2LP&VFOKQJ*<HUUDFP.NO;M<:G3?A0"2
MP@)N3UC1="C8"WU(U'??QX%[_725+!P+ZWN.=HC4["USJ+#EK0V\W>F5EG-I
MV N#J =^]CKYM<#OKPZT- =[L*O:CML>O@0VRRS&2!=>@L =!_+<V'?^8WN1
MJ#<[Z<,-02["HT+U:WR)(Y:PA6 [.S,7%+D::C7F=J1D<BH5\ 19 3F7_P"8
M)LD$WVT42/\ J%QY'![KEB%$L'(HY))=[LS/9O&)D.1WBW,[,#XOYQNLM!*4
M_" 4^ECZ @CL!_TV %A;OPUG);QK\7!/Q?<DEX>2;/31O$<MZT'*C0M4P);E
M-K<_DS *TON1>XOJ F^FH(UL+6#P&^5*>.[^JFI8XI72E?D+:^GAU3?W?9*$
M)&=204K-E)2K<A:B0D@JLKLA%PHBVG# A68EZ E@_P#FNA=_F"YPPI7?ET]6
MAK+A==P!*;+S!LI ^($G*%$7*B ;9K#38D%2;O*02+N=K^+_ #NY$-)(<TM3
MJ'/JND>7*4^V7D!*5ICISO+RD=,'*#?2R=2H :?RJ.FG"9"'!H ^8V:K7Z.+
MFY)?4"K<["[MIMX&$I;!21=-A>X(TL.V@(W &AUTX:H-HSNVK]=CJ.NC/#@0
MQO\ (NY!:AII5G\FQ%GL4A0TW\][WW'X>FO",U#0GR:]>IYWO _/H=;BVQI\
MW)BK/M@4EA_V>^<TMQ#97&P? 0R5-A1;4S7(DIPH)2I2590@!0%]P,HN#>&)
MG#"(PPFS1+*YBUHSJ"2.XE*5)=E)!02D$$ A[LTAFK[,2PM02224.0DV:E P
M8EJUJ:PW/8/A0JMR?JO7]XZD3'%4:#D6?4(*NF]1,/R0"J'(C$C,^X05$G47
M/@E8J=)2$([$IS%66;AL//<D:&=*6H6!9)#,X8UAJ9BDA@$D792$+^*DDCP(
MB]$?###5UQJE78ZU)"D%-9GR[9;I_A)J+LQ*24DI)( 4/AU"B3,<>54F83 3
M&+D_A$RB7 #$X<R0?([.*F'&=JJ5)(_Z%(__ (*3U+]3=V?S8]GR@<^L%2.7
M^,<48XBTV?/@S/WA0ZA0Z;.BNT]Y$B-)9DO8?DMI>9="V@TMAQJ0VZ+,IDLA
MU.OP3VIQ7L]C1Q#AN"P,K$B5-DI6I.)F#)-2$K 1,Q"DYB X)<AF8I*@:F-P
M^%Q^'5AI\A 0I25_PU3$J!2K,#WEJ#7!!!%20R@#%?T?LJ?9MZ@0[5^<$M:B
MD%;O,>I-A:CJI8;A1X;38622$LH:9;_E;;0@!(Z57^J_M8I2E"=(2"20E"%I
M2').4.LD!-@')  <O6* X%P5(#\.EE@')F3G+ ARTQJW+ 5L!1GC3OV4'LFM
MH2J73^8]1=S!5IO-'&:DIR:V#<>J,-K"R<JPXVYI>P2=0P_ZH^UDPM^*""0:
M(7B!<;">SVMMJ!!_M7!DT'"L*19U&>HGG6;3UO$E4C]F;[(],:3(3RHI]34T
M2E*<139^($+&;,I3J:L],;<N0D?$V0$W00$K4DUYOM[[5S@YXG/ (;+VD_+8
MT8SF.]0=WL8FEX/AB"R.&8%+,Y[%2C4?WK51W)'.%2![+O(KE-B^B3*'R<Y<
M0J+B.8FDMJAX0H,9^EU920F*&C%A,ID1Y2D"Z'4++5W7DJ2A*$.59G'^,<4P
M&(S\0Q,O%X26J<2)JR)LA)5V@)65*04)J"E0?N@E04K+K24R#(7V&'PTB9)[
MY,G#RD%:0%%RO(5 @)-U-86):VE+HE+I" S2Z; IC6@Z4"'&AMD#0#IQFVT[
M;:$]@ 3QQLW$S\1WI^(GSR+F9,7,>KMWR?*P>^L1JF3%^^M:FMF4I3=')8;
M4&D+X0;6M8>N@\G373\.W%91!8 4%!T]"&1Z#9.XT%KC?^XO\SOPW6[_ %YP
M1Z4RK46(OV)U&V^EN_8D6W[\([[TK\_$ML0_*%;H?7GZYB,7NYUN=CH?!L;
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M1XC46'P#>.OQ?E>,+2 HDJVO;YG?Z_+UXDB(:D\NKD^5@;PM1HI-B18   6
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M7Y4$$(4B.ET'2R@=?6Q)MWT!)TMK<\('"JUZ 6% = -;V%-8(:M1ACXT!/\
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D'?D#8TH](8KK:>HH>"0-MK_+UXB40]AKON1H1M#PHBQ^4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g90195g91c96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g91c96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *""^$"<CA"24T$!       5AP!6@ #&R5'' %:  ,;)4<< @   @  '
M)0  AR<C,U.3@Y,1P"!0 M36EC<F]S;V9T(%=O<F0@+2 Y,#$Y-5]324=(5"
M!3+3$@1DE'55)%4RYD;V-X.$))300E       00ISA%WWEST8V3#W%*N%VBS
MA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %     %
M!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G
M13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W
M!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M      "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F
M]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<F
MEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M      4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&
M)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;V
MP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&
M_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M       $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M           %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V
M]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4F
MQT                5&]P(%5N=$8C4FQT                4V-L(%5N=$
M8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W
M!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M  .$))30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M         _@   .$))30/R       *  #_______\  #A"24T$#0      !
M   '@X0DE-!!D       0    >.$))30/S       )           ! #A"24
MTG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M    $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M$ +0    8       $X0DE- _@      '   /________________________
M____\#Z     #_____________________________ ^@     __________
M___________________P/H     /____________________________\#Z
M  .$))300(       0     0   D    )      #A"24T$'@      !
M X0DE-!!H      S4    &              ,.   $E          !
M                    $             !)0   ,.
M    $                         $     $       !N=6QL     @
M9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M    !,969T;&]N9P          0G1O;6QO;F<   ,.     %)G:'1L;VYG
M $E     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M  !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9V
MEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7
M!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M$       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M       $)T;VUL;VYG   ##@    !29VAT;&]N9P  !)0    #=7)L5$585
M    $       !N=6QL5$585     $       !-<V=E5$585     $
M9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V
M5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&
M]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V
M5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115
M-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M    IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M     +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M     X0DE-!!$       $! #A"24T$%       !     HX0DE-! P     '9
M4    !    H    &L   '@  #(H   '7D &  !_]C_X@Q824-#7U!23T9)3$
M4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35
M-&5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                           !
M%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
M   !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD
M "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6
MUI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/   "
MQG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8R
MD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U
M)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M      6%E:(        /-1  $    !%LQ865H@                     %
MA96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M      )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8R
MYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                !D97-C
M   "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('
M-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&
M]U<B!S<&%C92 M('-21T(                             9&5S8P
M     L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3
M(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B
M!)14,V,3DV-BTR+C$                                  '9I97<
M   !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M  5Q_G;65A<P         !                         H\    "<VEG(
M    !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #
ML 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0
M"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 2
M4!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0
M') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ H
MX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@
M.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*
M@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@
M8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X
M8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@
ME/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"S
MD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@
MUT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\
M\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!
M*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%5
M85>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891
MB*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]
MH< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1
M^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V
M8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B
M>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+
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M8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L
M"P=;#JL6"QUK)+L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-E57<CA(9BDT-3E#1$5&1V1E=7B#AI?5_\0 ' $  @(# 0$
M P0"!0 !!@<(_\0 2!$  0,"!0(#!P(% @0$!0,% 0(1(0,Q  0205%A<04B
M@083,I&AL?#!T10C0N'Q,U(50V)R!Q8D@C13<Y*R%X/21%1CA*+_V@ , P$
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M8J2I\#.TO&O&'4?X[,FHC4?=J4-)0"$DD,Y4'<:21$RV$:WLO[.)9/\ P?)
M%IT*20\I\VHARS.'<8$M>]O7V@]#NP:;I_M <S:IK27:MVJ+6J5Z6DZQ0U8-
M7DTYY[.DSTH+-1V@,9$B(MR-H:XKBQ(!I7M%XG35I'B%9:T*25!;"FH+9)1;
MXD*L+A]V&,_\G>!+25'PC*TT*!8@%2DE(U:H4#I(<$L?F&Q G._M^>V'H&J7
MIH/'WQ-J?NO4 FJ:-J$].JTYL>4JU-(2>2(B=;)KQ:?('N:7JDSK5ZJ/[P*1
M#K>/^+TU+;Q#,ZJ:P%4U !W#!*"0$^94(\Z@5$ Z27&T>R7@"DI?PC)DK^!2
M4+8P3YO,\M+LSVA\0)SC]H[[:QCDGY?]IKQ9;39M<J1RS_OK2JAT73=2JRVD
M74;5;3[,]=Z=B*[!/'[L\\0BBC\N6#RI(5%^T7C&KR>)YKW9JI=2U,FG2J '
M4HA/O $*U#46 (XC!A[(^SI9_",D%)$@(4RB/]OG+BU[N7Q%5+[17V]](NZ7
M)S/[7'BW%0::U7NR0<UU'DK1U+]9Y-9M:=-HT]TZ,]"<QP2!?X\Q#I:*0O&$
MQ[0^/!2/>^*9M(.L*":P44Z%)'O%)"7"% P6L8 <C$S[)^SFE6GP7)'<*]V1
M"I83_0S&00YV;##=^U$]O*SS'+I\?M5>*FFT5?5H;$E?F2B[V8IDLSZ3-2]Z
MT^<5H/.>K&+T$<DR5I(DEJQ20SA8_P#F?QHUB$^+9I*$"HZO>I7K<DT_*M(2
M Q )!<"6>,"7[)>SH ;PC*%18 >[+L!YB?-#$$N7ZN7PTZS]I1]H54U.OI\'
MMD^*VHVBL%2[6TW6*$L;6HA--8ETR:E1?S*TU-UG::ST&"S":CR !,[7[2^.
M%6D>+Y@*@'3504E;.U/W8.I&D22!YG!#@X@/9/V> 4_A&3;=Z:G=MF42.SW:
MPN5ZG]IY[><D<U_E[VJO$J+EV_#&LFO:WKM:O7HL;%^Y!!ID3U+5SWJ73XJ\
MN9:KV[:1F..**&Y6:0@]I?'2IT^)UQ14$A56HL ((4J "'!6G2 &>7' A_Y4
M]G E)/A.5"B"4C00%,2?][F&<<=)Q&&L?:>?:."K-9TKVM?%PUO<8!-J%C5Z
MU6I5MUM06*1_XU%6KPVPJ4P6ELRS6[4=5%\V:) 2A[0>/E06KQ'-U*:E^Z U
M-.J5#JD DB/*#L^ YGV9]G::5#_A>4!2RB4H:UQ>TMR#SB/^8/M<?M&8='MV
M]/\ :W\4JT/+F@:3/?GGU[3HKEK5M>L5XZ-:ZDU>4&W)3EGNRU:BI^[H.AI7
M\RM-*]]DO$?&*Q*JGB.99"13"0HGWBB=-2H(!4$DG1#LDM) QS^;\'\"II&C
MPS*@J*RI6E@@,54DDZF!4P0KJO8 8!M1^U@^TN30*&G4O;9\8?WWJFH^\7;4
MFKQ,VDZ5'I]&Z]^:T-+,='3]-KZG!'>KEFEEU*9(K)C-98N+6AXIGBU6IFZP
MIOI""L%=1840 &$E92?A^$ QOBHK>$^%)"DHR=#4 "5:"$I20"5&?Z=3,S$L
M'G 'S!]L1]IAJ5N8\J>V=XZU^5.7=*!EY@LZM1BFNA(PM[5-1,M+RVL7M1S7
MT*B\R_PY:L3&-XKLB6.7SF<!*:N96NI46AZ85\$@I0C2' TN:JKN" Y*0JIS
M/AV1"==/*(0@4UJ2O3!9)<K<WU-[L.0Q#D *:)7^V@^U%U74M1]T]MKQVJU8
MH9WJUZO,M65(J],&*-GLMI ELS2".-Y9A7C,[R2RE:L)+1W'O\PA-(E9*E%
M5J 222ARR"X2TNDF[.2J,4@R^6JKJA%)( "].D>4,LA,W=4-!/9-EUS[8?[5
MBO!>U/4O;;\<],ABCB>O6',-...(6))#769!ITUCKD5#'3@ES;M(DEV>1:M>
M5GU3S-1133IK6LF5+)=I8LHQ-RWE0?(ER?+*IE:* NI6I4Z6EM-, !P78EG)
M3L 3K-R6@B:?;0_:K#WB<>W'X[K#+9454EU^I((%8&.,2?\ 1I),C>8PKL_F
MMT!LE49BVJLMTC5\()5I/Q,Q+;LS E@),N<)#+( 4I2  5!H<)> ]^L>NSX;
M8/MI_M5C'8F;VZ?'EE$PC57YAI1!<!F)RVF9C#9).3U(D9'220%*:BG2':'L
M_I%P/KVP!-.F4J)2!YB)EMQV!F\@#JP>Z'VS/VJA?2Y+_MT^.:PV_>)?@YDT
M]#'2A+#S[8_=;%7L2=:P1EE9(T'0"2A(JE=:4KT.2G2D0Y*B0X3_ -HD_7G!
MT4*>I'O$I 4ZH ^&2"KN& $=,,>H_;5_:I":5ZOMS>/D<)=T@B_I#4+967&9
M6.G'#,%;^&@Z4'P!NY)4*7I *BI0#F.1]AZ\F<+U$TRHE"&22P'4$_=B6 :P
MM&&N?[:K[5V&.9F]NWQZ4QLRR#^D5+*2$%0H/[L7/2-_+ ZCAV;9<@P6[,+A
MQU:^]OMN,!53 !(V)&YF>FWZ2)?'WIGVTWVKUE^M_;P\=UCB5S,9>8:I1%$;
MD,ZKIN2P5'?I4=3, %!Q@P4M24G<NP 8%]^@D@ VY;&4D!2G.EA=RWKM%[_+
M".W]MS]JW/.T\7MS^/,,+A8D@BYAIJJ",1HKC.F$L[QH6D8L6DF9W."YP1,
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M@D;-+@#]-B^W-A@WJ#!4D=^^0, ?+^7RV_/B!#N !  !)/TCYSWQ)8:7B!#
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MP>6W^>Y+1&$UE!&K4YV;9I>#'S>2&C$GZ;!RY#6@:W)'6I-<,%(RQ^;!#+%
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MEH5*D]NO(UN_2F)98G$:M(+J%JGNTDI4-%/45+\H470-.IF+ Z0[%L3-.HH
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ML@S\P6C%9AJ,QB>;4+L%D:7&4+) MC46JI8<-F/R0KLZ1.IM<J44DNM+&DE
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M9V"]3A3D%F4"0C.6P22Q+9)#;_[W$P0E@8 %W&S[._8>FV!:=3J?<]3Z[O\
M/UPF ^#N)(PP^%.ZD-NV",HW;&0RD9/40=I/];8@WY^_&'*!HRL#-A@)) KN
MH!4EI" 5WR.MU4]L%<@=EX@;+;GTV?Z22V^[/@J6&EVWM)$EN\]F8R^/Q7F$
M%N1Y&>Q85%FD<]3GKFC=^E\]0P5Z6.ZM@@C! XP@>3A]K2(<%[_3& J\TNLW
M+EVC<_._[8Q:E+T]$*OLL<9<8W4M\4BD8QLX"8!'W 1G)SM(+%PQ?EW;>]SO
M]<14;"(%N#Q],=DO[' .GQT]MI=_A\)/"0D$ '+\X<U-D^NX(^?KOOQ+$,*/
MVDT=7VANFCI&/]'KPSWS@_\ M!S]L1@@C^?IC'%3G?\ 7:9IC[JWV^7$V&+S
MPXO0TFWO%6O(2V[-U;;ICG0U! )''R^8SG<_IVQOPNFX_/ST[;X:9Y<AQ9XM
MVPET-O+U( ?[A SG?8G([>O\L\,$.D#8DN1)#L.NVW+>H69PYW#GOOM\\%&I
M;HV^V-O3Y?X_\/KP1 AI.YC=I'TF PYQNP[P9>S%X83^^ *XW1*0/NDL/E@G
MY'?]3P0)=)/T[?V?\C 5%E G;<[AO01-FZX;W)Z=@,YV!WR".X_';<?KQ%HZ
M6_#C"IPW4#JW)ZQS+X:I"3G)^FWKMC&_Y?D. K#-N6 _0>DM:PWQ- B.I^C_
M ..C89H#TVFQC[QVSCYG;^?\L?+B!-^G[/\ G8XD)4WH>99CVG$E:01T*3M@
M #Z$8W_/^7RSP"-\,)47!(#!VE]_\L?[8/J;9"G8@C8$_7./IVV[;Y'$'$D/
M#.1+W&]X_23B1+@GJ/U9[[#;G#XXS P/<HW;.=P>WI@^G_#B2@&!ONT;;&Y^
MF^!I4ZF:(;E^&F;[0TXECPBYB]WOQP-+T*'Z0"P4C!Z3D$C.1@YS\QV[<3[4
M90U$D@7!)/<1+,-]B7;8X].]B\Z:-8)4KX2[6?5I'-@&M_;%U[/,=:A16R9!
MEEVW4#.#L3G89QN1D;?/CS8T27# F=]YG^XX,#'L9S>D))("0!,S8\S#-&Y)
M!8@ <OB%3><23V5C4L?[8)SDYW#?$03\6QV/;?/$Z64J.Y*0-H@/T^;W[85K
M>)4R6<B[W=QPSVOWG$=\Y>*D2J8:M@, _2Y#*S%6) Z<=@ "-P-R/KQ=Y;*I
M"DNEW#D,&-Q^'H^\\[G_ !-DGW:OZM+EW'5Y-CUDFX.(TTGQCCT^:026$1'5
MT9')'PDD;@C!&3L-B1@D<6XRBJB0!3%W<  AVW#<6E\4J/$UTU$Z]()D/^Y.
MXEF/?$/Z[XMFAJ=J33[L@JSN66-'=%+[;AX\A<L,8*XVSGMBPH^&+"6?022X
M_J^6EFYMNS[U68\43K4IW#D"51L-R_%P_8/C[T?QWY@ E6*K+TBU ]@))U2R
M1(S=70P9$8!268,%9OQ/5PVG)4T)(\I*@0"7$_;9OUG"7_$EK(8J2Q<R^S="
MTV-^+XG30?%A.<8K%:G<GJ6106W'*M@ "T)52(F?J=@458I)6)Z8%&X*D<**
MR "@Z94"23LQM#26BYCOBP1XDI25@*!8!47NS/J(VGJT\,M'WC5-;DAGYA\F
M33)1$3/<7W6::*5E?4JENOYB6*CJ\X93)&XZXU*R! JXK) 4?(LI)47LQ%W<
MS!!)Z$!VQ 9XKJ$U-0LS$NF=B"% 6=C(V.+9<AZMS9H%Z#3DTVSK,U6-R8M/
M#3)J-:",Q^]Q&HC0^8@>*2*:&*2K:AGABD1G(0)9C+K +()*)*@"=1 ,L&=S
MM9V<,^.CR?B*2$(6IPS .D)$$.6   N[\;L<3[H]#5];J1W,J^@W(1>M15(Y
M&U2G7M2"99I]&LM'=2%)DCN16JD7N/F@R5VBCDFC:F70JE9(1[M)0"=*@:J7
M=]=-M026=@ 9=\7B*] I2ZM9C2&:FX8.FH205.9XXY">:=-@33Y].L2S3M$B
M)$\;R3QZ;-#$L]>T7(CIA$AEE0)*\C35Y8J4K&"7J@1J)2$J025J+E*@@C2S
M%G, ,.I(8'!=!J>=F >"Q)C:&,VCD]ZC\X5M2H=-%UAI21==RM,T<46$=$,I
M-DNT\BLJNRO(A:JP>%G:2NXB2*5I9#)05 KE*=9=TW(=H=B+@@F^%*S)+@DE
M)WA,-=IZ ,&B#& &CS#5M3>Y16IEKO$)8J1,<<].V'"6_+FE4-!80&)@(69Y
M%9'9@L0P-=)26!<(>P+AR"00Y)8@%HCN<"%8'5:!'SD=-K$[=<+EU;53>KUP
M5GG$CPK:]XD#SB-9A8)=V=3-.9V9H\&*2O*F(@54<:2NH62D$)#H> 1!(,O8
M0;NS#$@6LH'4 227+@;,\B-NK0<#',6ISZQ12F&IL*T,LF%"PAX,Q2>>KNG4
M_F2HD3!F+QM%)Y)5%4G:%$%!)828284((+$2TM8PX+QBU I8$6<]1RTEGZOQ
ML< -_47Z9M.$:0A?>X+,L*F!0B5^A*L+QOU2=,J(BR+&9)A7C$TQ#/U.TT6J
MGS#^6I(/F,G5J(+L")()9)46 V1JJLD. 7!(+;6209G@/=^J";2&MU)YJ-98
MYQ/!=:PZQK(A@+,*ZS$D],"V,3(68M:BBF1%:+J5NAFU4EI2I6I&E22 [L29
M!#$:C(MY2Q>^%:V73422DZ%N"7:X>\N6?J\6; -9YALU)M1EU"M*;\FE346L
MR225TFE)04M1=E*M*98.LR2K@R%XY9S*\;S/TN40E6@I4"-25I \RT@AJB2)
M\R0Y W4"0SL*/-%:0O6EE)"D,8U*=Z:G-D+3N22-0)+"88U@V=4>&;3_ #>N
MJ\K3P9+^[6;$\<[20ITMY<7O,B=0+ F8D@!)P#T^6(I(6*Y&DA(2J7538@ [
M%TW,[?[<<MG*9S"Z9RXE)J:DAO\ 4@E@9 "K@F>&5@E!KZG6TO56)74IX'AU
M*1)8'LF:0ZW7N"2N DE>+^-#(R!'9HYQ(2H!+1J+-'6Q=(4-#N$J#H4"D[N$
M@3N&X>=)*,PE*BEE %*V "DEBE2%18E1) V9[8).=UT;4J'+].!LUO>-3>W8
M9'IR/2M7JXI>=*W49KLD%6>C'#TRO'5J")(?/0E]4%K"UK 8H<@$/( 8DL[!
M]3C=C(?&LY20L)0H>12TI67 )$VAGNEFD.TX@GF+WJ$S2PNS016YJ<$ 22%X
MZ^G!*Z3SQ[&((DD1@9BS2O++-+F5Y"]UEPDE"5D#6A*R21YE+&K2+O\ U/8!
MF#MCF\YK25FF'336M"42R$(.@DR&9TE)<OJ)N3@;UG6;&H/I33S"1*.EUZ**
MI*QJE;J)(7OU2LHDF;8R.Y;;JX=HT@A-<2DKJ$B/, 4@,_0$D=;O;%;F*WO%
M4"HA011"0/Z3I43+/*F95X?MA)=D1! D*,L,G4)%"]1>P@,LIPP(&#,(^@$$
M@!F#,&/$Z3D$J+J86V27"1!W"7>=N<0K*"2D)"M$@M=2Q)U N&\Q%@P8L-Q<
MOTJ_6"'A& A.TD_26ZLXV0'<@C/PD' Z^')-@X/&UH+F9B"<($LX,$0Q:5!M
MXCT[M.$D4?4R$N"'DZF9LDY=6[[$  Y.P)(&=R.)$N3 #[8@D!@3YB3<@<&#
M:TSNV/RVZJZPJQ"/-)U*P9<=8W(ZER<JHSG/W<8[CC:0\D" SOP=SPW.U@2,
M:66BTD]R0Q]/V-A=$D)\M[,KHK -'7@7'7)(2KM(ZXSY0!)+R$E^GRP"-Q,J
M902 >26@#GB_RP+0P4LF?Z0+DG<B^F=KL0^,MBRTZ>[QH1#Y8Z"VQ"')>5\.
M%#2R%F+9V3HB7JZ<C0 27)ZN79^$^COUMNVRHJ=(!2.KN?0,'?T9Q:,?L%9S
M"9NEVK0E8VEC!PKN  N>^6P[  =@<D8P=*4D*9QJ4"1(L Q:_8VG$DH.G4RM
M*2Q/4RT1\^#ZX_=X9)B[%XU;#@8RY*KED(# +_LSU,=@"P*G;&:SP/K^?GIB
M)0E2B26%@&?Z]Y?TD8RU*XEM!I0OD5VB9P,!6?XW(; (,9D+=9! Z?GTYXPJ
M)#;GF0+<$=]FW!QB4^8J-DM9I<>L>MH&/NL@DMR,B,:[B9X@PZ9S$,E =R%P
MZQCJ4_>. 3WXQ1\HD$AGW#M-[_WG$D E9=+!H=G;;F##M:X<SAILP@@R=1ZV
MZ_,5@.E?XKA!OALX7)R <K_O9/!'@>GU[?X[8 Q)5T<V_/EWW#'LK_8WR6\=
M?;?<YQ_51X1J"?\ P\V\T#_#C>(X6?M)8S]H7IIS_P#5[\,]@!V_I!S_ )S^
MA(^NW%3G?]8?]B?J5#\O]L7GA_\ \.#N*BCMTW=]OQ\<ZNI+AC@; Y]00-^X
MW]3Z?3;Y!1M>_$$]#T9^[8?4& W'/U_O<]&PT::_1J28. =L?7;/Y'_CV&>#
M@N &D'Z&YZ?A[+'XRU[_ "N?0_/K@KO_ !1-VSMOGZ9)^>.V_$TARP/3< 'R
MC</L>8O)G1YDW(^L,"W,<GL< .H$%CN,]0S]>XP/GC;<]_TRPD0H VWX8!RS
M\O:^V%5$!B\/ZLQ !^A_O&&QW 3!/8CN,CY#UWQ@[;<!Q)PW+^C,=_\ <^WT
MPWRDDD>ISZ>H([#/;'Y^GUX&L.019C]"7[MT^6)I5 %S,R3ZC]B<-$8 O$9;
M<DYSCOOCT/;8_7 ].!&Q['&Q\9ZA_2.6^6UGQ(^D8Z$[8_R#G],\ )W%F%MX
MVY?#0MO?UDQ\M^,'U'I5 20#\/IL=A\..^1W)![_ #X&[I.[$VO._;8P()XG
M-Q>W$>I_.3+8<Y;L$:8+9P,_(>N<DC&!OOMW]>)2L,003&_SVQ)*5,&VMM&Q
MX^7RP8>&FF2ZA?L7X7Z(:\G^]D=7X C<C\?Q'%?XGEA6RJRICH! (N[ N?4O
MW8]#?>"9E5'.("2\!R#U:9N2WTQ;2S5ENZ"%!?"Q DX) P#Z]AZ;Y^?X<>1U
M0FGFJB79(61 NX&WU)O&/=Z057R--4DZ 2UW8;AC^O?%0N<[UNA9LU([3Y!)
M4]6R[G;;=>P/IZC\+K*4T$)40"=V#[3^Q(D@8Y?.5%I44ZRD2 E72T-Z,U^Y
MQ7S4N=M5@M3PV)GQU%5RVQ_ G92.ZG&,$C.-N.EH9"DM(4ER8)'&]NAX_?'+
M9C/5$%040)(#M>P9^W>3TQ&O,W.6H3=*0S>0<[S)]_+9S@8&#]!MD' XO,CD
M*<%2=8NT 0S%_G]V=ACFO$?%:S!-->@B%+ !#&8#1W?H["00ZM=*REKL]DL0
MQ4NV9&] <]E![XR>W?8<6JLO3=(%--.($$"6OR=MN=SBD&:KE*R:RZI,Z/\
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MC(TI"9_-21Q5Z(<*.I6?S3'TNW8+*5D;;.$P/AP6%V%I4 4L-;J#W 8*V_J
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M[#!SCTX33)MO+[M/K#^MGP^SC8&9[#Y'Y79S. V3*V(F("X<;9W!V48'KO\
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MS#.Y2ODJJLM604506< A) >4$W?H6&/5<GXG1SU!-6@4K2R0Y*5*"F&H$)8
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M*,&(I_-<UK<B C):2.-E+@!B'./BQU=L\%5[-4"]3*K"=3D(6"009=*B7$L
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M$_/'%^%(R],(2$P+ #K?ASZ]8Q0J15S-36I3)+RY!]!WW.[W&*?^+7..H:W
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M&!\L=NV>.#\>\:!"J%)1$LXN_ MO?C?<CV;V+]D@H#.YJF'*$J1J2/+N'!<
M)VY8'< [ZO!OPFT_3*,3&HL=>)%#,R!2P4 DX &5.-@3N.X!QQRV3R*\RKWU
M<.-3AW;8\26N^QW&/2<]G:>3IHRV7#%"&(2&.IB+CAX:7!>3B3.<>;:7+E%]
M/TLH92#&HC52 1LV<>G;ZDYQ@</UZJ,LA5.D Y+) V<6+V[R1M.*S+T%Y@^]
MJ.8U22Z@KUGDAI,B[X@^O)J&N.MBU)._F,0$!P@'5CL!@# WV!(W^?"J/>5"
MY)+NSV'KM;[8:60@!(2 1>8Z<DP.0!ZX;N9>4GE>JT<?6&=& ,98LW8@9SG
M) ./J=N-5J124Z02\EI>)##;F,;I5BH068,_00;"_ >;=O:AX6U;M*!YZ#.6
M/4Y*=) '<@* >VS'8CU/"U7+^1]"I%E!QMT=M\&IYA!41KTL3+MUWW^\X/>5
M--TGE'3&BA@2"2)&'6VS@$$8]#D>H[9WSON7+YA-"GH@&7V.\LT1'S!WPCFZ
M!S-0D@D,[C<@$ DF+AO\/BE'CWS36U35)*0F#%LI@,.KIZND[['?/H3C'<\-
MI<TU5(*C8D!Q$G]"'#OQ.$T4T(4$D 7VU,#O,['=N,:P?$KV"JWBGSWI?.%:
MVE73[$L;:G4B0]=D*Y8 L-_BZL.Q(8J1GTQZ%[(UZ10E.9JG2Y*DPQ+#EF W
M)[[X\P]N?"VS K4:8#TTDD!F<N98@G>6$],7EY1\"=)Y$TJFM#3H(JNB0B.J
M9@/X,BH5DL1(H9@57J"8P268DC))O/$32!6M,)) 2 6%@D=('7U>W-^'J*13
M0$O4DE3"5&+6XM+]VQ&7.GAIHW/,^L3Z]+8U"C"&2I7(0Q3L"&*3QDN7K]U\
MKX8F8 E!@<<A7S%.DH@%BYL3/^.-WQU5')5*R4E25$FX8!NQ(?MZ6,XJAS'[
M&5/Q)HUH-,Y?>*S';Z:[>ZPZ9I\,;9)*+36-9I"%V4JSLWPY!P>(T/$2A;TR
MM*F8L7)YZ7X8-ZX+4]FZN: %5"54D$%ZGD (((4%!]OGZ.:J:][!>H<L:AK=
MCF+6[?+NC1ZE'6JZC%$98*;S!UB.HPRF*;H:PGEJ8>IE4J">IL\6J/&PH^[J
MI3Y0$O50"ZB\;-_U-J!+7PC4]C*5,5*R*RPI2M0%*JZ4NSAB"5>8WN;2 <;&
MO8/^T(]K#[/WEZ+PXUCEJ+QY\!:U^6QI'+>IZC:T+7>64L3&Q:/*/,#U-1]U
MTVT1+9&B7ZEF@EJ9I:TE(RS];E'VG&3(IU::C2,)"5 I3<$I+$VEF8VN&-/F
M/9&I6254ZX-8 DZT*"E-(!#Z3M+AW,L8E3VQ?VBOQ3\0.7+OA_[/'A%J?@#J
M&I1FOK'B-S-K^G<T\XTH'#):K\K:;7T>OI&C67QTIK=F?4[D$99J=>E8$=F*
MWJ^+'.4 K)+"4U RCJ=9&P(8!(DNVY+''.)\,5DLQHS]-02DQ!8L6+28 #["
M-XQSPV=8N<W:W+KVLZIJW,O,&KWO>KNI:GJ%O4]:U74;,B]5FY;MO;O7[MF0
MJ!)++-/(Y !8G'',U3F=2PL$J6[D@J*H-S8ON7?8DXZ:DG*LA2- 2D^4)4$!
M)>2I,D]"9!@ AL=Q?V&?@9I_@IX*<I\Y<P<AP:5XK<TTN8^9=8U7F72(1S=7
MTV_J<E7EFB\EN)K^C5$Y82C/'I$9KK')>FL6H1;FL =IX%X?2R^0155EJ5/,
MU@LU%A#+;4=("E>8 I9V8'ZXY7QK,KS69J4O?U5Y>DO0A/O&#@#41H.D@J)/
MF<R0"Y8[U]>\7;4X,4\Y@"@@I$%C3;./A0?WCY_4\6S!+E@!<DOZN7[6_;%2
MBBD?""3O)[DGY;G$3ZIS]).7,<Q<')SU@ [Y/J2=\Y^GKZ\0-5), MR 6=VZ
MQOOV$8:30@6!.WIO_G %=YOED+YE)V/8XP#G [YS_,;[=SQ-*G>+-P?R?GZX
MQ5,)+3?>U^FQ#[AC&!>WS.Q#?&=_7(]1GYY^GH3]<GB8!)9V?;L\-]<1">@
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M0*LN2<!1^)!(!W)SD=P3U>G $TPFH&2#N^YE_2SVVO+X+5J!5(ERZ@0.AWO
M'RM<8L+I[UFJK'7$9?IZ9$ #%6P2O3\0VSZ8';OOO8TRDLD.[&(VL[<N>3\\
M<[52OWCJ)8_#P6!WOT@<OMA%)0<67GG&5(+*0>ECC)"]([ KDGY #/?C&+FP
M;C:6WO\ IUOB06%)"0VI,J!(+/\ +M8R><8K>JR1T9H4=1&5*-G+%2V5*@^I
MR1M\R>-&L="D@Q;K'#%]KM/7!:5#54!4+,0>9+ V]#A@\)O$BER9SL*.HR1Q
MU-3E8*[-A3*?O1[[;@!@#N0-@3OP?V>\3I9'/JH+5%=<*MNW2=HB^UTO;#P.
MKXEX6<S1&JKETD%-V2$N[-8="_&^+S:O!'J]83TPLU>>/K 7I9'1@<]7]D@*
M<8((^HSQZP"%)<&%!P>A&/!54UTEE*@0NFH@S/W #.6#/L^*%^-7L)>$'C2U
MO4-6TJ?E[F0JY',6@O)I]^)V8$$R0-$)5R6^!^M6))(.3Q6YSP?*9X$U*8U"
MRA!);GF_( <L8&+?(>.9SP\CW5592&24*=KNU^ +$O#[8UH>(WV6'B7IUF>O
MR#[0FL(L%7WB"#6ZDC2")3O&9ZLT7F*!\&61F 9>V!Q3*]E4H"A1K*'&H:@F
M!N-)+7^[XZJA[;+7I%:C\+"%E)4S$.X^7UVQ&<?V.'C]S56I'5?'KDV<3-)*
M9;FEZM,RK)&<1RH+?0YC;?8CJQMOD\*CV1D*-6FI1,E0+NX/-K,YY+\VJ?\
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MTGO+7B-_7&AFG!++(NVI@) 9C+="_;?!.WVH?M+0.(9.:58S"-BHK,0,IT(
M!*0&(&6;!)VWP,<#%-2@;"=@SLW4M$MWF<;5G$I5_6DL"SZO0A@_Y9FP?Z%]
MK/XY5/(JW9:5R& =)@$K5U9AU!W*B%P68DE@3C8=_6/NJB; :9>2/1M3<"!;
MC!49Y!@%0);42I0):3>T]2WRQUB?LT_MFZK[4GB5[3VD:QHU:A<Y2\/?#G47
MN1&NTE@ZAS!S!4:%GBC61D0U_,!D;=F/PC XG054*E!:-( #2[FV\^FQG=\
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M'2+[+G@OI/(7+FFAJD263!#N5W)(7J(P.P/<]_IOCCQKQCQ&IFZZ@"2"20>
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MS3@=K,LJ!6-%:TU= %ZBJ/,[8_M;=2]_EO8?P^E3TJS>:-724A;(2P)#+33
M!)$ !Q!@"^.!S7M[XDI0*<IE4TG#I.M1) +NLE6D>CNW$VGT71K'@SS)INIU
M=!L\S:7%!J]&D^D]4%RE)?H2R3-:K/,M0^]-66-99IC6DE>,1-#,44V?AISW
ML^:7AU:B<UX;6K+-+/4R4KRZB#4*<Q38/K4/B)(%B7<8J/$OX'VBU^)TZXRO
MB-"G3]YDJJ4FGF4^6D3EJJ5!3A!.I-1*@-(TC47%1^;_ &_>0M6US4.7JIM:
M%K%2>2"SIW,,,FDZG!*'(P:EM$D.1NK*&1U(*,5*D];2KTJP>FM*F-@03TAV
M#G;>>N.<50514RTE]B4ENA#BQY-K-@//C?1UYNMM6AE9QU8292.ECL!O@DY[
M#)_OX+;F=H/3:UGGGMC1+R"X+Z;0.HEI?;TOC,_/E1U)%I".^TBCOMZG?<G.
M.Y!!^7&\:<L8] ?[8:[//%=2<6(P"=B9 !CYC&V?3Y^O&6_"<8^W7Z2S?+[F
MS.)ZKX@4(HF+W(E(#'_:+DX&1@D$@^F2,_+TXT_0_3]_\;XPW$\]3S 8SU]-
MXK7XB^.VBZ'4M/)J4"="N3F9,](R2/F,=)]1Z<14H"5. &+EKON7;Y]6;?1>
M=@QL9](V_7&F#VHO;-@>"_INBZB'D99(GGBE5UCZ@WPITD^9*W8*#G(WP-^*
M^OF"?)2))MM (EK@<F+@@OC16@)4I9 2!8W/0 <7N#(;_<-+W,_,6H<VZO/J
M-^61^N1FB21NIL,V2['./,<DEMA@X4'"@<+(3I#_ !*/Q%PY4;C@3_C%;5J*
MK+)(9 ^!&P&Q[M<,W&&?W<G=>IAG 7!!'U.XV[[CU]>,U0"3O80=[S;^WK%G
M=I ^V,@A9".D%AG#$)@Y.1\  S@G&2>^, ;;X"'@\N[6GH+Q&PC;&$$;';ZP
M/3KC!Y++UD@YSY: GL2< D;9V./[AMQ(2-N(XVMW>&],1,$09+=BQDCG8]!C
M]92J("QP_4RCYA@%3(],E2<>@P<9..-#=V(N^Y=FCGH&V8<;Q^QL^'9V $8&
M!G+.<#I WP#WZCG;\>-""ZA(N9B6 N7@ORW)QJ6+W?:?O]7[X^O.:-2JY#3
M$])[(3\6/[(RWR)S@G;..-D)N1^/:"SOQO?&/I'1FCYD?(?IW\9)'<,3A1L<
MGX2/0 9R3V/_ ,Q^F^ O(< _79AP[W>XM=]0H/<<'EWF_3TY!QC%DKF,9(8G
M)]0H.0N=MCD$GTQVR>,#FX &[.'W!'TZGZ#0!!(N+ W(W;9HGA[7G)-89($P
M27D5BISL@#L"/F2<]_0^NW&P#)YM%KW'KS.)%V@;?@V_1ONG@FD$;_Q&)5T8
M@ =14Y) '^\S'&<[ 9SQ+ P5OVN&&Y_7GN><+*E*Q8L>=("&R64;%@,87)[
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M^?#B$AH&_7O#=6NXC&*,'M'0V%OH]BU]L^IZ+3GT6[46(SV[$++D#/26!3&
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M.@EW:9TM9QMSA"E]HO>GG'78LP^Z1VBF?<:^ C+2C,B(K- /=$=]HX992O\
M$99%>2RF" X3=)^(D[J(<<DB7(#MBN6HIU&HY6H% 6/^6EI%,. %,-(.R26+
MF/S3>88-'O?OM8(#9JT[=6K4:0RO;M7*DU%I+. $BK00SR2MY2JA:.*NBMUR
M.&$TR72IB"07L&O#3U[.3MA8UDH/O0@)4E)2D%6LU%*24NHF D NR6MI#R<1
MVH+29?MUD[;$@GMN/E],YP<]^&'9F-MVZF"\_5K1OBMN?,+$DMW/[MTMAQEG
M2S)([%8X8@ L9(Z%& D:9V+$;9?N?B.V2.( $#ZO8OR/7\C!U$**C "8(V:
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M%E*%I8D$W.P)N8#;DN>K8W72ZPHEF)( XLQ^?1QR[XO]R%J43T:JK_M,*6[
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M.&Z3OEF#=0+''4<' '%SE72ZB9)( )Z26&UK<''/9H!09($23L21ZV+D\_+
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M8[M6O6?%WVS],LR,]>GX7^%4T'4<E6EYKYG1@/D $&WSW]<D-++TD9BKF$)
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M1N,4OCRDHR5<D1H6 &Y0>A;KWWQK6=F]ZE&V#+)MC&.Y_3/X]OGQ[@ R =W
M^F/GY7Q*:VI3?/"N&L9S@#UP=M^V<_/C14$AR6_+>N)4Z9J%@[NS#\_3'9A^
MQ]4'J>-?MIR,#TR>%?A0JDC&>GF[FDX&PR-^_P"'&J%5%1:DI()2D.W=GZ2/
M[G&L]E5T*5):@P6M203R$@_*;M.*Y?M1JD_:8Z60,_\ 9I\*QG;_ +R>(W%/
MXHW\2'<_RT0':ZK[=?3YV_@[?P8=_P#568!VT\1CG,6!CN,@GN0#OVQVW/\
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M$1J<ER[MU;UFT=X&L@$V MWO9O4;]9Q&^IPTF9GNV&MU&G22O-C$T$B9Z3(
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M:DL5/F,P)XL<H$)0X0H$J8E(=P(-V;N#'%FK\V"I4+2Z4DZ2&DR SS<%N&[
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M(SE,9)5>KOC;)&X)SMGL>.%\8S@(6"8D$ #GT'ZOZ/ZU[-^$Z*:%J$ .27F
M8A^Y/0WQ<G0[=:.P%POF*P"@;CX0",G8?KG<>N!QSJ%@NY?401-HEY:'W<V;
M'9*3I#!+0S@%VM'/2S02>9PT?7HI*Z0.%8,,)MG+)L5SDY;<DD]_P[-A""D"
MY)OTC9OD)^> *J*!23(%QNQ?I^V#K3]8BH/'(BIDH7)!5>H'8KW*]0 (VSN
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MCX6'B%2K7H4@8605,\!^>TF6,=\-O/\ S%,TONRR%HX55 ,GISV4].?0#?\
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M>: +(.G(Q\_BS]!W[';_ "#PRB ;1;EA=M^!=I]"NI6Y<]AW)X]<.$J_PNH
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M'4@@#45,EI!-CZER9.WZ.'Z]!+)4BN,A@B:4]0BC,DB*" V8R,*^1DIE?3<
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M;NU\84@ D<6DL2V[CFQ:#;#'JVE:75L)!103^> _E(8Q)U$]\CI!;&?B"AD
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M-&0[8"(S*" % R<XW8$ ,1D#MWVX.H!12) !)(!(=W:-A#?OA1"M'O" -1#
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M<NVJ',$WW+?Y#X%4"?\ =:0"[V:0 -]V.^&JYI=G2[$NK1S*:L;9,>I=0DF
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MV,)G)"_-I"=\C('YY( 'FY('J8?L./KR!2GZ ![."/\ :.27NX[\-TLNQE8
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M)=F=07<(P4Y W VKQ4;2U):UH!45,225!V9K M=)):SQBP0EW)J)2%^5*'
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M)+.N, C!( Z448'R-HFDAD! "B@*4HJ<E)!!'EX<%B6//6K555YS4)&I:4I
M@+\K?%W'8 <X&;TE2*9#68!GDD+/$[8C ! "9WP3D=1(SN=MN+"B*BDG6
M $D!S+\;".K6>359E5%"D^Z+$K)4I*BU. &21L2\^N[!IMVUBE>&NJ/A%#.<
M]*Y"_>)R6^OS._8C+=*F5)"UN!) :7=RS>E[.PU'"=>NBG4**82H!(!/4@3R
M>3L7PV37ANKJN\9PW8MC/<=@"00!Z#&<YR&44"1J2;*D,X#S#F;WANF$:E9,
M@I!4T3(;L(@<;8:',DA^,X  ]/3N,;?IGZ>F_#@TH'E9S^;?AY.$R5+4RH#
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MO7YMV^AO!O'*6?H(!4DJ*!93"PERP<1WV=QBXG+\?+6M>4S-'YF=V!7*DXW
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M8(G26 ZL!04R0!@=/X^H...4\;RU*L\!W=X<,[%QWC?G'?>SV=KT D)*B&@
MEA81Z/\ MSL'\,_%F[(:[-.ZB/"NA;XBP._J=P._U(W^7G^:R1I*8B=N@<\
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MA)"QV/0%&%09_,YQZ<$2:BTJ4:2E269P!UWU&W(!-@+#6:25H!K(1I$@LZ@
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M.YP1MZO)+E(IN 1J45- 8AQ'$!V'/1"I 45LX(2EK$F6,^MQQ>,8!/C)9?N
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-XS&8]QF,Q[C,9C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g90195g94f87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g94f87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1.*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $VZ^270X0DE-! 0      "L< 5H  QLE1QP"   "   < E  %TQA=2P@
M5F%L97)I92 H0F%Y($%R96$I #A"24T$)0      $,F+7V44!.4P$<"*7-LD
M=DHX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q ;0S$H         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          'K   %G0         !                          $
M        !9T   'K                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   'K     %)G:'1L;VYG   %G0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !ZP
M  !29VAT;&]N9P  !9T    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     0X0DE-! P     "1@    !    H    #<   '@  !G
M(   "/P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M #< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$(1(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ RP)2 P$1  (1 0,1 ?_$ !\  0  !04!
M       !!08'" (#! D*"__$ &40  $$ @$" @0%"1,'" 4-  0" P4&  $'
M"!$2$Q05(3$)0517E!87(E&5E]+6UPHC,C8Y4F%Q=7B!D9*AM+?1U? 8&215
M6+'!&B4S0F*"LO%&<I;4V"8G*#0U5F5F9Z:UPN'_Q  < 0$  04! 0
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M;BU(L2DE8S*A&0F@'85):YF1L,><"'&ML;+(2&4:VWN/8<*3BNZ(ZW&(2YE
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M3XY.L.9-'+#B(:R?H#T<-#J5*D*3HXIXJDXFMV35-EFG1RN:V>TYSBYNDZ<
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MXT1$.034++,16I,"6CPQ[M>66Z\=&.G. /U!3=C2[2T#ZDI!GT2I.0HCHAI
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MA8KZ%-/C$C/)6R^P\VI3;K3J%-N(4I*T[3O>LD$@AP)#AV$<B/41S"@@$$$
M@C!!&01X$'D0K;[X=H;.U:B INJ,;UON!1KC<J)%[6KMO;JXBG3\)%N/[WWW
MYS@:G>ZE;VO?B5WN&S+DEV)">UTD4<KCRY^7('.SV8.01CD>]6N!&/D[F#N$
M;G1@>H-('S8QS/);*.-Y\'Q[B.7N2@V_'M;8LBY3+&,A/_4:6_8*;(33K:/M
M[F$D+[?GA"]^W!G:0&N@@SWN:)6O).>YLNP8SR 9C..1'(P(G Y$\Q[!M=PR
MT>GRH]Q'CAV3W$=JWM1'+HN]>C7FC2C#7M0S+\?30T@7K6O:@F8B[^R .M6_
M;I\>L*0C79/HB]_98#JY<-T<S6]^Q[<CTC?%CUY/9V<T(FQY,D;C^]&0,>DM
MD]'<.??RRMAZ?Y? [*)XZJ,NVC:=;^I[D<S1KG;?V:M!6&CP@2.Z=]T(W-+[
M[[)4I*>R]R&UB">-*UW<UT P2<\B\2CLQVMC).>P80NG!'Q+"WM)$Q#N79AA
MCYY\"X#TDYQN)Y'DQ>SL]Q?R5""=MZ=,:CZ[;6VE_P#8CJ#9[78GT*WO[!;4
M&KLG7B=0RK['0PC ++$#B<X;NF81SQY7$B9&,CF,//I(02N_Q13-QVG;&X'_
M "AKW.('I:"3]NK7,G'[&MZE9:1K7A[_ )Y=*Q:Z0TK6NV]J2];X.#:6WK6^
MVW4JVUK>MZ\??6^T&";):UK7N'FY&/![_)<Q[P? D.(!R"01A3QXP 7.+?\
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M2O>X>2QK'[OL ./3V'OQVKV&_ T_ I6#I5M0/5%U5,Q#G-H8)8_&G&D<8)-
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MT(3KV)3K7LS <YSW%SR7.)R7.)))\23D_:LMK6L :T!K0,  8 '@!X+GY"J
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M/,)C)F/0O;LU'Q8Z''DE'/ER]?/L5\4+TM"5Z]RM:WK[?;>M;UW_ &?;[?\
MCKMO"E:L(F$3")A$PB81,(F$3")A%([/^EJP_N'+?T C);\N/_./XJ'=A]1^
MY?(ZU[OX5_;_ %ZO]^_;]K/H_P /?O/\,?\ 9>4GT?=CY^[D?Z*.%"81,(F$
M7O!_,SGZG[??WT_(7]6_#6>0]._VU#_H8/\ EM+N.CO[/=_JG_[85Z'\XU=
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M=VNG.%'D'X9^=I5,(77E/<,L6^GR:Q?3I^BWRJR\I%5XTA<=@^LCV?Q!3:/
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M<-+2-I\ACB8G LK4Z^^R.00A@YD=8BS$,)U(1P.P5A2$LR(RCR;+7G(KU6N
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M >$[F&[ ,RN. WJ\'(<@>7<,-:TM"WFC.+H'Y)P'C&3DD;&\R1++GOQS( .
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M %+?1_\ )S]_%/\ DL_%'^UU?_O5USX_=_Z7?'C]?[?_ +=7^ND_E3]6(_\
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M@9'8/1CL VAH;DIY<C\J"^@/_P!Y9A++3RY'Y4%] ?\ [RPB>7(_*@OH#_\
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MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H=M=^_;V^[O\
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BV2G7?MK78I7(UKM[L(F$3")A$PB81,(F$3")A$PB81?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g90195g97e03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90195g97e03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %Q:^61 X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!M\.V@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              J8   70          $
M                 0             %T    J8
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   J8     4F=H=&QO;F<   70
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *F     %)G:'1L;VYG   %T     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !SA"24T$#      -
M  $   "@    20   >   (C@   ,Y  8  '_V/_M  Q!9&]B95]#30 "_^X
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M_))Q?D R+K0?$6/'_?D-))3JX'UHZ_@/!JRWW,'-623:T@<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$0$#$0'_Q  ?  $  00# 0$!            !P4&" D!! H# @O_Q !L$
M!@(!  0)! D-" L.!P$! @,$!08 !P@)$1(3%!48&5B6E]76(3A7TQ8Q4599
M=G>5I@H7(B,V-T%A>+2UMK<F.7&!D:&Q\"0E)RDU2&:&P='Q*#(S-$)%1D=)
M4G)UL^%#1%6%AZ7&TO_$ !P! 0$  @,! 0             ! P4"! 8'"/_$
M %,1  $# @,$! D'" @$!P$  P$  A$#(00Q004246$3<8&1!A0B4Z&QT=+P
M%2,R4E62P0<6%S.4HN'Q-$)R<W23LK,D-4-4)38W8G6"@\)$16/_V@ , P$
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MLZ#?=GSO'5G>Q5SQ729<]H8Y5&?*;:BQBB @$K+-)T@B!A,':2G&,BF<.L1
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M\@@3=,)E N,Y.I!BW=%N=X3"A]&5K6OISCG>YDE,)V?R[NOK[$PK$9S.@B#
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M(!:TJGV$&: B+M,W: $S ?SV!\(*>-VYM'8C<,^G4V=3Z1V(-1KF5?*HMAK
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M[>.0=NP,<4.[/N=H[#\(]EX'%8]GACBJGBM"I7<S$4BVF_HVEQ8'/KUFM<^
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M?R<H\</Y!ZY6,)U7#MZ[45<N5U3B)U%EE#J',(F,81$1SZPQC*;6LIM:QC0
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M,^I@@B09!N",B.*T0)!,]L<3I:.ZT7B"M^W-3^\O]'M^/*/^#]S^U?\ 4/\
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M82<C8=0$VO/KR@6$K8%T65Y4U]S\XU2X*BBC+7A:DNNL_8(HA?H&7IH$4ZQ
MIBE<3:"I2FZ^I1-,Y0[92B'FO###C$^#6UF$26888AO$'#5:>(D<XID=1(U7
M=V>\LQE Q])^Z;?7!9&F6]%Y@@1R]]V?FQ>Q3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A%A!TDWS%.3GY,I#^?1^$4C\+/F=<3_P"37HS^S"KX
M3X^)63&$3")A%Y9OU1I^ZOBA^+VX/Z2UWGV#\EOZK;7]Y@/].+7GMN?3P_\
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MHWVMMN/,R"!&9!!'UI (D*2^:G]Y?Z/;\>4?D_YO[5_T?].=78/_ )]\)O\
M#'_<P2YXK_E6"OD\]MJEAU^I.$_]YDZ0S\<U_P"KNL,>$'_GOP8_N!_NXM,)
M_P KQW-QG[M.?CU+0-GTE:<F]CF>8B#;ESY<DPH>H\3>;F.[TG0G@PAURL9,
M<^W0VL(YIA6-2;3GK.>DZ7Y$QQAA3(B_<?9D3S'6F%8]1 DB0 +]8S (R&E@
MF%3E/QJ+W@ZD.'#()A01P)F,^RUKQJ.H0+%,(=2#K<9:&1V99=284X9#G)GX
M'(=I*85X&_7,ZW.=B"1:U\\TPESS-X],YC2_"#DF$ZM9!G/F;7C7747UG'C'
M,*5_DEQ]G4S&*>&W=JJ3 2B(#U,;U!.3%ZP$/D,5,2F#KZA*(@/R".:_:]/I
M=E;3I'_J;/QK/O8:HW\5EH$MKT79;M6F;#@YO6;C(FTGK*_H_P"?E=>Y3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%A!TDWS$^3GY,I'^?1^$4
MC\+/F=<3_P"37HS^S"KX19,81,(F$7EF_5&G[J^*'XO;@_I+7>?8/R6_JMM?
MWF _TXM>>VV)=A_[-7T[OQ,P-;+S49]86BZ^/9$Z208SO/"8S3"D7X3QTD\Q
M>Q'KE,*P;"8GA;GRGEIP*84S.7,@#36/3$\A)3"I!%IBWKB<I]L".$L(0())
MN2?X&;F#I.?I#"=E\A%IL-(N#-YN9T"829F\<=!U1UZG6Y,FS"2;Y"1'+(=D
MQ;2)T3"9WN-9-[\9L<P3K?()A7*)X<2>61(FQ,1KE:4PH0<A;B)SCAQO87)D
M'J6[3HO07N_$_I.=,12B@VF=T;!; K+5L8Q7[I>BM;NX7*S!,04%;Q@Y@$$A
M2ZCE7=(@40,<N?/_  OC#[:\$<>_]33VA4PM8GZ(&(=AP-[2-P520;$-,V6U
MV?+\-CZ0/E&DUXB9^;WIB=9CG)'4I-UAL73'2SZHJG'[D5:HW5_-K6T26%TS
MO*2(B6/VY$IAU-ZM;5#J)JR4TL< ,^BQ6(_=2!SV:K'6=O+%7W74QF%Q_@5C
M:VT]E47XOP?Q=3I,?LYI)=@GG.M0SW6#^J^-UK0*-:&MIU6Y*=2CM*FVCB"*
M>*IB*54FU0:->=2=1())WFW)#KIZ3#1]DX4]''Q5XN-'B$ZVD]JVZT[4N<&U
M=M(>;N2#61F8M@IX01-91L9&Q*MHD7I$7#IG26KDS=%1$R:6'P2VA2V_X4[9
MVPYIIN9@Z%'!T*C@7TZ!+:;W6MO32!?$AIQ#@"005RQ]%V$P.'PX,@U'.JO
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M<".&1-[$F >N]SDF%-03>9SU.G/@)ZXRE,+D )R!BQ(G6V<W/(#^#"DZV N
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M@F&M%RRC3DBFR2;E[B7.*U&-Q;\74WC:FV139,P.)YG4YK!G/0KJ9WCF0.N
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MEH.7&$PECG;^.I-\[]E] "P@%I/,9CA&1_F!?@F%(R[P3PYR8ROKPE,*S,0
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M:?2PEQ8Y@2,C$7'H)XYY63"1K:,\\LN&4Y>R+,)/#68MK;(38Y3EF8F F$O
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M,\!ZN$/(QLOWZP?YN?\ UF/EFGYA_P!YOL2?CNG7+,<]=(>1C9?OU@_S<_\
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MS\#G&0'%/(QLOWZP?YN?_68^6:?F'_>;[$)G4GKOZ?B>62>1C9?OU@_S<_\
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M3T9OVSG<=O&4\B!A^%XXI^TYK]OUE^U_KU9/TB;&^PZW^90]BGR)4UKT[_\
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M (7C/\ZCZ>"?(=4Y5V3_ ';ID:_2F;W[$\UUIG\)QPJ^W\G]V\9_E_=']O\
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M_=KN5?2)SI@U.TE";2BR1Y6RBBQ#1C\7!$P.W[PBAOASJ?DEHR@:?TULNO\
M'1:D:BT]3=8-KOKNRWQW>["YH55A*K&2SV"G]>040R3G$HD\A+(IV1VHR<+%
M1;F?% 5L(LZ<(F$3")A$PB811Y';=U/+W5]K:)V?KR4V+%@Y&3H,==:V]NL<
M#,H'=B^JK:35G6@-2"!W/A#!/N"B!E>R @.$6+%JX/T7=6]=G;FY%M4;\1[
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MMQ[.I&MV\:U@X.#:'90D(S44629(JJ=\X45<K=2KMX[6ZE'+DY2"J8I1$@&
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M!>_6C(F4L]A?L&AS"DW=3,@LF4#N5!$BH#O4VLGZQ5W="JBZH;!8[8$QH1@
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M5RGW*E7.K2]DB;9(UV1$8><1A'#56OF?G2**JK!\*A55'A1$"E)U%3,4>OM
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7-R\?K_MJRANVY=+*?LNSVNR!0 B__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
